<SEC-DOCUMENT>0001558370-22-002719.txt : 20220303
<SEC-HEADER>0001558370-22-002719.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303073049
ACCESSION NUMBER:		0001558370-22-002719
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Passage BIO, Inc.
		CENTRAL INDEX KEY:			0001787297
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				822729751
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39231
		FILM NUMBER:		22706747

	BUSINESS ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		2678660312

	MAIL ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pasg-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/3/2022 12:17:03 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 6c223ed5-cc61-4db2-9b52-5a2bd7442680 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:pasg="http://www.passagebio.com/20211231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" xs:nil="true" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" name="us-gaap:CommitmentsAndContingencies" id="Hidden_6H4IbjKuXkq7KqvaOwzRcg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" xs:nil="true" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_3LQY5JCzy0eABdlL_wi0pg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_uxnYvl92C0aLe3HGJW_klg">3.48</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_d9qLBGxubU6zDuzaB89dBA">2.91</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_6prGth9q60Sva9NEJO1MMQ">53343959</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Ex0hA9flTU-eNkHfrRLOPw">38615967</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:LeasePracticalExpedientUseOfHindsight" id="Hidden_Sc9rc70L20a7-6a58pPOzQ">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityCentralIndexKey" id="Tc_SDyq9Gz7X0iLOz9QhAAunw_2_1">0001787297</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:CurrentFiscalYearEndDate" id="Tc_S8Y0QIwoqUCZHSMZ5LrwPA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:DocumentFiscalYearFocus" id="Tc_k8-l606GkEirL7o_2QHVUg_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:DocumentFiscalPeriodFocus" id="Tc_YA-cDuqt10CfW8Z1npXtRQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:AmendmentFlag" id="Tc_z4wwskUYDkWxfq9KEds9zw_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_1_2020_To_12_31_2020_ehPbbYoD4kCqWigfP_MTkg" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="Hidden_rps2tZ6LzEqxXNkA71X-1g">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pasg-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LYKOlHkUJk6ZytaJNaa93w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesTwoConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZuK3tkV4pU-7P0MkazMMfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_OZPCcIcvuE2lyKN-UB_SrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yq6XT26n3Eqy2E5_gcwEZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_jLdA8uvJqUuhFQXDPlOxiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_6cQRUFo1xEqxvR0_DcpgmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Jfpsy72LLUulUWiSGGQmGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m6L2u8TXOUSP7A9u-mhU5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SyLUO16mfUyXajW1h4qJLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b7aXerQ_FUGYF5XUuzOhIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N2zsouDDp0KGzHDs5rgYWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5Rk_6c3CBUS1hDM1NKi8Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7CN9CCTgHEi8F4aqrlVJUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KtAMQhONPUi9b_KILEFiog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vePEcvExi0yfQVSylYejVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wJ5SQuui7UmmH66JjXcNEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_aHwnSqJS7Eaecp2WOoB7vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjALmRT9kE6JDV3gpQtAgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LoCSKTtbL0OhUlAy4bzQyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7TeewkAeXES9W_l9V_dFQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_eEb-pqvetEOOQLXyvb5cMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_YdlvI73YvU2I-mGpcp7oeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KKuHOgYwnUOUC3x3lVmTsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_8g3nKyOXp0WB3RRJFPY0Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_WdT9SqzOo0K02mLduwDlzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LOgztTkbQ0WGq90WF8_dpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_eFQ_dfn7M0KtMER3R_n4pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_GybBG82pcU2WNDKqUYN4Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tb7mAE2KnkKD7-9H_fYxeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_jWNc7kjyfUCQZyuO_hmU9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_nz0HkNmO8kaGfzabjgTXHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_TZX4Wh_vEUaTQxedl8QHPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_Eec2VJTNMkK-WIJuen-_xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_9l6O5crOnU6_39cV6VEfVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_uM4mB8EAzEu-8Axzi0_XsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_RxCh3NZzy0OKjrjwUe4Zdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_aGYb1YEU4kCXSlYbal1wIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_hr_uYkiIdUi2u9pCZYZyfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_bS1e6udSiUmjvh8u8711pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QppymW2ZzUGGYeEkGfMJsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmxycgbmuUSxw-PaJOObzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_zzHhTfTUtkmAsOCCTtRAfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_ou_PBG4RvEihq6A2EvgcSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_AEwhzMB_OUyIYWxhHH_sKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_-AB_b6Gy40yD--yAZUlaJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_sCqVUi350ke4K2VTSeSwSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_YBzYmbyXZkO0AKGn6_kDpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_fiT7-OIXtU2fTbDpDThQDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_iPx0aGFkEUyzm5BeJrht2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_b-40t_BVvU-ZNd20D-z1kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefOperatingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pasg:PromissoryNoteWithRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_0lT3N_zSwUG3WlueyWRnJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pasg:PromissoryNoteWithRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MKdAL993WkmlGk1E6Ds3GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jOi_xjhbwk6ay-da4RmeYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_W0Jceks2UUu8HjUo4M49Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_ehPbbYoD4kCqWigfP_MTkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_e8i0wNfdJEOwKF4ht1pxvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0aYfPaNDZUKLpHmemdOVpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GVNitqFPWE2eFLAMk2cu3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_JV6ao2U_tkWKH0ie6bUjcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LKyQmyM_mEOvmrMoP6U72Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_vWJMqNXQZEadyp--CRitIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_62jnW-ZOyUGxlh6h8Z2Paw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cnF35_-O8kC3_ITgQtTTnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtK3dDq7kawG05hiybIvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_I5BRgy8uTUifNJBQXb4LQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_89c_UBK5AU6UAZMtdo0pYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_JdA4EKGM8EuzfT7R3EYZqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_cO90df-qlE2w4LRBHX_-6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_pP402F0Qh0OFBcMuVo7wbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_avGEAHh5YkKCdU7swCc-rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_rMsmezVxj0a84jy1lB0R9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_xubfLqarekqkZnz8HPVLxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_2Dnl9qndLEiZA71KgcQs7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_gJE9jyckc0uxCSxe63NjaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_a4xV6v1rwUKpdSlmiov0oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_p-FfJJcDT02MgnnCC4FKKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_B9cbaSVJx0CJKDD0vSu7dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_dTyFlaO3mUKM6PVp1FpYkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_z0eGE2veJk-OYbHDU3ohYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_0ZVBL1LBgk-2Lmwe-qa7sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W8IOiflxCUqSDBcWDbNx9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yP080bRNLkKlnvnFLFezGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Y4ZNWZufSESbSvoIUjVxUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_O3P6zlOMF0WLM5n7S-Ueww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_SViruIUiA0GgBqi7iFeZ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_rxBgbjMROU2SA9ft8QlsyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_1fYXv3HVhEKVNJ2zbLsrBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2031_nwAcjwnUlECe9uyTYzx_Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2031-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MWN-gxUTckSGX79Osy-sqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9gQrDgAqjkSE2Gb1oTaaSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_lmvSR935b0WEFgO0Y_lvng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yMsCjLmkD0S_oueWNaOXdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DOc0XterPEO_ABMw_SCRSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_TuoN6al3ek-oKV2lUg9dvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_eJE-uMNmcUG5vTVEbr9ZOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_-s2xGmVdVkGTPHiCmb4BJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_i2EyC4gK6EeZimGB107lUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UU9G0ivYy0Cp8ghABgy4wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesTwoConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-CYi_SN54kqIdkLi7k62Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fiaYf-Eno0KZLETdAJS4-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_Dg47llwd60Wt_myzLnSxow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2019_To_2_28_2019_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_QFerryslZEecn9p62PcHmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pasg:PromissoryNoteWithRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_srt_RangeAxis_srt_MaximumMember_WriT7NhV5E2Q4aLWditgXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_srt_RangeAxis_srt_MaximumMember_F_q5LSFCXU2s5384bFCZDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_7383hJsYRUaX8QecXw1x9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_hge6WzgOskii8rTOoQb_rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_fRoUpLtqpkitwlFzFSV1fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_Hlylcmv8XEyDesAxASGedA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_DUZDzlEv3kCLP31Wr2eujw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_IXEquSLDb0yKA8sbyQ-qig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_By7Uz8pPpEWAL_wK_0BdCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MYx6whEmKUaeZZi3nvIPow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_JY_Wj1FPNU6c8cjQsZNN0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_SCDOkqnfRkWyAeV9p2oFBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_-9UcmhqlFUOIPDQYaqM19g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember__lny6i38n0-juSxISzMBnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_U2yhmhWXYUGyV29jTRrJ-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_qDWtLlQQI0CDUl_45mabSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_r_NUEcfXZUWE7dm8OwgVfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_tJmj89_QHkOSI8IRh38VrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_MqFdKX6rV0uERMDWUtT6FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2022_twRvnJOWjEaYkHqwez-3iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_24po74v6kUOYh01Lzj_3ag"><xbrli:measure>pasg:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_plan_bYBMu5fRl0arekv0DtDLXA"><xbrli:measure>pasg:plan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_individual_kRSnx8nw1kG-RLCkCGj2iA"><xbrli:measure>pasg:individual</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Option_85izgBp0S0Shu2LfkufK4A"><xbrli:measure>pasg:Option</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_dtYM95ndTUuz97Ok3LqHiA"><xbrli:measure>pasg:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:6.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_abaf33f5_7b0a_4f33_8364_aa352e31610f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:DocumentType" id="Narr_W9srOZD6zkqUzFiQYhsjjA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6f7d295c_3914_4643_90b0_87b473e19600"></a><a id="Tc_Zc4NROe5iEKy93JJrGScrQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:DocumentAnnualReport" id="Tc_di4-UhRLQ0aKCcCAotuU2w_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:14.4pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:DocumentPeriodEndDate" id="Narr__4dB6psIxk6ELiDhgwIkAw"><b style="font-size:7pt;font-weight:bold;">December&#160;31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ba8fef0e_7520_4c63_8dff_1d31fc63aa48"></a><a id="Tc_S_Ap24OzX02Z_IRot048cQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:DocumentTransitionReport" id="Tc_TybWPOlB8EeiJun1aef2cg_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:14.4pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityFileNumber" id="Narr_56lEAkpYC0ulOkuWNk8-Iw"><b style="font-size:7pt;font-weight:bold;">001-39231</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:19pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityRegistrantName" id="Narr_lW6qDWurNEOTKGmMhR8ouQ"><b style="font-weight:bold;">PASSAGE BIO,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db8939f0_41ca_46f2_af10_7bc8325e7911"></a><a id="Tc_vZ3jYdkio0ekfF3DOIFwyw_2_0"></a><a id="Tc_1ee7XrNfk0m0F7nxq5Ix1w_2_2"></a><a id="Tc_kw5HcphHAkikrO9Mmy_ElA_3_0"></a><a id="Tc_xhpOxHwyJU-2NZfFa8bpsA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityIncorporationStateCountryCode" id="Tc_FXq9G94plUWsM4k1Q8uHjQ_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityTaxIdentificationNumber" id="Tc__SybC5-6WkeT6i0kYuG7Yw_1_2"><b style="font-size:9pt;font-weight:bold;">82-2729751</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_71689942_2921_4681_b41d_aa011eaa87ac"></a><a id="Tc_2ncg0YxV_UaoFp0PUvR99A_3_0"></a><a id="Tc_Md91nsTsb023lh4-q-tfxw_4_0"></a><a id="Tc_n5YLVl2PK0SdsLNu6t2KFg_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityAddressAddressLine1" id="Tc_zCTR2DFz6EeqJBytn_5T_A_1_0"><b style="font-size:9pt;font-weight:bold;">One Commerce Square</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityAddressAddressLine2" id="Tc_fW_3WCyI50-dAdaMy4yKIA_2_0"><b style="font-size:9pt;font-weight:bold;">2005 Market Street, 39</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-size:9pt;font-weight:bold;">&#160;Floor</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityAddressCityOrTown" id="Narr_FEY46joES0qMw0qb-9yE4Q"><b style="font-size:9pt;font-weight:bold;">Philadelphia</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityAddressStateOrProvince" id="Narr_az0ZhMO74kiKGcgTZ9YDwg"><b style="font-size:9pt;font-weight:bold;">PA</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityAddressPostalZipCode" id="Tc_2lTcWdELaUm5J8bksOCB_A_3_2"><b style="font-size:9pt;font-weight:bold;">19103</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:CityAreaCode" id="Narr_iXiAV-GhEUqc3czDz9rJmA"><b style="font-size:9pt;font-weight:bold;">267</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:LocalPhoneNumber" id="Narr_JNZsydKnDkSkZXMMIQFEUg"><b style="font-size:9pt;font-weight:bold;">866-0311</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_19cbd250_7596_407b_937a_2021e6942811"></a><a id="Tc_5TTBS7kOMkmrvomKtX-P4A_1_0"></a><a id="Tc_cYp-XUmvKU6Gtl0OIRoDdw_1_2"></a><a id="Tc_9zhy0pP0hUadLgTk2-fMUg_1_4"></a><a id="Tc_MfPOJ01EpEigX4gD29bc1A_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:41.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">Title of each class</p></td><td style="vertical-align:middle;width:0.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">Trading Symbol</p></td><td style="vertical-align:middle;width:1.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:41.11%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:middle;width:39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:Security12bTitle" id="Tc_0y8EXqQSEkmPMH0mI6CtnQ_2_0"><span style="font-size:8pt;">Common stock</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:0.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:TradingSymbol" id="Tc_3ubYZ7LCg0mPM9PiaXonwg_2_2"><span style="font-size:8pt;">PASG</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:1.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:41.11%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:SecurityExchangeName" id="Narr_jCkvROpbnkaHhuCoEldT5Q"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Stock Market LLC </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">(Nasdaq Global Select Market)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">None</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;Yes&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> &#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_0KdROKiSz0C4djixV5AKog"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;Yes&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> &#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityVoluntaryFilers" id="Narr_rnzMaGs88Ei1L4aztcs2vQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the issuer (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityCurrentReportingStatus" id="Narr_scRd8wbsXUaaYUnpMI_YdQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityInteractiveDataCurrent" id="Narr__VlSUKA0eECYMcYfq0_uSQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5ad02169_ca1e_4900_9c4b_67c9e1dacd3c"></a><a id="Tc_7-M_EpOdwUSmKT_D-aJTYw_1_0"></a><a id="Tc_iW3Apmu6LECgpvEXHNuBSQ_1_1"></a><a id="Tc_Hvomf7E-2kCRs6EkqUbV6g_1_4"></a><a id="Tc_hbpXP6piq0KEx7uSC8fgWg_1_5"></a><a id="Tc_xiLeTdt8SkS8PcFWGr_mxA_2_1"></a><a id="Tc_41EeJB0_gEGzEUeF6GZd4g_2_4"></a><a id="Tc_ITmWXRxpP0yYlojsHmM1sg_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityFilerCategory" id="Tc__dp7oV0WsUmFsKSa9Nw9Aw_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntitySmallBusiness" id="Tc_60Rcga3InUa2fidTEQygYQ_2_5"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">     <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:14.4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityEmergingGrowthCompany" id="Tc_DdQYI_RtBUmmCks8-Nferg_3_5"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityExTransitionPeriod" id="Narr_ZiFXVaQCkkSzSWxJnCkXnw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:IcfrAuditorAttestationFlag" id="Narr_KxsbocIsQ0-UruVVBhsWnQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange&#160;Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:EntityShellCompany" id="Narr_tfWb9Itxpke7n3vg1NTU7A"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the common equity held by&#160;non-affiliates&#160;of the Registrant on June&#160;30, 2021 (the last business day of the Registrant&#8217;s second fiscal quarter), based upon the closing price of $13.24 of the Registrant&#8217;s common stock as reported on The Nasdaq Global Market, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_MqFdKX6rV0uERMDWUtT6FQ" decimals="-5" name="dei:EntityPublicFloat" id="Narr_SruAn6QU90iT8CrQf6GWjg">483.3</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;">The number of shares of the registrant&#8217;s common stock outstanding as of March&#160;1, 2022, was <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_1_2022_twRvnJOWjEaYkHqwez-3iw" decimals="0" name="dei:EntityCommonStockSharesOutstanding" id="Narr_APgfPIKmiUGOPmOdfBwoMg">54,292,691</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Portions of the Registrant&#8217;s Definitive Proxy Statement (&#8220;Proxy Statement&#8221;) relating to the 2022 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant&#8217;s 2021 fiscal year and is incorporated by reference into Part III of this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_991a7872_9501_4807_923f_3116fea476fa"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNUAL REPORT ON FORM&#160;10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2pt 0pt 2pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTI_128887"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1Business_851218"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1Business_851218"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1ARiskFactors_934987"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1A.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1ARiskFactors_934987"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">45</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1BUnresolvedStaffComments_644817"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1B.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1BUnresolvedStaffComments_644817"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">98</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item2PropertiesandFacilities_24543"><b style="font-style:normal;font-weight:bold;">ITEM&#160;2.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item2PropertiesandFacilities_24543"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">99</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item3LegalProceedings_840413"><b style="font-style:normal;font-weight:bold;">ITEM&#160;3.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item3LegalProceedings_840413"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">100</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item4MineSafetyDisclosures_801065"><b style="font-style:normal;font-weight:bold;">ITEM&#160;4.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item4MineSafetyDisclosures_801065"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">101</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTII_199413"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">102</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><b style="font-style:normal;font-weight:bold;">ITEM&#160;5.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">102</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item6SelectedFinancialData_184761"><b style="font-style:normal;font-weight:bold;">ITEM&#160;6.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item6SelectedFinancialData_184761"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">103</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><b style="font-style:normal;font-weight:bold;">ITEM&#160;7.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">104</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><b style="font-style:normal;font-weight:bold;">ITEM&#160;7A.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">114</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><b style="font-style:normal;font-weight:bold;">ITEM&#160;8.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">115</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">138</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9AControlsandProcedures_95933"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9A.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9AControlsandProcedures_95933"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">138</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9BOtherInformation_661797"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9B.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9BOtherInformation_661797"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">140</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#item9c"><b style="font-style:normal;font-weight:bold;">ITEM 9C</b></a>.</p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#item9c"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">141</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTIII_442551"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">142</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><b style="font-style:normal;font-weight:bold;">ITEM&#160;10.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers of the Registrant and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">142</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item11ExecutiveCompensation_324480"><b style="font-style:normal;font-weight:bold;">ITEM&#160;11.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item11ExecutiveCompensation_324480"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">143</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><b style="font-style:normal;font-weight:bold;">ITEM&#160;12.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">144</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><b style="font-style:normal;font-weight:bold;">ITEM&#160;13.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">145</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><b style="font-style:normal;font-weight:bold;">ITEM&#160;14.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">146</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTIV_315772"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">147</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><b style="font-style:normal;font-weight:bold;">ITEM&#160;15.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">147</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><a href="#Item16Form10KSummary_733791"><b style="font-style:normal;font-weight:bold;">ITEM&#160;16.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item16Form10KSummary_733791"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 0pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><a href="#SIGNATURES_809350"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">152</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5ac5149c_8c33_4aed_aad7_5459c1b90844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Annual Report, including without limitation statements regarding our plans to develop and commercialize our product candidates, the timing of our ongoing or planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency of our cash and cash equivalents, the expected impact of the COVID-19 pandemic on our operations, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Annual Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Trademarks and Tradenames</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;PASSAGE BIO&#8221; is a registered trademark, and the PASSAGE BIO mark, the Passage Bio logo and all product names are our common law trademarks. All other service marks, trademarks and tradenames appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this prospectus appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 9pt;">Summary of Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 9pt;"><span style="font-weight:normal;">Our business is subject to a number of risks and uncertainties, including those immediately following this summary. Some of these risks are: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical stage genetic medicines company with a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. Our limited operating history may make it difficult for you to evaluate our success to date and to assess our future viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The novel strain of coronavirus, SARS-CoV-2, which causes COVID-19, has adversely impacted our business, including our preclinical development activities, clinical studies, and planned timing of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to raise additional funding before we can expect to become profitable from any potential future sales of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are early in our development efforts. Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The disorders we seek to treat have low incidence and prevalence and it may be difficult to identify patients with these diseases, which may lead to delays in enrollment for our trials or slower commercial revenue if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical and clinical development involve a lengthy and expensive process with an uncertain outcome. We may incur additional expenses or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gene therapy is a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause undesirable and unforeseen side effects, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely exclusively on our collaboration with Penn for our preclinical research and development, including for discovering, preclinically developing and conducting all IND-enabling studies for our clinical product candidates and our near-term future pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely and expect to continue to rely on third-party manufacturers to produce clinical supply of our product candidates; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or our rights under licensed patents is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ed9ea6d6_3425_4222_8e91_4a05b2339dff"></a><a id="_Hlk93564553"></a><a id="PARTI_128887"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_851218"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Overview</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We are a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system, or CNS, disorders with limited or no approved treatment options. Our vision is to finally fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases. The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success. We have entered into a strategic research collaboration with </span>the Trustees of the University of Pennsylvania&#8217;s, or Penn&#8217;s, Gene Therapy Program, or GTP<span style="letter-spacing:0.25pt;">, headed by Dr.&#160;James Wilson, a leader in the genetic medicines field. We also leverage our close working relationship with Penn&#8217;s Orphan Disease Center, or ODC, to develop historical and prospective comparable natural history patient profiles for comparison to participants in interventional trials. Through this collaboration we have assembled a deep portfolio of genetic medicine product candidates, for which we retain global rights, including our three clinical product candidates: PBGM01 for the treatment of GM1 </span>gangliosidosis, or GM1<span style="letter-spacing:0.25pt;">, PBFT02 for the treatment of </span>frontotemporal dementia, or <span style="letter-spacing:0.25pt;">FTD, and PBKR03 for the treatment of Krabbe disease.</span> <span style="letter-spacing:0.25pt;">We have six programs in the research stage: </span>PBML04 for metachromatic leukodystrophy, or MLD, PBAL05 for amyotrophic lateral sclerosis, or ALS, PBCM06 for Charcot-Marie-Tooth Type 2A, or CMT2A, and unnamed programs for Canavan disease, Parkinson&#8217;s disease and Huntington&#8217;s disease. We also have exploratory research programs for <span style="letter-spacing:0.25pt;">Alzheimer&#8217;s disease, or AD, and Temporal Lobe Epilepsy, or TLE.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We founded Passage Bio with the intent to build a differentiated CNS genetic medicines company delivering transformative therapies to patients by combining our team&#8217;s experience in rare and neurological disease development, manufacturing and commercialization with the pioneering research expertise of GTP in gene therapy. We are purposefully focusing on rare, monogenic CNS disorders for which we believe our genetic medicine approach provides distinct technical advantages based on decades of research by GTP. GTP conducts rigorous preclinical studies to identify promising product candidates. Our collaboration provides us with access to cutting edge capabilities and innovation in the field of genetic medicine research, including in capsid engineering and next-generation capsid libraries, vector engineering, transgene design and gene therapy modalities, animal disease models and related studies for lead-optimization of product candidates. Further, we believe our team&#8217;s deep clinical development experience in rare and neurological diseases will enable well planned clinical trials with the potential for efficient advancement to regulatory approval. In addition, we are engaging with key opinion leaders, practitioners and patient advocacy groups in the field of rare, monogenic CNS disorders that provide strategic input and help inform our clinical development activities. We believe that our ability to execute on the above tenets provides us with product candidates that have an improved profile for clinical development and an enhanced probability of success.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We are focused on developing and commercializing disease-modifying therapies that can have a transformative impact on patients&#8217; lives. Utilizing our rigorous selection process, we have assembled a deep portfolio of product candidates for rare, monogenic CNS disorders. Our first product candidate, PBGM01, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1</i><span style="letter-spacing:0.25pt;"> gene encoding lysosomal beta-galactosidase, or &#946;-gal, for GM1. Our second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> gene encoding progranulin, or PGRN, for FTD caused by progranulin deficiency, or FTD-GRN. Our third product candidate, PBKR03, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase, or </span><i style="font-style:italic;letter-spacing:0.25pt;">GALC</i><span style="letter-spacing:0.25pt;">, for Krabbe disease. There are currently no approved disease-modifying therapies for these diseases. We believe our clinical product candidates have the potential to provide patients with significantly improved outcomes, given our chosen route of intra cisterna magna, or ICM, administration, </span>the potential for enhanced benefits due to cross-correction of neighboring cells by secreted gene products, and our rigorous capsid and transgene selection process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Our research collaboration with GTP provides us with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to product candidates for certain CNS disorders. As part of this collaboration, we have exclusive rights to all </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">discovery work and IND-enabling research for product candidates in up to seventeen CNS indications that we select. In addition to our three clinical product candidates, we have six ongoing research programs and eight remaining options available to us to license additional programs from GTP until May 2026. </span>We also have exploratory research programs with GTP in non-rare, non-monogenic, or large, CNS indications, initially focused on AD and TLE, which can be expanded to other large, CNS diseases upon mutual agreement with GTP. <span style="letter-spacing:0.25pt;">Further, we have exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for our products developed with GTP, such as novel capsids, toxicity reduction technologies, delivery, and formulation. We have global commercial rights to all of our current and future product candidates and believe that our approach to developing therapies for life-threatening diseases that are currently underserved presents an opportunity to efficiently advance our product candidates through clinical development, regulatory approval and ultimately to commercialization.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We are led by pioneers and experts with decades of collective experience in genetic medicines and rare disease drug development, manufacturing and commercialization. Dr. Wilson, one of our scientific founders, is recognized as a world leader in research and development in the fields of genetic medicines and rare disease.</span><span style="color:#ff0000;letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.25pt;">Dr. Wilson&#8217;s continuing relationship with our company and involvement in both academic research and clinical drug development allows us to gain early insight into emerging technologies that informs our business strategy. We have assembled a team whose members have extensive experience in successfully developing, manufacturing and commercializing genetic medicine and rare disease products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our pipeline</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have assembled a deep portfolio of genetic medicine product candidates for rare, monogenic CNS disorders characterized by high unmet medical needs. We intend to further expand our portfolio with genetic medicine product candidates for rare, monogenic and large CNS disorders, as well as other treatment approaches as technology advances in the field. Our development programs consist of:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><img src="pasg-20211231x10k006.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated" style="display:inline-block;height:216.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">PBGM01 for the treatment of GM1</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently developing PBGM01, which utilizes a proprietary, next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding &#946;-gal for infantile GM1. Infantile GM1 is the most common and severe form of GM1, in which patients have mutations in the GLB1 gene that produce little or no residual &#946;-gal enzyme activity. &#946;-gal is an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside. Reduced &#946;-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressive neurodegeneration, with a life expectancy of two to ten years. Currently, there are no disease-modifying therapies approved for the treatment of GM1. Early onset infantile GM1 is characterized by onset in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">the first 6 months of life, while late onset infantile GM1 is characterized by onset between 6 and 24 months. We believe PBGM01 could provide patients with significantly improved outcomes. In preclinical studies we observed meaningful transgene expression in both the CNS and in peripheral organs affected in GM1. We are conducting clinical trials using an ICM method of administration, which involves an injection at the craniocervical junction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND, or Investigational New Drug application, from the U.S. Food and Drug Administration, or FDA, and approved clinical trial authorizations, or CTAs, in multiple countries for PBGM01, and we are actively proceeding with our Imagine-1 Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In March 2021, we dosed the first patient in our Imagine-1 Trial. In the fourth quarter of 2021, we reported initial safety and 30-day biomarker data from the initial cohort of two early onset GM1 patients treated with the low dose of PBGM01. We also reported interim safety data for the initial cohort that showed PBGM01 was well tolerated with no series adverse events and no evidence of dorsal root ganglion toxicity. In February 2022, we reported meaningful developmental improvement in assessments, utilizing the Bayley III and Vineland II scales, performed by trained healthcare providers and caregivers, respectively, for both patients in the initial cohort. Additionally, in February 2022, we reported that we dosed our first patients in Cohort 2, for late onset infantile with high dose PBGM01, and Cohort 3, for early onset infantile GM1 with low dose PBGM01, with initial biomarker and safety data expected to be reported in the second half of 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The FDA has granted Orphan Drug Designation, or ODD, Rare Pediatric Disease Designation, or RPDD, and Fast Track Designation, to PBGM01 for the treatment of GM1. The European Commission has granted Orphan designation for PBGM01. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">PBFT02 for the treatment of FTD-GRN</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;">We are currently developing PBFT02, which utilizes an AAV1 capsid to deliver a functional copy of the granulin gene, or GRN, encoding for human progranulin, or PGRN, for the treatment of frontotemporal dementia caused by progranulin deficiency, or FTD-GRN. FTD-GRN is an inheritable form of FTD in which patients have mutations in the GRN gene, causing a deficiency in PGRN. PGRN is a complex and highly conserved protein thought to have multiple roles in cell homeostasis, neurodevelopment, and inflammation. Emerging evidence suggests that PGRN deficiency in FTD and other neurodegenerative disorders may contribute to lysosomal dysfunction. Currently, there are no disease-modifying therapies approved for the treatment of FTD-GRN. Based on findings in preclinical studies, we believe that PBFT02 may provide FTD-GRN patients with significantly improved outcomes. We selected the AAV1 capsid and ICM administration for PBFT02 because this approach led to extensive and robust expression of human PGRN throughout the brain and spinal cord of NHPs, and due to the higher PGRN levels in CSF using AAV1 as compared with other serotypes tested. ICM administration of AAV1 to NHPs resulted in CSF levels of human PGRN in excess of 50-fold higher than those in healthy human subjects&#8217; CSF, and in excess of 5-fold higher than levels achieved in NHPs with AAVhu68 or AAV5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBFT02, which allows us to proceed with our upliFT-D Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to dose the first patient in our initial cohort of our upliFT-D Trial in early 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA has granted ODD and Fast Track Designation to PBFT02 for the treatment of FTD-GRN and the European Commission granted Orphan designation for PBFT02. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">PBKR03 for the treatment of Krabbe disease</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently developing PBKR03, which utilizes a proprietary, next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for Krabbe disease. Krabbe disease is an autosomal recessive lysosomal storage disease caused by mutations in the GALC gene, which provides instructions for making an enzyme called galactosylceramidase, which breaks down certain fats, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">including galactosylceramide and psychosine. This results in the accumulation of galactolipids such as psychosine, resulting in widespread death of myelin-producing cells in the CNS and in the peripheral nervous system, or PNS. Without myelin, nerves in the brain and other parts of the body cannot transmit signals properly, leading to the signs and symptoms of Krabbe disease. We believe PBKR03 may provide patients with significantly improved outcomes. In preclinical models, we have observed meaningful transduction of both the CNS and other critical peripheral organs for Krabbe disease patients using our ICM method of administration in combination with our next-generation AAVhu68 capsid. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBKR03, which allows us to proceed with our GALax-C Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBKR03 in patients with a diagnosis of early infantile Krabbe disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 38.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to dose the first patient in our initial cohort of our GALax-C Trial in early 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA has granted ODD, RPDD, and Fast Track Designation to PKBR03, and the European Commission granted Orphan designation for PBKR03. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Research Programs</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_Hlk92890436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We have six programs in preclinical research stages under our license agreement with Penn: PBML04 for MLD, PBAL05 for ALS, PBCM06 for CMT2A and unnamed programs for Canavan disease, Parkinson&#8217;s disease and Huntington&#8217;s disease. PBML04 is in preclinical development for MLD, which is caused by mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA</i><span style="letter-spacing:0.25pt;"> gene. PBAL05 is targeting patients with ALS who have a gain-of-function mutation in the </span><i style="font-style:italic;letter-spacing:0.25pt;">C9orf72</i><span style="letter-spacing:0.25pt;"> gene. PBCM06 is in development for CMT2A, which is caused by a mutation in the </span><i style="font-style:italic;letter-spacing:0.25pt;">MFN2</i><span style="letter-spacing:0.25pt;"> gene. Our unnamed programs comprise of: a program to treat patients with an inherited form of Parkinson&#8217;s disease with PRKN mutations; a program for the treatment of Canavan&#8217;s disease, which is caused by mutations in the aspartyoacylase, or </span><i style="font-style:italic;letter-spacing:0.25pt;">ASPA</i><span style="letter-spacing:0.25pt;">, gene; and a program for the treatment of Huntington&#8217;s disease, a repeat expansion disorder. Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for eight additional new indications in CNS diseases along with rights and licenses to new gene therapy technologies developed by Penn, such as novel capsids, toxicity reduction technologies and delivery and formulation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have exploratory research programs with GTP for large indications, initially focused on AD and TLE, which can be expanded to other large CNS diseases upon mutual agreement with GTP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our Strategy</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are a genetic medicines company focused on developing transformative therapies for CNS disorders with limited or no approved treatment options. Our vision is to fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To achieve our vision, we have assembled a world-class team whose members have decades of collective experience in genetic medicines and rare disease drug development and commercialization. We leverage this experience, along with the decades of experience of Dr.&#160;Wilson, as well as the transformative potential of genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening CNS diseases. Patients are considered every step of the way, in every decision we make.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Key elements of our strategy include:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Focus on underserved indications for which we can have a transformative impact on patients&#8217; lives.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We believe that genetic medicine has the potential to have a transformative impact on CNS disorders, and on patients&#8217; lives, by providing them with a treatment for life-threatening diseases with limited or no approved disease-modifying treatments.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Rapidly advance our clinical product candidates through clinical development and commercialization.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We leverage our collaboration with GTP, as well as our internal capabilities, to </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">select optimal product candidates for each indication based on extensive preclinical data, including animal data and disease-specific animal models and biomarkers, thus enhancing the probability of clinical success of our product candidates. Our goal is to select candidates that have the potential to address high unmet clinical needs and have transformative therapeutic effects for patients. If our clinical trials are successful, we plan to meet with regulatory authorities to discuss expedited regulatory approval strategies.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Advance and expand our pipeline by identifying and developing additional product candidates into the clinic.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We believe our differentiated drug development approach as well as our internal and partnered research capabilities may allow us to address a broad range of CNS disorders, thus expanding our pipeline. Through our collaboration with GTP, we are continuing to develop additional genetic medicine product candidates targeting life-threatening CNS disorders. Beyond our three clinical product candidates, we have six additional products advancing through the research stage. We also have the option to license eight additional CNS indications from GTP until May 2026.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Extend existing and establish new relationships with patients and patient advocacy groups.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Patients are at the core of what we do. We have been engaging with them and with their advocacy groups since our inception, and have acquired an intimate understanding of how we can positively impact their lives. These relationships deeply inform us as we develop and ultimately seek to commercialize our product candidates. Our relationship with Penn&#8217;s ODC, which is currently performing a natural history study for GM1 that we are funding, represents an example of our strategy, and has been helping us to engage effectively with patients. We have a collaboration with Invitae to facilitate genetic testing and support early identification of GM1 and Krabbe disease through Invitae&#8217;s Detect Lysosomal Storage Disorders, as well as provide clinical trial information to physicians and patients, and have partnered with InformedDNA to offer free genetic counseling and testing for adults who have been diagnosed with FTD.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Continue to develop proprietary manufacturing capabilities.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We believe the quality, reliability and scalability of our genetic medicine manufacturing techniques and know-how will be a critical advantage to our long-term success. We currently have access to a state-of-the-art purpose-fit manufacturing suite through Catalent Maryland, a unit of Catalent Biologics, Inc., or Catalent. We expect this facility will be capable of producing supplies of our product candidates sufficient to conduct our clinical trials and potentially for initial commercial launch of our clinical product candidates, if approved. Catalent will also provide packaging, labeling and distribution services, including its FastChain&#174; demand led supply offering, which we believe is well suited to studies of advanced therapy medicinal products. We have invested in our own laboratory, which is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. We also expect to open a pilot plant manufacturing suite to provide scale-up capabilities in support of our product pipeline and future development plans by the end of 2022. We will continue to invest in developing our manufacturing capabilities and plan to establish our own manufacturing facility for long-term commercial supplies.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Selectively enter into new discovery relationships with premier research institutions and expand our existing collaboration.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We will continue to foster our well-established relationship with Penn, and potentially enter into new collaborations to build our pipeline. We will look to nurture our genetic medicine technology capabilities by keeping abreast of advances in next-generation capsid development, promoter selection, transgene design, gene silencing and gene editing, which will help us to engineer optimal product profiles to address life-threating CNS disorders characterized by high unmet medical needs.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Genetic Medicine Background</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Each person&#8217;s genetic material, or genome, consists of deoxyribonucleic acid, or DNA, in sequences of genetic code called genes. The DNA in the human genome contains approximately three billion nucleotide base pairs, and small changes, or mutations, routinely occur in the base pairs. A mutation in a single gene can alter the amount or activity of the protein expressed by the gene, causing deformities and disease. Currently, there are estimated to be over 10,000 diseases caused by a genetic abnormality in a single gene. These are also known as monogenic </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">diseases. Based on research commissioned by us, we believe there are at least 790 rare monogenic CNS diseases, with few currently approved disease modifying treatments for any rare monogenic CNS diseases.</span><span style="letter-spacing:0.2pt;"> </span>In addition, gene therapy can also be applied to correct biological pathways that are not necessarily inherited or associated with a defective gene. This approach aims to reduce the expression of pathological proteins or increase the production of corrective biological targets. This is the basis for the programs that target non-hereditary conditions such as sporadic AD and TLE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The development of molecular therapeutics to modulate human gene expression and correct disease-causing genetic defects had its advent several decades ago, and with advances in science and a deeper understanding of human genetics it has expanded to include a broader range of genetic medicines with the potential to modulate gene expression through additional molecular mechanisms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">These transformative genetic medicines include gene therapy (delivery of an external gene to replace a defective gene), gene silencing (delivery of a DNA or ribonucleic acid, or RNA, based therapeutic that modulates the transcription or translation of an injurious gene product), gene editing (delivery of a DNA or RNA-based therapeutic that corrects the expression of targeted genes) and combinations of these therapeutic modalities. We believe that this expanded molecular biological tool-box will provide new therapeutics with the potential to deliver highly potent and safe interventions across a diverse set of CNS diseases, offering several advantages, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Potential to treat most diseases of genetic etiology.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Theoretically, it should be possible to design and deliver a genetic medicine to correct the expression of any human protein whose presence, absence or activity causes disease.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Potential to target mechanisms that have not been effectively or safely modulated by traditional small molecule or protein-based therapeutics.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> The inherent specificity of genetic medicines for unique nucleic acid sequences can provide a high therapeutic index resulting from high potency and the potential to deliver adequate doses while avoiding off-target safety liabilities.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Efficient delivery of transformative therapeutics.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Because genetic medicines are designed to deliver a long-standing effect following a single administration, a single dose of these therapeutics has the potential to provide clinical benefits for many&#160;years.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"><a id="_Hlk94529398"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Genetic medicines can be designed to mitigate challenges faced by other approaches in the development of therapeutics for the CNS. CNS disorders are among the most devastating in their impact on patients and their families. These disorders are generally life-threatening to patients. There is a significant need for genetic medicines that can target these disorders. </span><span style="letter-spacing:0.25pt;">Our initial programs focus on rare, monogenic CNS disorders because they offer a compelling opportunity for the effective application of genetic medicines. In the year ended December 31, 2021, we exercised options under the Penn Agreement to include Canavan disease and Huntington&#39;s disease to our portfolio, and also amended the Penn Agreement to broaden the scope under the Penn Agreement to include large CNS disorders, and entered into exploratory research programs to identify gene targets and develop therapeutic AAVs </span><span style="letter-spacing:0.25pt;">for large CNS disorders, initially TLE and AD. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our Approach</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The field of genetic medicine is rapidly expanding and we believe we have developed a differentiated approach to developing treatments for CNS disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success. Our gene therapy product candidates use an AAV, a small, non-pathogenic virus that is genetically engineered to function as a delivery vehicle, or vector. In our current clinical programs, the AAV is administered to a patient to introduce a healthy copy of a mutated gene, or the transgene, to the cells in a process referred to as transduction.</span> Our current approaches use AAVs to deliver either a (i) replacement non-mutant transgene, or (ii) a combination of a microRNA, known as miRNA, and replacement of a non-mutant transgene. <span style="letter-spacing:0.25pt;">The components of an AAV gene therapy vector include the therapeutic gene that makes up the DNA payload, or the transgene, the outer viral shell that encloses the DNA payload, or the capsid, and any promotors added to the vector to boost expression of the transgene. The AAV is often described by the serotype, or strain, of the vector. The core tenets of our approach include a rigorous process for selecting product candidates, mitigation </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">of early development risk through relationships with leading researchers and academic institutions, and mitigation of clinical development risk through deep relationships with patient advocacy groups, key opinion leaders and practitioners. Together, these relationships allow us to directly benefit from decades of collective experience, the latest technologies and contemporary perspectives from patients and their experiences. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Rigorous Process for Selecting Product Candidates</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In selecting our product candidates, we focus initially on optimizing transduction and expression of transgenes in the indication-specific target tissues. This involves prioritizing the following principles: selection of the route of administration to maximize transgene biodistribution; selection of capsid, transgene and promoter to optimize efficiency of transduction and expression; leveraging biological mechanisms such as cross-correction to maximize availability of transgene product to target cells; and the effective use of biomarkers to assess treatment effects on transduction, transgene expression and on disease pathophysiology.</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Optimal route of administration:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Identifying the optimal route of administration for AAV gene therapy is critical to achieving safe and effective levels of transgene expression in the targeted location in the CNS. The optimal route of administration for CNS treatments should also leverage the immuno-privileged aspects of the CNS to reduce the potential effects of neutralizing antibodies, or NAbs, on AAV capsids, which are often faced by gene therapy product candidates. We will evaluate preclinical studies and other data to decide the preferred route of administration on a program-by-program basis. For our three clinical product candidates, we believe that ICM administration is the optimal route of administration as compared to other potential delivery mechanisms due to its diffuse delivery distribution, potential for improved biodistribution to the brain and spinal cord and transduction, and lower expected toxicity. Administration through ICM can also reduce the potential impact of NAbs as compared with intravenous administration. We believe that by using ICM we can achieve comparable protein expression at lower dosages than would be required by other administration routes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Capsid, transgene and promoter selection:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> For each of our programs, we conduct rigorous studies to select the capsid, transgene and promoter to use for our product candidate. We identify the optimal AAV gene therapy for each of our indications depending on the target indication, our goal of CNS and/or PNS transduction, and the target brain regions and cell types. Typically, we compare multiple capsids in NHPs to identify the capsid best suited for each program.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Cross-correction:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Our three clinical product candidates exploit the cross-correction mechanism by which secreted gene product from transduced cells is taken up by non-transduced neurons. We believe this cross-correction mechanism can help overcome the limits of vector biodistribution and CNS transduction inefficiency that are characteristic of other genetic medicine approaches, and ultimately drive clinical benefit.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Effective use of biomarkers:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Our development program targets must have measurable, predictive biomarkers to inform early and efficient clinical development decisions. These include pharmacodynamic biomarkers to confirm achievement of target levels of transduction and gene expression, and disease activity and progression biomarkers to confirm downstream effects on the underlying disease pathophysiology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Mitigation of Early Development Risk of Programs Prior to IND submission</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have a strategic research collaboration with GTP, which is led by our co-founder and Chief Scientific Advisor, Dr.&#160;Wilson, and which we believe positions us at the forefront of gene therapy research. This collaboration provides us with access to differentiated discovery technology and expertise that informs the basis of our product candidate selection and subsequent development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Our strategic research collaboration with GTP provides us with access until August 2026 to one of the premier gene therapy research institutes in the world for the discovery and preclinical development of gene therapy product candidates and exclusive rights to certain CNS disorders, including next-generation AAV capsid technology and vector engineering, and state-of-the art preclinical animal studies, including NHP models. GTP </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">currently employs approximately 300 staff with cutting edge expertise and capabilities in gene therapy research and preclinical development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our collaboration with GTP allows us to choose programs that have been or will be validated through extensive testing in preclinical disease models, and once selected, to collaborate with GTP on further preclinical optimization of our product candidate, such as vector choice, transgene construct and route of administration. We believe this collaboration improves our probability of technical and regulatory success in developing product candidates that provide transformative clinical benefits.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Once we select a particular CNS indication for further development, GTP, with our close involvement and oversight, embarks on a rational discovery and development program to design product candidates that may provide improved clinical benefit. We usually evaluate transduction efficiency and biodistribution using multiple different capsids in NHPs to select the capsid best suited for the targeted indication. GTP also works to optimize the delivery method used for each product candidate by balancing delivery, efficacy, safety, host immunity and ease of administration. We believe the translational preclinical characterization provided by GTP, including the use of NHP models for vector screening and toxicology, reduces the early-stage development risk of our product candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Mitigation of Clinical Development Risk through Our Relationship with Penn&#8217;s ODC</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have a strong relationship with Penn&#8217;s ODC. As part of our research collaboration with GTP, we have access to Penn&#8217;s ODC&#8217;s insights and capabilities in the study of rare diseases. We leverage our close working relationship with Penn&#8217;s ODC to develop historical and prospective external data for each disease for use in building comparable patient profiles of participants in interventional trials. In addition, we believe Penn&#8217;s ODC&#8217;s close ties to leading clinical centers for rare, monogenic CNS disorders will improve our ability to identify potential patients for trial enrollment, and enhance patient retention and data quality. Penn&#8217;s ODC is currently performing a natural history study for GM1 funded by us.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our Product Candidates</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">GM1&#8212;PBGM01</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Overview of GM1</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">GM1 is a rare and often life-threatening monogenic recessive lysosomal storage disease that results in progressive damage to both the CNS and the peripheral tissues. The infantile form of the disease is characterized by onset in the first two years of life with symptoms including hypotonia (reduced muscle tone), progressive CNS dysfunction leading to deafness, blindness, enlarged liver and spleen, rigidity and progressive skeletal dysplasia that leads to restrictive lung disease and aspiration pneumonia. Early onset infantile GM1, or Type I, is characterized by onset in the first six&#160;months of life, while late onset infantile GM1, or Type IIa, is characterized by onset between six and 24&#160;months. The disease rapidly progresses, with a life expectancy of less than two years for early infantile GM1 and five to ten years for late infantile GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">GM1 is caused by recessive mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1</i><span style="letter-spacing:0.25pt;"> gene, which encodes lysosomal acid &#946;-gal, an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside. Reduced &#946;-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressing neurodegeneration. GM1 manifests as a continuum of clinical severity, ranging from infants with earlier onset and more severe and rapidly progressive disease to those with later juvenile or adult onset, slower progression and less severe manifestations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The United States incidence of GM1 has been estimated to be approximately 1 in 100,000 live births, with infantile GM1 representing approximately 62.5% of such cases. No states include GM1 in mandatory infant screening. We engaged a third-party data-analytics firm to conduct an analysis of a variety of de-identified electronic medical records. </span>Based on this analysis, we estimate the incidence of infantile GM1 to be approximately 1.4 in 100,000 live births. <span style="letter-spacing:0.25pt;">Currently, there are no approved disease-modifying therapies available. Supportive treatment options include the use of feeding tubes or ventilators for infants with GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Program selection</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We chose GM1 as one of our initial lead programs because it met our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success that will substantially impact on the lives of severely underserved patients. </span>Several key factors supported the decision to focus on GM1 for AAV gene therapy, as described below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Cross-correction</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">: Following treatment with PBGM01, we expect</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> newly synthesized</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> functional </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">&#946;-gal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> will be secreted by transduced cells and provide a source of secreted proteins that could be taken up by surrounding non-transduced and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">wise enzyme-deficient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cells. This cellular cross-correction could therefore lead to enzyme replacement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> broad</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ly throughout the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> CNS and peripheral organ</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Biomarkers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">: There are known biomarkers in GM1 that are measurable and available to assist in drug development.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Pharmacodynamic biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> In our preclinical studies, biomarkers including &#946;-gal activity and hexosaminidase, or HEX, activity showed treatment-related effects in PBGM01-treated </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GLB1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> knockout mice. CSF collected at the time of necropsy showed &#946;-gal activity exceeding that of disease-free heterozygous control mice. &#946;-gal activity in the brains of PBGM01-treated </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GLB1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> knockout mice was similar to activity in normal control mice. Peripheral organs, including the heart, lungs, liver and spleen, also exhibited elevated &#946;-gal activity in PBGM01-treated mice.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Disease progression biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Recent MRI studies of infants with GM1 have shown longitudinal changes in MRI in infants with GM1 consistent with progressive brain atrophy and ventricular enlargement, suggesting that brain MRI would be a useful biomarker to detect and help verify treatment effects on disease pathophysiology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Preclinical validation:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We used the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GLB1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> knockout mouse disease model showing clinical, biologic and histological manifestations of GM1 in preclinical studies. In these studies, we observed a robust dose-related improvement in both neurological status, enzyme activity, histologic lysosomal storage pathology and survival following treatment with PBGM01.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Product Candidate Development Strategy</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have chosen the earliest and most severe form of GM1 for clinical development for several reasons. Within GM1, infantile GM1 represents the greatest medical need, as early onset GM1 infants often do not survive past two&#160;years, and thus are in immediate need of an effective therapy. We expect treatment-related efficacy to be measurable sooner after treatment in this more rapidly progressing form of GM1. Patients with onset forms of GM1 later than infantile, which we define as an onset later than 24 months, are caused by less severe reductions of &#946;-gal enzyme activity, generally demonstrate slower progression and more variable clinical courses, likely requiring larger and longer clinical trials and a broader control group. If our initial clinical trials in infantile GM1 are successful, we intend to explore expansion of the indication with trials in later onset forms of GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Product Candidate</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are developing PBGM01 to treat infantile GM1, with a single dose of PBGM01 by ICM administration. PBGM01 utilizes a next-generation AAVhu68 viral vector to deliver modified DNA encoding the &#946;-gal enzyme to a patient&#8217;s cells. The goal of this vector and delivery approach is to increase levels of the &#946;-gal enzyme in both the CNS and the peripheral tissues. We selected the AAVhu68 capsid and ICM route of administration due to the superior transduction observed in cells of the CNS and peripheral organs, which are both affected in GM1 disease patients. Based on prior capsid comparison studies, the AAVhu68 vector has the potential to provide corrective &#946;-gal enzyme to both the CNS and peripheral tissues, which we believe gives us the potential to treat both the CNS pathologies and the peripheral manifestations observed in GM1 disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We believe gene replacement with PBGM01 and consequent wide brain distribution and uptake of the &#946;-gal enzyme has the potential to greatly reduce the accumulation of GM1 gangliosides, reversing neuronal toxicity, thereby restoring developmental potential and improving the quality of life for treated patients. We will evaluate </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">this clinically by assessing the prevention of further developmental regression and restoration of developmental trajectories, as measured by developmental milestones using accepted clinical scales, observer-reported outcomes and video recordings.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Preclinical studies</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The potential for efficacy of PBGM01 is supported by preclinical findings in GLB1 knockout (</span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1-/-)</i><span style="letter-spacing:0.25pt;"> mice. This mouse line develops several characteristics that are reminiscent of the neurological presentation of GM1, including a rapid accumulation of GM1 ganglioside in the brain shortly after birth followed by progressive motor abnormalities and a shortened survival. Intracerebroventricular, or ICV, injection of PBGM01 in </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1-/-</i><span style="letter-spacing:0.25pt;"> mice resulted in persistent dose-dependent elevations in &#946;-gal activity in the brain, CSF, serum, and in peripheral organs. Increased &#946;-gal activity was associated with phenotypic and histopathological benefits in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1-/-</i><span style="letter-spacing:0.25pt;"> mice including the resolution of pre-existing brain lysosomal storage lesions as assessed by lysosomal associated membrane protein 1, or LAMP-1, immunohistochemistry, improved neurological phenotypes in assays of clinical deficits and animals&#8217; gait, and increased survival. Preclinical findings were published by GTP in 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">NHP Toxicology Study </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A 120-day good laboratory practice, or GLP, compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBGM01 following ICM administration of vehicle or one of three dose levels of PBGM01. There were no blood or CSF abnormalities related to PBGM01 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals. PBGM01 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs. Vector distributed to the CSF and high levels of gene transfer were detected in the brain, spinal cord and dorsal root ganglia, or DRG. PBGM01 also reached high levels in peripheral blood and liver. PBGM01vector DNA was detectable in urine and feces five days post-administration and was undetectable within 60 days. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Measurement of transgene expression by &#946;-gal enzyme activity in CSF and serum of NHPs was limited by the nature of the assay, which could not distinguish human &#946;-gal enzyme versus endogenous rhesus enzyme. Rapid loss of transgene product activity after Day 14, which was likely due to an antibody response to the human transgene product, was an additional limitation. Despite these caveats &#946;-gal activity in the CSF and serum was detectable in animals from all dose groups 14 days after administration of PBGM01. In the CSF, animals receiving the two higher doses displayed &#946;-gal activity levels that were approximately two- and four-times higher than vehicle-treated control levels. Pre-existing NAbs to the vector capsid were detected in the serum of some animals and did not appear to influence gene transfer to the brain and spinal cord, or transgene product levels in the CSF. This observation supports the potential to achieve therapeutic activity in the CNS in infantile and late infantile patients with GM1 regardless of NAb status. Pre-existing NAbs to the vector capsid correlated with reduced gene transfer in the liver, however.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk96593016"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">PBGM01 administration resulted in asymptomatic degeneration of the DRG and the trigeminal ganglia, or TRG, sensory neurons and their associated central and peripheral axons. The severity of these lesions was typically minimal to mild. These findings were not clearly dose-dependent, although there was a trend of more severe lesions in the mid-dose and high dose cohorts. DRG and TRG lesions were less severe at Day 120 than Day 60, indicating they were not progressive. Two animals that exhibited the most severe axon loss and fibrosis of median nerves at necropsy on day 120 also exhibited impairments in nerve conduction in terms of reduced sensory nerve action potential, or SNAP, amplitudes in the median nerve. Reductions in SNAP amplitudes were evident by Day 28 with no subsequent progression. This observation was consistent with the findings of a retrospective analysis of DRG pathology in NHPs after AAV administration conducted by GTP. In an analysis of five preclinical studies, increased severity of axonopathy and fibrosis correlated with reduced SNAP amplitudes. In keeping with the findings of the retrospective analysis, the PBGM01</span><span style="letter-spacing:0.25pt;">-induced SNAP changes and sensory neuron degeneration were not associated with any clinical or neurological abnormalities in any animals up to 120 days post-dose</span><span style="letter-spacing:0.25pt;">.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:160.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In summary, based on our preclinical studies we believe that CSF delivery of PBGM01 has the potential to sufficiently increase b-gal levels in both the CNS and in peripheral tissues to overcome intracellular b-gal deficiency in GM1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our clinical development plan is to start with trials in infantile GM1, and if successful, explore expansion of the indication with trials in later onset forms of GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We initiated patient dosing in a multi-center, open-label, single-arm Phase&#160;1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1 in March 2021. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The<span style="letter-spacing:0.25pt;"> study</span> includes both<span style="letter-spacing:0.25pt;"> early and late infantile patients in separate, smaller cohorts. We plan to enroll a total of four cohorts of two patients each, with separate dose-escalation cohorts for late onset infantile GM1 patients</span>, defined as<span style="letter-spacing:0.25pt;"> onset prior to </span>24<span style="letter-spacing:0.25pt;">&#160;months in age</span> and after 6 months in age,<span style="letter-spacing:0.25pt;"> and early onset infantile GM1</span>, defined as onset prior to 6 months of age<span style="letter-spacing:0.25pt;">. </span>The study is assessing<span style="letter-spacing:0.25pt;"> </span>an initial<span style="letter-spacing:0.25pt;"> </span>low <span style="letter-spacing:0.25pt;">dose </span>(3.3x10&#708;10 genome copies/gm brain weight) <span style="letter-spacing:0.25pt;">that exceeds the </span>minimum effective dose, or <span style="letter-spacing:0.25pt;">MED, as determined in our preclinical studies, and a 3-fold greater high dose</span> (1.1x10&#708;11 genome copies/gm brain weight).<span style="letter-spacing:0.25pt;"> The first cohort </span>includes<span style="letter-spacing:0.25pt;"> patients diagnosed with late infantile GM1</span>.<span style="letter-spacing:0.25pt;"> There </span>is<span style="letter-spacing:0.25pt;"> a 60-day interval between </span>all <span style="letter-spacing:0.25pt;">subjects dosed within a cohort to allow review of biomarker and safety data before dosing the next subject. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We completed enrollment of the first cohort of two patients with late infantile GM1 receiving the initial low dose of PBGM01 in the second half of 2021 and reported interim safety and biomarker data in December 2021<span style="letter-spacing:0.25pt;">. </span>The interim assessment included safety and biomarker results covering six months for patient 1 and 60 days for patient 2. PBGM01 was well tolerated, with a positive safety profile, no serious adverse events, or SAEs, no complications related to ICM administration and no evidence of DRG toxicity. <span style="letter-spacing:0.25pt;">&#946;-gal </span>activity in CSF and serum increased in both patients. For patient 1, enzyme activity at 30 days was 1.5-fold over baseline and the increase was maintained at six months. For patient 2, enzyme activity at 30 days was 4.8-fold over baseline. In serum, enzyme activity for patient 1 was slightly above baseline at 30 days, 1.7-fold over baseline at three months, and maintained at six months. Serum enzyme activity for patient 2 at 30 days was 1.2-fold over baseline. CSF and serum <span style="letter-spacing:0.25pt;">&#946;-gal </span>activity for both patients rose above the enzyme concentrations documented in untreated infantile and juvenile GM1 participants in the ODC&#8217;s natural history study. Large differences were observed in GM1 gangliosides in CSF at baseline, with patient 2, who was more severely affected, showing baseline values four times higher than patient 1. In patient 1, CSF levels of GM1 ganglioside increased approximately 85 percent at 30 days and remained stable at that level at six months. In patient 2, levels decreased approximately 46 percent at 30 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;">GM1 Cohort 1 interim data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="pasg-20211231x10k007.jpg" alt="Chart, scatter chart&#10;&#10;Description automatically generated" style="display:inline-block;height:160.35pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:463.22pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><img src="pasg-20211231x10k008.jpg" alt="Graphic" style="display:inline-block;height:24.4pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:154.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Following the completion of this first cohort and review of safety outcomes, the Independent Data Monitoring Committee, or IDMC, recommended continuing the study with the recruitment for both the high dose late infantile GM1 and the initial dose early infantile GM1 cohorts. The first patient in each of those two cohorts was dosed in early 2022 and we anticipate reporting initial data from these cohorts in the second half of 2022. Upon completion of the initial low dose of the early infantile cohort, a high dose cohort is planned to be enrolled in that patient population. Following these dose-escalation cohorts, each patient population will be enrolled into a confirmatory cohort. Patients will be evaluated over two&#160;years for safety and efficacy, followed by an additional 36&#160;months of long-term follow up. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We expect that pre-specified primary endpoints will include safety and efficacy. Efficacy will be evaluated by the assessment of developmental milestones using accepted clinical scales, observer-reported outcomes and video recordings. Secondary outcomes will include serum and CSF &#946;-gal enzyme activity and disease progression endpoints including evaluations using EEG and MRI. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In February 2022, we reported meaningful developmental improvement in assessments, utilizing the Vineland-II and Bayley-III scales, for both patients in the initial cohort, as outlined below. These validated scales for assessing gross motor, fine motor, language and social development have been used previously in natural history studies. The Vineland-II determines developmental milestones through structured interviews with caregivers, while the Bayley-III assesses developmental milestones through direct observation of skills by a trained healthcare professional. Both assessments demonstrated progressive gains across all developmental areas which is not typical for children with GM1 late infantile. Notably, patient 2, more severely affected at baseline than patient 1, was also documented to have regained previously lost motor and language developmental milestones.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;">Interim Clinical Results: Vineland-II and Bayley-III: Patient 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pasg-20211231x10k009.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:154.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:480.46pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;">Interim Clinical Results: Vineland-II and Bayley-III: Patient 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pasg-20211231x10k010.jpg" alt="Chart&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:152.44pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:473.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Depending on the results from the dose escalation cohorts we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Natural History Data</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are currently funding a GM1 natural history study being conducted by Penn&#8217;s ODC to collect prospective data on clinical disease progression in infantile and juvenile GM1. This data will be used to construct natural history patient profiles for comparison to the profiles of treated participants in our planned Phase&#160;1/2 clinical trial.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Regulatory Designations and Clinical Trial Approvals </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBGM01, and we are actively proceeding with our Imagine-1 Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The FDA has granted Orphan Drug Designation, or ODD, Rare Pediatric Disease Designation, or RPDD, and Fast Track Designation, to PBGM01 for the treatment of GM1. The European Commission has granted Orphan designation for PBGM01. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Through our manufacturing partners, we have manufactured the PBGM01 clinical supply and have established a clinical supply chain to support global clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">FTD&#8212;PBFT02</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Overview of FTD-GRN</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">FTD is one of the more common causes of early-onset dementia, occurring with a median age of 55 years. FTD presents as a rapidly progressive clinical syndrome and causes impairment in behavior, language and executive function. Changes in personal and social conduct occur in early stages of the disease, including loss of inhibition, apathy, social withdrawal, hyperorality and ritualistic compulsive behaviors. These symptoms are severely disabling and may lead to misdiagnosis as a psychological or emotionally based problem, or, in the elderly, be mistaken for withdrawal or eccentricity. FTD progresses to immobility and loss of speech and expression. Survival averages eight&#160;years after onset of symptoms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In approximately 5% to 10% of individuals with FTD, the disease is caused by mutations in the granulin, or </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN,</i><span style="letter-spacing:0.25pt;"> gene, causing a deficiency of progranulin. PGRN is a complex and highly conserved protein thought to have multiple roles in cell biology, development and inflammation. Emerging evidence suggests that PGRN&#8217;s pathogenic contribution to FTD and other neurodegenerative disorders relates to a critical role in lysosomal function.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">There are no disease modifying therapies approved for the treatment of FTD. Anti-depressants have been shown to manage some behavioral symptoms. We engaged a third-party data-analytics firm to conduct an analysis of a variety of de-identified electronic medical records. Based on this analysis, we estimate the prevalence of FTD in the United States to be approximately 62,000. The prevalence of FTD due to </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> mutation found in literature is 5% to 10%. Accordingly, we estimate the prevalence of FTD-GRN deficiency in the United States to be approximately 3,000 to 6,000.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Program selection</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We chose FTD-GRN as one of our initial lead programs because it meets our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Cross-correction:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Following treatment with PBFT02, we believe overexpressing PGRN in a subset of cells in the CNS could provide a source of secreted protein that could be taken up by surrounding cells, resulting in the potential for cross-correction and broad restoration of neuronal lysosomal function across the entire brain.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Biomarkers:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> There are known biomarkers in FTD-GRN that are measurable and available to assist in drug development.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Pharmacodynamic biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> PGRN is a secreted protein that can be measured in the CSF and plasma, and it has been shown to be reduced in the CSF of human </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GRN</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> mutation carriers.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Disease progression biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We expect to be able to use recent progress in the identification of clinical disease progression biomarkers for FTD, including CSF, neuroimaging and retinal biomarkers, to facilitate clinical development by enabling early detection of treatment effects on disease pathophysiology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Preclinical Validation:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> In our preclinical studies in </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GRN</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> knockout mice, or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GRN -/- </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">mice, ICV administration of PBFT02 resulted in increased levels of PGRN in the CNS and CSF, with resolution of lysosomal storage lesions. ICM administration in NHPs, which do not have the disease phenotype, resulted in robust increases in PGRN levels in CNS and CSF.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Product Candidate</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are developing PBFT02 to treat patients affected with FTD-GRN with a single dose of PBFT02 by ICM administration. PBFT02 is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> gene to a patient&#8217;s cells. The goal of this vector and delivery approach is to provide higher than normal levels of PGRN to the CNS to overcome the progranulin deficiency in </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> mutation carriers, who have been observed to have reduced CSF PGRN levels ranging from 30% to 50% of the PGRN levels observed in normal, mutation non-carriers. We selected the AAV1 capsid and ICM administration route due to the widespread and robust expression of the human PGRN transgene observed throughout the brain and spinal cord in NHP studies, and because levels of human PGRN in the CSF exceeded those measured in healthy human CSF (greater than 50 times), and those in NHPs that received AAV5 or AAVhu68 serotypes (greater than 5 times). </span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Preclinical studies</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">PBFT02 was selected as our development candidate based on initial proof-of-concept studies utilizing AAVhu68 and follow-up studies comparing multiple vector constructs for ability to elevate PGRN. The initial proof-of-concept studies using an AAVhu68.hGRN construct in </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> knockout </span><i style="font-style:italic;letter-spacing:0.25pt;">(GRN -/-)</i><span style="letter-spacing:0.25pt;"> mice showed PGRN elevations and improved lysosomal function after vector doses that elevated CSF PGRN to approximately 10-fold over levels in healthy human controls and decreased deposits of lipofuscin, an electron dense marker of lysosomal dysfunction, broadly across the brain. The AAV1 capsid was selected for PBFT02 following a study that evaluated the expression of human PGRN protein in the CSF of adult NHPs after ICM administration of four different vector constructs. Proof of concept findings were published by GTP in 2020. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The comparison of AAVs in NHPs is shown in the figure below. NHPs received a single ICM administration of commensurate doses of AAV1, AAV5, or AAVhu68 expressing the human </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> transgene with a CAG promoter (n=2/group). A second tested AAVhu68 vector, or v2, utilized a different </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> coding sequence and a UBC promoter. We found that the production of PGRN protein in the CSF </span>rapidly <span style="letter-spacing:0.25pt;">exceeded levels found in healthy human control samples (&#8220;normal&#8221; line) in all </span>AAV-<span style="letter-spacing:0.25pt;">treated NHPs</span><span style="white-space:pre-wrap;">. AAV1 produced 50 times normal and greater than 5-10 times all other vectors tested.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comparison of Vector Serotypes:</b> <b style="font-weight:bold;">Production of Human PGRN-protein in CSF of NHPs following ICM-AAV administration.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="pasg-20211231x10k011.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:206.74pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:278.3pt;" /> <img src="pasg-20211231x10k012.jpg" alt="Diagram, schematic&#10;&#10;Description automatically generated" style="display:inline-block;height:99.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:91.86pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Lower limit of quantitation, or LLOQ; Healthy human control level, or Normal</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe PBFT02 has the potential to provide supra-physiological levels of progranulin available to neurons broadly throughout the brain, restoring lysosomal function and thereby slowing or stopping the progression of FTD pathogenesis. Further, ICM AAV1 did not strongly transduce the liver or significantly elevate levels of circulating PGRN, which may reduce the potential for unknown peripheral effects of PGRN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk96012713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The efficacy of the AAV1 vector was assayed in <i style="font-style:italic;">GRN -/-</i><span style="white-space:pre-wrap;"> mice. PBFT02 was administered via ICV delivery to adult mice at an age when lipofuscin deposition, lysosomal enzyme abnormalities, and neuroinflammation were present in brain regions involved in FTD-GRN pathophysiology including the frontal cortex, hippocampus, and thalamus. This stage of disease progression was selected to be consistent with the developmental stage of the intended patient population of young to middle-aged adult. Dose-dependent increases in human PGRN expression in the CSF following PBFT02 administration led to the correction of histopathologic and enzymatic changes in the mice. Benefits included a reduction in the accumulation of lipofuscin, reduced neuroinflammation, and elevated lysosomal hexosaminidase activity in key brain regions.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">NHP Toxicology Study </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk96589806"></a><a id="_Hlk96589261"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A 90-day GLP compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBFT02 following ICM administration at three dose levels. There were no blood or CSF abnormalities related to PBFT02 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals</span><span style="letter-spacing:0.25pt;">. </span><span style="letter-spacing:0.25pt;">PBFT02 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs. Vector distributed to the CSF and high levels of gene transfer were detected in the brain, spinal cord and DRG at Day 90. PBFT02 also reached significant concentrations in the peripheral blood, liver and spleen. PBFT02 </span><span style="letter-spacing:0.25pt;">vector DNA was detectable in urine and feces 5&#160;days post-administration and was undetectable within 60&#160;days. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Human PGRN was detectable in CSF and serum in all animals by 7 to 14&#160;days after PBFT02 administration, peaking between Days 14 to 28, and was generally dose dependent. Expression declined in all PBFT02-treated animals by Day 60, correlating with the appearance of antibodies against the human transgene product, which are </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">not expected to develop in haploinsufficient patients with FTD-GRN. ICM PBFT02 administration to NHPs resulted in approximately 15-times higher PGRN levels in CSF than in CSF from healthy humans, while the low dose of PBFT02 resulted in approximately 7-times higher PGRN levels. Pre-existing NAbs to the vector capsid were detected in the serum of 2 of 9 AAV-treated animals at baseline but did not appear to influence gene transfer to the brain and spinal cord, although their presence correlated with reduced hepatic gene transfer. We believe that these data support the possibility of achieving supraphysiological PGRN levels in the CNS of FTD patients following ICM administration of PBFT02. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">PBFT02 resulted in asymptomatic degeneration of DRG and TRG sensory neurons (8 of 9 AAV-treated animals), along with their associated central and peripheral axons (9 of 9 animals) at Day 90 post-administration. The severity of these lesions was typically minimal to mild, with a trend to more severe lesions in the mid-dose and high-dose groups. One PBFT02-treated animal exhibited a peripheral nerve conduction impairment in the median nerve, as detected by bilateral reductions in SNAP amplitudes on Day 28 and Day 90, that appeared to be treatment related as severe axon loss and endoneurial fibrosis were detected at necropsy. PBFT02-induced SNAP changes and sensory neuron degeneration were not associated with any clinical or neurological abnormalities in animals up to 90 days post-dose.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In summary, based on our preclinical studies we believe that CSF delivery of PBFT02 has the potential to sufficiently increase extracellular PGRN levels in the CNS to overcome intracellular PGRN deficiency, without greatly increasing peripheral PGRN levels.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Our clinical development plan is to treat FTD-GRN with a single dose of PBFT02 via ICM administration, with our initial clinical trial focused on early symptomatic FTD patients who have the </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> mutation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to dose the first patient in our initial cohort of our upliFT-D Trial in early 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">&#8203;<span style="letter-spacing:0.25pt;">This trial is expected to be a two-cohort dose-escalation trial, with three subjects per cohort, and with a potential for a third higher-dose cohort,</span> if considered necessary based on the results of the first two cohorts<span style="letter-spacing:0.25pt;">. The planned starting dose </span>(3.3x10&#708;10 genome copies/gm brain weight) <span style="letter-spacing:0.25pt;">will exceed the MED in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> knockout mouse model, with planned escalation to a higher dose </span>(1.1x10&#708;10 genome copies/gm brain weight)<span style="letter-spacing:0.25pt;white-space:pre-wrap;">. The primary endpoint of the trial is to assess safety and tolerability over 60 months. Secondary endpoints are to assess change from baseline to 24 months on biomarkers, including CSF and plasma progranulin levels, biomarkers of neurodegeneration and disease progression, and on clinical outcomes as measured by the Clinical Dementia Rating, or CDR&#174;, for improving evaluation of patients with frontotemporal lobar degeneration, or FTLD, or CDR&#174; plus NACC FTLD, and other neurocognitive assessments.  Interim analyses are planned for certain biomarkers starting at one month post dosing and for clinical outcomes beginning at one year post dosing.  The independent data monitoring committee, or IDMC, will review 30-day biomarker data and safety data for each subject in a cohort. All subjects will be followed for a total of five years to monitor safety and selected biomarker and efficacy measures. All subjects will be evaluated over two&#160;years for safety and efficacy, followed by an additional 36&#160;months of long-term follow up.</span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A scientific advice meeting with MHRA was held in November&#160;2020, providing feedback on our proposed protocol. Feedback was also obtained from other regulatory agencies outside the United States.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Depending on the results from the initial cohorts, we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.3pt;">Regulatory designations and Clinical Trial Approvals</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBFT02, which allows us to proceed with our upliFT-D Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The FDA has granted ODD and Fast Track Designation to PBFT02 for the treatment of FTD-GRN and the European Commission granted Orphan designation for PBFT02. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Through our manufacturing partners, we have manufactured the PBFT02 clinical supply to support clinical trial initiation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Krabbe disease&#8212;PBKR03</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Overview of Krabbe disease</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Krabbe disease is a rare and often life-threatening lysosomal storage disease that presents early in the patient&#8217;s life, resulting in progressive damage to both the brain and PNS. Infants may present with extreme irritability and excessive crying, feeding difficulties, fisted hands, poor head control, stiffness and arching. The early infantile form of Krabbe disease typically manifests before six&#160;months of age and is the most severe form, accounting for 60% to 70% of Krabbe disease diagnoses. In these patients the disease course is highly predictable and rapidly progresses to include loss of acquired milestones, staring episodes, apnea, peripheral neuropathy, severe weakness, unresponsiveness to stimuli, seizures, blindness, deafness and death by two&#160;years of age. Late infantile patients present symptoms that are similar to those of early infantile Krabbe disease, with a median survival of approximately five&#160;years from onset of symptoms. Late infantile Krabbe disease is defined by onset between seven to twelve&#160;months of age. It comprises approximately 10% to 30% of cases and exhibits greater variability in clinical presentation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Krabbe disease is an autosomal recessive lysosomal storage disease caused by mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GALC</i><span style="letter-spacing:0.25pt;"> gene, which provides instructions for making an enzyme called galactosylceramidase, which breaks down certain fats, including galactosylceramide and psychosine. The myelin-producing cells in the CNS and PNS are particularly sensitive to the accumulation of psychosine, resulting in widespread death of these cell populations. Without myelin, nerves in both the brain and other parts of the body cannot transmit signals properly, leading to the signs and symptoms of Krabbe disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;white-space:pre-wrap;">There are currently limited treatment options for patients with Krabbe disease. While human stem cell transplant, or HSCT, has become standard of care in many centers in the US for early infantile Krabbe patients who are pre-symptomatic or who have mild symptoms, it has limited use outside the US and is a treatment with limitations.  Most HSCT-treated children still have progressive gross motor delays ranging from mild spasticity to inability to walk independently, and limited use of their upper extremities. There is also a narrow window of treatment and a donor must be identified. When performed after the onset of overt symptoms in these patients, HSCT provides only minimal neurologic improvement and does not substantially improve survival.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Currently, ten states conduct mandatory screening for Krabbe disease and an additional four states passed legislation to include Krabbe disease in mandatory screening, but such screening has not yet been added. We engaged a third-party data analytics firm to conduct an analysis of screening data from six states with screening history available to our third-party data analytics firm and based on this evaluation of screening data, we believe the incidence of Krabbe disease to be approximately 2.6 in 100,000 births.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Program Selection</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We chose infantile Krabbe disease as one of our initial lead programs because we believe we can develop product candidates with a higher probability of technical and regulatory success. The indication presents cross-correction, biomarker data and preclinical validation that are supportive of advancing treatments for Krabbe disease into the clinic.</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Cross-Correction:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Following treatment with PBKR03, newly synthesized galactosylceramidase is expected to be secreted by transduced cells and provide a source of secreted protein that could be taken up by surrounding cells, resulting in the potential for cross-correction and broad CNS and PNS enzyme replacement.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Biomarkers:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> There are known biomarkers in Krabbe disease that are measurable and available to assist in drug development.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Pharmacodynamic biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> GALC activity has been shown to be reduced in patients with Krabbe disease and can be measured in CSF and plasma. Psychosine levels are also measurable and elevated in patients with Krabbe disease. We will measure these biomarkers in CSF and plasma to assess the efficiency of transduction and restoration of GALC activity by PBKR03.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Disease progression biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We will leverage a number of neuroimaging, electrophysiological and fluid biomarkers to assess treatment effects on disease progression, including CNS myelination as measured by diffusion-tensor MRI, nerve conduction velocity, or NCV, to assess peripheral nerve myelin and conduction, and visual and brain stem-evoked potentials to assess CNS myelination and conduction.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Preclinical validation:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> In preclinical studies in a mouse model of Krabbe disease, CSF delivery of PBKR03 resulted in GALC expression levels in the CNS that rescued motor function and improved survival. CSF delivery in mice also reduced peripheral nerve demyelination and globoid cell infiltration.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Product Candidate</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are developing PBKR03 to treat infantile Krabbe disease, the most common and severe form of Krabbe disease. PBKR03 utilizes a next-generation AAVhu68 capsid to deliver DNA encoding the GALC enzyme to a patient&#8217;s cells. PBKR03 will be administered as a single dose by ICM administration into the CSF.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The AAVhu68 capsid and ICM route of administration were selected for PBKR03 due to observations in preclinical studies of robust transduction of targeted cells in the brain, and in DRG sensory neurons and spinal cord lower motor neurons. Consequently, we believe that ICM PBKR03 has the potential to improve both the CNS pathologies and the significant peripheral neuropathies observed in many Krabbe disease patients. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Preclinical studies </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our Krabbe clinical program for PBKR03 is supported by robust pre-clinical proof of concept and pharmacology data in a naturally occurring GALC mutant mouse line, or Twitcher mice, in dogs with spontaneous GALC mutations, and in wildtype NHPs. Preclinical data were presented by GTP in 2020 to the American Society of Gene &amp; Cell Therapy&#8217;s, or <span style="letter-spacing:0.25pt;white-space:pre-wrap;">ASGCT, 24th Annual Meeting and by us in 2021 at the 3rd Annual Gene Therapy for Neurological Disorders Congress.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">To assess dose-dependent effects of PBKR03 in Twitcher mice, vector was administered via ICV delivery at the age of onset of peripheral demyelination. PBKR03 dose-dependently improved histopathological, biochemical, and clinical disease signs. The outcomes included increased GALC activity in the brain, serum, and in peripheral organs, which was associated with a significant reduction in histopathological markers of peripheral nerve damage including demyelination and globoid cell infiltration. Related functional improvements included reductions in clinical symptoms as assessed by scores of neurological decline and improvements in motor balance, coordination, and activity. PBKR03 administration to Twitcher mice also prevented the onset of lymphopenia, which often accompanies autonomic axon degeneration and significantly extended survival. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A preclinical study in Krabbe-affected dogs, or Krabbe dogs, evaluated treatment with an AAVhu68 vector containing a codon-optimized canine GALC cDNA, or vehicle, administered directly to the CSF using ICM administration. Krabbe dogs express naturally occurring autosomal recessive mutations in the GALC gene that result in residual enzymatic activity close to 0%, which is similar to GALC activity levels observed in patients with the infantile form of Krabbe disease. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk96358661"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Four Krabbe dogs received a single ICM administration of PBKR03 at two to three weeks of age, while two age-matched Krabbe dogs and one wildtype dog received vehicle by the same route </span><span style="letter-spacing:0.25pt;">and served as controls. AAV administration led to significant improvements in outcome measures in the Krabbe dogs. The two vehicle-treated Krabbe dogs reached the study&#8217;s pre-defined humane endpoint of severe hind limb weakness and inability to stand and walk on Study Day 35 or Day 66, consistent with the rapidly progressing natural history of the disease. In contrast, all of the four PBKR03-treated dogs maintained normal motor function for the duration of the study, and none reached the pre-defined humane endpoint associated with hindlimb weakness. Two of the AAV-treated </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">dogs were euthanized at the scheduled necropsy timepoint of 28 weeks, and the remaining two were euthanized at 39 and 82 weeks of age, respectively. One treated dog was euthanized following a suspected seizure at 39 weeks. Prior to seizure, the animal exhibited normal phenotype including normal motor function. Another of the AAV-treated dogs was euthanized at 82 weeks of age due to body weight loss following recurrent vomiting and regurgitation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">AAV-treatment elevated CSF GALC enzyme activity to above baseline levels by 28&#160;</span><span style="letter-spacing:0.25pt;white-space:pre-wrap;">days post-treatment in all dogs and maintained activity above that in vehicle-treated wildtype dog levels for the duration of the study, including up to 82 weeks in the longest-lived animal. The pathological impact of GALC elevations was assessed by measuring the accumulation of the GALC substrate psychosine in CSF. In the absence of GALC in Krabbe disease the cytotoxic substrate psychosine accumulates in the nervous system  affecting oligodendrocytes and Schwann cells, leading to progressive demyelination. Psychosine was undetectable in the CSF of vehicle-treated wildtype dogs from Day 0 through Day 180 post treatment. In the vehicle-treated Krabbe dogs, while psychosine was undetectable in the CSF at baseline (Day 0), levels were elevated in both animals by Day 28 and increased further prior to their humane endpoints. Elevations in psychosine correlated with the onset and progression of neurological symptoms in the vehicle-treated Krabbe dogs. In contrast, psychosine was undetectable at most time points for all four AAV-treated Krabbe dogs.   In the histological analysis, both vehicle-treated Krabbe dogs showed demyelination and globoid cell infiltration in the brain, spinal cord and peripheral nerves at post-mortem. In contrast, all four AAV-treated Krabbe dogs showed no evidence of demyelination or globoid cell infiltration in the spinal cord, and reduced levels of each in the brain and in peripheral nerves.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;white-space:pre-wrap;">AAV treatment also resulted in functional improvements in the Krabbe dogs. In vehicle-treated Krabbe dogs, NCV in sensory and motor nerves was markedly impaired at the earliest assessment age of 6 weeks. In contrast,  in AAV-treated dogs, NCVs were similar to those in the wildtype control dog for the duration of the study, assessed up to 81 weeks of age in the longest-surviving dog. Since hearing loss is common during Krabbe disease progression, animals&#8217; hearing thresholds were evaluated by the Brainstem Auditory Evoked Response, or BAER, test. One vehicle-treated Krabbe dog had a severe hearing impairment by 6 weeks of age with no determinable hearing threshold (&gt; 90 dB), while the other vehicle-treated Krabbe dog was not hearing-impaired with a threshold similar to that in the wildtype dog. All the treated Krabbe dogs had hearing thresholds similar to the vehicle-treated wildtype dog for the duration of the study, up to 81 weeks of age in the oldest dog.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In clinical pathology assessments, three AAV-treated Krabbe dogs presented with a mild and transient lymphocytosis two weeks post-injection. This finding was considered possibly treatment-related as it was not observed in the vehicle-treated Krabbe or wildtype animals. It was not considered adverse due to the low grade of elevation and its transient nature. No vector-related modifications of coagulation parameters or serum clinical chemistry were detected. Two AAV-treated Krabbe dogs presented transient mild CSF mononuclear pleocytosis 4 weeks post-injection. This finding was vector-related and was not considered adverse as it resolved by 10 weeks post-injection and was not accompanied by any neurological signs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">NHP Toxicology Study </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk96935663"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A 180-day GLP compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBKR03 following ICM administration at three dose levels. There were no blood or CSF abnormalities related to PBKR03 administration except for </span><span style="letter-spacing:0.25pt;">asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals</span><span style="letter-spacing:0.25pt;">. PBKR03 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs. PBKR03 vector DNA was detectable in urine and feces 5&#160;days post-administration, and was undetectable in urine within 60&#160;days and in feces within 90 days in the majority of animals. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Human GALC expression, as measured by enzyme activity, was evaluated in CNS tissues and major organs of the AAV-treated NHPs, however detection was limited by the inability of the assay to distinguish between human and rhesus GALC activity and the high endogenous activity in NHPs. Measurements were feasible in NHP CSF and serum, however, due to substantially lower endogenous GALC activities. GALC activity was elevated in CSF and serum by 7 days after PBKR03 administration. After the two higher doses, animals had CSF GALC activities </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">about 2-times higher than vehicle-treated animals. In serum, GALC activity was increased approximately 2-times (low dose) to 6.6-times (high dose) over activity in vehicle-treated animals. A rapid decline in serum GALC activity was observed after Day 14, which correlated with the onset of anti-human GALC antibody expression around Days 14 to 21. The presence of pre-existing NAbs to the vector capsid in the serum of 11 of 18 AAV-treated animals did not appear to impact GALC activity in the serum or CSF, supporting the potential to achieve therapeutic transgene expression in Krabbe patients regardless of NAb status.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">PBKR03 administration resulted in asymptomatic degeneration of primarily DRG sensory neurons along with their associated central and peripheral axons by Day 90 post-administration. The severity of the lesions was typically minimal to mild, with a trend to more severe lesions in the mid-dose and high-dose groups. DRG lesions did not progress between Day 90 and Day 180. One animal in the high dose group exhibited a unilateral nerve conduction impairment in a median nerve, as detected by reduced SNAP amplitude on Day 28 and Day 90, that appeared to be treatment related as median nerve axonopathy and endoneurial fibrosis were detected at necropsy. PBKR03-induced SNAP changes and sensory nerve degeneration were not associated with any clinical or neurological abnormalities in any animals up to 180 days post-dose.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In summary, based on our preclinical studies we believe that CSF delivery of PBKR03 has the potential to sufficiently increase GALC levels in both the CNS and in peripheral tissues to overcome intracellular GALC deficiency in Krabbe disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our clinical development plan is to start with trials in early infantile Krabbe disease, and if successful, consider further exploration of expansion of the indication with trials in later onset forms of Krabbe disease. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We expect to dose the first patient in our initial cohort of our GALax-C Trial in early 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We believe that gene replacement with PBKR03 has the potential to have </span>meaningful clinical benefit to Krabbe patients by<span style="letter-spacing:0.25pt;"> significantly reducing neuronal demyelination and damage in both the CNS and PNS that results from the accumulation of galactolipids, such as galactocerebroside and psychosine. We will measure clinical benefit by assessing developmental using accepted clinical scales, observer-reported outcomes and video recordings.</span><span style="letter-spacing:0.2pt;"> </span>&#8203;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We intend this trial to have two independent dose escalation cohorts (three subjects per dose) based on age at enrolment: dosing initially in subjects </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&gt;</span><span style="letter-spacing:0.25pt;"> 4 and </span>&lt; <span style="letter-spacing:0.25pt;">9 months of age, with dose escalation and initiation of dosing in subjects </span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&gt;</span><span style="letter-spacing:0.25pt;"> 1 and </span>&lt; <span style="letter-spacing:0.25pt;">4 months of age gated by safety in cohort 1. Planned starting doses for each cohort will exceed the MED in the twitcher mouse model, </span>starting with an initial low dose of 1.5 x 10&#708;11 GC/g estimated brain weight<span style="letter-spacing:0.25pt;"> with planned escalation to a high dose </span>of 5.0 x 10&#708;11 GC/g estimated brain weight<span style="letter-spacing:0.25pt;">, followed by a third confirmatory cohort </span>using a dose selected on the basis of results from previous cohorts<span style="letter-spacing:0.25pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The primary endpoint of the trial is to assess safety and tolerability over 60 months. Secondary endpoints are to assess change from baseline to 24 months on biomarkers, including CSF and plasma GALC activity and psychosine, and biomarkers of disease progression, and on clinical outcomes, as assessed using by the Bayley Scale of Infant and Toddler Development, and other developmental scales. Interim analyses are planned for certain biomarkers starting at one month post dosing. All subjects will be evaluated over two years for safety and efficacy, followed by an additional 36 months of long-term follow up.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In collaboration with Penn&#8217;s ODC, we are also currently planning to develop comparator data sets for our Krabbe clinical trial. Clinical understanding of Krabbe disease has been summarized in several case studies and natural history studies.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Based on the results from this Phase&#160;1/2 trial, we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Regulatory Designations</i><i style="font-style:italic;letter-spacing:0.2pt;"> and Clinical Trial Approvals </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBKR03, which allows us to proceed with our GALax-C Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBKR03 in patients with a diagnosis of early infantile Krabbe disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA has granted ODD, RPDD, and Fast Track Designation to PKBR03, and the European Commission granted Orphan designation for PBKR03. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Through our manufacturing partners, we have manufactured PBKR03 clinical supply to support clinical trial initiation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Trigeminal Ganglia and Dorsal Root Ganglia Toxicity</span><span style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The primary finding of the NHP toxicology studies for each of PBGM01, PBFT02 and PBKR03 was TRG and DRG toxicity with consequent peripheral and spinal cord axonopathy. These findings have been previously reported as an AAV platform risk based on NHP studies in which minimal to mild DRG toxicity was observed within 14 to 30&#160;days after dosing, without clinical manifestations. Chronic studies examining DRG toxicity have revealed no increase in severity and no clinical manifestations at four to six&#160;months or up to four&#160;years after administration. Similarly, no clinical manifestations were observed in any animals on detailed neurological examinations or daily observations in the PBGM01 and PBFT02 toxicology studies.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We believe the asymptomatic sensory neuron findings observed in NHPs treated with AAV vectors via the ICM administration route likely represent a universal DRG pathology in NHPs administered AAV gene therapy. Published data have shown that the administration of AAV vectors to NHPs via the blood or CSF can lead to damage of dorsal root ganglia and their associated axons. Similar findings were observed following IV administration of an engineered variant of AAV9. More recently, a meta-analysis of 33 non-clinical studies in 256 NHPs evaluated the severity of DRG pathology for five different capsids, five different promoters, and 20 different transgenes including an AAV9 vector expressing antibodies 170&#160;days after ICM administration, while also comparing different ROAs, doses, time courses, study conduct, animal age, and sex. This meta-analysis showed that mostly minimal to moderate asymptomatic DRG pathology characterized by mononuclear cell infiltrates, neuronal degeneration, and secondary axonopathy of central and peripheral axons were observed for all capsids and promoters tested, including 83% of NHPs administered AAV intrathecally and 32% of NHPs administered AAV intravenously. DRG pathology was absent prior to 14&#160;days post administration, was similar from 1-5&#160;months post-injection, and was less severe after 6&#160;months. The transgene appeared to have the greatest impact on the severity of the sensory neuron pathology, suggesting that transgene overexpression drives the early events leading to neuronal degeneration. Higher AAV doses correlated with increased severity. Infant and juvenile NHPs appeared to exhibit less severe pathology compared to adult NHPs. Animal sex and vector purification method had no impact. Sensory nerve conduction studies detected abnormalities in a minority of animals correlating with a greater severity of peripheral nerve axonopathy. For most studies, it was not possible to identify a no-observed-adverse-effect-level above the MED. To date, the NHP studies examining DRG toxicity have revealed no clinical manifestations at four to six&#160;months or up to four&#160;years after administration.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To better understand the clinical significance of these findings, we plan to implement clinical monitoring in our GM1, FTD and Krabbe disease interventional trials, consisting of both nerve conduction studies and neurological exams focused on sensory and peripheral nerve function.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">GTP has recently published data on certain technology regarding microRNA-mediated inhibition of transgene expression reduces DRG toxicity by AAV vectors. We plan to work with GTP to evaluate the appropriateness of incorporating this technology into our research programs, but do not expect to incorporate this early-stage technology into our current three clinical programs for GM1, FTD or Krabbe. We have access to this technology as part of our collaboration with GTP, whereby we have access to novel capsids, toxicity reduction technologies and delivery and formulation improvements.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">MLD - PBML04</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview of MLD &#8211; PBML04</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">MLD is a monogenic autosomal recessive sphingolipid storage disease caused by mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA</i><span style="letter-spacing:0.25pt;"> gene encoding the lysosomal enzyme arylsulfatase A, or ARSA. Reduced ARSA activity leads to the progressive build-up of toxic sulfatides in neurons and glia in the central and peripheral nervous systems.&#160;Neuronal cell death ensues with subsequent loss of motor and cognitive function, which is more severe and progresses faster in patients with early disease. We are targeting infantile-onset MLD, which is characterized by progressive muscle weakness, rigidity and gait abnormalities, developmental delays, and is typically fatal by 5 years of age. Estimations of worldwide prevalence of infantile-onset MLD vary within the range of 1 in 40,000 to 1 in 160,000 live births. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Product Candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We are developing PBML04, an AAVhu68 capsid expressing codon-optimized human </span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA</i><span style="letter-spacing:0.25pt;">, for ICM administration to increase the expression of ARSA in the CNS and periphery. We expect to submit an IND application in mid-2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">PBML04 preclinical preliminary efficacy studies utilized a novel mouse strain developed using CRISPR/Cas9 gene deletion, by GTP in conjunction with Jackson Labs, which was presented at the 2021 ASGCT conference. </span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA</i><span style="letter-spacing:0.25pt;"> -/- mice develop a phenotype that recapitulates aspects of MLD from 9-10 months of age, including clinical deficits such as weight, balance, coordination, and gait deficiencies, sulfatide accumulation in central and peripheral neurons, lysosomal abnormalities, and increased neuro-inflammation. In a preclinical study PBML04 treatment restored depleted ARSA activity in the brain and periphery. In a 15 month-long study comparing three doses of PBML04 administered via ICV, functional improvements were shown in </span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA</i><span style="letter-spacing:0.25pt;"> -/-, mice including significant improvements in an assessment of clinical motor performance and health, or the Neuroscore assay. Further, while only 5 out of 10 of vehicle-treated </span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA</i><span style="letter-spacing:0.25pt;"> -/- mice survived to the study endpoint 15 months post-treatment, all 30 PBML04-treated mice, which represents 10 per dose group, survived at the study end. We are in the process of completing analysis on additional endpoints.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">ARSA-/- Mouse Neuroscore</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">As shown in the figure below, four to five-month-old&#160;</span><i style="font-style:italic;letter-spacing:0.25pt;">ARSA -/-</i><span style="letter-spacing:0.25pt;"> mice or&#160;wildtype control&#160;mice were enrolled and scored on five parameters of clinical health and performance at baseline and at monthly intervals thereafter for 15 months. The groups approximated to baseline age of five months for graphing. The Neuroscore assay reflected the cumulative extent of impairment, generated by summing deficit scores of none to severe in five different parameters, including, posture, tremor, hind-limb clasping, gait and mobility, and grooming. Maximum possible cumulative score was 17. On Day 0&#160;mice&#160;received PBML04 at one of three doses, which were low, medium, or high, or a vehicle control (n = 10 per group). </span>Data points show mean&#160;Neuroscores&#160;with standard error of&#160;the&#160;mean.&#160;Wildtype mice showed little decline in Neuroscore assay up to 20 months of age, while vehicle-treated ARSA-/- mice showed a progressive decline over<span style="letter-spacing:0.25pt;"> the 15-month study. Onset and rate of decline in cumulative score was delayed and less severe in PBML04-treated ARSA-/- mice, and high dose-treated mice showed the least decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:274.36pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="pasg-20211231x10k013.jpg" alt="Graphic" style="display:inline-block;height:274.36pt;width:469.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">*** p &lt; 0.001, statistically significant difference compared with vehicle-treated <i style="font-style:italic;">ARSA</i>-/- mice (mixed effect model).</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Abbreviations:&#160; KO, <i style="font-style:italic;">ARSA</i>-/- knockout mouse;&#160;WT, wildtype mouse; LD,&#160;low dose; MD, mid dose; HD,&#160;high dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Other Research Programs</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have five additional programs in candidate selection or discovery stages of preclinical research, in collaboration with GTP. These include PBAL05 for ALS, PBCM06 for CMT2A, and our unnamed programs for Canavan disease, Parkinson&#8217;s disease and Huntington&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview of C9orf72 ALS - PBAL05</i><i style="font-style:italic;letter-spacing:0.25pt;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">C9orf72-mediated Amyotrophic Lateral Sclerosis, or C9orf72 <span style="letter-spacing:0.25pt;">ALS, is an adult-onset, rapidly progressing neurodegenerative disease characterized by dysfunction and death of upper and lower motor neurons leading to progressive weakness, loss of motor function, and death typically within three to five years of disease onset. Most cases of ALS are sporadic with an unknown etiology, but approximately 10% of patients have autosomal dominantly inherited forms. We are focusing on C9orf72-mediated ALS, since mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">C9orf72</i><span style="letter-spacing:0.25pt;"> gene are the most common mutation found in ALS patients including both familial (approximately 40% of familial ALS cases) and sporadic ALS cases (approximately 8% of sporadic ALS patients carry C9orf72 mutations), accounting for approximately 11% of all ALS cases. In 2020, prevalence of C9orf72 mutations were estimated to affect approximately 5,000 ALS patients worldwide. In these cases, the disease is caused by a hexanucleotide repeat expansion in the first intron of C9orf72. The pathogenic mechanism of C9orf72 mutations is not yet proven, but three potential mechanisms predominate, which are toxic gain of function arising from deposition of transcribed atypical dipepetide repeat proteins, and/or deposition of mutant ribonucleic acid, or RNA, and/or loss of function of endogenous proteins.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Our approach is to use a single AAV vector to deliver a miRNA and a codon-optimized miRNA-resistant C9orf72 transgene combination, to both deplete normal and mutant mRNA within cells with the miRNA and to replace with functional wildtype human transgene. </span>Preclinical pilot data showed that AAV-C9miRNA normalized elevated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">toxic poly(GP) dipeptide repeat protein levels in mouse brains with a mutation in the C9-ALS&#160;gene. <span style="letter-spacing:0.25pt;">This program is currently at the discovery stage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview of CMT2A - PBCM06</i><i style="font-size:12pt;font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">CMT2A is a sensory and motor neuropathy caused by mutations in the gene encoding the mitochondrial protein mitofusin-2, or MFN2. MFN2 is a GTPase that localizes to the outer mitochondrial membrane where it regulates mitochondrial fusion and mitochondrial binding to membranes of the endoplasmic reticulum. CMT2A may present in childhood or adulthood, with progressive distal limb weakness, muscle atrophy, and loss of sensation. Clinically, the classic form of CMT2A is characterized by physical weakness, foot deformities, difficulty in walking, and areflexia. After early childhood onset, however, loss of ambulation by adulthood is common. The worldwide prevalence is estimated to be approximately 1 in 100,000. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our approach is to use a single AAV vector to deliver a miRNA and a codon-optimized miRNA-resistant MFN2 transgene combination, to both deplete normal and mutant mRNA within cells with the miRNA and to replace with a functional wildtype human transgene. </span>Preclinical pilot data identified lead construct that ameliorates distal limb weakness (grip strength) after ICV delivery in mice with a mutation in the <i style="font-style:italic;">MFN2</i>&#160;gene. <span style="letter-spacing:0.25pt;">This program is currently at the discovery stage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Unnamed Research Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">With GTP we have three additional discovery stage preclinical programs, to develop genetic medicines for rare neurodegenerative disorders. One, initiated in 2021, is a pediatric program to treat children with the inherited leukodystrophy Canavan&#39;s disease. The other two programs address adult populations, one targeting a familial form of Parkinson&#39;s disease, and the other, which was also initiated in 2021, to treat Huntington&#39;s disease. Programs are currently in discovery stages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for eight additional indications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Exploratory Research Programs</i><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have an exploratory research program with GTP with the goal to develop genetic medicines for non-rare CNS disorders, initially focused on AD and treatment-resistant TLE, which can be expanded to other large CNS diseases upon mutual agreement with GTP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Manufacturing</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Gene therapy manufacturing is a critical factor in the successful development and commercialization of novel genetic medicines, and to that end, we have established a relationship with Catalent, a contract development and manufacturing organization, or CDMO, for our initial manufacturing needs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our gene therapy manufacturing strategy utilizes a production platform approach with HEK293 mammalian cells as the substrate, triple plasmid transient transfection and single-use fixed-bed iCELLis&#174; bioreactor system for the manufacture of our AAV product candidates. We are using a well-characterized production platform that has been used for both commercial and clinical AAV products and product candidates. We believe our approach will enable rapid development, control of product quality and regulatory compliance. Catalent has extensive experience with the iCELLis&#174; bioreactor platform and HEK293 transient transfection gene therapy manufacturing. As part of our research collaboration with GTP, we have access to broad and deep early-stage process science capabilities and experience to enable technology transfer of scalable processes to our CDMO, and state-of-the art analytical capabilities for product quality testing and analytical characterization. GTP currently provides us with the preclinical and toxicology research-grade vector supplies, while Catalent provides us with the cGMP AAV clinical supplies for our clinical trials. The production process for GM1, Krabbe, FTD and MLD has been scaled up to GMP standards at Catalent&#8217;s facility and clinical materials for these candidates have been or are being manufactured.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We have a collaboration agreement with Catalent, or the Collaboration Agreement, </span>that gives us access to a dedicated manufacturing suite<span style="letter-spacing:0.25pt;">. We initiated cGMP manufacturing in the dedicated suite, giving us the ability to </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">meet production requirements for our current clinical product candidates through clinical studies and early commercialization. We believe that our platform manufacturing approach along with the dedicated manufacturing capabilities and capacity provide a core strategic advantage and positions us to be a leading drug development company to address CNS disorders.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for our gene therapy product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We entered into a lease to support chemistry, manufacturing and controls laboratory operations for our gene therapy programs, which commenced in March 2021 in Princeton West Innovation Campus. In 2021, we completed our build out of this new laboratory that is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We believe that our manufacturing capabilities provide us with the advantages of better control of drug development timelines, improved control of vector supply for a portfolio of clinical assets and improved control of product quality through the improvements of the manufacturing platform.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also expect to open a pilot plant manufacturing suite at the Princeton West Innovation Campus to provide scale-up capabilities in support of our product pipeline and future development plans by the end of 2022. We will continue to invest in developing our manufacturing capabilities and plan to establish our own manufacturing facility for long-term commercial supplies.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also anticipate that we will continue to make significant investments to further optimize our manufacturing capabilities and platforms to produce high-quality, cost-effective AAV vectors and we will continue to make investments in process and analytical sciences, internally or with third parties, to evaluate and develop manufacturing process improvements that may increase the productivity and efficiency of our manufacturing platform processes.</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_Hlk92891219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Competition</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The biotechnology and pharmaceutical industries, including the genetic medicines field, are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property. We are aware of several companies focused on developing gene therapies in various indications as well as several companies addressing methods for modifying genes and regulating gene expression. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions with genetic medicine and other therapeutic approaches.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We consider our most direct competitors with respect to PBGM01 for the treatment of GM1 to be Sio Gene Therapies, Inc., or Sio, and Lysogene, S.A, or Lysogene. Sio is conducting its clinical trial for an IV gene therapy treatment for early and late infantile/juvenile GM1 and reported data from ten patients in October 2021. Lysogene, as of February 2022, reported having dosed three patients and enrolled a fourth patient in the safety cohort, after which Lysosgene will initiate treatment of twelve patients in the efficacy confirmatory cohort of its Phase 1/2 clinical trial for a gene therapy treatment administered via intracisternal magna for early and late infantile GM1. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We consider our most direct competitors with respect to PBFT02 for the treatment of FTD-GRN to be Alector, Inc. (partnered with GlaxoSmithKline), which is enrolling a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, and Prevail Therapeutics Inc. (now part of Eli Lilly &amp; Co), which has initiated a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN, and is expected to continue enrolling through 2023. Several other companies, including Applied Genetic Technologies Corporation, Orchard Therapeutics plc, AcuraStem Inc. and Shape Therapeutics Inc., are conducting preclinical research using gene therapy approaches to treat FTD-GRN patients. Denali Therapeutics Inc. in partnership with Takeda Pharmaceutical Company Limited has a preclinical recombinant progranulin protein under evaluation in addition to their oral EIF2a modulator in a Phase 1 clinical trial. We are also aware of other therapeutic approaches in preclinical development that may target FTD-GRN patients.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We consider our most direct competitor with respect to PBKR03 to be Forge Biologics Inc., which has an active clinical trial evaluating a Krabbe gene therapy candidate that combines bone marrow transplant and gene therapy. In addition, Neurogene Inc. has a gene therapy in pre-clinical development for Krabbe. We are also aware of other therapeutic approaches in preclinical development and an ongoing natural history study being conducted by the Children&#8217;s Hospital of Pittsburgh and certain academic studies for Krabbe disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally, new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">License Agreement</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">University of Pennsylvania</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We have a research, collaboration and licensing agreement, as amended, or the Penn Agreement, with Penn, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, we have the obligation to fund certain research relating to the preclinical development of selected rare, monogenic products in research programs as well as the new exploratory research program in non-rare and/or non-monogenic, or large, CNS indications, initially AD and TLE. We also fund discovery research conducted by Penn through August 2026, and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. Our discovery research funding commitment is $5.0 million annually, paid in quarterly increments of $1.3 million through June 30, 2026. Under the Penn Agreement, we have eight remaining options available to us to commence additional licensed programs for CNS indications until May 2026. If we were to exercise any of these remaining options, we would owe Penn a non-refundable upfront fee of $1.0&#160;million, with $0.5 million per product indication paid immediately and another $0.5 million fee owed upon achievement of a further developmental milestone. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.25pt;">The Penn Agreement requires that we make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, we are obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Upon successful commercialization of a product using the licensed technology, we are obligated to pay to Penn, on a licensed-product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, we are obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period. At any time after August&#160;2026, we may terminate the agreement in its entirety, or for a licensed product, for convenience upon 90&#160;days&#8217; prior written notice to Penn. Penn may terminate the agreement on an indication-by-indication basis if we fail to meet any diligence event and fail to timely cure such breach, or the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">agreement in its entirety if we fail to pay the research funding, fail to comply with applicable laws, grant a security interest in any of the licensed patent rights, fail to achieve certain financing obligations, or make certain challenges to the licensed patent rights. Either party may terminate the agreement for the other party&#8217;s insolvency or material breach that is not cured within a specified period of time. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We entered into an amendment, or the Amendment, to the Penn Agreement, on August 3, 2021. Under the Amendment, we expanded the scope of the collaboration to include certain non-rare and/or non-monogenic, or large, CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications; included an exploratory research collaboration to identify targets and early product candidates in such large CNS indications; and extended the term to August 3, 2026 by which product candidates for CNS indications may be selected for the entire agreement. The exploratory research program is focused on discovering targets and novel gene therapy candidates for large CNS diseases, initially focused on AD and TLE, and that can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is 3 years, which term can be extended by mutual agreement. During such term we will have an exclusive right of first negotiation to include additional targets to the exploratory research program in the agreed upon large CNS indications. Under the exploratory research program, we will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within AD and TLE (and any future large CNS indications that are mutually agreed upon) that arise from the exploratory research programs on substantially the same terms of the current Penn Agreement. The election of any option to any such product candidates will count against our remaining eight options and will trigger the aggregate $1.0 million option fee. As a result, we now will fund discovery research through August 3, 2026, and will now have until August 3, 2026 to exercise our remaining eight options. We made an upfront payment of $5.0 million; will reimburse Penn for expenses incurred in the exploratory research program; and will pay Penn a tiered transaction fee ranging from 1-2% of the net proceeds upon certain change of control events.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Penn will notify us of any patented manufacturing methods developed by GTP during the specified research term, and we have the option to obtain a non-exclusive license under those patent rights controlled by Penn for our licensed products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">On a CNS indication-by-indication basis, Penn has agreed that GTP will not collaborate with any commercial third party to develop another gene therapy product for the same indication during, or for one year following, its work for us on a given indication and licensed product. Under the licensed Penn patent rights, Penn retains the right to conduct (and to authorize non-commercial third parties to conduct) certain educational, research, clinical and patient care activities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Under the Penn Agreement, we are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product for each of the licensed indications for prophylactic, diagnostic and therapeutic uses in humans. We may satisfy this obligation by achieving, for each licensed product, certain diligence events by a specified achievement date, which dates may be extended under certain circumstances. Pursuant to the agreement, Penn will be responsible for preclinical development activities, including all IND-enabling non-clinical studies and research grade manufacturing, and other collaborative activities set forth in the plan for the funded research, and we will be responsible for regulatory strategy and operations, clinical development, GMP manufacture and commercialization of all licensed products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Intellectual Property</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary and/or intellectual property protection in the United States and other countries for our current product candidates and future products, as well as our core technologies, including our manufacturing know-how. We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business by seeking, maintaining and defending our intellectual property, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy. Additionally, we intend to rely on regulatory protection afforded through rare drug designations, data exclusivity and market exclusivity as well as patent term extensions, where available.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Currently, our patent protection consists of patent applications that we have in-licensed from Penn under the Penn Agreement for our product candidates in our licensed indications. The in-licensed patent applications are directed to new AAV capsids and certain defined variants, to recombinant AAV viruses, or rAAVs, capable of delivering certain genes into human cells to treat monogenic diseases of the CNS, to methods of treating those monogenic diseases with rAAV, as well as certain aspects of our manufacturing capabilities and related technologies. Our in-licensed patent portfolio currently includes:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">a patent family with applications pending in the United States and certain foreign jurisdictions with claims directed to rAAVs having an AAVhu68 capsid. We exclusively licensed the patent family for licensed products within our rare, monogenic field of use indications. Any patents that may issue from applications in this family are expected to expire on February&#160;27, 2038, absent any term adjustments or extensions;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to an rAAV containing a coding sequence of human &#946;-gal for use in treating GM1. The first patent family includes pending applications in twenty-three jurisdictions, including the U.S., Argentina, Brazil, Canada, China, Europe, Israel, India, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on September&#160;30, 2039, absent any term adjustments or extensions. The second patent family includes applications pending in Argentina, Pakistan, and Taiwan and a pending Patent Cooperation Treaty, or PCT, application. Based on the PCT filing, national and regional patent applications may be filed in the United States and over 150 foreign jurisdictions. Any patents that may issue from applications in this family are expected to expire on February&#160;1, 2041;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to rAAV for use in treating Krabbe. The first patent family includes pending applications in twenty-one jurisdictions, including the U.S., Argentina Brazil, Canada, China, Europe, Israel, India, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on February&#160;26, 2040, absent any term adjustments or extensions. The second patent family includes applications pending in Argentina, Pakistan, and Taiwan and a pending PCT application. Any patents that may issue from applications in this family are expected to expire in May&#160;11, 2041;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to rAAV for use in treating FTD. The first patent family includes applications pending in twenty one jurisdictions, including the US, Argentina Brazil, Canada, China, Europe, Israel, India, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on February&#160;21, 2040, absent any term adjustments or extensions. The second patent family includes applications in Argentina and Taiwan and a pending PCT application. Any patents that may issue from applications in this family are expected to expire in August&#160;2041;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to rAAV for use in treating MLD. The first patent family includes applications pending in twenty four jurisdictions, including the US, Argentina Brazil, Canada, China, Europe, Israel, India, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on May 4, 2040. The second patent family includes one pending unpublished U.S. provisional patent application. Any patents that may issue from applications in this family are expected to expire in January 2043, absent any term adjustments or extensions</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one patent family with claims directed to rAAV for use in treating ALS. The patent family includes </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">one pending unpublished U.S. provisional patent application. Any patents that may issue from applications in this family are expected to expire in January 2043, absent any term adjustments or extensions.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have options under the Penn Agreement to add additional intellectual property to our existing license, as described in the section &#8220;License Agreement&#8221;. To date, we have exercised an option with respect to Charcot-Marie Tooth disease, or CMT, </span>Canavan disease, Parkinson&#8217;s disease, and Huntington&#8217;s disease<span style="letter-spacing:0.25pt;">. At present, there are two patent families directed to these newly licensed indications:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to rAAV for use in treating CMT. The first patent family includes a pending PCT application and applications pending in Argentina and Taiwan. Any patents that may issue from applications in this family are expected to expire in July&#160;13, 2041, absent any term </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">adjustments and extensions.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;white-space:pre-wrap;"> The second patent family includes two pending unpublished U.S. provisional patent applications.  </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">Any patents that may issue from applications in this family are expected to expire in September 2042. </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The term of individual patents may vary based on the countries in which they are obtained. Generally, patents issued from applications filed in the United States are effective for 20&#160;years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of FDA regulatory review period. The restoration period cannot be longer than five&#160;years and the total patent term, including the restoration period, must not exceed 14&#160;years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective national filing date.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In addition to patents and patent applications that we license, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, significant aspects of our AAV manufacturing capabilities and gene therapy technology are based upon trade secrets and know-how. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, and obtain and maintain control and/or ownership of certain technologies, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how, including by implementing measures intended to maintain the physical security of our premises and the physical and electronic security of our information technology systems.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. With respect to our licensed intellectual property, we cannot be sure that patents will issue with respect to any of the pending patent applications to which we license rights or with respect to any patent applications that we or our licensors may file in the future, nor can we be sure that any of our licensed patents or any patents that may be issued in the future to us or our licensors will be commercially useful in protecting our product candidates and methods of manufacturing the same. Moreover, we may be unable to obtain patent protection for certain of our product candidates generally, as well as with respect to certain indications. See the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Government Regulation and Product Approval</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">FDA Approval Process</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDC Act, except the section of the FDC Act which governs the approval of New Drug Applications, or NDAs. Biological products, such as gene therapy products, are approved for marketing under provisions of the Public Health Service Act, or PHSA, via a Biologics License Application, or BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Biological product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational biologic to subjects, including healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with Good Clinical Practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial subjects. The trial protocol and informed consent information for subjects in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions if it believes that the subjects are subject to unacceptable risk.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&#160;1, the initial introduction of the biologic into subjects, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible. Phase&#160;2 usually involves trials in a limited patient population to determine the effectiveness of the drug or biologic for a particular indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase&#160;2 evaluations, Phase&#160;3 trials are undertaken to obtain additional information about clinical effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug or biologic and to provide adequate information for the labeling of the product. In most cases, the FDA requires two adequate and well-controlled Phase&#160;3 clinical trials to demonstrate the safety and efficacy of the drug or biologic. In rare instances, including instances of gene therapies intended for rare diseases, a single Phase&#160;3 trial may be sufficient </span><span style="letter-spacing:0.2pt;">when either (1) the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) the single trial is supported by other confirmatory evidence. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In addition, the manufacturer of an investigational drug in a Phase&#160;2 or Phase&#160;3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing and distribution of the product may begin in the United States. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee. Under an approved BLA, the applicant is also subject to an annual program fee. These fees typically increase annually. A BLA for a drug that has been designated as an orphan drug is not subject to an application fee, unless the BLA includes an indication for other than a rare disease or condition. The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the Agency&#8217;s determination that it is adequately organized and sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals to complete the review of BLAs. Most applications are classified as Standard Review products that are reviewed within ten&#160;months of the date the FDA accepts the BLA for filing; applications classified as Priority Review are reviewed within six&#160;months of the date the FDA accepts the BLA for filing. A BLA can be classified for Priority Review when the FDA determines the biologic product has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process for both standard and priority reviews may be extended by the FDA for three or more additional&#160;months to consider certain late-submitted information, or information intended to clarify information already provided in the BLA submission.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA may also refer applications for novel biologic products, or biologic products that present difficult questions of safety or efficacy, to be reviewed by an advisory committee&#8212;typically a panel that includes clinicians, statisticians and other experts&#8212;for review, evaluation, and a recommendation as to whether the BLA should be approved. The FDA is not bound by the recommendation of an advisory committee, but generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the product unless compliance with cGMPs is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe, pure, potent and effective in the claimed indication.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">After the FDA evaluates the BLA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the BLA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six&#160;months depending on the type of information included. An approval letter authorizes commercial marketing and distribution of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#8217;s safe use, or ETASU. An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved BLA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Additional Standard for Gene Therapy Products</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. FDA has issued various guidance documents regarding gene therapies, which outline additional factors that FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. For instance, FDA usually recommends that sponsors observe all surviving subjects who receive treatment using gene therapies that are based on adeno-associated virus vectors in clinical trials for potential gene therapy-related delayed adverse events for a minimum 5-year period. FDA does not require the long-term tracking to be complete prior to its review of the BLA.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Orphan Drug Designation</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biological products intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a product available in the United States for such disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the biological product and its potential orphan disease use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for a particular active moiety to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product in the approved indication. For large molecule drugs, including gene therapies, sameness is determined based on the principal molecular structural features of a product. As applied to gene therapies, the FDA has recently issued final guidance in which it stated it generally intends to consider certain key features, such as the transgenes expressed by the gene therapy and the vectors used to deliver the transgene, to be principal molecular structural features. With regard to vectors, the FDA generally intends to consider whether two vectors from the same viral class are the same or different on a case-by-case basis. The FDA does not intend to consider minor differences between transgenes and vectors to be different principal molecular structural features. When two gene therapy products express the same transgene and have or use the same vector, determining whether two gene therapies are the same drug may also depend on additional features of the final gene therapy product, such as regulatory elements and the cell type that is transduced (for genetically modified cells). In such cases, the FDA generally intends to determine whether two gene therapy products are different on a case-by-case basis. During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market a biological product containing the same principal molecular structural features for the same indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A product can be considered clinically superior if it is safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same biological product for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA user fee.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Rare Pediatric Disease Priority Review Voucher Program</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Under the Rare Pediatric Disease Priority Review Voucher program, the FDA may award a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a rare pediatric disease. The voucher entitles the sponsor to priority review of one subsequent marketing application. A voucher may be awarded only for an approved rare pediatric disease product application. A rare pediatric disease product application is an NDA or BLA for a product that treats or prevents a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18&#160;years; in general, the disease must affect fewer than 200,000 such individuals in the U.S.; the NDA or BLA must be deemed eligible for priority review; the NDA or BLA must not seek approval for a different adult indication (i.e., for a different disease/condition); the product must not contain an active ingredient that has been previously approved by the FDA; and the NDA or BLA must rely on clinical data derived from studies examining a pediatric </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">population such that the approved product can be adequately labeled for the pediatric population. Before NDA or BLA approval, the FDA may designate a product in development as a product for a rare pediatric disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To receive a rare pediatric disease priority review voucher, a sponsor must notify the FDA, upon submission of the NDA or BLA, of its intent to request a voucher. If the FDA determines that the NDA or BLA is a rare pediatric disease product application, and if the NDA or BLA is approved, the FDA will award the sponsor of the NDA or BLA a voucher upon approval of the NDA or BLA. The FDA may revoke a rare pediatric disease priority review voucher if the product for which it was awarded is not marketed in the U.S. within 365&#160;days of the product&#8217;s approval. The voucher, which is transferable to another sponsor, may be submitted with a subsequent NDA or BLA and entitles the holder to priority review of the accompanying NDA or BLA. The sponsor submitting the priority review voucher must notify the FDA of its intent to submit the voucher with the NDA or BLA at least 90&#160;days prior to submission of the NDA or BLA and must pay a priority review user fee in addition to any other required user fee. The FDA must take action on an NDA or BLA under priority review within six&#160;months of receipt of the NDA or BLA.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher program was reauthorized as part of the Consolidated Appropriations Act, 2021 allowing a product that is designated as a product for a rare pediatric disease prior to September 30, 2024 to be eligible to receive a rare pediatric disease priority review voucher upon approval of a qualifying NDA or BLA prior to September 30, 2026. It is unclear whether this program will continue to be reauthorized beyond the current sunset date in September 2024.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Fast Track Designation and Priority Review</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Breakthrough Therapy Designation</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA is also required to expedite the development and review of biological products that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the biologic product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The sponsor of a new biologic product candidate may request that the FDA designate the candidate for a specific indication as a Breakthrough Therapy concurrent with, or after, the filing of the IND for the biologic product candidate. The FDA must determine if the biological product qualifies for Breakthrough Therapy designation within 60&#160;days of receipt of the sponsor&#8217;s request.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Regenerative Medicine Advanced Therapy (RMAT) Designation</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The RMAT designation is an expedited program for the advancement and approval of regenerative medicine therapies that are intended to treat, modify, reverse, or cure a serious condition and where preliminary clinical evidence indicates the potential to address unmet medical needs for life-threatening diseases or conditions. Similar to Breakthrough Therapy designation, the RMAT allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated approval. Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the PHS Act and Title 21 of the Code </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">of Federal Regulations&#160;Part&#160;1271. The FDA confirmed that gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. For product candidates that have received a RMAT designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The timing of a sponsor&#8217;s request for designation and FDA response are the same as for the Breakthrough Therapy designation program.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Disclosure of Clinical Trial Information</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two&#160;years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Pediatric Information</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Under the Pediatric Research Equity Act, or PREA, NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Additional Controls for Biologics</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the lot manufacturing history and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of a BLA, biologics manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Biosimilars</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be deemed </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. The first biosimilar product was approved by the FDA in 2015, and the first interchangeable product was approved in 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure, or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four&#160;years from the date of licensure of the reference product. The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&#160;one year after first commercial marketing of the first interchangeable biosimilar, (ii)&#160;18&#160;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&#160;eighteen&#160;months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&#160;42&#160;months after the first interchangeable biosimilar&#8217;s application has been approved if a patent lawsuit is ongoing within the 42-month period.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Post-Approval Requirements</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Adverse event reporting and submission of periodic safety summary reports are required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase&#160;4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#8217;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Other U.S. Healthcare Laws and Compliance Requirements</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In the United States, biotechnology company activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General and the Office for Civil Rights), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. The laws biotechnology companies may have to comply with include the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, recommending or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti- Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">prescribers, purchasers, and/or formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. In addition, the statutory exceptions and regulatory safe harbors are subject to change.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus generally non-reimbursable, uses and purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Data privacy and security regulations by both the federal government and the states in which business is conducted may also be applicable. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA requires covered entities to limit the use and disclosure of protected health information to specifically authorized situations, and requires covered entities to implement security measures to protect health information that they maintain in electronic form. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Commercial distribution of products requires compliance with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. In addition, several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. Certain local jurisdictions also require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Sales and marketing activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Violation of any of the federal and state healthcare laws described above or any other governmental regulations may result in penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, refusal to enter into government contracts, oversight monitoring, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Coverage, Pricing and Reimbursement</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which regulatory approval is obtained. In the United States and markets in other countries, sales of any products for which regulatory approval is received for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Expensive pharmaco-economic studies may need to be conducted in order to demonstrate the medical necessity and cost-effectiveness of product candidates, in addition to the costs required to obtain the FDA approvals. Product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable the maintenance of price levels sufficient to realize an appropriate return on investment in product development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The marketability of any product candidates for which regulatory approval is received for commercial sale may suffer if the government and other third-party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the United States has increased and is expected to continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which regulatory approval is received, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Healthcare Reform</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices. On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The HHS plan includes, among other reform measures, proposals to lower prescription drug prices, including allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Employees and Human Capital Resources</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">As of December 31, 2021, we had 133 full-time employees. From time to time, we also retain independent contractors to support our organization. Of these employees, 29 held Ph.D., Pharm.D. or M.D. degrees, and 85 were engaged in research, development and technical operations. All of our employees are based in the United States. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Facilities</b><span style="letter-spacing:0.25pt;"> </span></p><a id="_Hlk93564753"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our principal executive office is located in Philadelphia, Pennsylvania, where we lease a total of approximately 37,000 square feet of office space, </span>which commenced in February 2021 and will expire in December 2031, subject to our option to extend the term of the lease by up to two additional five-year terms<span style="letter-spacing:0.25pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also lease approximately 62,000 square feet of laboratory space at the Princeton West Innovation Campus in Hopewell, New Jersey. This lease has a 15-year term from the lease commencement date of March 2021. We have the option to extend the term of the lease by up to two additional five-year terms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Legal Proceedings</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt;"><span style="letter-spacing:0.25pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:4pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;">We were incorporated under the laws of the State of Delaware in July&#160;2017 under the name Passage Bio, Inc. Our principal executive office is located at Two Commerce Square, 2001 Market Street, 28th&#160;Floor, Philadelphia, PA, 19103, and our telephone number is (267) 866-0311. Our website address is www.passagebio.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this prospectus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;background:#ffffff;margin:0pt;">We file annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission, or SEC, under the Securities Exchange Act of 1934, as amended, or Exchange Act. The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC. The public can obtain any documents that we file with the SEC at&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.sec.gov</span>. Copies of each of our filings with the SEC can also be viewed and downloaded free of charge at our website,&#160;https://investors.passagebio.com/<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</span>&#160;after the reports and amendments are electronically filed with or furnished to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ed79df61_5689_40be_b385_b0d4e2b3a9d1"></a><a id="Item1ARiskFactors_934987"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Risk Factors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 9pt;"><i style="font-family:'Arial Narrow';font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks and uncertainties described below, together with the other information contained in this annual report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a clinical stage genetic medicines company with a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage genetic medicines company with a limited operating history on which to base your investment decision. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations to date have been limited primarily to organizing and staffing our company, business planning, raising capital and entering into collaboration and vendor agreements for conducting preclinical research and clinical development activities for our product candidates. All of our clinical product candidates are still in clinical development or the preclinical testing stage. We have no products approved for commercial sale and have not generated any revenue from commercial product sales, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. We have funded our operations to date through proceeds from sales of our convertible preferred stock and public offerings and do not expect to receive revenue for many&#160;years, if ever.</p><a id="_3c7355ae_ce4f_458c_b914_51a411cefa16"></a><a id="_98fae5bf_b845_4dfb_bb3a_4b9f3bd7d2cc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses since our inception. We incurred net losses of $185.4 million and $112.2 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $356.3 million. Substantially all of our operating losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative expenses associated with our operations. We expect to continue to incur significant expenses and operating losses over the next several&#160;years and for the foreseeable future as we intend to continue to conduct research and development, clinical testing, regulatory compliance activities, manufacturing activities, and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that it will be several&#160;years, if ever, before we have a commercialized product. We anticipate that our expenses will increase substantially if, and as, we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to advance the preclinical and clinical development of our existing product candidates and discovery stage programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, quality control, regulatory, manufacturing, scientific and administrative personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to expand and build our internal manufacturing capabilities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We are in the process of transitioning rapidly from a small start-up company with a focus on hiring employees, establishing key collaborations and financing to a more fully-integrated company that is capable of supporting clinical development, manufacturing and commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never generated revenue from product sales and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale and have not generated any revenue from commercial product sales. To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities can include completing preclinical studies and initiating and completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products that are approved and satisfying any post marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to raise additional funding before we can expect to become profitable from any potential future sales of our products. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our product development efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will require substantial future capital in order to complete planned and future preclinical and clinical development for our portfolio of product candidates and potentially commercialize these product candidates, if approved. We expect our spending levels to significantly increase in connection with our preclinical studies and planned clinical trials of our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our licensing activities, our research and development programs or other operations.</p><a id="_7d786152_8bad_408a_9b60_cc95c622c687"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed significant amounts of cash since inception. As of December&#160;31, 2021, our cash, cash equivalents and marketable securities were $315.8 million. We expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements until the end of 2023. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives, which may not be available to us on acceptable terms, or at all. We may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are not available to us on a timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more product candidates or discovery stage programs or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize any product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or securities convertible into equity, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Product Development and Regulatory Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic&#160;could adversely impact our business, including our preclinical development activities and planned clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The ongoing COVID-19 pandemic, as well as future public health crises or similar outbreaks could adversely impact our business.&#160;As we diligently work to activate sites for our clinical programs, we are experiencing some impacts to our site initiation activities related to COVID-19, such as meeting delays with various investigational review bodies or ethics committees that have prioritized COVID-19 related clinical trials and staffing levels at site hospitals. For example, the clinical initiation of our upliFT-D clinical study for PBFT02 and the GALax-C clinical study for PBKR03 were substantially impacted by COVID-19-related issues. Our expected timelines for our clinical trials may be delayed further </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">by these impacts. As a result of the&#160;COVID-19&#160;outbreak, or similar pandemics, we may experience disruptions that could severely impact our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further delays or difficulties in clinical site initiation for our clinical candidates, including difficulties in obtaining IRB approvals, recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further delays or difficulties in enrolling patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the U.S. Food and Drug Administration, or the FDA, and comparable foreign regulatory agencies, which may impact timelines for regulatory submission and review, trial initiation and regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of planned key clinical trial activities, such as clinical trial site data monitoring and patient recruitment, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and planned clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or disruptions in preclinical development activities, particularly at Penn, including non-clinical experiments and investigational new drug application-enabling good laboratory practice standard toxicology studies due to unforeseen constraints in employee resources, vendor capacity, or supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in our CROs and collaborators meeting expected deadlines or complying with regulatory requirements related to preclinical development activities, preclinical studies and planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruptions of, or delays in receiving, supplies of our product candidates from our CMOs, particularly at Catalent, due to staffing shortages, productions slowdowns or stoppages&#160;and disruptions in delivery systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased rates of patients withdrawing from any planned clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of our preclinical development activities, preclinical studies and planned clinical trials, including the diversion of hospitals serving as any potential clinical trial sites and hospital staff supporting the conduct of our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations on employee or collaborator resources that would otherwise be focused on the conduct of our preclinical development activities, preclinical studies and planned clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced ability to engage with the medical and investor communities due to the cancellation of conferences scheduled throughout the&#160;year.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These and other factors arising from the&#160;COVID-19&#160;pandemic&#160;could worsen in countries that are already afflicted with&#160;COVID-19,&#160;could continue to spread to additional countries, or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct preclinical development activities, preclinical studies and planned clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the trading prices for our common stock and other biopharmaceutical companies, as well as the broader equity and debt markets, have been highly volatile as a result of the&#160;COVID-19&#160;pandemic and the resulting impact on economic activity. As a result, we may face difficulties raising capital when needed, and any such sales may be on unfavorable terms to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The&#160;COVID-19&#160;outbreak continues to rapidly evolve. The extent to which the outbreak impacts our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Such developments include the ultimate geographic spread of COVID-19, new variants, the duration of the outbreak, the speed and breadth of mass vaccinations for COVID-19 and the efficacy of such vaccines, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts. Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable, or experience significant delays in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are early in our clinical development efforts and our clinical product candidates have only recently been approved by regulatory authorities for clinical development. Additionally, we have a portfolio of programs that are in earlier stages of preclinical development and may never advance to clinical stage development. Our ability to generate product revenue, which we do not expect will occur for many&#160;years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product and we may never be able to develop or commercialize a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each of our programs and product candidates will require additional preclinical and/or clinical development, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. Our product candidates must be authorized for marketing by the FDA or certain other ex-U.S. regulatory agencies before we may commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The clinical and commercial success of our product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies, biocompatibility studies and minimally efficacious dose studies in animals, where applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials, including under the international current Good Clinical Practices, or cGCPs, and current Good Laboratory Practices, or GLPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">positive results from our future clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of arrangements with third-party manufacturers or our own facilities for clinical supply and, where applicable, commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial launch of our product candidates, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the benefits and use of our product candidates, including method of administration, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective competition with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment and maintenance of healthcare coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a physician training system and network for administration of our product candidates by administration into the ICM;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcement and defense of intellectual property rights and claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintenance of a continued acceptable safety, tolerability and efficacy profile of our product candidates following approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical development involve a lengthy and expensive process with an uncertain outcome. We may incur additional expenses or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in clinical or preclinical development and their risk of failure is high. We currently rely exclusively on GTP for our preclinical and IND-enabling studies. It is impossible to predict when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex and expensive clinical trials that our product candidates are safe and effective in humans. For example, our IND for PBGM01 for the treatment of GM1 was initially placed on clinical hold. Even though the FDA removed the clinical hold on the IND for PBGM01, other future product candidates may be subject to clinical holds in the future. Clinical testing can take many&#160;years to complete, and its outcome is inherently uncertain. We will rely on CROs for the clinical development of our clinical product candidates. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials or early cohorts of our clinical trials of our product candidates, including early biomarker data, may not be predictive of the results of later-stage clinical trials or later cohorts of our clinical trials. Early clinical trials and in particular initial cohorts of early clinical trials often enroll significantly fewer patients than later stage clinical trials or later cohorts of the same clinical trial and may not be as predictive as larger trials. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful or come to agreement on other aspects of clinical trial design. Moreover, a clinical trial can fail at any stage of testing. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials. There is typically a high rate of failure of product candidates proceeding through clinical trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our future clinical trials will ultimately be successful or support clinical development of our current or any of our future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We or our collaborators may experience delays in initiating or completing clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our clinical product candidates or any future product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, such as the FDA, may place our clinical trials on clinical hold; for example, the FDA placed our trial of PGM101 for the treatment of GM1 on clinical hold from July 2020 to December 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">institutional review boards, or IRBs, the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">novel therapies, such as gene therapies with less well-characterized safety profiles, may require slower or more staggered early clinical trial enrollment to adequately assess safety data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow up at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the related expenses of clinical trials of any of our product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to manufacture sufficient quantities of our product candidates for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other molecules in the same class as our product candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or ex-U.S. regulatory agencies may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of clinical sites we enroll, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs and clinical trial sites to ensure the proper and timely conduct of our future clinical trials, including the patient enrollment process, and we have limited influence over their performance. Additionally, we could encounter delays if treating physicians encounter unresolved ethical issues associated with enrolling patients in future clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. For example, treating physicians may with eligible patients for our Krabbe trial may instead elect to use a hematopoietic stem cell transplant approach in lieu of enrolling in our clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or other regulatory authorities, or if a clinical trial is recommended for suspension or termination by the Independent Data Monitoring Committee for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product development expenses will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several&#160;years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. We may experience unexpected or adverse results in our ongoing or future clinical trials. We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in their target indications before we can seek regulatory approvals for their commercial sale. Our initial clinical trials are beginning with relatively small cohorts before expanding in size in subsequent cohorts. If safety issues arise in an early cohort, we may be delayed or prevented from subsequently expanding into larger trial cohorts. Earlier gene therapy clinical trials conducted by others also utilized adeno-associated viral, or AAV, vectors. However, these studies should not be relied upon as evidence that our planned clinical trials will succeed. Trial designs and results from previous trials are not necessarily predictive of our future clinical trial designs or results, and initial positive results we may observe may not be confirmed upon full analysis of the complete trial data. In addition, the positive results we have observed for our product candidates in preclinical animal models may not be predictive of our future clinical trials in humans. Our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development even if they successfully advance through initial clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preliminary, topline, or interim data from our clinical trials that we or our partners announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may make public preliminary, topline or interim data from our clinical trials, including preliminary biomarker data. Preliminary or topline data from clinical trials remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data that were previously made public. Interim data from clinical trials that we may complete are also subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available. As a result, preliminary, topline and interim data should be viewed with caution until the final data are available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our reputation and business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gene therapy is a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Currently, only a limited number of gene therapy products have been approved in the United States and in foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our current product candidates are based on gene therapy technology and our future success depends on the successful development of this novel therapeutic approach. The regulatory requirements that govern any novel gene therapy product candidates we develop are not entirely clear and are subject to change. The clinical study requirements of the FDA and ex-U.S. regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">potential products. The regulatory approval process for novel product candidates such as ours may be more expensive and take longer than for other, better known or extensively studied product candidates. Further, as we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA or comparable foreign regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. To date, only a limited number of gene therapy products have been approved in the United States and foreign countries, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States or other jurisdictions. Further, approvals by ex-U.S. regulatory agency may not be indicative of what the FDA may require for approval, or vice versa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause undesirable and unforeseen side effects, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While new AAV vectors have been developed to reduce side effects previously reported in third-party gene therapy treatments, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration which, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. For example, in previous third-party clinical trials involving AAV vectors for gene therapy, some subjects experienced the development of a T-cell antibody response, whereby after the vector is within the target cells, the cellular immune response system triggers the removal of transduced cells by activated T-cells. Other recent clinical trials involving high doses of AAV vectors have also resulted in liver damage and death. Further, following administration of any AAV vector, patients are likely to develop NAbs specific to the vector administered. Other preclinical studies have suggested that high dosages of AAV administration may result in toxicity due to degeneration of the dorsal root ganglia. Preliminary results of our NHP toxicology studies for our PBGM01 and PBFT02 product candidates have demonstrated trigeminal ganglia and dorsal root ganglia toxicity. Based on these results, and if our vectors demonstrate a similar effect in other programs, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. Each of our clinical product candidates are expected to utilize ICM administration. While this method of administration has been available for decades, its use for therapies is relatively new, no therapies are currently approved using ICM administration, and it may be perceived as having greater risk than more common methods of administration, such as intravenous injection. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA or ex-U.S. regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategies, or REMS, to ensure that the benefits of the product outweigh its risks, which may include, among other things, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Adverse public perception of genetic medicines may negatively impact regulatory approval of, and/or demand for, our potential products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory approval of and/or demand for our potential products will depend in part on public acceptance of the use of genetic medicine for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that genetic medicines are unsafe, unethical or immoral, and consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been several significant adverse side effects reported in genetic medicine treatments in the past. For example, in 1999, there was public backlash against gene therapy following the death of a clinical trial subject in a gene therapy clinical trial that utilized an adenovirus vector. It was later discovered that adenoviruses could generate an extreme immune system reaction that can be life threatening. Dr.&#160;Wilson, our Chief Scientific Advisor, was a co-investigator of the 1999 trial while he was Director of the Institute for Human Gene Therapy of Penn. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy by us or our competitors, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception and potential regulatory delays in the clinical testing or approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As an organization, we have limited experience designing and no experience implementing clinical trials and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The design and implementation of clinical trials is a complex process. As an organization, we have limited experience designing and no experience implementing clinical trials, and we may not successfully or cost effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the related expenses to implement the clinical trial, which could lead to a shortfall in funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The disorders we seek to treat have low incidence and prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genetically defined disorders generally, and especially those for which our current product candidates are targeted, have low incidence and prevalence. For example, we estimate the incidence of GM1 in the United States is approximately 1.4 in 100,000 live births, that the United States incidence of Krabbe disease is approximately 2.6 in 100,000 births and that there are approximately 3,000 to 6,000 people in the United States with FTD-GRN. While certain states currently have mandatory newborn genetic screening for Krabbe disease, there is no mandatory screening for GM1. Without mandatory screening, it may be difficult for us to identify a sufficient number of eligible patients to conduct our clinical trials. These could be significant obstacles to the timely recruitment and enrollment of a sufficient number of eligible patients into our trials. Further, we expect to rely in part on our relationships with the Orphan Disease Center and other patient </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">advocacy groups to assist in identifying eligible patients, and any deterioration of those relationships could impede our ability to successfully enroll patients. Patient enrollment may be affected by other factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of the study protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks, benefits and convenience of administration of the product candidate being studied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of other clinical trials being conducted for the same indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites to prospective patients.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our inability to enroll a sufficient number of patients with these diseases for our planned clinical trials would result in significant delays and could require us to not initiate or abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, our projections of both the number of people who have GM1, FTD, Krabbe disease and our other product candidates, as well as the people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates, including third-party analyses commissioned by us. The total addressable market opportunity for our product candidates will ultimately depend upon, among other things, the final approved product labeling for each of our product candidates, if our product candidates are approved for sale in our target indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients globally may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Our products may potentially be dosed on a one-time basis, which means that patients who enroll in our clinical trials may not be eligible to receive our products on a commercial basis if they are approved, leading to lower revenue potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will receive regulatory approval to commercialize a product candidate and the approval may be for a more narrow indication than we seek.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to commercialization, our product candidates must be approved by the FDA pursuant to a biologics license application, or BLA, in the United States and by similar ex-U.S. regulatory authorities. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many&#160;years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. Our company does not have experience in submitting and supporting the applications necessary to gain marketing approvals. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Approval of our product candidates may be delayed or refused for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including the methods for collecting and analyzing data, the statistical analysis plan, and the lack of a concurrent control arm or a decision to use external or historical controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may not agree that the efficacy endpoints used in our clinical trials are appropriate to establish clinical benefit in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the FDA comparable foreign regulatory authorities a durable response to our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical programs or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the facilities of the third-party manufacturers with which we contract may not be adequate to support approval of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or REMS.&#160;These regulatory authorities may require precautions or contra indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the product labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, the regulatory authorities may require concurrent approval of a companion diagnostic device. For our product candidates, it may be necessary to use FDA-cleared or FDA-approved diagnostic tests to diagnose patients or to assure the safe and effective use of product candidates in trial subjects. The FDA refers to such tests as in vitro companion diagnostic devices. The FDA has issued guidance describing the agency&#8217;s current thinking about the development and regulation of in vitro companion diagnostic devices. The final guidance articulates a policy position that, when an in vitro diagnostic device is essential to the safe and effective use of a therapeutic product, the FDA generally will require approval or clearance of the diagnostic device at the same time that the FDA approves the therapeutic product. At this point, it is unclear how the FDA will apply this policy to our current or future gene therapy product candidates. Should the FDA deem genetic tests used for diagnosing patients for our therapies to be in vitro companion diagnostics requiring FDA clearance or approval, we may face significant delays or obstacles in obtaining approval of a BLA for our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The FDA and other ex-U.S. regulatory agencies have demonstrated caution in their regulation of gene therapy treatments. Ethical and legal concerns about gene therapy and genetic testing may result in additional regulations or restrictions on the development and commercialization of our product candidates, which may be difficult to predict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA and other ex-U.S. regulatory agencies at both the federal and state level in the United States, U.S. congressional committees, and foreign governments, have expressed interest in further regulating the biotechnology industry, including gene therapy and genetic testing. Any such further regulation may delay or prevent commercialization of some or all of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory requirements in the United States and abroad governing gene therapy products have changed frequently and may continue to change in the future. In addition to the FDA, the Institutional Biosafety Committee and IRB of each institution at which we conduct our planned clinical trials, would need to review the proposed clinical trial to assess the safety of the trial. Within the FDA, the Office of Tissues and Advanced Therapies, within the Center for Biologics Evaluation and Research, or CBER, consolidates the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee advises CBER on its review. Adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, including for 35&#160;days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop important activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad and will limit our ability to realize their full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In order to eventually market any of our product candidates in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction by jurisdiction basis regarding safety and efficacy. Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The foreign regulatory approval process involves all of the risks associated with FDA approval. In addition, gene therapy products are considered genetically modified organism, or GMO, products and are regulated as such in each country. Designation of the type of GMO product and subsequent handling and disposal requirements can vary across countries and is variable throughout the European Union. Addressing each specific country requirement and obtaining approval to commence a clinical trial in these countries could result in delays in starting, conducting, or completing a clinical trial. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets and expect to rely on third-party consultants. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in our efforts to build a pipeline of additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business model is centered on developing therapies for patients with CNS disorders by establishing focused selection criteria to select, develop and advance product candidates that we believe will have a high probability of technical and regulatory success through development into commercialization. We may not be able to continue to identify and develop new product candidates in addition to the pipeline of product candidates that we have established through our collaboration with Penn&#8217;s GTP. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely exclusively on our collaboration with Penn for our preclinical research and development programs, including for discovering, preclinically developing and conducting all IND-enabling studies for our clinical product candidates and our near-term future pipeline. Failure or delay of Penn to fulfil all or part of its obligations to us under the agreement, a breakdown in collaboration between the parties or a complete or partial loss of this relationship would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our collaboration with Penn is critical to our business. We initially entered into an amended and restated Research, Collaboration&#160;&amp; License Agreement in May 2020, as subsequently amended, or the Penn Agreement, with Penn to discover and develop certain AAV vector based therapeutics, and the products developed under such collaboration currently represent all of our product pipeline and research programs. We currently rely exclusively on Penn for all of our preclinical research and development capabilities, and in particular GTP under the direction of Dr.&#160;Wilson. Pursuant to the Penn Agreement, Penn is responsible for discovery, preclinical development activities, including all IND-enabling non-clinical studies and research grade manufacturing, and other collaborative activities set forth in the plan for the funded research. Either party has the right in certain circumstances to terminate the collaboration pursuant to the terms of the Penn Agreement. If Penn delays or fails to perform its obligations under the Penn Agreement, disagrees with our interpretation of the terms of the collaboration or our discovery plan or terminates our existing agreement, our pipeline of product candidates would be significantly adversely affected and our prospects will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term of the research funding portion of the Penn Agreement, under which we have the ability to acquire exclusive rights to additional gene therapy products for CNS indications, expires in August 2026. In addition, the discovery program, under which we have rights to new technologies for our product candidates is currently also set to expire in August&#160;2026. The term of the exploratory research program in large indications, initially TLE and AD, expires in August 2024. If we seek to extend our collaboration, we will need to negotiate a new or amended agreement, which may not be available to us on equally favorable terms, if at all. Penn has also entered into collaborations with third parties, including certain of our competitors, addressing targets and disease indications outside the scope of our collaboration. As a result, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Penn may have competing interests with respect to their priorities and resources. We may have disagreements with Penn with respect to the interpretation of the Penn Agreement, use of resources or otherwise that could cause our relationship with Penn to deteriorate. As a result, Penn may reduce their focus on, and resources allocated to, our programs, potentially delaying or terminating our ability to advance product candidates through preclinical studies. Additionally, if Dr.&#160;Wilson were to leave Penn or to otherwise no longer be meaningfully involved with us, our preclinical research and development capabilities may be substantially reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, under the Penn Agreement, Penn is primarily responsible for prosecuting and maintaining our licensed intellectual property, and it may fail to properly prosecute, maintain or defend such intellectual property. In such event, if we are unable to otherwise maintain or defend such intellectual property, we could face the potential invalidation of the intellectual property or be subjected to litigation or arbitration, any of which would be time-consuming and expensive. To enforce the licensed intellectual property rights under the Penn Agreement, we will need to coordinate with Penn, which could slow down or hamper our ability to enforce our licensed intellectual property rights. In such event, we could face increased competition that could materially and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our preclinical studies and clinical trials and rely on them to perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we have recruited a team that has experience with clinical trials, as a company we have no experience in conducting clinical trials. Moreover, we currently rely exclusively on Penn for our discovery and preclinical research and will continue to rely upon medical institutions, clinical investigators, contract laboratories and other third parties, or our CROs, to conduct clinical trials for our product candidates. We expect to rely heavily on these parties for execution of preclinical and clinical trials for our product candidates and control only certain aspects of their activities. If these parties reduce the levels of efforts and resources to our product candidate activities, prioritize work with a competitor of ours or if a dispute were to arise between us and these parties, they may not meet our expected deadlines or provide us with sufficient materials for our regulatory filings. Nevertheless, we will be responsible for ensuring that each of our preclinical and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We, Penn and our CROs will be required to comply with regulations, including cGCPs for conducting, monitoring, recording and reporting the results of preclinical and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any drugs in clinical development. The FDA enforces cGCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with cGCPs. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements in cGMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we currently design and intend to continue designing our planned clinical trials for our product candidates, for the foreseeable future CROs will conduct all of our planned clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less day-to-day control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any preclinical studies or clinical trials with which such CROs are associated with may be extended, delayed or terminated. In such cases, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates in the subject indication could be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to assist or provide the design, conduct, supervision and monitoring of clinical trials of our product candidates. Because we rely and intend to rely on these third parties and will not have the ability to conduct all clinical trials independently, we will have less control over the timing, quality and other aspects of clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our clinical trials, resulting in the clinical trials being delayed or unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The FDA generally requires preclinical studies to be conducted in accordance with GLPs and clinical trials to be conducted in accordance with cGCPs, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into alternative arrangements or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially adversely impact our ability to meet our desired clinical development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates. If any of our current or future collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may in the future enter into third-party collaborations for research, development and commercialization of other therapeutic technologies or product candidates. Biotechnology companies are our likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With any future collaboration agreements, we expect to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our potential future collaborations involving our product candidates may pose the following risks to us:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation, indemnification obligations and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may restrict our right to independently pursue new product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop our product candidates and research programs, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in finding additional collaborators for continuing development of certain of our product candidates or successfully commercializing or competing in the market for certain indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may decide to pursue collaborations with additional pharmaceutical and biotechnology companies for the development and potential commercialization of some of our product candidates. We face significant competition in seeking appropriate collaborators. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. In addition, a significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may have conflicts with our collaborators that could delay or prevent the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may have conflicts with our collaborators, including Penn, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our collaborators, including Penn, such collaborator may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a collaborator to pay us milestone payments or royalties we believe are due to us under a collaboration, which could require us to raise additional capital; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the collaborator to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the relevant agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future seek to engage in strategic transactions to acquire or in-license new products, product candidates or technologies. If we are unable to successfully complete, or realize the benefits from, such transactions it may adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, joint ventures and in-licensing of new products, product candidates or technologies that we believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that following any such strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the transaction or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently rely on third parties to develop, manufacture and test clinical supplies of our product candidates, including the materials used to administer our product candidates. For our initial clinical trials, we rely on the manufacturing facility of Catalent Maryland (formerly Paragon Bioscience), or Catalent, for supply of our product candidates, and on Penn to manage the transfer of technology to Catalent that is necessary for production. We recently established internal manufacturing operations for certain CMC and analytical capabilities and expect to establish a pilot plant and our own manufacturing facility for long-term commercial market supply. However, we have limited experience as a company in developing manufacturing facilities. We may face delays in building out our pilot plant or in constructing new facilities and transferring technology to our facilities or have difficulty hiring experts to staff and operate our own manufacturing facility and, accordingly, our production capacity could be limited. The manufacturing processes used to produce our product candidates are complex, novel and have not been validated for commercial use. Many factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our product candidates require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is consistent from lot-to-lot or will perform in the intended manner. Accordingly, we employ multiple steps to control the manufacturing process to assure that the process works consistently and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, low lot yields, product recalls, product liability claims or insufficient inventory. As a result, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet the FDA or other applicable standards or specifications with consistent and acceptable production yields and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA and ex-U.S. regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or ex-U.S. regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures, low lot yields or product recalls. Lot failures, low lot yields or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We, or our third-party collaborators, also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any problems in our, or our third-party collaborators&#8217;, manufacturing process or facilities could result in delays in our planned clinical trials and increased costs, and could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. It could also require us to find alternative manufacturing processes, which may be unavailable to us on attractive terms, or at all. Problems in our manufacturing process could restrict our ability to meet potential future market demand for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently rely and expect to continue to rely on third-party manufacturers to produce clinical supply of our product candidates, and we have not entered into binding agreements with any such manufacturers to support commercialization. The competition for gene therapy contract development, manufacturing and testing services is intense. Additionally, these manufacturers do not have experience producing our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce our product candidates at the quality, quantities, locations and timing needed to support commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While we are in the process of establishing manufacturing capability for certain CMC activities, we do not currently plan to independently manufacture most of the material for our planned clinical programs. We currently rely, and expect to continue to rely, on third parties for the production of our preclinical study and planned clinical trial materials, including the materials used to administer our product candidates and, therefore, we can control only certain aspects of their activities. The competition for gene therapy contract development, manufacturing and testing is intense. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves, including but not limited to potential competition from other genetic biotechnology companies for the use of such third-party manufacturers.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While we have secured an agreement with Catalent to manufacture clinical supply of our product candidates, we have not yet secured manufacturing capabilities for commercial quantities of our product candidates. Although we intend to establish our own manufacturing facility for long-term commercial market supply, we may need to rely on third-party manufacturers for the commercialization of our product candidates if regulatory approval is achieved. To date, while we have a collaboration agreement with Catalent for a dedicated clean room suite, we have only entered into agreements with such manufacturer to support our clinical studies. We may be unable to negotiate binding agreements with the manufacturers to support our potential commercialization activities at commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before any of our third-party manufacturers and suppliers can begin to commercially manufacture our product candidates, including the materials used to administer our product candidates, they must demonstrate to regulatory authorities that the planned chemistry, manufacturing and controls for our gene therapy product candidates meet certain requirements. Manufacturing of product candidates for clinical and commercial purposes must comply with the cGMP and applicable ex-U.S. regulatory requirements. The cGMP requirements govern quality control and documentation policies and procedures. Complying with cGMP and ex-U.S. regulatory requirements will require that we expend time, money and effort in production, recordkeeping and quality control to assure that our product candidates meet applicable specifications and other requirements. Our third-party manufacturers&#8217; also must demonstrate to the FDA and ex-U.S. regulators that they can make the product candidate in accordance with the cGMP requirements as part of a pre-approval inspection prior to FDA or similar ex-U.S. regulatory approval of the product candidate. Failure to pass a pre-approval inspection might significantly delay our ability to begin trials in the respective jurisdiction and FDA and ex-U.S. regulatory approval of our product candidates. If any of our third-party manufacturers fail to comply with these requirements, we would be subject to possible regulatory action, which could limit the jurisdictions in which we are permitted to sell our products. As a result, our business, financial condition and results of operations may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, our third-party manufacturers may fail to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if our third-party manufacturers comply with applicable regulatory requirements, we cannot assure you that they will be able to successfully manufacture additional product candidates at a larger scale in a timely or economical manner, or at all. If they are unable to successfully increase our manufacturing scale or capacity, the development, testing, and clinical trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our third-party manufacturers and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our third-party manufacturers and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. The operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any contamination in our third parties&#8217; manufacturing process, shortages of raw materials, labor or reagents or failure of any of our key suppliers to deliver necessary components of our platform could result in delays in our clinical development or marketing schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our or our third-party vendor&#8217;s ability to produce our gene therapies on schedule and could therefore harm our results of operations and cause reputational damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The raw materials required in our third-party vendors manufacturing processes are derived from biological sources. We cannot assure you that our third-party vendors have, or will be able to obtain on commercially reasonable terms, or at all, sufficient rights to these materials derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall, or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the clinical and commercial manufacturing of our product candidates, which could materially and adversely affect our operating results and development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers for the supply and manufacture of certain components of our technology. Should our ability to procure these material components from our suppliers be compromised, our ability to continuously operate would be impaired until an alternative supplier is sourced, qualified and tested, which could limit our ability to produce a clinical and commercial supply of our product candidates and harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers for certain materials and components required for the production of our product candidates, including the materials used to administer our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and quality and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to manufacture gene therapy products. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors that are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than ours, which may harm our business and financial condition, and our ability to successfully market or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries, including the genetic medicines field, are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property. We are aware of several companies focused on developing gene therapies in various indications as well as several companies addressing methods for modifying genes and regulating gene expression. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the treatment of GM1, there are no approved disease-modifying therapies. We consider our most direct competitors with respect to PBGM01 for the treatment of GM1 to be Sio Gene Therapies, Inc., or Sio, and Lysogene, S.A, or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Lysogene. Sio is conducting its clinical trial for an IV gene therapy treatment for early and late infantile/juvenile GM1 and reported data from ten patients in October 2021. Lysogene, as of February 2022, reported having dosed three patients and enrolled a fourth patient in the safety cohort, after which Lysosgene will initiate treatment of twelve patients in the efficacy confirmatory cohort of its Phase 1/2 clinical trial for a gene therapy treatment administered via intracisternal magna for early and late infantile GM1. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">For the treatment of FTD, there are no approved disease-modifying therapies. We consider our most direct competitors with respect to PBFT02 for the treatment of FTD-GRN to be Alector, Inc. (partnered with GlaxoSmithKline), which is enrolling a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, and Prevail Therapeutics Inc. (now part of Eli Lilly &amp; Co), which has initiated a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN, and is expected to continue enrolling through 2023. Several other companies, including Applied Genetic Technologies Corporation, Orchard Therapeutics plc, AcuraStem Inc. and Shape Therapeutics Inc., are conducting preclinical research using gene therapy approaches to treat FTD-GRN patients. Denali Therapeutics Inc. in partnership with Takeda Pharmaceutical Company Limited has a preclinical recombinant progranulin protein under evaluation in addition to their oral EIF2a modulator in a Phase 1 clinical trial. We are also aware of other therapeutic approaches in preclinical development that may target FTD-GRN patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">With respect to PBKR03 for the treatment of Krabbe Disease, we consider our most direct competitor with respect to PBKR03 to be Forge Biologics Inc., which has an active clinical trial evaluating a Krabbe gene therapy candidate that combines bone marrow transplant and gene therapy. There is some evidence that hematopoietic stem cell transplant is beneficial for pre-symptomatic infants with Krabbe disease, and it has become standard of care in many sites in the United States. In addition, Neurogene Inc. has a gene therapy in pre-clinical development for Krabbe. We are also aware of other therapeutic approaches in preclinical development and an ongoing natural history study being conducted by the Children&#8217;s Hospital of Pittsburgh and certain academic studies for Krabbe disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical, and other resources than we do, such as larger research and development, clinical, commercial and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally, new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in commercializing our product candidates against competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ethical, social and legal concerns about gene therapy could result in additional regulations restricting or prohibiting our products. Even with the requisite approvals from the FDA in the United States and other ex-U.S. regulatory authorities, the commercial success of our product candidates will depend, in part, on the acceptance of physicians, patients (which includes the patients caregiver when applicable) and health care payors of gene therapy products in general, and our product candidates in particular, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and, in particular, our product candidates, if approved for commercial sale, will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy, durability and safety of such product candidates as demonstrated in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment relative to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product candidate is approved by the FDA or ex-U.S. regulatory authorities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to prescribe new therapies and use ICM administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully train neurosurgeons and interventional radiologists in ICM administration of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA or ex-U.S. regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of competitive products, and the perceptions of such competitive products compared to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products or competing products and treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient third-party payor coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval. In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis sales, reimbursement, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. The development of our three clinical product candidates and ongoing research programs require significant resources. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or our rights under licensed patents is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our current product candidates and future products, as well as our core technologies, including our manufacturing know-how. We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business by seeking, maintaining and defending our intellectual property, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy. Additionally, for some of our product candidates, we intend to rely on regulatory protection afforded through rare drug designations, data exclusivity and market exclusivity as well as patent term extensions, where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Currently, our intellectual property protection consists solely of patent applications that we have in-licensed from Penn under the Penn Agreement. The in-licensed patent applications are directed to certain new AAV capsids, to recombinant AAV viruses, or rAAV, capable of delivering certain genes into human cells to treat monogenic disorders of the CNS, to methods of treating those monogenic diseases with rAAV, as well as to certain aspects of our manufacturing capabilities and related technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also have options under the Penn Agreement to add additional intellectual property to our existing license. To date, we have exercised four options: one with respect to Charcot-Marie Tooth disease; one for an inherited form of Parkinson&#8217;s disease; one for Canavan&#8217;s disease; and one for Huntington&#8217;s disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent&#160;years been the subject of much litigation. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our licensed patent applications will mature into issued patents, and cannot provide any assurances that any such patents, if issued, will include claims with a scope sufficient to protect our current and future product candidates or otherwise provide any competitive advantage. Additionally, patents can be enforced only in those jurisdictions in which the patent has issued. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty&#160;years after its first nonprovisional U.S. filing. The natural expiration of a patent outside of the United States varies in accordance with provisions of applicable local law, but is generally 20&#160;years from the earliest local filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, our exclusive license is subject to field restrictions and retained rights, which may adversely impact our competitive position. Our licensed patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our product candidates, including biosimilar versions of such products. In addition, the patent portfolio licensed to us is, or may be, licensed to third parties outside our licensed field, and such third parties may have certain enforcement rights. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against another licensee or in administrative proceedings brought by or against another licensee in response to such litigation or for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other parties have developed technologies that may be related or competitive to our own and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conflict with those claimed in our own patent applications or issued patents. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and in other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether the inventors of our licensed patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Further, we cannot assure you that all of the potentially relevant prior art relating to our licensed patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Further, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent prosecution process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, the scope of the claims initially submitted for examination may be significantly narrowed by the time they issue, if at all. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We cannot provide any assurances that we will be able to pursue or obtain additional patent protection based on our research and development efforts, or that any such patents or other intellectual property we generate will provide any competitive advantage. Moreover, we do not have the right to control the preparation, filing and prosecution of patent applications, or to control the maintenance of the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be filed, prosecuted or maintained in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we acquire patent protection that we expect should enable us to maintain competitive advantage, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Third parties, including competitors, may challenge the inventorship, scope, validity, or enforceability thereof, which may result in such patents being narrowed, invalidated or held unenforceable. If issued, our licensed patents may be challenged in patent offices in the United States and international markets, or in court. For example, we may be subject to a third-party submission of prior art to the U.S. Patent and Trademark Office, or USPTO, challenging the validity of one or more claims of our licensed patents, once issued. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our pending licensed patent applications. We may become involved in opposition, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review, derivation, interference, or similar proceedings in the United States or abroad challenging the claims of patents that we have licensed, once issued. Furthermore, patents that we have licensed may be challenged in court, once issued. Competitors may claim that they invented the inventions claimed in such patents or patent applications prior to the inventors of our licensed patents, or may have filed patent applications before the inventors of our licensed patents did. A competitor may also claim that we are infringing its patents and that we therefore cannot practice our technology as claimed under our licensed patent applications and patents, if issued. As a result, one or more claims of our licensed patents may be narrowed or invalidated. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if they are unchallenged, our licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, even if we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention if the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Moreover, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that uses a vector or an expression construct that falls outside the scope of our patent protection or license rights. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although currently all of our patent applications are in-licensed, similar risks would apply to any patents or patent applications that we may own or in-license in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to patent protection, if any of our product candidates are approved by the FDA as a biological product under a BLA in the United States, we believe the product would qualify for a 12-year period of exclusivity. Other regulatory exclusivities may be available, such as Orphan Drug exclusivity, with analogous data, marketing, and orphan exclusivities in various foreign countries. However, the scope of such regulatory exclusivities is subject to change, and may not provide us with adequate and continuing protection sufficient to exclude others from commercializing products similar to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">All of our current product candidates and research programs are licensed from or based upon licenses from a third -party and are field limited to certain indications. If this license agreement is terminated or interpreted to narrow our rights, our ability to advance our current product candidates or develop new product candidates based on these technologies will be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We now depend on Penn, and will continue to depend on Penn and on licenses and sublicenses from other third parties, as well as potentially on other strategic relationships with third parties, for the research, development, manufacturing and commercialization of our current product candidates. If any of our licenses or relationships or any in-licenses on which our licenses are based are terminated or breached, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose our rights to develop and market our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose patent or trade secret protection for our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience significant delays in the development or commercialization of our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not be able to obtain any other licenses on acceptable terms, if at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur liability for damages.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, even if not terminated or breached, our intellectual property licenses or sublicenses may be subject to disagreements over contract interpretation which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we experience any of the foregoing, it could have a materially adverse effect on our business and could force us to cease operations which could cause you to lose all of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we breach our license agreements it could have a material adverse effect on our commercialization efforts for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties, we could lose license rights that are important to our business. Our current clinical product candidates and pipeline are and our anticipated near term pipeline will be, licensed from Penn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Penn Agreement, we are subject to various obligations, including payment obligations, diligence obligations such as development and commercialization obligations, as well as potential royalty payments and other obligations. If we fail to comply with any of these obligations or otherwise breach our license agreements, our licensors may have the right to terminate the applicable license in whole or in part. Generally, the loss of any one of our current licenses, or any other license we may acquire in the future, could harm our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patent and other intellectual property rights to third parties under collaborative development relationships;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms or at all, we may be unable to successfully develop and commercialize the affected product candidates. In addition, if disputes arise as to ownership of licensed intellectual property, our ability to pursue or enforce the licensed patent rights may be jeopardized. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our strategy of obtaining rights to key technologies through in-licenses may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. The future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates or technologies. We cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The in-licensing and acquisition of these technologies is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies, our business, financial condition and prospects could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third parties may initiate legal proceedings alleging claims of intellectual property infringement, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and future products and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates, future products and technology. Our competitors or other third parties may assert infringement or misappropriation claims against us, alleging that our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing product candidates. For example, in connection with our formation, we were indirectly informed of claims that third parties may potentially raise against us or our collaborators regarding our AAVhu68 capsid. We believe that we would have valid defenses to these and any other such claims; however, if any such claims were ultimately successful, we might require a license to continue to use and sell any product candidates using such AAV vector. Such licenses may not be available on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February&#160;18, 2020, we received a letter from Regenxbio&#160;Inc., or Regenx, which stated its view that the use of our AAVhu68 capsid infringes patent claims to which Regenx has an exclusive license and which expire in 2024. Regenx also stated that it has exclusive licenses to various pending patent applications regarding the use of AAV vectors administered via ICM, and that these applications may lead to issued claims that Regenx believes may, if issued, cover our planned method of administration for our clinical product candidates. We believe we have valid defenses to the issued claims set forth by Regenx relating to AAVhu68. Further, the prosecution of pending patent applications is highly uncertain, and it is unclear whether any patents will issue from these pending Regenx patent applications at all, much less with claims that are relevant to the administration of our product candidates. Regenx also asked for information regarding our relationship with Dr.&#160;Wilson while he was serving as an advisor to Regenx. Regenx&#8217;s letter also offers to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">discuss licensing the applicable patent portfolios from them.&#160;In April&#160;2020, we responded to Regenx indicating that we do not believe we require a license to any of the specified Regenx patents or patent applications at this time, and that we found that Dr.&#160;Wilson&#8217;s relationship with us was consistent with his obligations to Regenx. We will continue to monitor the situation and, if necessary, take appropriate actions, which may include responding to further correspondence from Regenx, and engaging in discussions with Regenx regarding their claims.&#160;If any such patents were enforceable and such claims were ultimately successful, we might require a license to continue to use and sell any product candidates using such AAV vector. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, we do not know which processes we will use for commercial manufacture of our future products, or which technologies owned or controlled by third parties may prove important or essential to those processes. Given the vast number of patents in our field of technology, we cannot be certain or guarantee that we do not or will not infringe existing patents or that we will not infringe patents that may be granted in the future. Many companies have filed, and continue to file, patent applications related to gene therapy and orphan diseases. Some of these patent applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent applications can take many&#160;years to issue, may be confidential for 18&#160;months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our product candidates or future products. If a patent holder believes the manufacture, use, sale, offer for sale or importation of one of our product candidates or future products infringes its patent, the patent holder may sue us even if we have licensed other patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our licensed patent portfolio may therefore have no deterrent effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale, importation or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our future products or the manufacture or use of our future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future. If we were to challenge the validity of an issued U.S. patent in court, such as an issued U.S. patent of potential relevance to some of our product candidates or future products or manufacture or methods of use, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. There is no assurance that a court would find in our favor on questions of infringement or validity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found, or believe there is a risk we may be found, to infringe a third-party&#8217;s intellectual property rights, we could be required or may choose to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any such license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Without such a license, we could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our future products or force us to cease some of our business operations, which could materially harm our business. Alternatively, we may need to redesign our infringing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">products, which may be impossible or require substantial time and monetary expenditure. If we lose a foreign patent lawsuit alleging our infringement of a competitor&#8217;s patents, we could be prevented from marketing our therapeutics in one or more foreign countries and/or be required to pay monetary damages for infringement or royalties in order to continue marketing. Claims that we have misappropriated the confidential information, trade secrets or other intellectual property of third parties could have a similar negative impact on our business. Any of these outcomes would have a materially adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our future products or processes. Patent litigation is costly and time-consuming, and some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. We may not have sufficient resources to bring these actions to a successful conclusion. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts, adversely affect our ability to raise additional funds, and could limit our ability to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our contractors, collaborators, scientific advisors, employees and consultants and invention assignment agreements with our consultants and employees. We may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the contractors, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets. Enforcing a claim that a third-party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our trade secrets could otherwise become known or be independently discovered by our competitors. Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">accordance with the applicable rules, there are situations in which noncompliance can result in premature abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, we may not be able to stop a competitor from marketing drugs that are the same as or similar to our product candidates, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may not prosecute patents in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our in-licensed patent family drawn to AAVhu68 capsids is pending in major pharmaceutical markets including the United States, Canada, Europe, Japan, Korea, and China, as well as other jurisdictions; we will not be able to enforce the patent in any jurisdictions in which the application has not been filed. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and we or our licensor may be unable to predict and may fail to seek patent protection in jurisdictions in which protection may ultimately be desired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for&#160;years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent law in the United States and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Past or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, in March&#160;2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-inventor-to-file&#8221; patent system. Under a &#8220;first-inventor-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-inventor-to-file&#8221; provisions, only became effective in March&#160;2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case, <i style="font-style:italic;">Assoc. for Molecular Pathology v. Myriad Genetics,&#160;Inc.,</i> the U.S. Supreme Court held that certain claims to DNA molecules are not eligible for patent protection. We cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims asserting that our employees, consultants, advisors or collaborators have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of or other rights to what we regard as our own or licensed intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants or advisors, and the employees, consultants or advisors of our licensors, are currently, or were previously, employed at or affiliated with universities, hospitals or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Moreover, some of our licensors, and our or our licensors&#8217; employees, consultants or advisors are or have been affiliated or have a contractual relationship with multiple institutions and companies including our competitors and may have or have had an obligation to them. Such institutions and companies could challenge our license rights or our licensors&#8217; intellectual property ownership rights. Litigation may be necessary to defend against these claims and we may be obligated to indemnify our employees, consultants, advisors or collaborators in certain instances. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Hatch-Waxman Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if we were to seek a patent term extension, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of the intellectual property rights we have licensed are generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our clinical product candidates target indications are indications with small patient populations. In order for products that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such products must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size. If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect the cost of a single administration of gene therapy products, such as those we are developing, to be substantial when and if they achieve regulatory approval. Therefore, we expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of any of our product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, since CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Further, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours since there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to CMS and private payors, professional organizations such as the American Medical Association can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A Breakthrough Therapy Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may seek a Breakthrough Therapy Designation for our product candidates if the clinical data support such a designation for one or more product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">for clinical development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited the FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A Regenerative Medicine Advanced Therapy, or RMAT, Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We plan to seek RMAT Designations if the clinical data support such a designation for one or more product candidates. RMAT Designation is an expedited program for the advancement and approval of regenerative medicine products where preliminary clinical evidence indicates the potential to address unmet medical needs for life-threatening diseases or conditions. Similar to Breakthrough Therapy Designation, the RMAT Designation allows companies developing regenerative medicine therapies to work more closely and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated approval. FDA has confirmed that gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. For product candidates that have received an RMAT Designation, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">RMAT Designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for RMAT Designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of RMAT Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as an RMAT therapy, the FDA may later decide that the product candidate no longer meets the conditions for qualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A Fast Track Designation by the FDA may not lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have obtained Fast Track Designation for PBGM01 for the treatment of GM1 gangliosidosis, for PBFT02 for the treatment of FTD-GRN and for PBKR03 for the treatment of Krabbe disease. We may seek Fast Track Designation for one or more of our other product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">We have obtained Orphan Drug Designations for PBGM01 for the treatment of GM1 gangliosidosis, for PBFT02 for the treatment of FTD-GRN and for PBKR03 for the treatment of Krabbe disease. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user-fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven&#160;years, except in limited circumstances. For large molecule drugs, including gene therapies, sameness is determined based on the principal molecular structural features of a product. As applied to gene therapies, the FDA has recently issued final guidance in which it stated it generally intends to consider certain key features, such as the transgenes expressed by the gene therapy and the vectors used to deliver the transgene, to be principal molecular structural features. With regard to vectors, the FDA generally intends to consider whether two vectors from the same viral class are the same or different on a case-by-case basis. The FDA does not intend to consider minor differences between transgenes and vectors to be different principal molecular structural features. When two gene therapy products express the same transgene and have or use the same vector, determining whether two gene therapies are the same drug may also depend on additional features of the final gene therapy product, such as regulatory elements and the cell type that is transduced (for genetically modified cells). In such cases, FDA generally intends to determine whether two gene therapy products are different on a case-by-case basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">Although we have obtained Orphan Drug Designation for our clinical product candidates, and even if we obtain Orphan Drug Designation for additional product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. Similarly, the European Commission may also designate a product as an orphan drug under certain circumstances, and we have received Orphan designation for PBGM01 and PBKR03 from the European Commission. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rare Pediatric Disease designation by the FDA for any of our product candidates does not guarantee that the BLA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Under the Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying BLA for the treatment of a rare pediatric disease, the sponsor of such an application would be eligible for a rare pediatric disease priority review voucher that can be used to obtain priority review for a subsequent BLA or NDA. If a product candidate is designated before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026. While we have obtained Rare Pediatric Disease Designation for PBGM01 for the treatment of GM1 gangliosidosis and PBKR03 for the treatment of Krabbe disease, it is uncertain whether either product candidate will be approved by September 30, 2026. If approval is not obtained by then, we would not be in a position to obtain a priority review voucher, unless Congress further reauthorizes the program beyond the current sunset date in September 2024. Additionally, designation of a drug for a rare pediatric disease does not guarantee that a BLA will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Finally, a Rare Pediatric Disease Designation does not lead to faster development or regulatory review of the product or increase the likelihood that it will receive marketing approval. Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and the activities associated with their development and potential commercialization, including their testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMPs, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to physicians and recordkeeping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs and biologics to ensure drugs and biologics are marketed only for the approved indications and in accordance with the provisions of the approved product labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates beyond their potentially approved indications, we may be subject to enforcement action for off-label promotion. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such product candidates, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of any approved product from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-compliance with European requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates for which we intend to seek approval may face competition from biosimilars approved through an abbreviated regulatory pathway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA created an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12&#160;years after the original branded product is approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that if any of our product candidates is approved as a biological product under a BLA, it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Finally, there has been public discussion of potentially decreasing the period of exclusivity from the current 12&#160;years. If such a change were to be enacted, our product candidates, if approved, could have a shorter period of exclusivity than anticipated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. The full effect of recent United States healthcare reform and other changes in the healthcare industry, laws, and regulations and in healthcare spending is currently unknown, and the reform and other changes may adversely affect our business model. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. The commercial potential for our products, if any, could be affected by changes in healthcare spending and policy in the United States and abroad.  New laws, regulations, or judicial decisions or new interpretations of existing laws, regulations, or decisions, related to healthcare availability, the method of delivery, or payment for healthcare products and services could adversely affect our business, operations, and financial condition, if and when we are able to obtain marketing approval and commercialize our products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For example, the ACA was enacted in 2010 with a goal, among others, of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The ACA, among other things, expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, imposed a significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products, and enacted substantial provisions affecting compliance, which may affect our business practices with healthcare practitioners. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, the Biden Administration has indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. For example, on September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The HHS plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented, and to what extent these or any future legislation or regulations by the Biden administration will have on our business or future product candidates. In addition, former President Trump and President Biden both issued Executive Orders intended to favor government procurement from domestic manufacturers. These actions are likely to continue the downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation. For example, the ACA has faced ongoing legal challenges, including litigation seeking to invalidate some of or all of the law or the manner in which it has been implemented. More recently, the 2017 TCJA was signed into law, which eliminated certain requirements of the ACA, including the individual mandate. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. Thus, the ACA will remain in effect in its current form. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other reforms include the Drug Supply Chain Security Act, which imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the current regulations, guidance or interpretations will be changed, or what the impact of such changes on our business, if any, may be. Further, we are unable to predict whether additional governmental action will be taken in response to the COVID 19 pandemic and whether such action will adversely affect our ability to obtain marketing approval for or successfully commercialize our products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our operations and relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Restrictions under applicable U.S. federal and state healthcare laws and regulations may include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims laws, including the federal False Claims Act, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health, or HITECH, Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses, and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family, which includes annual data collection and reporting obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Other state laws require reporting of certain pricing information, including price increases. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates from government-funded healthcare programs, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">such as Medicare and Medicaid, disgorgement, oversight monitoring, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to rapidly expand our manufacturing, development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect to experience further growth in the number of our employees and the scope of our operations, particularly in the areas of manufacturing and clinical strategy, and growing our capability to conduct clinical trials. To manage our current development programs and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the research and development, clinical and business development expertise of our management, scientific and clinical team. We also benefit from the research expertise of Dr.&#160;Wilson, our Chief Scientific Advisor. Although we have entered into a consulting agreement with Dr.&#160;Wilson, he may terminate his relationship with us at any time. Although we have entered into employment letter agreements or employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and manufacturing strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recruiting and retaining qualified scientific, clinical, manufacturing and, if needed, sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs, particularly within the gene therapy space. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our internal computer systems, or those of our third-party collaborators or other contractors, may fail or suffer security breaches and cyber attacks, which could result in a material disruption of our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that we take reasonable steps that are designed to protect the security, integrity and confidentiality of the information we collect, use, store, and disclose, but inadvertent or unauthorized data access may occur despite our efforts. For example, our system protections may be ineffective or inadequate, or we could be impacted by software bugs or other technical malfunctions, as well as employee error or malfeasance. Additionally, privacy and data protection laws </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">are evolving, and it is possible that these laws may be interpreted and applied in a manner that is inconsistent with our data handling safeguards and practices that could result in fines, lawsuits, and other penalties, and significant changes to our or our third-party partners business practices and products and service offerings. To the extent that the measures we or our third-party business partners have taken prove to be insufficient or inadequate, we may become subject to litigation, breach notification obligations, or regulatory or administrative sanctions, which could result in significant fines, penalties, damages, harm to our reputation or loss of patients. While we have not experienced any material losses as a result of any system failure, accident or security breach to date, we have been the subject of certain phishing attempts in the past. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. Additionally, a party who circumvents our security measures could, among other effects, appropriate patient information or other proprietary data, cause interruptions in our operations, or expose patients to hacks, viruses, and other disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, insurance coverage to compensate for any losses associated with such events may not be adequate to cover all potential losses. The development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">To the extent that any disruption, security breach, or cyber-attack were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Depending on the nature of the information compromised, in the event of a data breach or other unauthorized access to our patient data, we may also have obligations to notify patients and regulators about the incident, and we may need to provide some form of remedy, such as a subscription to credit monitoring services, pay significant fines to one or more regulators, or pay compensation in connection with a class-action settlement (including under the new private right of action under the California Consumer Privacy Act of 2018, or the CCPA, which is expected to increase security breach litigation). Such breach notification laws continue to evolve and may be inconsistent from one jurisdiction to another. Complying with these obligations could cause us to incur substantial costs and could increase negative publicity surrounding any incident that compromises patient data. Additionally, the financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we may maintain, and there can be no assurance that the limitations of liability in any of our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above. Any of the foregoing could have an adverse effect on our business, reputation, operating results, and financial condition.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to utilize our net operating loss carryforwards may be subject to limitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had federal, state and local net operating loss carryforwards, or NOLs, of $126.6 million, $126.5 million and $116.3 million, respectively. $0.3 million of the federal NOLs will begin to expire in 2037, if not used prior to that date, and the remainder will carryforward indefinitely. State net operating loss carryforwards will begin to expire in 2037 and local net operating loss carryforwards will begin to expire in 2022. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any. Under legislative changes made by U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act, or the TCJA, U.S. federal net operating losses incurred in 2018 and in future&#160;years may be carried forward indefinitely, but the ability to utilize such federal net operating losses to offset taxable income is limited to 80% of our taxable income before the deduction for such net operating loss carryovers. It is uncertain if and to what extent various states will conform to the TCJA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income and post-change liability may be limited. We have not undertaken a Section&#160;382 study, and it is possible that we have previously undergone one or more ownership changes so that our use of net operating losses is subject to limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">U.S. federal income tax reform and changes in other tax laws could adversely affect us.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Tax laws are being re-examined and evaluated globally, and tax authorities are increasingly scrutinizing the tax positions of companies. Changes in tax laws and regulations in federal, state, local, and foreign jurisdictions could have material adverse impacts on our business, cash flows, operating results, or financial condition, and could materially affect our tax obligations and effective tax rate. For example, U.S. tax legislation enacted on December 22, 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Cuts and Jobs Act, significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. This legislation, among other things, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest and the use of net operating losses generated in tax years beginning after December 31, 2017 and allowed for the expensing of capital expenditures. The Tax Cuts and Jobs Act is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and the Internal Revenue Service, or IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was signed into law in March 2020, and subsequently in December 2020, the Continued Assistance for Unemployed Workers Act of 2020, or CARES Act II, was signed into law. The CARES Act and CARES Act II modify certain of the changes made by the Tax Cuts and Jobs Act. Changes in corporate tax rates, the realization of net deferred tax assets, and the deductibility of expenses under the Tax Cuts and Jobs Act, as amended by the CARES Act and CARES Act II, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, operating results and financial condition. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act, as amended by the CARES Act and CARES Act II, or any newly enacted federal tax legislation. Changes in tax laws or regulations in the various tax jurisdictions we are subject to that are applied adversely to us or our clients could increase the costs of our products and harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, we use our best judgment in attempting to quantify and reserve for our tax obligations. However, a challenge by a taxing authority, a limitation on our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions could have a material adverse effect on our business, results of operations, or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of FDA and ex-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time and expenses to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management and scientific resources from our business operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidates that we may develop.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently hold limited product liability insurance coverage. We will need to purchase additional product liability insurance coverage as we expand our clinical trials, and if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A successful product liability claim or series of claims brought against us, could decrease our cash and adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations that can harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">performance of particular companies. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of preclinical studies or clinical trials of our product candidates or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated or serious safety concerns related to the use of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive drugs or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our prospective patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning our collaborators, our external manufacturers or in-house manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain adequate product supply for any product candidate for preclinical studies, clinical trials or future commercial sale or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts or publications of research reports about us or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the biotechnology sector;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position or the announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other factors, including those described in this &#8220;Risk Factors&#8221; section, many of which are beyond our control.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors, principal stockholders and their affiliates exercise significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, our executive officers, directors, beneficial owners of 5% or more of our capital stock and their respective affiliates beneficially owned shares representing a substantial portion of our capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This group of stockholders has the ability to control us through this ownership position and may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have never declared or paid any cash dividends on our common stock and do not currently intend to do so for the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will be limited to the appreciation of stock. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in value of the stock. We cannot guarantee you that shares </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to establish and maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting within our Form 10-K. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. We will need to continue to dedicate internal and external resources to continually assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404 for a certain reporting period. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on The Nasdaq Stock Market LLC, or Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we grow, we expect to hire additional personnel and may utilize external temporary resources to implement, document and modify policies and procedures to maintain effective internal controls. However, it is possible that we may identify deficiencies and weaknesses in our internal controls. If material weaknesses or deficiencies in our internal controls exist and go undetected or unremediated, our financial statements could contain material misstatements that, when discovered in the future, could cause us to fail to meet our future reporting obligations and cause the price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will continue to incur increased costs as a result of operating as a public company and our management will continue to be required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a public company, particularly after we are no longer an &#8220;emerging growth company,&#8221; we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules&#160;subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i)&#160;the last day of the fiscal&#160;year in which we have total annual gross revenue of $1.07 billion or more; (ii)&#160;December&#160;31, 2025; (iii)&#160;the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three&#160;years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules&#160;of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the last business day of our most recently completed second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being permitted to present only two&#160;years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Form 10-K;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced disclosure obligations regarding executive compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may choose to take advantage of some, but not all, of the available exemptions. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year. We will continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0 million or (ii)&#160;our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The exclusive forum provisions in our restated certificate of incorporation and amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section&#160;22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule&#160;and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules&#160;and regulations thereunder.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020,&#160;we amended and restated our restated bylaws to provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of&#160;the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, Section&#160;203 of the DGCL may discourage, delay or prevent a change in control of our company. Section&#160;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and our restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors so that not all members of our board are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan, also known as a &#8220;poison pill&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit cumulative voting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, we are governed by the provisions of Section&#160;203 of the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to securities litigation, which could result in substantial expenses and could divert management attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock has been and may continue to be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not have any control over the analysts or the content and opinions included in their reports. If one or more of the analysts covering our business downgrade their evaluations of our stock, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain a large quantity of sensitive information, including confidential business and personal information in connection with our preclinical studies and our employees, and are subject to laws and regulations governing the privacy and security of such information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these constantly evolving laws can be subject to varying interpretations. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements with inconsistent or conflicting standards and given presently that there are no federal laws to preempt such state laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">California recently enacted the CCPA, which became operative on January 1, 2020 and became enforceable by the California Attorney General on July 1, 2020. Since, the CCPA has been amended on multiple occasions with additional regulations coming into force on August 14, 2020 with more recent amendments on March 15, 2021. Additionally, although not effective until January 1, 2023, in the November 2020 election, California voters passed the California Privacy Rights Act, or CPRA, which expands upon the CCPA. The CCPA requires (and the CPRA will require) covered companies to, among other things, provide new disclosures to California users, and affords such users new privacy rights such as the ability to opt-out of certain sales of personal information and expanded rights to access and require deletion of their personal information, opt-out of certain personal information sharing, and receive detailed information about how their personal information is collected, used, and shared. The CCPA provides for civil penalties for violations, as well as a private right of action for security breaches that may increase security breach litigation. Potential uncertainty surrounding the CCPA and CPRA may increase our compliance costs and potential liability, particularly in the event of a data breach, and could have a material adverse effect on our business, including how we use personal information, our financial condition, the results of our operations or prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States and prompt a number of proposals for new federal and state-level privacy legislation. Other states are beginning to pass similar laws. For example, an amendment to Nevada&#8217;s privacy laws, which went into effect October&#160;1, 2019, requires us to offer to consumers the right to opt-out of the sale of their personal information. In 2021, Virginia passed the Consumer Data Protection Act, or CDPA (enacted March 2021, effective January 1, 2023), and Colorado passed the Colorado Privacy Act, or CPA (enacted July 2021, effective July 1, 2023). We cannot fully predict the impact of the CCPA, CPRA, CDPA, CPA, or other similar laws or regulations on our business or operations, but they may require us to modify our data processing practices and policies that may incur costs and expenses in an effort to comply. Further, to the extent multiple state-level laws are later introduced, it may require costly and difficult efforts to achieve compliance with such laws that could expose us to fines and penalties for non-compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Outside of the United States, a new privacy regime, the General Data Protection Regulation or the GDPR, took effect in the European Economic Area, or the EEA, in May 2018. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. Additionally, the United Kingdom, or U.K., implemented the Data Protection Act, effective in May 2018 and statutorily amended in 2019, that contains provisions, including its own derogations, for how GDPR is applied in the U.K. From the beginning of 2021 (when the transitional period following Brexit expired), we have to continue to comply with the GDPR and also the U.K.&#8217;s Data Protection Act, with each regime having the ability to fine up to the greater of &#8364;20 million (&#163;17 million) or 4% of global turnover.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws (sometimes referred to as &#8220;third countries&#8221;), and imposes strict rules subject to substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our consolidated annual worldwide gross revenue). These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. Notably, the European Commission has adopted an adequacy decision in favor of the U.K., enabling data transfers from E.U. member states to the U.K. without additional safeguards. However, the U.K. adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/ extends that decision, and remains under review by the Commission during this period. The relationship between the U.K. and the E.U. remains uncertain, for example how data transfers between the U.K. and the E.U. and other jurisdictions will be treated and the role of the U.K.&#8217;s supervisory authority. Any changes or uncertainty as to the relationship between the U.K. and E.U. may lead to additional costs as we try to ensure compliance with new privacy legislation and will increase our overall risk exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On July 16, 2020, the Court of Justice of the European Union, or CJEU, invalidated the European Union-United States, or E.U.-U.S., Privacy Shield (under which personal data could be transferred from the E.U. to U.S. entities that had self-certified under the Privacy Shield scheme), or Privacy Shield on the grounds that the Privacy Shield failed to offer adequate protections to E.U. personal data transferred to the United States. In addition, while the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case by case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals. The use of standard contractual clauses for the transfer of personal data specifically to the United States remains under review by a number of European data protection supervisory authorities, along with those of some other E.U. member states. German and Irish supervisory authorities have indicated, and enforced in recent rulings, that the standard contractual clauses alone provide inadequate protection for E.U.-U.S. data transfers. Further, on June 4, 2021 the European Commission finalized new versions of the Standard Contractual Clauses, with the Implementing Decision now in effect as of June 27, 2021. Under the Implementing Decision, we will have until December 27, 2022 to update any existing agreements, or any new agreements executed before September 27, 2021, that rely on Standard Contractual Clauses as the data transfer mechanism. To comply with the Implementing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Decision and the new Standard Contractual Clauses, we may need to implement additional safeguards to further enhance the security of data transferred out of the EEA, conduct data transfer impact assessments, and review existing agreements which could increase our compliance costs, expose us to further regulatory scrutiny and liability, and adversely affect our business. The new standard contractual clauses apply only to the transfer of data outside of the EEA and/or Switzerland and not the United Kingdom, though the U.K.&#8217;s Information Commissioner&#8217;s Officer launched a public consultation on its draft international data transfer agreement in August 2021. We are monitoring the outcome of this.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We generally seek to comply with industry standards and are subject to the terms of our privacy policies and privacy-related obligations to third parties. We strive to comply with all applicable laws, policies, legal obligations and industry codes of conduct relating to privacy and data protection to the extent possible. However, it is possible that these obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. Any failure or perceived failure by us, even if unfounded, to comply with applicable privacy and data security laws and regulations, our privacy policies, or our privacy-related obligations to users or other third parties, or any compromise of security that results in the unauthorized release or transfer of personal information or other sensitive data, may result in governmental enforcement actions, litigation, or public statements against us by consumer advocacy groups or others and could cause our users to lose trust in us, which would have an adverse effect on our reputation and business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any significant change to applicable laws, regulations or industry practices regarding the use or disclosure of our users&#8217; data, or regarding the manner in which the express or implied consent of users for the use and disclosure of such data is obtained &#8211; or in how these applicable laws, regulations or industry practices are interpreted and enforced by state, federal and international privacy regulators &#8211; could require us to modify our practices, possibly in a material manner, may subject us to regulatory enforcement actions and fines, and may limit our ability to operate using the data that was voluntarily shared with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">manufacturing facilities, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. <span style="background:#ffffff;">In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear, and may heighten or intensify existing risk of natural disasters.&#160;</span>The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a77154d7_3ab8_4108_bbe0_166dc3ace37e"></a><a id="Item1BUnresolvedStaffComments_644817"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Unresolved Staff Comments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_73b55de9_5da3_4541_b3b1_640b2cd9b57f"></a><a id="Item2PropertiesandFacilities_24543"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Properties and Facilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.25pt;">Our principal executive office is located in Philadelphia, Pennsylvania, where we lease a total of approximately 37,000 square feet of office space, </span>that we use for our administrative, research and development and other activities, which commenced in February 2021 and will expire in December 2031, subject to our option to extend the term of the lease by up to two additional five-year terms<span style="letter-spacing:0.25pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also lease approximately 62,000 square feet of laboratory space at the Princeton West Innovation Campus in Hopewell, New Jersey. This lease has a 15-year term from the lease commencement date of March 2021. We have the option to extend the term of the lease by up to two additional five-year terms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e939afde_4988_4055_8772_20acba8df7ef"></a><a id="Item3LegalProceedings_840413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e76caa17_0d84_450d_9c4e_65da870cca11"></a><a id="Item4MineSafetyDisclosures_801065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_047b62a5_4a2a_4fbd_be7e_7c566def2d73"></a><a id="PARTII_199413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity</span><span style="font-style:italic;"> Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Market Information for Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our common stock has been listed on The Nasdaq Global Market under the symbol &#8220;PASG&#8221; since February&#160;28, 2020. Prior to that there was no public trading market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Holders of Record</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March&#160;1, 2022, there were approximately 8 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by this item regarding equity compensation plans is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Unregistered Sales of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Proceeds from Registered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March&#160;9, 2020, we completed our IPO and sold 13,800,000 shares of common stock at an IPO price of $18.00 per share. The offer and sale of all of the shares in the IPO were registered under the Securities Act pursuant to registration statements on Form&#160;S-1 (File Nos. 333-236214 and 333-236733), which was declared effective by the SEC on February&#160;27, 2020. No additional shares were registered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We received net proceeds from the IPO of approximately $227.7 million, after deducting underwriting discounts and commissions of approximately $17.4 million and estimated offering expenses of approximately $3.3 million. J.P. Morgan Securities LLC, Goldman Sachs&#160;&amp; Co. LLC and Cowen and Company, LLC acted as joint book-running managers of the offering and as representatives of the underwriters. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There has been no material change in the planned use of proceeds from our IPO as described in the Prospectus filed with the SEC pursuant to Rule&#160;424(b)(4)&#160;under the Securities Act on February&#160;28, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3a8b8855_869c_42e2_bf89_274b1bea760e"></a><a id="Item6SelectedFinancialData_184761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">[Reserved]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a1540f93_8305_4047_9671_0a3b78dfec31"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are a clinical stage genetic medicines company focused on developing transformative therapies for CNS disorders. Our vision is to finally fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases. The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success. We have entered into a strategic research collaboration with the Trustees of the University of Pennsylvania&#8217;s, or Penn&#8217;s, Gene Therapy Program, or GTP, headed by Dr.&#160;James Wilson, a leader in the genetic medicines field. We also leverage our close working relationship with Penn&#8217;s Orphan Disease Center, or ODC, to develop historical and prospective comparable natural history patient profiles for comparison to participants in interventional trials. Through this collaboration we have assembled a deep portfolio of genetic medicine product candidates, including our three clinical product candidates, all of which we retain global rights. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a84e3599_4b3f_4b01_9e0d_5f6e28bc2b02"></a><a id="_482c8b84_e000_4672_b2f6_e65e39b4999e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in July&#160;2017 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to acquiring and developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. Historically, we have funded our operations through the sale of convertible preferred stock and public offerings of common stock. Our net losses were $185.4&#160;million and $112.2 million for the&#160;years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $356.3 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. Our net losses may fluctuate significantly from quarter to quarter and&#160;year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.</p><a id="_6962f554_1ede_4f42_9ea1_4dd230b9ed45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had cash, cash equivalents and marketable securities of $315.8 million. We expect our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expense and capital expenditures requirements until the end of 2023. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">COVID-19 Impact</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are continuing to proactively monitor and assess the current coronavirus disease 2019, or COVID-19, global pandemic. Since early March 2020, we have activated a management team task force to assess the potential impact on our business that may result from this rapidly evolving crisis and to avoid any unnecessary potential delays to our programs. The safety and well-being of employees, patients and partners is our highest priority. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we diligently work to activate sites for our clinical programs, we are experiencing some impacts to our site initiation activities related to COVID-19, such as meeting delays with various investigational review bodies or ethics committees that have prioritized COVID-19 related clinical trials and staffing levels at site hospitals. For example, the clinical initiation of our upliFT-D clinical study for PBFT02 and the GALax-C clinical study for PBKR03 were substantially impacted by COVID-19-related issues. Our expected timelines for clinical trials could be further delayed by these impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">University of Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have a research, collaboration and licensing agreement, as amended, or the Penn Agreement, with Penn, for research and development collaborations and exclusive license rights to patents for certain products and technologies.&#160;Under the Penn Agreement, we have the obligation to fund certain research relating to the preclinical development of selected products in research programs as well as the new exploratory research program in non-rare and/or non-monogenic (or large) CNS indications, initially Alzheimer&#8217;s Disease, or AD, and Temporal Lobe Epilepsy, or TLE. We also fund discovery research conducted by Penn through August 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for products developed with GTP,&#160;such as novel capsids, toxicity reduction technologies and delivery and formulation improvements.&#160;Our discovery research funding commitment is $5.0 million a&#160;year for five&#160;years, with quarterly payments of $1.3 million through June 2026.&#160;Under&#160;the Penn Agreement we have eight remaining&#160;options available to us to commence additional licensed programs for CNS indications until May&#160;2026. If we were to exercise any of these remaining options, we would owe Penn a non-refundable aggregate fee of&#160;$1.0 million, with $0.5&#160;million per product indication paid immediately and another $0.5 million fee owned upon a further developmental milestone.</p><a id="_cp_text_2_21"></a><a id="_cp_text_1_22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Penn Agreement requires that we make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, we are obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon successful commercialization of a product using the licensed technology, we are obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, we are obligated to pay to Penn a&#160;percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement.</p><a id="_cp_text_1_24"></a><a id="_cp_text_2_25"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We and Penn entered into an amendment, or the Amendment, to the Penn Agreement, on August 3, 2021. Under the Amendment, we and Penn expanded the scope of the collaboration to include certain non-rare and/or non-monogenic, or large, CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications; included an exploratory research collaboration to identify targets and early product candidates in such large CNS indications; and extended the term to August 3, 2026 by which product candidates for CNS indications may be selected for the entire </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_32"></a><a id="_Hlk78782235"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">agreement. The exploratory research program is focused on discovering targets and novel gene therapy candidates for large CNS diseases, initially focused on AD and TLE, and that can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is 3 years, which term can be extended by mutual agreement. During such term we will have an exclusive right of first negotiation to include additional targets to the exploratory research program in the agreed upon large CNS indications. Under the exploratory research program, we will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within AD and TLE (and any future large CNS indications that are mutually agreed upon) that arise from the exploratory research programs on substantially the same terms of the current Penn Agreement. The election of any option to any such product candidates will count against our remaining eight options and will trigger the aggregate $1.0 million option fee. As a result, we now will fund discovery research through August 3, 2026, and will now have until August 3, 2026 to exercise our remaining eight options. We made an upfront payment of $5.0 million; will reimburse Penn for expenses incurred in the exploratory research program; and will pay Penn a tiered transaction fee ranging from 1-2% of the net proceeds upon certain change of control events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration and Manufacturing and Supply Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Catalent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2019, we entered into a collaboration agreement, or the Collaboration Agreement,&#160;with Catalent Maryland,&#160;Inc., or Catalent. As part of the Collaboration Agreement, we paid Catalent an upfront fee for the commissioning, qualification, validation and equipping of a dedicated clean room suite, or the Clean Room Suite. We will pay an annual fee for five years for the exclusive use of the Clean Room Suite, which commenced in November 2020 upon its validation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, we entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for our gene therapy product candidates. The Manufacturing and Supply Agreement provides for a term of five&#160;years which period may be extended once, at our option, for an additional five&#160;year-period. The Collaboration Agreement <span style="background:#ffffff;">continues to be in effect pursuant to its terms</span>. <span style="background:#ffffff;">Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for our gene therapy product candidates at the Clean Room Suite provided for in the Collaboration Agreement. There is a minimum annual purchase commitment owed to Catalent for five years beginning in November 2020, subject to certain inflationary adjustments. The Manufacturing and Supply Agreement provides for a term of five years which period may be extended once, at our option, for an additional five-year period. We have the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If we terminate the Manufacturing and Supply Agreement, we will be obligated to pay an early termination fee to Catalent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, we have an annual minimum commitment of $10.6 million per year owed to Catalent for five years from November 2020, subject to certain inflationary adjustments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development and Acquired In-Process Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval, including payments to Penn for preclinical research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in obtaining technology licenses related to technology that has not reached technological feasibility and has no alternative future use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel expenses, including salaries, benefits and share-based compensation expense for employees engaged in research and development functions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to funding research performed by third parties, including pursuant to agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses and fees paid to consultants who assist with research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocated expenses for facilities costs, including rent, utilities, depreciation and maintenance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We track outsourced development expenses and other external research and development expenses to specific product candidates on a program-by-program basis, such as expenses incurred under our collaboration with Penn, fees paid to CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other expenses which are deployed across multiple projects under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development expenses than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several&#160;years as we increase personnel costs, including share-based compensation, conduct our clinical trials, including later-stage clinical trials, for current and future product candidates and prepare regulatory filings for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred in obtaining technology licenses are expenses as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, commercial, quality, regulatory, operations and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, not otherwise included in research and development expense, legal expenses related to intellectual property and corporate matters, insurance expense, and expenses for accounting and consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts and continued increased expenses of operating as a public company. These increases will likely include increased expenses related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of The Nasdaq Stock Market, LLC and the SEC, insurance and investor relations expenses. If any of our current or future product candidates obtains U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a commercial sales and marketing team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Income, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income, net consists of interest earned on our cash equivalents and marketable securities, offset by amortization of premium and discount on our marketable securities and fees paid to our external asset manager.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December&#160;31, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth our results of operations for the&#160;years ended December&#160;31, 2021 and 2020.</p><a id="_a6adc941_7386_4750_b701_ae4082a4e303"></a><a id="_c7305c33_bd61_41fd_b804_3483ddafc06c"></a><a id="_7086ffc5_5994_4aa4_bd40_8a359dfc8d5a"></a><a id="_8e03cf99_71e7_4d69_9838_7bd01e2a59f5"></a><a id="_13233858_5e48_48e1_bb88_c8c627466045"></a><a id="_08d40d4d_b6b8_429c_9915_cbb15100bd3b"></a><a id="_df6646df_cd6c_43af_bb56_b8a9ad86158c"></a><a id="_cba72d69_19f7_4c3e_b541_5d0850947e62"></a><a id="_7ce0ff8d_dd52_4395_a065_def1f342984d"></a><a id="_fb40dcb7_963c_4c01_b709_6d01426f7d58"></a><a id="_26a82b8f_995e_4ae8_9ccb_ebe8a832785b"></a><a id="_2ce60b59_7025_47aa_a2d8_829420cb86a1"></a><a id="_32fd4e72_6c68_4861_b6d7_f75267d986bd"></a><a id="_49f47f09_e299_4704_abaa_275b0394c41e"></a><a id="_84c9c4ce_e8d5_422f_b31b_d3a5db64778e"></a><a id="_5dec3196_d427_4435_99c9_4278f1bd8402"></a><a id="_4570ab04_9046_47a8_9e7b_e0ce5053149f"></a><a id="_d00114c1_2759_434c_a3a9_f03e87dfb2e9"></a><a id="_a5012e5c_8cfb_4fb9_bb5d_6aaadaca3316"></a><a id="_7e974bb4_9004_4231_9a2b_1905f7a09b67"></a><a id="_49c9d549_cc75_4f55_915f_ac8a2fc173fb"></a><a id="_1d400d30_2715_4e6e_ad7f_0215b7d431db"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,673</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81,788</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,885</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in&#8209;process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,056</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,942</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (185,729)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (112,902)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (72,827)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 670</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (327)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (185,386)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (112,232)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (73,154)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by $35.9 million from $81.8 million for the&#160;year ended December&#160;31, 2020 to $117.7 million for the&#160;year ended December&#160;31, 2021. The increase was primarily due to increases of: $19.7 million in personnel-related expenses, including share-based compensation, due to an increase in employee headcount in the research and development function and expenses related to the modification of stock options, which increased by $5.5 million; $18.7&#160;million in clinical manufacturing expenses related to manufacturing supply for our clinical product candidates and in preparation of an IND filing for a research program; $10.9 million in clinical operations expenses to support the clinical trials of our clinical product candidates; and, $3.7 million in facility and other expenses. These increases were partially offset by decreases of: $2.5 million in professional services and consulting expense; and, $14.6 million in research and development expenses with Penn, which relates to expenses incurred for preclinical work performed in preparation for IND filings for our clinical programs. We expect that expenses associated with Penn will continue to vary from period to period based on the status of our preclinical pipeline and the timing of preclinical work performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We track outsourced development, outsourced personnel costs and other external research and development costs of specific programs. We do not track our internal research and development costs on a program-by-program basis. Research and development expenses are summarized by program in the table below:</p><a id="_393023cf_788e_416c_8049_92df0a6a7f27"></a><a id="_b3bb601a_c665_4e91_9d22_7a2a509cbc0e"></a><a id="_88e81e98_acd7_4812_a5ce_1e0293b03216"></a><a id="_7b913a78_35af_45e3_a6f3_64435549e499"></a><a id="_9be1c65f_f0ac_48e2_afcc_df9505b16fa3"></a><a id="_fc210116_1c98_4da6_845d_336c1a678e0d"></a><a id="_96b73214_66f3_4f5f_a6f1_f02ebe53c1a6"></a><a id="_7f3e6878_5e06_4b32_a428_9979973781ff"></a><a id="_4498a5ee_827d_4493_931a_7258dc0005cb"></a><a id="_0e046d2e_d9e8_4379_87c6_ea8e1b359627"></a><a id="_75c39257_1c53_424b_819b_949fd8368f77"></a><a id="_81fd08c2_0171_4ab3_9239_cb988f66f537"></a><a id="_e5e1f94d_9073_482f_a8d4_e8084ecacaa5"></a><a id="_e139206b_43e7_475f_a46a_dac35f5d91a8"></a><a id="_7029c759_0621_4874_a519_8b4f54738d79"></a><a id="_d0109285_74ac_4a81_acc7_35d4784416f9"></a><a id="_f8bb52b4_4607_470a_9baa_5f177d5cd802"></a><a id="_31aab12a_8fa0_4fce_b205_c581559aeb79"></a><a id="_55216162_1cf6_4fef_9055_1a23a0185584"></a><a id="_a689238c_da14_44b0_ad76_de811023d146"></a><a id="_b44fa3ef_2266_44b2_a6eb_0858ede2c3be"></a><a id="_e0c8640e_3412_4065_803f_83634c44768a"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Program Specific Expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">GM1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,871</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,176</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">FTD&#8209;GRN</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,982</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,944</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Krabbe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,893</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">MLD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,826</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other Programs and Discovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,529</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,042</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unallocated Internal Expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel-related (including share-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,956</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,219</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,771</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,688</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,673</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81,788</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process research and development expenses were $8.0 million for the&#160;year ended December&#160;31, 2021 compared to $1.0 million for the&#160;year ended December&#160;31, 2020. We incurred $1.5 million in license fees, $1.5 million </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in fees related to the achievement of a development milestone, and $5.0 million in fees related to the August 2021 amendment with Penn during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $30.0 million from $30.1 million for the&#160;year ended December&#160;31, 2020 to $60.1 million for the&#160;year ended December&#160;31, 2021. The increase was primarily due to increases of: $21.8 million in personnel-related and share-based compensation expense due to increases in employee headcount; and, $8.2 million in facility, professional services and other expense related to expanding our operations to support our research and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Income, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income, net was $0.3 million and $0.7 million for the years ended December 31, 2021 and 2020, respectively. Interest income is primarily attributable to interest income earned on our cash, cash equivalents and marketable securities, partially offset by amortization of premium and discount on our marketable securities and fees paid to our external asset manager. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><a id="_749a5358_31a3_421e_9ef7_94e60a1d439c"></a><a id="_c13625c9_621c_44f0_897f_9eed7397fe04"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Historically, we have funded our operations through the sale of convertible preferred stock and public offerings of common stock. In January 2021, we received $165.8 million in net proceeds from the sale of our common stock. As of December&#160;31, 2021, we had $315.8 million in cash, cash equivalents and marketable securities and had an accumulated deficit of $356.3 million. We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expense and capital expenditures until the end of 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our primary use of cash is to fund operating expenses, most significantly research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish additional collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect existing stockholders&#8217; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 5, 2021, we entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we may, but are not obligated to, offer and sell, from time to time, shares of our common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent. No sales of common stock have been made pursuant to this Sales Agreement to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table shows a summary of our cash flows for the periods indicated:</p><a id="_9e32795d_73e5_4ac0_afc7_3039ef657e84"></a><a id="_0f4e42b6_5d58_41a2_8a7c_f3577936b057"></a><a id="_92326dd0_9ab7_48e8_8a81_ae9df73a0593"></a><a id="_c72469ea_484a_468a_9439_3ffa6e64b707"></a><a id="_b7925e7b_699a_47bf_ad0e_63939f7c88cb"></a><a id="_0ee8f08b_f136_4197_8a49_1645292b7a6e"></a><a id="_cb7b4b0f_c2c7_4b7e_bd1e_ff5eb046ee42"></a><a id="_927e9826_8411_4711_800d_fc0624e45ecd"></a><a id="_a12baf7f_de82_4209_950b_47ec28d94317"></a><a id="_e7c2b480_c29d_4c1e_8c46_bdee00dd41fa"></a><a id="_e63599f8_69b4_4f24_badd_5dc3a71b21d0"></a><a id="_12f5494c_af3a_40d2_9eef_031bca22f31c"></a><a id="_bbf7750b_1c7e_43c3_a1a1_f4332b3dedc6"></a><a id="_74c274b7_0a5d_4928_8f84_59a4797300c8"></a><a id="_982fc7c6_3334_4a42_a574_a2d8e91406bb"></a><a id="_e3013d5b_98e2_4506_95a1_7e5521fc095e"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (126,879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (80,520)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (45,814)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (172,106)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 166,656</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 228,754</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,037)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,872)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31, 2021, we used $126.9 million of net cash in operating activities, primarily to fund our operations related to the development of our product candidates and related general and administrative support activities. Cash used in operating activities reflected our net loss of $185.4 million, which was partially offset by adjustments to reconcile net loss to net cash used in operating activities of $47.1 million related to acquired in-process research and development expense, share-based compensation, depreciation and amortization, amortization of premium and discount of marketable securities, net and changes in deferred rent as well as a $11.4 million net increase in cash flows resulting from changes in our operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the year ended December 31, 2020, we used $80.5 million of net cash in operating activities, primarily to fund our operations related to the development of our product candidates. Cash used in operating activities reflected our net loss of $112.2 million, which was partially offset by non-cash charges of $17.3 million related to acquired in-process </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">research and development expense, share-based compensation, depreciation and amortization, amortization of premium and discount, net and changes in deferred rent as well as a $14.4 million net increase in cash flows resulting from changes in our operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Net Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December 31, 2021, we purchased $202.5 million in marketable securities and had sales and maturities of $182.4 million in marketable securities. Additionally, we used $17.6 million for the purchase of property and equipment and we used $8.0 million to purchase technology rights from Penn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December 31, 2020, we purchased $266.1 million in marketable securities and had sales and maturities of $95.6 million in marketable securities. Additionally, we used $1.1 million for the purchase of property and equipment and we used $0.5 million to purchase technology rights from Penn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Net Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31, 2021, financing activities provided $165.8 million from the sale of our common stock, we received $0.9 million from the issuance of common stock under our employee stock purchase plan, we received $0.3 million from the exercise of stock options, partially offset by payments for offering costs of $0.3 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31, 2020, financing activities provided $228.3 million from the sale of our common stock, we received $0.2 million from the issuance of common stock under our employee stock purchase plan, and we received $0.3 million from the exercise of stock options. </p><a id="_29a9780f_cc9e_4c04_b4cc_020481604162"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual obligations and other commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">We lease approximately 37,000 square feet of office space in Philadelphia, Pennsylvania. The lease will expire in&#160;December 2031. We have an option to extend the term of the lease by up to two additional five-year terms. The aggregate estimated rent payments due over the initial term of the lease is $11.8&#160;million, with rent payments beginning in 2022. The landlord provided us with a tenant improvement allowance of up to $2.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:0pt;">We lease approximately 62,000 square feet of laboratory space in Hopewell, NJ. The lease will expire in March 2036. The aggregate estimated rent payments due over the initial term of the lease is approximately $40.3 million, with rent payments beginning in 2021. The landlord provided us with a tenant improvement allowance of up to $1.3 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement with Catalent, we have an annual minimum commitment of $10.6 million per year owed to Catalent through November 2025, subject to certain inflationary adjustments. We have the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If we terminate the Manufacturing and Supply Agreement, we will be obligated to pay an early termination fee to Catalent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">Under the Penn Agreement, we agreed to fund discovery research conducted by Penn for five years, beginning in May 2020. Our funding commitment is $5.0 million a year through June 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">The contractual obligations and commitments above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation are not included in the preceding table as the amount and timing of such payments are not known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">The contractual obligations and commitments above do not include any potential milestone or royalty payments that we may be required to make under the Penn Agreement. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'Arial Narrow';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and share-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note&#160;3 to our annual financial statements included elsewhere in this Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We accrue an expense for preclinical studies and clinical trial activities performed by Penn and other vendors based on an estimate of progress to completion of specific tasks using facts and circumstances known to us at that time. We determine the estimates by reviewing contracts, vendor agreements and change orders, and through discussions with our internal clinical personnel and external service providers as to the progress to completion of trials or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We make estimates of our accrued research and development expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize compensation costs related to share-based awards granted to employees and directors, including stock options and restricted stock units, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting share-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We estimate the fair value of stock options using the Black-Scholes option-pricing model, which requires assumptions, including the fair value of our common stock prior to our initial public offering, volatility, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield. Certain assumptions used in our Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties, and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, our share-based compensation expense could be materially different in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The subjective assumptions is estimated as follows:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#8212;We do not have sufficient historical trading history based on the length of time we have been a public company. Therefore, the expected volatility is estimated based on the average volatility for a composite of comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty. As a public company we have and will continue to use the average volatility for comparable publicly traded biotechnology companies until we have sufficient trading history of our own stock commensurate with the estimated expected term of our options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">See Note&#160;3 to our financial statements found elsewhere in this Form 10-K for a description of recent accounting pronouncements applicable to our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">JOBS Act Accounting Election</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS ACT, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards would apply to private companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will remain an emerging growth company until the earliest of (1)&#160;the last day of our first fiscal&#160;<span style="white-space:pre-wrap;">year  (a)&#160;in which we have total annual gross revenues of at least $1.07 billion, or (b)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221;, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June&#160;30th, (2)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period and (3)&#160;December&#160;31, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0 million or (ii)&#160;our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_437b3d24_9919_4cc4_baba_7095424d892a"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. However, we believe that our exposure to interest rate risk is not significant as the majority of our investments are short-term in duration and due to the low risk profile of our investments, a 10% change in interest rates would not have a material effect on the total market value of our investment portfolio. We have the ability to hold our marketable securities until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we held $315.8&#160;million in cash, cash equivalents and marketable securities, all of which was denominated in U.S. dollar assets, and consisting primarily of cash accounts in banking institutions and investments in money market funds, certificates of deposit, commercial paper, corporate bonds and investments in U.S. and non-U.S. treasury securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also exposed to market risk related to changes in foreign currency exchange rates, as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. For the&#160;year ended December&#160;31, 2021, a majority of our expenditures were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09a7a573_7452_420a_994f_28a5da508895"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PASSAGE BIO,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO AUDITED FINANCIAL STATEMENTS</p><a id="_d10027ef_964f_41cc_af6c_174b3a72c90e"></a><a id="_2462c838_4fdf_4ddb_8c1f_4e9642e4a26d"></a><a id="_26285a9d_cc23_4e91_b9c5_7029250690ee"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:91.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:91.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:6.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:91.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:91.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> <span style="font-size:9pt;">(</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:AuditorName" id="Narr_dm9ojAqRZEKyUwXXcJVmXw"><span style="font-size:9pt;">KPMG LLP</span></ix:nonNumeric><span style="font-size:9pt;">, </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:AuditorLocation" id="Narr_sEARR78q0EKIzzeaB4zp3A"><span style="font-size:9pt;">Philadelphia, PA</span></ix:nonNumeric><span style="font-size:9pt;">, Auditor Firm ID:</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="dei:AuditorFirmId" id="Narr_Qiw7hIoIo0qZw0xVSeOHaw"><span style="font-size:9pt;">185</span></ix:nonNumeric><span style="font-size:9pt;">)</span></p></td><td style="vertical-align:top;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">116</p></td></tr><tr><td style="vertical-align:bottom;width:91.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#BalanceSheets_463357"><span style="font-style:normal;font-weight:normal;">Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">117</p></td></tr><tr><td style="vertical-align:bottom;width:91.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#StatementsofOperationsandComprehensiveLo"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">118</p></td></tr><tr><td style="vertical-align:bottom;width:91.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#StatementsofConvertiblePreferredStockand"><span style="font-style:normal;font-weight:normal;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">119</p></td></tr><tr><td style="vertical-align:bottom;width:91.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#StatementsofCashFlows_152708"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">120</p></td></tr><tr><td style="vertical-align:bottom;width:91.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><a href="#NotestoFinancialStatements_627885"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 0pt 0pt;">121</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09ff467a_40be_40eb_aada_d9a78ce900f7"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors<br />Passage Bio, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Opinion on the</i><span style="font-weight:normal;"> </span><i style="font-style:italic;font-weight:normal;">Financial Statements</i></p><a id="_0"></a><a id="_1"></a><a id="_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying balance sheets of Passage Bio, Inc. (the Company) as of December&#160;31,&#160;2021 and 2020, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements).&#160;In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Basis for Opinion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Philadelphia, Pennsylvania<br />March&#160;3, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4d3892df_c738_4c31_aedb_654e748fcdfc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><a id="BalanceSheets_463357"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><a id="_25fb32fd_5435_41ad_9164_73be572e0ce8"></a><a id="Tc_9eQMItZ_70aGA_Nnz82mRA_1_2"></a><a id="Tc_yZvK-wFDjU6oJ6yCKhFfmw_2_0"></a><a id="Tc_IE9Nur3Ky0yraIpdLKK6Jg_2_2"></a><a id="Tc_6oro0P-N3UypuNhQ75uwnQ_2_5"></a><a id="Tc_r0plduZhAkCXRBP-W9sfdQ_3_0"></a><a id="Tc_7KHhCwzgGES2Cs_tobYVpg_4_0"></a><a id="Tc_wcsUWxKMkE-oPYjBiB5rAA_5_0"></a><a id="Tc_PrYt6FvXnU6okYHi1cCfjw_5_2"></a><a id="Tc_I2GEZxgLR06vNP1BlCdRbw_5_5"></a><a id="Tc_pfv3dzzOt0eljZyFTmxtVA_6_0"></a><a id="Tc_jKCrI-V5uE2EBP42Tb1ncA_7_0"></a><a id="Tc_kZHlhlbPm0yUv6htif7Pnw_8_0"></a><a id="Tc_9YK5i8JRVk2yuvZZnhN5lQ_9_0"></a><a id="Tc_EXwUc29unE6SlgmhtlkV8Q_10_0"></a><a id="Tc_jmfTuou6Z0W0UdoLbk7bMw_11_0"></a><a id="Tc_F2weVjX_hUaDDGgW8U_eFQ_12_0"></a><a id="Tc_pLTSzsv9a0iLlaupITL4bQ_12_2"></a><a id="Tc_J38VquPYDEmJusAWdzDryA_12_5"></a><a id="Tc__8sZ6vy7MUuA1j4ZTb6ueA_13_0"></a><a id="Tc_j-OUUfY3mU6gRHyyxuilig_14_0"></a><a id="Tc_AP26pVw8yU-nmitwwPydrw_15_0"></a><a id="Tc_bBqi5AzXHUiI4g8tWO-B4w_15_2"></a><a id="Tc_HzrBkTCcPU6gS4Wtl4bGcA_15_5"></a><a id="Tc_vw4y2gcoF0mwcE_sS6ezGA_16_0"></a><a id="Tc_C7vu6Dmpnk6hr8tPEArLBw_17_0"></a><a id="Tc_5NIeD21PEky0JmjFCiYeNw_18_0"></a><a id="Tc_KwVVvaC9KEOzAf_9sMOcBw_19_0"></a><a id="Tc_n7yixuqlgUWla0BsWKkBUA_19_3"></a><a id="Tc_K41rh4vPz0i4C4MFk0tQIg_20_0"></a><a id="Tc_BQsOkI4bUUKHbcqXRcHZZw_22_0"></a><a id="Tc_-u0sQ6Mi0kuuMuPVE3YBNQ_24_0"></a><a id="Tc_LJBDM7vrE06opnD9LiMD4Q_25_0"></a><a id="Tc_nif3uDylXUu0ld1bk-zMig_26_0"></a><a id="Tc_tuGo_9jgqkOf04WW4XtZxg_27_0"></a><a id="Tc_ZHlMLBr5Lkq2qcgegJt9IQ_28_0"></a><a id="Tc_adg6NyiiKEanQabYhT2IKw_29_0"></a><a id="Tc_6oBzJurUXU2PaiWsVf3tAA_30_0"></a><a id="Tc_jAM4X_vW9kanVLOqkMai9w_30_2"></a><a id="Tc_YmytlogqL0S3Q52ml2j5Gg_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gBxWRoX-Sk-79qBbNu22PA_5_3">128,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JlMw8K209E-jOvxha5rKzg_5_6">135,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_F6rhcSH57k69qJtM_6VRXQ_6_3">186,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_IDcIl34uvkeFwrvkxd9IOg_6_6">169,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_FvGSCa8IREK13wt5DENrOg_7_3">1,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Mhmba-OXFUiNspyxzyOpgA_7_6">1,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" scale="3" id="Tc_jED8khd4v0SuNHz0Vbd6yg_8_3">7,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" scale="3" id="Tc_R87VKWQXZUaY4iWp1sxP9g_8_6">10,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_2gdYJ7pL1k28eBsuuLl58g_9_3">325,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_r8dpAACeAUWxFdWOhZwO9A_9_6">317,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_toCpSQplmEOyR1-hZSXuNw_10_3">23,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_4_-LuL0m70uI6_m5wMFLrg_10_6">2,795</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Gj6f9wHh40e7yLbMI5xXdw_11_3">6,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_8Gz2smF8qEifRVn7S2PDNQ_11_6">8,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_bh347ll81Eat-gEHYM2hiA_12_3">355,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_T5GT7dY2GUewJqtmoUsL_w_12_6">328,007</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_xnT9uWay50mlSn0DCOE3Ew_15_3">9,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_kRywCvGmu0SIlCg7KWxaDA_15_6">5,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_mB6yO41Tf060_QpQVsI3xw_16_3">20,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_u-AMKVvz6Eq2BeLdmpoMpA_16_6">15,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_8y8qWrcdN0maVa73NZqEjw_17_3">29,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_vSMjHuLhTECJrCQCfNegmQ_17_6">21,175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="Tc_b_cpDxe-aUiuFN-BBkn-Sg_18_3">6,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="Tc_AHIEkEv3e0OvrTPtXtieKg_18_6">2,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_cNP2HN0yjkORzX9p0woDLw_19_6">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Hf0F7MORV0ufllGiK-7RrA_20_3">36,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_CdM59HGDrUKxOh9dhtFrOg_20_6">23,293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and Contingencies (note&#160;8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_QgNCtn7eyUOzPW1ncWmTGg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_sz-KdUHvtEq3f2CMH7LOlw">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4cdNIl66Gka8n5QOYDqvdw"><ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_bp68NOzV20SJWQVPq9Lbpw">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_7o4RrhuI8k6HXmEHIM170A">54,244,996</ix:nonFraction> shares issued and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_t1keXmyoGUS9IuESOdP88g">54,244,996</ix:nonFraction> shares outstanding at December&#160;31,&#160;2021 and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_1DrFzj-aYEyJsdHjZvjRvA">45,917,084</ix:nonFraction> shares issued and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_pbTzwKXtEUOxVqVo0G8beQ">45,614,807</ix:nonFraction> shares outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_EdJHc2tCvUSHVZ2KUI2x2g_25_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_gXuE3MIeC0u_DW8W9e6SDQ_25_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid&#8209;in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_7XsEpu9DIE6yXwd71Sct6g_26_3">675,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_O47s-Fs2WUOTgz8lXk-ziw_26_6">475,617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_gLplj5MHWEGjk4Gd91v_Rw_27_3">413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_FRlUA7dQlUyDBxHUe78e7Q_27_6">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_nGGlxgqr4EK5sXLojdXXyQ_28_3">356,281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_01k8perK3UarsTVgbQzIOQ_28_6">170,895</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1EO7_O4at0mGHOi_eM_8WA_29_3">318,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LpGE5KP7LUeVVejBM8jOtQ_29_6">304,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_KX8K0PB21EKKe7PglDGUVA_30_3">355,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_mdj5Cp3YtkuwX9qndvtY-Q_30_6">328,007</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ded839d9_5670_4a3b_822c_544109504e5d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Passage Bio,&#160;Inc.</p><a id="StatementsofOperationsandComprehensiveLo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statements of Operations and Comprehensive Loss</b></p><a id="_55c39055_083f_4482_b0c5_bfcebec7f2c3"></a><a id="Tc_3NAlrLeTd0mjbFneeRzWdA_1_2"></a><a id="Tc_2klSg7c00kWiH3sF0l0bSg_2_0"></a><a id="Tc_HyR7j_Ec2Ee2XWB2OCMP6A_2_2"></a><a id="Tc_V9aaxHABuk6xoMCtq_aoBA_2_5"></a><a id="Tc_tMgnMvAiv0KmgiMsEvKN1g_3_0"></a><a id="Tc_5Nje1HHWP0WOYUeZAaHd3w_4_0"></a><a id="Tc_q0WjPrmmjkKmlhCfp62tNw_4_2"></a><a id="Tc_VdOdM_ZDZEqjfa0jAUVHiQ_4_5"></a><a id="Tc_T6M_g4babEuHzdkYGdMBhw_5_0"></a><a id="Tc_7gjQaweNuUafH8So0tjLDw_6_0"></a><a id="Tc_4gvOOovDk0G0j8driZfeLg_7_0"></a><a id="Tc__qkWhMMdfU-u50FZmlHyqA_8_0"></a><a id="Tc_k8XUBOyEikOYRSa5RFBVfw_9_0"></a><a id="Tc_g0F_rwWLIUm6Mf-YjgVGmQ_9_2"></a><a id="Tc_QuOy2w5iwUyexTNA_1W0WQ_9_5"></a><a id="Tc_2e5fPI5jE0CLaUF3RG4yQg_10_0"></a><a id="Tc_UER5rGBp3k-h7ZKp4hYBIQ_11_0"></a><a id="Tc_H0psEq0b70m3slQR5xO5hg_12_0"></a><a id="Tc_KzFvTCTrhkG1i7PoA_cEAw_13_0"></a><a id="Tc_phTMI8XYpk-W68NhecTs5w_14_0"></a><a id="Tc_Y4wjWbdkVkicPb2Uku8wuQ_14_2"></a><a id="Tc_sTjBskpR1UKzlMgDsN2Ydw_14_5"></a><a id="Tc_fqnAdbwaIUeFh2ttB0RGrA_15_0"></a><a id="Tc_VJVdUC7yb0aFt1TPJgANbQ_16_0"></a><a id="Tc_6gs5V1B41EGLZwA8rW659Q_16_2"></a><a id="Tc_aXgiasNybUaPTslWA1j_Rg_16_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_WdQV0jCKr0-Tpi6176Ihmw_4_3">117,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_7FOuhe1kHkaYt8S5F8ASJQ_4_6">81,788</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquired in&#8209;process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_Y1dnrrkZzkeHrklhWbOexQ_5_3">8,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_JqIjz1oqAUGxk_nk2XUKhw_5_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_exAf-gaZp0C0DUvg-xeRKA_6_3">60,056</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_zNakWUgmyEa7-2v4s4w2AA_6_6">30,114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_2fD67b4Hg0a_7J_WGA-Ryw_7_3">185,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_jR-qnSSUxk6kIDsjqwhkLQ_7_6">112,902</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_4x_urNWLWkSE7zF3ElczjQ_8_3">343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_3cEet52gR0iAl08eCupIGQ_8_6">670</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sVc6oDHM40SYzhLGQR813A_9_3">185,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_iRe_GOH_6k2jFbQUq2JJ6Q_9_6">112,232</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uxnYvl92C0aLe3HGJW_klg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_i4Vlsh15SUebiBFRJMwNww_11_3">3.48</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_d9qLBGxubU6zDuzaB89dBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_OW0lynplhkqKsbognRuegQ_11_6">2.91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_mnODuyqv4kq946MzZtFl3g_12_3">53,343,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_8uVEM_Dol0GOhu0bVnqHpg_12_6">38,615,967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dIEQQ6vjmUq7tvMj5CXgrg_14_3">185,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xfrRnj2_G0amMqgavqtCbQ_14_6">112,232</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_UVbJ2DvH306tEsaDas5dmQ_15_3">401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_W7sDxu9qb02OBO-MNC2BAQ_15_6">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_HzZ1V7D4_Emqeixx5xAPdg_16_3">185,787</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_m0n5wOjFjk6yv8a9N2Eang_16_6">112,244</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1619d17_40fa_4b08_ab97_8dc2296b1990"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><a id="StatementsofConvertiblePreferredStockand"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</b><b style="font-weight:bold;"> (Deficit)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><a id="_3578a2fa_d9f9_4fa3_aa83_cec1e3cdf250"></a><a id="Tc_aKBKjcFRlk--QEch01MUzw_3_2"></a><a id="Tc_EA1u0G6wdES1bXowWb8Rgw_3_19"></a><a id="Tc__CEqCoMxJU-N3_qZlgcZCQ_4_27"></a><a id="Tc_41IOARumE06qm36GoOjgww_5_2"></a><a id="Tc_pfjotgDeoEuy8oEzKbct5g_5_7"></a><a id="Tc_wqSvWOb790qk9rRJJ9bn_Q_5_13"></a><a id="Tc_6xPXaGeOakyjaAOdLsaPEw_5_19"></a><a id="Tc_6DGeycj3oUWBOsfWzAhDWw_5_24"></a><a id="Tc_KcvK-CLNGUiA5JUZakaKNw_5_27"></a><a id="Tc_p4OPzqgb20K3lACQHRMXvw_5_30"></a><a id="Tc_ektXtbUMfkKvY_Tzb70jCg_6_0"></a><a id="Tc_ZWWKELtcMUqNMKqxu3IELQ_6_2"></a><a id="Tc_VhONebt9u0q82mt3tZKT9g_6_4"></a><a id="Tc_zJqkHfQ3tUe4JB_WubztMQ_6_7"></a><a id="Tc_JcdMgWwooUyds2HYbVkVGg_6_9"></a><a id="Tc_0aajeyIZOUewK7K8pAkjdg_6_13"></a><a id="Tc_N0nQ3-Z8PkeKHcrwQ2Q2mg_6_15"></a><a id="Tc_538WgVeezUe-Buy6jy76cw_6_19"></a><a id="Tc_9ul9ofaROESR8A4u8fNGUA_6_21"></a><a id="Tc_7mrleWPWCUeeoP0sKFzvRw_6_24"></a><a id="Tc_creiiDFMEUqaDfIsizzSVQ_6_27"></a><a id="Tc_6tKWUNS-rUWyAX3N7ccX9w_6_30"></a><a id="Tc_gP33N0FBmEG8xcV3zjFX9A_6_33"></a><a id="Tc_I_UUXOC9Iki_fX1JJ4Bmxg_7_0"></a><a id="Tc_EaC_pVUJ70eXB_LOUykR3A_7_4"></a><a id="Tc_cJtqyCK3_km9ERFQcfrUYA_7_9"></a><a id="Tc_5w4PAW7CFUSydBOfOenw4A_7_15"></a><a id="Tc_F-WuHeF0mESumMp5Bq5C1g_7_21"></a><a id="Tc_vm99a8Fb_UeFJSh7Pip5Eg_7_22"></a><a id="Tc_88Q5kH6nFkWOvWrPsloggA_7_24"></a><a id="Tc_hW7rKh-va0609gH0rIXBSg_7_27"></a><a id="Tc_1fQUUrV6IEah8DFDvGKqWg_7_28"></a><a id="Tc_810ktppJFUG45w4hd1GYJw_7_30"></a><a id="Tc_MXNdnqID-EyefEWNy6IcsQ_7_33"></a><a id="Tc_8MqGcNO15k65Lld9xxExAw_8_0"></a><a id="Tc_gQl2crOhJU6SnFrr4RGMMQ_8_2"></a><a id="Tc_Ci2FMWxJzkGqcsPJa7GVcA_8_5"></a><a id="Tc_IVItrGok6EK1l10pnrVv3g_8_7"></a><a id="Tc_oo1sPYNeIkK1FNWHPmjfAQ_8_10"></a><a id="Tc_D-3yRiuMokGmdQaE8-ElMA_8_13"></a><a id="Tc_H3h9UpUYrUKjaDyH0xFrww_8_16"></a><a id="Tc_HBW3SbtzfUWhi4qXQB_uSA_8_22"></a><a id="Tc_xhOCFEf5bEOx41K3KnlIUw_8_28"></a><a id="Tc_EFzc2U3YUk2h5rUpAbvlCw_8_31"></a><a id="Tc_5lU8RefUtkyQ5qkPDwcmRQ_9_0"></a><a id="Tc_igkzgN7Lx0SoUO0ZKh1Qaw_9_2"></a><a id="Tc_TePJsBx8K0urs8TLmWmk1A_9_5"></a><a id="Tc_2r37yRoJaUKQLEi_-dKYBA_9_7"></a><a id="Tc_pSVvRmzOE0Gqr3RQ0_WFHQ_9_10"></a><a id="Tc_3fz9fNHZqEm0vLZvRe_l0A_9_13"></a><a id="Tc_60wCn47qrEOdm6sbsmaBTA_9_16"></a><a id="Tc_i174DM1npkSMfQlkhQzpPg_9_22"></a><a id="Tc_KOZ4fF3uDUWSAd-CORvQTA_9_28"></a><a id="Tc_jizBdOL_gE6PjqdcJTgp7Q_9_31"></a><a id="Tc_wB-sqKWcQECHEdNgY_Kv4w_10_0"></a><a id="Tc_LCmxW8cVyEG2ihpDUmBcKQ_10_2"></a><a id="Tc_wXF1TMoxpUud-q7wMe6wbw_10_5"></a><a id="Tc_H1A04xnmT0u9CkOzK3UbOg_10_7"></a><a id="Tc_D54bxD6j80CjVj6C_hExxw_10_10"></a><a id="Tc_ok3PD-Xjkk-EkyKFxmFBSQ_10_13"></a><a id="Tc_mVxgs45i-0yt_I-HhoPILg_10_16"></a><a id="Tc_ZOj-pextmE6bZD5Bi4-ppw_10_22"></a><a id="Tc_nkgttWUxpUS8uohXTxkxrg_10_28"></a><a id="Tc_xvP0oDf87UWZBtfkGBSzLQ_10_31"></a><a id="Tc_xZmTgYU11E2oI1Cf2MmyFg_11_0"></a><a id="Tc_2v5XApSgpEOnrVlBunkElQ_11_28"></a><a id="Tc_w64jgHWRSUOn1x88XrfPbQ_11_31"></a><a id="Tc_NZvJLez7AEujjJOiwPxLAw_12_0"></a><a id="Tc_Xf7Mvns520Gtb6xh516faw_12_2"></a><a id="Tc_9DKc69M6bEKy0JWqz0bleQ_12_5"></a><a id="Tc_-el8Y6kzcECsHZOPnrWnWQ_12_7"></a><a id="Tc_v363dfo39USOeGYCcbLcIQ_12_10"></a><a id="Tc_tAkgcO6N0UeG4OY0YyMCtQ_12_13"></a><a id="Tc_Nj2K7OFLC0axVKVyHlogLA_12_16"></a><a id="Tc_iPRfNiCN8k-Gc7nOFl_CBQ_12_28"></a><a id="Tc_o74dUXMkwEWZA0eys24CSQ_12_31"></a><a id="Tc_tc12t3NmMkuj7dgKJgO_sw_13_0"></a><a id="Tc_8GZr5gmt2ka8GFnqpS-Y7Q_13_2"></a><a id="Tc_B5Q_N4IFqEmWRWPD_x97lg_13_5"></a><a id="Tc_V0EzW0AFIUqUbYuFqwMl4A_13_7"></a><a id="Tc_rS45g4024Eu3MiTt4S-ytA_13_10"></a><a id="Tc_7POV49qjBESOWrzAGFZ0SQ_13_13"></a><a id="Tc_KMPwIwgwL0S7xm7ZHcBUiQ_13_16"></a><a id="Tc_w0lB0TUjiUSrQXTu65AdOw_13_19"></a><a id="Tc_-zWQN_jjvUS7nOjz8k-m_w_13_22"></a><a id="Tc_6WrEp069h0icFBou-erl7Q_13_25"></a><a id="Tc_lADlUzaTgUuxkc32DPrOSw_13_31"></a><a id="Tc_MjMCoN4O5UiNLZPKTq5wTQ_14_0"></a><a id="Tc_vds1JDxQb0CHGDE4b1rZDg_14_2"></a><a id="Tc_zQgF74FCHUexIZPGmjXb0A_14_5"></a><a id="Tc_DqcTjyWDMU6eQMiZkApruA_14_7"></a><a id="Tc_4LWdDwTnt0iBtnGkUh1wow_14_10"></a><a id="Tc_sPLxXyyjw0icdlbRhkNLsA_14_13"></a><a id="Tc_UrkK4VlSREOgdgqcAQcdhw_14_16"></a><a id="Tc_-msIdDydZ0KG6twaDZfoKw_14_19"></a><a id="Tc_Hzc0qNMXpEuQJThL5IIYfg_14_22"></a><a id="Tc_rUPJzR2JN0yTQnEdR8sYUg_14_28"></a><a id="Tc_snJ4LNx08EKAxG7nU5lGrA_14_31"></a><a id="Tc_22wozJdZX0u571B8PciyZg_15_0"></a><a id="Tc_NyOcxo776kGANueVFRcdPw_15_2"></a><a id="Tc_8vhFLkbl8Uudj9yX-oFmZw_15_5"></a><a id="Tc_0tjww91tuES-fcLG1rvqMQ_15_7"></a><a id="Tc_dhtIhxFvyEC8j3-7Kz3CZw_15_10"></a><a id="Tc_P2BWYnEdZkKymxh0JE4zSw_15_13"></a><a id="Tc_ekBRmdLE40iB4FJ_51_7gA_15_16"></a><a id="Tc_WGwAktPwkUu81SovFdQQgQ_15_19"></a><a id="Tc_b2m5xhiCoEqOI4td5RHZcw_15_22"></a><a id="Tc_l9Sys5OzIE6wUN1AS3QU2Q_15_25"></a><a id="Tc_18PDUXm6pkiXmzQHq-60LA_15_28"></a><a id="Tc_PPni1LJf30qKXKX6PBAMPQ_16_0"></a><a id="Tc_00xscl5kcEKhc0H7BgzrKQ_16_2"></a><a id="Tc_K6b5WXs3pU2NQvQgGckI9Q_16_4"></a><a id="Tc_aOn1Px-axEKYmlU7wF6Pzw_16_5"></a><a id="Tc_SkgHQsFlsEysDqzE6uubZw_16_7"></a><a id="Tc_1QgehnbxBkG5tMaahC0kHg_16_9"></a><a id="Tc_3UYPSZRbrEadThujABYiUQ_16_10"></a><a id="Tc_JJEU053zdkalbDhKpneH8g_16_13"></a><a id="Tc_NwzdHFKabk2i0BECgmxw9A_16_15"></a><a id="Tc_1iVTEOlw0UeWDzvW_RV6ug_16_16"></a><a id="Tc_xtlYEfhD4UmiNFpaEn1iYw_16_21"></a><a id="Tc_O_864o9mNUSOjN5jXQjaXA_16_24"></a><a id="Tc_9vr2olBWPEOeHMaZDsgfeg_16_27"></a><a id="Tc_xV8OcPf34EOzx03nkYeuEQ_16_30"></a><a id="Tc_vp7wzDmXHUSLvtWSMCHNJg_16_33"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;white-space:nowrap;width:36.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible preferred stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:39.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity (deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;A</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;A</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">comprehensive&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:3.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_G3OFmV_s8UW8mFhRziW45A_7_2">63,023,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_9TAKbhiLzUegqz9d5MI8jw_7_5">74,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LYKOlHkUJk6ZytaJNaa93w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_iva_XV43iEag80H8ehMJlg_7_7">22,209,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LYKOlHkUJk6ZytaJNaa93w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc__quT5aIyVUWiqjedq9b3qw_7_10">46,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZuK3tkV4pU-7P0MkazMMfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_E2kys6am9UewgAIZA3gGJA_7_13">33,592,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZuK3tkV4pU-7P0MkazMMfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_JB-hdvuebUu6EIpRiSG0cA_7_16">109,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wJ5SQuui7UmmH66JjXcNEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_PhYWZzf5kESGqsRLGsyHBw_7_19">4,293,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KtAMQhONPUi9b_KILEFiog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_DLUGJyXDokSTRTo05gZxlg_7_25">2,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7CN9CCTgHEi8F4aqrlVJUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nQhj8mF9VEKaj2jveeWGcw_7_31">58,663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_JV6ao2U_tkWKH0ie6bUjcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LoZ-mouVekOE4HRI53kWBQ_7_34">56,253</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of early exercise option awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="INF" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" scale="0" id="Tc_04kUHc7TGkW9wILdKVwl7g_8_19">599,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_X1MXWb3qTU2uyGJ6pV6ebQ_8_25">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_G_xJqqbN3USYozGiPbREQA_8_34">35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_m50OcpVvsUW1iW-jCPRhUA_9_19">99,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_u3vNGVbBCEScmyw2-0WAMA_9_25">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_LoxORPrX9k266oyzyVBc0w_9_34">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of shares in connection with employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_Krm1zNEtuk6vUqcp_yTPAQ_10_19">20,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_ufwNHJRrzkCHPkNrn3yvmg_10_25">284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_hCwfJt47qEqrhrgq5oWR7A_10_34">284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of convertible preferred stock upon initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-CYi_SN54kqIdkLi7k62Zw" decimals="INF" format="ixt:numdotdecimal" name="pasg:ReclassificationsOfTemporaryToPermanentEquityShares" scale="0" id="Tc_I78bpTi-qU6wbfEkFLcHIA_11_2">63,023,258</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-CYi_SN54kqIdkLi7k62Zw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="Tc_ofJROSbCXEW4HGwYQETmhg_11_5">74,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UU9G0ivYy0Cp8ghABgy4wg" decimals="INF" format="ixt:numdotdecimal" name="pasg:ReclassificationsOfTemporaryToPermanentEquityShares" scale="0" id="Tc_4XLowbY7H0e3--XyKkxQUg_11_7">22,209,301</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UU9G0ivYy0Cp8ghABgy4wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="Tc_TuFsUJO6pEukD-XD_nZoWA_11_10">46,311</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fiaYf-Eno0KZLETdAJS4-w" decimals="INF" format="ixt:numdotdecimal" name="pasg:ReclassificationsOfTemporaryToPermanentEquityShares" scale="0" id="Tc_90vLgbyCJUKWzh99WbytRw_11_13">33,592,907</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fiaYf-Eno0KZLETdAJS4-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="Tc_zhHwcEZDy0OUhNwKz9I9-Q_11_16">109,897</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="INF" format="ixt:numdotdecimal" name="pasg:ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" scale="0" id="Tc_IdCmUQdkHEW4ssKAhcdYNQ_11_19">26,803,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="-3" format="ixt:numdotdecimal" name="pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" scale="3" id="Tc_vcINVAGz7kSuIKRGJgiO8g_11_22">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA" decimals="-3" format="ixt:numdotdecimal" name="pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" scale="3" id="Tc_DnKv70Gj4U2GsHE14wAVlg_11_25">230,602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" scale="3" id="Tc_Medd9TAuB0uVOFjScQPMIA_11_34">230,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Sale of common stock in initial public offering, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuanceCosts" scale="3" id="Narr_Qo8BWBDTb0CUJ81q-WlWfQ">3,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_dS9p0PkLF0yZeE91z03_qQ_12_19">13,798,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_99VWAiZCfkCC8JiH5iIxBg_12_22">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_VQfKfeJT1UyEqLNcbkyeow_12_25">227,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ufD_wgHCHkyei77BGWqRMw_12_34">227,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmxycgbmuUSxw-PaJOObzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_0X3deTGnwEi0iaF--KZvZA_13_28">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_N_9nS28znUm7-LZ4XZtJ7w_13_34">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Share&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_FHiPnfvBFECVuF-UiPQo-Q_14_25">14,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ytepBm3C00uOs45Ji2NGyA_14_34">14,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jOi_xjhbwk6ay-da4RmeYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RZUgbxrpvkKDDzGRfWjm4g_15_31">112,232</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_l1DmrXypJEydDlv-a2cOUQ_15_34">112,232</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FGGr5Kfq4UC6UEb89n-KvA_16_19">45,614,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZCITWq1BZU-5Tz6O75HKcw_16_22">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N2zsouDDp0KGzHDs5rgYWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LyMoA-abBUqLYtddd5Yldg_16_25">475,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5Rk_6c3CBUS1hDM1NKi8Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2NLZw5TooUOwu_d5IfNo9Q_16_28">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b7aXerQ_FUGYF5XUuzOhIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_1XBuYoaNAUyKlJzj3Gej5A_16_31">170,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lpyHhsy-B0WyumepzhHBlg_16_34">304,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_48eb9e25_28dc_43cb_a19f_167dc11b009a"></a><a id="Tc_RT4VOJXmYEiZcBK3CuH1yg_3_2"></a><a id="Tc_hqStfZQ9WEK2DahEgz1sWQ_4_2"></a><a id="Tc_df8Fsojbj0qbxo5LMa30cQ_4_7"></a><a id="Tc_LrFaTG24b0-OjrCfpzprJQ_4_10"></a><a id="Tc_roX_YtX-CUaYrp94bdpxCw_4_13"></a><a id="Tc_VpGp6v-FeECwgukuOrb6dA_5_0"></a><a id="Tc_kd8_qLofiUiJN1NHxMrWEA_5_2"></a><a id="Tc_Ye0lSDQawEq_iyFddDTiBQ_5_4"></a><a id="Tc_gNSqqFxFWk-Lk0anYgM1KA_5_7"></a><a id="Tc_AsCW2GgtlUSp5jGuKA9M7A_5_10"></a><a id="Tc_IfesmJ3db0-CdU6WUzS7yA_5_13"></a><a id="Tc_kk76ysAQ70GYwpubSf9S6Q_5_15"></a><a id="Tc_HlofGAfK1USfXrhNs0PbUA_6_0"></a><a id="Tc_IiK7Tl_9X0qo-QrxLS7sng_6_4"></a><a id="Tc_qZAuRTM5UkilCdDtmvDxGg_6_6"></a><a id="Tc_uJHmbfWpzUeSj1xojs9trw_6_9"></a><a id="Tc_iE-wlsQ7h0eG8VQ3I8aqew_6_12"></a><a id="Tc_nqgSgpnyD0K-mCUJiAtvVA_6_15"></a><a id="Tc_3wxA1QL8jUm14Ft2S5K9Eg_7_0"></a><a id="Tc_Q23H7O1pVk2Qkn_3JA5nyQ_7_5"></a><a id="Tc_51JuO-HX8U-v-MY-c_RDmg_7_10"></a><a id="Tc_mo7qxJWnM0ClSY5zvC-f6A_7_13"></a><a id="Tc_zRF0GLm3kE2_mVwHknoGaA_8_0"></a><a id="Tc_bg5EXpJ6PkWSU9f-Wv0jzQ_8_5"></a><a id="Tc_wh3o0s19Pk-gPhLWhAhaQQ_8_10"></a><a id="Tc_jbzyGjbJCEWBoACJt1hW6g_8_13"></a><a id="Tc_M-59jV0ZKE-dRlWvS8CFLA_9_0"></a><a id="Tc_sApQ4nar6EatW1_p8biwmw_9_5"></a><a id="Tc_XqHL-MA0o0my1OKoh44EuQ_9_10"></a><a id="Tc_2A4prksgl0SxF94idD8caw_9_13"></a><a id="Tc_AuTNRVKKwEqra3c-AmNQBQ_10_0"></a><a id="Tc_1TPNRvw2v0ec6dLOpgmTnw_10_10"></a><a id="Tc_KyxztsseUE-ktpLLf6WNcA_10_13"></a><a id="Tc_0tSsd18mO0eMcNcDcnnwtg_11_0"></a><a id="Tc_0vqeyg1BBUS04zkp3DxKVw_11_2"></a><a id="Tc_5nuwhs6IXUinKwWeaXLRGg_11_5"></a><a id="Tc_MVHb7_AxWkmezwqPDFhu_Q_11_7"></a><a id="Tc_46WMVO_rSEWQFo3BKXRduQ_11_13"></a><a id="Tc_uX-73Wx2zkaUNylzzMri3w_12_0"></a><a id="Tc_xcqXRiG460GP7LtwGrMlXw_12_2"></a><a id="Tc_nRUrkX0nQ0md7fovPP_KuA_12_5"></a><a id="Tc_-w2M7F3z2U-oy0y2MNXJ5A_12_10"></a><a id="Tc_F9JV23ieJU-zc56G1unpFQ_12_13"></a><a id="Tc_ugdlQ82W4U2SpNXKFEvDug_13_0"></a><a id="Tc_mz1fQzt7mUePia4sNUYvGQ_13_2"></a><a id="Tc_cFAYAv6cSkG2_bLbhV_2vg_13_5"></a><a id="Tc_MjcKOK5fmEC5BrnINvWhTw_13_7"></a><a id="Tc_oHHCviTdEUGCXkGMJGn7DA_13_10"></a><a id="Tc_GBu1WejEBkyliP_kwl4-1Q_14_0"></a><a id="Tc_Niayjxwld06x45AOjXqLlg_14_4"></a><a id="Tc_VB2zLAcB4U-CwArKSIYnpA_14_6"></a><a id="Tc_nYuUudA5_U2Po_xjPsvMEA_14_9"></a><a id="Tc_kgpdBbAgQUOkAxkAODQgAA_14_12"></a><a id="Tc_UJfssg-XNUiYY91J84wE-Q_14_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;width:61.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;width:61.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity </b></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive&#160;income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_iU8yT7qomkStN-DJWb8O5Q_6_2">45,614,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vcXhbEvzbEucWLgwV6-vXQ_6_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N2zsouDDp0KGzHDs5rgYWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QPpZUw3wEU-Wl-_RVknhzw_6_7">475,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5Rk_6c3CBUS1hDM1NKi8Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NxgI8U1fnkOU4tHGWRqN5g_6_10">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b7aXerQ_FUGYF5XUuzOhIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dqFhfh2T9UmilOq0Eh1Lsw_6_13">170,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_C_PJKiVq2EKOtKyNV-whIA_6_16">304,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Vesting of early exercise option awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA" decimals="INF" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" scale="0" id="Tc_DFHKPyZZP0eO32BY1Xxtvg_7_2">302,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_KtpVzMWFnESV6CSlxIeTbw_7_7">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_E2hK7JdCn0yh32UrUOYgxw_7_16">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Exercise of stock options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_oJvDnAY-ckm8xfQLsIL4MQ_8_2">186,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_BkCz8MhfH0yWsfFO4totiA_8_7">301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_UNu8NpxnNEWqG8De_BVw4w_8_16">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of shares in connection with employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_AEBYQ-A2gEONoW50MerwzQ_9_2">91,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_EbwACSSAs02o7L8znXrcGg_9_7">887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_IK0DJEMIOk6U1enybvYoaQ_9_16">887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuanceCosts" scale="3" id="Narr_OLXsH0G1tUyzTjYCkEckIA">669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_KW6AUYw_w0izcWSmxv0EBQ_10_2">8,050,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_uDoqmKKHOUWYDBsHhd6wwQ_10_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_y3_n_jzL1UmU7fklxqwR9Q_10_7">165,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ft9iSmEJX0qEpTumwBzwVw_10_16">165,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QppymW2ZzUGGYeEkGfMJsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_MPCjgo4Xrk-U6UR79oOB0A_11_10">401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_7LgW5jrlrEmmPJvb_OqDog_11_16">401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Share&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_5FSKb1ASRkCrU1X62fv25g_12_7">32,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_AcofDE3rw0KhKqwZk363Fg_12_16">32,691</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MKdAL993WkmlGk1E6Ds3GQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XKI7JpHZK0y_HJXikRGa8w_13_13">185,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zEqKp5hq20-SeoXH_aa2JQ_13_16">185,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vePEcvExi0yfQVSylYejVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_8yfOnmHnCkKVg-IA0AOMMw_14_2">54,244,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vePEcvExi0yfQVSylYejVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ccK0wEAs102W-HZvU90fhw_14_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m6L2u8TXOUSP7A9u-mhU5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pMYmsinqnUi3iwHKf28CpA_14_7">675,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SyLUO16mfUyXajW1h4qJLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jK4lTIyjxUOM5StkxO-9tw_14_10">413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Jfpsy72LLUulUWiSGGQmGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_e6dyrzF8fkmziBl-qfx6Vw_14_13">356,281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_K3m_NHRcikuGANu8w-Y5nw_14_16">318,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2953a3c1_24e0_41b6_a4d7_a7d804b4ae6a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><a id="StatementsofCashFlows_152708"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><a id="_2267f59c_7543_4c93_8696_d5001f684adb"></a><a id="Tc_zIxt7vzl9UmLMCpUMnK0IA_1_2"></a><a id="Tc_MnLneeFb-U2gPn-G4ybsnA_2_2"></a><a id="Tc_qwUmHK-Ab0qUFbMQsv_nsQ_3_0"></a><a id="Tc_KX_6NF1oJEKKdl5tKupubQ_3_2"></a><a id="Tc_Rc-6Euiyc0OLeE5xDKV0Bg_3_5"></a><a id="Tc_BDTbhhcKX0abfky_S5GEiA_4_0"></a><a id="Tc_Ws-3fBzQuUKjaAhsta1AAA_5_0"></a><a id="Tc_ozxRQIIJd0yQ32-C-DQo8Q_5_2"></a><a id="Tc_C1Aotw9YtkS67cMPcSvWvw_5_5"></a><a id="Tc_zQjAS0xK8Uq0UmEsB1sA-w_6_0"></a><a id="Tc_H9QioYYZVECS5PCHMf-9fg_7_0"></a><a id="Tc_SF93Kx0uHUqF-eyLgkBNAQ_8_0"></a><a id="Tc_txYU8yPNeE6nddrccNIipg_9_0"></a><a id="Tc_6jB5x0SGLUijjQBQ61mJnw_10_0"></a><a id="Tc_Xjx2KPMn8Ui9k3mAUr7PFg_11_0"></a><a id="Tc_oXBXf4jrQEOpFOIJUYXoGA_12_0"></a><a id="Tc__9FFzpm1VU6DQjAOvKnclQ_13_0"></a><a id="Tc_9C13dFLrRk6yheSynGtDaA_14_0"></a><a id="Tc_qczihOs53kyIC4MLIQLcVA_15_0"></a><a id="Tc_pWZOMEiUT0q4gWLNm8u1Bw_16_0"></a><a id="Tc_abMqS0DbZk2FcpZGXkTyew_17_0"></a><a id="Tc_W-BN6n9GA0Se5FZmhrseww_18_0"></a><a id="Tc_b8RjNLx3hkWzE_9zsgYzuw_19_0"></a><a id="Tc_YIQa9kW6rEKRwAD2G24G1Q_20_0"></a><a id="Tc_okGdbzuCZUCgFsJGitoZuw_21_0"></a><a id="Tc_F9JRBnRDTkCs7kHl4YKySA_22_0"></a><a id="Tc_a6rDUJscu0Cb2Kh7r7zNcw_23_0"></a><a id="Tc_-pznmT3lj0SRYiI4qrbdIQ_24_0"></a><a id="Tc_sPNI1qdPMEygezAm3c6teA_25_0"></a><a id="Tc_-UyQjJASWkGQMwYBTUNvTg_26_0"></a><a id="Tc_Hh7KE2JGZ0CP0AxQturrAg_26_6"></a><a id="Tc_Cb2kTI7QnUiujpXhijWvHQ_27_0"></a><a id="Tc_APo1oiU0gEeDivhAYPsWVg_28_0"></a><a id="Tc_Cc_9G1y1lka3r693AKswmQ_29_0"></a><a id="Tc_8ZR_ydKAHUG0s-NdYlLUOw_30_0"></a><a id="Tc_cLb9UDdSoUKit-WPi7F0gw_31_0"></a><a id="Tc_KF9nt30IC0qN8SEfIG_ldQ_32_0"></a><a id="Tc_DrfmfkDvekezPClqyqlRZA_32_2"></a><a id="Tc_lXbEdUUz10Wj5m6yybGLKg_32_5"></a><a id="Tc_3eX3fhmtOE-41TRjOknGuQ_33_0"></a><a id="Tc_AS_I09dnyEiI_sLP9b-pYg_34_0"></a><a id="Tc_cnTLLiSejEqte2wgYRfe1A_34_2"></a><a id="Tc_StU2dZSrv0q4gn92JLOH8g_34_5"></a><a id="Tc_PtDXadMQX0eruU6m6NOaxA_35_0"></a><a id="Tc_kGwWeuqLC0i0U7FVCpiMHA_35_2"></a><a id="Tc_MjVPmoAJT0-nDQkPhwezNA_35_5"></a><a id="Tc_P3q1rUYEik-YXWqmdcQEZQ_36_0"></a><a id="Tc_DkbgpXOsUUyj1uWjXh4PQw_36_2"></a><a id="Tc_Qt9ZMBCzn0WIVv2gX8ZlQw_36_5"></a><a id="Tc_eJmq_R9TQUSdbSzoPbxJtw_37_0"></a><a id="Tc_x0t-bGY_8kOQwEeZp0wYvg_37_2"></a><a id="Tc_eI7keysCt0mBVszSoxpkqQ_37_3"></a><a id="Tc_CM4DOD77AEinZ--BEJIEYg_37_5"></a><a id="Tc_7QPbvU4RwEmnZvD5IQUiMA_38_0"></a><a id="Tc_H5jgXW6N2EKLe2zgf8eYcQ_38_2"></a><a id="Tc_iXhtXvuq4kmDE756JyA2Uw_38_3"></a><a id="Tc_p6GnaBx8BUWIxwETEIfmWA_39_0"></a><a id="Tc_dbzkqBoe-U-zU_GYmpNiDA_39_2"></a><a id="Tc_WyrrVO4gY0mVyDEFjo3ujg_39_3"></a><a id="Tc_wKab1km_Z06KmzI1ijufDw_39_5"></a><a id="Tc_blwpEo3EB0a0Fv0vUld7lA_40_0"></a><a id="Tc_6PIT8miLpE6KsahZXfOMsQ_40_2"></a><a id="Tc_wlWfehW6TUO3xaWP5Jy2Sg_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_H1xC7pvbuUKfoPcS5NElPA_5_3">185,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3gsMz--Sk0CB33uMdn3smg_5_6">112,232</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Acquired in&#8209;process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_CrPYlj-eW0ikd8cELeSH3A_7_3">8,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_OO0Ey6AqlEe41OPjNQkJjQ_7_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_wm8-ewKSk0S9AFMlsOopGA_8_3">1,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_MTYnHcueIU-eF8B7TdRMmQ_8_6">800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Share&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_XdRtBdFKr0OERxuqf6gPpA_9_3">32,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4IF0C_OPXEG9QCY-iBxnhg_9_6">14,580</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of premium and discount on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_ZdhbK2IIXkmIGsmAfFUIMA_10_3">2,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_HdLeSIp8G0imUlcdoGnJjA_10_6">633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInDeferredRent" scale="3" id="Tc_bnU6CEyvN0yS-0HbQ58oIg_11_3">2,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInDeferredRent" scale="3" id="Tc_CCQ_tPOEZEet6iIXMuyTBQ_11_6">259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses and other current assets, and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_2UuyEKWgCkaUfokUCSWyOg_13_3">1,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_QRqhSqX2XU6su_XyZi73vg_13_6">1,871</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" sign="-" scale="3" id="Tc_P8KB5Po7BUCX3G4_waT8Tw_14_3">3,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" scale="3" id="Tc_WjJo69FeuUujTbFwKFS1UA_14_6">4,216</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_YAZKpdqahkmw6R-ARawLiA_15_3">2,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_R8H-0ole5Eungc0RLmQ8XQ_15_6">4,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_s-Wnh7OZqESA-lh8V8gmOA_16_3">3,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_rQx_gJDDFEKozQxNEIsIsg_16_6">12,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_cjvnaRzZrUutVl9wCuyZmQ_17_3">126,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Vku4L-Z22E-2tI_PjF3zsw_17_6">80,520</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_q1jT1N_hm0Ks8F9g3LSefQ_19_3">202,546</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_EXWjharP30SIfYiHmZvVsQ_19_6">266,057</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Sales or maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_Wy4mM-21M0eC0mnEqnh_PQ_20_3">182,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_aaofrplzX0ik2pZJkxTFxg_20_6">95,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Purchases of technology licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_czAb1PhuY06C9joIC8c-dw_21_3">8,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_rdatpPYuXkCJ2UfvrpkMIw_21_6">500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="Tc_MLl4FeyAPkW_qaeCTuNBfw_22_3">17,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="Tc_v5r9LuXfRUebcy1Bq6fzgQ_22_6">1,146</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_TDQPwvxW50KLi3gBPRJN4w_23_3">45,814</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_hTLdHfo77E29drs6CeCMIQ_23_6">172,106</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows provided by financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Proceeds from issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_9nS21s-GF0mE6GYvkhZZPA_25_3">165,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_iPrm7H6pPUOvZsiU-x9ymw_25_6">228,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Payment of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_aekDVWEyHEGzddkKgkxQog_26_3">338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Proceeds from the exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_ayfiY5kDmE612IRlNF1G6A_27_3">301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_CDpqGLyveEGJ6YYFaasv-w_27_6">284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Proceeds from the issuance of common stock under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_GRA3ZCYBbU6n6PjIWtJ09Q_28_3">887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_COSCwiCCFkmOcUPFUwjvBw_28_6">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_yjw_fzWOwkub5byllI2bag_29_3">166,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_8CLDhuhh2U-cTexxpEstBw_29_6">228,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_V470QJUneESPVLDbyw5QgA_30_3">6,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_-KOmJep_fEK_hFvz7fsuww_30_6">23,872</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_pSzPwPDHlkS5CLyzfJoZaQ_31_3">135,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2019_JV6ao2U_tkWKH0ie6bUjcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_983lpJm9Uki9iNKXdJqCvQ_31_6">158,874</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_kH6CLD_P_0ugsFXpCBVqpw_32_3">128,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_cetP-_AVlE2wIVmsVr6OBA_32_6">135,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of non&#8209;cash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" sign="-" scale="3" id="Tc_FQqj0Y9p8kuj4mWtYHHqMg_34_3">401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" sign="-" scale="3" id="Tc_iuvijA1Bgk6i_sTf3UhGfg_34_6">12</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Property and equipment in deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInDeferredRent" scale="3" id="Tc_lLr3WTFqKEOzbMQnePXjEw_35_3">2,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInDeferredRent" scale="3" id="Tc_zCKBX3iNwkKJ_7N4VA17rA_35_6">1,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Property and equipment in accounts payable and accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_5k-KyYkvm0WH5ZNZGXXZqw_36_3">2,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_CY82pnWXvEuGN2C2WCyGSQ_36_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Acquired in&#8209;process research and development in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_HqnMl8qkR0qG-GtKoeBrpQ_37_6">500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Deferred financing costs in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_Y_iS6ICPpkmls_4Bo0BbAg_38_6">161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Reclassification of deferred offering costs paid in a prior period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" scale="3" id="Tc_UL2Lu_JFwEWUqQoCnV-pOA_39_6">763</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Vesting of early exercise option awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="pasg:VestingOfEarlyExerciseOptionAwards" scale="3" id="Tc_GI3QLXNHpEuPDnA0ZfNprg_40_3">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="pasg:VestingOfEarlyExerciseOptionAwards" scale="3" id="Tc_6y8YENL17Emvk5NJj81-vw_40_6">35</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3b97db87_e550_4c15_89dd_7c2a817c12e7"></a><a id="NotestoFinancialStatements_627885"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Financial Statements</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:NatureOfOperations" id="Tb_ovWBgD6jh0elHUyBg1-eJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Passage Bio,&#160;Inc., or the Company, a Delaware corporation incorporated in July&#160;2017, is a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system diseases, or CNS disorders, with limited or no approved treatment options. The Company has a strategic research collaboration with the Trustees of the University of Pennsylvania&#8217;s, or Penn, Gene Therapy Program, or GTP, that provides the Company with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to certain CNS indications. Under this collaboration, GTP conducts discovery and preclinical activities enabling Investigation New Drug, or IND, applications and the Company conducts all clinical development, regulatory strategy, and commercialization activities under the agreement. The Company also has a collaboration agreement and a development services and clinical supply agreement with Catalent Maryland,&#160;Inc., or Catalent, for clinical scale manufacturing requirements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:RisksAndLiquidityTextBlock" id="Tb_huhoh0__KkOcUzwcF_Rdow" continuedAt="Tb_huhoh0__KkOcUzwcF_Rdow_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Risks and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_HCxj6k9Ix0mwLlkdA0fEhA">356.3</ix:nonFraction> million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the Company closed its initial public offering, or IPO, in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_BDEkN6r_xESdDoDuuiLe5Q">13,798,900</ix:nonFraction> shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjALmRT9kE6JDV3gpQtAgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_FXg5DFX8PEOf4WlKLC3-aw">18.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_XbdOBsojNkCgx192uhPfjg">227.5</ix:nonFraction> million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr__Iij9pnSnUC5sKxuA0rPCQ">8,050,000</ix:nonFraction> shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_aHwnSqJS7Eaecp2WOoB7vA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_RQOs5EuugEqMHpzJETW4IQ">22.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_jH56Jp9610u9O0OUqCrGHg">165.8</ix:nonFraction> million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations have consisted primarily of organizing the Company, securing financing, developing licensed technology, performing research, conducting preclinical studies and clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In accordance with Accounting Standards Update, or &#8220;ASU&#8221;, No. 2014-15<i style="font-style:italic;">, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, the Company has evaluated whether there are certain conditions and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_huhoh0__KkOcUzwcF_Rdow_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash, cash equivalents and marketable debt securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_sld2iRkR0EmnxnzuOjWfgg" continuedAt="Tb_sld2iRkR0EmnxnzuOjWfgg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:BasisOfPresentationPolicyTextBlock" id="Tb_RtjHqtleW0qz7p2G7M7Nyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and ASU promulgated by the Financial Accounting Standards Board, or FASB. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:UseOfEstimates" id="Tb_OuHj6EhHm0quQuOsMC51FQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_lenkrpIswESO_9AzpTQgJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_pAaa1Q2btkq32cyo2VHNBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:SegmentPolicyPolicyTextBlock" id="Tb_p05HQ1dTEUaWMUnaU0grWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_dtYM95ndTUuz97Ok3LqHiA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_0A1Tzoaug0eM2L0OXRvACw">one</ix:nonFraction> segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_PHFVCnXymUGW8YcwGFWt5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sld2iRkR0EmnxnzuOjWfgg_cont1" continuedAt="Tb_sld2iRkR0EmnxnzuOjWfgg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_qbbP4_G6VE28ziCBkGaHIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its marketable securities as available-for-sale, which include certificates of deposit, commercial paper, corporate debt securities, U.S. government debt securities and non-U.S. government debt securities with original maturities of greater than three&#160;months from date of purchase. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#8217; equity. Gains or losses on marketable securities sold are based on the specific identification method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_Nto_ctmtJkG630mzqs2z6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Property and Equipment, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_eFQ_dfn7M0KtMER3R_n4pg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_su1NEbWVek6A367hQBl0Yw">three years</ix:nonNumeric> for computer hardware and software, <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_WdT9SqzOo0K02mLduwDlzA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ZkptYraEokWo6IgDyzCJdw">five years</ix:nonNumeric> for office equipment, <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_GybBG82pcU2WNDKqUYN4Xg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_tn02diWQxUat5EAx5i1YDA">five years</ix:nonNumeric> for laboratory equipment and <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LOgztTkbQ0WGq90WF8_dpQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_3XWXyZqVbkqlueneLd9qlg">seven years</ix:nonNumeric> for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2021, and 2020, <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_6ZX2KiSwzkiPUe8uBMa2zw"><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_yp4k7ieF3E6B3nu-hEA58A">no</ix:nonFraction></ix:nonFraction> impairment expenses were recognized. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_eL-5XbeQoUi4ZK08WVayKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of share-based awards for stock options requires the input of assumptions, including, the expected term of the options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The expected term of the stock options is estimated using the &quot;simplified method,&quot; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, which is considered the subjective assumption, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in estimating the fair value of share-based awards for stock options represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_5Tgm48nMA0aPRs8TNbJvQw" continuedAt="Tb_5Tgm48nMA0aPRs8TNbJvQw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organization, contract manufacturing organizations, and employee-related expenses, including salaries, benefits, and share-based compensation. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sld2iRkR0EmnxnzuOjWfgg_cont2" continuedAt="Tb_sld2iRkR0EmnxnzuOjWfgg_cont3"><ix:continuation id="Tb_5Tgm48nMA0aPRs8TNbJvQw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management makes estimates of the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. Nonrefundable advance payments for goods and services, including fees for preclinical services, clinical services, manufacturing services and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_b6O_4NVtFEiqDZuC974WNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2021, and 2020, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_wov5DHGArU-cOOZQpY9X4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FASB ASC Subtopic 740-10, <i style="font-style:italic;">Accounting for Uncertainty of Income Taxes</i>, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_b66h3ZVcAkSOQTy4Yt1GWA" continuedAt="Tb_b66h3ZVcAkSOQTy4Yt1GWA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_DMnOn4HYyEK-f0bCKCoQmw_1_2"></a><a id="Tc_Bkpnr-F0rEiMirmYCPhYGA_2_2"></a><a id="Tc_6p1ivon2okWU2whhBNMjeQ_2_4"></a><a id="Tc_hVAT_sSDEkea4OKxeiA_Kw_3_0"></a><a id="Tc_RGB24WeMVkexM0_tbO7bVQ_4_0"></a><a id="Tc_PaY6UKUT7kmMWP21ru-5LA_4_4"></a><a id="Tc_3DsD16WKF0eoCO3SbmjlqQ_5_0"></a><ix:continuation id="Tb_sld2iRkR0EmnxnzuOjWfgg_cont3"><ix:continuation id="Tb_b66h3ZVcAkSOQTy4Yt1GWA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_QS7OiVjy9kKj-RLyX_0BoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options (including shares subject to repurchase at December 31, 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_SViruIUiA0GgBqi7iFeZ0w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gWw_hsSQdEqsN3InVlZmbg_3_2">9,416,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_1fYXv3HVhEKVNJ2zbLsrBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_q9HZ-hRotk-I_mB53-hAGA_3_4">6,928,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Y4ZNWZufSESbSvoIUjVxUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_9zMLjT9epEC3INfwFY7UaQ_4_2">290,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_O3P6zlOMF0WLM5n7S-Ueww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_jLF4ZWYFF0KyVHNjXerh8Q_5_2">33,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_rxBgbjMROU2SA9ft8QlsyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YbEOUGMiOEKEX4YBtugdCw_5_4">4,044</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_gxBQ1SUG8ESsqJXhCPKu_A_6_2">9,741,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_OMp5Eu5F5k65duiG_ZfqnQ_6_4">6,932,155</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_iVKTdXB3_0O3KHe4TH2_KQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, <i style="font-style:italic;">Leases</i>, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve&#160;months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain <span style="-sec-ix-hidden:Hidden_Sc9rc70L20a7-6a58pPOzQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">practical expedients</span></span> available. As the Company elected to use the extended transition period for complying with new or revised accounting standards as available under the Jobs Act, the standard is effective for the Company beginning January&#160;1, 2022. The Company will utilize the practical expedients available under ASU No.&#160;2016-02, including, electing the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs. In addition, the Company will apply the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less. The Company will not have a material cumulative adjustment to the statement of operations and comprehensive loss on January 1, 2022. The Company expects a material adjustment to the balance sheet in connection with the recognition of right-of-use assets and lease liabilities on January 1, 2022, with right-of-use assets approximating $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_iPx0aGFkEUyzm5BeJrht2g" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_quZjNIuytkiL-pGw76sELQ">17.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_1_1_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_fiT7-OIXtU2fTbDpDThQDw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_xqqUUPlo20mcPXa9ZOeZSw">24.0</ix:nonFraction> million and lease liabilities approximating $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_iPx0aGFkEUyzm5BeJrht2g" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_aBsO_SBQsE6RsPS2h-BMNQ">24.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_1_1_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_fiT7-OIXtU2fTbDpDThQDw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_XyDTDzkYhkigqBpr3_pfsg">31.0</ix:nonFraction> million, subject to finalization of the Company&#8217;s incremental borrowing rate. The difference between right-of-use assets and lease liabilities relates to adjustments to unamortized balances of deferred rent and lease incentives existing as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2022 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_AFs4CmYy5EWRyVLvRetkUg_1_2"></a><a id="Tc_2fLmxdlaHU-yp9L7q3xQ2A_2_0"></a><a id="Tc_JYBDxsIv1Uy4jIbXsy5zTA_2_2"></a><a id="Tc_HuDpGNYIcU6aPJWKPdj7dA_2_5"></a><a id="Tc_vfS_Ihyh0kiihWhqEAW7zA_2_8"></a><a id="Tc_sIx3IDIvm0icdd-N9yOG8w_2_11"></a><a id="Tc_D9oIxrLAqkG6rM2hVIOWJQ_3_0"></a><a id="Tc_hMfKHEYsDEWM-jyq3E0EqA_4_0"></a><a id="Tc_BVCHLX6p40yvTxaIpkVcUA_4_2"></a><a id="Tc_JJ-AbFmZCU6b8wTBfU0UbQ_4_5"></a><a id="Tc_Hq6CfOkLX02ariLEDlYXiA_4_6"></a><a id="Tc_LelNYrEYvUORNZy3_iOmcw_4_8"></a><a id="Tc_GGw8ibIkOEim3PGr9NA9Dg_4_9"></a><a id="Tc_esL8WyWZekaKE8s-hqnL0A_4_11"></a><a id="Tc_0c7nNZYAzkyHVbsYwqd0uw_5_0"></a><a id="Tc_uRhoeQdCHku_JnDPW8J6VQ_5_6"></a><a id="Tc_1I5-uQuh40K4FCiJrOEAkA_5_9"></a><a id="Tc_vhqNocgOJkycPw6FgymoyA_6_0"></a><a id="Tc_cyCeL2hfskCu9d6EMFAOzQ_6_2"></a><a id="Tc_MwHMKIJefUypkI_dspQI9g_6_5"></a><a id="Tc_WLhBWIo6EEKazoB5ijq0cA_6_6"></a><a id="Tc_XHEEUiOEm0iHJq4qUKv99Q_6_8"></a><a id="Tc_xaXmWYQpQUmZYFc8nOS3Vg_6_9"></a><a id="Tc_H_A3K2pcJUiHOWQFVcrKkA_6_11"></a><a id="Tc_TEEzY3nSCUuPx9WKXcL42Q_8_0"></a><a id="Tc_nDG3_CNn7kCNL7jEdeYKig_9_0"></a><a id="Tc_s3awx9kpDkKGlVUjqGDN9A_9_2"></a><a id="Tc_CLhHa-Jm3kq5WxawiB0sUw_9_5"></a><a id="Tc_PFxMWvgAdU6nbJdqIndybw_9_6"></a><a id="Tc_BN0w8fPFokyGdic6_wjCTQ_9_8"></a><a id="Tc_C2I4wYJGvkyjPagcHtWxLw_9_9"></a><a id="Tc_E4yQDBmlCEq5s4SG1XUAmg_9_11"></a><a id="Tc_-OBn8lE-aUu4V8pHxWt6hQ_10_0"></a><a id="Tc_O3zMCNA3LEK-hQlaIOrvNw_10_6"></a><a id="Tc_3F_CvgmGqEuATiRyvuWxIA_10_9"></a><a id="Tc_vVn2NOZHrEKlNnDgZK_PBQ_11_0"></a><a id="Tc_4LrLZ8gzYkmkiQijPnFEGQ_11_6"></a><a id="Tc_ioPTIz_3ZEe8WFtL7-TI_w_11_9"></a><a id="Tc_GvwFD7gUfk-6b5drXBzdmg_12_0"></a><a id="Tc_t1mRbFrgE0KYOKKPyPwLoA_12_2"></a><a id="Tc_e8G00q09GEeNxliTpnVjOw_12_5"></a><a id="Tc_8x0qVgQmkUmlbwj67_fW5A_12_6"></a><a id="Tc_3fw2U_rNEUi4faCa3opXrA_12_8"></a><a id="Tc_6OdrFO8wA0qlZ2eA_NiwQQ_12_9"></a><a id="Tc_GoBTDpfS4k6JbvTUg8tBrA_12_11"></a><a id="Tc_QI84xzcCm0Sot9FLcFu4WQ_1_0"></a><a id="Tc_EpeYFlHEAEq_RX448c5czA_1_2"></a><a id="Tc_52RgLCGAmkGpvuzBYA0aiw_1_5"></a><a id="Tc_4GC-v5qnMkWZKYIBgi0y-g_1_8"></a><a id="Tc_kD_RNJbo_0iwDp2pi-10lQ_1_11"></a><a id="Tc_2d4gMce9j0GqG4LunR-G8A_2_0"></a><a id="Tc_Zm89WEkHe068ZfdMCy5Z6g_3_0"></a><a id="Tc_xjjTRFZZiEyAcc-Kak8xAg_3_2"></a><a id="Tc_FMYCzl2JH0my85R4L10Jvg_3_5"></a><a id="Tc_lFsMl-5r-kygDaulTimDQw_3_6"></a><a id="Tc_082u54iUkEGqzaOXGSA8cA_3_8"></a><a id="Tc_td5fRCeW70eQ0fRRmWHY4Q_3_9"></a><a id="Tc_thpgj3is2kGBQ4shCNAQqQ_3_11"></a><a id="Tc_CU9tcQ0M7Ea_4bvcjWEO1A_4_0"></a><a id="Tc_8TLVRjo_b0qqXuzmS9cwFQ_5_0"></a><a id="Tc_hOpH8y-jpUitIEgMZuxrng_6_0"></a><a id="Tc_EMi_DR_n-UG8Tdg6V9wQFw_6_6"></a><a id="Tc_wq1H9vVrLEOdbBLdqx4cCA_7_0"></a><a id="Tc_LHw5UkVp4Eq5SQA5yILM6Q_8_0"></a><a id="Tc_4gqzJSmwgU29hTnzqla_Tg_8_2"></a><a id="Tc_3JSxKF_VuEi5_2xpdan0sg_8_5"></a><a id="Tc_47XoS8i2n0GTkFhR4C7miw_8_8"></a><a id="Tc_6ykAMa7UfESYGbQUacpFfg_8_11"></a><a id="Tc_OYfwuAimBUquTEw0BmuXMg_10_0"></a><a id="Tc_xeQ9w1XFBkm_wK-CaJDVRg_11_0"></a><a id="Tc_ZmXCGQWV0km5YbjxtJqVUA_11_2"></a><a id="Tc_elcihtki9kqCMLmM5UcG3w_11_5"></a><a id="Tc_OZmznqdxOUCJXD6bPMXZkQ_11_6"></a><a id="Tc_UDtli24KIkKFRQTxwqnFzw_11_8"></a><a id="Tc_D0Fb26uVAkekEaXxizlz7w_11_9"></a><a id="Tc_8x3qolo_lkKylTsFd1ySgQ_11_11"></a><a id="Tc_5O_BXiA4tUm48lK3LEJWPw_12_0"></a><a id="Tc_YPebbTtWl0qqV5WrQ-0M1Q_13_0"></a><a id="Tc_wqJCyshFnEKjL1ylmqebNg_14_0"></a><a id="Tc_7RYy7KgOmUGfIikxav69ew_15_0"></a><a id="Tc_jG17H_6H6EGk7MlHcO1law_15_6"></a><a id="Tc_0g3677_SIE2QHa9-NEOSYg_15_9"></a><a id="Tc_Kej9s8iS7kmaE8QS370_Tw_16_0"></a><a id="Tc_M-6oAoaZZUibVwdHpYZtwQ_16_2"></a><a id="Tc_i2H_gJCBmku55xepU7HSaQ_16_5"></a><a id="Tc_TXStYct9OUyApOXZ1CVTGw_16_8"></a><a id="Tc_MIiDkgZZe0WhTIDTKsS43Q_16_11"></a><a id="_43e9c7cd_cd4f_451a_b84f_247483c42c23"></a><a id="Tc_P6n8T7k8G02Dmu5CxbDfCQ_1_0"></a><a id="Tc_kL-QJoAGhU6bmrmsElNRGQ_1_2"></a><a id="Tc_eWStjrW2C06xbPQNnGXvzg_1_5"></a><a id="Tc_FhqW4mcd7USCZyj2IE0cHw_2_0"></a><a id="Tc__IYxUlYC90C38Qn_3F0v7Q_2_2"></a><a id="Tc_WfZZDZiVl0GM0kC-JLNLfw_2_5"></a><a id="Tc_rAvTvrw9sESX5HsiEpIziA_3_0"></a><a id="Tc_tulyRu0nPUOFxy_zflTBoA_4_0"></a><a id="Tc_q7hZltvPakSZOQ8H8MSTaw_4_2"></a><a id="Tc_Vx7qsS4J9k2J2Y7tlt3AnA_4_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_6HhcAtlKYkKRhpwdXdZp7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Cash, cash equivalents and marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of cash and cash equivalents:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_sG7VPUEVyEaqviwb7LKHJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_62jnW-ZOyUGxlh6h8Z2Paw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_fzwOb3_i8kisRSrEVABAJg_4_3">44,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_62jnW-ZOyUGxlh6h8Z2Paw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Y351TY8CvkirdowhMEYkmA_4_12">44,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_vWJMqNXQZEadyp--CRitIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_Z34R7Su51kWwx12J0fJTVA_5_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_vWJMqNXQZEadyp--CRitIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_PTWkbALFxkCn9FJ3SXM5zg_5_12">84,416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_73stKRFgTUmyMisPXYo6iQ_6_3">128,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_vO0_rQ7PH0ePLp7Sg0IzQg_6_12">128,965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_89c_UBK5AU6UAZMtdo0pYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_k6YLCAYKc0uDDZihvjdwIQ_9_3">46,660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_89c_UBK5AU6UAZMtdo0pYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_4CXItbxbQ0a6Wc0hcN7oKg_9_12">46,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_I5BRgy8uTUifNJBQXb4LQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_-nhO9l9K90GJ7chaXNtDMg_10_3">84,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_I5BRgy8uTUifNJBQXb4LQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_tYZxI5hUi0qhL0dfa2Ntdw_10_12">84,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_JdA4EKGM8EuzfT7R3EYZqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc__sIXR3UWZk2YwIQ012Eegg_11_3">3,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_JdA4EKGM8EuzfT7R3EYZqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_SWJp38Z2bESQbmnlSNuF4w_11_12">3,933</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_kqytiDwGhkClAuF6wzXVFg_12_3">135,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_3ahUgQ6wMU2X0aDBo1GdCg_12_12">135,002</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of marketable securities:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_hyyeJjlBqEGU_BjGqBHzlA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.7201729%;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_dTyFlaO3mUKM6PVp1FpYkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_8h2svkDQWE--2ECDUH7FvA_3_3">5,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_dTyFlaO3mUKM6PVp1FpYkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_03W4g5f27ka9N2YqdLFaGQ_3_12">5,296</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_-1miveaEgke7UFPq_-fWAg_4_3">26,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Npu8jpFt0kGVMX1vF_FjIA_4_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_hXixzHqn5k-myTyzTMkU6Q_4_9">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_iORtoC1b9keZyGJl0tVvuA_4_12">26,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_AnYXrxA2EUGyuZEHs9Lbig_5_3">145,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_EnxXnHdL-kCaWTb3JhjWJA_5_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_1fzoCwDABkK-xPM8TDh6Xg_5_9">418</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_KXtTG70jEkCn0hc9yL0kCA_5_12">145,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_lZd6JKueaE23h15-VFCBVQ_6_3">1,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_VGOHQlknTESVYDhOn5wXwQ_6_9">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_kDYmaJzNPE2I92u8h3LsJg_6_12">1,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_0hhZRExUp0mJahXPAjrlKQ_7_3">7,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_9pgBdFFl60WgaDGB-rqhGg_7_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_Cc621Vjrh0CITi7qMLDRlA_7_9">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_WwWLDZhLdk-uCUn-sgVb8w_7_12">7,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_xPRL2qSjtk65cr6SuA0CKg_8_3">187,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_o0UmzF_K7EevF745u6fV3w_8_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_xd4RvYszJkyexZorxaeZ1w_8_9">431</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ltGRHz8xYU6jcjGfvVlV4Q_8_12">186,808</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_0ZVBL1LBgk-2Lmwe-qa7sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_YDXXaVMsH0-W91LOjAbkkg_11_3">6,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_0ZVBL1LBgk-2Lmwe-qa7sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_5dtuAjFh1EeP2XPOFQZEnQ_11_12">6,115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_Q_Lytah3GU26KFYAAoYB0w_12_3">47,872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_baVwn_9ewUaQfUoboDCYBQ_12_6">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_y6keJKwCkUyfkltGhqC5iw_12_9">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_8pN5ipHUnEK7LFfd_1Gk8g_12_12">47,877</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_SIcizvdmWkOYyxTCA-h2Ww_13_3">85,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_73lo77PL90CAsLTRag6-sA_13_6">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_ZPRGCztlFkGJ6q2hH31h_w_13_9">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ClgOZ8yuP026CratRKgUjw_13_12">85,577</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_bZbjCfI78kymtWdJk3cN4w_14_3">24,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_ij97lODGGkmRnUgz-qKimg_14_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_tPOtiZJknEi0IoDzXQISyg_14_9">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_5B_tR2MsMUOJT8q6wkwF2A_14_12">24,344</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_z0eGE2veJk-OYbHDU3ohYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_dWvDkaY9ikKIp-S_UwrMHw_15_3">5,902</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_z0eGE2veJk-OYbHDU3ohYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_fm_tAF0XuEeuQfGRo8074w_15_12">5,902</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_f1QDfPjYYUCTIBlUA6qiPw_16_3">169,827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_FvtVyYnnREGx1Bx8rpt8Cw_16_6">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_HEOrAQG0OEmndmWP65St2w_16_9">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_VZd7IhJyoU69-3cCOCVKEg_16_12">169,815</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">S</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Tb_1qbtrf6NrE68ZWj-S8OXoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The contractual maturities of our marketable securities as of December 31, 2021, are as follows:<b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_YsI8GjWrCEOPpPjE8jHQnA_2_3">103,012</ix:nonFraction></p></td><td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="Tc_hjvDUNUy2USQwSjzCtizrA_2_6">102,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due after one year through five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="Tc_OFJo-GIHUkuW1aG7C9NlSw_3_3">84,209</ix:nonFraction></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="Tc_tH464nDmykG8PPadTkTgTw_3_6">83,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="3" id="Tc_UWWTqMW58EqbxCf0FdVOEg_4_3">187,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="3" id="Tc_ABv6k_iNx0-MZ1EMczSxpQ_4_6">186,808</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_x5j0jGvW_UK2obYRIYOpRg" continuedAt="Tb_x5j0jGvW_UK2obYRIYOpRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><i style="font-style:italic;">Level 1:</i><span style="white-space:pre-wrap;">  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><i style="font-style:italic;">Level 2:</i><span style="white-space:pre-wrap;">  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><i style="font-style:italic;">Level 3:</i><span style="white-space:pre-wrap;">  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_41MeZvWqCUmRddWckB-Z9g_1_2"></a><a id="Tc_WAwz24MPhEWjWFdBpN1LMw_2_2"></a><a id="Tc_J06H5VPvjEC1m_ii4mN15A_3_2"></a><a id="Tc_qZZYhmr9RUSjA4f04FD_3A_4_2"></a><a id="Tc_jt1Ur_tFO0auJWI7NBHeZw_4_5"></a><a id="Tc_TY1k2qknw06ijp0olM7Pdg_5_3"></a><a id="Tc_Di2CF5ehBEyxKLy0M451nw_5_5"></a><a id="Tc_H88D9OsI0U6iiaykTj6ftA_5_8"></a><a id="Tc_XgCqIWg_A0OGaRu43H07kA_6_2"></a><a id="Tc_KRteFDc2REyai5gR3IWfaA_6_5"></a><a id="Tc_6TecQEEBP0WehU3CoEeFqw_6_9"></a><a id="Tc_AIxB_WOFUkW5Ch9wPjexEQ_7_2"></a><a id="Tc_4WLNRM3MSkKGGWKTgq824A_7_5"></a><a id="Tc_n5Kwb-ANxUyx62lOlsJsrA_7_8"></a><a id="Tc_rQZ7-U9WW0CdADA3yup28g_8_0"></a><a id="Tc_do6MglmuwEaCE99TNXqFug_8_2"></a><a id="Tc_lgCe-Vj2eky-9LtV-y0TSQ_8_5"></a><a id="Tc_Ks_NnNoVu0W6RRFMVmxD_Q_8_8"></a><a id="Tc_PwpBgLRjmEOV1DpgDgxGZQ_9_0"></a><a id="Tc_NnqRYBcUIkqo0pghhcKT-A_10_0"></a><a id="Tc_TID5gCL51USZG2wJKYxyXg_11_0"></a><a id="Tc_Mcpw6YCYX0KEKg_ztw2sdQ_12_0"></a><a id="Tc_FBGoDfwaa0OPYkUZWSZigA_12_2"></a><a id="Tc_FIhma9M_-EqV6gv0DZQ-MA_12_5"></a><a id="Tc_J4zziCHvLkqVGHVxPt0SPw_12_6"></a><a id="Tc_psMNafmNMEO9QtosVTBIUw_12_8"></a><a id="Tc_E_CppoSA6EuZJi2tubhAMw_12_9"></a><a id="Tc_33IRL_I8e0Wgxw3AqVHx0Q_13_0"></a><a id="Tc_-ZelLtuvyESJyGvkJeRUoA_13_6"></a><a id="Tc_5H3E7LGShUODDP2RXellXQ_13_9"></a><a id="Tc_I9d-h_QSdkGGzHeEZANqKQ_15_0"></a><a id="Tc_1ctIb9w9cUm5x6FKlh8rPg_16_0"></a><a id="Tc_hqWQIuu89Ei5Hj6L8XP1yQ_16_3"></a><a id="Tc_U8kkaj5H90KJIGYtHp40Fw_16_9"></a><a id="Tc_C88PHvEvZ0yIWuPZI08qWg_17_0"></a><a id="Tc_Glsixq1gDUqkHVg_feDd8Q_17_3"></a><a id="Tc_QUU7GBEqjkGeohJl5YZ6qw_17_9"></a><a id="Tc_KKmL2FKq4EuLtGv12-DZvg_18_0"></a><a id="Tc_KVqmb8O8kkCm2lyg8Cz77Q_18_3"></a><a id="Tc_vKgxa6OW9kuwG_IQoviUNw_18_9"></a><a id="Tc_q-TD4lFEFEuayui0gJge3g_19_0"></a><a id="Tc_3ssFQzq1UEGcstAWrtJoXw_19_3"></a><a id="Tc_JOi5dugvR0mYAuaCky133g_19_9"></a><a id="Tc_RWpT_uVIq0K-Q7ylss1MUw_20_0"></a><a id="Tc_VroHf8-sakmo7Y-Gq_Rb0w_20_3"></a><a id="Tc_VpKOK8mzmUWSoFSynMniqg_20_9"></a><a id="Tc_Xw33me1VsUeciFyyPV1uLQ_21_0"></a><a id="Tc_AVCt_9ceFUGnksPRoktxuA_21_3"></a><a id="Tc_ZedhmIaOl0aagZ4alQktNA_21_9"></a><a id="Tc_YnlHVY2VdUy2SnXystWYow_23_0"></a><a id="Tc_EwS0i5Jdc0GL6ZEsnEv37w_23_2"></a><a id="Tc_8O-8mPyy-UqbTSrTI9GkbA_23_5"></a><a id="Tc_7Fm024FcK0CY_CpwcE0itA_23_8"></a><a id="Tc_OAePgsrR3UeDaUYEYFpWfQ_23_9"></a><a id="Tc_7EaSrhyYl0CNg-IRBhtKUQ_25_0"></a><a id="Tc_tIAvb2UvZU-ZW-IWAmyqow_26_0"></a><a id="Tc_9NO_TEihJ0u32vj_tQoUEQ_27_0"></a><a id="Tc_gex5CQ1CqES8VDa_lmMn7w_28_0"></a><a id="Tc_qgzmRprNYU2Ckedryr1jfQ_28_2"></a><a id="Tc_GEPOcynrO0KFVoLQIvLpJg_28_5"></a><a id="Tc_31dlll9Kc0y2jrxLrAxdSQ_28_6"></a><a id="Tc_s3pcpWkJ3k-fllxs7IWt1A_28_8"></a><a id="Tc_-fguS2azmE-j2r1JgA4Gvw_28_9"></a><a id="Tc_txzHZbxdUEaAXOWEvnKsZQ_29_0"></a><a id="Tc_WH80zGwcLUGEIVaQ-OdQNA_29_3"></a><a id="Tc_yHUm-bIlbUamNufziI4Omw_29_9"></a><a id="Tc_hznq6R7p70qLWxiSM8kSPw_30_0"></a><a id="Tc_IXjbMd1TEUyFHhpZRF1J4Q_30_9"></a><a id="Tc_Yh9oDiO8JU6blbotkqOYag_32_0"></a><a id="Tc_H76egfjHB0Ghply-UZp4BA_33_0"></a><a id="Tc_HaMUVFL9X0aHoVDh1_eJ2w_33_3"></a><a id="Tc_v7aCZN7X-0arVDigY2KasA_33_9"></a><a id="Tc_DB1DyfKtY0KXH7vsJkU-mw_34_0"></a><a id="Tc_gZVXethqHkq9ExQ4fgWnVg_34_3"></a><a id="Tc_HtPXKD244UeaJJ4j0XHVBQ_34_9"></a><a id="Tc_UPqFbOwmVUO6S5Ah3ENvrQ_35_0"></a><a id="Tc_iZ1_iwvgg0y7497UWq8TUw_35_3"></a><a id="Tc_d8i7D4Xc2UKY1ZZVLDyNPQ_35_9"></a><a id="Tc_Tg5aNgqZFUy-0Xukd2PsBw_36_0"></a><a id="Tc_nLly1lyzvkmeE-iAjleAkQ_36_3"></a><a id="Tc_tR2EcnCPhEenStfyEPxqXQ_36_9"></a><a id="Tc_odJrlNTzR0aogdRZGyBABA_37_0"></a><a id="Tc_j52SxBNPk0u3mfCxxnRRkQ_37_3"></a><a id="Tc_REDu3j7se0W6jToNcw9kvw_37_9"></a><a id="Tc_AvfXyPNJB0qoFr0hIaAQlQ_38_0"></a><a id="Tc_mYL_jxUahUGX9LBlafSBxA_38_3"></a><a id="Tc_QAzb1r8RxEypHqJ7B-orZg_38_9"></a><a id="Tc_zhUEOH5pZ02mbg8dqqIZ0A_40_0"></a><a id="Tc_EpO43JrbtUuuHwJU0cneCw_40_2"></a><a id="Tc_Lg8f43a49UW8s5GIUMYzBw_40_5"></a><a id="Tc__-tzERxf2kma1Mvv_xhgKg_40_8"></a><a id="Tc_xul6c-c66EiEY_hhepjrcw_40_9"></a><ix:continuation id="Tb_x5j0jGvW_UK2obYRIYOpRg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_2NGGv0Ih5kKep5ocx0UKWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LKyQmyM_mEOvmrMoP6U72Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_NqKat9ukd0qBRyNFGxXVPQ_12_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_EII3h5FOukeUel3cT8v7-Q_13_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_xubfLqarekqkZnz8HPVLxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_57ZkApOD5UGBbfBHfFmKuQ_16_6">5,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_rMsmezVxj0a84jy1lB0R9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_I7UWrmwZMk-FNJn-Ma-mTA_17_6">26,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_avGEAHh5YkKCdU7swCc-rA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_WIrJklaM0kGUl1ruzQ7eFg_18_6">145,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_cO90df-qlE2w4LRBHX_-6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_o4CoS47KaEC14qheoTng0w_19_6">1,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_pP402F0Qh0OFBcMuVo7wbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_em4TIKboEE2Efp4HirIW0w_20_6">7,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W8IOiflxCUqSDBcWDbNx9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_MuhO1Qa1f0GFpkMoJYiBQA_21_6">186,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_pafVsx53tEKrUcbBMX_pgA_23_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W8IOiflxCUqSDBcWDbNx9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_BkyTzfllNUKAOO1nZqyhaA_23_6">186,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cnF35_-O8kC3_ITgQtTTnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_-2NglE2qzEmUOBv4yLn3iw_28_3">84,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtK3dDq7kawG05hiybIvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc__vU8Nts8l0SWJlvOLVGjUw_29_6">3,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yP080bRNLkKlnvnFLFezGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_wTVBWt0zo0yo4b57xq9j9g_30_3">84,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_XrTM6BlRTUu7BQgG1TBq9w_30_6">3,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_B9cbaSVJx0CJKDD0vSu7dQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_0-oMOcQsCEOq-RSX1yACnw_33_6">6,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_p-FfJJcDT02MgnnCC4FKKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_20d_2CuNvkGzkNGP6JgZwg_34_6">47,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_a4xV6v1rwUKpdSlmiov0oA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ByWbQ9QKfUaBnynmt719GQ_35_6">85,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_2Dnl9qndLEiZA71KgcQs7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_LsJMnILOCk-4PDiL5trLTw_36_6">24,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_gJE9jyckc0uxCSxe63NjaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_hmDOCx2uvUyJ7hVOb4J0rw_37_6">5,902</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_AvaTKn2Bv0y4O3BL9yxy2A_38_6">169,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yP080bRNLkKlnvnFLFezGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Xx-OgTXJRkeRqABb-A8H-w_40_3">84,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_6MNiqXVHnkm0CuVAa99xBg_40_6">173,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_F1SAP3IjsEOL4oUcxKysww_2_0"></a><a id="Tc_SvQjDRrkkkutiMXTTD1BEw_2_2"></a><a id="Tc_QRs7ARP3kkOqejltA91wbw_2_4"></a><a id="Tc_WwOFeKvF_Ui2jySB1kz-3w_3_0"></a><a id="Tc_vRUwp36RNUWAmw7jw0RAWg_3_1"></a><a id="Tc_qSb1eQaKG0OVQf-yy_7kig_3_4"></a><a id="Tc_uqQFeuMsPk-EBRsc7rnLbg_3_5"></a><a id="Tc_OFlVDZ0QJUmWodqSNeAchQ_4_0"></a><a id="Tc_hz_MCqJlI0m6EQT6G0SAow_5_0"></a><a id="Tc_AzzFD7G84Euvt-DAxIjtWQ_6_0"></a><a id="Tc_K8oxZEQ5IEaE6RLUumRe6A_7_0"></a><a id="Tc_HWQQR1eXX0CQ73s1S5hsOg_8_0"></a><a id="Tc_LH1HZYh3fkK006RDDAiRxQ_9_0"></a><a id="Tc_pJ33UW-IvU-h9rqCsboqRw_10_0"></a><a id="Tc_M-RzNPO1hkejs3X0C2J6sg_11_1"></a><a id="Tc_H9wcLX-NxkyIp2JiZ3zQUA_11_4"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_CT_xNjQMBUiJ2WbMxld0yw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net, consist of the following: </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_K9kSj_hUJEu3EuDbQTprxg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:105.29%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:middle;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_Eec2VJTNMkK-WIJuen-_xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_gmhSOKfsnkO2LkWJELS6Sg_3_2">8,916</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment</p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tb7mAE2KnkKD7-9H_fYxeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cb6etoxr90G0oU71SIoCtw_4_2">621</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_uM4mB8EAzEu-8Axzi0_XsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_p4Z90GEV-UStBytV-JQFjw_4_5">80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer hardware and software</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_9l6O5crOnU6_39cV6VEfVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc__y7-rFHxlkuuuQD0A8WNfA_5_2">1,028</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_bS1e6udSiUmjvh8u8711pA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_FZdT7NXbmE6uOHRcnv2vYg_5_5">425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_nz0HkNmO8kaGfzabjgTXHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_AgClFsRipkGh1vDT5rABDA_6_2">1,487</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_aGYb1YEU4kCXSlYbal1wIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_eFS8LqfJ_E2Ofn-rqTCK5w_6_5">272</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_jWNc7kjyfUCQZyuO_hmU9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_3jnWMV1VhUiS1P6jnjymaA_7_2">13,409</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_RxCh3NZzy0OKjrjwUe4Zdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Oq86ow3oyUinya0ASbfTmw_7_5">1,638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:middle;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_TZX4Wh_vEUaTQxedl8QHPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_k-Dn8V8izEaQDotAnYwbpA_8_2">822</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_hr_uYkiIdUi2u9pCZYZyfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0BycKzqTxk2ykRHmA1D6Gw_8_5">1,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_UHzW6p3A-UKRYuqlfVhzKA_9_2">26,283</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_yvTpILTwMEWJAagvI_M6Hw_9_5">3,729</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_bd4Rfxe-YUuMP-5buA_iRA_10_2">2,477</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_6Ff6kQajPkKQhh-IdUWZ9Q_10_5">934</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_H1sLk61sT0yS5KlvyYaTKA_11_2">23,806</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_4wve3Jh8nUm4B5j0WHbv8g_11_5">2,795</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_53TT-5dPSkq5gItJ5oojSg_1_0"></a><a id="Tc_t3oEa8te_0eWWl5L7OdRVQ_1_2"></a><a id="Tc_u1v0JcgLmkGwndflZ866nA_1_5"></a><a id="Tc_DrqAN9jf30KONGV4tAQtvA_2_0"></a><a id="Tc_9OqwSaMFJkaXp9i33AwVKw_2_2"></a><a id="Tc_bE7f9sYZnEGBH7TCRy0D4w_2_5"></a><a id="Tc_vmWjtiEf7UCJ3-QKZMM_zQ_3_0"></a><a id="Tc_HdIi_PZZzkOqb8Bazov4vA_4_0"></a><a id="Tc__30fnnxY-0a0mj38XaUoBQ_5_0"></a><a id="Tc_puAcqYSfPkGxYe_-oFu1mg_5_6"></a><a id="Tc_uSwA0QaOHkemU6spPXkr_A_6_0"></a><a id="Tc_jToRvmqBNEmHguKCsXJ9gg_7_2"></a><a id="Tc_Fb65Lx0NvE2-YhrRXQDKnw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="Tb_uSjDjB-oZUaLH2cKMwLesg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb__MyofBpKuEK_YGHYHxv-sA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_py_P22lzeU2DDxqUCpfs3w_2_3">877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_oRQRB-MXvU-w0xEN6OB8BQ_2_6">720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_9Z_vWOo2L0OJv_dIJewaaQ_3_3">10,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_FDWDgs4IkEmN-yvZ0xyhEA_3_6">5,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedResearchAndDevelopmentExpense" scale="3" id="Tc_P621nWhPxUafgs3VIiW1xg_4_3">8,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedResearchAndDevelopmentExpense" scale="3" id="Tc_3pzB8uUJSEu1DrJqg49hbw_4_6">9,466</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent" scale="3" id="Tc_WOe_wXL2X0KU1AT4-xRJCw_5_3">161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_GFlt-XckO0y664_B_ADrmA_6_3">500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_z7KEzANUn0uon1i5Boy7vw_6_6">541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_wVctAuLxbkODnchdsSCUNw_7_3">20,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_i7ai-OhFNEq546Fqyj0n-A_7_6">15,910</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_L8IQpevdt0yC2JBKI5Saiw" continuedAt="Tb_L8IQpevdt0yC2JBKI5Saiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amended and Restated Research, Collaboration and License Arrangement with Penn</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company has a research, collaboration and licensing agreement with Penn, as amended, or the Penn Agreement, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, in addition to the obligation to fund certain research relating to the preclinical development of selected products, the Company will fund discovery research conducted by Penn through August 3, 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery research for the Company&#8217;s products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. This funding commitment for the discovery research is </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAnnualFeePayable" scale="6" id="Narr_hvYntO4lPk6CT-HFszzA2Q">5.0</ix:nonFraction></span><span style="font-weight:normal;"> million annually, paid in quarterly increments of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementQuarterlyFeePayable" scale="6" id="Narr_7Gbtce0Fi0yhb_BUj8ufUg">1.3</ix:nonFraction></span><span style="font-weight:normal;"> million through August 3, 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As a result of an Amendment in August 2021, the Penn Agreement includes an exploratory research program focused on discovering targets and novel gene therapy candidates for large CNS diseases, initially focused on AD and TLE, and can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is until August 2024, which term can be extended by mutual agreement. During such term, the Company will have an exclusive right of first negotiation to include additional targets to the exploratory research program within the agreed upon large CNS indications. Under the exploratory research program, the Company will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within AD and TLE (and any future large CNS diseases that are mutually agreed upon) that may arise from the exploratory research programs on </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_L8IQpevdt0yC2JBKI5Saiw_cont1" continuedAt="Tb_L8IQpevdt0yC2JBKI5Saiw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">substantially the same terms of the current Penn Agreement. The Company made an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_JY_Wj1FPNU6c8cjQsZNN0A" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementUpfrontPaymentMade" scale="6" id="Narr_3L5rnhCAUECq_PLdGDIPjA">5.0</ix:nonFraction> million in connection with the amendment to the Penn Agreement in August 2021; will reimburse Penn for expenses incurred in the exploratory research program; will pay an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_qDWtLlQQI0CDUl_45mabSQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" scale="6" id="Narr_TeYYIXhxeUy6B7bz-bCaOQ">39.0</ix:nonFraction> million in development milestones for each product candidate for which the Company has exercised its option in large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications (in lieu of the milestones set forth in the existing Penn Agreement), in addition to the royalties and commercial milestones for products set forth under the existing Penn Agreement; and will pay Penn a tiered transaction fee ranging from <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_-9UcmhqlFUOIPDQYaqM19g" decimals="2" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementTieredTransactionFeePayablePercent" scale="-2" id="Narr_C_SSRKMHRE6fp-7xiGiLMQ">1</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember__lny6i38n0-juSxISzMBnA" decimals="2" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementTieredTransactionFeePayablePercent" scale="-2" id="Narr_bp6MiJ_GZ0mbm7_stLkZ1g">2</ix:nonFraction><span style="white-space:pre-wrap;">% of the net proceeds upon certain change of control events.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Penn Agreement, the Company has <ix:nonFraction unitRef="Unit_Standard_Option_85izgBp0S0Shu2LfkufK4A" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" scale="0" id="Narr_SBx-QE1XJ0-Sv-vYehJJrg">eight</ix:nonFraction> remaining options available to commence additional licensed programs for CNS indications and has until August 3, 2026, to exercise these options.&#160;If the Company were to exercise any of these options, it would owe Penn a non-refundable upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_SCDOkqnfRkWyAeV9p2oFBg" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementUpfrontPaymentMade" scale="6" id="Narr_TL0qx24LQEGWrI520nfBWA">0.5</ix:nonFraction>&#160;million per product indication, with another $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" scale="6" id="Narr__CX1MLiiSkOpnf2Ni6NdMA">0.5</ix:nonFraction> million fee owed upon a further developmental milestone. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Penn Agreement requires that the Company make payments of up to (i) $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_r_NUEcfXZUWE7dm8OwgVfw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" scale="6" id="Narr_YvAodEKvY06axsKlgDmtVw">16.5</ix:nonFraction>&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_tJmj89_QHkOSI8IRh38VrA" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" scale="6" id="Narr_gfPBP2EnPEyNSCbDBSKK4g">39.0</ix:nonFraction> million per product candidate in the aggregate arising from the exploratory program for large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt-sec:numwordsen" name="pasg:DevelopmentMilestonePaymentsPayable" scale="3" id="Narr__whLRGjROEWq84dGyRquyA">no</ix:nonFraction> development milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_tJmj89_QHkOSI8IRh38VrA" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementSalesMilestonePaymentsPayable" scale="6" id="Narr_mFXXkWE-fkmHmb7DulmeNQ">55.0</ix:nonFraction>&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon successful commercialization of a product using the licensed technology, the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Under the Penn Agreement, the Company incurred research and development expenses of $</span><span style="letter-spacing:0.25pt;"><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_4eXCDB_ZWE6mgKj2W3hJWA">17.8</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million and </span><span style="letter-spacing:0.25pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KKuHOgYwnUOUC3x3lVmTsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_YgNNhazggk-A-E508UyIxg">32.4</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million during the years ended December 2021 and 2020, respectively. During the year ended December 31, 2021, the Company paid Penn </span><span style="letter-spacing:0.25pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:AdditionalTechnologyLicenseFeePaid" scale="6" id="Narr_pqCGTIRYbUuK9pV-lam9SA">1.5</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million related to the achievement of a development milestone, </span><span style="letter-spacing:0.25pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementPaymentMadeOnOptionExercise" scale="6" id="Narr_jGAKkPFSBE-A8KWhlMx5XQ">1.5</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million related to option exercises under the Penn Agreement, and a </span><span style="letter-spacing:0.25pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:PaymentsForTechnologyLicenseFee" scale="6" id="Narr_vOPbQoT4PEGge4hqlBxn0w">5.0</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million payment related to the August 2021 amendment, which were recognized as in-process research and development expense. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Catalent Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Company entered into a collaboration agreement, or the Collaboration Agreement, with Catalent. As part of the Collaboration Agreement, the Company paid Catalent an upfront fee for the commissioning, qualification, validation and equipping of a clean room suite, or the Clean Room&#160;Suite. Subject to validation of the Clean Room&#160;Suite, which was completed in the fourth quarter of 2020, the Company will pay an annual fee for <ix:nonNumeric contextRef="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_U2yhmhWXYUGyV29jTRrJ-Q" format="ixt-sec:durwordsen" name="pasg:CollaborationAgreementAnnualFeePayableTerm" id="Narr_dsuCO--coEOwsV7X_dS_8g">five&#160;years</ix:nonNumeric> for the use of the Clean Room&#160;Suite&#160;and is also committed to minimum annual purchase commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the Company entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. The Manufacturing and Supply Agreement confirms the terms contemplated by the Collaboration Agreement. The Collaboration Agreement continues to be in effect pursuant to its terms.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_L8IQpevdt0yC2JBKI5Saiw_cont2" continuedAt="Tb_L8IQpevdt0yC2JBKI5Saiw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates at the Clean Room&#160;Suite&#160;at a Catalent facility provided for in the Collaboration Agreement. The Manufacturing and Supply Agreement provides for a term of <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A" format="ixt-sec:durwordsen" name="pasg:TermOfManufacturingAndSupplyAgreement" id="Narr_eAbyPZVOy0OeJbbMO3JVug">five&#160;years</ix:nonNumeric> which period may be extended once, at the Company&#8217;s option, for an additional <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A" format="ixt-sec:durwordsen" name="pasg:ManufacturingAndSupplyAgreementAdditionalExtensionTerm" id="Narr_CkqepnWyTEeHsu8tAFr-hA">five-year</ix:nonNumeric> period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If the Company terminates the Manufacturing and Supply Agreement, it will be obligated to pay an early termination fee to Catalent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, the Company has an annual minimum commitment of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_8g3nKyOXp0WB3RRJFPY0Kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="Narr_KHNFkcoWQkO9p4Wjc8MuWw">10.6</ix:nonFraction> million per&#160;year owed to Catalent for <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A" format="ixt-sec:durwordsen" name="pasg:CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" id="Narr_eKKleEdXmUGqYc0wnFpsAg"><span style="white-space:pre-wrap;">five&#160;years</span></ix:nonNumeric><span style="white-space:pre-wrap;"> from the validation of the Clean Room, subject to certain inflationary adjustments. For the years ended December 31, 2021 and 2020, the Company paid amounts in excess of the minimum commitment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company leased office space in Philadelphia, Pennsylvania under a noncancelable lease, as amended. The lease was classified as an operating lease and the Company recognized rent expense on a straight-line basis over the lease term. The lease was terminated in February 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the Company entered into a new lease agreement, or New Lease Agreement, for larger office space in Philadelphia to accommodate the Company&#8217;s continued growth and serve as the new corporate headquarters. The New Lease Agreement commenced in February&#160;2021 and expires in December&#160;2031. The Company has an option to extend the term of the New Lease Agreement by up to <ix:nonFraction unitRef="Unit_Standard_item_24po74v6kUOYh01Lzj_3ag" contextRef="As_Of_4_30_2020_srt_RangeAxis_srt_MaximumMember_F_q5LSFCXU2s5384bFCZDA" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" scale="0" id="Narr_Rczjg5gqsU-phQK-Y80YBA">two</ix:nonFraction> <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_srt_RangeAxis_srt_MaximumMember_WriT7NhV5E2Q4aLWditgXg" format="ixt-sec:durwordsen" name="pasg:NewLeaseAgreementOperatingLeaseRenewalTerm" id="Narr_-SbVOLY_j0K2aFkpd-InWA">five-year</ix:nonNumeric> terms. The landlord provided the Company with a tenant improvement allowance of up to $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_4_30_2020_srt_RangeAxis_srt_MaximumMember_F_q5LSFCXU2s5384bFCZDA" decimals="-5" format="ixt:numdotdecimal" name="pasg:TenantImprovementAllowanceReceivable" scale="6" id="Narr_9hcMVLojD0-hW1-n-URsFQ">2.8</ix:nonFraction><span style="white-space:pre-wrap;"> million, for which the related expenditures were paid directly by the landlord. The expenditures were recorded as leasehold improvements with a corresponding amount recorded as a lease liability incentive within deferred rent in the balance sheet.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December&#160;<span style="white-space:pre-wrap;">2020, the Company entered into a lease agreement for laboratory space, or Laboratory Lease Agreement, in Hopewell, New Jersey.  The laboratory is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. The Laboratory Lease Agreement commenced in March 2021 and is expected to expire in 2036. The Company has an </span><span style="-sec-ix-hidden:Hidden_rps2tZ6LzEqxXNkA71X-1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">option to extend</span></span><span style="white-space:pre-wrap;"> the term of the Laboratory Lease Agreement by up to <ix:nonFraction unitRef="Unit_Standard_item_24po74v6kUOYh01Lzj_3ag" contextRef="Duration_12_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_7383hJsYRUaX8QecXw1x9A" decimals="INF" format="ixt-sec:numwordsen" name="pasg:LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" scale="0" id="Narr_qgtC2vFLz0aBLjBfUEPNMA">two</ix:nonFraction> </span><ix:nonNumeric contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_W0Jceks2UUu8HjUo4M49Rw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_tSiQQ5xfzUOiiRiC-EbCLQ"><span style="white-space:pre-wrap;">five-year</span></ix:nonNumeric><span style="white-space:pre-wrap;"> terms. The landlord provided the Company with a tenant improvement allowance of </span>$<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-5" format="ixt:numdotdecimal" name="pasg:TenantImprovementAllowanceReceivable" scale="6" id="Narr_dowwri81kUy3VIYISlc8hA">1.3</ix:nonFraction> million in connection with the Laboratory Lease Agreement, for which the related expenditures were paid by the Company and will be reimbursed by the landlord. As of December 31, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_e8i0wNfdJEOwKF4ht1pxvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="6" id="Narr_cmrrzwgeQUi6g31_KR0cTA">1.3</ix:nonFraction> million of leasehold improvements related to the tenant improvement allowance was recorded as a lease liability incentive within deferred rent and the remaining receivable from the landlord of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt:numdotdecimal" name="pasg:RemainingTenantImprovementAllowanceReceivable" scale="6" id="Narr_y5D2t6iUS0WHd8OVXttJcg">0.3</ix:nonFraction> million was recorded within prepaid expenses and other current assets. As of December 31, 2021, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-5" format="ixt:numdotdecimal" name="pasg:ProceedsFromTenantImprovementAllowance" scale="6" id="Narr_BNCt_G_zdkKSl-iFtWpHwg">1.0</ix:nonFraction> million of reimbursement from the landlord related to the tenant improvement allowance, which is reflected as an operating inflow in the statement of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ccw9QhVZvkKuGPvw_yv7IQ_1_0"></a><a id="Tc_KjhqEG2gW0SSUyu03-Ccrw_2_0"></a><a id="Tc_RKPKCtkVWUCwT9YQVgljTw_2_2"></a><a id="Tc_PSfwekSx90esK-ws9ymwpg_3_0"></a><a id="Tc_IB8eRJzcVkOisHdP2FWcQA_4_0"></a><a id="Tc_o_2gfziiSUaB2AGzeebShA_5_0"></a><a id="Tc_MvgCISODUUKqiLND4KOQlg_6_0"></a><a id="Tc_d0EfC-pHpkSaKcC0TwAwHA_7_0"></a><a id="Tc_-Ztm7dSwCk6BDhBcss6EtA_8_2"></a><ix:continuation id="Tb_L8IQpevdt0yC2JBKI5Saiw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments under the Company&#8217;s lease arrangements as of December 31, 2021 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_ywrrk-4i0kqXzk4ono42Dw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_8xQSNW6hYUiHRuwP2NcpcQ_2_3">2,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_B0WRMuuSpES7P2Dhckd1iQ_3_3">3,453</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_tHRmt0r1lkSs14Se5g6ruA_4_3">3,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_4jjGjmCg8EiBLrqPxiVcHg_5_3">3,651</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_bxrtPg2BuUCPx717Mha7kg_6_3">3,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_hHYutlew8ESCB--CCrbdBw_7_3">33,534</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Nj2gEWg7G0-iOA3WZINE1Q_8_3">50,826</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognized rent expense of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_g8nm1poiwEOA-pChNDVvnw">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_8w6dSsMh3kCKe9q3kjeYOg">0.6</ix:nonFraction> million during the&#160;years ended December&#160;31, 2021 and 2020, respectively, related to its operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as described in the respective employment agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Infringement Claim</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February&#160;18, 2020, the Company received a letter from REGENXBIO&#160;Inc., or Regenx, which stated its view that the use of the Company&#8217;s AAVhu68 capsid infringes patent claims to which Regenx has an exclusive license and which expire in 2024. Regenx also stated that it has exclusive licenses to various pending patent applications regarding the use of AAV vectors administered via instar-cisterna magna injection, and that these applications may lead to issued claims that Regenx believes may, if issued, cover the Company&#8217;s planned method of administration for the Company&#8217;s clinical product candidates. The Company believes it has valid defenses to the issued claims set forth by Regenx relating to AAVhu68. Further, the prosecution of pending patent applications is highly uncertain, and it is unclear whether any patents will be issued from these pending Regenx patent applications at all, much less with claims that are relevant to the administration of the Company&#8217;s product candidates. Regenx also requested information regarding the Company&#8217;s relationship with Dr.&#160;Wilson while he was serving as an advisor to Regenx. Regenx&#8217;s letter also offers to discuss licensing the applicable patent portfolios from them. In April&#160;2020, the Company responded to Regenx indicating that it does not believe it requires a license to any of the specified Regenx patents or patent applications at this time, and that it found that Dr.&#160;Wilson&#8217;s relationship with the Company was consistent with his obligations to Regenx. The Company will continue to monitor the situation and, if necessary, take appropriate actions, which may include responding to further correspondence from Regenx, and engaging in discussions with Regenx regarding their claims. If any such patents were enforceable and such claims were ultimately successful, the Company might require a license to continue to use and sell any product candidates using such AAV vector. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="pasg:StockholdersEquityAndTemporaryEquityTextBlock" id="Tb_jMbYWNpwsUutUwjCpGutTg" continuedAt="Tb_jMbYWNpwsUutUwjCpGutTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Convertible Preferred Stock and Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the Company completed its IPO in which the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5ywAfV8y7Emiz8ksbxvDzQ">13,798,900</ix:nonFraction> shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjALmRT9kE6JDV3gpQtAgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_yNFWG2eT9kyNt2J9EzH6mw">18.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_SG25fsiQwk2-WwIzAoR3uQ">227.5</ix:nonFraction> million after deducting underwriting discounts, commissions, and other offering expenses paid by the Company. In addition, immediately prior to the initial closing of the IPO on March 3, 2020, (i)&#160;all of the Company&#8217;s outstanding shares of convertible preferred stock converted into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0aYfPaNDZUKLpHmemdOVpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_lNU12kn6aEKQwptFzm3U1Q">26,803,777</ix:nonFraction> shares of common stock and (ii)&#160;the Company filed an amended and restated certificate of incorporation to, among other things, increase the number of authorized shares of common stock to <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GVNitqFPWE2eFLAMk2cu3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_6mZ2YXanfEewoZ2ylImjCQ">300.0</ix:nonFraction> million.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_jMbYWNpwsUutUwjCpGutTg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qixg5vgkHkyecFEA6Oz7bg">8,050,000</ix:nonFraction> shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_aHwnSqJS7Eaecp2WOoB7vA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_PqgXdnMzskKsFDv2bWr6AA">22.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_271c0TvPIU2U8uNdPEyuqw">165.8</ix:nonFraction> million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 5, 2021, the Company entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may, but are not obligated to, offer and sell, from time to time, shares of the Company&#8217;s common stock with an aggregate offering price up to $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_jLdA8uvJqUuhFQXDPlOxiA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_fKyGXCqzi06_A36KcHfvvw">125.0</ix:nonFraction> million through Cowen, as sales agent. <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_6cQRUFo1xEqxvR0_DcpgmQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MOC-CVh3CkmWZkI1Wesd4g">No</ix:nonFraction> sales of common stock have been made pursuant to this Sales Agreement to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_vo-w9QpbpEWr1yYMuxWcpQ_1_2"></a><a id="Tc_FjEjY-U6Qk-obwbCFQEFZw_2_0"></a><a id="Tc_Et3T13-Q-UyyG3FR7vXPng_2_2"></a><a id="Tc_2NqBgKRMc0qqMTY6D6JlZw_2_5"></a><a id="Tc_qE8s3IyeD0SGkSDJO9MNuw_3_0"></a><a id="Tc_mQUf_Wsc-kSCfAgNmtr9wQ_3_2"></a><a id="Tc_pPydKIcOz0GUjUMZNRuZTQ_3_5"></a><a id="Tc_X_Pl9haDaUy3t8dnDcB6KA_4_0"></a><a id="Tc_DGHk-2EL0k-RTUtTNjUs0A_5_2"></a><a id="Tc_10hfY3d87k-TSIlu9gn6jQ_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Cs0oSuJSEUKSzMYtfq1G6g" continuedAt="Tb_Cs0oSuJSEUKSzMYtfq1G6g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_plan_bYBMu5fRl0arekv0DtDLXA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NumberOfEquityIncentivePlans" scale="0" id="Narr_e2OHJiBnTUGylKaAMs8oNA">three</ix:nonFraction> equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and Inducement Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares authorized under the Incentive Plan as of December&#160;31, 2021 was <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_YdlvI73YvU2I-mGpcp7oeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_91_wmOdDUEe1CHFTRexjaA">7,658,677</ix:nonFraction>. Of this amount, <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_YdlvI73YvU2I-mGpcp7oeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_proT6AwZEUSN31e_EmgIgQ">3,637,509</ix:nonFraction> shares were available for future grants as of December&#160;31, 2021. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Plan shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continuing for <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg" format="ixt-sec:durwordsen" name="pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Narr_FBciUcxhKUiU3dFUwJpvEQ"><span style="white-space:pre-wrap;">ten&#160;years</span></ix:nonNumeric><span style="white-space:pre-wrap;">, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg" decimals="INF" format="ixt-sec:numwordsen" name="pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" scale="-2" id="Narr_pE6cNpzY7Ey3LXIli4wudA">five</ix:nonFraction>&#160;percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares authorized for issuance under the Incentive Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_DUZDzlEv3kCLP31Wr2eujw" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_e0rhmpR25E-FOnELHQanXw">2,712,249</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_By7Uz8pPpEWAL_wK_0BdCQ" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_MTYrg5u_nEK2kM1HCfMZlQ">2,295,854</ix:nonFraction> shares in January 2022 and 2021, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options under the Incentive Plan vest based on the terms in each award agreement, generally over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_5aXwDY2X5kmr-Jvnc86H2A">four-year</ix:nonNumeric> periods, and have a term of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg" format="ixt-sec:durwordsen" name="pasg:SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" id="Narr_lLvwOJq1xE-_E-dsc_yXBw">ten&#160;years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Inducement Plan was approved by the Company&#8217;s board of directors in July 2021. The total number of shares authorized under the Inducement Plan was <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_eEb-pqvetEOOQLXyvb5cMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_TLaLokTBikaLrIjwwAadMw">1,000,000</ix:nonFraction>. Of this amount, <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_eEb-pqvetEOOQLXyvb5cMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_une0xL96M0eB4-dZrT2riA">12,900</ix:nonFraction> shares were available for future grants as of December 31, 2021. The Inducement Plan provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options under the Inducement Plan vest based on the terms in each award agreement and have a term of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_TuoN6al3ek-oKV2lUg9dvA" format="ixt-sec:durwordsen" name="pasg:SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" id="Narr_zQq-8-Kx3kaAOhHT0ckSBw">ten years</ix:nonNumeric><span style="white-space:pre-wrap;">. The Company&#8217;s restricted stock units vest based on the terms in each award agreement and have a term based on each award agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations for the period presented:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_VMgB9ZKdvkybvb1woVBBkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9gQrDgAqjkSE2Gb1oTaaSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vhH8Gxh-SkK6k37RpHj9dA_3_3">15,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yMsCjLmkD0S_oueWNaOXdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_PPBeH78DfUGCCTzyohCxug_3_6">5,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_lmvSR935b0WEFgO0Y_lvng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_7WuijlBiukOt95S_qLtHmA_4_3">17,259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DOc0XterPEO_ABMw_SCRSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_zO9C_5plmE2GqVI6z8MXBg_4_6">9,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_xl4vsPTgjEOxRPh1EKhu3g_5_3">32,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_xDq6FM-7nk6znAydaBSjzw_5_6">14,580</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_qj2Jf7kDlk-zo-Mv4GadhQ_1_7"></a><a id="Tc_xCR6yG3v0kCzDo2hvVHIJQ_2_4"></a><a id="Tc_wG_nyhJng0S6ox-SrIY8-A_2_7"></a><a id="Tc_mPKiXTisAUWI_njaQd8_4g_3_4"></a><a id="Tc_beoxjfDi2UeqLJPcXL8F3Q_3_7"></a><a id="Tc_2pXaOSFq6kyY5nEH4_Vv8g_4_2"></a><a id="Tc_zgA25TQ6Y0CyYEiQoOLddQ_4_4"></a><a id="Tc_7VnSaFbiB0a5CQ3PCap7fg_4_7"></a><a id="Tc_ur742gNFfkiYuvGw_K9J_A_5_2"></a><a id="Tc_u7jM6PqFqkyIHR41F3jK8Q_5_4"></a><a id="Tc_Qkst9s6cckitZ6PFlclTwQ_5_7"></a><a id="Tc_LInyS7MwVEmF6dOu3QjUPA_6_0"></a><a id="Tc_JH1zV-iX00-_CjU2Wk9iFA_6_4"></a><a id="Tc_6POfWjuB2EmWWCkFGYmjEw_7_0"></a><a id="Tc_VfEXUgBUBkG9sxd5SBMvtg_8_0"></a><a id="Tc_ZXANg-vjTEWPHClXVAKgsg_9_0"></a><a id="Tc_tgrKR-1uzkiZjwd7Oc6LnQ_10_0"></a><a id="Tc_Bn59FmiTtE2JgFxlNYnq8A_10_4"></a><a id="Tc_8RdYpBNrjk2rKGEV3ulHMQ_11_0"></a><a id="Tc_q9CaTu_jQUyilokkwhPwdA_11_4"></a><a id="Tc_wMgnWppnjkK-J8pFIYIDUA_12_0"></a><a id="Tc_ZGJxo_ipx0iZCJQ_9ZIEgw_12_4"></a><a id="Tc_7zxbN-BjGUWEPZdi5SM11Q_1_2"></a><a id="Tc_8_6i9Ezqfkmw7qS6rC-BTQ_2_2"></a><a id="Tc_-8riFa81tkyEYK6_jasIEQ_2_5"></a><a id="Tc_pRXbRSTn30m-qMaB24HiOw_3_0"></a><a id="Tc_FkBoqJs_KkmVZ3mBxLyTug_3_3"></a><a id="Tc_ZBoVki0gEkmBkU0NyAzs-w_3_6"></a><a id="Tc_kDWf0hSL0k-zGMXEvZSqDw_4_0"></a><a id="Tc_vD_KmooYsU2Ti3edsXoVtQ_4_3"></a><a id="Tc_8kJEqj2tTkmTsYX2OuWOZQ_4_6"></a><a id="Tc_hZ-8FbT1fUCORwtz6UP2tw_5_0"></a><a id="Tc_MP_TQSjQmk2aWnGVHz7Buw_5_3"></a><a id="Tc_LvuwwHI9sEm7EOcFJjhvFg_5_6"></a><a id="Tc_SCVB8k6cm0C34pNE_joRNQ_6_0"></a><ix:continuation id="Tb_Cs0oSuJSEUKSzMYtfq1G6g_cont1" continuedAt="Tb_Cs0oSuJSEUKSzMYtfq1G6g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020, the Company modified certain awards and recognized $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_nKXY2USw70SJyiwlLzLYSQ">0.7</ix:nonFraction> million related to the modifications, $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yMsCjLmkD0S_oueWNaOXdA" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_jv6wWtLQsEmI1SRtc3Leug">0.6</ix:nonFraction> million of which was recognized in research and development expense and $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DOc0XterPEO_ABMw_SCRSQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_84egIPqkd0y9BGm8Jk1SSQ">0.1</ix:nonFraction> million was recognized in general and administrative expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company modified certain awards and recognized $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr__iphuLeWTUmifiTozIfOog">7.4</ix:nonFraction> million related to the modifications, $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9gQrDgAqjkSE2Gb1oTaaSA" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_GCa4WcewnkmGTNvrOTa1fg">6.1</ix:nonFraction> million of which was recognized in research and development expense and $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_lmvSR935b0WEFgO0Y_lvng" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_xs9qiz_QTEq8HdLqAK1YVg">1.3</ix:nonFraction> million was recognized in general and administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the&#160;year ended December&#160;31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_kqkFf2HSk0Ct0t8ELLzZxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_HSOqjA1mOkSOIARglRCmzg_6_2">6,928,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QZDUsxNnF022yU98EXXeag_6_5">12.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_wxflquqIxUuZiZfPRT4Zog_6_7"> 9.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="Tc_IDN2LM56L0qhUgVJHzJd5Q_7_2">3,980,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fdLRETHuE0iICe6heEXKtA_7_5">16.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_laXBLidEkki35T8rkebRLg_8_2">146,787</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_sLYph3RkUkKFJ5QACWhL0Q_8_5">2.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_vAmBOGjr4UCmMmmxnuGT0Q_9_2">1,345,215</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_bRhVbou2A0yOHUYFcJnfTg_9_5">15.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_vGx22Zp0BkaLH2Sk4P6-0A_10_2">9,416,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zC7W1mbhMkmTOoXiIHVsGA_10_5">13.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_OLbrae_HQ06MUoHIeqJwPg_10_7"> 8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_EEIEVAgaD0euoxx4JE1Ifg_11_2">3,651,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_VZdLk-4rb0-YKxIsVHkxOg_11_5">12.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_gxGrAeqnP0qSojWHXCSo1g_11_7"> 8.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested or expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_niRay-Jz4UuK9G17eGJ8Vw_12_2">9,416,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fnU9pYe8SEqGRgyPrwKrsg_12_5">13.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_7uxLDVNbGUGCYdzs5jnakQ_12_7"> 8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="0" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" scale="0" id="Narr_MA2LB84e1E60njUNGDrhlQ">1,308,244</ix:nonFraction> options to purchase common stock are unvested, but exercisable, under early exercise provisions as described below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_DWE2hae8XEOVl0OJmLucig">12.75</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_PFxdDdxsjkC8o_EkYbw4OA">11.54</ix:nonFraction> for the&#160;years ended December&#160;31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_WP_liE9Oc0eCn-SyllVpRA">1.3</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_otCiKg28PkSdWEDuvmPMtQ">2.0</ix:nonFraction> million and during the year ended December 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options outstanding as of December 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Narr_ALFvrtvrYky_M1kDMEsJaw">1.6</ix:nonFraction> million and the aggregate intrinsic value of options exercisable as of December 31, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr_kUMGkT80K0uT_yxjOuHkWA">1.4</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_0Mey1SDkkk2ECNBOPNl2dA"><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_-NKBkLI2w0axRW-tKXB2Sg">58.8</ix:nonFraction></ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_eBNq5cHA3Em0LTbKahRaxA">2.8</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_GjbeLQaOHU-SHesQklbwsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_edcOk6i87EGlvvgutNQ68Q_3_2">99.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_5a-_nRFIh0-zfXxuj5YEsQ_3_5">95.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_op-KMqgwykCsd2_4_Oxurg_4_2">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_fxGN4cLAB02vG1wOcQ2ihA_4_5">1.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Ktuxy4QIAEiHwYuWPufnXg_5_2"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_6R_WEXRgd02WjTYz4jqMew_5_5"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_poyWNiDCNkSQC86wgrBdFw_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_zRgQGMabv0OH7CzYkVkRTQ_6_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_QdHKGJwB2UOLshaGLpklFw_1_2"></a><a id="Tc_spJo9FAdW0yNDTopWPK_gA_2_0"></a><a id="Tc_x3PkppSHAEyb3xxgb5r-Ug_3_0"></a><a id="Tc_OtvpvbCpakKN2p8krD9Mzw_4_0"></a><a id="Tc_UCjF0Mo9BUawA2bnzGB4yw_4_2"></a><a id="Tc_AvbOXZ1g_0KccITiC0GE2g_1_6"></a><a id="Tc_J5eawlqW2kWBPNYHeCIEyw_2_3"></a><a id="Tc_RgSfXF9jIkiUp2z0AkUp8A_2_6"></a><a id="Tc_7dalIld09k21BSersNe0HA_3_0"></a><a id="Tc_DgucvnDnF06bUHqkilskrQ_3_3"></a><a id="Tc_jW1wQUwt2kOcgS-dy91gGQ_3_5"></a><a id="Tc_VTv-wYpFmEye_vMYfqPnzA_3_6"></a><a id="Tc_a8BcyZgBs06q2p6ULROpzA_4_0"></a><a id="Tc_6WdW5FRZRkqYqzAuEgPJ9g_4_5"></a><a id="Tc_Qn-JPXN8xEut3N97TLDZ1w_5_0"></a><a id="Tc_I2pQ5fh3Ek6zW9cgQU2e-A_6_0"></a><a id="Tc_GX320bc14k2Rvz9Xf-puFQ_6_5"></a><a id="Tc_hlyPKRrwrESBF1lO39Roqw_7_0"></a><a id="Tc_Bs0vIYUy30u2vPXfkV7k0w_7_5"></a><ix:continuation id="Tb_Cs0oSuJSEUKSzMYtfq1G6g_cont2" continuedAt="Tb_Cs0oSuJSEUKSzMYtfq1G6g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The 2018 Plan and 2020 Plan provide certain holders of stock options an election to early exercise prior to vesting. The Company has the right to repurchase early exercised options without transferring any appreciation in the value of the underlying shares to the employee if the employee terminates employment before the end of the original vesting period. The repurchase price is the lesser of the original exercise price or the then fair value of the Company&#8217;s common stock.  There were </span><ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt-sec:numwordsen" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" scale="0" id="Narr_0tQI_RB7b02FWZp9QTmjaQ">no</ix:nonFraction><span style="white-space:pre-wrap;"> early exercises of options during the year ended December 31, 2021.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity relating to early exercises of stock options during the&#160;year ended December&#160;31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="Tb_XhsqOW1mUUGqW6sahbtydg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_n8X9SlKgpE-4Djzm9rWyEg_2_2">302,277</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_mB_MiT7Xlk6f3719S_sRaw_3_2">302,277</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nonrecourse Promissory Notes&#160;with Related Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, <ix:nonFraction unitRef="Unit_Standard_individual_kRSnx8nw1kG-RLCkCGj2iA" contextRef="As_Of_2_28_2019_Dg47llwd60Wt_myzLnSxow" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NumberOfExecutiveOfficers" scale="0" id="Narr_H4rG7rfFF0agFiipTr_ZSA">two</ix:nonFraction> of the Company&#8217;s then executive officers, elected to early exercise <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_-s2xGmVdVkGTPHiCmb4BJA" decimals="INF" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" scale="0" id="Narr_e-V8E_lRQEm_7r8V6kBfdQ">688,875</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_eJE-uMNmcUG5vTVEbr9ZOg" decimals="INF" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" scale="0" id="Narr_pF7Mt7G_U0iJ442wGlEjCw">309,994</ix:nonFraction> stock options, respectively, in exchange for cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_0lT3N_zSwUG3WlueyWRnJA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedParties" scale="6" id="Narr_my6I7K53bESXu-PrL9EZCw">0.2</ix:nonFraction>&#160;million and nonrecourse promissory notes, or the Notes, of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_b-40t_BVvU-ZNd20D-z1kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedParties" scale="6" id="Narr_7t5KEMC5Z02uW4Z2Fg1-8w">0.8</ix:nonFraction>&#160;million. The Notes&#160;bore interest at <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_2_1_2019_To_2_28_2019_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_QFerryslZEecn9p62PcHmA" decimals="4" format="ixt:numdotdecimal" name="pasg:NotesReceivableInterestRatePercentage" scale="-2" id="Narr_iWEX2uI9g0ql9xPr1U9Lmw">2.91</ix:nonFraction>% and were secured by the underlying shares of common stock that were issued. In January&#160;2020, the Company forgave the Notes&#160;and associated interest related to the early exercise of stock options. An aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_1_31_2020_i2EyC4gK6EeZimGB107lUg" decimals="INF" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" scale="0" id="Narr_HxqIppYwk0-aZ8uffoB6oQ">406,897</ix:nonFraction> shares that were previously not considered outstanding for accounting purposes due to being secured by the Notes&#160;became outstanding upon the forgiveness of the Notes&#160;in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year-ended December 31, 2021, the Company accelerated the vesting of each executive officer&#8217;s early exercise of stock options awards in relation to each of their separations from the Company such that all early exercised stock options were vested for accounting purposes as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company issues RSUs to employees that vest over periods as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is recognized straight-line over the vesting period of the RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes activity related to RSU awards during the year ended December 31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_0uJOwyfrB0W9jkfyG-sSgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January 1, 2021</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_XsiMCzt-YEKiELqIdRyLZg_4_3">360,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_uw9wkyrPgkio5opu8ZiHkQ_4_6">15.54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_60dzbCm6xkq60BY-Eas9MA_5_3">40,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_8BNLiqtAsUGSGnfQ0ECgXg_5_6">18.85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="Tc_p4Dc-Htvb0S0iS7gmMFp-w_6_3">30,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_0Bzufi89602TuCFwM7sMuQ_6_6">18.48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LoCSKTtbL0OhUlAy4bzQyQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_Hy24BLAinEqAz9oMC4K8_Q_7_3">290,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LoCSKTtbL0OhUlAy4bzQyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_FCOQ67LkJkODmy4UCYbCLg_7_6">14.78</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021, the total unrecognized expense related to all RSUs was $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="Narr_ap-J7y4_2kauJUbd7DwkAQ">3.5</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_UOoxpJqmQkayDcpk1DP9EQ"><span style="white-space:pre-wrap;">3.0</span></ix:nonNumeric><span style="white-space:pre-wrap;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Cs0oSuJSEUKSzMYtfq1G6g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective on February&#160;28, 2020. The total number of shares authorized under the ESPP as of December 31, 2021, was&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_Hlylcmv8XEyDesAxASGedA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_CkZMYKacG02Z4oWVg7LEQg">893,170</ix:nonFraction> shares of the Company&#8217;s common stock. Of this amount, <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7TeewkAeXES9W_l9V_dFQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_dEWCBQ3300-yPQdjnYcJnw">781,936</ix:nonFraction> shares were available for future grants as of December&#160;31, 2021. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continuing for <ix:nonNumeric contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MWN-gxUTckSGX79Osy-sqw" format="ixt-sec:durwordsen" name="pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Narr_WLgxBwLwqU-XZi6Ihxg0gA"><span style="white-space:pre-wrap;">ten&#160;years</span></ix:nonNumeric><span style="white-space:pre-wrap;">, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw" decimals="INF" format="ixt-sec:numwordsen" name="pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" scale="-2" id="Narr_Z65PzFAdDESso3Gdlsqmfw">one</ix:nonFraction>&#160;percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares authorized for issuance under the ESPP increased by </span><ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_IXEquSLDb0yKA8sbyQ-qig" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_JUs9WWICxUWEjwWUvdIUEA">542,449</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MYx6whEmKUaeZZi3nvIPow" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_UCkSS9dp_0GCaEnPSaORFA">459,170</ix:nonFraction> shares in January 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#8217;s common stock at <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" scale="-2" id="Narr__Tz-wXXIuUaZzd3gc02yEQ">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" scale="-2" id="Narr_9xHgnS6xAkSR2Co4Ufaheg">15</ix:nonFraction>% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_Hlylcmv8XEyDesAxASGedA" decimals="0" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" scale="0" id="Narr_ADE-7LWlgE-1TyifSC1sWw">25,000</ix:nonFraction> worth of the Company&#8217;s common stock for each calendar&#160;year in which such right is outstanding. During the years ended December 31, 2021 and 2020, <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_hge6WzgOskii8rTOoQb_rg" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" scale="0" id="Narr_kC7dKxbmoU2Uqkq8G4iVUA">91,125</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_fRoUpLtqpkitwlFzFSV1fw" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" scale="0" id="Narr_HTqU0U3Cbkqaz3l3S59kSw">20,109</ix:nonFraction> shares, respectively, were purchased under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with the guidance in ASC 718-50&#160;&#8211;<i style="font-style:italic;">&#160;Compensation&#160;&#8211; Stock Compensation</i>, the ability to purchase shares of the Company&#8217;s common stock at <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" scale="-2" id="Narr__gl87WW30Ueb0tM8NVszvw">85</ix:nonFraction>% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<b style="font-weight:bold;">, </b>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_hge6WzgOskii8rTOoQb_rg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_vTLxq4jbxE-EEMuyUypRQA">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_fRoUpLtqpkitwlFzFSV1fw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_N0vmGPoKjUmudXHA_tgK7Q">0.2</ix:nonFraction> million during the years ended December&#160;31,&#160;2021 and 2020, respectively, related to the ESPP.</p></ix:continuation><a id="Tc_N9_sVBAL7k-7FzwVme9x7g_1_2"></a><a id="Tc_vDt8NTd7l0-ACh8_d0Nz-w_2_0"></a><a id="Tc_9bXdaShyVESD0ejCykJ3gg_2_2"></a><a id="Tc_UPfdVe1xgEu3s8RKfoHD-g_2_5"></a><a id="Tc_c4optwtJvEOizK_6Tu45qg_3_0"></a><a id="Tc_PDO5tJTXEEqwrAWENz2h3Q_4_0"></a><a id="Tc_bla0PlapTEqtdNFGjdgxlQ_4_2"></a><a id="Tc_PmnQFBKxF0WNe4PGQ4_hIQ_4_5"></a><a id="Tc_l9FVUSy7jkWfAb05I4gHdw_5_0"></a><a id="Tc_dXptnqNcg0afOYI0Tjcv4g_6_0"></a><a id="Tc_BjgKdx4JTkSN1VlRQ8dcZg_7_0"></a><a id="Tc_mRWh6R7weEOwG6O_65ND-Q_8_0"></a><a id="Tc_AVHPU7GWyUOnx03ps0rboA_9_0"></a><a id="Tc_qkDNreD4m0SGnyn-XrtgJg_10_0"></a><a id="Tc_81gWwNJ7K0-eI0Yw4x8c9w_11_0"></a><a id="Tc_ENN8N_i7JU-lV-8A4ZAvZw_12_0"></a><a id="Tc_zXIqARNPZ0m0Im7B1j6EBA_12_2"></a><a id="Tc_ubTwCNqzsEejq9-mppdTQA_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_USiK1cqQY0mhUrqtFhPRgA" continuedAt="Tb_USiK1cqQY0mhUrqtFhPRgA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_w1Ri1OE8dk267psDLS9ejA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_kqStB6TcnUK3BR5GM0oiew_4_3">42,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_-L554CuBN0WiyV2pN4AwSw_4_6">23,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_ruDU6TLAZkCqQWF34K2KbA_5_3">22,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc__NNbSoYehEue8lEPa3QNjA_5_6">8,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration and license agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement" scale="3" id="Tc_qYlaHTuLM0uQNR89LG4r_A_6_3">3,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement" scale="3" id="Tc_wjrBUF9bxEyZY2ExWxIQMQ_6_6">1,463</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_10Aw3fxH0UWfNO1G0ieYcg_7_3">51,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_r4PvQ61WzEirPvTguheCxg_7_6">23,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_OjyQuZ3tpEyAWJaD4Ktuxg_8_3">11,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_4jcjCG-Pm0iNA-ehadmsjA_8_6">4,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_Tclr7DPrJUeoZP9ajvgDFA_9_3">3,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_gOZsKO9BzUSZcagrKPcsEg_9_6">1,801</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_QoT3R-_aTU-KFbfinb93BA_10_3">135,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_OwFJn-Hmw0iCeKfRN5w5VA_10_6">62,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_7VA5R8mh80WGefBfrK48rA_11_3">135,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_ExXMLSgvy0OBvZsKmNViTQ_11_6">62,962</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_6Khk5f-blkulQcdET5Jq7w_12_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_pXgvj1hltE6tRubC-TpFOg_12_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_dn4qkMtL50GbMIHK-ubpCg_1_2"></a><a id="Tc_ETEhfQE0mUm_MbF-4ViD0A_2_2"></a><a id="Tc_9JD2X6nwE0-izUIoWoU-QQ_3_2"></a><a id="Tc_0kVw4mKU60iSgGQnqRz84A_3_4"></a><a id="Tc_wInkXfkHsUe4GcKyalA0bw_4_0"></a><a id="Tc_k6j5LBHdDUWviKE8QVzQwg_4_3"></a><a id="Tc_gs_AcaAPpUGGnT3qrFFNwQ_4_5"></a><a id="Tc_4eW-rtRn906uFPhZhkqWrg_5_0"></a><a id="Tc_MZB3fwynjkCPADUDUw7AXQ_6_0"></a><a id="Tc_gXjC8BH6DkKqwMBiP7rBKg_7_0"></a><a id="Tc_95ymugm75ky0i7gsGeItgA_8_0"></a><a id="Tc_mdjP7cIGj0CUmwiTT-ssrA_9_3"></a><a id="Tc_lCIxXVbbbkKjwDXAprA18A_9_5"></a><a id="Tc_PyFX75wiEE266WJq6xfX5A_1_2"></a><a id="Tc_MTyjc1dEz0Ww6GuDUKz3kw_2_0"></a><a id="Tc_nLPrEk3pzkCH4jP8Fbu1mw_2_2"></a><a id="Tc_XVcCno_nIEyEz_C72-aGmg_2_5"></a><a id="Tc_GnzL9s4tBECvVRQLsO7plw_3_0"></a><a id="Tc_jgCYXzB6FU6AXaN1TH3m4Q_3_2"></a><a id="Tc_YVRx2FPMAUmwFYROMU5EJw_3_5"></a><a id="Tc_ug0uKTScm06hG7UxqDkraQ_4_0"></a><a id="Tc_TRYfdsWGO0yfF_fRBzg8dQ_5_0"></a><a id="Tc_31uvy9rJa0eUKxKvpZC4aA_6_0"></a><ix:continuation id="Tb_USiK1cqQY0mhUrqtFhPRgA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2020. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_yh-fpQcGiEiMEnyCwOCung">72.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_Pl6MnzEQO0WLE8Y3RZZjFw">44.6</ix:nonFraction> million during the&#160;years ended December&#160;31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_K_AzfXNfsku9nT4p5pj0RA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_GJzX57sBjEWWF6oOuaLDoQ_4_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_TV2MEVf5FECebExiZQzebw_4_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_Wc9szh0OxkyTARfJ0_7JWQ_5_2">11.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_50RBJLs_gUu9Xx7u-WP1Zw_5_4">12.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="4" format="ixt:numdotdecimal" name="pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="Tc_LUOwvpxFSk-eC0-OWcml6g_6_2">1.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="4" format="ixt:numdotdecimal" name="pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="Tc_7QCPPGDdSEOPBPAwEGV7tA_6_4">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_LZ246mMx-UiTPVOFFqgVqA_7_2">7.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_UGfvI8bm10C5lqfbOs75rw_7_4">6.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_lCdEnkxKIEKPRm7S1j-iVw_8_2">38.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_Y0Z335q1YUWj11z7W57Fvw_8_4">39.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_AMKk68h8SkG-20SYddePHA_9_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ" contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_qxYmjWJOPkWdqR-1uelccw_9_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes carryforwards of federal, state and local net operating losses (NOL) and research and development and orphan drug tax credits:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="Tb_Kpoy_OZ9i0GrZwD781_Bpw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_zzHhTfTUtkmAsOCCTtRAfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_XbkrBI45UEeI7PfFB8b2pA_3_3">126,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_-AB_b6Gy40yD--yAZUlaJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_6kqmCVkjHEGgp2fBFrBcLQ_3_6">69,317</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_ou_PBG4RvEihq6A2EvgcSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_J9J-DGOxlUCTRAH5OrCHgQ_4_3">126,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_sCqVUi350ke4K2VTSeSwSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_ZPcriUMMY02mB_246IwuTA_4_6">69,313</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_AEwhzMB_OUyIYWxhHH_sKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_5dLwL3BtIE2qmUpBE_iX6Q_5_3">116,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_YBzYmbyXZkO0AKGn6_kDpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_gKHyEkyCNkyhG1hH5HWYVw_5_6">69,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_OZPCcIcvuE2lyKN-UB_SrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Tc_vHTg6wycQ0en0qLV1-mGGw_6_3">22,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yq6XT26n3Eqy2E5_gcwEZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Tc_gd6qPhg0p0KDjIQlmPe88A_6_6">8,958</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes, however; all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. The NOL carryforwards for local income taxes related to the city of Philadelphia begin expiring in 2022. As of December&#160;31, 2021, the Company also had federal research and development and orphan drug tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2031_nwAcjwnUlECe9uyTYzx_Cg" decimals="-5" format="ixt:numdotdecimal" name="pasg:TaxCreditCarryForwardSubjectToExpiration" scale="6" id="Narr_wWhwF0IMsEGbxKHfRYGtTw">22.2</ix:nonFraction> million that will begin to expire in 2038, unless previously utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December&#160;31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="6" id="Narr_KLhn4Wgid02olzwB7nVamA">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA" contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" id="Narr_5KGThFkvVkSYqa9zu0gP8A">no</ix:nonFraction> amounts have been recognized in the Company&#8217;s statement of operations. Tax&#160;years from 2018 and after remain subject to examination by the taxing jurisdictions. The NOL and tax carryforwards remain subject to review until utilized.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_QU8-66Tm40GpZykMaqfYXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3c1ff5fa_3aee_4175_be48_f678a1117604"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_c1f684ae_d739_427a_b018_c71ff6201059"></a><a id="Item9AControlsandProcedures_95933"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;<span style="font-style:italic;">Controls and Procedures</span><span style="font-style:italic;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the supervision of and with the participation of our management, including our chief executive officer, who is our principal executive officer, and our chief financial officer, who is our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2021, the end of the period covered by this Annual Report. The term &#8220;disclosure controls and procedures,&#8221; as set forth in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.5pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our&#160;chief executive officer and chief financial officer&#160;and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#8226;</p></td><td style="vertical-align:top;width:87.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#8226;</p></td><td style="vertical-align:top;width:87.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#8226;</p></td><td style="vertical-align:top;width:87.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our management, with the participation of our&#160;chief executive officer and chief financial officer, assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its <i style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</i>. Based on our assessment, our&#160;management has concluded that, as of December&#160;31, 2021, our internal control over financial reporting is effective based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. For as long as we remain an &#8220;emerging growth company&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, we intend to take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d)&#160;and 15d-15(d)&#160;of the Exchange Act that occurred during the quarter ended December&#160;31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd07f09f_9193_4f65_8c00_1723d9b01f1b"></a><a id="Item9BOtherInformation_661797"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;&#160;<span style="font-style:italic;">Other Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1e4e8056_5510_4dea_a1e4_aff5b58761f9"></a><a id="item9c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 9C.     Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d873dbec_80d3_47f5_9895_6e42bf30a489"></a><a id="PARTIII_442551"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;10.</b></span>&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b76ef0ef_2012_4ece_b803_c05127ce077e"></a><a id="Item11ExecutiveCompensation_324480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7890f89f_5ad3_45b9_919b_7792ac90e761"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e8a51a1e_3325_4423_85d3_27432c57ed3c"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8aed468b_9beb_4a03_851d_74705463e8b1"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14.&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b67139e4_e477_4f96_b095_efacffd5e835"></a><a id="PARTIV_315772"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;&#160;&#160;&#160;<span style="font-style:italic;">Exhibits and Financial Statement Schedules</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statements:</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements required by Item&#160;15(a)&#160;are filed as part of this Annual Report on Form&#160;10-K under Item&#160;8 &#8220;Financial Statements and Supplementary Data.&#8221;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.35pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statement Schedules</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statement schedules required by Item&#160;15(a)&#160;are omitted because they are not applicable, not required or the required information is included in the financial statements or notes thereto as filed in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibits.</i></td></tr></table><div style="margin-top:12pt;"><a id="_0fd5fe4b_7502_4402_b377_9ff8b8b03ba6"></a></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Filing</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:10.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex3137f59e2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Restated Certificate of Incorporation, dated March 3, 2020.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000110465920039591/tm2013978d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Bylaws, dated March 26, 2020.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 27, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-4_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Investors&#39; Rights Agreement, dated August&#160;21, 2019, by and among the Registrant and certain of its stockholders.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837021002287/pasg-20201231ex43f0b5efe.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 3, 2021</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1<span style="background:#ffffff;">&#8224;&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex10109dea8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Development Services and Clinical Supply Agreement, dated April 13, 2020, by and between the Registrant and Catalent Maryland, Inc.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex102f078db.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Lease, dated April 10, 2020, by and between the Registrant and Commerce Square Partners - Philadelphia Plaza, L.P.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex103f31965.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">First Amendment to Lease, dated April 10, 2020, by and between the Registrant and Philadelphia Plaza &#8211; Phase II LP</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement between the Registrant and its directors and officers</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated 2018 Equity Incentive Plan, as amended, and forms of award agreements.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2020 Equity Incentive Plan of the Registrant, and forms of award agreements.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2020 Employee Stock Purchase Plan of the registrant</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9+</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement dated February 14, 2020, by and between the Registrant and Bruce Goldsmith.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.05%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated January 8, 2019, as amended on January 31, 2020, by and between the Registrant and James Wilson, M.D., Ph.D.</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11<span style="background:#ffffff;">&#8224;&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020010495/pasg-20200630ex1049f486a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Sponsored Research, Collaboration and License Agreement, dated May 5, 2020, by and between the Registrant and The Trustees of the University of Pennsylvania</span></a>.</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 13, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12<span style="background:#ffffff;">&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020013472/pasg-20200930ex101899b73.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated August 13, 2020, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 10, 2020</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.03%;"><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13<span style="background:#ffffff;">&#708;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465921005296/tm2038048d5_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2, dated November 2, 2020, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-252313</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 19, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14<span style="background:#ffffff;">&#8224;&#708;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465921005296/tm2038048d5_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 3, dated December 9, 2020, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-252313</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 19, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15&#708;</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465920137129/tm2038048d3_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated December 15, 2020 by and between the Registrant and Hopewell Campus Owner, LLC</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.03%;"><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001787297/000155837021008991/tmb-20210719xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Equity Inducement Plan</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-25800</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 19, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 4, dated June 2, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001787297/000155837021014460/pasg-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 5, dated August 3, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">0013-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 4, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 6, dated November 12, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 7, dated December 3, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21+</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001787297/000155837021014460/pasg-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated August 23, 2021 by and between the Registrant and Simona King.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">0013-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 4, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22+&#8224;</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex10d22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 5, 2021 by and between the Registrant and Eliseo Salinas.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23+&#8224;</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex10d23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation Agreement, dated October 30, 2021 by and between the Registrant and Jill Quigley.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP, an independent registered public accounting firm.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Power_of_Attorney"><span style="font-style:normal;font-weight:normal;">Power of Attorney. Reference is made to the signature page hereto.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to </span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.03%;"><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section 302 of the Sarbanes-Oxley Act of 2002.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1*</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2*</p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20211231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.INS</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.SCH</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.CAL</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.DEF</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.LAB</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.PRE</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.25pt;">104</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL).</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">+ </span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Indicates management contract or compensatory plan, contract or agreement.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">&#8224; </span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulations S-K.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">&#708; </span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_35a841cf_1df6_4171_8083_d6d90f256598"></a><a id="Item16Form10KSummary_733791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16.&#160;&#160;&#160;&#160;Form&#160;10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Registrants may voluntarily include a summary of information required by Form&#160;10-K under Item&#160;16. We have elected not to include such summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_407ca1df_03d7_442f_a246_db4b4621a228"></a><a id="SIGNATURES_809350"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;the Securities Exchange Act of 1934, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PASSAGE BIO, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 3, 2022</p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Bruce Goldsmith, Ph.D</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dr. Bruce Goldsmith, Ph.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and President</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 3, 2022</p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_31d13cc4_7703_4df4_9588_63214da30aa2"></a><a id="Power_of_Attorney"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each person whose individual signature appears below hereby authorizes and appoints Bruce Goldsmith, Ph.D., Simona King and Edgar B. Cale, and each of them, with full power of substitution and resubstitution, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agents or his substitute or substitutes may lawfully do or cause to be done by virtue thereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Bruce Goldsmith, Ph.D</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive&#160;Officer and Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Bruce Goldsmith, Ph.D</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:20.8pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Simona King</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Chief Financial Officer and Corporate Secretary</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Simona King</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.25pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Maxine Gowen, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Maxine Gowen, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.7pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Athena Countouriotis, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Athena Countouriotis, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:19.9pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Saqib Islam</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Saqib Islam</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Sandip Kapadia</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Sandip Kapadia</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.7pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Liam Ratcliffe M.D., Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Liam Ratcliffe M.D., Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.15pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Derrell Porter, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Derrell Porter, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.15pt;"><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Tom Woiwode, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;3,&#160;2022</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Tom Woiwode, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:216.6pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>pasg-20211231xex10d17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:17:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.25pt 0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT 10.17</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.25pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.55pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.55pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:143.7pt;text-indent:-143.7pt;margin:0pt 0pt 0.15pt 39.75pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AMENDMENT No. 4 TO AMENDED AND RESTATED RESEARCH, COLLABORATION AND LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 27.55pt;">This AMENDMENT No. 4 to the Amended and Restated Research, Collaboration and License Agreement dated May 5, 2020 is entered into as of June 2, 2021 (the &#8220;Amendment No. 4 to Restated Agreement Effective Date&#8221;) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (&#8220;Passage&#8221;) with offices at One Commerce Square, 2005 Market St, 39<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Floor, Philadelphia, PA 19103, and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Floor, Philadelphia, PA 19104 (&#8220;Penn&#8221;) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020, as amended by the Amendment No.1 dated August 13, 2020, Amendment No. 2 dated November 2, 2020, and Amendment No. 3 dated December 9, 2020 (the &#8220;Restated Agreement&#8221;). Passage and Penn are referred to collectively as the &#8220;Parties&#8221; and individually as a &#8220;Party.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 27.55pt;">WHEREAS, the Parties wish to amend the Restated Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 27.55pt;">NOW, THEREFORE, in consideration of the promises and mutual covenants contained in the Restated Agreement and herein, and intending to be legally bound hereby, the Parties amend the Restated Agreement and otherwise agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;">The Research Program contained in Exhibit B of the Restated Agreement is hereby amended to include the additional work outlined in Schedule A to this Amendment No. 4 to Restated Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;">The budget for the additional work is included in Schedule B to this Amendment No. 4 to Restated Agreement, and this budget is intended to be in addition to those previously included under the Restated Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">A complete amended and restated payment schedule is set forth as Schedule C to this Amendment No. 4 to Restated Agreement. The payment schedule denotes payments for the Research Program that have already been made to Penn as well as future payments owed to Penn, as of March 31st, 2021.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;">This Amendment No. 4 to Restated Agreement and the Restated Agreement contain the entire understanding between the Parties and supersede any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Restated Agreement and this Amendment No. 4 to Restated Agreement. No amendments, changes, modifications or alterations of the terms and conditions of this Amendment No. 4 to Restated Agreement shall be binding upon any Party, unless provided in writing and signed by an authorized representative of each Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;">All terms and conditions of the Restated Agreement not changed by this Amendment No. 4 to Restated Agreement shall remain in full force and effect.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Signatures on this Amendment No. 4 to Restated Agreement may be communicated by e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment No. 4 to Restated Agreement shall be effective as if simultaneously executed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 27.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.64pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Signature page follows.)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27.55pt;">IN WITNESS WHEREOF the Parties hereto have caused this Amendment No. 4 to Restated Agreement to be executed and delivered by their duly authorized representatives as set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">AGREED ON BEHALF OF:</b></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">AGREED ON BEHALF OF:</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">PASSAGE BIO INC.</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">THE TRUSTEES OF THE UNIVERSITY OF</p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">PENNSYLVANIA</p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">By: /s/ Bruce Goldsmith</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">By: /s/ John S. Swartley</p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">(Signature)</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 38.15pt;">(Signature)</p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 38.15pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Name: Bruce Goldsmith, Ph.D.</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Name: John S. Swartley</p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Title: President and CEO</p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Title: Managing Director, Penn Center for</p></td></tr><tr><td style="vertical-align:bottom;width:46.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Innovation</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27.55pt;">ACKNOWLEDGED AS READ AND <br>UNDERSTOOD BY INSTITUTION PRINCIPAL <br>INVESTIGATOR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dr. James Wilson</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Signature)</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Dr. James Wilson</p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.15pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AMENDMENT No. 4 TO AMENDED AND RESTATED RESEARCH, COLLABORATION AND LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Program Budgets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[*]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Complete Payment Schedule</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(including any payments due under this Amendment No. 4 to the Restated Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[*]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>3
<FILENAME>pasg-20211231xex10d19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:17:47 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:51.25pt;text-align:center;text-indent:-51.25pt;margin:0pt 135pt 0pt 108pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AMENDMENT No. 6 TO AMENDED AND RESTATED RESEARCH, COLLABORATION AND LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 27pt;">This AMENDMENT No. 6 to the Amended and Restated Research, Collaboration and License Agreement dated May 5, 2020 is entered into as of November 12, 2021 (the &#8220;Amendment No. 6 to Restated Agreement Effective Date&#8221;) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (&#8220;Passage&#8221; or &#8220;Licensee&#8221;) with offices at 2005 Market St, 39<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Floor, Philadelphia, PA 19103, and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9<sup style="font-size:7.5pt;vertical-align:top;">th </sup>Floor, Philadelphia, PA 19104 (&#8220;Penn&#8221;) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020, as amended by the Amendment No.1 dated August 13, 2020, Amendment No. 2 dated November 2, 2020, Amendment No. 3 dated December 9, 2020, Amendment No.4 dated June 2, 2021, and Amendment No. 5, dated August 2, 2021 (the &#8220;Restated Agreement&#8221;). Passage and Penn are referred to collectively as the &#8220;Parties&#8221; and individually as a &#8220;Party.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 27pt;">WHEREAS, the Parties wish to amend the Restated Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 27pt;">NOW, THEREFORE, in consideration of the promises and mutual covenants contained in the Restated Agreement and herein, and intending to be legally bound hereby, the Parties amend the Restated Agreement and otherwise agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="display:inline-block;text-indent:0pt;width:13.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">1.</font></font>The Research Program contained in Exhibit B of the Restated Agreement is hereby amended to include the additional work outlined in Schedule A to this Amendment No. 6 to Restated Agreement for the [*] programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 27pt;"><font style="display:inline-block;text-indent:0pt;width:13.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">2.</font></font>The budget for the additional work is included in Schedule B to this Amendment No. 6 to Restated Agreement, and this budget is intended to be in addition to those previously included under the Restated Agreement for the [*] programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="display:inline-block;text-indent:0pt;width:13.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">3.</font></font>The Parties agree that Licensee has exercised its option to Canavan Disease under Section 2.6 of the Restated Agreement (i.e., a New Indication Option). The new Research Plan and Budget are included in Schedule C to this Amendment No. 6 to the Restated Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="display:inline-block;text-indent:0pt;width:13.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">4.</font></font>A complete amended and restated payment schedule is set forth as Schedule D to this Amendment No. 6 to Restated Agreement. The payment schedule denotes payments for the Research Programs that have already been made to Penn as well as future payments owed to Penn, as of October 1, 2021 for the [*] and Canavan programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 27pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:13.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font>Pursuant to Section 4.1.2 of the Restated Agreement, Licensee will pay the first half ($500,000) of the New Indication Option Fee for the Canavan Disease being added to the License before pre-clinical pharmacology data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:13.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font>The definitions of (a) 1.37 <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Gene Therapy Product<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font> and (b) 1.41 <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Indication<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font> in the Restated Agreement is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 58.5pt;">&#8220;<b style="font-weight:bold;">Gene Therapy Product</b>&#8221; means a pharmaceutical product (or proposed or prospective pharmaceutical product) that inserts one or more functional genes or proteins into a patient&#8217;s CNS or PNS cells using a parvovirus vector, including but not limited to an AAV. For clarity, Gene Therapy Products may include [*], but do not include [*]. For clarity, [*].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:78pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Indication</b><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font> means each of the following indications for a Gene Therapy Product: (a) ALS through parvovirus vector delivery of nucleic acid polymers that silence nucleic acid or protein polymers encoded by the <i style="font-style:italic;">C9ORF72 </i>gene, (b) Krabbe disease (globoid cell leukodystrophy) through parvovirus vector delivery of nucleic acid polymers for expression of</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 96pt;">galactosylceramidase. (c) MLD through parvovirus vector delivery of nucleic acid polymers for expression of arylsulfatase A, (d) GLB1 Deficiency, for GM1 gangliosidosis-1 and MPS IV through parvovirus vector delivery of nucleic acid polymers for expression of GLB1, (e) Frontotemporal dementia (FTD) through parvovirus vector delivery of nucleic acid polymers for expression of progranulin, (f) CMT2A through parvovirus vector delivery of nucleic acid polymers that silence and/or overexpress nucleic acid or protein polymers encoded by the MFN2 gene, (g) Parkinson<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</font>s Disease through parvovirus vector delivery nucleic acid polymers for expression of PARK2 (referred to as <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>PARK2<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font> and <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Parkin<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>), (h) Canavan Disease through parvovirus vector delivery nucleic acid polymers to overexpress aspartoacylase (ASPA), and (i) parvovirus vector delivery of nucleic acid polymers for a specific named gene replacement transgene for a specific disease indication with treatment targeted to a specific locus (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">New Indication</b><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>) added to the Agreement through exercise of a New Indication Option (collectively, the <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Indications</b><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">7.</font></font>This Amendment No. 6 to Restated Agreement and the Restated Agreement itself contain the entire understanding between the Parties and supersede any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Restated Agreement and this Amendment No. 6 to Restated Agreement. No amendments, changes, modifications or alterations of the terms and conditions of this Amendment No. 6 to Restated Agreement shall be binding upon any Party, unless provided in writing and signed by an authorized representative of each Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.55pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">8.</font></font>All terms and conditions of the Restated Agreement not changed by this Amendment No. 6 to Restated Agreement shall remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">9.</font></font>Signatures on this Amendment No. 6 to Restated Agreement may be communicated by e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment No. 6 to Restated Agreement shall be effective as if simultaneously executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 196.7pt;">[Remainder of page intentionally blank]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 196.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">IN WITNESS WHEREOF the Parties hereto have caused this Amendment No. 4 to Restated Agreement to be executed and delivered by their duly authorized representatives as set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:21.6pt;"><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">AGREED ON BEHALF OF:</b></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">AGREED ON BEHALF OF:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">PASSAGE BIO INC.</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">THE TRUSTEES OF </p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">THE UNIVERSITY OF</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">PENNSYLVANIA</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: /s/ Bruce Goldsmith</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: /s/ John. S Swartley</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">(Signature)</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">(Signature)</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Bruce A. Goldsmith, Ph.D.</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: John S. Swartley</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and CEO</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Managing Director, Penn Center for</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Innovation</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 78pt;">ACKNOWLEDGED AS READ AND<br> UNDERSTOOD BY INSTITUTION PRINCIPAL<br> INVESTIGATOR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">/s/ Dr. James Wilson</p></td><td style="vertical-align:bottom;width:51.66%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 18pt;">(Signature)</p></td><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Name: Dr. James Wilson</p></td><td style="vertical-align:bottom;width:51.66%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule A to ARCA Amendment 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit B of ARCA </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Research Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[*]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule B of ARCA Amendment 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit C of ARCA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Research Program Budgets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[*]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule C to Amendment 6 of Research, Collaboration and License Agreement (ARCA)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;"><b style="font-weight:bold;">[*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.1pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule D of ARCA Amendment 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Complete Payment Schedule</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">(including any payments due under this Amendment No. 6 to Restated Agreement)</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;">[*]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>4
<FILENAME>pasg-20211231xex10d20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:17:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.25pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT 10.20</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.25pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.05pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.05pt 0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:41.95pt;text-indent:-41.95pt;margin:0pt 0pt 0pt 117.3pt;"><b style="color:#231f20;font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#231f20;">AMENDMENT No. 7 TO AMENDED AND RESTATED RESEARCH, COLLABORATION AND LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 27pt;"><font style="color:#231f20;font-size:12pt;">This AMENDMENT No. 7 to the Amended and Restated Research, Collaboration and License Agreement is entered into as of December 3, 2021 (the &#8220;Amendment No. 7 Effective Date&#8221;) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (&#8220;Passage&#8221; or &#8220;Licensee&#8221;) with offices at 2005 Market St, 39</font><sup style="color:#231f20;font-size:9pt;vertical-align:top;">th</sup><font style="color:#231f20;font-size:12pt;white-space:pre-wrap;"> Floor, Philadelphia, PA 19103,  and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9</font><sup style="color:#231f20;font-size:9pt;vertical-align:top;">th</sup><font style="color:#231f20;font-size:12pt;"> Floor, Philadelphia, PA 19104 (&#8220;Penn&#8221;) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020, as amended by the Amendment No.1 dated August 13, 2020, Amendment No. 2 dated November 2, 2020, Amendment No. 3 dated December 9, 2020, Amendment No.4 dated June 2, 2021, Amendment No. 5, dated August 2, 2021, and Amendment 6, dated November 12, 2021 (the &#8220;Restated Agreement&#8221;). Passage and Penn are referred to collectively as the &#8220;Parties&#8221; and individually as a &#8220;Party.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 27pt;"><font style="color:#231f20;font-size:12pt;">WHEREAS, the Parties wish to amend the Restated Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 27pt;"><font style="color:#231f20;font-size:12pt;">NOW, THEREFORE, in consideration of the promises and mutual covenants contained in the Restated Agreement and herein, and intending to be legally bound hereby, the Parties amend the Restated Agreement and otherwise agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="color:#231f20;font-size:11pt;">1.&#160;&#160;</font><font style="color:#231f20;font-size:12pt;">The Parties agree that Licensee has exercised its option to Huntington&#8217;s Disease under Section 2.6 of the Restated Agreement (i.e., a New Indication Option). The new Research Plan and Budget are included in Schedule A to this Amendment No. 7 to the Restated Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="color:#231f20;font-size:11pt;">2.&#160;&#160;</font><font style="color:#231f20;font-size:12pt;">Pursuant to Section 4.1.2 of the Restated Agreement, Licensee will pay the first half ($500,000) of the New Indication Option Fee for Huntington&#8217;s Disease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.55pt 27pt;"><font style="color:#231f20;font-size:11pt;">3.&#160;&#160;</font><font style="color:#231f20;font-size:12pt;white-space:pre-wrap;">This Amendment No. 7 to Restated Agreement and the Restated Agreement itself contain the entire understanding between the Parties and supersede any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Restated Agreement and this Amendment No. 7  to Restated Agreement. No amendments, changes, modifications or alterations of the terms and conditions of this Amendment No. 7 to Restated Agreement shall be binding upon any Party, unless provided in writing and signed by an authorized representative of each Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 27pt;"><font style="color:#231f20;font-size:11pt;">4.&#160;&#160;</font><font style="color:#231f20;font-size:12pt;">All terms and conditions of the Restated Agreement not changed by this Amendment No.7 to Restated Agreement shall remain in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="color:#231f20;font-size:11pt;">5.&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-size:12pt;">Signatures on this Amendment No. 7 to Restated Agreement may be communicated by e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment No. 7 to Restated Agreement shall be effective as if simultaneously executed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;font-size:12pt;">[Remainder of page intentionally blank]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="color:#231f20;font-size:12pt;">IN WITNESS WHEREOF the Parties hereto have caused this Amendment No. 7 to the Restated Agreement to be executed and delivered by their duly authorized representatives as set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-size:12pt;font-weight:bold;">AGREED ON BEHALF OF</b><font style="font-size:12pt;">:</font></p></td><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AGREED ON BEHALF OF:</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">PASSAGE BIO INC.</font></p></td><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">THE TRUSTEES OF THE UNIVERSITY OF </font></p></td></tr><tr><td style="vertical-align:bottom;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">PENNSYLVANIA</font></p></td><td style="vertical-align:bottom;width:60.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.18055344%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.36%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;"> </font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:34.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:55.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: </font></p></td><td style="vertical-align:bottom;width:31.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Bruce Goldsmith</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: </font></p></td><td style="vertical-align:bottom;width:54.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ John S. Swartley</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:31.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(Signature)</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:55.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(Signature)</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:34.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:55.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: Bruce A. Goldsmith, Ph.D.</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: John S. Swartley, PhD</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: President and CEO</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: Managing Director, Penn Center for Innovation</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:12pt;">ACKNOWLEDGED AS READ AND </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:12pt;">UNDERSTOOD BY INSTITUTION </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:12pt;">PRINCIPAL INVESTIGATOR</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 10.5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Dr. James Wilson</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:12pt;">Name: Dr. James Wilson</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Schedule A to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Amendment 7 of Research, Collaboration and License Agreement (ARCA)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>5
<FILENAME>pasg-20211231xex10d22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:17:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT 10.22</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">THIS EMPLOYMENT AGREEMENT (this &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:12pt;">&#8221;) is entered into as of March 5, 2021 by and between Passage BIO, Inc. (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221;), and Eliseo Oreste Salinas (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-size:12pt;">&#8221;) (collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Parties</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, the Parties desire to enter into this Agreement on the terms and conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">NOW THEREFORE</b><font style="font-size:12pt;">, in consideration of the mutual covenants contained herein, the Parties agree upon the following terms and conditions of employment of the Employee by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Company and the Employee agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:12pt;">. The following terms used in this Agreement shall, unless otherwise clearly required by the context, have the meanings assigned to them in this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 1</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Annual Salary</font><font style="font-size:12pt;">&#8221; means the annual salary payable to the Employee, initially in the amount of $460,000, less applicable deductions, and as may be changed from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-size:12pt;">&#8221; means the Board of Directors of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-size:12pt;">&#8221; means a good faith determination by the Board that any of the following has occurred: (i) the Employee&#8217;s commission of, conviction of, or plea of nolo contendere to, a felony or an act constituting common law fraud, which has or is reasonably expected to have a material adverse effect on the business or affairs of the Company; (ii) the Employee&#8217;s willful and repeated failure to perform in any material respect the Employee&#8217;s duties for the Company; (iii) the Employee&#8217;s intentional breach of the Company confidential information obligations, invention assignment agreement, or any written Company policy that has been communicated to the Employee in advance of the Employee&#8217;s breach, and (iv) the Employee&#8217;s intentional and material breach of this Agreement; provided, however, that prior to any determination that &#8220;Cause&#8221; under this Agreement has occurred, the Board shall (A) provide to the Employee written notice specifying the particular event or actions giving rise to such determination and (B) provide the Employee an opportunity to be heard within 30 days of such notice and, (C) provide the Employee with 30 days from the date the Employee is heard to cure such event or actions giving rise to a determination of &#8220;Cause,&#8221; if curable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Change of Control</font><font style="font-size:12pt;">&#8221; means (i) a sale, conveyance, exchange or transfer (excluding any venture-backed or similar investments in the Company) in which any person or entity (other than persons or entities who as of immediately prior to such sale, conveyance, exchange or transfer own more than fifty percent (50%) of the total voting power of the then-outstanding securities in the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 40.5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Company) either directly or indirectly becomes the beneficial owner, directly or indirectly, of securities of the Company representing more than fifty (50%) percent of the total voting power of all its then outstanding voting securities; (ii) a merger or consolidation of the Company in which its voting securities immediately prior to the merger or consolidation do not represent, or are not converted into securities that represent, a majority of the voting power of all voting securities of the surviving entity immediately after the merger or consolidation; (iii) a sale of substantially all of the assets of the Company or a liquidation or dissolution of the Company, provided that, in each cases (i)-(iii) of this definition, a transaction or series of transactions shall only constitute a Change of Control if it also satisfies the requirements of a change in control under U.S. Treasury Regulation 1.409A-3(i)(5) (v), 1.409A-3(i)(5)(vi), or 1.409A-3(i)(5)(vii).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Code</font><font style="font-size:12pt;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Conflict of Interest</font><font style="font-size:12pt;">&#8221; has the meaning set forth </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">in Section 4.3</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Date of Termination</font><font style="font-size:12pt;">&#8221; means the date that is the Employee&#8217;s last day of employment at the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-size:12pt;">&#8221; means any of the following taken without the Employee&#8217;s written consent and provided (a) the Company receives, within ninety (90) days following the initial date on which the Employee knows of the occurrence of any of the events set forth in clauses (i) through (iv) below, written notice from the Employee specifying the specific basis for the Employee&#8217;s belief that the Employee is entitled to terminate employment for Good Reason, (b) the Company fails to cure the event constituting Good Reason within thirty (30) days after receipt of such written notice thereof, and (c) the Employee terminates employment within thirty (30) days following expiration of such cure period: (i) a material reduction of the Employee&#8217;s responsibilities, authority or duties to a level materially less than the responsibilities, authorities or duties the Employee occupied or possessed, on the date immediately preceding such reduction; (ii) a material reduction in the Employee&#8217;s Annual Salary; (iii) the Company&#8217;s requiring the Employee to be based at any office or location more than thirty (30) miles from </font><font style="font-size:11pt;">Employee&#8217;s then-current principal place of employment immediately prior to such relocation</font><font style="font-size:12pt;">; or (iv) the Company&#8217;s material breach of any provision of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Omnibus Plan</font><font style="font-size:12pt;">&#8221; means the Company&#8217;s shareholder approved incentive plan or plans, which may include long-term equity-based compensation plans, short-term performance-based compensation plans and any other similar plans, as such may be in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Title and Duties; Start Date</u><font style="font-size:12pt;">. The Employee shall serve as Chief Research and Development Officer of the Company. The Employee will have duties and responsibilities that are customary for the Employee&#8217;s position, and shall initially report to the CEO of the Company. The Employee will devote all of his business time to the Company. &#160;Your employment will commence on March 29, 2021 or earlier, if possible (your &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Start Date</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compensation and Benefits</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.1</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Annual Salary</u><font style="font-size:12pt;">. The Annual Salary will be payable in accordance with the payroll policies of the Company in effect from time to time, but in no event less frequently than</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">twice each month, less any deductions required to be withheld by applicable law and less any voluntary deductions made by the Employee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.2</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Incentive Compensation</u><font style="font-size:12pt;">. The Employee shall be eligible to receive an annual performance bonus, with a target amount equal to 45% of the Annual Salary, based upon the achievement of performance objectives established in writing by the Board or CEO and subject to the terms of the applicable bonus plan(s). Bonus payouts, if any, will be paid no later than March 15 of the year following the calendar year to which the bonus is applicable, and will be pro-rated based, as applicable, on hire date and/or approved leaves of absence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.3</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Signing Bonus</u><font style="font-size:12pt;">. &#160;You will be paid two (2) signing bonuses in connection with your employment with the Company consisting of (i) $</font><font style="font-size:12pt;">50,000</font><font style="font-size:12pt;"> payable within thirty (30) days following your Start Date, and (ii) $50,000 payable within thirty (30) days following the six (6) month anniversary of your Start Date, provided in each case that you are still employed by the Company upon such payment date. If you resign your employment without Good Reason or your employment is terminated for Cause prior to twelve (12) months of continuous service with the Company, such signing bonuses will be repayable by you to the Company in full at the time of termination. You agree that the Company reserves the right to withhold any balance payable to the Company from any form of compensation due to you, except where prohibited by United States federal or state law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.4</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Participation in Employee Benefit Plans</u><font style="font-size:12pt;">. The Employee may participate in any group life, hospitalization or disability insurance plan, health program, retirement plan, similar benefit plan or other so called &#8220;fringe benefits&#8221; of the Company for which the Employee is eligible. The Employee&#8217;s participation in any such plans shall be on the terms and conditions set forth in the governing plan documents as they may be in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.5</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">General Business Expenses</u><font style="font-size:12pt;">. The Company shall pay or reimburse the Employee for all business expenses reasonably and necessarily incurred by the Employee in the performance of the Employee&#8217;s duties under this Agreement, consistent with the Company&#8217;s business expense reimbursement policy, as in effect from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.6</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company Policies</u><font style="font-size:12pt;">. The Employee understands and agrees to abide by Company&#8217;s insider trading policy, code of conduct, and any other reasonable policies and programs adopted by the Company regulating the behavior of its employees, as such policies and programs may be amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.7</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">RSU Award</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">The Board will grant you a restricted stock unit to acquire 40,000 shares (&#8220;</font><b style="font-size:12pt;font-weight:bold;">RSU Tranche 1</b><font style="font-size:12pt;">&#8221;) under the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Equity Plan</b><font style="font-size:12pt;">&#8221;). RSU Tranche 1 will vest as to 1/3 on each of June 15, 2021, September 15, 2021 and December 15, 2021, provided that, subject to Section 5 below, vesting will depend on your continued service with the Company on the applicable time based vesting dates, and will be subject to the terms and conditions of the written agreement governing the grant, the Equity Plan and this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">The Board will grant you a restricted stock unit to acquire 60,000 shares (&#8220;</font><b style="font-size:12pt;font-weight:bold;">RSU Tranche 2</b><font style="font-size:12pt;">&#8221;) under the Equity Plan. RSU Tranche 2 will vest as to 1/4th of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">shares on the each of the first, second, third and fourth annual anniversaries of the first Quarterly Vesting Date (as such term is defined below) following your Start Date; provided that, subject to Section 5 below, vesting will depend on your continued service with the Company on the applicable time based vesting dates, and will be subject to the terms and conditions of the written agreement governing the grant, the Equity Plan and this Agreement. For purposes of this Section 3.7(b), &#8220;</font><b style="font-size:12pt;font-weight:bold;">Quarterly Vesting Dates</b><font style="font-size:12pt;">&#8221; shall mean March 15, June 15, September 15, and December 15.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.8</font><font style="display:inline-block;width:21pt;"></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Option Award</u><font style="font-size:12pt;">. The Board will grant you an option to purchase 275,000 shares (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Option</b><font style="font-size:12pt;">&#8221;) under the Equity Plan. The Option will vest as to 1/4</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> of the shares on the 1-year anniversary of your Start Date, and as to 1/48th of the shares each month thereafter; provided that, subject to Section 5 below, vesting will depend on your continued service with the Company on the applicable time based vesting dates, and will be subject to the terms and conditions of the written agreement governing the grant, the Equity Plan and this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Protection of Company Trade Secrets and Proprietary Information</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.1</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">EIACNA</u><font style="font-size:12pt;">. As an employee of the Company, the Employee will have access to certain confidential information of the Company and the Employee may, during the course of the Employee&#8217;s employment, develop certain information or inventions that will be the property of the Company. To protect the Company&#8217;s interests, as a condition of employment, the Employee must abide by the Company&#8217;s standard Employee Invention Assignment, Confidentiality, and Non-Competition Agreement (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">EIACNA</font><font style="font-size:12pt;">&#8221;) entered into between the Employee and the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.2</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Breach of Obligations to Prior Employers</u><font style="font-size:12pt;">. The Company hereby directs the Employee not to bring with the Employee any confidential or proprietary material of any former employer or to violate any other obligations the Employee may have to any former employer. The Employee represents that by signing this Agreement and the Company&#8217;s EIACNA and the Employee&#8217;s commencement of employment and continued employment with the Company will not knowingly violate any agreement currently in place between the Employee and current or past employers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.3</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Conflicts of Interest</u><font style="font-size:12pt;">. The Employee agrees that during the Employee&#8217;s employment with the Company the Employee will not undertake or engage in any other employment, occupation, or business enterprise that would create a conflict of interest with the Company (a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Conflict of Interest</font><font style="font-size:12pt;">&#8221;), including ownership of a material interest in any supplier, contractor, distributor, subcontractor, customer or other entity with which the Company does business or acceptance of any material payment, service, loan, gift, trip, entertainment, or other favor from a supplier, contractor, distributor, subcontractor, customer or other entity with which the Company does business, and that the Employee will promptly inform the Board as to each offer received by the Employee to engage in any such activity. The Employee further agrees to disclose to the Company any other facts of which the Employee becomes aware which might in the Employee&#8217;s good faith judgment reasonably be expected to involve or give rise to a Conflict of Interest or potential Conflict of Interest.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.1</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accrued Payments</u><font style="font-size:12pt;">. In general, on termination of the Employee&#8217;s employment for any reason, the following amounts will be paid to the Employee, or the Employee&#8217;s estate, as the case may be:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">All accrued but unpaid Annual Salary, payable in the next regularly scheduled pay period following the Employee&#8217;s Date of Termination or such earlier date as may be required by law;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Accrued but unused vacation time, to the extent payment is either required by law or provided for in the Company&#8217;s vacation or paid-time-off policy, as such may be in effect from time to time;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">Any amounts payable to the Employee under the terms of any employee benefit plans in which the Employee was a participant;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Reimbursement of any of the Employee&#8217;s business expenses not previously reimbursed, to the extent provided for under the Company&#8217;s business expense reimbursement policy; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">Payment of any amounts that are determined to be due under the terms of the Omnibus Plan, or any grants or awards made thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.2</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination for Cause</u><font style="font-size:12pt;">. The Company has the right, at any time during the Employee&#8217;s employment, subject to all of the provisions hereof, exercisable by serving notice, effective on or after the date of service of such notice as specified therein, to terminate the Employee&#8217;s employment under this Agreement and discharge the Employee for Cause.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.3</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination without Cause</u><font style="font-size:12pt;">. The Company has the right, at any time during the Employee&#8217;s employment, to terminate the Employee&#8217;s employment without Cause by providing the Employee with notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.4</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination without Cause or Resignation for Good Reason outside of a Change in Control</u><font style="font-size:12pt;">. In the event of a termination of employment resulting from (i) a termination by the Company of the Employee&#8217;s employment for any reason other than Cause, death or disability (as defined in Section 22(e)(3) of the Code) or (ii) the Employee&#8217;s voluntary resignation of employment for Good Reason, in each case </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">other than</u><font style="font-size:12pt;"> within 2 months prior to, or 12 months following a Change of Control, then subject to the Employee&#8217;s satisfaction of the Severance Conditions (defined above), the Employee will be entitled to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">Severance. Should the termination occur during the first twelve (12) months of employment, the Employee will be entitled to a lump sum payment equal to the Employee&#8217;s Annual Salary for an additional nine (9) months after the Date of Termination (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Severance</font><font style="font-size:12pt;">&#8221;). Should the termination occur after the first twelve (12) months of employment, the lump sum Severance payment will be increased from nine (9) months of Annual Salary to twelve (12) months of Annual Salary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Bonus. &#160;The Company will pay Employee a lump sum payment equal to Employee&#8217;s annual incentive target bonus amount for the year of termination, prorated </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">based on the number of days in the applicable calendar year during which Employee was employed by the Company prior to the Date of Termination (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Prorated Bonus</font><font style="font-size:12pt;">&#8221;)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">COBRA. Consistent with the terms of COBRA and the Company&#8217;s health insurance plan, the Company shall provide the Employee a taxable lump sum payment equal to 12 months of the monthly COBRA premium the Employee would be required to pay to continue the group health coverage in effect on the Date of Termination (which monthly amount shall be based on the premium for the first month of COBRA coverage), which payment shall be made regardless of whether the Employee elects COBRA continuation coverage (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">COBRA Payment</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">Equity Awards. &#160;Each of the Employee&#8217;s unvested options to purchase shares of the Company common stock as well as any and all other stock-based awards granted to the Employee, including but not limited to stock bonus awards, restricted stock, restricted stock units or stock appreciation rights (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Equity Awards</font><font style="font-size:12pt;">&#8221;), shall accelerate and become vested and, if applicable, exercisable and any forfeiture restrictions thereon shall lapse with respect to the number of then-unvested &#160;shares subject to the Equity Awards that would have vested during the next twelve(12) month period following Employee&#8217;s termination date as if Employee remained employed by the Company through such period (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Equity Acceleration</font><font style="font-size:12pt;">&#8221;). &#160;All of Employee&#8217;s vested stock options (after giving effect to the foregoing acceleration) shall remain exercisable until the earlier of the first anniversary of Employee&#8217;s termination of service and the original expiration date for such stick option as set forth in the applicable award agreement evidencing such grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">the Employee will be entitled to receive the Severance, Prorated Bonus, the COBRA Payments and Equity Acceleration referenced in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5.4</u><font style="font-size:12pt;"> and on the terms of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5.4</u><font style="font-size:12pt;"> within thirty (30) calendar days of the Date of Termination provided the Employee has satisfied the following &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Severance Conditions</font><font style="font-size:12pt;">&#8221;: (1) the Employee has resigned from all officer and director positions the Employee may have held with the Company, if requested by the Company; (2) the Employee has returned all material Company property in the Employee&#8217;s possession; (3) the Employee has materially complied with the Employee&#8217;s obligations under the EIACNA and continues to materially comply with such obligations; and (4) the Employee has executed a general release of all known and unknown claims that the Employee may have against the Company or persons affiliated with the Company in substantially the form attached hereto as </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b><font style="font-size:12pt;"> (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Release</font><font style="font-size:12pt;">&#8221;) and the Release becomes effective and irrevocable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(f)</font><font style="display:inline-block;width:24.01pt;"></font><font style="font-size:12pt;">For the avoidance of doubt, this Section 5.4 shall not apply in the event of a termination of employment by reason of death or disability.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.5</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination without Cause or Resignation for Good Reason in connection with a Change of Control</u><font style="font-size:12pt;">. &#160;In the event of a termination of employment resulting from (i) a termination by the Company of the Employee&#8217;s employment for any reason other than Cause, death or disability (as defined in Section 22(e)(3) of the Code) or (ii) the Employee&#8217;s voluntary resignation of employment for Good Reason, in each case within 2 months prior to, or 12 months following a Change of Control, then subject to the Employee&#8217;s satisfaction of the Severance Conditions (defined above), the Employee will be entitled to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">the payments and benefits referenced in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5.4</u><font style="font-size:12pt;">; provided that &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Severance</font><font style="font-size:12pt;">&#8221; shall also be deemed to include 100% of the Employee&#8217;s then-current incentive target bonus for the year in which such termination of employment occurs (in lieu of the Prorated Bonus); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">each of the Employee&#8217;s then-outstanding unvested options to purchase shares of the Company common stock as well as any and all other stock-based awards granted to the Employee, including but not limited to stock bonus awards, restricted stock, restricted stock units or stock appreciation rights (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Awards</font><font style="font-size:12pt;">&#8221;) shall accelerate and become fully vested and, if applicable, exercisable and any forfeiture restrictions thereon shall lapse, effective as of the date of such termination of service; </font><i style="font-size:12pt;font-style:italic;text-decoration:underline;text-decoration-color:#000000;">provided, however</i><font style="font-size:12pt;">, that the grant agreement for the purpose of any Award that would otherwise vest upon satisfaction of performance metrics or factors other than the continuation of the Employee&#8217;s employment with the Company (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Performance-Based Awards</font><font style="font-size:12pt;">&#8221;) may provide for alternative treatment in lieu of the foregoing and, absent any such treatment in the grant agreement, the vesting acceleration provided for herein shall be deemed to have been met based on the achievement of the Performance-Based Award at the greater of &#8220;at target&#8221; or, if determinable, actual performance. Notwithstanding anything to the contrary herein or in any equity plan or any applicable award agreement pursuant to Awards granted thereunder, if the successor or acquiring corporation (if any) of the Company refuses to assume, convert, replace or substitute the Employee&#8217;s unvested Awards in connection with a Change of Control, each of the Employee&#8217;s unvested Awards that are not assumed, converted, replaced or substituted, shall accelerate and become fully vested and if applicable, exercisable, effective immediately prior to the Change of Control. With respect to Performance-Based Awards, the grant agreement may provide for alternative treatment in lieu of the foregoing and, absent any such treatment in the grant agreement, the vesting acceleration provided for herein shall be deemed to have been met based on the achievement of the Performance-Based Award at the greater of &#8220;at target&#8221; or, if determinable, actual performance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">For the avoidance of doubt, this Section 5.5 shall not apply in the event of a termination of employment by reason of death or disability.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Tax Matters</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.1</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Withholding, Taxes, Deductions</u><font style="font-size:12pt;">. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law as referenced in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.2</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Code Section 409A</u><font style="font-size:12pt;">. The following provisions shall apply in connection with compliance with Code Section 409A:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">The intent of the Parties is that payments and benefits under the Agreement that are not exempt from Section 409A of the Code shall be in compliance with Code Section 409A (and regulations and guidance promulgated by the IRS and/or Treasury related to Code Section 409A) (together &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Code Section 409A</font><font style="font-size:12pt;">&#8221;) to the maximum extent permitted, the Agreement shall be interpreted to be in compliance therewith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">taxable benefits subject to Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">separation from service</font><font style="font-size:12pt;">&#8221; within the meaning of Section 409A of the Code, and for purposes of any such provision of this Agreement, references to a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">termination</font><font style="font-size:12pt;">,&#8221; &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">termination of employment</font><font style="font-size:12pt;">,&#8221; &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">termination of the Term</font><font style="font-size:12pt;">,&#8221; or like terms shall mean &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">separation from service</font><font style="font-size:12pt;">.&#8221; The determination of whether and when a separation from service has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, U.S. Treasury Regulation Section 1.409A-1(h) or any successor provision thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">It is intended that each installment, if any, of any payments and benefits provided hereunder to which Code Section 409A is applicable shall be treated as a separate &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">payment</font><font style="font-size:12pt;">&#8221; for purposes of Code Section 409A. Neither the Company nor the Employee shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)</font><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">In the event, as of the date of the Employee&#8217;s &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">separation from service</font><font style="font-size:12pt;">,&#8221; the Employee is a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">specified employee</font><font style="font-size:12pt;">&#8221; (within the meaning of that term under Code Section 409A(a)(2)(B)), then with regard to any payment or the provision of any benefit that is subject to Code Section 409A (whether under this Agreement, or pursuant to any other agreement with, or plan, program, payroll practice of, the Company) and is due upon or as a result of the Employee&#8217;s separation from service, such payment or benefit shall not be made or provided, to the extent making or providing such payment or benefit would result in additional taxes or interest under Section 409A of the Code, until the date which is the earlier of (A) the expiration of the six (6)-month period measured from the date of such &#8220;separation from service,&#8221; and (B) the date of the Employee&#8217;s death and shall then be paid in a single sum as soon as practicable on or after the date such payment is permitted to be made under this paragraph.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:12pt;">All reimbursements and in-kind benefits provided under this Agreement or otherwise to the Employee, to the extent such payments or benefits are subject to Code Section 409A, shall be made or provided in accordance with the requirements of Section 409A of the Code and specifically, consistent with Treasury Regulation Section 1.409A-3(i)(1)(iv).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.3</font></font><font style="font-size:12pt;">Certain Excise Taxes. Notwithstanding anything to the contrary in this Agreement, if the Employee is a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code), and the payments and benefits provided for in this Agreement, together with any other payments and benefits which the Employee has the right to receive from the Company or any of its affiliates, would constitute a &#8220;parachute payment&#8221; (as defined in Section 280G(b)(2) of the Code), then the payments and benefits provided for in this Agreement shall be either (a) reduced (but not below zero) so that the present value of such total amounts and benefits received by the Employee from the Company and its affiliates will be one dollar ($1.00) less than three times the Employee&#8217;s &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">base amount</font><font style="font-size:12pt;">&#8221; (as defined in Section 280G(b)(3) of the Code) and so that no portion of such amounts and benefits received by the Employee shall be subject to the excise tax imposed by Section 4999 of the Code or (b) paid in full, whichever produces the better net after-tax position to the Employee (taking into account any applicable excise tax under Section 4999 of the Code and any other applicable taxes, and as determined by the Company and its advisors in their sole discretion). Nothing in this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 6.3</u><font style="font-size:12pt;"> shall require the Company to be responsible for, or have</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">any liability or obligation with respect to, the Employee&#8217;s excise tax liabilities under Section 4999 of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnification</u><font style="font-size:12pt;">. The Company will agree to indemnify the Employee with respect to activities in connection with the Employee&#8217;s employment hereunder on the terms and conditions set forth in its standard Indemnification Agreement for officers and directors, to entered into between the Employee and the Company upon or shortly following the execution of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Attorney&#8217;s Fees</u><font style="font-size:12pt;">. &#160;The Company will reimburse, promptly upon presentation of invoices, Employee&#8217;s expenses for legal or other advisors incurred in the review and finalization of this Agreement, up to an aggregate $3,750.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.1</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">At Will Employment</u><font style="font-size:12pt;">. Employment with the Company is for no specific period of time and, at all times, is &#8220;at will&#8221; in nature, which means the employment relationship can be terminated by either of the Employee or the Company for any reason, at any time. Any statements or representations to the contrary (and, indeed, any statements contradicting any provision in this Agreement) are superseded by this Agreement. Further, the Employee&#8217;s participation in any stock option or benefit program is not to be regarded as assuring the Employee of continuing employment for any particular period of time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.2</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:12pt;">. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered via email, as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">if to the Company, to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">Chip Cale, [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">if to the Employee, to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">Eliseo Oreste Salinas, [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">Any party may change its address for notice hereunder by notice to the other party hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.3</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement</u><font style="font-size:12pt;">. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements (including but not limited to prior employment agreements, incentive plans and agreements), written or oral, with respect thereto, however, the terms of any benefit plans shall remain in force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.4</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Waivers and Amendments</u><font style="font-size:12pt;">. This Agreement may be amended, superseded, canceled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by the parties or, in the case of a waiver, by the party waiving compliance. No delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any waiver on the part of any party of any such right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">hereunder, preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.5</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law</u><font style="font-size:12pt;">. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania (without giving effect to the choice of law provisions thereof).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.6</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Assignment and Successors</u><font style="font-size:12pt;">. This Agreement, and any rights and obligations hereunder, may not be assigned by the Employee and may be assigned by the Company only to a successor by merger or purchasers of substantially all of the assets of the Company or its affiliates; provided, however, that this Agreement shall inure to the benefit of and may be enforced by the Employee&#8217;s heirs and legal representatives. &#160;The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company expressly to assume and agree to perform under this Agreement in the same manner and to the same extent that the Company would have been required to perform it if no such succession had taken place, except under circumstances in which such assumption occurs by operation of law. &#160;As used in this Agreement, &#8220;Company&#8221; shall mean both the Company as defined above and any such successor that assumes and agrees to perform this Agreement, by operation of law or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.7</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:12pt;">. This Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.8</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Headings</u><font style="font-size:12pt;">. The headings in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.9</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Presumption against Interest</u><font style="font-size:12pt;">. This Agreement has been negotiated, drafted, edited and reviewed by the respective parties, and therefore no provision of this Agreement shall be construed against any party as being drafted by said party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.10</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Duty to Mitigate</u><font style="font-size:12pt;">. The Employee shall not be required to mitigate damages with respect to the termination of the Employee&#8217;s employment under this Agreement by seeking other employment or otherwise, and there shall be no offset against amounts due to the Employee under this Agreement on account of subsequent employment except as specifically provided in this Agreement. Additionally, amounts owed to the Employee under this Agreement shall not be offset by any claims the Company may have against the Employee, and the Company&#8217;s obligation to make the payments provided for in this Agreement, and otherwise to perform its obligations hereunder, shall not be affected by any other circumstances, including, without limitation, any counterclaim, recoupment, defense or other right which the Company may have against the Employee or others.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.11</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Dispute Resolution</u><font style="font-size:12pt;">. If any dispute arises out of or relates to this Agreement, or the breach thereof, the Employee and the Company agree to promptly negotiate in good faith to resolve such dispute. If the dispute cannot be settled by the parties through negotiation, the Employee and the Company agree to try in good faith to settle the dispute by mediation under the then- current employment mediation rules of the American Arbitration Association (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">AAA</font><font style="font-size:12pt;">&#8221;) </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">before resorting to arbitration or any other dispute resolution procedure. If the parties are unable to settle the dispute by mediation as provided in the preceding sentence within 30 days of a written demand for mediation, any Arbitrable Claims (as defined herein) shall be resolved by binding arbitration before one (1) arbitrator in accordance with the AAA&#8217;s then-current rules for the resolution of employment disputes (currently the Employment Arbitration Rules and Mediation Procedures, which may be accessed at https://www.adr.org/sites/default/files/EmploymentRules_Web2119.pdf), with the Company to cover cost of arbitration, but excluding any attorney fees. The arbitration shall be held in Philadelphia County, Pennsylvania, or such other location to which the parties mutually agree. The arbitrator shall among other things determine the validity, scope, interpretation and enforceability of this arbitration clause. The award shall be a reasoned award and rendered within 30 days of the conclusion of the arbitration hearing. The decision of the arbitrator shall be final and binding and judgment upon the award rendered may be entered in any court having jurisdiction thereof. &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Arbitrable Claims</font><font style="font-size:12pt;">&#8221; refers to any claim controversy or dispute arising out of or relating to the Employee&#8217;s employment with the Company and the termination thereof, including, but not limited to, claims arising from or related to this Agreement or the breach thereof, or claims for unpaid wages, wrongful termination, torts, stock or stock options or other ownership interest in the Company, and/or discrimination (including harassment) based upon any federal, state, or local ordinance, statute, regulation or constitutional provision. Notwithstanding the foregoing provisions of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9.11</u><font style="font-size:12pt;">, either party may seek injunctive relief from a court of competent jurisdiction located in Philadelphia County, Pennsylvania, in the event of a breach or threatened breach of any covenant contained in the EIACNA.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[Remainder of Page Intentionally Left Blank]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date written below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><b style="font-size:12pt;font-weight:bold;">EMPLOYEE</b><font style="font-size:12pt;">:</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">COMPANY</b><font style="font-size:12pt;">:</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Passage BIO, Inc.</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="font-size:12pt;">/s/ Eliseo Salinas</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:42.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Bruce Goldsmith</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="font-size:12pt;">Eliseo Oreste Salinas</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bruce Goldsmith</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="font-size:12pt;">Date:&#160;&#160;March 5, 2021</font></p></td><td style="vertical-align:top;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:42.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">March 5, 2021</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[*]</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>6
<FILENAME>pasg-20211231xex10d23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:17:55 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Exhibit 10.23</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">October 30, 2021</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">VIA E-MAIL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><font style="font-size:12pt;">Jill Quigley</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 48pt;"><font style="font-size:12pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 84pt;"><font style="display:inline-block;text-indent:0pt;width:24pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Re:</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Terms of Transition and Separation of Employment</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 84pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 48pt;"><font style="font-size:12pt;">Dear Jill:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;">This letter confirms the agreement (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:12pt;">&#8221;) between you and Passage Bio, Inc. (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221;) concerning the terms of your transition and the termination of your employment with the Company without Cause (as defined in the Amended and Restated Employment Agreement that you entered into with the Company on November 12, 2018, as amended, attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:12pt;"> (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Employment Agreement</font><font style="font-size:12pt;">&#8221;). If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Separation of Employment</u><font style="font-size:12pt;">: &#160; As we have discussed, we have agreed that it is in our mutual best interests for you and the Company to part ways and for your employment with the Company to end on December 31, 2021. The Company has discussed with you the terms under which it is willing to continue your employment through the Transition Period, as described further below.</font></div><div style="margin-top:0.05pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Continued Employment; Separation Benefits</u><font style="font-size:12pt;">: The Company agrees to continue your employment on the following terms:</font></div><div style="margin-top:0.25pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Date of Separation; Transition Period and Communications Regarding Transition</u><font style="font-size:12pt;">: Subject to the provisions of Section 2(d) below, your last day of employment with the Company will be December 31, 2021 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Date of Separation</font><font style="font-size:12pt;">&#8221;). Between now and the Date of Separation (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Transition Period</font><font style="font-size:12pt;">&#8221;), you agree to be available at the request of the Company&#8217;s CEO or members of the Executive Team on a remote basis upon reasonable notice for limited assistance with transition of the responsibilities, duties, and knowledge relative to your position. During the Transition Period, </font><b style="font-size:12pt;font-weight:bold;">[*]</b><font style="font-size:12pt;">. On October 26, 2021, the Company issued internal communications regarding your transition as attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u><font style="font-size:12pt;">. The Company agrees that all external communications from the Company&#8217;s President and CEO, members of the Executive Team and their representatives shall be consistent with Exhibit D including, but not limited to, the Company&#8217;s Form 8-K statements (a form of which is also included in Exhibit D) and statements during earnings calls regarding your transition from Company.</font></div><div style="margin-top:0.25pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compensation and Benefits</u><font style="font-size:12pt;">: During the Transition Period, the Company will continue to pay you your current base salary of four hundred fifty-three thousand three hundred ninety dollars ($453,390), your current personal transportation and commuting allowance of two thousand dollars ($2,000) per month, and you will continue to be eligible to participate in benefits customarily afforded to other employees, including bonus awards, participation in the Company-sponsored health benefits plan and continued vesting of options, to the fullest extent allowed by the governing plans, agreements, and policies.</font></div><div style="margin-top:0.15pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Separation Benefits</u><font style="font-size:12pt;">:</font></div><div style="margin-top:0.3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">i.</font><font style="font-size:12pt;">At the end of the Transition Period, and in exchange for your agreement to the general release and waiver of claims and covenant not to sue set forth in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:12pt;"> (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Release</font><font style="font-size:12pt;">&#8221;), </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">to be signed no earlier than the Date of Separation</u><font style="font-size:12pt;">, and your other promises and obligations outlined herein, the Company agrees to provide you with the following separation benefits: (1) a lump sum payment in the total gross amount of four hundred fifty-three thousand three hundred ninety dollars ($453,390.00) (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Severance</font><font style="font-size:12pt;">&#8221;); (2) a lump sum payment in the total gross amount of two hundred four thousand twenty-five dollars and fifty cents ($204,025.50) (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">2021 Bonus</font><font style="font-size:12pt;">&#8221;); (3) COBRA Continuation (as defined below); (4 ) 100% of the unvested shares underlying the stock options granted to you pursuant to (A) the February 6, 2019 Notice of Stock Option Grants (Employee Grant Numbers OPT-3, OPT-4 and OPT-5); (B) the January 15, 2020 Notice of Stock Option Grant (Option 16-ISO and Option 16-NQ); and (C) the February 27, 2020 Notice of Stock Option Grant (Option 35 and Option 35 Split) shall be deemed fully vested as of the Date of Separation; and (5) the Company agrees to extend your post-employment deadline to exercise any unexercised vested shares (including, but not limited to, shares that become vested pursuant to Section 2(c)(i)(4) above) subject to the January 15, 2020 Notice of Stock Option Grant and February 27, 2020 Notice of Stock Option Grant to the </font><b style="font-size:12pt;font-weight:bold;">[*] </b><font style="font-size:12pt;">anniversary of the Date of Separation (Section 2(c)(i)(1)-(5) above, collectively, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Separation Benefits</font><font style="font-size:12pt;">&#8221;). For the avoidance of doubt, the Company acknowledges and agrees that, effective as of the Date of Separation and contingent on the Release becoming effective, all shares previously acquired by you pursuant to the exercise of options granted to you pursuant to the February 6, 2019 Notice of Stock Option Grant (Employee Grant Number OPT-3) will become fully vested and not subject to the repurchase option described therein.</font></div><div style="margin-top:0.25pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.59pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">ii.</font><font style="font-size:12pt;">The Severance and the 2021 Bonus shall be paid, less applicable taxes and withholdings, within thirty (30) days following the effective date of the Release.</font></div><div style="margin-top:0.25pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iii.</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">COBRA Continuation</font><font style="font-size:12pt;">&#8221; means that, provided that you elect COBRA coverage, the Company will pay all premiums and other costs of such COBRA coverage for you and your eligible dependents to maintain your health insurance benefits for one year from the Date of Separation, at no cost to you. The Company will pay all costs associated with COBRA Continuation directly to the health insurance carrier and those payments will not be taxable to you.</font></div><div style="margin-top:0.25pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:99.15pt;margin:0pt 0pt 0pt 48pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:144pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">iv.</font><font style="font-size:12pt;">You expressly acknowledge that the consideration provided above in this Section 2(c) fully satisfies any and all severance obligations the Company may have to you under Section 6.4 of the Employment Agreement or otherwise.</font></div><div style="margin-top:0.4pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="color:#010000;font-size:12pt;">&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Death or Incapacity</u><font style="font-size:12pt;">: In the event of your death prior to December 31, 2021, the Company will provide to your estate the Separation Benefits that the Company would have otherwise provided to you under this Agreement. Your disability or incapacity in any respect will not impact the Company&#8217;s obligations under this Agreement including, but not limited to, the Company&#8217;s obligation to provide you with the Separation Benefits.</font></div><div style="margin-top:0.3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 5.5pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Final Pay</u><font style="font-size:12pt;">: On the Date of Separation, the Company will pay you f or all wages, salary, transportation and commuting allowance, bonuses, commissions, reimbursable expenses previously submitted by you, accrued vacation (if applicable) and any similar payments due you from the Company as of your termination of employment. By signing below, you acknowledge that the Company does not owe you any other amounts, except as otherwise may become payable under this Agreement and the Release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 5.5pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Return of Company Property; Retrieval of Personal Property</u><font style="font-size:12pt;">: You hereby warrant to the Company that the only Company computer you currently have in your possession is the Company issued Surface Pro laptop computer. You further warrant that, no later than the Date of Separation, you will return to the Company the Surface Pro laptop computer that the Company provided to you in connection with your employment. Other than devices no longer in your possession, custody, or control, you warrant that (i) the Surface Pro laptop is the only computer and (ii) your current personal cell phone is the only cell phone that you have used to conduct Company business since the commencement of your employment with the Company and that you do not have any Company information on any other computer or device. Prior to the Date of Separation, you will conduct a diligent review of your home remote workspace and return or destroy any physical Company documents in your possession. You will provide reasonable cooperation to allow the Company to remove any Company-owned applications and data from your personal cell phone without deleting your personal data. At a mutually-agreeable time on or before November 15, 2021, the Company will allow you access to Company premises so you may retrieve your personal belongings from your office and you agree to return your office access badge to the Company at that same time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 5.5pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Post-Employment Obligations</u><font style="font-size:12pt;">: You hereby acknowledge that: (a) you continue to be bound by the attached Employee Invention Assignment, Confidentiality, and Non- Competition Agreement (</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:12pt;"> hereto) (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restrictive Covenant Agreement</font><font style="font-size:12pt;">&#8221;), as amended by Section 6 below; (b) as a result of your employment with the Company, you have had access to the Company&#8217;s proprietary and/or confidential information, and you will continue to hold all such information in strictest confidence and not make use of it on behalf of anyone; and (c) you must, and by your signature below confirm that you shall, deliver to the Company, no later than the Date of Separation, all documents and data of any nature containing or pertaining to such information, and not take with you, or otherwise retain in any respect, any such documents or data or any reproduction thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 48pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment of Restrictive Covenant Agreement</u><font style="font-size:12pt;">: You and the Company agree that Section 14(a) of the Restrictive Covenant Agreement is hereby amended and restated in its entirety as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 74.9pt;"><font style="font-size:12pt;">&#8220;(a) </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Non-Competition</u><font style="font-size:12pt;">. I understand that the Company&#8217;s interests in protecting its investments, goodwill, Proprietary Information. trade secrets, and/or technologies make it reasonable for the Company to ask me to agree that I will not compete with the Company for a reasonable period after the termination of my employment for any reason, whether voluntary or involuntary. Accordingly, I further agree that I will not, during the six (6) month period following the termination of my employment (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Post-Employment Period</font><font style="font-size:12pt;">&#8221;), anywhere within the United States (including state and state- equivalents and county and country equivalents within the United States) (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restricted Territory</font><font style="font-size:12pt;">&#8221;), directly or indirectly, provide services that are the same or similar in function or purpose to the services I provided to the Company as Chief Operating Officer or such other non-attorney roles as I may have held, whether provided as an employee, consultant, director, owner or in any other capacity, to any person or entity (including any business in planning or formation) that is or intends to be engaged in the design, development, manufacture, production, marketing or sale of any gene therapy product, investigational compound or technology for use in GM1, FTD-GRN, Krabbe or MLD, CMT2A, ALS, Parkinson&#8217;s Disease, Huntington&#8217;s Disease, Alzheimer&#8217;s Disease and Temporal Lobe Epilepsy. It will not be deemed to be a violation of this section for me to make or hold either of the following investments: (a) ownership, as a passive investor, of up to two percent (2%) of any publicly traded company; or (b) an equity interest of up to two percent (2%) in any venture capital fund or other investment vehicle that makes investments in early stage companies so long as I do not participate in or influence the investment decision process of such fund or vehicle.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 5pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Arbitration</u><font style="font-size:12pt;">: Except for any claim for injunctive relief arising out of a breach of a party&#8217;s obligations to protect the other&#8217;s proprietary information, the parties agree to arbitrate, in Philadelphia, Pennsylvania through JAMS, any and all disputes or claims arising out of or related to the validity, enforceability, interpretation, performance or breach of this Agreement, whether sounding in tort, contract, statutory violation or otherwise, or involving the construction or application or any of the terms, provisions, or conditions of this Agreement. Any arbitration may be initiated by a written demand to the other party. The arbitrator&#39;s decision shall be final, binding, and conclusive. The parties further agree that this Agreement is intended to be strictly construed to provide for arbitration as the sole and exclusive means for resolution of all disputes hereunder to the fullest extent permitted by law. The parties expressly waive any entitle ment to have such controversies decided by a court or a jury. All costs unique to arbitration incurred by you or the Company in connection with any arbitration initiated pursuant to this Section 7 including, but not limited to, all arbitrator fees, will be fully and promptly paid by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 47.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Attorneys&#8217; Fees</u><font style="font-size:12pt;">: If any action is brought to enforce the terms of this Agreement, the prevailing party will be entitled to recover its reasonable attorneys&#8217; fees, costs and expenses from the other party, in addition to any other relief to which the prevailing party may be entitled.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Reimbursement of Legal Fees</u><font style="font-size:12pt;">: The Company will reimburse you up to </font><b style="font-size:12pt;font-weight:bold;">[*]</b><font style="font-size:12pt;"> for legal fees incurred by you in connection with the negotiation and execution of this Agreement. You agree to promptly (and no later than thirty (30) days after the Effective Date) submit appropriate (non-privileged, non-detailed) documentation in connection therewith and the Company shall reimburse you for such legal fees no later than thirty (30) days following receipt of such documentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</u><font style="font-size:12pt;">: The contents, terms and conditions of this Agreement (excluding Exhibits A, C and D) must be kept confidential by you and may not be disclosed except to your immediate family, accountant or attorneys or pursuant to subpoena or court order. You agree that if you are asked for information concerning this Agreement, you will state only that you and the Company reached an amicable resolution of any disputes concerning your separation f rom the Company. Any breach of this confidentiality provision shall be deemed a material breach of this Agreement. Nothing in this Section 10 prohibits you from disclosing the contents, terms and conditions of this Agreement: (1) in connection with an action to enforce the Agreement&#8217;s terms; (2) if the Company discloses the contents, terms or conditions of this Agreement to any third party; or (3) as otherwise required by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Mutual Non-disparagement</u><font style="font-size:12pt;">: You agree that you will not, directly or indirectly, disparage or make negative remarks regarding the Company or its current executive officers, directors, and employees, including, but not limited to, any statement posted on social media (including online company review sites) or otherwise on the Internet, whether or not made anonymously or with attribution. The Company agrees that its current executive officers, f or so long as they are employed by or providing services to the Company, will not, directly or indirectly, disparage or make negative remarks regarding you, including, but not limited to, any statement posted on social media or otherwise on the Internet, whether or not made anonymously or with attribution. For the avoidance of doubt, the Company agrees that all Company communications regarding your transition from the Company shall be consistent with the communications set forth in Exhibit D. Nothing in this section shall prohibit you or the Company from providing truthful information in response to a subpoena or other legal process.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnification; No Duty to Mitigate:</u><font style="font-size:12pt;"> The Company&#8217;s indemnification obligations set forth in Section 8 of the Employment Agreement remain in full force and effect, and survive your separation from employment with the Company. The Release attached as Exhibit B does not waive or release the Company&#8217;s indemnification obligations set forth in Section 8 of the Employment Agreement. As set forth in Section 9.10 of the Employment Agreement (which section is incorporated by reference), you have no duty to mitigate damages with respect to the termination of your employment by seeking other employment or otherwise, and there shall be no offset against any of the consideration set forth in Section 2(c) of this Agreement on account of your subsequent employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 47.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.1pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Complete and Voluntary Agreement</u><font style="font-size:12pt;">: This Agreement, together with Exhibits A, B, C and D hereto, and any agreements between you and the Company concerning your equity interests in the Company (as modified herein), constitute the entire agreement between you and the Company with respect to the subject matter hereof and supersedes all prior negotiations and agreements, whether written or oral, relating to such subject matter. You acknowledge that neither the Company nor its agents or attorneys have made any promise, representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this Agreement for the purpose of inducing you to execute the Agreement, and you acknowledge that you have executed this Agreement in reliance only upon such promises, representations and warranties as are contained herein, and that you are executing this Agreement voluntarily, free of any duress or coercion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severability</u><font style="font-size:12pt;">: The provisions of this Agreement are severable, and if any part of it is found to be invalid or unenforceable, the other parts shall remain fully valid and enforceable. Specifically, should a court, arbitrator, or government agency conclude that a particular claim may not be released as a matter of law, it is the intention of the parties that the general release, the waiver of unknown claims and the covenant not to sue above shall otherwise remain effective to release any and all other claims provided that the Company timely provides you with all payments and other consideration described in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.1pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">15.</font></font><font style="color:#010000;font-size:12pt;">&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Modification; Counterparts; Electronic/PDF Signatures</u><font style="font-size:12pt;">: &#160; It is expressly agreed that this Agreement may not be altered, amended, modified, or otherwise changed in any respect except by another written agreement that specifically refers to this Agreement, executed by authorized representatives of each of the parties to this Agreement. This Agreement may be executed in any number of counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Execution of an electronic or PDF copy shall have the same force and effect as execution of an original, and a copy of a signature will be equally admissible in any legal proceeding as if an original.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">16.</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law</u><font style="font-size:12pt;">: This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">17.</font></font><font style="color:#010000;font-size:12pt;">&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effective Date</u><font style="font-size:12pt;">: This Agreement is effective on the date it is signed by both parties (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.1pt 0pt;"><font style="font-size:12pt;">If you agree to abide by the terms outlined in this Agreement, please sign and return it to me by October 30, 2021. I wish you the best in your future endeavors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 48pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.95pt 128.75pt;"><font style="font-size:12pt;">[</font><i style="font-size:12pt;font-style:italic;">Remainder of page left blank intentionally; signature page follows</i><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.95pt 128.75pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Sincerely,</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">PASSAGE BIO, INC.</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By: /s/ Bruce Goldsmith</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Bruce Goldsmith, PhD.</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">President and Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 300pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">READ, UNDERSTOOD AND AGREED</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:26.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:39.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jill Quigley</font></p></td><td style="vertical-align:top;width:26.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48.25pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date: </font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><font style="font-size:11pt;">10/30/2021</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jill Quigley</p></td><td style="vertical-align:top;width:26.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:39.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:26.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:39.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.25pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AMENDED AND RESTATED EMPLOYMENT AGREEMENT EFFECTIVE </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NOVEMBER 12, 2018 (AS AMENDED NOVEMBER 12, 2018)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[*]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.25pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EMPLOYEE INVENTION ASSIGNMENT, CONFIDENTIALITY, AND NON- COMPETITION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">(As Amended by Section 6 of this Agreement)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.3pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">COMMUNICATIONS REGARDING EMPLOYEE DEPARTURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[*]</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>pasg-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:17:57 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the registration statements (Nos. 333-236734, 333-253922, and 333-258000) on Form S-8 and the registration statement (No. 333-253955) on Form S-3 of our report dated</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;"> </sup><font style="font-family:'Times New Roman','Times','serif';">March 3, 2022, with respect to the financial statements of Passage Bio, Inc. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 3, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>pasg-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:18:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Bruce Goldsmith, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">I have reviewed this Annual Report on Form 10-K of Passage Bio, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><div style="margin-top:8pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 3, 2022</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:49.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Bruce Goldsmith</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bruce Goldsmith, Ph.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>pasg-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:18:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Simona King, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">I have reviewed this Annual Report on Form 10-K of Passage Bio, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 3, 2022</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>pasg-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:18:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Bruce Goldsmith, Chief Executive Officer of Passage Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Annual Report on Form&#160;10-K&#160;of the Company for the fiscal year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 3, 2022&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;/s/ Bruce Goldsmith</p></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bruce Goldsmith, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>pasg-20211231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/3/2022 12:18:07 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Simona King, Chief Financial Officer of Passage Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Annual Report on Form&#160;10-K&#160;of the Company for the fiscal year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 3, 2022</p></td><td colspan="2" style="vertical-align:top;width:50.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer and</i></p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Principal Accounting Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pasg-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q \L# 2(  A$! Q$!_\0
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M?#LGB;Q%!9 'R =\[8^Z@Z_GTH*A%SDHKJ>K_"#2+RP\.RWEQ(ZQ7;[HH3T
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M[!X@_P"A@M__  6+_P#%T?8/$'_0P6__ (+%_P#BZVJJ#5+!KK[*MW$9P<%
M2<'TSTS[9S1<+%#[!X@_Z&"W_P#!8O\ \71]@\0?]#!;_P#@L7_XNK[:G8I9
M/>M=Q"U0D-+GY00<$?G3$UC37LI+P7T MHR1)*S;0A]#G&*+A8I_8/$'_0P6
M_P#X+%_^+H^P>(/^A@M__!8O_P 76O#-'<0I-"X>-U#*R]&![BGT7"R,7[!X
M@_Z&"W_\%B__ !='V#Q!_P!#!;_^"Q?_ (NMJBBX6,7[!X@_Z&"W_P#!8O\
M\71]@\0?]#!;_P#@L7_XNMJBBX6**^$;5U#274[.>6("@$_3'%+_ ,(?9?\
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M,M)+$B[O0/3<O'_CM)_PK'2O^?V]_-/_ (FHO^%M>'O^>-__ -^5_P#BJ/\
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M*?T;_H(:A^:?_$T?\*?T;_H(:A^:?_$UW?VN/T;\J/M<?HWY4^2/8W^HX?\
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M@@9KI***0!1110 4444 %%%% !4<_P#J7^E25'/_ *E_I0!B:B+AM,NA:_\
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M0NH8+N()&<>OTJ,7MJTB1BYA+N 542#)!]!GF@ \NX_Y[K_W[_\ KT>7<?\
M/=?^_?\ ]>I#-$)EA,B"5AD)N&2/7%(D\4DCQI(C.GWE# E?J.U #/+N/^>Z
M_P#?O_Z]'EW'_/=?^_?_ ->IZ* (/+N/^>Z_]^__ *]'EW'_ #W7_OW_ /7J
M>FLZH 68*"<<G'- $7EW'_/=?^_?_P!>CR[C_GNO_?O_ .O4JNK%@K E3@@'
MI22RQP1/+-(L<:#<SL< #U)H C\NX_Y[K_W[_P#KT>7<?\]U_P"_?_UZ=)=6
M\,'GRSQI#P?,9@%YZ<U+0!!Y=Q_SW7_OW_\ 7H\NX_Y[K_W[_P#KU/4+7=NL
MS0M/$)5 8H7&0"< X^M ">7<?\]U_P"_?_UZ/+N/^>Z_]^__ *]3T4 0>7<?
M\]U_[]__ %Z/+N/^>Z_]^_\ Z]3T4 0>7<?\]U_[]_\ UZ/+N/\ GNO_ '[_
M /KU/10!!Y=Q_P ]U_[]_P#UZ/+N/^>Z_P#?O_Z]3T4 0>7<?\]U_P"_?_UZ
M/+N/^>Z_]^__ *]3T4 0>7<?\]U_[]__ %Z/+N/^>Z_]^_\ Z]3T4 0>7<?\
M]U_[]_\ UZ/+N/\ GNO_ '[_ /KU/10!!Y=Q_P ]U_[]_P#UZ9,DXB;,R]/^
M>?\ ]>K51S_ZE_I0!E[9?^>H_P"^/_KT;9?^>H_[X_\ KT^F>=$)O),L?FXS
MY>\;L?3K0 ;9?^>H_P"^/_KT;9?^>H_[X_\ KT[>NXKN7<!DC/./I2!T*;PZ
ME?[V1C\Z $VR_P#/4?\ ?'_UZ-LO_/4?]\?_ %Z(Y8YDWQ2)(A_B1@P_,4^@
M!FV7_GJ/^^/_ *]&V7_GJ/\ OC_Z]/HH 9ME_P">H_[X_P#KT;9?^>H_[X_^
MO3Z* +JQS[1^_7I_SS_^O2^7<?\ /=?^_?\ ]>LO6/%>C>'PB:A>!)67(B12
M[8]<#I6/_P +1\,?\_%Q_P" [5+DENS&6(I0=I22?J=9Y=Q_SW7_ +]__7H\
MNX_Y[K_W[_\ KUR?_"T?#'_/Q<?^ [4?\+1\,?\ /Q<?^ [4<\>Y/UNA_.OO
M.L\NX_Y[K_W[_P#KT>7<?\]U_P"_?_UZY/\ X6CX8_Y^+C_P':C_ (6CX8_Y
M^+C_ ,!VHYX]P^MT/YU]YUGEW'_/=?\ OW_]>CR[C_GNO_?O_P"O7)_\+1\,
M?\_%Q_X#M1_PM'PQ_P _%Q_X#M1SQ[A];H?SK[SK/+N/^>Z_]^__ *]'EW'_
M #W7_OW_ /7KD_\ A:/AC_GXN/\ P':C_A:/AC_GXN/_  ':CGCW#ZW0_G7W
MG6>7<?\ /=?^_?\ ]>CR[C_GNO\ W[_^O7)_\+1\,?\ /Q<?^ [4?\+1\,?\
M_%Q_X#M1SQ[A];H?SK[SK/+N/^>Z_P#?O_Z]'EW'_/=?^_?_ ->N3_X6CX8_
MY^+C_P !VH_X6CX8_P"?BX_\!VHYX]P^MT/YU]YUGEW'_/=?^_?_ ->CR[C_
M )[K_P!^_P#Z]<G_ ,+1\,?\_%Q_X#M1_P +1\,?\_%Q_P" [4<\>X?6Z'\Z
M^\ZSR[C_ )[K_P!^_P#Z]'EW'_/=?^_?_P!>N3_X6CX8_P"?BX_\!VH_X6CX
M8_Y^+C_P':CGCW#ZW0_G7WG6>7<?\]U_[]__ %Z/+N/^>Z_]^_\ Z]<G_P +
M1\,?\_%Q_P" [4?\+1\,?\_%Q_X#M1SQ[A];H?SK[SK/+N/^>Z_]^_\ Z]'E
MW'_/=?\ OW_]>N3_ .%H^&/^?BX_\!VH_P"%H^&/^?BX_P# =J.>/</K=#^=
M?>=9Y=Q_SW7_ +]__7H\NX_Y[K_W[_\ KUR?_"T?#'_/Q<?^ [4]/B=X7<'-
MY*O^];O_ (4<\>X?6J'\Z^\ZGR[C_GNO_?O_ .O1Y=Q_SW7_ +]__7KF/^%F
M>%O^?]_^_#_X4?\ "S/"W_/^_P#WX?\ PHYH]Q_6:/\ .OO1T_EW'_/=?^_?
M_P!>CR[C_GNO_?O_ .O7,?\ "S/"W_/^_P#WX?\ PH_X69X6_P"?]_\ OP_^
M%'-'N'UFC_.OO1T_EW'_ #W7_OW_ /7H\NX_Y[K_ -^__KUS'_"S/"W_ #_O
M_P!^'_PH_P"%F>%O^?\ ?_OP_P#A1SQ[A]9H_P Z^]'3^7<?\]U_[]__ %Z/
M+N/^>Z_]^_\ Z]<Q_P +,\+?\_[_ /?A_P#"C_A9GA;_ )_W_P"_#_X4<\>X
M?6:/\Z^]'3^7<?\ /=?^_?\ ]>CR[C_GNO\ W[_^O7,?\+,\+?\ /^__ 'X?
M_"C_ (69X6_Y_P!_^_#_ .%'/'N'UFC_ #K[T=/Y=Q_SW7_OW_\ 7H\NX_Y[
MK_W[_P#KUS'_  LSPM_S_O\ ]^'_ ,*/^%F>%O\ G_?_ +\/_A1S1[A]9H_S
MK[T=/Y=Q_P ]U_[]_P#UZ/+N/^>Z_P#?O_Z]<Q_PLSPM_P _[_\ ?A_\*/\
MA9GA;_G_ '_[\/\ X4<T>X?6:/\ .OO1T_EW'_/=?^_?_P!>CR[C_GNO_?O_
M .O7,?\ "S/"W_/^_P#WX?\ PH_X69X6_P"?]_\ OP_^%'-'N'UFC_.OO1T_
MEW'_ #W7_OW_ /7H\NX_Y[K_ -^__KUS'_"S/"W_ #_O_P!^'_PH_P"%F>%O
M^?\ ?_OP_P#A1S1[A]9H_P Z^]'3^7<?\]U_[]__ %Z/+N/^>Z_]^_\ Z]<Q
M_P +,\+?\_[_ /?A_P#"C_A9GA;_ )_W_P"_#_X4<T>X?6:/\Z^]'3^7<?\
M/=?^_?\ ]>CR[C_GNO\ W[_^O7+_ /"S/"W_ #_O_P!^'_PJ[I?CC0=8OEL[
M*Z>2=E+!3$PX')Y(HYEW&L12D[*2OZFWY=Q_SW7_ +]__7H\NX_Y[K_W[_\
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MG\::Q<V6C+!ILC)J%Y*L$!7J">I_*J]G>22>Y/M;1<I*UCH?+N/^>Z_]^_\
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M $!-._\  9/\*/\ A%?#_P#T!-._\!D_PH]D^X?V/4_F1\VT5])?\(KX?_Z
MFG?^ R?X4?\ "*^'_P#H":=_X#)_A1[)]P_L>I_,CYMHKZ2_X17P_P#] 33O
M_ 9/\*/^$5\/_P#0$T[_ ,!D_P */9/N']CU/YD?-M%?27_"*^'_ /H":=_X
M#)_A1_PBOA__ * FG?\ @,G^%'LF']CU/YD?-M%?27_"*^'_ /H":=_X#)_A
M1_PBOA__ * FG?\ @,G^%'LF']CU/YD?-M%?27_"*^'_ /H":=_X#)_A3?\
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MW%_*CR(O[@H SZ6K_DQ?W!2^3'_<% &?2U?\F/\ N"CR8_[@H H"EJ]Y4?\
M<%'E1_W!0!2KD[ETL?B3;37#"..ZLFBC=C@%P<XS7<^4G]T54U'1M-U>V^SW
M]G%/%G(#CH?4'J*NG)1>NS,ZL')*VZU.)U$ZA9^*=-M;;Q!=W#75P7DM3LVQ
MQ#D]!G';FFZK=W]YXZC.GZ:;]-*CRR><(P)'Z')]!78:7X:T;1G=]/L(H7<8
M9^68CTR235JTTFQL9;B6VMUC>X?S)6!)+MZG-:^UBMETM_5C'V$VM7;6_?\
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M'_"C-U_=A_[Z/^%3D@#)-(2 ,DXH AS=?W8?^^C_ (49NO[L/_?1_P *GHH
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M[_Z4?:8O[_Z4 -S=?W8?^^C_ (49NO[L/_?1_P *=]IB_O\ Z4?:8O[_ .E
M#<W7]V'_ +Z/^%&;K^[#_P!]'_"G?:8O[_Z4?:8O[_Z4 -S=?W8?^^C_ (49
MNO[L/_?1_P *=]IB_O\ Z4?:8O[_ .E #<W7]V'_ +Z/^%&;K^[#_P!]'_"G
M?:8O[_Z4?:8O[_Z4 -S=?W8?^^C_ (49NO[L/_?1_P *=]IB_O\ Z4?:8O[_
M .E #<W7]V'_ +Z/^%&;K^[#_P!]'_"G?:8O[_Z4?:8O[_Z4 -S=?W8?^^C_
M (49NO[L/_?1_P *=]IB_O\ Z4?:8O[_ .E #<W7]V'_ +Z/^%&;K^[#_P!]
M'_"G?:8O[_Z4?:8O[_Z4 -S=?W8?^^C_ (49NO[L/_?1_P *=]IB_O\ Z4?:
M8O[_ .E #<W7]V'_ +Z/^%&;K^[#_P!]'_"G?:8O[_Z4?:8O[_Z4 -S=?W8?
M^^C_ (49NO[L/_?1_P *=]IB_O\ Z4?:8O[_ .E #<W7]V'_ +Z/^%&;K^[#
M_P!]'_"G?:8O[_Z4?:8O[_Z4 -S=?W8?^^C_ (49NO[L/_?1_P *=]IB_O\
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M'"\-N"TF4WXP6"C&#R3T]ZZM[2VD\S?;Q-YF-^Y =V.F?7%,FT^RN XFM()
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M!_T"K;_OFE8^:Q&15*E64XS5F[ZGA_-'->X?\(GH'_0*MO\ OFC_ (1/0/\
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MB_[^'_XFC=<?\\HO^_A_^)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?_B:EHH
MBW7'_/*+_OX?_B:-UQ_SRB_[^'_XFI:* (MUQ_SRB_[^'_XFC=<?\\HO^_A_
M^)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?_B:EHH BW7'_/*+_OX?_B:-UQ_S
MRB_[^'_XFI:* (MUQ_SRB_[^'_XFC=<?\\HO^_A_^)J6B@"+=<?\\HO^_A_^
M)HW7'_/*+_OX?_B:EHH BW7'_/*+_OX?_B:-UQ_SRB_[^'_XFI:* (MUQ_SR
MB_[^'_XFC=<?\\HO^_A_^)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?_B:EHH
MBW7'_/*+_OX?_B:-UQ_SRB_[^'_XFI:* (MUQ_SRB_[^'_XFC=<?\\HO^_A_
M^)J6B@"+=<?\\HO^_A_^)J.9KCR6S%'T_P">A_\ B:LU'/\ ZE_I0!E9E_N)
M_P!]G_"C,O\ <3_OL_X5)10!'F7^XG_?9_PHS+_<3_OL_P"%28)[&B@"/,O]
MQ/\ OL_X49E_N)_WV?\ "I** (\R_P!Q/^^S_A1F7^XG_?9_PJ2B@"/,O]Q/
M^^S_ (49E_N)_P!]G_"I** +RM<;1^ZBZ?\ /0__ !-.W7'_ #RB_P"_A_\
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MU_.J*&[KC_GE%_W\/_Q-&ZX_YY1?]_#_ /$T[SH_[Z_G1YT?]]?SH ;NN/\
MGE%_W\/_ ,31NN/^>47_ '\/_P 33O.C_OK^='G1_P!]?SH ;NN/^>47_?P_
M_$T;KC_GE%_W\/\ \33O.C_OK^='G1_WU_.@!NZX_P">47_?P_\ Q-&ZX_YY
M1?\ ?P__ !-.\Z/^^OYT>='_ 'U_.@!NZX_YY1?]_#_\31NN/^>47_?P_P#Q
M-.\Z/^^OYT>='_?7\Z &[KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\ $T[SH_[Z
M_G1YT?\ ?7\Z &[KC_GE%_W\/_Q-&ZX_YY1?]_#_ /$T[SH_[Z_G1YT?]]?S
MH ;NN/\ GE%_W\/_ ,31NN/^>47_ '\/_P 33O.C_OK^='G1_P!]?SH ;NN/
M^>47_?P__$T;KC_GE%_W\/\ \33O.C_OK^='G1_WU_.@!NZX_P">47_?P_\
MQ-&ZX_YY1?\ ?P__ !-.\Z/^^OYT>='_ 'U_.@!NZX_YY1?]_#_\31NN/^>4
M7_?P_P#Q-.\Z/^^OYT>='_?7\Z &[KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\
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M%=__ ,(WI7_/K_X\?\:3_A&=*_Y]S_WV:GZK/N3]5GW.!HKOO^$9TK_GW/\
MWV:/^$9TK_GW/_?9H^JS[A]5GW.!HKOO^$9TK_GW/_?9H_X1G2O^?<_]]FCZ
MK/N'U6?<X&NST@8TJW_W:M'PQI1_Y8,/HYJ]#I]O;PK%&K!%& -V:VH494Y7
M9M0HRIRNRI15[[)%[_G1]DB]_P ZZ3I*-%7OLD7O^='V2+W_ #H HT5>^R1>
M_P"='V2+W_.@"C15[[)%[_G1]DB]_P Z *-%7OLD7O\ G1]DB]_SH HT5>^R
M1>_YT?9(O?\ .@"C15[[)%[_ )T?9(O?\Z *-%7OLD7O^='V2+W_ #H HT5>
M^R1>_P"='V2+W_.@"C15[[)%[_G1]DB]_P Z *-%7OLD7O\ G1]DB]_SH HT
M5>^R1>_YT?9(O?\ .@"C15[[)%[_ )T?9(O?\Z *-%7OLD7O^='V2+W_ #H
MHT5>^R1>_P"='V2+W_.@"C15[[)%[_G1]DB]_P Z *-%7OLD7O\ G1]DB]_S
MH HT5>^R1>_YT?9(O?\ .@"C15[[)%[_ )T?9(O?\Z *-%7OLD7O^='V2+W_
M #H HT5>^R1>_P"='V2+W_.@"C15[[)%[_G1]DB]_P Z *-%7OLD7O\ G1]D
MB]_SH HT5>^R1>_YT?9(O?\ .@"C15[[)%[_ )T?9(O?\Z *-%7OLD7O^='V
M2+W_ #H HT5>^R1>_P"='V2+W_.@"C15[[)%[_G1]DB]_P Z *-%7OLD7O\
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M* (_,;_GB_YK_C1YC?\ /%_S7_&I** (_,;_ )XO^:_XT>8W_/%_S7_&I**
M(_,;_GB_YK_C1YC?\\7_ #7_ !J2B@"\LS[1_H\O3U7_ !IWG2?\^TOYK_C2
M27$-O&K32I&"."[ 5%_:EA_S^0?]_!2<DA.26[)O.D_Y]I?S7_&CSI/^?:7\
MU_QJ'^U+#_G\@_[^"C^U+#_G\@_[^"ES1[BYH]R;SI/^?:7\U_QH\Z3_ )]I
M?S7_ !J'^U+#_G\@_P"_@H_M2P_Y_(/^_@HYH]PYH]R;SI/^?:7\U_QH\Z3_
M )]I?S7_ !J'^U+#_G\@_P"_@H_M2P_Y_(/^_@HYH]PYH]R;SI/^?:7\U_QH
M\Z3_ )]I?S7_ !J'^U+#_G\@_P"_@JQ'+'-&)(W5T/1E.0:::>PTT]AOG2?\
M^TOYK_C1YTG_ #[2_FO^-2T4QD7G2?\ /M+^:_XT>=)_S[2_FO\ C4M% $7G
M2?\ /M+^:_XT>=)_S[2_FO\ C4M% $7G2?\ /M+^:_XT>=)_S[2_FO\ C4M%
M $7G2?\ /M+^:_XT>=)_S[2_FO\ C4M&: (O.D_Y]I?S7_&CSI/^?:7\U_QJ
M7(]:,CUH B\Z3_GVE_-?\:/.D_Y]I?S7_&I<CUHR/6@"+SI/^?:7\U_QH\Z3
M_GVE_-?\:ER/6DR/44 1^=)_S[2_FO\ C1YTG_/M+^:_XU)D>HHR/44 1^=)
M_P ^TOYK_C1YTG_/M+^:_P"-29'J*,CU% $?G2?\^TOYK_C1YTG_ #[2_FO^
M-29'J*,CU% $?G2?\^TOYK_C1YTG_/M+^:_XU)N'J*-P]10!'YTG_/M+^:_X
MT>=)_P ^TOYK_C4FX>HHW+ZC\Z (_.D_Y]I?S7_&CSI/^?:7\U_QJ3<OJ/SH
MW+ZC\Z (_.D_Y]I?S7_&CSI/^?:7\U_QJ3<O]X?G1N7^\/SH C\Z3_GVE_-?
M\:/.D_Y]I?S7_&I-R_WA^=&]?[P_.@"/SI/^?:7\U_QH\Z3_ )]I?S7_ !J3
M>O\ >'YT;U_O#\Z (_.D_P"?:7\U_P :/.D_Y]I?S7_&G[U_O#\Z-Z_WA^=
M#/.D_P"?:7\U_P :/.D_Y]I?S7_&G[T_O#\Z-Z?WE_.@!GG2?\^TOYK_ (T>
M=)_S[2_FO^-/WI_>7\Z/,3^^OYT ,\Z3_GVE_-?\:/.D_P"?:7\U_P :?YB?
MWU_.CS$_OK^= #/.D_Y]I?S7_&CSI/\ GVE_-?\ &G[T_O+^=&]/[R_G0 SS
MI/\ GVE_-?\ &CSI/^?:7\U_QI^]/[R_G1O3^\OYT ,\Z3_GVE_-?\:/.D_Y
M]I?S7_&G[T_O+^=&]?[P_.@!GG2?\^TOYK_C1YTG_/M+^:_XU)O7^\/SHWK_
M 'A^= $?G2?\^TOYK_C1YTG_ #[2_FO^-2;U_O#\Z-R_WA^= $?G2?\ /M+^
M:_XT>=)_S[2_FO\ C4FY?[P_.C<OJ/SH C\Z3_GVE_-?\:/.D_Y]I?S7_&I-
MR^H_.C<OJ/SH C\Z3_GVE_-?\:/.D_Y]I?S7_&I-P]11N'J* (_.D_Y]I?S7
M_&CSI/\ GVE_-?\ &I,CU%&1ZB@"/SI/^?:7\U_QH\Z3_GVE_-?\:DR/44N:
M &HQ9<E"A]#C^E.HHH *\^UO_D-77^__ $KT&O/M;_Y#5U_O_P!* /0:***
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MV"C]:K_VSI7_ $$K/_O^O^-%T)M+=F9_PED?_0%US_P7O1_PED?_ $!=<_\
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MRQKMRZ#=TR1S1H&I@_\ "61_] 77/_!>]'_"61_] 77/_!>];D5S!."89HY
MO!V,#C\JP-)\0W%_XOUO2)8H5@L!$8W7.YMPR<\T[#LQ_P#PED?_ $!=<_\
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M *^\X0^([S5=?T-'UG6OLUQH\5RQT:UW!YC)M9G78Q5>H[8J].-4TWQ7K?\
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M4X],F6!99@R*(KD.ZOM)Y7' XZYS["KL?ARP1XI&$TDT<PG\Z24EV<# )/?
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M_P")H_X5!H?_ #^ZA_WVG_Q-'LI!_9>)\OO/%L#T'Y48'H/RKVG_ (5!H?\
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M\\IO^_9I?,%'F"@!/M(_YY3?]^S1]I'_ #RF_P"_9I?,%'F"@!/M(_YY3?\
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M!]K@_P">JT?:X/\ GJM3T4 0?:X/^>JT?:X/^>JU/10!!]K@_P">JT?:X/\
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M]K@_YZK4R_<'TI: (/M<'_/5:/M<'_/5:GHH @^UP?\ /5:/M<'_ #U6IZ*
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MM7M)VM[6)5EC<[B @&U#GH0*Z?1M-71]%L=-20R+:P)"'88+!1C./PIZ6?\
M7?\ X B]6-XFU.?2M,CFMY(8WDN(H3),N50.X4G&1T!]:V:S]8TF/6+6*WE?
M:B3QS'Y0P;8P;!!['%(9DZ7XEFDLKN6[MWN!;W+0K/9PLR3* "7 R<8R0>3R
M#BI=0\46WV:XCL&EEN!9BZ1UB)148$JQ)XQQTJ76_#D>L) @F6.*)67R7B$D
M9!&,[<@;AV/;TJ&U\*1VMM- +MV$MA'8Y*#@(&&[ZG=TH>P+<CM?$\=S8:>Z
MW $CO!%-(;=F1W=02JD$#/OR!FK4'BS2YB#OFCC*R,LLD+*K["=X![D8-4[7
MP9%9P6UM#?2+:V\T4Z0[!A70?-CT#=2.QSZU9MO#"VT-BB7;$VC3,I,8.[S-
MW4>V[]*;!>99/B"U%G#<>5<[IVQ##Y)\R3C.5'<8YS4+>+-- B\L7,KR([B.
M.!BR[" X([$$]#56W\)&U5);>]$5W'.TT96 "%-R[641YX!'/!Z\U/:^%HK:
MZ2X%T[2>5,LA*CYVD();VQC@4@%.LM#<"]DF\VPNEC2RAACW/*Q!8MZ],<'T
M-:5[J5O86BW$^\!R%1 A+LQZ*%ZYJA/X?\WP];Z2)HV2&-8RTT D# #&<9&#
MW!!XJ6[T,7&E6EHMU*)K1D>&XD^=MR="P_BSWIL#(L/$\DMQ,;F<0Q#4&@5)
M;9MVP1AMO!&TYR<G-:P\1V9LHKD17)\]L01B$[Y>,@J.XQSFJ<?A7;.D[W[O
M*+PW;'R@ 6*;,8]*K-X'MY(]TDT+S"?ST1K4&!3@J?W6<<@\X(YYI= -:7Q%
M91V*7H6XDMSG>Z0D^5@X.[TP>HZT]=>L6GGC5W*6Z[I9@A\M.,X+>N.:Q]1\
M$P7]K';B>**(1-&8UM5\M23G>B9 5O?FI[CPC#>7"M<7 ,0MS 1'$$=U*[<.
MV?F'< CKWH T].UFUU*1XXA+'(JAPDT90LAZ, >QK1K&T+P_#HJML2UW%0@>
M&U6)BHZ;B,DG\A[5LT, HHHH **** "BBB@ J.?_ %+_ $J2HY_]2_TH RY9
M!%"\C=$4L?P%<?#XJO5LC=R2V5Q&;62X81+C[/@_(&(8YSQZ&NLO;?[993VP
MD,?FH4W@9QGVJG/HEO+HZ:;$5@B&P,8XP-P7'4>^* .>/BV\@TF[O'FL[F&%
M(]MS'$502,1N3&X[L>QJSJ'B#5H-/AO+>WM_])D'D0R*2WE 99C@]2.0.U:,
MWAV*>\EE>X8PRW*7#P% 5)48QGWI;3P\EJ]J&NGEAM?,$4;(.%?MG/.!D4 2
MZ;JC:C?70CV&UC2,H0/F+,,G-:E9>AZ+'H=K+!'.\WF2M)N< $ ]%X["M2@
MHHHH **** .7UW4KF>^DA\QTBC.T(#@?4UD[W_OM_P!]&NXU+PY;ZBXG61H9
M2!N(&0?PK/\ ^$,_Z??_ !RN"I0J.3>YP5*%1R;W.7WO_?;_ +Z-&]_[[?\
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M?WV_.CS)/[[?G4_V-_[RT?8W_O+0!!YDG]]OSH\R3^^WYU/]C?\ O+1]C?\
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M\C&?;FN+HH<%>XN9A1115DA1110 4444 %=IIO\ R#;?_<%<77::;_R#;?\
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M 'V*FHH A^U6_P#SWB_[[%'VJW_Y[Q?]]BIJ* (?M5O_ ,]XO^^Q3)KJW,+
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MG8L<#N3FJ5[ZB=K#****HD**** "BBB@ HHHH **** "BBB@ KM--_Y!MO\
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MS"BBBF(**** "BEXV^])23N1&?,VK-6_K0EMK::\N$M[>)I9I#A44<DU8O\
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M_K8J_NV+VL>&M/T>[L-/>>::\N9QN92 J1%L#C'WC5FY\,:')=:EIMA=7O\
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M$DFD^;=D;5L9"[2'N6]/I2?,AJS,75]$T/3C9VRRWYN[E(Y"0 ZH#UX R3Z
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M!^==/HVFKH^B6.FK(95M8$A#D8+!1C./PJS]JM_^>\7_ 'V*/M5O_P ]XO\
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M_P!]B@"6BHOM5O\ \]XO^^Q1]JM_^>\7_?8H EHJ+[5;_P#/>+_OL4?:K?\
MY[Q?]]B@"6HY_P#4O]*3[5;_ //>+_OL5'-<VYA8">/I_?% &=<0)=6TL#DA
M)$*'!P<$5DP^'W$4$=Q?&46T316VV$)LR,;CR=S8^@]JU_/B_P">J?\ ?0H\
M^+_GJG_?0H P[GPK%<01Q&[D7RK98(SL!P0P.XC/.2.E/7PZS7#7$]^\DKW"
M7#GR@ =HP% SP._>MGSXO^>J?]]"CSXO^>J?]]"BX&"_A;?++<?;%2Y>9)@8
M[<+'N7H63=R3W.14]]X>_M%I9+B\8RO$L898@ I5MV<9YY[?K6OY\7_/5/\
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MI):6DUTBR11),7^5@",DJ,=<>E69/$&DPW36TFH6ZS(VQD+\JV,X/H<'I0]
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MBX%:C ]*L_V?>_\ /E<_]^6_PH_L^]_Y\KG_ +\M_A1<"M15G^S[W_GRN?\
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MPT['-2>#IFE0M()HY;.*UN(S=2Q+\@(R GW@<G@X^M67\,7#23$30A7U.*\
M(/W$"#'U^6MS^UM._P"?^U_[_+_C1_:VG?\ /_:_]_E_QIZWN+0Y&31]2T_Q
M)9M;K!,TMQ=S@OO"*K(  6 .#QZ&K=MX4OM.C=+:>VF^TVQ@G,P8!,LS90 '
M(^<C:<=!S71_VMIW_/\ VO\ W^7_ !H_M;3O^?\ M?\ O\O^-'2P[F';^&KZ
MPAU%+&^2.2:""*"4K\P\M2.?KZCI5:S\)WT-XMQ+<1_\A!+LJ99)2%";2N]N
M2<_2NE_M;3O^?^U_[_+_ (T?VMIW_/\ VO\ W^7_ !HN[W%H8VM^&9M6U":=
M;B.-'M/)4$$G>'##/^SQ@U!>>'-2OKDZA(]G'=F:!_*!9H]L3%NN 23GTX]Z
MZ#^UM._Y_P"U_P"_R_XT?VMIW_/_ &O_ '^7_&D.YS,OA&\EN1J#3K]J:>25
MX(KF2%,,H7 =1NXV]<<^U:=]X;6Y\+KH\+_9]FUE*R.0"&W8W$[NO?.:T_[6
MT[_G_M?^_P O^-']K:=_S_VO_?Y?\: N<E?:-=V-QI<L%LANY-0623=/-..$
M(RSMR/KCCWJ6;P;>RQY^TP"207#2#YMJM*, +[#%=1_:VG?\_P#:_P#?Y?\
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MT[_G_M?^_P O^-']K:=_S_VO_?Y?\: (_L\O]PT?9Y?[AJ3^UM._Y_[7_O\
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MT_[_ *_XT?;]-_Y_[3_O^O\ C0 G]IW?_/F/^^Z/[3N_^?,?]]TOV_3?^?\
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MH_M.[_Y\Q_WW2_;]-_Y_[3_O^O\ C1]OTW_G_M/^_P"O^- "?VG=_P#/F/\
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ML*3UYY.,#I5VG=DIQE>W0R_^$9T'_H":;_X"1_X4?\(SH/\ T!--_P# 2/\
MPK4I"P! ) SP/>B['9&9_P (SH/_ $!--_\  2/_  H_X1G0?^@)IO\ X"1_
MX5J49HNPLC+_ .$9T'_H":;_ . D?^%'_",Z#_T!--_\!(_\*TO,3:&WKM)P
M#GCTIU%V%D9?_",Z#_T!--_\!(_\*/\ A&=!_P"@)IO_ ("1_P"%:E&:+L+(
MR_\ A&=!_P"@)IO_ ("1_P"%'_",Z#_T!--_\!(_\*TU964,I!!Z$<TM%V%D
M9?\ PC.@_P#0$TW_ ,!(_P#"C_A&=!_Z FF_^ D?^%:E%%V%D9?_  C.@_\
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M_ 2/_"LZY\;V$.J3V$-EJ-VUNP6>6VM]Z1$^O.?R%2:QXPMM'F>-]-U2X2)
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M#ZU9CM=9U:ZT:&[THV,6G.LLLK3*P=E& $QS@^^*[*BE<?*%%%%(85Y]K?\
MR&KK_?\ Z5Z#7GVM_P#(:NO]_P#I0!Z#1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GVM_P#(
+:NO]_P#I110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pasg-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& ZP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT >QZ5JMCK>FPZCIMPMQ:3 F.500&&<=^:N5POP=_P"25Z)_US;_ -#-=U0
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MDQN@P5/&,@%<=34?C36KS5M/\3-?>)/L[6NJ)9P:-M0!XP5(;!&XDY/(XXH
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MG96FG6J6MC:PVUM&,)#!&$1?H!P*GHHH **** "BBB@ HHHH **** "BBB@
MHHHH *PO&/\ R*]S_P!=(?\ T:E;M87C'_D5[G_KI#_Z-2JC\2$]C=HHHJ1A
M1110 445"MW;/=26R7$37$2AI(@X+H#G!(Z@'!_*@":BJECJFGZFLC:??6UV
ML;;7-O,L@4^AP3@U;H **** "BBB@ JM?Z=8ZI;&VU"RM[N G)BN(ED4_@01
M5FB@"@VB:2^F#3'TNR:P P+4VZ&(?\ QC]*6/1=*BM[:WCTRR2"UD$MO&L"A
M8G (#(,84\GD>IJ]10!0O-#TG4;E+F^TNRN9T4HLL]NCLJGJ 2,@4_\ LC3
MQ;^SK3<T'V4GR%R8>?W?3[G)^7IR:N44 4H](TR%[5XM.M$>T0I;,L"@PJ>H
M3CY0<#@5D:IX+TO6O%,&MZE#%=B&S:T%I<0K)&<N&W88'D8KI** (TMXHK<6
M\,:Q1*NU4C&T*/8#I7GNC?"#2](U^UU,7\LPM9FGAC-O$C[CG[\JJ'<<]&)K
MT:B@#+A\,Z#;SF>#1--BF._,B6D:M\XPW('<<'UJ_;6MO96T=M:0106\2[8X
MHD"J@] !P!4M% !1110 4444 %%%% !1110 444F1G&1GTH 6BDR <9&:6@
MK"\8_P#(KW/_ %TA_P#1J5NUA>,?^17N?^ND/_HU*J/Q(3V-VBBBI&%%%% !
M114'VRU^V_8OM,/VOR_-\C>/,V9QNV]<9XSTS0!/16;_ ,)%H?EW<G]LZ?LL
MVVW3?:DQ <XPYS\ISQSWJ];W$-U;QW%O-'-#(H9)(V#*P/0@C@B@"2BBB@#-
MC\/Z+%J#W\>CZ>E[("'N%MD$C9ZY;&3FBU\/:)8QW$=IH^GVZ7*E9UBMD02@
M\$, /F!]ZTJ* (K:VM[.VCMK6"."")0L<42!50#L . *K:EHFDZRJ+JFF65\
MJ'*BZMTE"_3<#BKU% %--)TV)K5H]/M$-H"+<K"H\D'KLX^7/M3!HFDBVDMA
MI=EY$DOGO%]G3:TF<[R,8+9 .>N:OT4 9%YX5\.ZC>F]O=!TNYNFQF>>SC=S
MCI\Q&>*U'BCDB,3QHT9&THPR"/3%/HH S;#P]HFE/(^G:/I]FTHQ(;>V2,N/
M?:!FF6WAG0+,L;70]-@+HT;&*TC7<K?>4X'0X&1WK5HH RK[PYI=]IYM#9P0
MA;5[6"6&)5>WC9=A$9Q\G''%<EX:^$FD^']2%Y+<"]"V[VRPM:0Q(T;##"0(
MH\S(X^;->A44 4H=(TRWF6:'3K2*5(!;*Z0*I$77RP0/N\#Y>E1V>@:-IWG_
M &'2;"U\_/G>1;(GF9_O8'/XUHT4 9D/AS0K>U^RPZ+IT5N91-Y26J*GF#D-
M@#&X>O6EN?#NB7EU)=76C:?/<2J%DEEM49W Z DC)%:5% %"ZT+2+V^BOKO2
MK&>[B_U<\MNC2)]&(R*<FC:7'J;:FFFV:Z@PVM=+ HE(]"^,_K5VB@ HHHH
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M+Q%_V#+G_P!%-6[7->/K&TN_ ^N27-M#,\&G7+Q-(@8HWEMR,]#Q0!TM%%%
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M/YBC<W_/,_F*?10 S<W_ #S/YBC<W_/,_F*?10 S<W_/,_F*-S?\\S^8I]%
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M:H&G=7"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1YT?_/1/^^A53^R;0=!+_P!_G_QI?[*MNQG'_;9O\:#LO4[+[_\ @%KSH_\
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MH_\ GHG_ 'T*?10*,5%6BK(9YT?_ #T3_OH4>='_ ,]$_P"^A3Z*"AGG1_\
M/1/^^A1YT?\ ST3_ +Z%/HH 9YT?_/1/^^A1YT?_ #T3_OH4^B@!GG1_\]$_
M[Z%'G1_\]$_[Z%/HH 9YT?\ ST3_ +Z%'G1_\]$_[Z%/HH 9YT?_ #T3_OH4
M>='_ ,]$_P"^A3Z* &>='_ST3_OH4>='_P ]$_[Z%/HH 9YT?_/1/^^A1YT?
M_/1/^^A3Z* &>='_ ,]$_P"^A1YT?_/1/^^A3Z* &>='_P ]$_[Z%'G1_P#/
M1/\ OH4^B@!GG1_\]$_[Z%!FCP?WB?\ ?0I]!Z&@#SFM'0B%UF D@#YN3_NF
MLZM+0?\ D-0?\"_]!-=L_A9RQW1VE%%%<1U!6%XQ_P"17N?^ND/_ *-2MVL+
MQC_R*]S_ -=(?_1J54?B0GL;M%%%2,*X;5;WQ)H^MW=RFE6"Z>S92\ALY)Y-
MN!DR*CANW8'@"NYKSGQ=#JL&I2W&JZWIT>DROMM;6:YD@!&!D,$7+GKWQCM0
M!V/A[4O[6TE+O[=8WH9B!+9 A..Q!)(([@UIN2J,P4L0,A1W]JPO!TEM)X?0
MVB::D(D8 :=N\K_QX Y]:W)HEG@DA?.R12K8.#@C'6@#BK'QY<7RB.*Q@:XE
MGBMXU$K 12MNW1RY4%70(Q( /ZBNFT/4WU73VFEA$,\4TEO,BMN4.C%3@\9'
M&16.G@:U586;4;UKBV6%+6?$2M (\[0 $ /!(^8'@FMW2]-BTJQ%M$\DGSO(
M\DF-TCLQ9F. !DDGH* ,OQ%J>GI=:=8/?6RWK7L#BW,JB0KNZ[<YQ6]YT?\
MST3_ +Z%9>O_ .JT_P#Z_P"#_P!"K7H 9YT?_/1/^^A1YT?_ #T3_OH4^B@#
M(M9HK/6[FT,BB.Y7[3%SQN& X_53^)K4\Z/_ )Z)_P!]"N1^(/B:U\-6-E<L
MADOA/OMHQQG P^3V&&Q^(JAX*^)D?BC4#IUU9"VNRI>+8^Y9,#)'/0XH.?VT
M(S]FWJ=[YT?_ #T3_OH4>='_ ,]$_P"^A7F'Q!US58+JUD:,:?!%9W4R6UX2
MPNYD"E$!AE'S') &2>O!JU=:DS^._#SQL87FDQ<6T-X\LXW0D[9(2 $C4_QC
M/..F:#H/1?.C_P">B?\ ?0H\Z/\ YZ)_WT*?10 SSH_^>B?]]"CSH_\ GHG_
M 'T*?10 SSH_^>B?]]"CSH_^>B?]]"GT4 ,\Z/\ YZ)_WT*/.C_YZ)_WT*?1
M0 SSH_\ GHG_ 'T*/.C_ .>B?]]"GT4 ,\Z/_GHG_?0H\Z/_ )Z)_P!]"GT4
M ,\Z/_GHG_?0H\Z/_GHG_?0I]% #/.C_ .>B?]]"CSH_^>B?]]"GT4 ,\Z/_
M )Z)_P!]"CSH_P#GHG_?0I]07=[:Z?;M<7MS#;0*0#)-($49Z<GB@"?.1D45
M3EU;389K>&74+6.6YQY"/,H:7/3:,_-U[5<H **** "BBB@ HHHH ****  @
M$8/(KEQX8U.UB-EIWB&:VTXY"Q&!7>)3_"CGH.>,@XKJ*Y#Q-K]WIFI?9;&6
M._FDC&=*2W=I2#D;MZ?<!]6P..M '3V%E#IUA!90 B*! BY.3@>OO5BL'PIY
MT6G-;3:9?6!C(98KJ<3  CHC@DD#!X/(SZ5O4 %9'A?_ )%JP_ZY_P!36O61
MX7_Y%JP_ZY_U- $VN2,FCW"H2))0(4(Z@N=O]:GFF@TRR0$81 $CC4<L<8"@
M>M9VN7D45]IMN^3EVG**,EM@   ]2SK^1JY:6DKS_;;T*9R,1Q@Y$*^@]_4T
M&+DW)QCO^06EI*\PO;W!N",)&/NP@]AZGU-7Z**#2,5%604444%!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $4UU!;8\Z9(\]-QQFJEQ/
MI-^J17$EM, P95<@X8="*Q/$_P#R$(O^N0_F:Q*WC235S&<]XM:'HW;BBF1?
MZE/]T4^L#8*PO&/_ "*]S_UTA_\ 1J5NUA>,?^17N?\ KI#_ .C4JH_$A/8W
M:***D85QGB=(9/%&G(C:G%/(JPR3V=TL(1';"Y&"6^8=.U=G7G&J75OXRGM]
M-6SMCK$5Q,)-\DJ_8XHW(!?8RMEL+@9P<YZ"@#M=!D671X2DMQ)M+(6N7#N2
M&(.6'7I6E6-X4E67PW:;+>*W"!H_+ASLRK$97/.#C/XUJW$\5K;R7$[A(HE+
MNQZ #DF@"2N:\?/>+X'UP6T$$D9TZY$K23%"B^6W*@*=Q]B1]:V--U#^TH3,
M+6>!.-OG;,N#W 5CCZ'!]JS_ !M_R(7B+_L&7/\ Z*:@#=HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "JEQJEA:7#6]Q>0Q3+"9RCN 1&#@MCT!
M[U;KEO$WA.779Y[B&Z2"9K401,RD[3N;=GV*L10!NRZMI\"%Y;R%%!<$EQ_
M</\ D>M6+>XANK>.X@D62&10R.IR&![UR4O@K_2Y;I)Q++(]T[0W$\S1$2ON
M ";L(1ZJ <\TFH>&]3N-.TBQ?[/>&!9A,]RS%5R/DY^\Q7@!CR<9)R<T =BS
M*N-S 9.!D]338I4FB62-@R,,AAWKA1X#O6U*:ZN+JTNE,T<J1RQ* Q5LY;:@
M.<$\DL?<4QO &HO?"9]79H_),9 (&/E(QG9N*\YQO SSC(H [_<N_9N&[&<9
MYQ2GH:YC3?"::9K\=_#':^2BR(B[2&B5L$!/QW9^M=.>AH \YK2T'_D-0?\
M O\ T$UFUI:#_P AJ#_@7_H)KMG\+.6.Z.THHHKB.H*PO&/_ "*]S_UTA_\
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MJQ_OS?\ @/)_\30'MJ?\R^\T**H?VU8_\])/^_#_ .%']M6'_/5_^_+_ .%
M>VI_S+[R_15#^VK#_GLW_?IO\*/[:T__ )[_ /CC?X4![:G_ #+[R_15#^VM
M._Y^1_WRW^%']M:=_P _2_D?\* ]M3_F7WE^BJ']M:;_ ,_:?K1_;6F_\_D7
MYT![:G_,OO+]%4/[;TS_ )_8?^^J/[;TS_G^@_[[% >VI_S+[R_15#^V]+_Z
M"%M_W\%']MZ7_P!!&U_[^K0'MJ?\R^\M7(G-NXM6C6?'R-*I90?< @G\Z\YB
ME\16G@)4U.PEO]4GNIH(&:TEE>V5W=3*_P!YMH0\;1D@@=#FN\_MO2O^@E:?
M]_E_QJEJOBK2]-T^2X2ZAN)!PL44@8D_AT'O03+$4H1<G)61YIK?AN^^T:9;
MZ79ZC-:6]II\$<;VKJMX(ILE9"0/(V_>R=N1ZU[/7,>$O%G_  D*2Q3PB.ZB
M^8[ =I7/Z&NGH'0KPKP52F[IA1110:A1110 4444 %%%% !7G%Y<ZW;ZU>7"
M:UJ"07(4HD>AM+M4%A@GL1Z]^M>CUP?B/48FUM?[.N8[2Y,:EKZ74Q%"0">/
M+&[>001]T?6@#KM&C$6C6B"6XE"Q ;[A=LC>[#L:O55TQI&TRV:6ZCNI#&-T
M\8PLA]0/2K5 $%W9P7UN8+A"\9() 8KT]Q6'X;O[2U\)V860,85\GRT^9MX/
MW<=<U>\1VVH7>B7$.F3"*Y(X]6'< ]B?6N!^'^F:A_:YOL>7:1;A(SC[QQT'
MO[T'GXC%U*=>%&$+\W7^NW4[/2;>6\UV^U*]53+$%MX4'(B&-S >_P P!/M7
M05F:""VE)<GK=,UQ^#'(_3%:=!V4HJ,0HHHH- HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH Y3Q/_ ,A&+_KD/YFL2MOQ/_R$8O\
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M6 CF9 W[MN& /S#V- '2T4SRQZM_WT:/+'JW_?1H ?13/+'JW_?1H\L>K?\
M?1H ?13/+'JW_?1H\L>K?]]&@!]%,\L>K?\ ?1H\L>K?]]&@!]%,\L>K?]]&
MCRQZM_WT: 'T4SRQZM_WT:/+'JW_ 'T: 'T4SRQZM_WT:/+'JW_?1H ?13/+
M'JW_ 'T:/+'JW_?1H ?13/+'JW_?1H\L>K?]]&@!]%,\L>K?]]&CRQZM_P!]
M&@!]%,\L>K?]]&CRQZM_WT: 'T'H:9Y8]6_[Z-!C&#RW_?1H \\K2T'_ )#4
M'_ O_036;6CH0SK, Y_BZ?[IKMG\+.6.Z.UHHHKB.H*PO&/_ "*]S_UTA_\
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M_P!]&CRQZM_WT: 'T4SRQZM_WT:/+'JW_?1H ?13/+'JW_?1H\L>K?\ ?1H
M?13/+'JW_?1H\L>K?]]&@!]%,\L>K?\ ?1H\L>K?]]&@!]%,\L>K?]]&CRQZ
MM_WT: 'T4SRQZM_WT:/+'JW_ 'T: 'T4SRQZM_WT:/+'JW_?1H ?1110 444
M4 %%%% !1110 4444 (<8.<8[YKF;SPIHL^&M+A].<2+*/LDVU-ZG<&\O[N<
MC/2NDEB2>)XI4#QN"K*>A![5YEXDT;2=/U=;:UT30+2U4)ON+RW)&6#D'((
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MM9I]/^RJJ1M:N5;8J[57/7 !K4L=)M=.=WMQ*&D^]NF=E)]0I.!D\\ 5=HH
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M_P"A5KT'+'"0CB'B+N[5O(****#J"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&R%.T9
M..!7GCW@U;0+62^\2M8+:I+_ &F5DB659@<A&5U/ .<#'(QBO0R0H))  Y)/
M:N+U75O",FJ6%^?[)NI#.R33B-970*IYR 2,-MY[9H Z+P]-<7'AW3Y;O=Y[
MP*7++M)XZD=JTZ9#-'<0I-"ZO&ZAE=3D$'H13Z (+Q+M[<K93P0SY&'FA,JX
M[_*&4_K6=X4##PMIP<@OY7S%1@$Y/0<XK8K(\+_\BU8?]<_ZF@#7HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E/$_
M_(1B_P"N0_F:Q*W/%"-]NB?!VF/&??)K$4%F"@9)X %=E/X4<T_B9Z%%_J4_
MW13Z;&,1(#UVBG5QG2%87C'_ )%>Y_ZZ0_\ HU*W:PO&/_(KW/\ UTA_]&I5
M1^)">QNT445(Q&)"D@9(' ]:YBY\2:Q9\W&@1Q(3A6DU"-0?SKJ*X#QA%I.I
M^5J;2VLSQR&WMTN+-IU:6-\LN ,[3AE.!V]J .STNZ:]TZ*X:%(6<$E$D#@<
M_P!X<&IKMHULYFEB>6,(2T:(7+#'0 <D^U97A&**+PO9+!+#)&5+ PH4098G
M"@\@#ISSQ6W0!S?A)4=+^[6TFLC<RJXM7M9(1$H4*!\RC+$#)(XR<=LE/'R7
MK>!]<-K/;QQC3KDS++"7+KY;<*0Z[3UY(/TKI:YOQ[>6MKX&UV.XN88GFTZY
M2)9) I=O*;@ ]3]* .AQ)_>7_OG_ .O1B3^\O_?/_P!>GT4 ,Q)_>7_OG_Z]
M&)/[R_\ ?/\ ]>GT4 ,Q)_>7_OG_ .O1B3^\O_?/_P!>GT4 ,Q)_>7_OG_Z]
M&)/[R_\ ?/\ ]>GT4 ,Q)_>7_OG_ .O1B3^\O_?/_P!>GT4 ,Q)_>7_OG_Z]
M&)/[R_\ ?/\ ]>GT4 ,Q)_>7_OG_ .O1B3^\O_?/_P!>GT4 ,Q)_>7_OG_Z]
M&)/[R_\ ?/\ ]>GT4 ,Q)_>7_OG_ .O1B3^\O_?/_P!>GT4 ,Q)_>7_OG_Z]
M&)/[R_\ ?/\ ]>GT4 ,Q)_>7_OG_ .O1B3^\O_?/_P!>GT4 ,Q)_>7_OG_Z]
M&)/[R_\ ?/\ ]>GT4 4FTRV=BS06Y8\DF/\ ^O4D-E%;MNABA1CQE8\?UJS1
M3NQ604444AA6%XQ_Y%>Y_P"ND/\ Z-2MVL+QC_R*]S_UTA_]&I51^)">QNT4
M45(PHHHH *1\;&W D8Y &:6B@#S)HDOICJ$.C7MO9+?6_GV!TV5"T";QO*E!
MO.]E8A<D*HZUV'A*WDM]$8/#)!$]U/)!#(A1HXFD8H-IY7Y2..W2MVB@#G_$
M27QN=.=+BV%G]M@S$8&,A;=UW[\8]MOXUNXD_O+_ -\__7K$\07MHL^G69NH
M1=-?0,(3(-Y&[KMZXK>H 9B3^\O_ 'S_ /7HQ)_>7_OG_P"O3Z* &8D_O+_W
MS_\ 7HQ)_>7_ +Y_^O3Z* &8D_O+_P!\_P#UZ,2?WE_[Y_\ KT^B@!F)/[R_
M]\__ %Z,2?WE_P"^?_KT^B@!F)/[R_\ ?/\ ]>C$G]Y?^^?_ *]/HH 9B3^\
MO_?/_P!>C$G]Y?\ OG_Z]/HH 9B3^\O_ 'S_ /7HQ)_>7_OG_P"O3Z* &8D_
MO+_WS_\ 7HQ)_>7_ +Y_^O3Z* &8D_O+_P!\_P#UZ,2?WE_[Y_\ KT^B@!F)
M/[R_]\__ %Z,2?WE_P"^?_KT^B@!F)/[R_\ ?/\ ]>C$G]Y?^^?_ *]/HH 9
MB3^\O_?/_P!>C$G]Y?\ OG_Z]/HH **** "BBB@ HHHH **** "BBB@"&\MD
MO;*>UD+!)HVC8J>0",5RL'AC7+2<2VVIZ:KBW%L'-@=QC'0'#XKL** ,;PWI
M=_H^FI97MY#<I$H6(QPF,@#KGDYK9HKS_P *2^;KMAY,A:]%K<_VTH8DK+YB
M>6'!Z-GS-O\ L@XXH ] K(\+_P#(M6'_ %S_ *FM"[-T(";-(6FR,"9BJX^H
M!-<WX<?7QX>LA';Z:4\O@M/(#U/^Q0!U=%9'F>(O^?;2_P#O_)_\11YGB+_G
MVTO_ +_R?_$4 :]%9'F>(O\ GVTO_O\ R?\ Q%59-1\01ZK;V!M-,+S02S!O
MM$F $:,$?<[^8/RH Z&BLCS/$7_/MI?_ '_D_P#B*/,\1?\ /MI?_?\ D_\
MB* ->BLCS/$7_/MI?_?^3_XBCS/$7_/MI?\ W_D_^(H UZ*YW2]2U_5-(LM0
M2STR-+J!)U1KB3*AE#8/R>]6_,\1?\^VE_\ ?^3_ .(H UZ*R/,\1?\ /MI?
M_?\ D_\ B*/,\1?\^VE_]_Y/_B* ->BN?_M'Q!_:GV#[)IF_R?.W?:),8W8Q
M]RK/F>(O^?;2_P#O_)_\10!KT5D>9XB_Y]M+_P"_\G_Q%'F>(O\ GVTO_O\
MR?\ Q% &O17.ZKJ6OZ5I%[J,EGILB6D$D[(MQ)E@JEL#Y/:K?F>(O^?;2_\
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M,4VLHB8FXD^8E%?(^3_:Q^% '045D>9XB_Y]M+_[_P G_P 11YGB+_GVTO\
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M -_Y/_B*K7.H>(+:ZLX&M-,8W4C1J1<2?+A&;GY/]F@#H**R/,\1?\^VE_\
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M6SVSP#*Y'F@!B#R O?J.E 'IE%<QX4AM(;S5/[*ACATIFB,*0ILC\S;\Y48
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M "*]S_UTA_\ 1J54?B0GL;M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
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M_KI#_P"C4JH_$A/8W:***D84444 %%%% !1110 4444 %%%% !1110 4444
M%4[_ $RVU(VAN Q-K<+<Q;3CYU! S[<FKE% &3+X<T^:]FNW63S9;F*Z;#\;
MXU"K^&!2/X;TZ3.Y9#F^74#\_P#RU&,?AQTK7HH RM+T"VTAP+2>Z%NN[RK9
MI28HMQR0H]/0$G';%4-0\*Q:EJ>K?:"#IVK6*6UW&'(?<A;:R\=U<@_[HKI*
M* ,(^$]/F%RU[)<WLT\!MS-<29=(S@E5P %R0#P.2!Z"J&K>"X[G0=9M+>>6
M:\U*%8FFO)B=NW[I&!QMZC Z@?6NLHH Q)_"UC<V=I9R2W(M+>..,VZ2D1R!
M""NX?4=L9[YJ?1=,FT\ZA+<.C3WEV]PVPG & JCGT55K4HH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K"\8_\BO<_P#72'_T:E;M87C'_D5[G_KI#_Z-2JC\2$]C=HHHJ1A1
M110 4444 %07-]:604W5U! &^Z99 N?IFIZ*!.]M#G]9\8:7I=@TT-U!=3'A
M(HI V3[XZ"N6\,^/IOMSP:S(#%,^4EQ@1D]C_L_RKOM2TVVU:Q>TNX]\;_FI
M]1[USGASP-;Z->R7=S(MS*K'R..%'8D?WJ#RL33QSQ,)4Y+E_#YJ^OE^AO?V
M[H__ $%;'_P(3_&H_$&IOI?A?4M4M1'));6DD\6[E&*H2,X/(X[&M2JVHV$&
MJ:;=:?<@FWN8FAD"G!*L,'GZ&@]2*E]I_P!?><A:^.OLVDWE]?7.FWUM!*L:
M7MG(L$$A*;BH,DC#<,8X8Y)'2I)?&=V9=1>*T1+*&WM)X)V4.6$S <KO'8\=
M,8/7I70ZKH-IJ\5ND[31FW),;PR;6 *E&&?0J2*K/X3TQT,>)Q&UO%;L@D.&
M6(@H3[C'6@HQY/B7HZ'4MN)3903SE(IXVD80YW H&RN<<;L9J>X\77GVFT@M
M](D$K7R6TZ3.N51HRZD$-C)'Y8-:4WA>QGL[ZR>:Z^Q7L<D4EL)?D DSNV\9
M!Y/?O4MQX>L;B9IB9DE::.?>CX(9%VKC\.#]: (]>U._TV?2S;);&"XO8[><
MRABV'./E ( /?)STQCG(VJR]7T.#66MC/<748MY%E00R;1O!R">.<5I@8 &2
M<=S0 M17%S!:0//<S1PPH,M)(P55^I/ J6B@#(;Q5X>52W]NZ8<#.!=Q_P"-
M>93?&NZ75B(M+@;3@^,%CYK+ZYZ?ABO9" 001D&N"F^$?AV;5FO2;E8V?>UL
MKC83^6<?C0<M>-=V]FSHX/%WAV>".4:WIRAU#;7ND##(S@C/!K3M+VTU"#S[
M*ZAN8L[?,AD#KGTR*ECC2*-8XU"HH"JHZ #M3J#H2EU9PVE^-+NYUF[AEGTZ
MXBADNUDM;92L]LD+L%:1BY'S #J%Z^E3V_CEM3FTO^R[2*XAN+][.X=+A) F
MV,OE65L'C![]".M;S>']/?1;S26C9K2\,S3*6.296+/S]6-00^%K&$(PFNVE
M2[^V><TV7,FW8<GT*\8H*,)/B1IUNEI'>R1>?,,O\Z0D R,@VQLY9CQT7/ZX
MJU+XV9[6\>UTN??&+M8'D9=LCV[%6'!R!QGMFM.V\+V5DT36<UU;&,;3Y4N/
M,&XMALCGEF_.I(_#.FQ1B,1N5#W+X+DY,[%I/S)/TH =!=:C?^';>ZB%M9WD
MT2.3<*9(X\C).%89X[;A]:7P[J%QJFAP7ETL8DDW8>)2J2J&(61022 PPP&3
MP>IIESX=M+OP\NB337+6H54)\SYV4= 3CD=B#U'6M"SM?L=LL/GS3;?XYFW-
M^= $]%%% !1110 4444 %87C'_D5[G_KI#_Z-2MVL+QC_P BO<_]=(?_ $:E
M5'XD)[&[1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O]H/]
MT4?:#_=%%%58FX?:#_=%'V@_W11118+A]H/]T4?:#_=%%%%@N'V@_P!T4?:#
M_=%%%%@N'V@_W11]H/\ =%%%%@N'V@_W11]H/]T4446"X?:#_=%'V@_W1111
M8+A]H/\ =%'V@_W11118+A]H/]T4?:#_ '11118+A]H/]T4?:#_=%%%%@N'V
M@_W11]H/]T4446"X?:#_ '11]H/]T4446"X?:#_=%'V@_P!T4446"X?:#_=%
M'V@_W11118+A]H/]T4?:#_=%%%%@N'V@_P!T4?:#_=%%%%@N'V@_W11]H/\
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2%@N'V@_W11]H/]T4446"Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pasg-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M W\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKIWB32]5O#:VLTQFP[*);:6(2!&"L49U < D [2<9'K69X8\.2:3J=Y>7EO
M]Y+;6T3WRJI>=EC D);[W+ 'GKQ66/!VH_\ ",W1-U=MJ?ESQV\#21!(4>7<
MRH0N"74 9<MC/89H [VBO/M,\&Q.NGV]QI5V=.2\EEGM-16T"#,0"D1V_P"[
MVE@#C'W@6([U!!X.OWLO-NM/$FH6VGV,5G(\JL\4L<CE]K9X(&SYN_3)YH ]
M(J!;VW;4)+%9,W,<2S.F#PC%@ISTY*-^5>?7NF3Z1'KFKII)@6TG&HPW%RL/
MVBXD$C%HP\;,60H650X##?CG^&T/"VIVRO<Q6XEO(;2UN4;>H\V[6>::9!D\
M;_,9<GC$G7B@#OJCGF6WMY)G#E(U+L(T9V( SPJ@DGV )->:ZAX3UAI])=-/
M\ZYB$$[W,*6P*3M<&6XWR2?O N#\HC/)+ \8JQ/X.O4TVZDM=.1=0NXM4CGD
M#H&E65G,*LV>1]S Z+[<T >A2S1PV[SR-MC12[$CH ,FBWGCNK:*XA8M%*@=
M"5(RI&1P>1^-<$OAJ_E\>17MQI2FU9W2XF6.U$4L!MR@5S_KG;?@$-E>!@<
MC8_LN=/B!_:,.E,\<D>R:]N5A8(H3Y1 P;S5R3AE9=IY(P?O &C?>*-(TV]>
MUNKF17CV><Z6\CQP;ON^9(JE8^Q^8C@@].:23Q5H\.J-I\EQ,DR3+;L[6LHA
M$K ,J&7;LW$,N!NY) ZFL>^LM6@37]+M](:ZCU9V>*\$L8BC\R-8V\T,P?Y=
MI/RJV5QWR!6DTC5MFL:)'I<Q@OKR.1-0DEB\I8UBA4L0&,F_,;8&S&<<@<@
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M56P)-NTXYP<+9GTK4EO3!9Z%)%9W%YI]TI62%$M8XC$&C*A_O*(^B@KCH>Q
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M8'E[@4#9W'CU +L7C+19?M7SWT8M%+3M-IUQ$(^ V"6C W$$$+U.1@'-6/\
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pasg-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $V \(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X[3O&S
M2P>(_P"T;:.VGT61@Z*Y(=,95N?6@#L:*XG1?&UU=S6AU."QLX9=/-[(!<$R
M(,_W<=,=ZVM,\8>'M8OC9:?J]K<W(3S/+C?)*^H]: -RBL*W\8^'[W4I=-L]
M7M)KZ,-F%7R<CJ!V/X5C:#X_LV\*QZMXBO;.R:2XEB7&5#!6(&!R3Q0!VU%8
MDOC#P]!I]M?R:Q:+:76?)F,GROCJ ?6A/&'AZ30VUE=7M3IZMM,^_P"4-Z>N
M?:@#;HKC?"?C)O$WB/6[6"6UFT^T*?9Y80<L".<G/]!4NI^+Y[#Q=)HJVD;Q
MIILE[YA<@Y7^''I0!UM%8GA+7)/$?ABRU:6%(7N$W&-&) Y]36W0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !17#>)?&6KZ;XI71=+LM/D(LFO'DO+EHAA3R!A3S]:OV/CW26
M\+6.MZO-'I:78^6.9LDD==N!EA[XH ZJBLBS\4:'J%Q:V]IJ=O-+=1&:!4;/
MF(#@D?2L2?QHMQXHT.RTJ>VN;"]:=)I0"2&C[ Y'?V- '945@1^-_#,M[<6<
M>M6CW%NK/(BOD@+]['KCVS5I/$FCR)ISIJ$#+J1(M"#GSN,\?A0!JT5S?BOQ
M++X=ETA(K9)OMUZELV]B-H/<8KGKWXCW=K8Z[<#3H&.FZDED@,C?.K$#<>.#
MS0!Z+13(G\R)'(QN4'%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\K\;^$-<O?%I?1[7?I^KQ)!J,@=1Y
M85LYP3DY''%>J44 ><Z]X9U*;Q/<S65DS6?]B/:1L&4#?V7K52W\(ZLH\'HM
MCY/V.REAN7!4>2S+@9P>>?3->CW&HV=K.(9YUC<H9/FX 4=23T ^M%CJ-EJ<
M'GV-S%<1@[2T;9 /I0!Y1X6\%:G8W>G6VIZ9K3R:?*[I.=2C-F"<_,B?>R<]
M,#ZTD/A[Q?8>'],M8;2^2!;FX:ZBL)XH[C#,2A#L<!?7!S7L5% 'D&A>#]<@
ML/"T5WI<@-IJLUQ<K+(CE$.<,3GYOPHO?!^O++J-Y!IAF$6O"^CMO,0&XBQC
M*Y.,^QQ7KKNL:EG8*HZDG %0Q7UM-=RVD<@:>)59UP> >G/2@#SWP[X>\02Z
M[XDOI(I_#QU"2.2&2+R9F  Y!!#+GUX_&GWGAG6CXS^UMYU]$-%EMFO'\M#)
M*<X!5< 'Z#%>@7=Y;V,(FN9/+C+!=V"1DG Z5/0!S7@#3;S2/!.FV-_ 8+F*
M/#QL02IS[$BNEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ&'((R*A@O+>YFGABD#20,%E7!!4D9'7V- #X%*6\:L,$* 1^%2444 %%%%
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M\W_?5'EC^\W_ 'U0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0_F:/*7T/YF@!]%,\I?0_F:/*7T/YF@!]%-5 O3^=.H **** "BBB@ HHHH
M**** "BBB@ HHHH Y_Q/#:I +W4+Z_BLT*(\=O<F!!N;&]F7#8&>><<52\)K
M'/<2RV[:K;1Q@$6]U>&X21'!*-\V65L#.W((R,]:L>+-2U&WM?LFFV.I/+(4
M)N+2.,A5+X907; ?;G&0>HJ;PP9/)N1*=9W;Q_R%/+W=/X=G;ZT ;]%0I=6\
MDTD23Q-)']]%<$K]1VI8+F"ZC\RWFCE3.-T;AAGTR* %N/\ CWE_W#_*J7A_
M_D6]+_Z\XO\ T 5=N/\ CWE_W#_*J7A__D6]+_Z\XO\ T 4 :-%%% !1110
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M_3I0!W%G UM:QPO<2SE1CS)L;V^N /Y5/5#59;R"Q:6SDM8B@+.]R&*A0,]
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M+10 FU?[H_*C:O\ ='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O]T?E2T4
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MQ?\ H J[<?\ 'O+_ +A_E5+P_P#\BWI?_7G%_P"@"@#1HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:KJ]AHEB]YJ-S';P)_$YZ
MGT [FL#6_&L=O>G2=#MCJNL'CRHC\D7O(W0?2LQ_!TTEI=ZUXGNAJ.II [11
M8_<6YP>%4\'ZFMX45HZFB?WLF4K*YY[<?$N^?QX^KZ?Y9@<"WBAN&*KLSP6Q
MTYYKTAO$'CB"#SYO#.FO$%W%TU(*,>N6KR"+4;EYD4):DE@ #:18//?Y:]DL
M_!UQJB0S^)+]KM% *64'[N!/P'6O3Q=*G2Y>9*WS;_0X*&-]O=4XO]#&MOB5
MK^I&:#3O"+3SIP7BNA)&I]R% /YUEM-KVH7/G^*/#6OWZJV4M;8*L"_\!!R:
M];MK6WLX%@MH8X8E&%1%  _"IL5PK$P@W[.%OOO]YU.CSI>TU_+[CA;;QQ%I
M\"P#P?KUI$HP$2R&!^ -2'XGZ0AQ+INN1?[^GO\ TKMJ,5DZE-ZN/XFR5M$<
M8OQ2\+_\M;BZA_ZZ6D@_I4T?Q.\&R=-<A!_VHW7^:UU916^\H/U%0R6-I+_K
M+6%_]Z,'^E+FH_RO[_\ @!J8<?C_ ,)R?=\06 _WI0O\ZN1>*_#TW^KUO3F^
MERG^-3R>']%E_P!9I%@_^];(?Z53E\%^&9OOZ#IQ^ENH_D*/W/G^ :F@FL:9
M)_J]1M'_ -V=3_6K"W4#C*31L/9P:YM_AOX/D.6\/V>?55(_D:P/%7PTTM-$
ME_X1[0P^H,0J8N2@0=V^9L'Z>]5&%&32YFODO\PU.QT'Q'8>(X;F2P<L+>9H
M6SZCO]#U%:]>0?#?PUXL\,Z^S7.GJ-/N%,<Y6YC;8PZ' ;MT_&O7Z6(IQISM
M!W0)W04445@,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M26KT^:1V-07%[:VBYN;F&$>LD@7^=<OIVJWT%O;KJ>HZ,9&A9IG:X4%)?X5
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M1O.-.\*Z?81GI+>JN?\ OE177V]I;6D82W@BA0?PQH%'Z5-3]K1A\$+^KO\
M@K+\RUAZ:VBON1R2^#KB[ _M35693UAM(EA3\P,FI[GP+HTM@;6"(V[,06F7
M#2'';+9Q^%;=QJ=C:!OM%Y!'MZAI "*Y+Q7XOA%I'!H]]F8OEY(NRXZ9QWSV
M]*VHU,55FE3=O167X(QQ&)H8:#E)K3IU+VC^![71=2CO;>^NF= 058+A@>QP
M*ZJO+?">OZE_;MM:S7=Q/#,Q#*[EL'!.<G)[5ZE48^-:-1*M*[L& QE/%TW4
MIJRO;4****XCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M  \BO-9["P7Q%?6D5LDJ"X5IEOM>EBWLP!XB (*^F>N,5Z57 ZNTJ^*;@2Z0
MMP[H!:XTH2@L-N&,N/J#DC&* -KQR(?^$2O6FNWM@D992D_E;F'0$@@D>W>N
M?\67MY-I=@\,-U+I\:0RB>U="LDF0 "=X.!SQW.*] DACG0+-$CCKAE!&?QI
M5AC6,1K&@0=%"C _"@ #,8MP0[B,[3P?I7/VES>3^*\W-@;8BR8*#,K[OG7T
MZ5T=9#?\C>G_ %XM_P"AK0!J;G_YY_K1N?\ YY_K3Z* &;G_ .>?ZT;G_P">
M?ZT^D9@BEF. !DF@#RWQ5XDUV#Q*D:K):B!LPQ#D2>Y_O9KN-!DUV6 W&KB!
M?, *0Q+@I]237$W'CN?5=3N+FPT*VNK?3I,1/+GS9#G!VGH/UKK)O&^DVME'
M/<N8'= QBE(4J?0YK?DE**M$XXXNC=WEL7;KP[I=]?F]N]/6>? &9') Q[9Q
M6E$@@C$<4"QHO15P *X.?XHZ5(Y2*^@B_P!V)YF/TP,5 ?&.GW9^>#Q%J.>B
MPV3(AI<B7QR_7_@?B+ZW!_ K_A_P?P.[N-6M+7_6RQ@_W0P)_(57&KSW'_'G
MIT\GH\GR+7+V_B6ZBQ_9_@+53Z/*JQY_$YJU_;WC>?\ U'@^"$=FN-07^0I<
MU-;*_K_P/\Q^TG+=V]$W^+7Z&Z8-9N3^]N(K=#_#",G\S2IHEMNWSI+<OZS2
M9_2N:N]1\>06SW%W_P (WIMNHRTDTLC;?Z5SZ:[XYU2YD@TG48KW:H8O:V0C
MB/TDDX-)XB2VT]/ZN+EA?6+D_/\ X.G7Y'J8\JTB)$4<,:CDY"@5SFI>.;*W
M#I8Q->.I"F13MA0G@9<\5R/B#3KM(Q'XC\4S/(ZKY5E9Q[YBW<8Z?CBHM!^&
ME_?2O/?W=[96$N"8))=TL@'3<!A1^1IQI3DN:6B[O].XIU:C?)'3R5F^F_2/
M7OJMB35/$5Y?WDME=-/>W22!1IUFWE0D'NTO.0*L0Z!;W$7_ !46M6%A:!PR
M:=97"1H .TC$Y<UOQ?"WPJAR]G--Z^9<.0?P!%7H/A_X3MSE-"L_^!IN_F32
M<HQ^#[^O_ '2H2B^;E5^[;;^]K\K(HVWB/P+H44D=I?Z9"COYC+#)O&[UP,T
M/\4?"X.(;J>Y/_3"W=OZ"KEQ+X2T5O+2RL!-T$5M;*SD_0"A+K7-0&-.TV'3
M8#TFN0-^/9!_6JCAYM<ST7=Z?\.*IBWS<JES/LDV_P ]/F9TGQ,LRA>WT+7)
MD'\7V3:/S)KD]?\ $[^)9T<6<]I B[1',P);W(!Q7H<7A2&9Q+JUY<:C(.=L
MK$1CZ**T;C0M*NK<02Z?;M&HPH" 8'L1R*Z*%6CAYJ>LG]R_K[CDQ6&Q>+I.
M#:BG]_X;?B>=^#KK68IYX]+MXIUVC>)F(5/3'-=7CQG+)UTR%?Q:MZQTNQTV
M/99VL4((P2B\GZGJ:MTJ^+52HY1@OF:X3+I4:*ISJ/3L[+_,Y8:7XLDDS+KD
M,2^D4(/\P*%\-:J[DW'B/4&![1'9_4UU-%8_69]++Y+_ ".CZC2?Q-OUE+_,
MY5?!5MN+3WNI3D_WKC'\JDB\$:+&Q9[*24G_ )Z3$_RQ7344?6JW\S&L!AOY
M$_57_,Q8?#&BP_=TB _[_P _\\U;ATRQMQB'3;:/_=C4?TJ_16;JSENV;1H4
MH?#%+Y(A1!&,) JC_9P*?N?_ )Y_K3Z*@TL,W/\ \\_UHW/_ ,\_UI]% QFY
M_P#GG^M&Y_\ GG^M/HH 9N?_ )Y_K1N?_GG^M/HH 9N?_GG^M&Y_^>?ZT^B@
M!FY_^>?ZT;G_ .>?ZT^B@!JECU7'XTZBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#G?&TTD'AF5XW929H5.)_(!!D4$-(.44C@D=!1X4V_9[HBWBA^<<1Z
MFU[GCN6^[]*D\8RM%X;G(BCD!>-6WVIN-JEP"PC .X@<@>HK'\&:E;17UYI:
M)G+AH9QI;6GFC;D[@$"\= >,^G% #I(9/^$AU\6NC3%+FQ6--]OY<4TJF0L"
MWON7GOFG>";&]L[F[,Z7CQ-! BSWT>R4,H(,8&>47/!]SRW6NRP/2C&* *&J
MQ7\L!^Q7<-OA6W^9;F7=QV^9<?K47A\/_P (WI?SC_CSA_A_V![UH7'_ ![R
M_P"X?Y52\/\ _(MZ7_UYQ?\ H H O8D_OK_WS_\ 7HQ)_?7_ +Y_^O3Z* &8
MD_OK_P!\_P#UZ,2?WU_[Y_\ KT^B@#(\0Z[!X;TB74;Q\QI@!5'+$G  YJ1-
M;TY[6*X_M.T2.1 ZEY%7@C/<UQ'Q,\.^)_$]Q:VNF6T36$(WDM.J[G/L?0?S
MJ/P1\-[>#3Y8O$_A^RDN5?,<ID$F]3V(!QQ_6NM4J2I*<I:]E8F[N=A<>,/#
MUM_KO$&FK_VV4_R-9\GQ*\)QCC7[:3VBC9_Y"M2W\(^'+7'DZ'IR8_Z=U_PK
M0BTVQ@_U-E;Q_P"Y$H_D*RO171_A_DQZG)?\+0\/N<6[W]R?^F-A(?YXH'Q#
M,W_'IX9\0S^G^@[ ?Q)KM^ ,"DR ,]J.>ETC^/\ P LSB?\ A,?$DQQ;>!]2
M]C/-&@_G1_;7Q F/[KPK80@]YKX']!6K-XSTI+DV]NMU>3!MI6V@9L'Z]*VK
ME[EK%WLDC^T%<HL^0,^^*?/%?87X_P"8OF<EO^)$_P#RS\.VH]VE<C^E>2>-
M_$6N7>N?8]0U&*9[%\*UFAC4-WQWSVS7MUI!K\5Y%<:MK-G'#NQ]GAB 5R>V
MYN:\'\:ZS<R>,=1,.8$28J$!SG'<Y]::QU/#/FE%/T.W!9=5QLG&F[6[GM7@
M!M";08?[$\B.1HP]POWI-W?><Y/-7]8U^]T^^2SMM,>XED'R.\BQHQ]!DY)^
ME9'@^*Y'A/3]08VVD(#YL^Q0_GQ_[3-RI/7BL:[FM]83R[:8VFA0S,[:C=,7
MED8]5ASR!VXJ8WK2<U\/=G'B'##7C4?O+HO\]K>9>B\8ZSXC1=.T2U1+QBRW
M-U@^7:@''?JU5!X+TS1(1=^(=<GDGDR9HHG($Y/M]XUL:8;V:R2Q\,V TW3A
M_P OEROS/[JO<^YK:TWPQ8V$OVJ<O>7IY:YN#N/X=A4RJ:<L-OS..-:=1\U*
M*]7LM]N_JDDS&L;?5+^UBM-)LTTC2XTV1S3)NF*_[(.<?C6WI7AFRTEO-C'G
M7)^]<3#<Y/U[?A5B]\0:1IX/VK4;:,C^'S 3^0YK*;QM:2Y&G6&H7Q]8H"%_
M[Z-5#"U9*\8NWX?Y&BHQYO:57S2[O]%T.DQ)_?7_ +Y_^O1A_P"^O_?/_P!>
MN+O/%>KKG>ND:2G]Z^O5+#_@(-8-]XC6XMI"WB^2ZFQA8-/@*H3Z%\=*VCA+
MNTII/RU_*_YEU*].FKR=CNYO$=C;:P^FSW,<4B1^8TCX"CVZ]:IR^--.\PQ6
M)GU"7^[:P%A^?2O)AYIN1-)^];=D[SNW?7/6O1((-:GMU^Q^'[2T0@8,LQZ>
MN :]"O@,/A^7F=_FDO\ /[CF6/I2^!\WIK^6WS-,7OBS4.+>PM-.C/1[I][C
M_@(H/A6ZO>=7UV[N0>L41\J/\A51/#&O2N6FU.T@!Z+#$7'ZXK2M_"[(?](U
M2XE_W41/Z&N:56$/X<DO1:_>_P#,TA6E/>G+YV_S_0=#IOA[0L[5L+=P,EI,
M%_S)S3)_&.BP<?;UD..D43-^O2M)=%L54 Q%B/XBQR:=_8]C_P \3_WV?\:Y
MN>E)WJN3?]>II.-9_ TOE?\ 5&&/&+W&W[!I%_<[NC&+8OYY-"ZEXMN<>3I-
MI;*3UGDSC\ <UN?V/8_\\3_WVW^-']CV/_/'_P ?/^-/VE!?#'[]?U1E]7K2
M^.J_DDOT;_$Q/[,\570'VC6[>W&<D6\6>/J0*0^#?M&?MVM7]R"<[2^%_+FM
MS^Q['_GC_P"/G_&C^Q['_GC_ ./G_&CZQ;X7;TBD'U&D_CO+U;?_  #-@\&Z
M) 219QR$]Y2S?S-6+SPYIEY:_9WMH8X\YS"@0Y^HJU_8]C_SQ_\ 'S_C4%WI
M$(MS]F@!E/3+GC]:2JN4DW-W_KS-%A:"BXJ"MZ&9X?\ #6EV,[75I)-)-&Q4
M-*P.!]!@5TN)/[Z_]\__ %ZR-,LKVSN<NB^6PPV&%;51B).4[N5_Q+HT:=*/
M+3C9>0S$G]]?^^?_ *]&)/[Z_P#?/_UZ?16!J,Q)_?7_ +Y_^O1B3^^O_?/_
M ->GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y[=S/)XNU
M".2-+A4FC">=K3VQ0;1PL2\$=\]SGTKT*O-/$5VL/B"]N)+>)I;>2/RH?[$,
MXG7 R6F"D@]>AXQWH ]'FGBMH6EGE2*-1EG=@ /J344VHV-O+#%/>6\4DW^J
M1Y54R?[H)Y_"N>\5R6.K^"[B46TMTLD9-NGV61FW]CLVY!SZBJ6M7,%[8:=I
MWV2X5;F-#/=&QE/EQJ1E>$)W$] <8ZT =O60W_(WI_UXM_Z&M:N2T>4QDC(R
M*YZT741XK_TY[1F^Q-L\A''&]>N2: .CHIF)/5?R-&)/5?R- #Z1E#H589!&
M"*;B3U7\C1^\]5_(T <7!X)ELEDBL_)2%I&<!G.>3]*VM,\*Z3:6D:RZ79O.
MOWI'C$C$^NYAFL35/BEX?TG6CID\DSNC;9)8H\I&?<YR?P%=&->LG:T6&Y28
MW:EH#$I97P,]1P/QJYXKVD5"ZT)CE4L.U4<'[W?[S0BMH(!B*".,>B(!3W=(
MT9W8*BC)8G  KF[WQ%/:Q6\UV;?3XI%<213$M<*W1=BKD'\:Q[:WUW6S;RQH
M\?E1-$;Z]&TRJW4^2/E_,5E?L*=6E2?*W>79:O\ R7S9T>H>*M+L$!,ZR%X#
M-$5/R2 =@_3-82Z]XD\1#;HU@+.TEAP;BY!#1OZJ>C#\*OVGA72=%A%W?21S
MM$/]==<(@]EZ 55?Q3J.MRFU\+6:RQCY6U"=2L*?[H_BK2G1G4UZ?@83KS6_
MN^6\G^B^Y^I#<>'M&TD#5?%>I&^N @0M<'Y#CL(QUI\=]KWB2,0Z);?V-I.,
M"ZF3$C+_ +"=OK5NP\(6UG/_ &GK-T-1OQR9[K[D?^ZO05:G\5VHD,%@CZA.
M.-ELA('U;I733IQ7\*/,^_3^O7[C&<U%?O9<J?2^K_7Y(FT3PKINB$S1(T]X
M_,EU.=\C'Z]OPK1O=1L].C\R[N8X5_VVP3]!WK%\CQ+JH_?3PZ5 ?X8AOD/X
M]!5BS\+:?:2><\8NKCJ9KDEV/Y\"E*,;\U6=WY:_CM]URH5*C7+0IV7=Z?AO
M]]B ^);F_.S1=,FN!_SWF_=Q_KR:3^P=3U+G6-5<1GK;VGR+]">IKH0K@ #8
M .P%&)/5?R-3[=1_AJWXO^O2Q7U5S_C2<O+9?<OU;*EAH^GZ8N+.UCC/=@,L
M?J3S5ZF8D]5_(T8D]5_(UC*3D[R=V=,(1@N6"LA]%,Q)ZK^1HQ)ZK^1J2Q]%
M,Q)ZK^1HQ)ZK^1H ?13,2>J_D:,2>J_D: 'T4S$GJOY&C$GJOY&@!]%,Q)ZK
M^1HQ)ZK^1H ?13,2>J_D:,2>J_D: 'T4S$GJOY&C$GJOY&@!]%,Q)ZK^1HQ)
MZK^1H ?13,2>J_D:,2>J_D: 'T4S$GJOY&C$GJOY&@!]%,Q)ZK^1HQ)ZK^1H
M ?135W?Q$?A3J "BBB@ HHHH **** "BBB@ HHHH **** .=\77<:Z3):QW\
M,-RQ1S";M;>26,,-RJQ(VD@$9_6H/!CLZ7[1,R67F+]GMI+U;EXOE^;+!FP"
M>0N3W]:L^++1'TJ2XCLX);D%$\TVJS2(A;DJI!W$ D@>O8U!X,EFGLY)&T_[
M)&R0\FT^SL\FS]Y\N 2 W0X]<<"@#IZ*Y>T\^+Q=KD,^HW,L#6<,JK)(%6'+
M2#Y   O '/7U-)X5DN(]4U:RN'G7R_*DC@EN6N-BL"-WF$G[Q!^7MCWH Z6X
M_P"/>7_</\JI>'_^1;TO_KSB_P#0!3M4O);6W(CL+JZW*V?(V?+QWW,OZ5%X
M?<_\(WI?[MO^/.'T_N#WH U**9O/_/-OT_QHWG_GFWZ?XT /HIF\_P#/-OT_
MQHWG_GFWZ?XT 97B#Q'9^'K42W&9)7XCA4_,W^ HT_Q1H^I&W2"]B,TXRL)/
MS@^A':O.OB7?6R>(8HY?*B=(1EF/S-DGK^57? ^I2PZ9(^FZ"+Z3S/FN4E5>
MW3)Z56EMM3SWCDJK@XNW>S:;6]K'?ZMJ%W811FSTR:^D=L;8W"A?<DTS2)]9
MN#*VJ6=O:IQY:1REV_'M7.WWC#6+.*XDDTBUC^S[?-4W8D9-W3*KR*S[KQKK
MT3S1L= M"F"C3W60X/7&"3Q]*2=](J[.E5D]6FEYJRZ=[=_U.KU/P[_:MV9)
MM4OTMR /L\,NQ?KP,U-$VE>'--6(W"P6Z.$W2RECN8\ D]S7F=[XOO+WS(7\
M3H0[JR)86<@=,=@W&0:B36-;>:ZFT^WO#)<N&ED^Q)&LC#@$[LXK58?$2TY;
M>NAD\?0B]$Y>EO+N_P!-T>GOJDO^D)I^ESS20SK'(K@0A@>KJ3PP%.>UU:Y,
MJRWT=LJSAX3;)EC&.JON[GVKSV"/QWJ!&;V2 'K^]W'_ ,<%3W6D7]A&)=<\
M3W:@]$$VTGZ#))JU@JC=FU?M?_*Y4<=4?P4;>K7_  ?R.^71-/3S6EB\X/-Y
M^)V+A']5ST_"O*M=U_1]4\02W,GA>RN7MI"AF>9LRX/M@?F#6M::#>:F0UA8
M3"$_\O>HR,V1ZA">?RK'O/#UP+N1'U/3"48K\UP%/_?..*]#"9?A^9QKM/R_
MX8<\7B(M2<^3T?\ G8BUCQ1>>(I(XKA8]/TR/&+4'<#C^]C&?IQ6A9:QI]M(
MCVVDWFK7B !'F0E$]EC4' KM?#6F6&GZ!!)<VMF9,$M<!E<-SUW&K,OBW2H7
M\BU\V[E'2.UCW?J.*RJ.$IN%.G=+ST_"WXLXW2HP?M:T[M]]?N1RDFN>/]2&
M++19;93TW1K'C\7.?TJH_A+QSJIW7U[:Q+W$]R\F!]% %=D;[Q+J'_'KIL-C
M$?\ EI<MN?\ [Y%)_P (U+>'=J^I7MYZQH1''^0-1[64-Y*/^%*_WK_,T=2=
M3^'&3]?=7XZ_@<,?"\.F-B\\71QR_P#/+3[-2_X-R?SJPGA$ZF ([;7+U#_R
MUU*^,2?]\+BO1K+2M/TY<6FGI$?[P49_/K5W>?\ GFWZ?XUA.M!N[3D^\G^G
M_!!82I/XY6]-?Q=_R1Y]8_"JP5@]TMO'CGR[:/./^!-DUU5GX3T2RB,<=C&V
M1@M)\Q_^M^%:^\_\\V_3_&C>?^>;?I_C4/$5&K)V7EI^1K3P&'@[\MWW>OYG
M/Q^!]#CN_/$$I'41F4[0?Y_K71*H50 , <4W>?\ GFWZ?XT;S_SS;]/\:SG4
MG/XVWZF]*A2I7]G%*_96'T4S>?\ GFWZ?XT;S_SS;]/\:@U'T4S>?^>;?I_C
M1O/_ #S;]/\ &@!]%,WG_GFWZ?XT;S_SS;]/\: 'T4S>?^>;?I_C1O/_ #S;
M]/\ &@!]%,WG_GFWZ?XT;S_SS;]/\: 'T4S>?^>;?I_C1O/_ #S;]/\ &@!]
M%,WG_GFWZ?XT;S_SS;]/\: 'T4S>?^>;?I_C1O/_ #S;]/\ &@!]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 V21(HVDD=411EF8X 'N:\ZU2Z^
MT:Y<26UZ)IY)$^QW<6L(D4"\95H]_/.?X6SFO19$26-HY$5T8896&01[UY_?
M(UIXCN+>'1T=2H%JD.E*\8;Y<$R <'[V<D8 H ]"'2BJ]W?6NG6C7-[<16\"
M?>DE<*H_$U#=ZSIMBT*W5[!"9O\ 5[W W#U^GO0!>K(;_D;T_P"O%O\ T-:U
M^M9#?\C>G_7BW_H:T :]%%% !1110!\S>)- :3Q1J#VK@V[7#'+G##GG]<UZ
M]X?LM:GT*TLM/$6DZ:D8 E&&FD]2 .!FEU'1O!]YJKW4VI)%)OS)$DP"D]\\
M9%:>I^,=$T.TCBMW%S)L'E6]M\W';)Z ?6BE@IJ7NQ=V<=;-,7BX\F-K+DAM
MRM*_KU^ZQ=TWPSIFEL;@QF>YZM<W!WO]<GI6?J'C.-KIM/T&U?5;\<'RC^ZC
M]V?I7*M<^(O&4G[VWF6Q)XM;=O+C(_VY#R?H*Z:P\)70M5M[F\6TM1_RZ:>O
MEJ?]YNIKO^K4Z.M9J_;_ (;7\O4Y(8CG7+A(:=[6_%Z?F_(R;BRM'N%N?&&K
M"^N0<QZ=;9,2'TVCJ?K6[%>ZU>Q+#I.EQZ=:@866Z&"![(*V-/T33M+'^B6D
M:-W?&6/XGFK]1/$0>ROZ[?)+3\S>&%JOXY6]-_G)Z_<D<['X4CN'$NL7L^H2
M#G:[;8Q]%%;MO:P6D0BMX8XD'144 5+17/.M.>DG_E]QU4L/2I:P6O?K]^X4
M445F;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OBIXT\/
MS^;!;3ABBB.XA:56)8  (O+-Z =\<CK5;PC'#%:2K'J4UT76.81NC(D2.N5"
M!B2%(SU8\CVIWB2:6\>+1;2R2YN)T,Q:2X:!850CY]R@MNW$8P*@\&VT6GQ7
MFGO;2PWUNR+,9+DS[UV_(5<@';@$ 8&,'ZD VET72ENY+M=,LQ<R AYA N]L
M]<G&3FI;/3[+3HC%8V=O:QDY*01A 3ZX JS10!'<?\>\O^X?Y52\/_\ (MZ7
M_P!><7_H J[<?\>\O^X?Y52\/_\ (MZ7_P!><7_H H T:*** "BBB@#Y_P#B
MMH^JS>-9ITMKF>!XT\MHXF8*/3('U_.KO@SPC>W.AW$.IZG?Z=;RR BSC3F3
M_:]J]@U.QNKUT$;HL:]B3R:ETRTEM(627RR<Y!7K5PHTX2]M>[?0[JF85:F$
MCA;647NM'Y>GJ<5%X TB25I'MM4OI' #275SLS]<8)_&M:T\$:= 08]*TZ''
M<QF5O_'LBNL9E12S$ #DDGI7/7GB^S29K;38I=2NAQLMQE5_WGZ"NJ%2O5TI
MK_+_ "/*]A26K2+L&@VL*!<G:/X8U"+^0%4[_6-"T>3RB%GNCPL$*^9(3_3\
M:P+W4KB];;K.M1V<1_Y<=-.^0^S.*NZ89K9-GA_PT80>MS>G:6]SW-;^P<5>
MH[^FB^]_HGZF4L71B^6+N^RU?W+]2T#XEUL814T6S/<_/.P^G1:DATGP_P"'
MF^TW<T;W1Y,]W)OD)]L_T%._L76K_G4M::)#UBLEV#_OH\U;L_"VD6;;UM%E
MEZF2<^8Q_.LY5H)<JE9=HK\V]7^(N>O/X(6\Y/\ 17_-%4^+(K@E-*T^[OVZ
M;D38G_?1KSG4+'4IM1N)7T^X5FD)*K&S ?CCFO9U4*H50 !T I:6'QL<.VX0
MW\_Z_(Y<7ED\7%*K4V[+3_/\3D- \*6,^E6MQJ"7$TI3/E3N=J>P6NIM[2WM
M(Q';P1Q(.R*%'Z5-17-5KSJMN3.[#X6E0BE!*_?JPHHHK$Z0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X34DM[GQ5<M]I73S;A7DN+.VD\UP,9
M#2?=/4<;6P.XKN)9%BB>1_NJ"37GMW;S7<Z>(KS2)(M,E(9XX=1<.T9(P[Q!
M=IX ) ;..N>E '3>,85N/#-W$+*2[F9"(5CA\Q@^."/3ZU@7UO=R-/(NF7<R
MWVEI:Q#R2"C@\A\_=!SG)XXKO1@CVI<"@"O:0R06$,!8&1(E0MU&0,9K%M8K
M^/Q9_IEW!,QLFVF*W,>!O7KEVS^E=%60W_(WI_UXM_Z&M &KB3^\O_?/_P!>
MC$G]Y?\ OG_Z].HH ;B3^\O_ 'S_ /7I"),?>7_OG_Z]/HH \5O]/OFU&Z(L
M[D@RL01$W//TKO\ PYX5TZ#3[>ZDM%:Y=0S>>N<'Z&NKHKT*^83JP4%I\SQ\
M)DU+#U'4D^:_=;# C* %*@#H O\ ]>EQ)_>7_OG_ .O3J*\\]@;B3^\O_?/_
M ->C$G]Y?^^?_KTZB@!N)/[R_P#?/_UZ,2?WE_[Y_P#KTZB@!N)/[R_]\_\
MUZ,2?WE_[Y_^O3J* &XD_O+_ -\__7HQ)_>7_OG_ .O3J* &XD_O+_WS_P#7
MHQ)_>7_OG_Z].HH ;B3^\O\ WS_]>C$G]Y?^^?\ Z].HH ;B3^\O_?/_ ->C
M$G]Y?^^?_KTZB@!N)/[R_P#?/_UZ,2?WE_[Y_P#KTZB@!N)/[R_]\_\ UZ,2
M?WE_[Y_^O3J* &XD_O+_ -\__7HQ)_>7_OG_ .O3J* &XD_O+_WS_P#7HQ)_
M>7_OG_Z].HH ;B3^\O\ WS_]>C$G]Y?^^?\ Z].HH ;B3^\O_?/_ ->C$G]Y
M?^^?_KTZB@!N)/[R_P#?/_UZ,2?WE_[Y_P#KTZB@!N)/[R_]\_\ UZ,2?WE_
M[Y_^O3J* &XD_O+_ -\__7HQ)_>7_OG_ .O3J* $ ;^(@_08I:** "BBB@ H
MHHH **** "BBB@ HHHH **** ,[4-!TW5;B.>\MR\L:E%=970A202/E([@4[
M3=&T_23,;* QM,09&+LY; P.6)-7Z* *]]/):V%Q<10F:2.-G6('!<@9 S6'
MX1\13>(8;J1_L\D<)0+- &52Q7+)AN<KQD]#GV-;>H646I:=<V,Y817$;1N4
M.#@C!P:HZ/H2Z7<7%R]T]S<S)'&SM&D8")G:-J #N>?\* +M]=6]M;N)YXHM
MRG&]PN>/>LW0=4L$\.Z8K7UL&%I$"#,O'R#WK3O+"VOH]MQ;PRD A3)&&VY^
MM4K#P[IUIIUK;26-I(\,21L_D+\Q  )Z4 6O[6T[_G_M?^_R_P"-']K:=_S_
M -K_ -_E_P :;_8NE_\ 0-L_^_"?X4?V+I?_ $#;/_OPG^% #O[6T[_G_M?^
M_P O^-']K:=_S_VO_?Y?\:;_ &+I?_0-L_\ OPG^%']BZ7_T#;/_ +\)_A0!
MRWB'QS+I6H&"SBM;F+8&#^83R<\<52C^),\T)ACL(FO6/RCS-J >IR<FK/B+
MP)/JFI^?8R6=M!L"^7L*\\Y/RC%:/AGPG_95I-!J,=E=[GW(WE;B/4?,*]B^
M"AAE*R<^VIQ0I5^=MRZOTMT.:EM-:U^0-JNKV4$/7R3<KM'_  %3S^)K:L_#
MNB10K'=ZTEP@_P"623K%'_WRIKI_[%TO_H&V?_?A/\*/[%TO_H&V?_?A/\*Y
M)X^M)<L;179*Q7U.G)WJ-R]7I]VWX%6S/A_3UQ:/I\/NLB9_/.:N?VMIW_/_
M &O_ '^7_&F_V+I?_0-L_P#OPG^%']BZ7_T#;/\ [\)_A7'*3D[MW.F,(P5H
MJR'?VKIW_/\ 6O\ W^7_ !H_M;3O^?\ M?\ O\O^-4[[PWIUTL 2RLT\N=)3
M_HZ\A3DCIWJU_8NE_P#0-L_^_"?X4BAW]K:=_P _]K_W^7_&C^UM._Y_[7_O
M\O\ C3?[%TO_ *!MG_WX3_"C^Q=+_P"@;9_]^$_PH =_:VG?\_\ :_\ ?Y?\
M:/[6T[_G_M?^_P O^--_L72_^@;9_P#?A/\ "C^Q=+_Z!MG_ -^$_P * '?V
MKIW_ #_6O_?Y?\:/[6T[_G_M?^_R_P"-4Y_#>G37]I<+96:K!OW+]G7YLC'I
M5K^Q=+_Z!MG_ -^$_P * '?VMIW_ #_VO_?Y?\:/[6T[_G_M?^_R_P"--_L7
M2_\ H&V?_?A/\*/[%TO_ *!MG_WX3_"@!W]K:=_S_P!K_P!_E_QH_M;3O^?^
MU_[_ "_XTW^Q=+_Z!MG_ -^$_P */[%TO_H&V?\ WX3_  H =_:NG?\ /]:_
M]_E_QH_M;3O^?^U_[_+_ (U2'AO3O[5-W]BL]A@$7E_9UZ[B<]/>K?\ 8NE_
M] VS_P"_"?X4 ._M;3O^?^U_[_+_ (T?VMIW_/\ VO\ W^7_ !IO]BZ7_P!
MVS_[\)_A1_8NE_\ 0-L_^_"?X4 ._M;3O^?^U_[_ "_XT?VMIW_/_:_]_E_Q
MIO\ 8NE_] VS_P"_"?X4?V+I?_0-L_\ OPG^% #O[5T__G^M?^_R_P"-']K:
M=_S_ -K_ -_E_P :I6WAO3H;V\G:RLV6=E95^SK\N% ]/;-6_P"Q=+_Z!MG_
M -^$_P * '?VMIW_ #_VO_?Y?\:/[6T[_G_M?^_R_P"--_L72_\ H&V?_?A/
M\*/[%TO_ *!MG_WX3_"@!W]K:=_S_P!K_P!_E_QH_M;3O^?^U_[_ "_XTW^Q
M=+_Z!MG_ -^$_P */[%TO_H'6?\ WX3_  H =_:NGC_E^M?^_P O^-']K:=_
MS_VO_?Y?\:I6'AO3K2*97LK.0O/)*#]G7@,Q('3MG%6_[%TO_H&V?_?A/\*
M'?VMIW_/_:_]_E_QH_M;3O\ G_M?^_R_XTW^Q=+_ .@;9_\ ?A/\*/[%TO\
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MFBL;^PI_^@[JO_?R/_XBC^PI_P#H.ZK_ -_(_P#XB@#9HK&_L*?_ *#NJ_\
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M\!MVMC;]4)!/S;NN1Z4ND^&+#1=2N+NS5D$L21"/>Q"!<],D^OX8H VZ***
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M)>Q6WE@;97!#$MW7YF(&.IZFN@H **** "BBB@ HHHH **** "BBB@ HHHH
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MMD$$ CH:Y#6_#-UK:1JUNEM+/ L%U-'?.!M#9VE H$G!."<?>KKU&U0OH,4
M+1110 4444 %%%% !4<\OD022^6\FQ2VR-<LWL!W-25#=FX%G,;1(WN0A\I9
M6*J6QQD@$@9]J ,>3Q790:;?W=Q;7L+V+;)K8P[Y02H88"$@Y!'(./7&*V;6
MX2[M(;F/.R5%D7/7!&1_.N7M](U>/PQJ5I);6SZE>AC+,UV2)7==I8GR_E &
M %P> !GO6]HL-S;:-:6]W'&D\,2QL(Y-Z_*,9!P/3TH OT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML4D44ES"DDW^K5I "_T'?\*JV^OZ3<VQN(M1MC")#$7,H WC^'GO6"WA&YS
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MZUV">/ 44GPWXA)QR18\?SK9G\-Z%<7C7$^EV4ER[;R[Q L3ZYK5 "@ # '
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M"D;RRM*SIN52 "BLN><]\=#5(>.+L6R,VGPM+.(FA$$K2@!R1\VU<YX[ YH
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M 4444 %%%!&1B@ JG=:MI]C*(KJ]@A<C.V1P#BLR3PMYDK/_ &WK"[B3A;G
M'TXKGM9\"ZA<W:O:WK7";<;KR8E\_ETKLHT:$I6G.WR/-Q.)Q<(7ITKOUN=[
M#-'<0K+"ZR1L,JRG((IEU=065M)<7,J10QC+NYP%'N:YNQ\(2164*3:QJ<<B
MKAD@N<(#[<=*FOO#DXT"_L[:_N[F:=0$-U<9VD'L<<?E652G3C?EE?Y'11JU
MYVYZ=OF;EG?6VH6XN+299HB<!UZ58KBF\/ZK<7MC=R($%MQ*DMV96G&> Q"@
M<=1QUK/L/#%]?6#-]EAMED!60M*VZX_>$Y<8XX^OY5@=1Z+2,P52S< #)-<6
MGA.ZAUN[N/F,#JXB,,J1_(5P(S^[W8';YL#TJ*#POJ<:V&VWM$>!73)9"J(?
M8(/G_P!M=OOF@#MXY$FC62-@R,,@CO3+FZAL[9[BX?9%&,LV"<#\*XM/"&K"
M.2'[7''%Y!:/$C,1.1@GITQ_^JKNG>'+NV\+WNGX\N:<_*C2H44\=-B* #CT
MH ZM'5T#J<JPR#[4ZN"C\*:PTVI&3[*BW$ B_=OM#G<#DX4'IQEB365XBT2:
MPDAM&MD>Q>5W2%$+* <<+Q@/D<?6@#U*BN*&A:SD)!%;) GG/$99FR?, PK*
M!QC'/)KF;[1+[3Y+2UU"W26!G:188T#A<N#A,*%#\>@XH ];HKD?#?AV\TW6
M9[RY9SY@;YQ(@#@G(W*$#9'NQQ774 %%%% !1110 45%<0_:(&B\R2/=_%&V
M&'XU0_L3_J):A_W^_P#K5<8Q:U=C.<II^[&_S-+>N\IN&\#.W/.*=7,KH6H_
M;O,:Y<1DX+"<[]OUQ6E_8G_42U#_ +_?_6K65*G'[9C"M5E?W/Q+5]J5EID(
MEO;F*!&.T&1L9/H/6IXY(YHUEB=71AE64Y!'L:Q;_3;V&]L+ZR1+M[6.2(QW
M$I4D-M^8-@\_+Z=#6)J.@:FUS=7OD0K*-TRW4,C-*J>45\E5P.,G(YQQG&:Y
MV=*VU.XXJL;NSAF,;2Q)(T@3!X)<C('N2!7G'A_P[_:L W64 1)6:?Y"D4A,
M(1=HQR01DY[Y-;#>$[^1(7NX[6\>&YMI@DLA(.R((_)4X.>??':@9VD,T<\8
M>)@R$D9'L<5)7"0>$]32XC,J6TK>:CQW)F;?:A92Y"C'.Y3C@CK@Y K2\.^&
M[C1[V*=Q"NZ"1;@HY)D<R;E)R.< D>W3I0!U-(RAE*L 01@@]Z6B@"."WAMH
MA%!%'%&.0J*%'Y"G.BNC(ZAE88((R"*=10!'#!%;Q+%#&D<:]$10 /P%2444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)8HY
MH7CD :-P0P)ZBJT]G+-J%O<K>SQ1Q*ZM F-DA8<$\9R.U4/["NC:V\+ZU?2>
M4DB.S;?WVX'!; _ASQBE=K8T4(M:R_/S_KYC=&L_#:7<KZ.+(SQ920V[@E?8
MX-;M>8>!/AKJGAC79;^ZU11& 46.W)_>@_W\C@>WK7=0Z3<Q"V#:O>2>3,TC
M;MO[T'.$;CH,_I256I4]ZI>_J;XFA0IU'&E4YEZ#=0U/1+"]5+V2W2X;:Y+1
MY*@' 9B =HY."<=ZMG3].?:YM+5L*RJ3&IP&^\!QT/?UK'O]&U-KK4OL9M'@
MU&-4D:=V#1$ C@!2'&#T)7GZUF3>"+HK>P0WD:6QAQ:CG<DC !R>",$+[_>;
MBJ.0ZF#3]-M[?R[2VMK>-U*#R$5.#UQ@?YQ69);^'=!TI;.6W@-M)\C@P*_F
ME1G+X')P.]4=(\(R65T+F9+8NL4@C5F$HC=BO*XC0*.#P%'7WK.@\$:L(9A-
M/9*TC[MJ'"YV,I.%C4#)([$^I- '9)IFF36(A%A:FU=5_=&!=I Y'RXQQFI/
M[-L/M"7'V*V\Z-/+23REW*OH#C('M4UO&8K>.-B"54*<>PJ2@"I+I>GSQ&*6
MQMI(RH4H\*D$=<8QTJ6*TMH HAMXHPJ[!L0#"^G';VJ:B@"I/I>GW,4<4]C;
M2QQG<BR0JP4^H!'%))I.G3-&TMA:N8CNC+0J=A]1QQ5RB@"LFGV4<CR):6ZN
MY)9A$H+$\$DXYS20Z986T2Q065M%&I+*B1*H!/4@ 5:HH IKI.G+*TJV%J)&
M78S"%<E?0G'3VIE]HUCJ%K+!+ BB3[S(BAOSQ5^B@"BFC:7&L 33K0>0=T6(
M%^0^J\<'Z5>HHH **** "C%%% &%=>#?#M[J#7]SI-M+=LP<S,#NR.^<UN!0
MH '04M%4Y2ENP&/%'+M\R-7V-N7<,X/J/>H+G3;&]!%U96\^[&?-B5LXZ=15
MJBI HC2;5=3COU7$L4/D1J  JKG/ Q3VTK3WN'N'L;5IY!AY#"I9AZ$XR:MT
M4 5)M,L+E=L]C;2KNWX>)6^;&,\CK4S6MNZ(C01,J?<!0$+QCCTXJ6B@"BFB
MZ5' 8$TVS6$DDQK @4D\$XQBE_LC3"(!_9]IB 8A_<+^['^SQQ^%7:* *D^E
MZ?=6XM[BQMI80V\1R0JR[O7!&,^]22V5K.L:S6T,BQ',8>,$(<8R,].*GHH
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pasg-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $R [4# 2(  A$! Q$!_\0
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M'/'S?/\ +V]: .^HKR/0OB+%X>\%>%[.817.H7=B9V>]OUMHP@)&6D?.6)R
M.^#6_I?Q2T_49+5WLWM[.YTV6_BN&E!R8F(ECP!U7&<YY% '>T5B>'O$4>MZ
M'IU_<1QV-Q>Q+*MJ\P9PK?=],Y&#T[UY?H/B36KC1? DLVJ7;O>:Y<07#-(2
M98PS@*WJ!@<4 >UT5Q7P[U*]U&/Q$;VZEN/(UFXAB\QL[$&,*/0"NUH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPQX:7PVNIA;IKC[=?27AR@79OQ\O7G&.M;U%% !1110 4444 %%%% !1110
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MY@]&_P"^31Y@]&_[Y-.HH ;Y@]&_[Y-'F#T;_ODTZB@!OF#T;_ODT>8/1O\
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M\V_3_&@!U%-WG_GFWZ?XT;S_ ,\V_3_&@!U%-WG_ )YM^G^-)O/_ #S;]/\
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MYYM^G^-&\_\ /-OT_P : '44W>?^>;?I_C3ATH **** "BBB@ HHHH ****
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M#-9C?$_P\S%;3[;?,.UK:N_\P*#-UJ:W:.S) &3TID<L<J[HW5UZ94Y%>/\
MQ$\7:IJGAY([;2-5TZQ:4":>XC\L.,<+P<X)_E6'\([O4(_&*6ULSM:R1.;A
M,_* !PQ]#G'/O0<[QB]JJ:6Y[_13-S_W!_WU1E_[@_[ZH.P?13,O_<'_ 'U1
ME_[@_P"^J 'T4S+_ -P?]]49?^X/^^J 'T4S+_W!_P!]49?^X/\ OJ@!]%,R
M_P#<'_?5&7_N#_OJ@!]%,R_]P?\ ?5&7_N#_ +ZH ?1306)Y4 ?6G4 %%%%
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M &8D_OK_ -\__7HQ)_?7_OG_ .O3Z* &8D_OK_WS_P#7HQ)_?7_OG_Z]/HH
M9B3^^O\ WS_]>C$G]]?^^?\ Z]/HH : V>6!'L*=110 4444 %%%% !1110
M4444 %%%% !1110!Y[XYO;.UUV%KW?!'' L@G@U V\DA)D7:%QAP,G)R"H<^
MM;V@:W'_ ,([+--' L=CB'%B6F0J$4@)QDD!@N/4&L?Q#/XD%S(MU]JM].^T
M*JOID"RDP;QN+L<NK;<GY5Z]S76P(L6C1_V9&DH,0,0E<H'R.K-@G)ZDD$T
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MQ@YQC&:]81MZ*V,9&<5Q.B&[N/$;+KLFH^>%!@AGMEC@)_BV[,JV.V6)KN*
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M29'J*,CU% "T4F1ZBC(]10 M%)D>HHR/44 +129'J*,CU% "T4F1ZBC(]10
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M\B9UCC]V8'%)#X*T?3[&XEUO51$$*^9%!.=L.>@).377Q>$]+CM[JV*2M:W
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M4<]+^5_?_P  /;5WM3^]K_-E,_%/PTHR6U #U.GRC_V6H_\ A;7A0=;B\_\
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M^OYT>;'_ 'U_.G44 -\V/^^OYT>;'_?7\Z=10 WS8_[Z_G1YL?\ ?7\Z=10
MWS8_[Z_G1YL?]]?SIU% #?-C_OK^='FQ_P!]?SIU% #?-C_OK^='FQ_WU_.G
M44 -\V/^^OYT>;'_ 'U_.G44 -\V/^^OYT>;'_?7\Z=10 WS8_[Z_G1YL?\
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MK<1,]S&T:!("2-@! !R1G@D\8-;=U=1V<!FE64J#C$4+R-_WRH)_2@"EH/\
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M;_ODT>8OHW_?)H =13?,7T;_ +Y-'F+Z-_WR: '44WS%]&_[Y-'F+Z-_WR:
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M&>['S9/\*!X46Y.[5-2O+T]T+[$_[Y%7[&,?CFOEK_P/Q,_K-2?\.F_GHO\
M/\"[>>)-(L25FOHM_P#<C.]OR%4O^$BOKSC2]$NI0>DMP1$GZUJV>CZ=IX'V
M6RAB(_B"#/Y]:NT<]&/PQOZ_Y+_,/9XF?Q34?1?J_P#(YW[#XDOO^/K4X+)#
M_!:1[F_[Z-/B\(:8'$EWY]]+_?NI2WZ=*WZ*3Q-3:.GIH"P5*]YKF?F[_GH1
M06L%JFRWACB0?PHH4?I4M%%8MMZLZDDE9!1112&%%%% !1110 4444 %%%%
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M\F @2$@@J3TX(SSGCCGM5VROK;4;9;BTF66(DC<O8@X((Z@@]C0!F_V7J_\
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MB_PH_LO5_P#H/R?^ D7^%;5% &+_ &7J_P#T'Y/_  $B_P */[+U?_H/R?\
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MX&\G)/VM!@^8<BM+^TM9_P"@"?\ P,CK7!CC.P;5+$G XR>YI] &+_:6L_\
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MTM9_Z )_\#(Z/[2UG_H G_P,CK:HH Q?[2UG_H G_P #(Z/[2UG_ * )_P#
MR.MJB@#%_M+6?^@"?_ R.C^TM9_Z )_\#(ZVJ* ,7^TM9_Z )_\  R.H;77=
M5O(FEAT)MJR/&<W<?WD8J?U!K>9U3&Y@N3@9.,F@!(QA0J@DG XR3R: ,?\
MM+6?^@"?_ R.C^TM9_Z )_\  R.MJB@#%_M+6?\ H G_ ,#(Z/[2UG_H G_P
M,CK:HH Q?[2UG_H G_P,CH_M+6?^@"?_  ,CK:HH Q?[2UG_ * )_P# R.C^
MTM9_Z )_\#(ZVJ* ,7^TM9_Z )_\#(Z/[2UG_H G_P #(ZVJ* ,7^TM9_P"@
M"?\ P,CH_M+6?^@"?_ R.MJB@#&BUF]6_M;:]TMK=;ABB2"X1\,%+<@<] :V
M:9F*0[OD<H>O!VG^E*CI(,HRL.F0<T .HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *9*S)"[(AD8*2$4@%CZ#/%/HH X#^R=3EN+C41:7TJK>6MSMNS&
M+B7RR=R@*0NU005''.[ZUTOANTN+>WO9KB P-=WDEPL3$;D4@ 9QQD[<_C6U
M10 4444 %%%% !1110 4444 %%%% !7,>+K>\OX%L[6VOI"V&41F/R'(/W9<
MG<%^G:NGHH YAS>WOBRW-WI]TEI9']PZJI221EP7)W9  ) &,Y.:Z>BB@ HH
MHH **** "BBB@ HHHH **** (YV9+>1D1W8*2%0C<?IGC/UKBX=#U6_CU+:9
M88[F6-RVI(&EF"@Y0B-@ O3'3O7<44 8WA6TO;'P];VU^L:3H7RL8P "Q([F
MMFBB@ HHHH **** "BBB@ HHHH **** .8\56][?F&UMK>^DPZ. AC^SN0P.
M),G=@>U4;#3-8M/$9,:7BH]X\TTIG!MWB8= F?O9]L^]=K10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5RWC@6CZ0T4[62S/'((C=0&
M3MR$QT?ICK]#74T4 >9W"))/*MS;3)JLGV,Z>)%+2HH"[MK8XP0^[\<]:]+7
M.T9ZXI:* "BBB@ HHHH **** "BBB@ HHHH 0G )->>V<^DVVJZO=216TVEB
MQ4R_8[9E1=KL0DB<[Y#G],$#OZ'1B@#F_!2P#2)Y('MPL]R\WV>W8,EONY$8
MQQD#&<<9)KI*** "BBB@ HHHH **** "BBB@ HHHH Y/QX+272&AF>R2=XI!
M$;J R$\<B,CH_3'4^QK(U2/59==T"[GTNX,$4]NMN&F4F/,;>87'7?SMSZ*?
M[U>AT4 %%%% !1110 4444 %%%% !1110 4UR C%NF.>,TZB@#RZYSC7'TGR
M3"]M&&DL(&1(U$GS!UZM)M)/7. >!77^$9-UG=QQ1VWV2.X*V\]M (4F7:"2
M%''!XR.N*Z+%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 449HH **** "BBB@ HHHH Y;4VM[GQ5]DU2X:*S2U$MNIF,2N^[#
M'((R0,<>]9=MJEWI>KW;PS02V<^IK!L8$N<Q)AM^?IVYKM[BTM[M56X@BF"G
M<HD0-@^O-.,$).3$A.[=]T=?7ZT <5#XCU>6UL&GOM/MFO(9)_-> [%"=$&7
MY)ZYSV/%(?%FK,@NR+6."-+5I(#&2S&4D'YMW XR.*[.6RM9HEBEMX7C4Y5&
M0$ ^P-/:")L[HD.[&<J.<=* .%N_$5[=6\R//9O%<&YA:U12)8 @;#,=W.=H
M[#[PQ2VGB6]@@@6.2U\NW^S0"T9299@Z+E@<\=>.".#7;BTMA-),((A)(,.^
MP98>A/>D:RM7D61K>(R*NQ7V#<%] >HH \Z7Q7J&JVUZ[SVQMXF4>6@,;JWF
M[1RLFXC'? YK9/BBZ6TN[I[ZS4^<T$5HD6Z6,A]H))<#GKS@#(YK9T_PS8Z?
M.)0\\^Q#'$MP^\1(3DA>/7'7)XK2>QM':5GM86:48D)C!WCT/'/XT <=H.L3
M:UKFF7-QY8E$%S&=A&#M=1G@D?D2*K3:]<)XN.I*+QM/2?["6Y%OC'WNN,[\
M#..U=[';00[?*AC3:,+M4# I'M8)(6A:)#&V<KM&.: /.[;QQJ\]M>72O9NB
M%4$>Q5,3%]N23)RH'<[>?2M^35-1E\$ZC=7(A%S&KJK0NIW#L3M9@#STR:T=
M/\,V.GRE]T]QB,PHMPX<1QDY*@8Z=.N3Q6FUE;-9-9B%%MV4IY:J  #Z 4 <
M7<ZUJFG;K;3Y;);:T2UC59(BQ;S.,DAAZ9Z4Y/%&I2!;1[JRMY4EG1[J2(['
M\L @!=W!.?7M786]A;VUM' J!EC55!< DA>F3WITME:SQ^7+;0NF[?M:,$;O
M7!'6@#B7\6ZN4-UBTBABC@>2$QL6?S"0<-N&!QD<54%QJES+:"74XI;A-6D2
M,O#_ *H!3P0&Y]NE>B&"%LYBC.<9RHYQTIHM;=96D$$0=CN+!!DGUS0!Q]KX
MIO+B33/M+6RVUQF*7RT#DON*C*[LJIQU ;WK8\(NS:,\9)*0W$L:$_W0QQ6L
MUE;,ROY$0= 0CA!N3/7![4EC8PZ=9I;6X(C3)^8Y)).22?J: +-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1SRK!!),^=J*6./0#
M-24A 8$$9!ZB@#C[C5];3PF^NFXMU$L*2Q0109:,,RX&XG#':<'@<]*T!XKC
MRD/]G7C7C71M?LZ^7D.$\S).[;C;SG/M4B^%;-;.2R^TWALF "6YF^2(;@V%
MXSC@8R3@<"K*:!9)J'VT"3SOM)N?O\;_ "_+Z>FWMZT 4#XQLU!E>TNUM668
MPW&U2LQB!+ #=D<*V,@ XH3QA;,CAK&\CN,Q".W8)OE\T$IC#8'W6SDC&#FI
M?^$1TW,BEK@PLLHC@,OR0^8"'*#'!.3U)QDXQ3YO"VG3,[_ODE*PJLBR8:,Q
M;MC+Z'YC]<T 9TGBU5U"*1Q+!:PV]T;NW= 9%DC:( <9S]_C!P=PJS+XO@M]
M\5Q874%XLB1BWD:($[E9@V_?LQA&_BZC'I4__")Z8T1259IBT<R2,\AW2>:5
M+LQ'?*+@C&,<5FZKX-%Q#"8G-Y*+A99_ML[*955&55WH,J!NSP.><]<T 20^
M,4D:.<V\_EW-K;RV]KY:^:S2NX4%M^WD)GL  3GL+5UXKMK&^L;.[M9H)KMD
M0*\D6Y69MH&T/EAGNH(&:CMO":/80C4;N:>_6*)#<HY!4QNS(5SW&\C)SD=:
ME;PE927L5T]S>M(K1/)F?B9HCE&?CG!/08'M0 RPUYX?!LVLW[AVA$[L>%W!
M'8*/3L!533O%SQZ,&U)89M2CO#9R):NJHS[=X(+M@#9SR>O'7BMAO#U@VDQZ
M8RR-:),)BC-G>1)YF&]5W=JQ];\%VUU-'/86]NH\Y))K5G:&.7:CJ""@RI^?
MDX.0 * %7X@:5FT$D4T;7$4,S(SQ[XUE.$RH;+'N=N<#K5[5-:>RUM(=S"WM
M[&>]N%506=5*A0,_5C^ IFF>&6M5MI[C4+IKU8T2Y>*0JLX4DJ&[G;G&<@D=
M<U9U+0QJ&J1W)<")[2:SN%R0S1O@C![$%?U- %&/QG TH633+^%<P;W<1X19
MCMC8X<]3P0,D=Q4I\6VJR$M9W8MBTR17&U=DK1!BZ@;LC[CX) !V_2K$GAG3
MY5D5A+B1;=6Q)V@;<GZ]?6H_^$4T_P Z1B]R8F\TI 9?W<32 AV0=B=S=SC<
M<8S0!1N?&;"Q\VVTFY:?=:L(9GC0F*9]JOG<1V(P>0<9XYI;#Q/*NK7=K?V\
MXC:_^S03!4V(3"KA#@Y)SNYP1D@9J_-X7T^6-UW3H6@@@#I)@J(6+1D<=03G
M/>I#X<L6?>QF+_:UO2WF8)E"!,_3 Z>M &:?%!O=/L-3LE:.U:^C@E60HQ='
M.S^$G:P9E)!P1C!%=37.-X4C26)HKB1]]Y'<W4D[;GD$8^1> !P0O)YP.]='
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '(7/BW7(+J:*/P7J<R(Y59%ECPX!X(^M<3X]\=>)XH+2
M.+3K[04=F+.[*6E(Q@ CH!^M>RX'I4%U96M[%Y5W;0SQYSLE0,,_0T'/4I3G
M%I2///#/CCQ+/X?M9)_"^H:DY4C[7$R*LH!P#@UN?\)%J][HVK/-H-]I+P6C
MR12S.ARV#C&._>NL2-(T5$1511A548 %.Q07"$HI7E<X:34M7TF&QC'^OFB)
M_P!(G:X )>-020%SPQ.*9<>,-7AFM[<0VAD$DJ/(Y6))F23;M4O(-I(YXWGV
MKO*,9H-3E?$>O:IIU^\5B+7RXH$E82QLQ8M($QD,,#G/0U5G\4:C!;I'--8V
MSK/-"]W-$WE,4 *@+NX+9_O=CC-=I10!P$?B75H;J[:YN[: 2-;D1W$)Q:*Z
M#+'Y@2N<CG'/4BMC0];U+5-0CBD-LL"P&1F2)LS?.RAE);A2 #WZ_C73T4 %
M%%% !1110 4444 %%%% !1110 4444 8%WKVI6]U)%%X=O9T4X$BNN&]Q7-^
M)/%VOVJ0>3ILVG*QY:95<N?0=A7H>*0JK##*"/<4CBKX:M4BXQJM7\E_P'^)
MREGXFUF2SA>7PU>2.5!+HRJ&]P#TJV=:U6?3+Z1=&N;2>*(M%YI5]Y]@*Z'%
M%,UIT:D6N:HW\E_D>?6_B.XMH[K[#>-?2>7&PEGG$R!F8 @HH4QL,GY<]JOR
M>)=3BU"6V\VP:1'>-H'0QL@"Y$K$MPI/MCWKLJ,4'0<9IOBN[NKO2XY9;8QW
M)*.(XP7+@]@)#\G^V-P]<4Z[U[6QJD\%NUBD*SO"GF0.S *F[)(8 ^F.*['
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MGD9-=I'+',@>-U=3T96R/TI]8&YY]/XBUB*TLU>_C5Y5G9'AMS,TI4KL4_*
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MFTC.=51=FG]S.NS17AFC^)O%TOB"WB6YN;AC*0+>9]L;<'@G'2O1?[3\;_\
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MID4]TUN#<0V\PD2V.(1(7##:7&[&P=2.OTH [^BN'MO%FHI]CM[I[1[J=K7
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MI!<M%=M;1[EE:2XVSS(64_\ /1@F,9P" 0"/ES5I="U=KZQFDMV/E."[!TR
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M[J\T=^EE8V7VN;RO.<^:(U5"<#!(.2<' ]N2*B;Q5I:/*KR2KL#8;R6VR%2
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M-N77R1R-UX<U34D$ERUE!<VUN(K0PN[#>"#O;*C XZ#/UJG-X'NWNK:7SXY
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M6<<9W$$]\<GBM.STR"QN+B:(OOGV;]S9'RJ%&/P%7:* "BBB@ HHHH ****
M"BBB@ HHHH *HG1=,((-A;8-S]K(\L<S?\]/][WJ]12M<I2<=F<CXA^''A_Q
M'.L\\+VTV\N\EL0AD)Z[N#D\=>M;%GX:T:PT^*R@TZW$$;I(%* Y=0 '/JW
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pasg-20211231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &? BX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HI** %HI,\TE #J*2D!H =129H% "T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSR3^==(*Y_PU9Z[:+/\ VW>QW+$_NRBXQ70"I8Q:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BC-&: "BC-&: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!#R,>M<1>> ITU.:_T?6)-/:;)=!%N!/Y
MBNWQ1CF@#E/#_@F'2;V34;RZ:^U"3.Z9DV]>.E5&\"W%CJ-Q=Z#JYT];@[I(
M3#O!/<]17;8HQ0!R>C>##8ZD^I:AJ#7]ZR[1(8]@4?3)JSX=\*+H&I7]VMXT
M_P!K;.PIC;S71[:,4 +BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J.:6."(R2NJ(.26.*DJO>6L%W;-%<1+(A'*MTH BM-3M+RQ^V0S*T'/S]N*
MI6/B6PO[OR(V9221&S# D^E<]8H$^'T\<(*!21M4]!GM3]6%L="TC[(N93CR
M"G!Z<T["-QO%&G)J'V5I&QNV&7:=H;TS6T"& (.0>17$P?9AX(O0X42&20'/
M)\S/\ZU-6O-5L/#5O)I5NL]T(U^1QGM0P.C%+7DFI>-_%VGR6ZWUG!;QR.JY
M"<G)[5ZRK;@#[4ACJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **2B@!:*2EH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I",@BEHH J6^G6UM9FUCC_<G.5/.<UGV'A;3M.NEN(?/9DSL624LJ9]!V
MK;HH PAX3TP7YN_W^XOO,?FGRRWKMK;"[1@  #M3J* /-?BP,+H__7P/YBO1
MH?\ 5)]*\Z^+/W-'_P"O@?S%>C0_ZE/H*I["'T445(PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **0U2U#5+33(?,N90@/0'O2;
M25V#=M697BS7+G1+:*2V"%G;!W#-<K_PGNJ^EO\ ]\57\3^(QKA6** I#&<A
MB<DUS6.>A_*N"M6FY>YL>5B,5-5+4]CV7P_J$NIZ3%<S;?,;KM&!6K7F>CV_
MB1-/CDL)1Y)Y5:T?[8\3V8_?V E]RQ%=$*WNKF.Z%7W4Y([NBN%7QU=PMBYT
MS'J58U9B^(-@Q DMY4JU6B6JL'U.QIDDB11L[L JC))KGX/&>D3'_7%.?XJH
M>*=>M)]'>.TN5=VX(7THE6BE>X2JQ47),OR>-=(CF\OS';MN49'YUO6]Q%<P
MK+$X9&&00<UX6 ,C:O&.>>M=?X4\3P:5 ;6\#;&/RMGI6%+%*4K,X\/C?:2Y
M9'I6:*J66H6M_$)+:574^E6JZTTST%J+1113 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \V^
M+/W='_Z^!_,5Z-#_ *E/H*\Y^+/W='_Z^!_,5Z-#_J4^@JGL(?1114C"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2C-(SJ@RQ  [F@!:CEG2"
M-I)&"JO)R:Y_6/%]C8%H("9[GH%7IGZUS\6G:[XFG$MY(T-L3]QCMX^E8SJV
MTCJS*517M'5FAJWC7<_V;28VDE/&\C@57T_PK>:I-]JUBX+*1D1Y-=1I>@6.
ME1_N8$,G=R,G\ZU *2IREK)@J;;O-E*VTFQM8%BBMHU4#& M2_8+3_GWC_[Y
M%6:3.*UY8KH:<J&I%'&NU%"@=A2D ]139)XX5+RN$4=R<"N<U+QII]HQBMRU
MQ-V"+Q^=*4HQW$Y*.YT3Q0D'<B?B!7-:Y?Z#9ADN(8Y9.R*HK'*^)?$3D#?;
M6Y]3MXK8TOP396A$ET/M,O<N21G\:QE>>B1FY2EHE]YQ\EK-K=S_ ,2_34@C
MS@,PJSJ'A<Z9I)N9V+S$XP@/%>FQ0QPH$B140= HP*5XUD7:ZAAZ$9I?5EU9
M'U=6=V>%.A&,@D?[IK1L9GMX&\VQ\Z!C\V%Y%>O?8+3_ )]HO^^!3Q:P+&46
M&,(>HVC!J/J=M4S".!Y9<RD>4P0VTTXETJ[:UGZ[),Y^G'%;=OXHU7275-3A
M::/IN4@G\ZWM2\':=>AFBC$,AYRO%<W<Z+K^D@B,_:[8=48Y&/H:7).F:<DZ
M>IUVF^)M.U/B*0J_]U^*V 01D'/TKR5CI5S)MEB;3[D=PIVY^@Z5H6UYKVEX
M>"X^V6_^R^_CZ=JTCB&OB1<:[^TCTJC-<II_CBQF(BO%DMY>^Y:HZYXW:*?R
M=,*MCK(P!!K1UX)7N:.O32NV=S2UQOAWQ?)J%XMI>*!(W"LHX-=C5PFIJZ+A
M-35T+1115E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'FOQ9^[H__ %\#^8KT>'_4I]!7G'Q9^[H__7P/YBO1X?\
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MWA/3-.VL(C)(/XI#FK^C6/\ 9VEP6QY9!S6ABNN%)63EN=L*:2N]QJ*%
M]J=116QJ%%%% !1110 &FD C!'%.HH R[_0-,U%6%Q:IN/\ $ORG\Q7+7GA#
M4-/8R:/<R%>\;&N]HQ6<Z49K4SE2C+<\JGF S%KFFLC#CSD0J?TZUSUPL8G;
MR26CS\I->W75G!=Q,DT88&O&]6A6'4[A%1@JN0!@UP5Z7LUH>=CJ-HW)O#[E
M=>L3Z2#VKV4=*\9T 9UVRX;_ %@_A->RKT%=&$^%G1@+^SU'4445UG:%%%%
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M% %=+&VC<.D*AAT(J?%+10 4444 %%%% !1110 4444 %%%% !1110 4444
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M7>H^)=0<V3K^[MPA8@_[( XKK5&3CSGGN,N=P2NS4^-MPRV.GVVU,22%M_\
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MY.G:IN?+XBEAO;<N'>E^I[%17FB^(O%&AX%[IYGB'!<J0*U=-^(UE=.$NX3
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M $K(\>>(_#^@68%Y;1W5T^1'"J DGW]*X/PCX8UCQ7<O?74,=EI[DE5/4>@
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M%9'AS54U72HI0V7"X?ZUL54JKJ^\SGE1=&3@]T+1114B"BBB@ HHHH ****
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MY%9'+B<0\14=22LV%%%%68!1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 449HH **** "BBB@ HHHH **** $/2LKQ#9W5_HDT%F$-P2K('; )#
M]?PK5-5[R\BL;<SS-A 0"?J<4 <=>0^+;R*S1]-L5,$BOD71.<'/I71:3<:Y
M-,XU.QM;>,?=,4V\G]*T'O+>/RM\JKYIPF?XC4] "TG>EI.M $9GB258VD4.
MW1<\FI*Y6XL3;^,;*=KF:42(_P C8PM:'B;7)=!TIKN&T>Z<' 1!DT <A\6
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MF-ZR9D#X,CM_(5MR1C"[W,^9MZ'9R11SQ%)461&ZJXR#^%.1%C0(BA448 '
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MCN:&T9S2U@:?X@O+V]6"70KVV0C_ %LN,#\C3M1U^[L;LPQ:)>W*@9\R+&*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****  U'+$D\312*&1P05/<5(1FDQ[T <S)X2\I
MB-.U*\M(F/,2RG8OKM&.*U-)T2UTE7,1DDGD.9)IGW.WXUI8HQ0 M%%% !11
M10!YK\6 2NCX!/\ I Z?45Z-#_JD^E<#\388)GTE9[CR0)L@^IXXKN+.25T
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M$EN&EVO"%3/7=2L%RQ14$\LR8\J(/^-.1Y&BW-&%?^[F@=R6BJ\,L[L1)"$
M[YHFFG1P(X0ZGOFG85RQ14;O((LJ@+_W<TV"29P?-B"?CFD.Y-159YK@3!5@
M!3^]FI)GE1,QQASZ9IV%<EHJ*%Y'3,D80^F:C6><S[#!A/[V:0[EFDIC.XD"
MA,J>II] #'FCC=4>159ON@G!-*\BQJ6D8*H[DX%<[KYQKVE]>IZ?6KWB3/\
M8<^WKQ_.@#4SG!'2J5QK.FVDOE3W]O')_=:0 CZTZ>1H='>1#\ZPY'UQ61H6
MAV4NEK<74$=Q/<_.[R ,>>U &^)XC#YPE0Q8SOW#&/K52+6]+N)?*BU&U>3.
M-JR@G-<6XG2[NM#69EM3<JH/]U2,XKI-1\.::NCR+#;QPO$A=9(U ;(&>M.P
M&^.M.K,\/W+W>AV<\A.]XQG-:=( HHHH **** "BBB@ HHHH **** "BBB@
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M%<QJ)2T44 %%%% !1110 4E+10 4444 %%%% !1110 E%+10 4444 )12T4
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M-9CX?C0DE$)6,D?PT ;;7$*3K"TBB1N0N>34U<I<Z9%:^,K.[1YGDE1]P+<
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MX6Y#C/\ 8-[_ -]C_"BS ])HKS;_ (6[#_T +W_OH?X4?\+=A_Z %[_WT/\
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M ISZ?%<7L-TV?,A!"D'UJQ)&DJ[9(U<>C#(J2B@"M]AM/^?6#_OV*7[':_\
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M_P"^!2?8[7_GVA_[X%3T4 0?8[7_ )]H?^_8H^QVO_/M#_WP*GHH @^QVO\
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pasg-20211231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #- +T# 2(  A$! Q$!_\0
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M5Q&NZCXETAO#JF>T\B2\M+6[DVDO.[MM? Z*._?K7;T %%%% !1110 4444
M%%%% !113)4\V%X]Q7<I&X=1F@!]9VKZS!HT,<LZ.PD;:-@SSC-9W_"+/_T&
M+_\ [[K"\3Z))8VL#B[NKK=)C;(=P'!YKCK5JT*;DHV^9S5:M2,&U$Z#3_%E
MEJ-]%:113*\F<%AQP"?Z5OUY5HFGRW6L6\),T 8M^\0$%?E)KL_^$6?_ *#%
M]_WW6>%Q%:I!MQO^!%"M5G&[5SHJ*HZ7IQTV%XS=37&YMVZ4Y(XZ5FZ_XH&A
M7<5O_9.HWK2)O#6L!=1SC!/8UW1;:NU8ZXMM:F#X?T^RO?B1XV>ZM()VCEM
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pasg-20211231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20211231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (E ZL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **"0!DG %9VE:_I.N&Y&E:A;WGV:3RYC"^X(W
MID<4 :-%8FO^,/#WA?RQK6K6UF\HRB.V78>H49./?%7-(UK3->L%OM)OH+RV
M8E?,A;< 1U!]#[&@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/>,_^0';?]A73O\ TMAH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KGO&?_(#MO\ L*Z=_P"EL-=#7/>,
M_P#D!VW_ &%=._\ 2V&@#H:*** "BBB@"&YNK>SB\VZN(H(\XWRN%&?3)KAO
MBAX]N_!_@^UUK0_L%XTUZMOF;,D>THY.-C#G*COZUUNN:!I?B33_ +!K%FEW
M:[P_ELQ W#H>"/6O-?BMX!8_#>ST/PAHI*Q:DMP;> YP-D@+?,>>2* ///\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,V_U_2]+U*PTZ\O$BO-0<I:P\EI"!D].@]SQ7.W
MGQ7\'V/B@^'[C4]MXL@A=O+8Q))TVE^@.>#V'<]:XOQSK6F^$_C3:Z[XAMWE
MLUT5A8-Y9<+<"0GCT."1GMN%<)%IVGVOP)U+5]8M5DUO7[_=8RM#NE8AU^Z<
M9'20^X/?- 'U'15;3DFCTNT2X),ZPH)"?[VT9_6K- !7/>,_^0';?]A73O\
MTMAKH:Y[QG_R [;_ +"NG?\ I;#0!T-%%% !1110!7O+B6UMS)#9SW;Y \J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !67K.H7FFP_:(HM.-LBYEEO+
MUH GY1L#^8K4KQCXY7MV+O2K+<RV;1M+@=&?..?H,?G5TX\TK&5>I[.#D=EH
MGCFX\02M#80:(\ZLZ^2VJN'8*Q&X#R.0<9'L1G%=FA8HI< /CY@IR ?8\9KY
M!MKF:SNHKFWD:.:)@Z.IP5(Z&OKFRDEEL;>2==DSQ*SKC&&(Y'YU=:FH6L8X
M6NZJ?-NB>BBBL3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \[
M^)GB_3-)DL]$;PTOB75[E3-;V#0"4(!D;R-K'J#T'8\BN#\-?%9KO1%U;Q7H
MUO=6=GJT4,/V>V 33P8VPX&#TX R<^G(KJ?'Q\0>$?'MMXXT?1FUBT?3_L%W
M;IG?& ^\,, D \<X(X.>HKQGP?\ \)-K&@ZOX+T?17D&J7437=U(K;;95(.&
MXPO0')Y[ 9H ]^N-8\0>*?&.I:+X=U6#2M/TF.+[3>_9EN'FED7<%4,=H4#J
M>N:O>#-?U2YU76O#>O/#-JFD/&?M,*;%N89%W(^WL>Q XK(^'=NND^-O&NCR
M-^^CGMIDW=7C,6 P]>F*F\.$7GQF\7W<)W06UK:VKN.ADP6(^HZ'TH ]"KGO
M&?\ R [;_L*Z=_Z6PU?U/3+N_DC:VUS4-."C!2U2!@_N?-B<_D17,>)M&O[3
M3[.>;Q-JM[&NJZ=F">.U"/F\A')2%6XZ\$=/3B@#N:*** "BBB@ HJ&YN4M8
M?-D65ESC$432'\E!-9EYXCMK>V9HX+QIF^2%'LYD#N>%7+* ,GWJ)5(0^)F<
MZL(?$[&LDT4KR)'(C-&VUPK9*G&<'TX(I]<PMM_PC#P7\KM)'./+U!U4L3(2
M2L@ Y^\2OT8>E:RZU:LP417^2<<V$X'YE*B%9;3T9$*ZVJ:/M?\ K_AS1HHH
MK8W"BO"?"WC%[337\)Z-<PPZWJ6LW:?:IA^[M%+L=Q[-(0#M3N>O'7N]>C@^
M&/PNU:ZTA6:YACWFXF.^2:>1@OFN3]YLL#^&.E '<-+&CJC2*K-]U2<$_2GU
MPFF_"KPR=+C_ +:L!JNI2H&NKZ[D9Y9)".2&SE1GIC&*;X GN]-U_P 2^$+B
M[FN[?2)89+.:=MSB&9"PC+=]N, F@#O:*R=:\3:)X<\C^V=3MK'S]WE>>^W?
MMQG'TR/SKFO /Q"TOQ#I5A;76M6<VN3M*#;J0'.UG(^4?[ !H [NBN9^(O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=O7OVJY\-7-SXE\7ZAJ"&SUVZN8?MFF$9^RHJ$1_-T?<"3N'!H ]'KGO&?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_,6''I72VC*]I&R7/VI2.)LJ=_O\H _(5,:CGT_(RH583NH_FG^K)J***LZ
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MB;P[=_!2W\*JCW?B(WK-:0QPMF%FER"&QCE21@9/->C^/_C#X,6XFT&?1?\
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M?_ )_P#X[1Y.L?\ /]8_^ 3_ /QVM"BND]?V,>[^]_YF?Y.L?\_UC_X!/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJO>7$MK;F2&SGNWR!Y4!0-]?G91^M %BBL!?$MR][+9KX;U8W$4:
M2NF^UX5RP4Y\[')1ORK:MY7FMTDD@D@=ADQ2%2R^QVDC\B:;5B5)/8EKGI6/
MB>Y>VC)&BPL5GD'_ "]N#S&O_3,'[Q_B/'3-/O9Y==O)=*LI&CLXCMOKI#@D
M_P#/%#_>_O$?=''4\;4$$5M!'!!&L<4:A41!@*!T %/87Q:=!ZJ%4*H 4#
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M]+8: .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<I]CE7<)'.T#U!ST(.17R5CG'>OH/X:>$;>U\)VMQJNFPO>2NTJ>?$&:-#T
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MY^8MS^':K[26]Y''I6F73312Y:XG%PTQ2+."-Y).6/ YXY/:LE4E:[7X_P#
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MPH Z*N>\9_\ (#MO^PKIW_I;#70USWC/_D!VW_85T[_TMAH Z&BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBL[7M9M_#^B76J763%;INVCJQZ!1]20*$
MKZ";25V5[G_D==+_ .P?=_\ HRVK9KYXN/BWK\VO1:HD-F@A1XHX-A*['*%@
M3G)/R+SQ7K.A>-)?$^D0W&D:5))<,-LQF;RX8''4%\9;L<*#P1G%:SI2BE<Y
MZ6(A-M(ZTD $DX ZDUC/XA2Y=H=&MGU*4'!D1ML"'_:E/!^B[C[4T>'VOB'U
MR[:_[_9E7R[9?^ 9._\ X&6^@K:1$C14155%& JC  K/1&_O/R,7^P[G4?FU
MR],Z'_ESM\QP#V;G<_\ P(X/]T5L0P16T*0P1)%$@PJ(H55'H .E257O'NTM
MRUC!!--D82>8Q+CO\P5C^E%VP22U.?N=$TK_ (3O3IO[-M/->RNI6?R5RSK)
M  QXZC<W/N?6NHKFI8?$LFM6NH_V;I(\BWF@\O\ M*3YO,:-LY\CC'E]/?VK
M=LWNWMPU]!!#-DY2"8RKCM\Q53^E.6R)A:[LBQ1114F@57O+.*^MS!,TZH2#
MF"=X6_[Z0@_K5BB@-S#'A/2UG:<2:F)74(T@U6ZW,H)(!/F=!N;'U/K6O;P)
M:VZ01F0H@P#)(TC?BS$D_B:EHIMM[B44MD%%%%(84444 %%%% !1110 4456
MU"]CTZPFNI 2L:Y"CJQZ!1[DX'XTFTE=BE)15WL4;>>)O%E_")%,@LX,KGD8
M:4G_ -"7\Q6O7-2:;<:?IT6JA?,U.%VN;@)UE#?ZQ![!0,?[BUH0ZQ/<01S1
M:-?O'(H96$D&"#R#_K:PIU.722UW^\YJ53EO&:UWV;T9JT5CR:^8?];IETG^
M]/;#_P!JU6/B^U!Q]DF8^BW%LQ_(2UI[2/G]S*>*I1W?X,Z&JM[:37:(L.H7
M-F5.2T"QDM['>C#\JQ_^$M0_<T35Y/\ KG"C_P G-4=9\975O;1P66CWL5]<
ML$@^V1JJ]0"<!B3C(X]2*3K12N[_ ',B6,H<K=_S&0+)!-K;CQ%J)>"Y52L2
M6Q:5C&@7@Q?>)&WC ^7UR3I:=]JMXFMH9!=ZI(0UY=R ;(VQC!V@ D#@*,>I
MQFLC7]$ETG2K/4+0^9<6N/M1W;?.W$EFW=CEFY[!B>U=!I^M:,FC6UPES;V=
MLZ95)I%C*>H.3U!R#[UG14F_?W7Z_P!6^\PI*;FXSTMKOW[?E?U[EZSL([3<
M^YI;B3_63R<L_P#@/0#@5:K'_P"$HT=O]1=-=>GV2%Y\_P#?"FC^W)I/^/;1
M-4F]"T:1#_R(RG]*Z3NBX15HFQ6;K&J/IZ016T'VB^NI/+MX2VT$XR68]E !
M)/X=ZA^UZ_-_JM*LX!ZW%X21_P !5"/_ !ZLVY.H67B;2+[5YK0V[+-:H88V
M412/M*[F9CG.PJ.!R?>@4IZ:#HH?$6C/>7[I9:@EQ*)[BWMD>.1<(J?NRS$-
MP@.#C)SST%68=0OO$4*2:839:;(,B\=0991_TS0_='^TW_?/>MB\O+?3[.6[
MNYEB@B7<[L> *S?"UO-;^'K<3Q-$\CRSB)A@QK)(SJI]" P% N6TN5/0NZ?I
MEIID3);1X9SNDD8EGD;U9CRQ^M7***#5)+1!1110,**** "BBB@ HHHH ***
M* "BBB@!DL4<\31RQK)&PPRN,@_45S=AI]EI7CB:*"!($FT]3;HO"@B1O,"C
MH.L60*Z>J.IZ3;:K%&L_F))$V^&:%RDD3=,JP_ET/>@B<;V:W0FN2VD.A7SW
MX4VH@82!OX@1C'U/04:''<Q>']-CO,_:DM8EFW==X49S^-8NA:0-007NJ7MW
MJ$EO=SI"EPR^6GES.BMM50"V%!R<\YQBNIH%"\GSG'?$RYM+3PGYMWK.IZ2!
M<Q^7/IT9>1I.=J$ ="?<9( SS@^5_P!L>.5\437KVMQ'>'2(TDO$T]#>BT\U
M\2_9O,P'+<$9.  =M?0C(K@!E# $$9&>1TK(3PW91^+I?$HDN/MTEF+-D+CR
M_+#;NF.N>^>YH-#EM#N],F^$=W<#Q'K5Q8&&<S:G-&PN4Y.\J-I/!SSSCUXX
M\W;5_%UQJ/AJ>P2YU>*"6<Z3>:I:K#<39A;?A/,_>@*-P8[=Q '-?0_EQF-H
MRB[&SE<<'/7CWK)U7PW9:OK6CZK<23K<:2[R6XC<!27 !W#'/ ]NIH Y;X87
MZW\6L22ZYK6HZ@)D^V1:E:?9_LSX/RHG(7CJ QZ#@9Y\SU;5-5N="N[;1K_4
MO$'A];Z M<:S;>2(I?/3"I*2&;+<%=F%!)XKZ,"J"2% +=2!UK'\1^&+#Q/H
MW]E7C316_FI+_H[!#N4Y'8]^: .&\"ZK?7_CBZ3Q!JVLIKJVS;M(ELA!:Q1[
MERR8+A@#@!]P)SWZ5ZE2;5W!MHW 8!QSBEH **** "BBB@ HHHH **** "BB
MB@#Q#XH>(8/!_P 5])UNVT66_OX[ "4-_JVC9G VG!*.,'GG@XQ2?\-$<<^#
M;[_P(_\ L*ZKQ]XN\;Z!KL-KX:\+?VK9/;+(\_DR/MD+,"N5('0*?QKB[GXN
M?$JSN;>WN_!,-O)<OY<(F@E02-_=!+8)]NM '3ZCXDT7Q;XRCL-1U:PL]#T5
MUEN(;FY2,W=WU"88C*1]3V+<<XJY\'M2L+C0M2M8+VVEN/[4NYO*256?89.&
MP#G:<]>E=>/#>AW8%S=Z#IC7,OSRL]HA8N>3DD9)S6;X(\%V_A"RNHPEJ]Q/
M=2R^?% $81NV0F>N!Z=* -C4Y];BDC&E:?I]TA'SFZOG@(/L%A?/YBN8\37/
MB233[-;_ $K2H+4ZKIV^2#4Y)7'^F0XPI@4'G'\0_'I7<USWC/\ Y =M_P!A
M73O_ $MAH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;))'#$TLKJD: LS
M,<!1ZDT .KC_ (@0QZUH%QX?MM\VISA7B@B )7# AG/15XZG\,FM'[??:[\F
MDEK6P/WM0=/FD'_3%3_Z&W'H&ZUIZ=IEII<#16L9!<[I)&)9Y&_O,QY8^YJE
M[KN9R]]./0^69?#VLP:B-/DTN\%V3@1>2Q8^X]1R.1ZU]"_#CPY<^&?"4=I>
M86ZFE:XE0'.PD !<_11^.:U+G_D==+_[!]W_ .C+:MFM*E5R21A0PT:<F[A1
M116)UA1110 4444 %%%% !1110 4444 %%%% !115>Z2\=5^QSP1-GYC-"9
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MBRZFCQLUY& Z_9+=<CGD9!'U!]*[96#J&4@J1D$'@B@!:*** "BBB@ HHHH
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MCQ-X3\-Z9I]G>6'A_2K2ZCU73MDT%G'&ZYO(0<,!D9!(_&@#N:*** "BBB@
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M]]I3:VN>1L;?DV6[=D;<<XQC=G\*U-#LI;>6\N)_MXEG92WVLP\D#&1Y7'3
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M"5I5QC=V\H_G[5]$Z+IYTG0M/TXR"0VEM' 7 QNV*%SCMG% %ZBBB@ HHHH
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MW0__  33?_)5 '045S_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\ !--_\E4
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MW0__  33?_)5 '045S_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\ !--_\E4
M=!17'PW'C"7Q%>Z3_:^AC[-:07/F_P!D3?-YKS+MQ]IXQY.<YYW=L<Z'V/QA
M_P!!W0__  33?_)5 '045S_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\ !--_
M\E4 =!17/_8_&'_0=T/_ ,$TW_R51]C\8?\ 0=T/_P $TW_R50!T%%<?#<>,
M)?$5[I/]KZ&/LUI!<^;_ &1-\WFO,NW'VGC'DYSGG=VQSH?8_&'_ $'=#_\
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MN;9P"A5C]['S?*.A)]ZU/A%$3I.O7]O"\.E7^LW%QIR,I4&$X 91V4D' ]J
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M]*YWQ3JVC^*?'G@V+PS=6]_J=I?"XN+FS8.(;4#YU=UX ;IC/\^0#UBBBB@
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M5T]U':6Z7+_>F6,!V^IQDU8HH **** "JLFFV,TC2265L[MR6:)23^.*M44
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MVO\ WY7_  JY10!&EO#%#Y,<4:18(V*H"\]>*='&D4:QQHJ(HP%48 _"G44
M%%%% ",JNA1U#*PP01D$54_LG3?^@?:?]^5_PJY10!$]K;R6WV9X(F@QM\ID
M!7'ICI3;6RM+&,QV=K#;QDY*PQA!GZ"IZ* "BBB@!KHLB,CJ&1AAE89!'I57
M^R=-_P"@?:?]^5_PJY10!#+:6T]M]FFMXI(, >4Z K@=!@\4Z"W@M85AMX8X
M8E^ZD:A5'X"I** "BBB@!DL4<\9CFC22-NJNH(/X&JW]DZ;_ - ^T_[\K_A5
MRB@"*2V@FMS;RPQO"1@QLH*D>F.E%O;06D*PVT$<,2]$C0*H_ 5+10 4444
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M0;^W^*=]X.L\II_B>^MKUL=ERV\_0,7/_ 177V44=O\ M030Q($CCTQ411T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>pasg-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 12:17:21 PM-->
<!--Modified on: 3/3/2022 12:17:21 PM-->
<xsd:schema targetNamespace="http://www.passagebio.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pasg="http://www.passagebio.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails">
        <link:definition>40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails">
        <link:definition>40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" id="DisclosureFairValueOfFinancialInstrumentsDetails">
        <link:definition>40501 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseDetails">
        <link:definition>40802 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41101 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" id="DisclosureIncomeTaxesEffectiveTaxRateDetails">
        <link:definition>41102 - Disclosure - Income Taxes - Effective tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" id="DisclosureRisksAndLiquidityDetails">
        <link:definition>40201 - Disclosure - Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails">
        <link:definition>40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" id="DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails">
        <link:definition>40801 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails" id="DisclosureConvertiblePreferredStockAndCommonStockDetails">
        <link:definition>40901 - Disclosure - Convertible Preferred Stock and Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" id="DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails">
        <link:definition>41001 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41002 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" id="DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails">
        <link:definition>41005 - Disclosure - Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" id="DisclosureShareBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>41006 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" id="DisclosureIncomeTaxesNetOperatingLossesDetails">
        <link:definition>41103 - Disclosure - Income Taxes - Net operating losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidity" id="DisclosureRisksAndLiquidity">
        <link:definition>10201 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities" id="DisclosureCashCashEquivalentsAndMarketableSecurities">
        <link:definition>10401 - Disclosure - Cash, cash equivalents and marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>10501 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10701 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock" id="DisclosureConvertiblePreferredStockAndCommonStock">
        <link:definition>10901 - Disclosure - Convertible Preferred Stock and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11001 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" id="DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>30503 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30803 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>31003 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
        <link:definition>41003 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" id="DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails">
        <link:definition>41004 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element id="pasg_SeriesOneConvertiblePreferredStockMember" name="SeriesOneConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_SeriesTwoConvertiblePreferredStockMember" name="SeriesTwoConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" name="IncreaseDecreaseInPrepaidResearchAndDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_VestingOfEarlyExerciseOptionAwards" name="VestingOfEarlyExerciseOptionAwards" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_PrepaidResearchAndDevelopmentAssetCurrent" name="PrepaidResearchAndDevelopmentAssetCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_RisksAndLiquidityAbstract" name="RisksAndLiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_RisksAndLiquidityTextBlock" name="RisksAndLiquidityTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_StockholdersEquityAndTemporaryEquityTextBlock" name="StockholdersEquityAndTemporaryEquityTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_BasisOfPresentationPolicyTextBlock" name="BasisOfPresentationPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_RisksAndLiquidityTable" name="RisksAndLiquidityTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" name="StockOptionsIncludingSharesSubjectToRepurchaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_AccruedResearchAndDevelopmentExpense" name="AccruedResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementUpfrontPaymentMade" name="CollaborationAgreementUpfrontPaymentMade" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_CollaborationAgreementAnnualFeePayable" name="CollaborationAgreementAnnualFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" name="CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" name="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" name="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" name="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" name="EmployeeStockPurchasePlanStockPurchasePricePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_PromissoryNoteWithRelatedPartiesMember" name="PromissoryNoteWithRelatedPartiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_InterimChiefExecutiveOfficerMember" name="InterimChiefExecutiveOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_InterimChiefOperatingOfficerMember" name="InterimChiefOperatingOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_NotesReceivableInterestRatePercentage" name="NotesReceivableInterestRatePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" name="ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" name="ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_RisksAndLiquidityLineItems" name="RisksAndLiquidityLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_StockIssuanceCosts" name="StockIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_TermOfManufacturingAndSupplyAgreement" name="TermOfManufacturingAndSupplyAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" name="ManufacturingAndSupplyAgreementAdditionalExtensionTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" name="NewLeaseAgreementOperatingLeaseRenewalTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" name="NewLeaseAgreementOperatingLeaseNumberOfExtensions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="pasg_TenantImprovementAllowanceReceivable" name="TenantImprovementAllowanceReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" name="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" name="ShareBasedCompensationArrangementExpensesDueToModifications" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_NumberOfEquityIncentivePlans" name="NumberOfEquityIncentivePlans" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" name="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" name="ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementQuarterlyFeePayable" name="CollaborationAgreementQuarterlyFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_ReclassificationsOfTemporaryToPermanentEquityShares" name="ReclassificationsOfTemporaryToPermanentEquityShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" name="StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" name="StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" name="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" name="CashCashEquivalentsAndMarketableSecuritiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_CatalentMarylandInc.Member" name="CatalentMarylandInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" name="DeferredTaxAssetsCollaborationAndLicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_StateTaxAuthorityMember" name="StateTaxAuthorityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_LocalTaxAuthoritiesMember" name="LocalTaxAuthoritiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_TaxCreditCarryForwardSubjectToExpiration" name="TaxCreditCarryForwardSubjectToExpiration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_SegmentPolicyPolicyTextBlock" name="SegmentPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" name="DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_PropertyAndEquipmentInDeferredRent" name="PropertyAndEquipmentInDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" name="NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" name="CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementAnnualFeePayableTerm" name="CollaborationAgreementAnnualFeePayableTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" name="LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" name="EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" name="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_DevelopmentMilestonePaymentsPayable" name="DevelopmentMilestonePaymentsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" name="CollaborationAgreementSalesMilestonePaymentsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_PaymentsForTechnologyLicenseFee" name="PaymentsForTechnologyLicenseFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" name="AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_OperatingLeasesForLaboratorySpaceMember" name="OperatingLeasesForLaboratorySpaceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_EquityInducementPlan2021Member" name="EquityInducementPlan2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" name="PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" name="AccruedLiabilitiesPropertyAndEquipmentCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_AdditionalTechnologyLicenseFeePaid" name="AdditionalTechnologyLicenseFeePaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" name="CollaborationAgreementTieredTransactionFeePayablePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" name="CollaborationAgreementPaymentMadeOnOptionExercise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromTenantImprovementAllowance" id="pasg_ProceedsFromTenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RemainingTenantImprovementAllowanceReceivable" id="pasg_RemainingTenantImprovementAllowanceReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfExecutiveOfficers" id="pasg_NumberOfExecutiveOfficers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LaboratoryEquipmentMember" id="pasg_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ComputerHardwareAndSoftwareMember" id="pasg_ComputerHardwareAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SalesAgreementWithCowenAndCompanyLlcMember" id="pasg_SalesAgreementWithCowenAndCompanyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>pasg-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 12:17:21 PM-->
<!--Modified on: 3/3/2022 12:17:21 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementBalanceSheets" roleURI="http://www.passagebio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.passagebio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureFairValueOfFinancialInstrumentsDetails" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesEffectiveTaxRateDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" />
  <calculationLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637819066402238634" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637819066402238634" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637819066402238634" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637819066402238634" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637819066402248668" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819066402248668" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819066402248668" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819066402248668" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_637819066402248668" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819066402248668" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637819066402248668" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637819066402248668" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819066402248668" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637819066402248668" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819066402248668" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637819066402248668" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819066402248668" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819066402248668" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637819066402248668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819066402248668" xlink:to="us-gaap_AdditionalPaidInCapital_637819066402248668" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637819066402248668" xlink:to="us-gaap_CommonStockValue_637819066402258659" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637819066402258659" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637819066402258659" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637819066402258659" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637819066402258659" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637819066402258659" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637819066402258659" xlink:to="us-gaap_LiabilitiesCurrent_637819066402258659" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637819066402258659" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_637819066402258659" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637819066402258659" xlink:to="us-gaap_AccountsPayableCurrent_637819066402258659" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637819066402258659" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637819066402258659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637819066402258659" xlink:to="us-gaap_InvestmentIncomeInterest_637819066402258659" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637819066402258659" xlink:to="us-gaap_OperatingIncomeLoss_637819066402268660" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637819066402268660" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637819066402268660" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637819066402268660" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066402268660" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637819066402268660" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637819066402268660" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_637819066402268660" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066402268660" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066402268660" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637819066402268660" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066402268660" xlink:to="us-gaap_ProceedsFromStockPlans_637819066402268660" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066402268660" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637819066402268660" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637819066402268660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066402268660" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637819066402268660" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066402278658" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066402278658" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637819066402278658" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066402278658" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819066402278658" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066402278658" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_637819066402278658" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066402278658" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_637819066402278658" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_637819066402278658" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637819066402278658" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819066402278658" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819066402278658" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_637819066402288653" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInDeferredRent" xlink:label="pasg_IncreaseDecreaseInDeferredRent_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="pasg_IncreaseDecreaseInDeferredRent_637819066402288653" order="5" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637819066402288653" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_ShareBasedCompensation_637819066402288653" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637819066402288653" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066402288653" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819066402288653" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066402278658" xlink:to="us-gaap_NetIncomeLoss_637819066402288653" order="10" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819066402298652" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819066402298652" order="2" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066402298652" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_637819066402298652" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819066402298652" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_637819066402298652" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819066402298652" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Instruments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819066402298652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819066402298652" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066402308668" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819066402308668" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637819066402308668" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637819066402308668" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819066402308668" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_637819066402308668" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_637819066402308668" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637819066402308668" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent_637819066402308668" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Operating Lease (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637819066402318660" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637819066402318660" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637819066402318660" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637819066402318660" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637819066402318660" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637819066402318660" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637456100089155636" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637456100089155636" xlink:to="us-gaap_DeferredTaxAssetsNet_637819066402318660" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637819066402318660" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637819066402318660" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637819066402318660" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637819066402318660" xlink:to="us-gaap_DeferredTaxAssetsGross_637819066402328657" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066402328657" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637819066402328657" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066402328657" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819066402328657" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066402328657" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_637819066402328657" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066402328657" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637819066402328657" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066402328657" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819066402328657" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066402328657" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_637819066402328657" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes - Effective tax rate (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819066402328657" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819066402328657" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819066402328657" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637819066402338659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637819066402338659" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637819066402338659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637819066402338659" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819066402338659" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819066402338659" order="5" use="optional" weight="-1" priority="3" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>pasg-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 12:17:21 PM-->
<!--Modified on: 3/3/2022 12:17:21 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureRisksAndLiquidityDetails" roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureFairValueOfFinancialInstrumentsDetails" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureConvertiblePreferredStockAndCommonStockDetails" roleURI="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesNetOperatingLossesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.passagebio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="pasg-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.passagebio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesOneConvertiblePreferredStockMember" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pasg_SeriesOneConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesTwoConvertiblePreferredStockMember" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pasg_SeriesTwoConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesBConvertiblePreferredStockMember" xlink:label="pasg_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pasg_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesOneConvertiblePreferredStockMember" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="pasg_SeriesOneConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesTwoConvertiblePreferredStockMember" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="pasg_SeriesTwoConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesBConvertiblePreferredStockMember" xlink:label="pasg_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="pasg_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="pasg_ReclassificationsOfTemporaryToPermanentEquityShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="pasg_ReclassificationsOfTemporaryToPermanentEquityShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityTable" xlink:label="pasg_RisksAndLiquidityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pasg_RisksAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="pasg_RisksAndLiquidityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember" xlink:label="us-gaap_DemandDepositsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_DemandDepositsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="pasg_ComputerHardwareAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_ComputerHardwareAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CatalentMarylandInc.Member" xlink:label="pasg_CatalentMarylandInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="pasg_CatalentMarylandInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAnnualFeePayable" xlink:label="pasg_CollaborationAgreementAnnualFeePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAnnualFeePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementQuarterlyFeePayable" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementQuarterlyFeePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementUpfrontPaymentMade" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementUpfrontPaymentMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DevelopmentMilestonePaymentsPayable" xlink:label="pasg_DevelopmentMilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_DevelopmentMilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PaymentsForTechnologyLicenseFee" xlink:label="pasg_PaymentsForTechnologyLicenseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_PaymentsForTechnologyLicenseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AdditionalTechnologyLicenseFeePaid" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_AdditionalTechnologyLicenseFeePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAnnualFeePayableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TermOfManufacturingAndSupplyAgreement" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_TermOfManufacturingAndSupplyAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Operating Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TenantImprovementAllowanceReceivable" xlink:label="pasg_TenantImprovementAllowanceReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_TenantImprovementAllowanceReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DeferredRentCreditNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" xlink:label="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RemainingTenantImprovementAllowanceReceivable" xlink:label="pasg_RemainingTenantImprovementAllowanceReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_RemainingTenantImprovementAllowanceReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ProceedsFromTenantImprovementAllowance" xlink:label="pasg_ProceedsFromTenantImprovementAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_ProceedsFromTenantImprovementAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Convertible Preferred Stock and Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pasg_SalesAgreementWithCowenAndCompanyLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="pasg_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="pasg_EquityIncentivePlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EquityInducementPlan2021Member" xlink:label="pasg_EquityInducementPlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="pasg_EquityInducementPlan2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="pasg_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="pasg_EmployeeStockPurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="pasg_NumberOfEquityIncentivePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_NumberOfEquityIncentivePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" xlink:label="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PromissoryNoteWithRelatedPartiesMember" xlink:label="pasg_PromissoryNoteWithRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pasg_PromissoryNoteWithRelatedPartiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_InterimChiefExecutiveOfficerMember" xlink:label="pasg_InterimChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pasg_InterimChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_InterimChiefOperatingOfficerMember" xlink:label="pasg_InterimChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pasg_InterimChiefOperatingOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfExecutiveOfficers" xlink:label="pasg_NumberOfExecutiveOfficers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_NumberOfExecutiveOfficers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="us-gaap_NotesReceivableRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_NotesReceivableRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NotesReceivableInterestRatePercentage" xlink:label="pasg_NotesReceivableInterestRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_NotesReceivableInterestRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes - Net operating losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StateTaxAuthorityMember" xlink:label="pasg_StateTaxAuthorityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="pasg_StateTaxAuthorityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="pasg_LocalTaxAuthoritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="pasg_LocalTaxAuthoritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pasg_TaxCreditCarryForwardSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>pasg-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 12:17:21 PM-->
<!--Modified on: 3/3/2022 12:17:21 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research And Development Asset, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total, property plant and equipment net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies (note 8)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,244,966 shares issued and 54,244,966 shares outstanding at December 31, 2021 and 45,917,084 shares issued and 45,614,807 shares outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesOneConvertiblePreferredStockMember" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SeriesOneConvertiblePreferredStockMember" xlink:to="pasg_SeriesOneConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A 1 Convertible Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesTwoConvertiblePreferredStockMember" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SeriesTwoConvertiblePreferredStockMember" xlink:to="pasg_SeriesTwoConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A 2 Convertible Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesBConvertiblePreferredStockMember" xlink:label="pasg_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SeriesBConvertiblePreferredStockMember" xlink:to="pasg_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series B Convertible Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development in Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications of Temporary to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="pasg_ReclassificationsOfTemporaryToPermanentEquityShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="pasg_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications Of Temporary To Permanent Equity, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications Of Temporary To Permanent Equity, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pasg_ReclassificationsOfTemporaryToPermanentEquityShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock upon initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock vesting of common stock previously subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Vesting Of Common Stock Previously Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercise option awards</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that have been vesting of common stock previously subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Vesting Of Common Stock Previously Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercise option awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options and vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options and vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares in connection with employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares in connection with employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" xlink:to="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of reclassification of convertible preferred stock upon consummation of initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Convertible Preferred Stock Upon Consummation Of Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" xlink:to="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of reclassification of convertible preferred stock upon consummation of initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Convertible Preferred Stock, Shares Upon Consummation Of Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock upon initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock in initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock in initial public offering, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuanceCosts" xlink:label="pasg_StockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockIssuanceCosts" xlink:to="pasg_StockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of stock issuance incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of premium and discount on marketable securities, net</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInDeferredRent" xlink:label="pasg_IncreaseDecreaseInDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInDeferredRent" xlink:to="pasg_IncreaseDecreaseInDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in deferred rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets, and other assets</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in prepaid research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Prepaid Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and amount of increase (decrease) in current liabilities classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales or maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of technology licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows provided by financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock under employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PropertyAndEquipmentInDeferredRent" xlink:label="pasg_PropertyAndEquipmentInDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PropertyAndEquipmentInDeferredRent" xlink:to="pasg_PropertyAndEquipmentInDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of property and equipment in deferred rent during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property And Equipment In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in deferred rent</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in accounts payable and accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property And Equipment In Accounts Payable And Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in accounts payable and accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of acquired in process research and development in accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In Process Research And Development In Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development in accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of deferred financing costs included in accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Financing Costs Included In Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred financing costs in accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" xlink:label="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" xlink:to="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Deferred Offering Costs Paid In A Prior Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Deferred Offering Costs Paid In A Prior Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of deferred offering costs paid in a prior period</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_VestingOfEarlyExerciseOptionAwards" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_VestingOfEarlyExerciseOptionAwards" xlink:to="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of vesting of early exercise option awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Of Early Exercise Option Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercise option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="pasg_RisksAndLiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityAbstract" xlink:to="pasg_RisksAndLiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="pasg_RisksAndLiquidityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityTextBlock" xlink:to="pasg_RisksAndLiquidityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to risk and liquidity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks And Liquidity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock and Common Stock</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockholdersEquityAndTemporaryEquityTextBlock" xlink:label="pasg_StockholdersEquityAndTemporaryEquityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockholdersEquityAndTemporaryEquityTextBlock" xlink:to="pasg_StockholdersEquityAndTemporaryEquityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockholdersEquityAndTemporaryEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to stockholders equity and temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockholdersEquityAndTemporaryEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity And Temporary Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockholdersEquityAndTemporaryEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock and Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="pasg_BasisOfPresentationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_BasisOfPresentationPolicyTextBlock" xlink:to="pasg_BasisOfPresentationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SegmentPolicyPolicyTextBlock" xlink:label="pasg_SegmentPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SegmentPolicyPolicyTextBlock" xlink:to="pasg_SegmentPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SegmentPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SegmentPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_SegmentPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In-Process Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of details regarding the Company's portfolio of cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of details regarding the Company's portfolio of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Final Maturities of Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued liabilities and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum rental payments for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions applied to options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity relating to early exercises of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityTable" xlink:label="pasg_RisksAndLiquidityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityTable" xlink:to="pasg_RisksAndLiquidityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to risk and liquidity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks And Liquidity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="pasg_RisksAndLiquidityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks And Liquidity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer hardware and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_LaboratoryEquipmentMember" xlink:to="pasg_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to stock options (including shares subject to repurchase).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options (including shares subject to repurchase)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2016-02</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset impairment charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedient, Use of Hindsight [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, practical expedient</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember" xlink:label="us-gaap_DemandDepositsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemandDepositsMember" xlink:to="us-gaap_DemandDepositsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DemandDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash accounts in banking institutions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates of deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. government securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-U.S. government securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due within one year, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due after one year through five years, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due within one year, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due after one year through five years, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="pasg_ComputerHardwareAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ComputerHardwareAndSoftwareMember" xlink:to="pasg_ComputerHardwareAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Computer Hardware and Software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer hardware and software.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and related benefits</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="pasg_AccruedResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedResearchAndDevelopmentExpense" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying balance as of the balance sheet of accrued research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:to="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs of property and equipment Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Property and Equipment, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and restated agreement with Penn</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CatalentMarylandInc.Member" xlink:label="pasg_CatalentMarylandInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CatalentMarylandInc.Member" xlink:to="pasg_CatalentMarylandInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CatalentMarylandInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Catalent Maryland, Inc. (Catalent) (formerly Paragon Bioservices, Inc.).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CatalentMarylandInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Catalent Maryland, Inc. (Catalent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAnnualFeePayable" xlink:label="pasg_CollaborationAgreementAnnualFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAnnualFeePayable" xlink:to="pasg_CollaborationAgreementAnnualFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of annual fee payable during the period under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Annual Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual fee payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementQuarterlyFeePayable" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementQuarterlyFeePayable" xlink:to="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Quarterly Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Quarterly Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly fee payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:to="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of remaining options available to the Company to commence additional licensed programs for rare, monogenic CNS indications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Remaining Options Available To Commence Additional License Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of CNS indications</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementUpfrontPaymentMade" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementUpfrontPaymentMade" xlink:to="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment made during the period under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Upfront Payment Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payments</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:to="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront fee payable upon clinical candidate designation under the collaboration agreement if the company were to exercise the options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Upfront Fee Payable Upon Clinical Candidate Designation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront fee payable upon clinical candidate designation</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DevelopmentMilestonePaymentsPayable" xlink:label="pasg_DevelopmentMilestonePaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DevelopmentMilestonePaymentsPayable" xlink:to="pasg_DevelopmentMilestonePaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable on development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone payment</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:to="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of tired transaction fee payable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Tiered Transaction Fee Payable, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, tiered transaction fee percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PaymentsForTechnologyLicenseFee" xlink:label="pasg_PaymentsForTechnologyLicenseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PaymentsForTechnologyLicenseFee" xlink:to="pasg_PaymentsForTechnologyLicenseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PaymentsForTechnologyLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash paid for technology license fee during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PaymentsForTechnologyLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Technology License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PaymentsForTechnologyLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for technology license fee</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AdditionalTechnologyLicenseFeePaid" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AdditionalTechnologyLicenseFeePaid" xlink:to="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Technology License Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Technology License Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional technology license fee paid</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:to="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of annual fee payable during the period under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Annual Fee Payable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual fee payable, term</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:to="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for which the annual fee is payable for the use of clean room suite under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Period For Which Annual Fee is Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which annual fee is payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TermOfManufacturingAndSupplyAgreement" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TermOfManufacturingAndSupplyAgreement" xlink:to="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of manufacturing and supply agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Of Manufacturing And Supply Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of manufacturing and supply agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:to="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the additional extension term of manufacturing and supply agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing And Supply Agreement, Additional Extension Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional extension term of manufacturing and supply agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:to="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid on option exercise under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Payment Made On Option Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment made on option exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Remaining Minimum Amount Committed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount agreed to purchase in batches of drug product</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Amount Payable Per Product Candidate Upon Achievement Of Specific Development Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable per product candidate upon achievement of specific development milestone</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable per product candidate  for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable per product candidate for rare, monogenic disorders</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable per product candidate for large CNS indications upon achievement of specific development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Amount Payable Per Product Candidate for Large CNS Indications, Upon Achievement Of Specific Development Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable per product candidate arising from the exploratory program for large CNS indications</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable on sales milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Sales Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_OperatingLeasesForLaboratorySpaceMember" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the operating lease agreement for laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases For Laboratory Space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of extensions available under the new lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Lease Agreement, Operating Lease, Number Of Extensions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of extension terms</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the renewal term under new lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Lease Agreement, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended term of new lease agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TenantImprovementAllowanceReceivable" xlink:label="pasg_TenantImprovementAllowanceReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TenantImprovementAllowanceReceivable" xlink:to="pasg_TenantImprovementAllowanceReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tenant improvement allowance receivable from the landlord under operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvement Allowance Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvement allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Terminate [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to extend</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" xlink:label="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" xlink:to="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of times the lease term can be extended under the operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Number Of Options To Extend The Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term extended, number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension term</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RemainingTenantImprovementAllowanceReceivable" xlink:label="pasg_RemainingTenantImprovementAllowanceReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RemainingTenantImprovementAllowanceReceivable" xlink:to="pasg_RemainingTenantImprovementAllowanceReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RemainingTenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of remaining tenant improvement allowance receivable as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RemainingTenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Tenant Improvement Allowance Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_RemainingTenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining tenant improvement allowance receivable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ProceedsFromTenantImprovementAllowance" xlink:label="pasg_ProceedsFromTenantImprovementAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ProceedsFromTenantImprovementAllowance" xlink:to="pasg_ProceedsFromTenantImprovementAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ProceedsFromTenantImprovementAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash inflow from tenant improvement allowance during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ProceedsFromTenantImprovementAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Tenant Improvement Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ProceedsFromTenantImprovementAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from tenant improvement allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:to="pasg_SalesAgreementWithCowenAndCompanyLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Sales Agreement, with Cowen and Company LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement, with Cowen and Company, LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued on stock conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="pasg_EquityIncentivePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EquityIncentivePlan2020Member" xlink:to="pasg_EquityIncentivePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2020 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2020</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EquityInducementPlan2021Member" xlink:label="pasg_EquityInducementPlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EquityInducementPlan2021Member" xlink:to="pasg_EquityInducementPlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EquityInducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2021 Equity Inducement plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EquityInducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Inducement Plan 2021</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="pasg_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanMember" xlink:to="pasg_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="pasg_NumberOfEquityIncentivePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NumberOfEquityIncentivePlans" xlink:to="pasg_NumberOfEquityIncentivePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equity incentive plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Equity Incentive Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grant</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period till which there is automatic increase in rights granted under the Plan</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of the total number of shares of the Company's common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" xlink:label="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" xlink:to="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration from date of grant (issuance of an option) to when option auto expires.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Additional Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of common shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Stock Purchase Price Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of stock purchase price</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Employee Contribution Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of maximum employee contribution</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock that can be purchased</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that can be purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan Number Of Shares That Can Be Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:to="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of share based compensation arrangement expenses due to modifications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Expenses Due To Modifications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense due to modifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Ending of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted and early exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Ending of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested Exercisable at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average recognize period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested Exercisable at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options (or share units) unvested and exercisable under early exercise during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Unvested, Exercisable Under Early Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options unvested and exercisable during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested stock option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period for recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of early exercise of stock options during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PromissoryNoteWithRelatedPartiesMember" xlink:label="pasg_PromissoryNoteWithRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PromissoryNoteWithRelatedPartiesMember" xlink:to="pasg_PromissoryNoteWithRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PromissoryNoteWithRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to nonrecourse promissory note with related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PromissoryNoteWithRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Note With Related Parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_InterimChiefExecutiveOfficerMember" xlink:label="pasg_InterimChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_InterimChiefExecutiveOfficerMember" xlink:to="pasg_InterimChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_InterimChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to interim chief executive officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_InterimChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_InterimChiefOperatingOfficerMember" xlink:label="pasg_InterimChiefOperatingOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_InterimChiefOperatingOfficerMember" xlink:to="pasg_InterimChiefOperatingOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_InterimChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to interim chief operating officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_InterimChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Chief Operating Officer</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfExecutiveOfficers" xlink:label="pasg_NumberOfExecutiveOfficers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NumberOfExecutiveOfficers" xlink:to="pasg_NumberOfExecutiveOfficers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NumberOfExecutiveOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NumberOfExecutiveOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Executive Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NumberOfExecutiveOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of executive officers</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non-vested options early exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested, Early Exercised Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares early exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="us-gaap_NotesReceivableRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableRelatedParties" xlink:to="us-gaap_NotesReceivableRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Receivable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes receivable in exchange of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NotesReceivableInterestRatePercentage" xlink:label="pasg_NotesReceivableInterestRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NotesReceivableInterestRatePercentage" xlink:to="pasg_NotesReceivableInterestRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NotesReceivableInterestRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options that became outstanding due to being secured by Notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NotesReceivableInterestRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Receivable Interest Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NotesReceivableInterestRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate of notes receivable</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options that became outstanding due to being secured by Notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options Became Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that becomes outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Weighted average grant date fair value, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Weighted average grant date fair value, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Amount Capitalized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Collaboration and License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and license agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, net, total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance increased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax benefit at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate reconciliation, total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StateTaxAuthorityMember" xlink:label="pasg_StateTaxAuthorityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StateTaxAuthorityMember" xlink:to="pasg_StateTaxAuthorityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StateTaxAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to state tax authorities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StateTaxAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="pasg_LocalTaxAuthoritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_LocalTaxAuthoritiesMember" xlink:to="pasg_LocalTaxAuthoritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_LocalTaxAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to local tax authorities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_LocalTaxAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research tax credits</label>
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:to="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of the tax credit carry-forward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carry Forward Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward subject</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties related to uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax examination, penalties and interest expense</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>pasg-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/3/2022 12:17:21 PM-->
<!--Modified on: 3/3/2022 12:17:21 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.passagebio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementBalanceSheets" roleURI="http://www.passagebio.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.passagebio.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureNatureOfOperations" roleURI="http://www.passagebio.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureRisksAndLiquidity" roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecurities" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureConvertiblePreferredStockAndCommonStock" roleURI="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.passagebio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureFairValueOfFinancialInstrumentsTables" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureRisksAndLiquidityDetails" roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureFairValueOfFinancialInstrumentsDetails" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureConvertiblePreferredStockAndCommonStockDetails" roleURI="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureShareBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesEffectiveTaxRateDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20211231.xsd#DisclosureIncomeTaxesNetOperatingLossesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.passagebio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637819066402868664" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637819066402868664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637819066402868664" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637819066402868664" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637819066402868664" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637819066402868664" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637819066402868664" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637819066402868664" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637819066402868664" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637819066402868664" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637819066402868664" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637819066402868664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637819066402868664" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637819066402878729" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637819066402878729" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637819066402878729" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637819066402878729" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637819066402878729" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637819066402878729" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637819066402878729" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637819066402878729" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637819066402878729" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637819066402878729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637819066402878729" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637819066402888650" order="23" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637819066402888650" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637819066402888650" order="25" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637819066402888650" order="26" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637819066402888650" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637819066402888650" order="28" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637819066402888650" order="29" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637819066402888650" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637819066402888650" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637819066402888650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637819066402888650" order="32" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637819066402898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637819066402898656" order="33" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637819066402898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637819066402898656" order="34" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637819066402898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637819066402898656" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637819066402898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637819066402898656" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637819066402898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637819066402898656" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637819066402898656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637819066402898656" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637819066402908652" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819066402908652" xlink:to="us-gaap_AssetsCurrentAbstract_637819066402908652" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819066402908652" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637819066402908652" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819066402908652" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637819066402908652" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819066402908652" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637819066402908652" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819066402908652" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_637819066402908652" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637819066402908652" xlink:to="us-gaap_AssetsCurrent_637819066402908652" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819066402908652" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637819066402908652" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819066402908652" xlink:to="us-gaap_OtherAssetsNoncurrent_637819066402908652" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637819066402908652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637819066402908652" xlink:to="us-gaap_Assets_637819066402908652" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819066402918733" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637819066402918733" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819066402918733" xlink:to="us-gaap_AccountsPayableCurrent_637819066402918733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819066402918733" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_637819066402918733" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637819066402918733" xlink:to="us-gaap_LiabilitiesCurrent_637819066402918733" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637819066402918733" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637819066402918733" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_Liabilities_637819066402918733" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies_637819066402918733" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_637819066402918733" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_CommonStockValue_637819066402918733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637819066402918733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_AdditionalPaidInCapital_637819066402918733" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637819066402928653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637819066402928653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_StockholdersEquity_637819066402928653" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637819066402918733" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637819066402928653" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637819066402928653" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066402928653" xlink:to="us-gaap_StatementClassOfStockAxis_637819066402928653" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637819066402928653" xlink:to="us-gaap_ClassOfStockDomain_637819066402928653" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesOneConvertiblePreferredStockMember" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637819066402928653" xlink:to="pasg_SeriesOneConvertiblePreferredStockMember_637819066402928653" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesTwoConvertiblePreferredStockMember" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637819066402928653" xlink:to="pasg_SeriesTwoConvertiblePreferredStockMember_637819066402928653" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesBConvertiblePreferredStockMember" xlink:label="pasg_SeriesBConvertiblePreferredStockMember_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637819066402928653" xlink:to="pasg_SeriesBConvertiblePreferredStockMember_637819066402928653" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066402928653" xlink:to="us-gaap_StatementLineItems_637819066402928653" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637819066402928653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402928653" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637819066402928653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402928653" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637819066402938662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402928653" xlink:to="us-gaap_CommonStockSharesAuthorized_637819066402938662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402928653" xlink:to="us-gaap_CommonStockSharesIssued_637819066402938662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402928653" xlink:to="us-gaap_CommonStockSharesOutstanding_637819066402938662" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637819066402938662" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819066402938662" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637819066402938662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819066402938662" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066402938662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819066402938662" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637819066402938662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637819066402938662" xlink:to="us-gaap_OperatingIncomeLoss_637819066402938662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest_637819066402938662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637819066402938662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_637819066402938662" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637819066402938662" xlink:to="us-gaap_EarningsPerShareBasic_637819066402938662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637819066402938662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637819066402938662" xlink:to="us-gaap_EarningsPerShareDiluted_637819066402938662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637819066402938662" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637819066402948657" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637819066402938662" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637819066402948657" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637819066402948657" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637819066402948657" xlink:to="us-gaap_NetIncomeLoss_637819066402948657" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637819066402948657" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_637819066402948657" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637819066402948657" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637819066402948657" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066402948657" xlink:to="us-gaap_StatementEquityComponentsAxis_637819066402948657" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819066402948657" xlink:to="us-gaap_PreferredStockMember_637819066402948657" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819066402948657" xlink:to="us-gaap_CommonStockMember_637819066402948657" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819066402948657" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637819066402948657" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637819066402948657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819066402948657" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637819066402948657" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819066402948657" xlink:to="us-gaap_RetainedEarningsMember_637819066402958733" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637819066402948657" xlink:to="us-gaap_EquityComponentDomain_637819066402958733" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066402948657" xlink:to="us-gaap_StatementClassOfStockAxis_637819066402958733" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637819066402958733" xlink:to="us-gaap_ConvertiblePreferredStockMember_637819066402958733" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesOneConvertiblePreferredStockMember" xlink:label="pasg_SeriesOneConvertiblePreferredStockMember_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637819066402958733" xlink:to="pasg_SeriesOneConvertiblePreferredStockMember_637819066402958733" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesTwoConvertiblePreferredStockMember" xlink:label="pasg_SeriesTwoConvertiblePreferredStockMember_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637819066402958733" xlink:to="pasg_SeriesTwoConvertiblePreferredStockMember_637819066402958733" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SeriesBConvertiblePreferredStockMember" xlink:label="pasg_SeriesBConvertiblePreferredStockMember_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637819066402958733" xlink:to="pasg_SeriesBConvertiblePreferredStockMember_637819066402958733" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637819066402958733" xlink:to="us-gaap_ClassOfStockDomain_637819066402958733" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066402948657" xlink:to="us-gaap_StatementLineItems_637819066402958733" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402958733" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637819066402958733" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637819066402958733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637819066402958733" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_637819066403048655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_637819066403048655" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:label="pasg_ReclassificationsOfTemporaryToPermanentEquityShares_637819066403048655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" xlink:to="pasg_ReclassificationsOfTemporaryToPermanentEquityShares_637819066403048655" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637819066403048655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637819066403048655" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637819066403048655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637819066402958733" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637819066403048655" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066402958733" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819066403058666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockholdersEquity_637819066403058666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637819066403058666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_SharesOutstanding_637819066403058666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_637819066403058666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_637819066403058666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_637819066403058666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_637819066403058666" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637819066403058666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637819066403058666" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819066403058666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819066403058666" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637819066403068786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637819066403068786" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637819066403068786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637819066403068786" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637819066403068786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637819066403068786" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637819066403068786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637819066403068786" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering_637819066403068786" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering_637819066403068786" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering" xlink:label="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering_637819066403078778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering_637819066403078778" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819066403078778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819066403078778" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819066403078778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819066403078778" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_637819066403078778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_637819066403078778" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637819066403078778" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637819066403078778" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819066403088667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_NetIncomeLoss_637819066403088667" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637819066403088667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_StockholdersEquity_637819066403088667" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637819066403088667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637819066403048655" xlink:to="us-gaap_SharesOutstanding_637819066403088667" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockIssuanceCosts" xlink:label="pasg_StockIssuanceCosts_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="pasg_StockIssuanceCosts_637819066403098747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_NetIncomeLoss_637819066403098747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066403098747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637819066403098747" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_ShareBasedCompensation_637819066403098747" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637819066403098747" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInDeferredRent" xlink:label="pasg_IncreaseDecreaseInDeferredRent_637819066403098747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="pasg_IncreaseDecreaseInDeferredRent_637819066403098747" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819066403108669" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819066403108669" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637819066403108669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819066403108669" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_637819066403108669" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819066403108669" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637819066403108669" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637819066403108669" xlink:to="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_637819066403108669" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637819066403098747" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637819066403108669" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637819066403108669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637819066403108669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637819066403118668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_637819066403118668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_637819066403118668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637819066403108669" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637819066403118668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637819066403118668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637819066403118668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637819066403118668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637819066403128674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" xlink:to="us-gaap_ProceedsFromStockPlans_637819066403128674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637819066403118668" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637819066403128674" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637819066403128674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637819066403128674" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378190664031286741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378190664031286741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_637819066403128674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PropertyAndEquipmentInDeferredRent" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_637819066403128674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="pasg_PropertyAndEquipmentInDeferredRent_637819066403128674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_637819066403138656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_637819066403138656" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities_637819066403138656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities_637819066403138656" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities_637819066403138656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities_637819066403138656" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod" xlink:label="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod_637819066403138656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod_637819066403138656" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_VestingOfEarlyExerciseOptionAwards" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_637819066403138656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637819066403128674" xlink:to="pasg_VestingOfEarlyExerciseOptionAwards_637819066403138656" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637819066403148667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637184925736553018" xlink:to="us-gaap_NatureOfOperations_637819066403148667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureRisksAndLiquidity" xlink:type="extended" xlink:title="10201 - Disclosure - Risks and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="pasg_RisksAndLiquidityAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="pasg_RisksAndLiquidityTextBlock_637819066403148667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityAbstract_637184925736553018" xlink:to="pasg_RisksAndLiquidityTextBlock_637819066403148667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637819066403148667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637184925736553018" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637819066403148667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities" xlink:type="extended" xlink:title="10401 - Disclosure - Cash, cash equivalents and marketable securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637819066403148667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637819066403148667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments" xlink:type="extended" xlink:title="10501 - Disclosure - Fair Value of Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637819066403148667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637184925736553018" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637819066403148667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637819066403158663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637819066403158663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10701 - Disclosure - Accrued Expenses and Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_637819066403158663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736553018" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_637819066403158663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637819066403158663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637819066403158663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock" xlink:type="extended" xlink:title="10901 - Disclosure - Convertible Preferred Stock and Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockholdersEquityAndTemporaryEquityTextBlock" xlink:label="pasg_StockholdersEquityAndTemporaryEquityTextBlock_637819066403158663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_637184925736709226" xlink:to="pasg_StockholdersEquityAndTemporaryEquityTextBlock_637819066403158663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11001 - Disclosure - Share-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042126439" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637819066403158663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042126439" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637819066403158663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100088567206" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100088567206" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637819066403168663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637819066403168663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pasg_BasisOfPresentationPolicyTextBlock_637819066403168663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637819066403168663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637819066403168663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637819066403168663" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SegmentPolicyPolicyTextBlock" xlink:label="pasg_SegmentPolicyPolicyTextBlock_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pasg_SegmentPolicyPolicyTextBlock_637819066403168663" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637819066403168663" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_637819066403168663" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637819066403168663" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637819066403168663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637819066403168663" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637819066403178662" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_637819066403178662" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637819066403178662" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637819066403178662" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637819066403178662" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637184925736709226" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637819066403178662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_637819066403178662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637819066403178662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_637819066403178662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_637819066403178662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Fair Value of Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637819066403188661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637184925736709226" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_637819066403188661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637819066403188661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_637819066403188661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_637819066403188661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_637819066403188661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637819066403188661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637819066403188661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - Share-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637819066403198663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637819066403198663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637819066403198663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_637819066403198663" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_637819066403198663" order="5" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637819066403198663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637819066403198663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_637819066403198663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="pasg_RisksAndLiquidityAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityTable" xlink:label="pasg_RisksAndLiquidityTable_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityAbstract_637184925736709226" xlink:to="pasg_RisksAndLiquidityTable_637819066403198663" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637819066403198663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityTable_637819066403198663" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637819066403198663" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637819066403198663" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403208662" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403208662" xlink:to="us-gaap_IPOMember_637819066403208662" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403208662" xlink:to="us-gaap_OverAllotmentOptionMember_637819066403208662" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="pasg_RisksAndLiquidityLineItems_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityTable_637819066403198663" xlink:to="pasg_RisksAndLiquidityLineItems_637819066403208662" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_637819066403208662" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637819066403208662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_637819066403208662" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819066403208662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_637819066403208662" xlink:to="us-gaap_SharePrice_637819066403208662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819066403208662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_637819066403208662" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819066403208662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637184925736709226" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403218781" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403218781" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403218781" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403218781" xlink:to="us-gaap_ComputerEquipmentMember_637819066403218781" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403218781" xlink:to="us-gaap_OfficeEquipmentMember_637819066403218781" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403218781" xlink:to="pasg_LaboratoryEquipmentMember_637819066403218781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403218781" xlink:to="us-gaap_FurnitureAndFixturesMember_637819066403218781" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637819066403218781" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637819066403218781" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637819066403218781" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637819066403218781" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_637819066403218781" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637819066403218781" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637819066403218781" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637819066403218781" xlink:to="us-gaap_EmployeeStockMember_637819066403218781" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637819066403218781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637819066403218781" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637819066403218781" xlink:to="us-gaap_TypeOfAdoptionMember_637819066403228821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637819066403228821" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637819066403228821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" xlink:to="srt_RangeAxis_637819066403228821" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637819066403228821" xlink:to="srt_RangeMember_637819066403228821" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819066403228821" xlink:to="srt_MinimumMember_637819066403228821" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819066403228821" xlink:to="srt_MaximumMember_637819066403228821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637819066403218781" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_NumberOfOperatingSegments_637819066403228821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637819066403228821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_637819066403228821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_AssetImpairmentCharges_637819066403228821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637819066403238654" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_637819066403238654" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637819066403238654" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637819066403228821" xlink:to="us-gaap_OperatingLeaseLiability_637819066403238654" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403238654" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403238654" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637819066403238654" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637819066403238654" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403238654" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DemandDepositsMember" xlink:label="us-gaap_DemandDepositsMember_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403238654" xlink:to="us-gaap_DemandDepositsMember_637819066403238654" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403238654" xlink:to="us-gaap_MoneyMarketFundsMember_637819066403238654" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403238654" xlink:to="us-gaap_CommercialPaperMember_637819066403238654" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_637819066403238654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403238654" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_637819066403238654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_637819066403238654" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_637819066403248663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_637819066403248663" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_637819066403248663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_637819066403248663" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819066403248663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403248663" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403248663" xlink:to="us-gaap_FinancialInstrumentAxis_637819066403248663" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637819066403248663" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" xlink:to="us-gaap_CertificatesOfDepositMember_637819066403248663" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" xlink:to="us-gaap_CommercialPaperMember_637819066403248663" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637819066403248663" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_637819066403248663" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403248663" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_637819066403248663" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637819066403248663" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_637819066403248663" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_637819066403248663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_637819066403248663" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_637819066403248663" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_637819066403248663" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637819066403258660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_637819066403248663" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637819066403258660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_637819066403248663" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637819066403258660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_637819066403248663" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066403258660" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_637819066403258660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_637819066403258660" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637819066403258660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_637819066403258660" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_637819066403258660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_637819066403258660" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_637819066403258660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_1" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819066403258660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819066403258660" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637819066403258660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819066403258660" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_637819066403258660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_637819066403258660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_637819066403258660" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_637819066403258660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637402475098741011" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637402475098741011" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637819066403268660" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637819066403268660" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819066403268660" xlink:to="us-gaap_FairValueInputsLevel1Member_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637819066403268660" xlink:to="us-gaap_FairValueInputsLevel2Member_637819066403268660" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637819066403268660" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637819066403268660" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637819066403268660" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637819066403268660" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637819066403268660" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403268660" xlink:to="us-gaap_MoneyMarketFundsMember_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637819066403268660" xlink:to="us-gaap_CommercialPaperMember_637819066403268660" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" xlink:to="us-gaap_FinancialInstrumentAxis_637819066403268660" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637819066403268660" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" xlink:to="us-gaap_CertificatesOfDepositMember_637819066403278659" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" xlink:to="us-gaap_CommercialPaperMember_637819066403278659" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637819066403278659" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_637819066403278659" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637819066403268660" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_637819066403278659" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637819066403268660" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637819066403278659" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637819066403278659" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637819066403278659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637819066403278659" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637819066403278659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637819066403278659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637819066403278659" xlink:to="us-gaap_AssetsFairValueDisclosure_637819066403278659" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819066403288660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819066403288660" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403288660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403288660" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" xlink:to="pasg_LaboratoryEquipmentMember_637819066403288660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" xlink:to="us-gaap_OfficeEquipmentMember_637819066403288660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="pasg_ComputerHardwareAndSoftwareMember_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" xlink:to="pasg_ComputerHardwareAndSoftwareMember_637819066403288660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" xlink:to="us-gaap_FurnitureAndFixturesMember_637819066403288660" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_637819066403288660" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403288660" xlink:to="us-gaap_ConstructionInProgressMember_637819066403288660" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637819066403288660" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637819066403288660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637819066403288660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637819066403288660" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637819066403288660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637819066403288660" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637819066403298659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637819066403288660" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637819066403298659" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637819066403298659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637819066403298659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_637819066403298659" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_637819066403298659" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="us-gaap_OtherLiabilitiesCurrent_637819066403298659" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_637819066403298659" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819066403298659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819066403298659" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819066403298659" xlink:to="us-gaap_TypeOfArrangementAxis_637819066403308814" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637819066403308814" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819066403308814" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819066403308814" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_637819066403308814" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819066403298659" xlink:to="dei_LegalEntityAxis_637819066403308814" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637819066403308814" xlink:to="dei_EntityDomain_637819066403308814" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CatalentMarylandInc.Member" xlink:label="pasg_CatalentMarylandInc.Member_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637819066403308814" xlink:to="pasg_CatalentMarylandInc.Member_637819066403308814" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819066403298659" xlink:to="srt_RangeAxis_637819066403308814" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637819066403308814" xlink:to="srt_RangeMember_637819066403308814" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819066403308814" xlink:to="srt_MinimumMember_637819066403308814" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819066403308814" xlink:to="srt_MaximumMember_637819066403308814" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637819066403298659" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAnnualFeePayable" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_637819066403308814" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementAnnualFeePayable_637819066403308814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementQuarterlyFeePayable" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementQuarterlyFeePayable_637819066403318711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_637819066403318711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementUpfrontPaymentMade" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementUpfrontPaymentMade_637819066403318711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_637819066403318711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DevelopmentMilestonePaymentsPayable" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_DevelopmentMilestonePaymentsPayable_637819066403318711" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_637819066403318711" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637819066403318711" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PaymentsForTechnologyLicenseFee" xlink:label="pasg_PaymentsForTechnologyLicenseFee_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_PaymentsForTechnologyLicenseFee_637819066403318711" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_AdditionalTechnologyLicenseFeePaid" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_AdditionalTechnologyLicenseFeePaid_637819066403318711" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementAnnualFeePayableTerm_637819066403318711" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_637819066403318711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_637819066403318711" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TermOfManufacturingAndSupplyAgreement" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_TermOfManufacturingAndSupplyAgreement_637819066403328658" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_637819066403328658" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_637819066403328658" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_637819066403328658" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_637819066403328658" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_637819066403328658" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_637819066403328658" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_637819066403328658" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066403328658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637819066403308814" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_637819066403328658" order="21" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Operating Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637819066403338790" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637819066403338790" xlink:to="srt_RangeAxis_637819066403338790" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637819066403338790" xlink:to="srt_RangeMember_637819066403338790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819066403338790" xlink:to="srt_MaximumMember_637819066403338790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637819066403338790" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403338790" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637819066403338790" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403338790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637819066403338790" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember_637819066403338790" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637819066403338790" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="us-gaap_OperatingLeaseExpense_637819066403338790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_637819066403338790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_637819066403338790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_637819066403338790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TenantImprovementAllowanceReceivable" xlink:label="pasg_TenantImprovementAllowanceReceivable_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="pasg_TenantImprovementAllowanceReceivable_637819066403348663" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637819066403348663" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_637819066403348663" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm" xlink:label="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm_637819066403348663" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637819066403348663" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_RemainingTenantImprovementAllowanceReceivable" xlink:label="pasg_RemainingTenantImprovementAllowanceReceivable_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="pasg_RemainingTenantImprovementAllowanceReceivable_637819066403348663" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ProceedsFromTenantImprovementAllowance" xlink:label="pasg_ProceedsFromTenantImprovementAllowance_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="pasg_ProceedsFromTenantImprovementAllowance_637819066403348663" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637819066403338790" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637819066403348663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637819066403348663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637819066403348663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637819066403358656" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637819066403358656" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637819066403358656" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637819066403358656" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637819066403348663" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637819066403358656" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Convertible Preferred Stock and Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_637184925736709226" xlink:to="us-gaap_StatementTable_637819066403358656" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066403358656" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637819066403358656" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637819066403358656" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403358656" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637819066403358656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403358656" xlink:to="us-gaap_IPOMember_637819066403358656" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637819066403358656" xlink:to="us-gaap_OverAllotmentOptionMember_637819066403368663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066403358656" xlink:to="srt_RangeAxis_637819066403368663" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637819066403368663" xlink:to="srt_RangeMember_637819066403368663" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637819066403368663" xlink:to="srt_MaximumMember_637819066403368663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066403358656" xlink:to="us-gaap_TypeOfArrangementAxis_637819066403368663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637819066403368663" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819066403368663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637819066403368663" xlink:to="pasg_SalesAgreementWithCowenAndCompanyLlcMember_637819066403368663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637819066403358656" xlink:to="us-gaap_StatementLineItems_637819066403368663" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066403368663" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637819066403368663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066403368663" xlink:to="us-gaap_SharePrice_637819066403368663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066403368663" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637819066403368663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066403368663" xlink:to="us-gaap_ConversionOfStockSharesIssued1_637819066403368663" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637819066403368663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066403368663" xlink:to="us-gaap_CommonStockSharesAuthorized_637819066403368663" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637819066403368663" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637819066403378664" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042438838" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042438838" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403378664" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403378664" xlink:to="us-gaap_PlanNameAxis_637819066403378664" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637819066403378664" xlink:to="us-gaap_PlanNameDomain_637819066403378664" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="pasg_EquityIncentivePlan2020Member_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819066403378664" xlink:to="pasg_EquityIncentivePlan2020Member_637819066403378664" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EquityInducementPlan2021Member" xlink:label="pasg_EquityInducementPlan2021Member_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819066403378664" xlink:to="pasg_EquityInducementPlan2021Member_637819066403378664" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="pasg_EmployeeStockPurchasePlanMember_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637819066403378664" xlink:to="pasg_EmployeeStockPurchasePlanMember_637819066403378664" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403378664" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="pasg_NumberOfEquityIncentivePlans_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_NumberOfEquityIncentivePlans_637819066403378664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637819066403378664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637819066403378664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_637819066403378664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_637819066403378664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_637819066403388660" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637819066403388660" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm" xlink:label="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm_637819066403388660" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_637819066403388660" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_637819066403388660" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_637819066403388660" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_637819066403388660" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_637819066403388660" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_637819066403388660" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637819066403388660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403378664" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637819066403388660" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042595071" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042595071" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403398651" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403398651" xlink:to="us-gaap_IncomeStatementLocationAxis_637819066403398651" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637819066403398651" xlink:to="us-gaap_IncomeStatementLocationDomain_637819066403398651" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637819066403398651" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637819066403398651" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637819066403398651" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637819066403398651" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403398651" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403398651" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403398651" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637819066403398651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_637819066403398651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403398651" xlink:to="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_637819066403398651" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637819066403408669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_637819066403408669" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819066403408669" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637819066403408669" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637819066403408669" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378190664034086691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378190664034086691" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637819066403408669" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637819066403408669" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637819066403408669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637819066403408669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637819066403418677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637819066403418677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637819066403418677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637819066403418677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637819066403418677" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637819066403408669" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637819066403418677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819066403418677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637819066403418677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819066403418677" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637819066403418677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819066403418677" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637819066403428705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637819066403418677" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637819066403428705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_637819066403428705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637819066403428705" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637819066403428705" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637819066403428705" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637819066403428705" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637819066403428705" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637819066403428705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637819066403428705" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819066403438656" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819066403438656" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637819066403438656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819066403438656" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637819066403438656" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819066403438656" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637819066403438656" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637819066403438656" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637819066403438656" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403438656" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637819066403438656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403438656" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637819066403438656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403438656" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819066403448665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403438656" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637819066403448665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403438656" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637819066403448665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod_637819066403448665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403448665" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403448665" xlink:to="us-gaap_RelatedPartyTransactionAxis_637819066403448665" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637819066403448665" xlink:to="us-gaap_RelatedPartyTransactionDomain_637819066403448665" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_PromissoryNoteWithRelatedPartiesMember" xlink:label="pasg_PromissoryNoteWithRelatedPartiesMember_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637819066403448665" xlink:to="pasg_PromissoryNoteWithRelatedPartiesMember_637819066403448665" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403448665" xlink:to="srt_TitleOfIndividualAxis_637819066403448665" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637819066403448665" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637819066403448665" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_InterimChiefExecutiveOfficerMember" xlink:label="pasg_InterimChiefExecutiveOfficerMember_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637819066403448665" xlink:to="pasg_InterimChiefExecutiveOfficerMember_637819066403448665" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_InterimChiefOperatingOfficerMember" xlink:label="pasg_InterimChiefOperatingOfficerMember_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637819066403448665" xlink:to="pasg_InterimChiefOperatingOfficerMember_637819066403448665" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403448665" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NumberOfExecutiveOfficers" xlink:label="pasg_NumberOfExecutiveOfficers_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" xlink:to="pasg_NumberOfExecutiveOfficers_637819066403458663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares_637819066403458663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedParties" xlink:label="us-gaap_NotesReceivableRelatedParties_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" xlink:to="us-gaap_NotesReceivableRelatedParties_637819066403458663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_NotesReceivableInterestRatePercentage" xlink:label="pasg_NotesReceivableInterestRatePercentage_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" xlink:to="pasg_NotesReceivableInterestRatePercentage_637819066403458663" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403448665" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding_637819066403458663" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403458663" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403458663" xlink:to="us-gaap_AwardTypeAxis_637819066403458663" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637819066403458663" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637819066403458663" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637819066403458663" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637819066403458663" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637819066403458663" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403458663" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403458663" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637819066403468662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637819066403468662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637819066403468662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_637819066403468662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_6378190664034686621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_637819066403458663" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_6378190664034686621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403458663" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637819066403468662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637819066403468662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637819066403468662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_637819066403468662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6378190664034686621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637819066403468662" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6378190664034686621" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403458663" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_637819066403468662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637819066403468662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637819066403458663" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637819066403468662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637819066403478660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637819066403478660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_637819066403478660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_637819066403478660" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637819066403478660" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_637819066403478660" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsGross_637819066403478660" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGross_637819066403478660" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637819066403478660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsNet_637819066403478660" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637819066403478660" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637819066403478660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637819066403478660" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes - Effective tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819066403538757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637819066403538757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819066403538757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637819066403538757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637819066403538757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637819066403538757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637819066403538757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637819066403538757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819066403538757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637819066403538757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637819066403538757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637819066403538757" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes - Net operating losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100089245391" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089245391" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637819066403548680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637819066403548680" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637819066403548680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637819066403548680" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637819066403548680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637819066403548680" xlink:to="us-gaap_DomesticCountryMember_637819066403548680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_StateTaxAuthorityMember" xlink:label="pasg_StateTaxAuthorityMember_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637819066403548680" xlink:to="pasg_StateTaxAuthorityMember_637819066403548680" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="pasg_LocalTaxAuthoritiesMember_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637819066403548680" xlink:to="pasg_LocalTaxAuthoritiesMember_637819066403548680" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637819066403548680" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637819066403548680" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637819066403548680" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637819066403548680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637819066403548680" xlink:to="us-gaap_ResearchMember_637819066403548680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637819066403548680" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" xlink:to="us-gaap_OperatingLossCarryforwards_637819066403548680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637819066403548680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637819066403548680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20211231.xsd#pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_637819066403558664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" xlink:to="pasg_TaxCreditCarryForwardSubjectToExpiration_637819066403558664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_637819066403558664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_637819066403558664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_637819066403558664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637819066403548680" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_637819066403558664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897341039096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PASSAGE BIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2729751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Commerce Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2005 Market Street, 39th&#160;Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-0311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PASG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,292,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343232120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 128,965<span></span>
</td>
<td class="nump">$ 135,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">186,808<span></span>
</td>
<td class="nump">169,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent', window );">Prepaid research and development</a></td>
<td class="nump">7,567<span></span>
</td>
<td class="nump">10,961<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">325,066<span></span>
</td>
<td class="nump">317,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,806<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,204<span></span>
</td>
<td class="nump">8,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">355,076<span></span>
</td>
<td class="nump">328,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,448<span></span>
</td>
<td class="nump">5,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">20,050<span></span>
</td>
<td class="nump">15,910<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">29,498<span></span>
</td>
<td class="nump">21,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">6,921<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,419<span></span>
</td>
<td class="nump">23,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,244,966 shares issued and 54,244,966 shares outstanding at December 31, 2021 and 45,917,084 shares issued and 45,614,807 shares outstanding at December 31, 2020</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">675,346<span></span>
</td>
<td class="nump">475,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(413)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(356,281)<span></span>
</td>
<td class="num">(170,895)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">318,657<span></span>
</td>
<td class="nump">304,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 355,076<span></span>
</td>
<td class="nump">$ 328,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PrepaidResearchAndDevelopmentAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897341230440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">54,244,996<span></span>
</td>
<td class="nump">45,917,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,244,996<span></span>
</td>
<td class="nump">45,614,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897341258712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 117,673<span></span>
</td>
<td class="nump">$ 81,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">60,056<span></span>
</td>
<td class="nump">30,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(185,729)<span></span>
</td>
<td class="num">(112,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (185,386)<span></span>
</td>
<td class="num">$ (112,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic</a></td>
<td class="num">$ (3.48)<span></span>
</td>
<td class="num">$ (2.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted</a></td>
<td class="num">$ (3.48)<span></span>
</td>
<td class="num">$ (2.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">53,343,959<span></span>
</td>
<td class="nump">38,615,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">53,343,959<span></span>
</td>
<td class="nump">38,615,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (185,386)<span></span>
</td>
<td class="num">$ (112,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(401)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (185,787)<span></span>
</td>
<td class="num">$ (112,244)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897338157864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred stock </div>
<div>Series A-1 convertible preferred stock</div>
</th>
<th class="th">
<div>Preferred stock </div>
<div>Series A-2 convertible preferred stock</div>
</th>
<th class="th">
<div>Preferred stock </div>
<div>Series B convertible preferred stock</div>
</th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 74,397<span></span>
</td>
<td class="nump">$ 46,311<span></span>
</td>
<td class="nump">$ 109,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">63,023,258<span></span>
</td>
<td class="nump">22,209,301<span></span>
</td>
<td class="nump">33,592,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of convertible preferred stock upon initial public offering</a></td>
<td class="num">$ (74,397)<span></span>
</td>
<td class="num">$ (46,311)<span></span>
</td>
<td class="num">$ (109,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of convertible preferred stock upon initial public offering (in shares)</a></td>
<td class="num">(63,023,258)<span></span>
</td>
<td class="num">(22,209,301)<span></span>
</td>
<td class="num">(33,592,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,663)<span></span>
</td>
<td class="num">$ (56,253)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,293,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of early exercise option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of early exercise option awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares in connection with employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering', window );">Conversion of convertible preferred stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">230,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering', window );">Conversion of convertible preferred stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,803,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">227,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,798,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112,232)<span></span>
</td>
<td class="num">(112,232)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">475,617<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(170,895)<span></span>
</td>
<td class="nump">304,714<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,614,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of early exercise option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of early exercise option awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares in connection with employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">165,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185,386)<span></span>
</td>
<td class="num">(185,386)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 675,346<span></span>
</td>
<td class="num">$ (413)<span></span>
</td>
<td class="num">$ (356,281)<span></span>
</td>
<td class="nump">$ 318,657<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,244,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of reclassification of convertible preferred stock upon consummation of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification of convertible preferred stock upon consummation of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications Of Temporary To Permanent Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been vesting of common stock previously subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock vesting of common stock previously subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897344351288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_StockIssuanceCosts', window );">Issuance cost</a></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">$ 3,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issuance incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897341103752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (185,386)<span></span>
</td>
<td class="num">$ (112,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,543<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">32,691<span></span>
</td>
<td class="nump">14,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium and discount on marketable securities, net</a></td>
<td class="nump">2,778<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">2,075<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, and other assets</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">3,394<span></span>
</td>
<td class="num">(4,216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">2,201<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,983<span></span>
</td>
<td class="nump">12,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(126,879)<span></span>
</td>
<td class="num">(80,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(202,546)<span></span>
</td>
<td class="num">(266,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable securities</a></td>
<td class="nump">182,374<span></span>
</td>
<td class="nump">95,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of technology licenses</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(17,642)<span></span>
</td>
<td class="num">(1,146)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(45,814)<span></span>
</td>
<td class="num">(172,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">165,806<span></span>
</td>
<td class="nump">228,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">166,656<span></span>
</td>
<td class="nump">228,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(6,037)<span></span>
</td>
<td class="num">(23,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">135,002<span></span>
</td>
<td class="nump">158,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">128,965<span></span>
</td>
<td class="nump">135,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(401)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_PropertyAndEquipmentInDeferredRent', window );">Property and equipment in deferred rent</a></td>
<td class="nump">2,769<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities', window );">Property and equipment in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities', window );">Acquired in-process research and development in accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities', window );">Deferred financing costs in accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod', window );">Reclassification of deferred offering costs paid in a prior period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_VestingOfEarlyExerciseOptionAwards', window );">Vesting of early exercise option awards</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquired in process research and development in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred financing costs included in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment in accounts payable and accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PropertyAndEquipmentInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property and equipment in deferred rent during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PropertyAndEquipmentInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Deferred Offering Costs Paid In A Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_VestingOfEarlyExerciseOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of vesting of early exercise option awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_VestingOfEarlyExerciseOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339892120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Passage Bio,&#160;Inc., or the Company, a Delaware corporation incorporated in July&#160;2017, is a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system diseases, or CNS disorders, with limited or no approved treatment options. The Company has a strategic research collaboration with the Trustees of the University of Pennsylvania&#8217;s, or Penn, Gene Therapy Program, or GTP, that provides the Company with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to certain CNS indications. Under this collaboration, GTP conducts discovery and preclinical activities enabling Investigation New Drug, or IND, applications and the Company conducts all clinical development, regulatory strategy, and commercialization activities under the agreement. The Company also has a collaboration agreement and a development services and clinical supply agreement with Catalent Maryland,&#160;Inc., or Catalent, for clinical scale manufacturing requirements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339785272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_RisksAndLiquidityAbstract', window );"><strong>Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Risks and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $356.3 million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020, the Company closed its initial public offering, or IPO, in which the Company issued and sold 13,798,900 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $18.00 per share for net proceeds of $227.5 million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations have consisted primarily of organizing the Company, securing financing, developing licensed technology, performing research, conducting preclinical studies and clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In accordance with Accounting Standards Update, or &#8220;ASU&#8221;, No. 2014-15<i style="font-style:italic;">, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, the Company has evaluated whether there are certain conditions and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash, cash equivalents and marketable debt securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to risk and liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339874808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and ASU promulgated by the Financial Accounting Standards Board, or FASB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its marketable securities as available-for-sale, which include certificates of deposit, commercial paper, corporate debt securities, U.S. government debt securities and non-U.S. government debt securities with original maturities of greater than three&#160;months from date of purchase. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#8217; equity. Gains or losses on marketable securities sold are based on the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Property and Equipment, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2021, and 2020, no impairment expenses were recognized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of share-based awards for stock options requires the input of assumptions, including, the expected term of the options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, which is considered the subjective assumption, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in estimating the fair value of share-based awards for stock options represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organization, contract manufacturing organizations, and employee-related expenses, including salaries, benefits, and share-based compensation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management makes estimates of the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. Nonrefundable advance payments for goods and services, including fees for preclinical services, clinical services, manufacturing services and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2021, and 2020, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FASB ASC Subtopic 740-10, <i style="font-style:italic;">Accounting for Uncertainty of Income Taxes</i>, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options (including shares subject to repurchase at December 31, 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,928,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,044</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,741,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,932,155</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, <i style="font-style:italic;">Leases</i>, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve&#160;months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain <span style="-sec-ix-hidden:Hidden_Sc9rc70L20a7-6a58pPOzQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">practical expedients</span></span> available. As the Company elected to use the extended transition period for complying with new or revised accounting standards as available under the Jobs Act, the standard is effective for the Company beginning January&#160;1, 2022. The Company will utilize the practical expedients available under ASU No.&#160;2016-02, including, electing the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs. In addition, the Company will apply the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less. The Company will not have a material cumulative adjustment to the statement of operations and comprehensive loss on January 1, 2022. The Company expects a material adjustment to the balance sheet in connection with the recognition of right-of-use assets and lease liabilities on January 1, 2022, with right-of-use assets approximating $17.0 million to $24.0 million and lease liabilities approximating $24.0 million to $31.0 million, subject to finalization of the Company&#8217;s incremental borrowing rate. The difference between right-of-use assets and lease liabilities relates to adjustments to unamortized balances of deferred rent and lease incentives existing as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2022 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339792280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, cash equivalents and marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Cash, cash equivalents and marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of cash and cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,660</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,002</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of marketable securities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.7201729%;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,169</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,988</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,852</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,808</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,115</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,877</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,577</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,344</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,902</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 169,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 169,815</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">S</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The contractual maturities of our marketable securities as of December 31, 2021, are as follows:<b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,012</p></td><td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,963</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due after one year through five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,209</p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,845</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343335448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><i style="font-style:italic;">Level 1:</i><span style="white-space:pre-wrap;">  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><i style="font-style:italic;">Level 2:</i><span style="white-space:pre-wrap;">  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"><i style="font-style:italic;">Level 3:</i><span style="white-space:pre-wrap;">  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339846776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net, consist of the following: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:105.29%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:middle;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,916</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment</p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer hardware and software</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,487</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,409</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,638</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:middle;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 822</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,314</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,283</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,729</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,477)</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (934)</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,806</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,795</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339874808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 720</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,183</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,466</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,910</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339938472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amended and Restated Research, Collaboration and License Arrangement with Penn</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company has a research, collaboration and licensing agreement with Penn, as amended, or the Penn Agreement, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, in addition to the obligation to fund certain research relating to the preclinical development of selected products, the Company will fund discovery research conducted by Penn through August 3, 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery research for the Company&#8217;s products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. This funding commitment for the discovery research is </span><span style="font-weight:normal;">$5.0</span><span style="font-weight:normal;"> million annually, paid in quarterly increments of </span><span style="font-weight:normal;">$1.3</span><span style="font-weight:normal;"> million through August 3, 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As a result of an Amendment in August 2021, the Penn Agreement includes an exploratory research program focused on discovering targets and novel gene therapy candidates for large CNS diseases, initially focused on AD and TLE, and can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is until August 2024, which term can be extended by mutual agreement. During such term, the Company will have an exclusive right of first negotiation to include additional targets to the exploratory research program within the agreed upon large CNS indications. Under the exploratory research program, the Company will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within AD and TLE (and any future large CNS diseases that are mutually agreed upon) that may arise from the exploratory research programs on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">substantially the same terms of the current Penn Agreement. The Company made an upfront payment of $5.0 million in connection with the amendment to the Penn Agreement in August 2021; will reimburse Penn for expenses incurred in the exploratory research program; will pay an aggregate of $39.0 million in development milestones for each product candidate for which the Company has exercised its option in large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications (in lieu of the milestones set forth in the existing Penn Agreement), in addition to the royalties and commercial milestones for products set forth under the existing Penn Agreement; and will pay Penn a tiered transaction fee ranging from 1-2<span style="white-space:pre-wrap;">% of the net proceeds upon certain change of control events.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Penn Agreement, the Company has eight remaining options available to commence additional licensed programs for CNS indications and has until August 3, 2026, to exercise these options.&#160;If the Company were to exercise any of these options, it would owe Penn a non-refundable upfront fee of $0.5&#160;million per product indication, with another $0.5 million fee owed upon a further developmental milestone. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Penn Agreement requires that the Company make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon successful commercialization of a product using the licensed technology, the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Under the Penn Agreement, the Company incurred research and development expenses of $</span><span style="letter-spacing:0.25pt;">17.8</span><span style="letter-spacing:0.25pt;"> million and </span><span style="letter-spacing:0.25pt;">$32.4</span><span style="letter-spacing:0.25pt;"> million during the years ended December 2021 and 2020, respectively. During the year ended December 31, 2021, the Company paid Penn </span><span style="letter-spacing:0.25pt;">$1.5</span><span style="letter-spacing:0.25pt;"> million related to the achievement of a development milestone, </span><span style="letter-spacing:0.25pt;">$1.5</span><span style="letter-spacing:0.25pt;"> million related to option exercises under the Penn Agreement, and a </span><span style="letter-spacing:0.25pt;">$5.0</span><span style="letter-spacing:0.25pt;"> million payment related to the August 2021 amendment, which were recognized as in-process research and development expense. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Catalent Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Company entered into a collaboration agreement, or the Collaboration Agreement, with Catalent. As part of the Collaboration Agreement, the Company paid Catalent an upfront fee for the commissioning, qualification, validation and equipping of a clean room suite, or the Clean Room&#160;Suite. Subject to validation of the Clean Room&#160;Suite, which was completed in the fourth quarter of 2020, the Company will pay an annual fee for five&#160;years for the use of the Clean Room&#160;Suite&#160;and is also committed to minimum annual purchase commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the Company entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. The Manufacturing and Supply Agreement confirms the terms contemplated by the Collaboration Agreement. The Collaboration Agreement continues to be in effect pursuant to its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates at the Clean Room&#160;Suite&#160;at a Catalent facility provided for in the Collaboration Agreement. The Manufacturing and Supply Agreement provides for a term of five&#160;years which period may be extended once, at the Company&#8217;s option, for an additional five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If the Company terminates the Manufacturing and Supply Agreement, it will be obligated to pay an early termination fee to Catalent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, the Company has an annual minimum commitment of $10.6 million per&#160;year owed to Catalent for <span style="white-space:pre-wrap;">five&#160;years</span><span style="white-space:pre-wrap;"> from the validation of the Clean Room, subject to certain inflationary adjustments. For the years ended December 31, 2021 and 2020, the Company paid amounts in excess of the minimum commitment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company leased office space in Philadelphia, Pennsylvania under a noncancelable lease, as amended. The lease was classified as an operating lease and the Company recognized rent expense on a straight-line basis over the lease term. The lease was terminated in February 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the Company entered into a new lease agreement, or New Lease Agreement, for larger office space in Philadelphia to accommodate the Company&#8217;s continued growth and serve as the new corporate headquarters. The New Lease Agreement commenced in February&#160;2021 and expires in December&#160;2031. The Company has an option to extend the term of the New Lease Agreement by up to two five-year terms. The landlord provided the Company with a tenant improvement allowance of up to $2.8<span style="white-space:pre-wrap;"> million, for which the related expenditures were paid directly by the landlord. The expenditures were recorded as leasehold improvements with a corresponding amount recorded as a lease liability incentive within deferred rent in the balance sheet.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December&#160;<span style="white-space:pre-wrap;">2020, the Company entered into a lease agreement for laboratory space, or Laboratory Lease Agreement, in Hopewell, New Jersey.  The laboratory is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. The Laboratory Lease Agreement commenced in March 2021 and is expected to expire in 2036. The Company has an </span><span style="-sec-ix-hidden:Hidden_rps2tZ6LzEqxXNkA71X-1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">option to extend</span></span><span style="white-space:pre-wrap;"> the term of the Laboratory Lease Agreement by up to two </span><span style="white-space:pre-wrap;">five-year</span><span style="white-space:pre-wrap;"> terms. The landlord provided the Company with a tenant improvement allowance of </span>$1.3 million in connection with the Laboratory Lease Agreement, for which the related expenditures were paid by the Company and will be reimbursed by the landlord. As of December 31, 2021, $1.3 million of leasehold improvements related to the tenant improvement allowance was recorded as a lease liability incentive within deferred rent and the remaining receivable from the landlord of $0.3 million was recorded within prepaid expenses and other current assets. As of December 31, 2021, the Company received $1.0 million of reimbursement from the landlord related to the tenant improvement allowance, which is reflected as an operating inflow in the statement of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments under the Company&#8217;s lease arrangements as of December 31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,884</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,453</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,550</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,651</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,754</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,534</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,826</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognized rent expense of $3.4 million and $0.6 million during the&#160;years ended December&#160;31, 2021 and 2020, respectively, related to its operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as described in the respective employment agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Infringement Claim</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February&#160;18, 2020, the Company received a letter from REGENXBIO&#160;Inc., or Regenx, which stated its view that the use of the Company&#8217;s AAVhu68 capsid infringes patent claims to which Regenx has an exclusive license and which expire in 2024. Regenx also stated that it has exclusive licenses to various pending patent applications regarding the use of AAV vectors administered via instar-cisterna magna injection, and that these applications may lead to issued claims that Regenx believes may, if issued, cover the Company&#8217;s planned method of administration for the Company&#8217;s clinical product candidates. The Company believes it has valid defenses to the issued claims set forth by Regenx relating to AAVhu68. Further, the prosecution of pending patent applications is highly uncertain, and it is unclear whether any patents will be issued from these pending Regenx patent applications at all, much less with claims that are relevant to the administration of the Company&#8217;s product candidates. Regenx also requested information regarding the Company&#8217;s relationship with Dr.&#160;Wilson while he was serving as an advisor to Regenx. Regenx&#8217;s letter also offers to discuss licensing the applicable patent portfolios from them. In April&#160;2020, the Company responded to Regenx indicating that it does not believe it requires a license to any of the specified Regenx patents or patent applications at this time, and that it found that Dr.&#160;Wilson&#8217;s relationship with the Company was consistent with his obligations to Regenx. The Company will continue to monitor the situation and, if necessary, take appropriate actions, which may include responding to further correspondence from Regenx, and engaging in discussions with Regenx regarding their claims. If any such patents were enforceable and such claims were ultimately successful, the Company might require a license to continue to use and sell any product candidates using such AAV vector. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339908680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Convertible Preferred Stock and Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_StockholdersEquityAndTemporaryEquityTextBlock', window );">Convertible Preferred Stock and Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Convertible Preferred Stock and Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2020, the Company completed its IPO in which the Company sold 13,798,900 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $18.00 per share. The Company received net proceeds of $227.5 million after deducting underwriting discounts, commissions, and other offering expenses paid by the Company. In addition, immediately prior to the initial closing of the IPO on March 3, 2020, (i)&#160;all of the Company&#8217;s outstanding shares of convertible preferred stock converted into an aggregate of 26,803,777 shares of common stock and (ii)&#160;the Company filed an amended and restated certificate of incorporation to, among other things, increase the number of authorized shares of common stock to 300.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 5, 2021, the Company entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may, but are not obligated to, offer and sell, from time to time, shares of the Company&#8217;s common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent. No sales of common stock have been made pursuant to this Sales Agreement to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockholdersEquityAndTemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to stockholders equity and temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockholdersEquityAndTemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339840824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and Inducement Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares authorized under the Incentive Plan as of December&#160;31, 2021 was 7,658,677. Of this amount, 3,637,509 shares were available for future grants as of December&#160;31, 2021. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Plan shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continuing for <span style="white-space:pre-wrap;">ten&#160;years</span><span style="white-space:pre-wrap;">, in an amount equal to five&#160;percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares authorized for issuance under the Incentive Plan increased by 2,712,249 and 2,295,854 shares in January 2022 and 2021, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options under the Incentive Plan vest based on the terms in each award agreement, generally over four-year periods, and have a term of ten&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Inducement Plan was approved by the Company&#8217;s board of directors in July 2021. The total number of shares authorized under the Inducement Plan was 1,000,000. Of this amount, 12,900 shares were available for future grants as of December 31, 2021. The Inducement Plan provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options under the Inducement Plan vest based on the terms in each award agreement and have a term of ten years<span style="white-space:pre-wrap;">. The Company&#8217;s restricted stock units vest based on the terms in each award agreement and have a term based on each award agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations for the period presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,525</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,055</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,580</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2020, the Company modified certain awards and recognized $0.7 million related to the modifications, $0.6 million of which was recognized in research and development expense and $0.1 million was recognized in general and administrative expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company modified certain awards and recognized $7.4 million related to the modifications, $6.1 million of which was recognized in research and development expense and $1.3 million was recognized in general and administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,928,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,980,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146,787)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,345,215)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,651,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested or expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, 1,308,244 options to purchase common stock are unvested, but exercisable, under early exercise provisions as described below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted was $12.75 and $11.54 for the&#160;years ended December&#160;31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised was $1.3 and $2.0 million and during the year ended December 31, 2021 and 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options outstanding as of December 31, 2021 was $1.6 million and the aggregate intrinsic value of options exercisable as of December 31, 2021 was $1.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $58.8&#160;million, which the Company expects to recognize over a weighted-average period of 2.8&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The 2018 Plan and 2020 Plan provide certain holders of stock options an election to early exercise prior to vesting. The Company has the right to repurchase early exercised options without transferring any appreciation in the value of the underlying shares to the employee if the employee terminates employment before the end of the original vesting period. The repurchase price is the lesser of the original exercise price or the then fair value of the Company&#8217;s common stock.  There were </span>no<span style="white-space:pre-wrap;"> early exercises of options during the year ended December 31, 2021.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes activity relating to early exercises of stock options during the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302,277</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302,277)</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nonrecourse Promissory Notes&#160;with Related Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, two of the Company&#8217;s then executive officers, elected to early exercise 688,875 and 309,994 stock options, respectively, in exchange for cash proceeds of $0.2&#160;million and nonrecourse promissory notes, or the Notes, of $0.8&#160;million. The Notes&#160;bore interest at 2.91% and were secured by the underlying shares of common stock that were issued. In January&#160;2020, the Company forgave the Notes&#160;and associated interest related to the early exercise of stock options. An aggregate of 406,897 shares that were previously not considered outstanding for accounting purposes due to being secured by the Notes&#160;became outstanding upon the forgiveness of the Notes&#160;in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year-ended December 31, 2021, the Company accelerated the vesting of each executive officer&#8217;s early exercise of stock options awards in relation to each of their separations from the Company such that all early exercised stock options were vested for accounting purposes as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company issues RSUs to employees that vest over periods as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is recognized straight-line over the vesting period of the RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes activity related to RSU awards during the year ended December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January 1, 2021</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 360,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.54</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (40,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.85</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.48</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.78</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2021, the total unrecognized expense related to all RSUs was $3.5 million, which the Company expects to recognize over a weighted-average period of <span style="white-space:pre-wrap;">3.0</span><span style="white-space:pre-wrap;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective on February&#160;28, 2020. The total number of shares authorized under the ESPP as of December 31, 2021, was&#160;893,170 shares of the Company&#8217;s common stock. Of this amount, 781,936 shares were available for future grants as of December&#160;31, 2021. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continuing for <span style="white-space:pre-wrap;">ten&#160;years</span><span style="white-space:pre-wrap;">, in an amount equal to one&#160;percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares authorized for issuance under the ESPP increased by </span>542,449 and 459,170 shares in January 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#8217;s common stock at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 worth of the Company&#8217;s common stock for each calendar&#160;year in which such right is outstanding. During the years ended December 31, 2021 and 2020, 91,125 and 20,109 shares, respectively, were purchased under the ESPP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with the guidance in ASC 718-50&#160;&#8211;<i style="font-style:italic;">&#160;Compensation&#160;&#8211; Stock Compensation</i>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<b style="font-weight:bold;">, </b>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $0.4 million and $0.2 million during the years ended December&#160;31,&#160;2021 and 2020, respectively, related to the ESPP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339951192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,464</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,959</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration and license agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,463</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,150</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,125</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,962</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62,962)</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2020. The valuation allowance increased by $72.1 million and $44.6 million during the&#160;years ended December&#160;31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes carryforwards of federal, state and local net operating losses (NOL) and research and development and orphan drug tax credits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,317</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">126,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,313</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">116,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,053</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,958</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes, however; all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. The NOL carryforwards for local income taxes related to the city of Philadelphia begin expiring in 2022. As of December&#160;31, 2021, the Company also had federal research and development and orphan drug tax credit carryforwards of $22.2 million that will begin to expire in 2038, unless previously utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. Tax&#160;years from 2018 and after remain subject to examination by the taxing jurisdictions. The NOL and tax carryforwards remain subject to review until utilized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339907848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897340888008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_BasisOfPresentationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and ASU promulgated by the Financial Accounting Standards Board, or FASB. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_SegmentPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its marketable securities as available-for-sale, which include certificates of deposit, commercial paper, corporate debt securities, U.S. government debt securities and non-U.S. government debt securities with original maturities of greater than three&#160;months from date of purchase. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#8217; equity. Gains or losses on marketable securities sold are based on the specific identification method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Property and Equipment, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2021, and 2020, no impairment expenses were recognized. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of share-based awards for stock options requires the input of assumptions, including, the expected term of the options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, which is considered the subjective assumption, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in estimating the fair value of share-based awards for stock options represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organization, contract manufacturing organizations, and employee-related expenses, including salaries, benefits, and share-based compensation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management makes estimates of the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. Nonrefundable advance payments for goods and services, including fees for preclinical services, clinical services, manufacturing services and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2021, and 2020, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FASB ASC Subtopic 740-10, <i style="font-style:italic;">Accounting for Uncertainty of Income Taxes</i>, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options (including shares subject to repurchase at December 31, 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,928,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,044</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,741,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,932,155</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, <i style="font-style:italic;">Leases</i>, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve&#160;months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain <span style="-sec-ix-hidden:Hidden_Sc9rc70L20a7-6a58pPOzQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">practical expedients</span></span> available. As the Company elected to use the extended transition period for complying with new or revised accounting standards as available under the Jobs Act, the standard is effective for the Company beginning January&#160;1, 2022. The Company will utilize the practical expedients available under ASU No.&#160;2016-02, including, electing the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs. In addition, the Company will apply the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less. The Company will not have a material cumulative adjustment to the statement of operations and comprehensive loss on January 1, 2022. The Company expects a material adjustment to the balance sheet in connection with the recognition of right-of-use assets and lease liabilities on January 1, 2022, with right-of-use assets approximating $17.0 million to $24.0 million and lease liabilities approximating $24.0 million to $31.0 million, subject to finalization of the Company&#8217;s incremental borrowing rate. The difference between right-of-use assets and lease liabilities relates to adjustments to unamortized balances of deferred rent and lease incentives existing as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2022 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_SegmentPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_SegmentPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339874808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options (including shares subject to repurchase at December 31, 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,928,111</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,044</p></td></tr><tr><td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,741,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,932,155</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897344364696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, cash equivalents and marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of details regarding the Company's portfolio of cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,660</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,002</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of details regarding the Company's portfolio of marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.7201729%;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,169</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,988</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,852</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,808</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,115</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,877</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85,577</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,344</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,902</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 169,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 169,815</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Final Maturities of Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The contractual maturities of our marketable securities as of December 31, 2021, are as follows:<b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,012</p></td><td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,963</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due after one year through five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,209</p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,845</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,808</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343312536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,902</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339866696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:105.29%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:middle;width:40.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:18.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,916</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment</p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer hardware and software</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,487</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,409</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,638</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:middle;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 822</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,314</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,283</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,729</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,477)</p></td><td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (934)</p></td></tr><tr><td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,806</p></td><td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,795</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339817656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 720</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,183</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,466</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,910</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897339953592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum rental payments for operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,884</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,453</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,550</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,651</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,754</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,534</p></td></tr><tr><td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,826</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897340879640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense category</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,525</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,055</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,580</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,928,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,980,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146,787)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,345,215)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Exercisable at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,651,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested or expected to vest at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions applied to options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of activity relating to early exercises of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January&#160;1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302,277</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (302,277)</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity [Table Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January 1, 2021</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 360,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.54</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (40,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.85</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.48</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.78</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897424203256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,464</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,959</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration and license agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,463</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,806</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,150</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,125</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,962</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62,962)</p></td></tr><tr><td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of net operating loss carryforwards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,317</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">126,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,313</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">116,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,053</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,958</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897338233080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (356,281)<span></span>
</td>
<td class="num">$ (170,895)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,798,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="nump">$ 165,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336828424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">9,741,251<span></span>
</td>
<td class="nump">6,932,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientUseOfHindsight', window );">Lease, practical expedient</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember', window );">Stock options (including shares subject to repurchase)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">9,416,998<span></span>
</td>
<td class="nump">6,928,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">290,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientUseOfHindsight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientUseOfHindsight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897338118392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">$ 128,965<span></span>
</td>
<td class="nump">$ 135,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">128,965<span></span>
</td>
<td class="nump">135,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember', window );">Cash accounts in banking institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">44,549<span></span>
</td>
<td class="nump">46,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">44,549<span></span>
</td>
<td class="nump">46,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">84,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">$ 84,416<span></span>
</td>
<td class="nump">84,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336857960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 187,221<span></span>
</td>
<td class="nump">$ 169,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">186,808<span></span>
</td>
<td class="nump">169,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">26,503<span></span>
</td>
<td class="nump">47,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">26,503<span></span>
</td>
<td class="nump">47,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">145,577<span></span>
</td>
<td class="nump">85,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">145,169<span></span>
</td>
<td class="nump">85,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,996<span></span>
</td>
<td class="nump">24,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">24,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">7,849<span></span>
</td>
<td class="nump">5,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 7,852<span></span>
</td>
<td class="nump">$ 5,902<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897338197784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year, Amortized Cost</a></td>
<td class="nump">$ 103,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">84,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">187,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year, Fair Value</a></td>
<td class="nump">102,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Fair Value</a></td>
<td class="nump">83,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total, Fair Value</a></td>
<td class="nump">$ 186,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336488488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 128,965<span></span>
</td>
<td class="nump">$ 135,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">186,808<span></span>
</td>
<td class="nump">169,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">26,503<span></span>
</td>
<td class="nump">47,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">145,169<span></span>
</td>
<td class="nump">85,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">24,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">7,852<span></span>
</td>
<td class="nump">5,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">84,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">84,409<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">84,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">84,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">186,808<span></span>
</td>
<td class="nump">169,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">186,808<span></span>
</td>
<td class="nump">173,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">26,503<span></span>
</td>
<td class="nump">47,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">145,169<span></span>
</td>
<td class="nump">85,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">24,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 7,852<span></span>
</td>
<td class="nump">5,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343281000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 26,283<span></span>
</td>
<td class="nump">$ 3,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(2,477)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total, property plant and equipment net</a></td>
<td class="nump">23,806<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">8,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">13,409<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">$ 1,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897338389080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">10,014<span></span>
</td>
<td class="nump">5,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AccruedResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,498<span></span>
</td>
<td class="nump">9,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent', window );">Property and equipment</a></td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 20,050<span></span>
</td>
<td class="nump">$ 15,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs of property and equipment Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336560584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaboration Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_DevelopmentMilestonePaymentsPayable', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and Development in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pasg_CatalentMarylandInc.Member', window );">Catalent Maryland, Inc. (Catalent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementAnnualFeePayableTerm', window );">Annual fee payable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable', window );">Period for which annual fee is payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_TermOfManufacturingAndSupplyAgreement', window );">Term of manufacturing and supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm', window );">Additional extension term of manufacturing and supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Minimum amount agreed to purchase in batches of drug product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement with Penn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementAnnualFeePayable', window );">Annual fee payable</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementQuarterlyFeePayable', window );">Quarterly fee payable</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram', window );">Number of CNS indications | Option</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementUpfrontPaymentMade', window );">Upfront payments</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation', window );">Upfront fee payable upon clinical candidate designation</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="nump">$ 32,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_PaymentsForTechnologyLicenseFee', window );">Payments for technology license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_AdditionalTechnologyLicenseFeePaid', window );">Additional technology license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementPaymentMadeOnOptionExercise', window );">Payment made on option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate upon achievement of specific development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate arising from the exploratory program for large CNS indications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement with Penn | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementTieredTransactionFeePayablePercent', window );">Collaboration agreement, tiered transaction fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement with Penn | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementTieredTransactionFeePayablePercent', window );">Collaboration agreement, tiered transaction fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate for rare, monogenic disorders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AdditionalTechnologyLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Technology License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AdditionalTechnologyLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate for large CNS indications upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate  for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAnnualFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual fee payable during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAnnualFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAnnualFeePayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of annual fee payable during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAnnualFeePayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementPaymentMadeOnOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount paid on option exercise under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementPaymentMadeOnOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period for which the annual fee is payable for the use of clean room suite under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementQuarterlyFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Quarterly Fee Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementQuarterlyFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payable on sales milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementSalesMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementTieredTransactionFeePayablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of tired transaction fee payable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementTieredTransactionFeePayablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront fee payable upon clinical candidate designation under the collaboration agreement if the company were to exercise the options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementUpfrontPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment made during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementUpfrontPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DevelopmentMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payable on development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DevelopmentMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional extension term of manufacturing and supply agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of remaining options available to the Company to commence additional licensed programs for rare, monogenic CNS indications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PaymentsForTechnologyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for technology license fee during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PaymentsForTechnologyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TermOfManufacturingAndSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of manufacturing and supply agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TermOfManufacturingAndSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pasg_CatalentMarylandInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pasg_CatalentMarylandInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897341153240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">$ 2,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,921<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_RemainingTenantImprovementAllowanceReceivable', window );">Remaining tenant improvement allowance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ProceedsFromTenantImprovementAllowance', window );">Proceeds from tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember', window );">Operating Leases For Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions', window );">Number of extension terms | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm', window );">Extended term of new lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm', window );">Lease term extended, number | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of times the lease term can be extended under the operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of extensions available under the new lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the renewal term under new lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ProceedsFromTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from tenant improvement allowance during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ProceedsFromTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RemainingTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of remaining tenant improvement allowance receivable as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RemainingTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tenant improvement allowance receivable from the landlord under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336538984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,806<span></span>
</td>
<td class="nump">$ 227,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_SalesAgreementWithCowenAndCompanyLlcMember', window );">Sales Agreement, with Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sales Agreement, with Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock in initial public offering, net of issuance costs</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,798,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued on stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,803,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_SalesAgreementWithCowenAndCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_SalesAgreementWithCowenAndCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897342274952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,691,000<span></span>
</td>
<td class="nump">$ 14,580,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member', window );">Equity Incentive Plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,658,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,637,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease', window );">Percent of the total number of shares of the Company's common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of common shares reserved for future issuance</a></td>
<td class="nump">2,712,249<span></span>
</td>
<td class="nump">2,295,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member', window );">Equity Inducement Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of common shares reserved for future issuance</a></td>
<td class="nump">542,449<span></span>
</td>
<td class="nump">459,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage', window );">Percentage of stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage', window );">Percentage of maximum employee contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased', window );">Maximum amount of common stock that can be purchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,125<span></span>
</td>
<td class="nump">20,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that can be purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration from date of grant (issuance of an option) to when option auto expires.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336526088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 32,691<span></span>
</td>
<td class="nump">$ 14,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications', window );">Share-based compensation expense due to modifications</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">15,432<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications', window );">Share-based compensation expense due to modifications</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">17,259<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications', window );">Share-based compensation expense due to modifications</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of share based compensation arrangement expenses due to modifications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementExpensesDueToModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336332104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning of period</a></td>
<td class="nump">6,928,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">3,980,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(146,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,345,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending of period</a></td>
<td class="nump">9,416,998<span></span>
</td>
<td class="nump">6,928,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and Exercisable at December 31, 2021</a></td>
<td class="nump">3,651,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at December 31, 2021</a></td>
<td class="nump">9,416,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning of period</a></td>
<td class="nump">$ 12.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">16.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">15.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending of period</a></td>
<td class="nump">13.72<span></span>
</td>
<td class="nump">$ 12.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested Exercisable at December 31, 2021</a></td>
<td class="nump">12.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at December 31, 2021</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested Exercisable at December 31, 2021</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at December 31, 2021</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise', window );">Number of share options unvested and exercisable during the period</a></td>
<td class="nump">1,308,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 58.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) unvested and exercisable under early exercise during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343291464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">95.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested balance, Beginning</a></td>
<td class="nump">302,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="num">(302,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested balance, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of early exercise of stock options during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336495864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>individual </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_NumberOfExecutiveOfficers', window );">Number of executive officers | individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding', window );">Number of shares that becomes outstanding</a></td>
<td class="nump">406,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pasg_InterimChiefExecutiveOfficerMember', window );">Interim Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares', window );">Number of shares early exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pasg_InterimChiefOperatingOfficerMember', window );">Interim Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares', window );">Number of shares early exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pasg_PromissoryNoteWithRelatedPartiesMember', window );">Promissory Note With Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_NotesReceivableInterestRatePercentage', window );">Interest rate of notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pasg_PromissoryNoteWithRelatedPartiesMember', window );">Promissory Note With Related Parties | Interim Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Notes receivable in exchange of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pasg_PromissoryNoteWithRelatedPartiesMember', window );">Promissory Note With Related Parties | Interim Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedParties', window );">Notes receivable in exchange of stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NotesReceivableInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options that became outstanding due to being secured by Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NotesReceivableInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of executive officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options that became outstanding due to being secured by Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options early exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pasg_InterimChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pasg_InterimChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pasg_InterimChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pasg_InterimChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pasg_PromissoryNoteWithRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pasg_PromissoryNoteWithRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897336509928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested balance, Beginning</a></td>
<td class="nump">302,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested balance, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value</a></td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average recognize period</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">360,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested balance, Ending</a></td>
<td class="nump">290,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value</a></td>
<td class="nump">$ 15.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value</a></td>
<td class="nump">18.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value</a></td>
<td class="nump">18.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Ending</a></td>
<td class="nump">$ 14.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Total unrecognized expense</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average recognize period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343292200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 42,351<span></span>
</td>
<td class="nump">$ 23,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">22,244<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement', window );">Collaboration and license agreement</a></td>
<td class="nump">3,976<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">51,806<span></span>
</td>
<td class="nump">23,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">11,245<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">3,431<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">135,053<span></span>
</td>
<td class="nump">62,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(135,053)<span></span>
</td>
<td class="num">(62,962)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased</a></td>
<td class="nump">$ 72,100<span></span>
</td>
<td class="nump">$ 44,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897343427624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="num">(11.90%)<span></span>
</td>
<td class="num">(12.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development</a></td>
<td class="num">(7.10%)<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">38.90%<span></span>
</td>
<td class="nump">39.80%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation, total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139897338120360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net operating losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2031</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pasg_TaxCreditCarryForwardSubjectToExpiration', window );">Tax credit carry forward subject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research tax credits</a></td>
<td class="nump">22,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">126,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">126,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 116,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TaxCreditCarryForwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carry-forward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TaxCreditCarryForwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>pasg-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pasg="http://www.passagebio.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pasg-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LYKOlHkUJk6ZytaJNaa93w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesTwoConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZuK3tkV4pU-7P0MkazMMfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_OZPCcIcvuE2lyKN-UB_SrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yq6XT26n3Eqy2E5_gcwEZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_jLdA8uvJqUuhFQXDPlOxiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_6cQRUFo1xEqxvR0_DcpgmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Jfpsy72LLUulUWiSGGQmGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m6L2u8TXOUSP7A9u-mhU5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SyLUO16mfUyXajW1h4qJLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b7aXerQ_FUGYF5XUuzOhIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N2zsouDDp0KGzHDs5rgYWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5Rk_6c3CBUS1hDM1NKi8Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7CN9CCTgHEi8F4aqrlVJUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KtAMQhONPUi9b_KILEFiog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vePEcvExi0yfQVSylYejVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wJ5SQuui7UmmH66JjXcNEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_aHwnSqJS7Eaecp2WOoB7vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjALmRT9kE6JDV3gpQtAgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LoCSKTtbL0OhUlAy4bzQyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7TeewkAeXES9W_l9V_dFQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_eEb-pqvetEOOQLXyvb5cMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_YdlvI73YvU2I-mGpcp7oeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KKuHOgYwnUOUC3x3lVmTsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_8g3nKyOXp0WB3RRJFPY0Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_WdT9SqzOo0K02mLduwDlzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LOgztTkbQ0WGq90WF8_dpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_eFQ_dfn7M0KtMER3R_n4pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_GybBG82pcU2WNDKqUYN4Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tb7mAE2KnkKD7-9H_fYxeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_jWNc7kjyfUCQZyuO_hmU9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_nz0HkNmO8kaGfzabjgTXHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_TZX4Wh_vEUaTQxedl8QHPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_Eec2VJTNMkK-WIJuen-_xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_9l6O5crOnU6_39cV6VEfVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_uM4mB8EAzEu-8Axzi0_XsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_RxCh3NZzy0OKjrjwUe4Zdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_aGYb1YEU4kCXSlYbal1wIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_hr_uYkiIdUi2u9pCZYZyfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_bS1e6udSiUmjvh8u8711pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QppymW2ZzUGGYeEkGfMJsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmxycgbmuUSxw-PaJOObzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_zzHhTfTUtkmAsOCCTtRAfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_ou_PBG4RvEihq6A2EvgcSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_AEwhzMB_OUyIYWxhHH_sKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_-AB_b6Gy40yD--yAZUlaJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_sCqVUi350ke4K2VTSeSwSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_YBzYmbyXZkO0AKGn6_kDpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_fiT7-OIXtU2fTbDpDThQDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_iPx0aGFkEUyzm5BeJrht2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_b-40t_BVvU-ZNd20D-z1kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pasg:PromissoryNoteWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_0lT3N_zSwUG3WlueyWRnJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pasg:PromissoryNoteWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MKdAL993WkmlGk1E6Ds3GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jOi_xjhbwk6ay-da4RmeYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_W0Jceks2UUu8HjUo4M49Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_ehPbbYoD4kCqWigfP_MTkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_e8i0wNfdJEOwKF4ht1pxvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0aYfPaNDZUKLpHmemdOVpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GVNitqFPWE2eFLAMk2cu3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_JV6ao2U_tkWKH0ie6bUjcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LKyQmyM_mEOvmrMoP6U72Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_vWJMqNXQZEadyp--CRitIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_62jnW-ZOyUGxlh6h8Z2Paw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cnF35_-O8kC3_ITgQtTTnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtK3dDq7kawG05hiybIvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_I5BRgy8uTUifNJBQXb4LQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_89c_UBK5AU6UAZMtdo0pYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_JdA4EKGM8EuzfT7R3EYZqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_cO90df-qlE2w4LRBHX_-6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_pP402F0Qh0OFBcMuVo7wbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_avGEAHh5YkKCdU7swCc-rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_rMsmezVxj0a84jy1lB0R9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_xubfLqarekqkZnz8HPVLxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_2Dnl9qndLEiZA71KgcQs7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_gJE9jyckc0uxCSxe63NjaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_a4xV6v1rwUKpdSlmiov0oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_p-FfJJcDT02MgnnCC4FKKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_B9cbaSVJx0CJKDD0vSu7dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_dTyFlaO3mUKM6PVp1FpYkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_z0eGE2veJk-OYbHDU3ohYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_0ZVBL1LBgk-2Lmwe-qa7sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W8IOiflxCUqSDBcWDbNx9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yP080bRNLkKlnvnFLFezGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Y4ZNWZufSESbSvoIUjVxUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_O3P6zlOMF0WLM5n7S-Ueww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_SViruIUiA0GgBqi7iFeZ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_rxBgbjMROU2SA9ft8QlsyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_1fYXv3HVhEKVNJ2zbLsrBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2031_nwAcjwnUlECe9uyTYzx_Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2031-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MWN-gxUTckSGX79Osy-sqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9gQrDgAqjkSE2Gb1oTaaSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_lmvSR935b0WEFgO0Y_lvng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yMsCjLmkD0S_oueWNaOXdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DOc0XterPEO_ABMw_SCRSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_TuoN6al3ek-oKV2lUg9dvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_eJE-uMNmcUG5vTVEbr9ZOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_-s2xGmVdVkGTPHiCmb4BJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pasg:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_i2EyC4gK6EeZimGB107lUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UU9G0ivYy0Cp8ghABgy4wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesTwoConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-CYi_SN54kqIdkLi7k62Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fiaYf-Eno0KZLETdAJS4-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pasg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2019_Dg47llwd60Wt_myzLnSxow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="Duration_2_1_2019_To_2_28_2019_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_QFerryslZEecn9p62PcHmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pasg:PromissoryNoteWithRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_srt_RangeAxis_srt_MaximumMember_WriT7NhV5E2Q4aLWditgXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2020_srt_RangeAxis_srt_MaximumMember_F_q5LSFCXU2s5384bFCZDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_7383hJsYRUaX8QecXw1x9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_hge6WzgOskii8rTOoQb_rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_fRoUpLtqpkitwlFzFSV1fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_Hlylcmv8XEyDesAxASGedA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_DUZDzlEv3kCLP31Wr2eujw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_IXEquSLDb0yKA8sbyQ-qig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_By7Uz8pPpEWAL_wK_0BdCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MYx6whEmKUaeZZi3nvIPow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_JY_Wj1FPNU6c8cjQsZNN0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_SCDOkqnfRkWyAeV9p2oFBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_-9UcmhqlFUOIPDQYaqM19g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember__lny6i38n0-juSxISzMBnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_U2yhmhWXYUGyV29jTRrJ-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_qDWtLlQQI0CDUl_45mabSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_r_NUEcfXZUWE7dm8OwgVfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_tJmj89_QHkOSI8IRh38VrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_MqFdKX6rV0uERMDWUtT6FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2022_twRvnJOWjEaYkHqwez-3iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_24po74v6kUOYh01Lzj_3ag">
        <measure>pasg:item</measure>
    </unit>
    <unit id="Unit_Standard_plan_bYBMu5fRl0arekv0DtDLXA">
        <measure>pasg:plan</measure>
    </unit>
    <unit id="Unit_Standard_individual_kRSnx8nw1kG-RLCkCGj2iA">
        <measure>pasg:individual</measure>
    </unit>
    <unit id="Unit_Standard_Option_85izgBp0S0Shu2LfkufK4A">
        <measure>pasg:Option</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_dtYM95ndTUuz97Ok3LqHiA">
        <measure>pasg:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      id="Hidden_6H4IbjKuXkq7KqvaOwzRcg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      id="Hidden_3LQY5JCzy0eABdlL_wi0pg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="2"
      id="Hidden_uxnYvl92C0aLe3HGJW_klg"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">-3.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="2"
      id="Hidden_d9qLBGxubU6zDuzaB89dBA"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">-2.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="0"
      id="Hidden_6prGth9q60Sva9NEJO1MMQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">53343959</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="0"
      id="Hidden_Ex0hA9flTU-eNkHfrRLOPw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">38615967</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:LeasePracticalExpedientUseOfHindsight
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Hidden_Sc9rc70L20a7-6a58pPOzQ">true</us-gaap:LeasePracticalExpedientUseOfHindsight>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_SDyq9Gz7X0iLOz9QhAAunw_2_1">0001787297</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_S8Y0QIwoqUCZHSMZ5LrwPA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_k8-l606GkEirL7o_2QHVUg_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_YA-cDuqt10CfW8Z1npXtRQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_z4wwskUYDkWxfq9KEds9zw_6_1">false</dei:AmendmentFlag>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="Duration_12_1_2020_To_12_31_2020_ehPbbYoD4kCqWigfP_MTkg"
      id="Hidden_rps2tZ6LzEqxXNkA71X-1g">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_W9srOZD6zkqUzFiQYhsjjA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_di4-UhRLQ0aKCcCAotuU2w_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr__4dB6psIxk6ELiDhgwIkAw">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_TybWPOlB8EeiJun1aef2cg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_56lEAkpYC0ulOkuWNk8-Iw">001-39231</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_lW6qDWurNEOTKGmMhR8ouQ">PASSAGE BIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_FXq9G94plUWsM4k1Q8uHjQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc__SybC5-6WkeT6i0kYuG7Yw_1_2">82-2729751</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_zCTR2DFz6EeqJBytn_5T_A_1_0">One Commerce Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_fW_3WCyI50-dAdaMy4yKIA_2_0">2005 Market Street, 39th&#160;Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_FEY46joES0qMw0qb-9yE4Q">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_az0ZhMO74kiKGcgTZ9YDwg">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_2lTcWdELaUm5J8bksOCB_A_3_2">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_iXiAV-GhEUqc3czDz9rJmA">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_JNZsydKnDkSkZXMMIQFEUg">866-0311</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_0y8EXqQSEkmPMH0mI6CtnQ_2_0">Common stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_3ubYZ7LCg0mPM9PiaXonwg_2_2">PASG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_jCkvROpbnkaHhuCoEldT5Q">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_0KdROKiSz0C4djixV5AKog">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_rnzMaGs88Ei1L4aztcs2vQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_scRd8wbsXUaaYUnpMI_YdQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr__VlSUKA0eECYMcYfq0_uSQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc__dp7oV0WsUmFsKSa9Nw9Aw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_60Rcga3InUa2fidTEQygYQ_2_5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_DdQYI_RtBUmmCks8-Nferg_3_5">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_ZiFXVaQCkkSzSWxJnCkXnw">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_KxsbocIsQ0-UruVVBhsWnQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_tfWb9Itxpke7n3vg1NTU7A">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_MqFdKX6rV0uERMDWUtT6FQ"
      decimals="-5"
      id="Narr_SruAn6QU90iT8CrQf6GWjg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">483300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_1_2022_twRvnJOWjEaYkHqwez-3iw"
      decimals="0"
      id="Narr_APgfPIKmiUGOPmOdfBwoMg"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">54292691</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_dm9ojAqRZEKyUwXXcJVmXw">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_sEARR78q0EKIzzeaB4zp3A">Philadelphia, PA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_Qiw7hIoIo0qZw0xVSeOHaw">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_gBxWRoX-Sk-79qBbNu22PA_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">128965000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_JlMw8K209E-jOvxha5rKzg_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135002000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_F6rhcSH57k69qJtM_6VRXQ_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">186808000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_IDcIl34uvkeFwrvkxd9IOg_6_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">169815000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_FvGSCa8IREK13wt5DENrOg_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1726000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_Mhmba-OXFUiNspyxzyOpgA_7_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1405000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_jED8khd4v0SuNHz0Vbd6yg_8_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">7567000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_R87VKWQXZUaY4iWp1sxP9g_8_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">10961000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_2gdYJ7pL1k28eBsuuLl58g_9_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">325066000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_r8dpAACeAUWxFdWOhZwO9A_9_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">317183000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_toCpSQplmEOyR1-hZSXuNw_10_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">23806000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_4_-LuL0m70uI6_m5wMFLrg_10_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2795000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_Gj6f9wHh40e7yLbMI5xXdw_11_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">6204000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_8Gz2smF8qEifRVn7S2PDNQ_11_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8029000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_bh347ll81Eat-gEHYM2hiA_12_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">355076000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_T5GT7dY2GUewJqtmoUsL_w_12_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">328007000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_xnT9uWay50mlSn0DCOE3Ew_15_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">9448000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_kRywCvGmu0SIlCg7KWxaDA_15_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5265000</us-gaap:AccountsPayableCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_mB6yO41Tf060_QpQVsI3xw_16_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">20050000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_u-AMKVvz6Eq2BeLdmpoMpA_16_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">15910000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_8y8qWrcdN0maVa73NZqEjw_17_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">29498000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_vSMjHuLhTECJrCQCfNegmQ_17_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">21175000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_b_cpDxe-aUiuFN-BBkn-Sg_18_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">6921000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_AHIEkEv3e0OvrTPtXtieKg_18_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2077000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_cNP2HN0yjkORzX9p0woDLw_19_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">41000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_Hf0F7MORV0ufllGiK-7RrA_20_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">36419000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_CdM59HGDrUKxOh9dhtFrOg_20_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">23293000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="INF"
      id="Narr_QgNCtn7eyUOzPW1ncWmTGg"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Narr_sz-KdUHvtEq3f2CMH7LOlw"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="INF"
      id="Narr_4cdNIl66Gka8n5QOYDqvdw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Narr_bp68NOzV20SJWQVPq9Lbpw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Narr_7o4RrhuI8k6HXmEHIM170A"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">54244996</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Narr_t1keXmyoGUS9IuESOdP88g"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">54244996</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="INF"
      id="Narr_1DrFzj-aYEyJsdHjZvjRvA"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">45917084</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="INF"
      id="Narr_pbTzwKXtEUOxVqVo0G8beQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">45614807</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_EdJHc2tCvUSHVZ2KUI2x2g_25_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_gXuE3MIeC0u_DW8W9e6SDQ_25_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_7XsEpu9DIE6yXwd71Sct6g_26_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">675346000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_O47s-Fs2WUOTgz8lXk-ziw_26_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">475617000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_gLplj5MHWEGjk4Gd91v_Rw_27_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-413000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_FRlUA7dQlUyDBxHUe78e7Q_27_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_nGGlxgqr4EK5sXLojdXXyQ_28_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-356281000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_01k8perK3UarsTVgbQzIOQ_28_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-170895000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_1EO7_O4at0mGHOi_eM_8WA_29_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">318657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_LpGE5KP7LUeVVejBM8jOtQ_29_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">304714000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_KX8K0PB21EKKe7PglDGUVA_30_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">355076000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_mdj5Cp3YtkuwX9qndvtY-Q_30_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">328007000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_WdQV0jCKr0-Tpi6176Ihmw_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">117673000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_7FOuhe1kHkaYt8S5F8ASJQ_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">81788000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_Y1dnrrkZzkeHrklhWbOexQ_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_JqIjz1oqAUGxk_nk2XUKhw_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_exAf-gaZp0C0DUvg-xeRKA_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">60056000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_zNakWUgmyEa7-2v4s4w2AA_6_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">30114000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_2fD67b4Hg0a_7J_WGA-Ryw_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185729000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_jR-qnSSUxk6kIDsjqwhkLQ_7_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112902000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_4x_urNWLWkSE7zF3ElczjQ_8_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">343000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_3cEet52gR0iAl08eCupIGQ_8_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">670000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_sVc6oDHM40SYzhLGQR813A_9_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_iRe_GOH_6k2jFbQUq2JJ6Q_9_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112232000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="2"
      id="Tc_i4Vlsh15SUebiBFRJMwNww_11_3"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">-3.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="2"
      id="Tc_OW0lynplhkqKsbognRuegQ_11_6"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">-2.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="0"
      id="Tc_mnODuyqv4kq946MzZtFl3g_12_3"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">53343959</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="0"
      id="Tc_8uVEM_Dol0GOhu0bVnqHpg_12_6"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">38615967</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_dIEQQ6vjmUq7tvMj5CXgrg_14_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_xfrRnj2_G0amMqgavqtCbQ_14_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112232000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_UVbJ2DvH306tEsaDas5dmQ_15_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-401000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_W7sDxu9qb02OBO-MNC2BAQ_15_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_HzZ1V7D4_Emqeixx5xAPdg_16_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185787000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_m0n5wOjFjk6yv8a9N2Eang_16_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112244000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ"
      decimals="INF"
      id="Tc_G3OFmV_s8UW8mFhRziW45A_7_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">63023258</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ"
      decimals="-3"
      id="Tc_9TAKbhiLzUegqz9d5MI8jw_7_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">74397000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LYKOlHkUJk6ZytaJNaa93w"
      decimals="INF"
      id="Tc_iva_XV43iEag80H8ehMJlg_7_7"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">22209301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_LYKOlHkUJk6ZytaJNaa93w"
      decimals="-3"
      id="Tc__quT5aIyVUWiqjedq9b3qw_7_10"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">46311000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZuK3tkV4pU-7P0MkazMMfg"
      decimals="INF"
      id="Tc_E2kys6am9UewgAIZA3gGJA_7_13"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">33592907</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ZuK3tkV4pU-7P0MkazMMfg"
      decimals="-3"
      id="Tc_JB-hdvuebUu6EIpRiSG0cA_7_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">109897000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wJ5SQuui7UmmH66JjXcNEA"
      decimals="INF"
      id="Tc_PhYWZzf5kESGqsRLGsyHBw_7_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">4293039</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KtAMQhONPUi9b_KILEFiog"
      decimals="-3"
      id="Tc_DLUGJyXDokSTRTo05gZxlg_7_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7CN9CCTgHEi8F4aqrlVJUA"
      decimals="-3"
      id="Tc_nQhj8mF9VEKaj2jveeWGcw_7_31"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-58663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_JV6ao2U_tkWKH0ie6bUjcw"
      decimals="-3"
      id="Tc_LoZ-mouVekOE4HRI53kWBQ_7_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-56253000</us-gaap:StockholdersEquity>
    <pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="INF"
      id="Tc_04kUHc7TGkW9wILdKVwl7g_8_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">599202</pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase>
    <pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"
      decimals="-3"
      id="Tc_X1MXWb3qTU2uyGJ6pV6ebQ_8_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">35000</pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_G_xJqqbN3USYozGiPbREQA_8_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">35000</pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="INF"
      id="Tc_m50OcpVvsUW1iW-jCPRhUA_9_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">99780</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"
      decimals="-3"
      id="Tc_u3vNGVbBCEScmyw2-0WAMA_9_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_LoxORPrX9k266oyzyVBc0w_9_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="INF"
      id="Tc_Krm1zNEtuk6vUqcp_yTPAQ_10_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">20109</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"
      decimals="-3"
      id="Tc_ufwNHJRrzkCHPkNrn3yvmg_10_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">284000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_hCwfJt47qEqrhrgq5oWR7A_10_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">284000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pasg:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-CYi_SN54kqIdkLi7k62Zw"
      decimals="INF"
      id="Tc_I78bpTi-qU6wbfEkFLcHIA_11_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">63023258</pasg:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_-CYi_SN54kqIdkLi7k62Zw"
      decimals="-3"
      id="Tc_ofJROSbCXEW4HGwYQETmhg_11_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">74397000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <pasg:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UU9G0ivYy0Cp8ghABgy4wg"
      decimals="INF"
      id="Tc_4XLowbY7H0e3--XyKkxQUg_11_7"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">22209301</pasg:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesTwoConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UU9G0ivYy0Cp8ghABgy4wg"
      decimals="-3"
      id="Tc_TuFsUJO6pEukD-XD_nZoWA_11_10"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">46311000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <pasg:ReclassificationsOfTemporaryToPermanentEquityShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fiaYf-Eno0KZLETdAJS4-w"
      decimals="INF"
      id="Tc_90vLgbyCJUKWzh99WbytRw_11_13"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">33592907</pasg:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_pasg_SeriesBConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_fiaYf-Eno0KZLETdAJS4-w"
      decimals="-3"
      id="Tc_zhHwcEZDy0OUhNwKz9I9-Q_11_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">109897000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <pasg:ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="INF"
      id="Tc_IdCmUQdkHEW4ssKAhcdYNQ_11_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">26803777</pasg:ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering>
    <pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="-3"
      id="Tc_vcINVAGz7kSuIKRGJgiO8g_11_22"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3000</pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering>
    <pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"
      decimals="-3"
      id="Tc_DnKv70Gj4U2GsHE14wAVlg_11_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">230602000</pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering>
    <pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_Medd9TAuB0uVOFjScQPMIA_11_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">230605000</pasg:ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering>
    <pasg:StockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Narr_Qo8BWBDTb0CUJ81q-WlWfQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3495000</pasg:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="INF"
      id="Tc_dS9p0PkLF0yZeE91z03_qQ_12_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">13798900</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2tEDkJnE90S6xZBXIO6tGg"
      decimals="-3"
      id="Tc_99VWAiZCfkCC8JiH5iIxBg_12_22"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"
      decimals="-3"
      id="Tc_VQfKfeJT1UyEqLNcbkyeow_12_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">227498000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_ufD_wgHCHkyei77BGWqRMw_12_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">227499000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmxycgbmuUSxw-PaJOObzA"
      decimals="-3"
      id="Tc_0X3deTGnwEi0iaF--KZvZA_13_28"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_N_9nS28znUm7-LZ4XZtJ7w_13_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B9_uW8mdw0uDlFX3ujQffA"
      decimals="-3"
      id="Tc_FHiPnfvBFECVuF-UiPQo-Q_14_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">14580000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_ytepBm3C00uOs45Ji2NGyA_14_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">14580000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jOi_xjhbwk6ay-da4RmeYA"
      decimals="-3"
      id="Tc_RZUgbxrpvkKDDzGRfWjm4g_15_31"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112232000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_l1DmrXypJEydDlv-a2cOUQ_15_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112232000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw"
      decimals="INF"
      id="Tc_FGGr5Kfq4UC6UEb89n-KvA_16_19"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">45614807</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw"
      decimals="-3"
      id="Tc_ZCITWq1BZU-5Tz6O75HKcw_16_22"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N2zsouDDp0KGzHDs5rgYWQ"
      decimals="-3"
      id="Tc_LyMoA-abBUqLYtddd5Yldg_16_25"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">475617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5Rk_6c3CBUS1hDM1NKi8Jw"
      decimals="-3"
      id="Tc_2NLZw5TooUOwu_d5IfNo9Q_16_28"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b7aXerQ_FUGYF5XUuzOhIg"
      decimals="-3"
      id="Tc_1XBuYoaNAUyKlJzj3Gej5A_16_31"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-170895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_lpyHhsy-B0WyumepzhHBlg_16_34"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">304714000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw"
      decimals="INF"
      id="Tc_iU8yT7qomkStN-DJWb8O5Q_6_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">45614807</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x3d2RviPEE-XMUz-YPBizw"
      decimals="-3"
      id="Tc_vcXhbEvzbEucWLgwV6-vXQ_6_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N2zsouDDp0KGzHDs5rgYWQ"
      decimals="-3"
      id="Tc_QPpZUw3wEU-Wl-_RVknhzw_6_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">475617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5Rk_6c3CBUS1hDM1NKi8Jw"
      decimals="-3"
      id="Tc_NxgI8U1fnkOU4tHGWRqN5g_6_10"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b7aXerQ_FUGYF5XUuzOhIg"
      decimals="-3"
      id="Tc_dqFhfh2T9UmilOq0Eh1Lsw_6_13"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-170895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_C_PJKiVq2EKOtKyNV-whIA_6_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">304714000</us-gaap:StockholdersEquity>
    <pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA"
      decimals="INF"
      id="Tc_DFHKPyZZP0eO32BY1Xxtvg_7_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">302277</pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase>
    <pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ"
      decimals="-3"
      id="Tc_KtpVzMWFnESV6CSlxIeTbw_7_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">45000</pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_E2hK7JdCn0yh32UrUOYgxw_7_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">45000</pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA"
      decimals="INF"
      id="Tc_oJvDnAY-ckm8xfQLsIL4MQ_8_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">186787</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ"
      decimals="-3"
      id="Tc_BkCz8MhfH0yWsfFO4totiA_8_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">301000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_UNu8NpxnNEWqG8De_BVw4w_8_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">301000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA"
      decimals="INF"
      id="Tc_AEBYQ-A2gEONoW50MerwzQ_9_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">91125</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ"
      decimals="-3"
      id="Tc_EbwACSSAs02o7L8znXrcGg_9_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_IK0DJEMIOk6U1enybvYoaQ_9_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pasg:StockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Narr_OLXsH0G1tUyzTjYCkEckIA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">669000</pasg:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA"
      decimals="INF"
      id="Tc_KW6AUYw_w0izcWSmxv0EBQ_10_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ksjXaMEnM0-Mv3dfncb0fA"
      decimals="-3"
      id="Tc_uDoqmKKHOUWYDBsHhd6wwQ_10_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ"
      decimals="-3"
      id="Tc_y3_n_jzL1UmU7fklxqwR9Q_10_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">165805000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_ft9iSmEJX0qEpTumwBzwVw_10_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">165806000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QppymW2ZzUGGYeEkGfMJsA"
      decimals="-3"
      id="Tc_MPCjgo4Xrk-U6UR79oOB0A_11_10"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-401000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_7LgW5jrlrEmmPJvb_OqDog_11_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-401000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_L6tF0w72cEqRA1tMbh7IzQ"
      decimals="-3"
      id="Tc_5FSKb1ASRkCrU1X62fv25g_12_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">32691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_AcofDE3rw0KhKqwZk363Fg_12_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">32691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MKdAL993WkmlGk1E6Ds3GQ"
      decimals="-3"
      id="Tc_XKI7JpHZK0y_HJXikRGa8w_13_13"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_zEqKp5hq20-SeoXH_aa2JQ_13_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vePEcvExi0yfQVSylYejVg"
      decimals="INF"
      id="Tc_8yfOnmHnCkKVg-IA0AOMMw_14_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">54244996</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vePEcvExi0yfQVSylYejVg"
      decimals="-3"
      id="Tc_ccK0wEAs102W-HZvU90fhw_14_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_m6L2u8TXOUSP7A9u-mhU5w"
      decimals="-3"
      id="Tc_pMYmsinqnUi3iwHKf28CpA_14_7"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">675346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SyLUO16mfUyXajW1h4qJLA"
      decimals="-3"
      id="Tc_jK4lTIyjxUOM5StkxO-9tw_14_10"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Jfpsy72LLUulUWiSGGQmGg"
      decimals="-3"
      id="Tc_e6dyrzF8fkmziBl-qfx6Vw_14_13"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-356281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_K3m_NHRcikuGANu8w-Y5nw_14_16"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">318657000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_H1xC7pvbuUKfoPcS5NElPA_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_3gsMz--Sk0CB33uMdn3smg_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-112232000</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_CrPYlj-eW0ikd8cELeSH3A_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_OO0Ey6AqlEe41OPjNQkJjQ_7_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_wm8-ewKSk0S9AFMlsOopGA_8_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1543000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_MTYnHcueIU-eF8B7TdRMmQ_8_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_XdRtBdFKr0OERxuqf6gPpA_9_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">32691000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_4IF0C_OPXEG9QCY-iBxnhg_9_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">14580000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_ZdhbK2IIXkmIGsmAfFUIMA_10_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2778000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_HdLeSIp8G0imUlcdoGnJjA_10_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">633000</us-gaap:AmortizationOfDebtDiscountPremium>
    <pasg:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_bnU6CEyvN0yS-0HbQ58oIg_11_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2075000</pasg:IncreaseDecreaseInDeferredRent>
    <pasg:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_CCQ_tPOEZEet6iIXMuyTBQ_11_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">259000</pasg:IncreaseDecreaseInDeferredRent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_2UuyEKWgCkaUfokUCSWyOg_13_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-1842000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_QRqhSqX2XU6su_XyZi73vg_13_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-1871000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_P8KB5Po7BUCX3G4_waT8Tw_14_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-3394000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_WjJo69FeuUujTbFwKFS1UA_14_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4216000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_YAZKpdqahkmw6R-ARawLiA_15_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2201000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_R8H-0ole5Eungc0RLmQ8XQ_15_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4588000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_s-Wnh7OZqESA-lh8V8gmOA_16_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3983000</pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_rQx_gJDDFEKozQxNEIsIsg_16_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">12197000</pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_cjvnaRzZrUutVl9wCuyZmQ_17_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-126879000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_Vku4L-Z22E-2tI_PjF3zsw_17_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-80520000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_q1jT1N_hm0Ks8F9g3LSefQ_19_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">202546000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_EXWjharP30SIfYiHmZvVsQ_19_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">266057000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_Wy4mM-21M0eC0mnEqnh_PQ_20_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">182374000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_aaofrplzX0ik2pZJkxTFxg_20_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">95597000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_czAb1PhuY06C9joIC8c-dw_21_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_rdatpPYuXkCJ2UfvrpkMIw_21_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_MLl4FeyAPkW_qaeCTuNBfw_22_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">17642000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_v5r9LuXfRUebcy1Bq6fzgQ_22_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1146000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_TDQPwvxW50KLi3gBPRJN4w_23_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-45814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_hTLdHfo77E29drs6CeCMIQ_23_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-172106000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_9nS21s-GF0mE6GYvkhZZPA_25_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">165806000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_iPrm7H6pPUOvZsiU-x9ymw_25_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">228262000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_aekDVWEyHEGzddkKgkxQog_26_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">338000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_ayfiY5kDmE612IRlNF1G6A_27_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">301000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_CDpqGLyveEGJ6YYFaasv-w_27_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">284000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_GRA3ZCYBbU6n6PjIWtJ09Q_28_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">887000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_COSCwiCCFkmOcUPFUwjvBw_28_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">208000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_yjw_fzWOwkub5byllI2bag_29_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">166656000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_8CLDhuhh2U-cTexxpEstBw_29_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">228754000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_V470QJUneESPVLDbyw5QgA_30_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-6037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_-KOmJep_fEK_hFvz7fsuww_30_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-23872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_pSzPwPDHlkS5CLyzfJoZaQ_31_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135002000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_JV6ao2U_tkWKH0ie6bUjcw"
      decimals="-3"
      id="Tc_983lpJm9Uki9iNKXdJqCvQ_31_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">158874000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_kH6CLD_P_0ugsFXpCBVqpw_32_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">128965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_cetP-_AVlE2wIVmsVr6OBA_32_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135002000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_FQqj0Y9p8kuj4mWtYHHqMg_34_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-401000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_iuvijA1Bgk6i_sTf3UhGfg_34_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-12000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <pasg:PropertyAndEquipmentInDeferredRent
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_lLr3WTFqKEOzbMQnePXjEw_35_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2769000</pasg:PropertyAndEquipmentInDeferredRent>
    <pasg:PropertyAndEquipmentInDeferredRent
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_zCKBX3iNwkKJ_7N4VA17rA_35_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1314000</pasg:PropertyAndEquipmentInDeferredRent>
    <pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_5k-KyYkvm0WH5ZNZGXXZqw_36_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2143000</pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_CY82pnWXvEuGN2C2WCyGSQ_36_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">48000</pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_HqnMl8qkR0qG-GtKoeBrpQ_37_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">500000</pasg:AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_Y_iS6ICPpkmls_4Bo0BbAg_38_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">161000</pasg:DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_UL2Lu_JFwEWUqQoCnV-pOA_39_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">763000</pasg:ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod>
    <pasg:VestingOfEarlyExerciseOptionAwards
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_GI3QLXNHpEuPDnA0ZfNprg_40_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">45000</pasg:VestingOfEarlyExerciseOptionAwards>
    <pasg:VestingOfEarlyExerciseOptionAwards
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_6y8YENL17Emvk5NJj81-vw_40_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">35000</pasg:VestingOfEarlyExerciseOptionAwards>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_ovWBgD6jh0elHUyBg1-eJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Nature of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Passage Bio,&#160;Inc., or the Company, a Delaware corporation incorporated in July&#160;2017, is a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system diseases, or CNS disorders, with limited or no approved treatment options. The Company has a strategic research collaboration with the Trustees of the University of Pennsylvania&#x2019;s, or Penn, Gene Therapy Program, or GTP, that provides the Company with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to certain CNS indications. Under this collaboration, GTP conducts discovery and preclinical activities enabling Investigation New Drug, or IND, applications and the Company conducts all clinical development, regulatory strategy, and commercialization activities under the agreement. The Company also has a collaboration agreement and a development services and clinical supply agreement with Catalent Maryland,&#160;Inc., or Catalent, for clinical scale manufacturing requirements.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <pasg:RisksAndLiquidityTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_huhoh0__KkOcUzwcF_Rdow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Risks and Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $356.3 million as of December&#160;31, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In March&#160;2020, the Company closed its initial public offering, or IPO, in which the Company issued and sold 13,798,900 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $18.00 per share for net proceeds of $227.5 million&#160;after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations have consisted primarily of organizing the Company, securing financing, developing licensed technology, performing research, conducting preclinical studies and clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In accordance with Accounting Standards Update, or &#x201c;ASU&#x201d;, No. 2014-15&lt;i style="font-style:italic;"&gt;, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;, the Company has evaluated whether there are certain conditions and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash, cash equivalents and marketable debt securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.&lt;/p&gt;</pasg:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_HCxj6k9Ix0mwLlkdA0fEhA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">-356300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA"
      decimals="INF"
      id="Narr_BDEkN6r_xESdDoDuuiLe5Q"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">13798900</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjALmRT9kE6JDV3gpQtAgA"
      decimals="INF"
      id="Narr_FXg5DFX8PEOf4WlKLC3-aw"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">18.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA"
      decimals="-5"
      id="Narr_XbdOBsojNkCgx192uhPfjg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">227500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w"
      decimals="INF"
      id="Narr__Iij9pnSnUC5sKxuA0rPCQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_aHwnSqJS7Eaecp2WOoB7vA"
      decimals="INF"
      id="Narr_RQOs5EuugEqMHpzJETW4IQ"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">22.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w"
      decimals="-5"
      id="Narr_jH56Jp9610u9O0OUqCrGHg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">165800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_sld2iRkR0EmnxnzuOjWfgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and ASU promulgated by the Financial Accounting Standards Board, or FASB. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.3pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include certificates of deposit, commercial paper, corporate debt securities, U.S. government debt securities and non-U.S. government debt securities with original maturities of greater than three&#160;months from date of purchase. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#x2019; equity. Gains or losses on marketable securities sold are based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2021, and 2020, no impairment expenses were recognized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or options. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of share-based awards for stock options requires the input of assumptions, including, the expected term of the options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, which is considered the subjective assumption, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in estimating the fair value of share-based awards for stock options represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organization, contract manufacturing organizations, and employee-related expenses, including salaries, benefits, and share-based compensation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management makes estimates of the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. Nonrefundable advance payments for goods and services, including fees for preclinical services, clinical services, manufacturing services and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2021, and 2020, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;FASB ASC Subtopic 740-10, &lt;i style="font-style:italic;"&gt;Accounting for Uncertainty of Income Taxes&lt;/i&gt;, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options (including shares subject to repurchase at December 31, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,928,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,741,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,932,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve&#160;months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain &lt;span style="-sec-ix-hidden:Hidden_Sc9rc70L20a7-6a58pPOzQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;practical expedients&lt;/span&gt;&lt;/span&gt; available. As the Company elected to use the extended transition period for complying with new or revised accounting standards as available under the Jobs Act, the standard is effective for the Company beginning January&#160;1, 2022. The Company will utilize the practical expedients available under ASU No.&#160;2016-02, including, electing the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs. In addition, the Company will apply the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less. The Company will not have a material cumulative adjustment to the statement of operations and comprehensive loss on January 1, 2022. The Company expects a material adjustment to the balance sheet in connection with the recognition of right-of-use assets and lease liabilities on January 1, 2022, with right-of-use assets approximating $17.0 million to $24.0 million and lease liabilities approximating $24.0 million to $31.0 million, subject to finalization of the Company&#x2019;s incremental borrowing rate. The difference between right-of-use assets and lease liabilities relates to adjustments to unamortized balances of deferred rent and lease incentives existing as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/i&gt;, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2022 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <pasg:BasisOfPresentationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_RtjHqtleW0qz7p2G7M7Nyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and ASU promulgated by the Financial Accounting Standards Board, or FASB. &lt;/p&gt;</pasg:BasisOfPresentationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_OuHj6EhHm0quQuOsMC51FQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.3pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_lenkrpIswESO_9AzpTQgJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_pAaa1Q2btkq32cyo2VHNBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <pasg:SegmentPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_p05HQ1dTEUaWMUnaU0grWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/p&gt;</pasg:SegmentPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Narr_0A1Tzoaug0eM2L0OXRvACw"
      unitRef="Unit_Standard_segment_dtYM95ndTUuz97Ok3LqHiA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_PHFVCnXymUGW8YcwGFWt5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_qbbP4_G6VE28ziCBkGaHIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include certificates of deposit, commercial paper, corporate debt securities, U.S. government debt securities and non-U.S. government debt securities with original maturities of greater than three&#160;months from date of purchase. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#x2019; equity. Gains or losses on marketable securities sold are based on the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_Nto_ctmtJkG630mzqs2z6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2021, and 2020, no impairment expenses were recognized. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_eFQ_dfn7M0KtMER3R_n4pg"
      id="Narr_su1NEbWVek6A367hQBl0Yw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_WdT9SqzOo0K02mLduwDlzA"
      id="Narr_ZkptYraEokWo6IgDyzCJdw">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_GybBG82pcU2WNDKqUYN4Xg"
      id="Narr_tn02diWQxUat5EAx5i1YDA">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_LOgztTkbQ0WGq90WF8_dpQ"
      id="Narr_3XWXyZqVbkqlueneLd9qlg">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Narr_6ZX2KiSwzkiPUe8uBMa2zw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Narr_yp4k7ieF3E6B3nu-hEA58A"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_eL-5XbeQoUi4ZK08WVayKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or options. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of share-based awards for stock options requires the input of assumptions, including, the expected term of the options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, which is considered the subjective assumption, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in estimating the fair value of share-based awards for stock options represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_5Tgm48nMA0aPRs8TNbJvQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organization, contract manufacturing organizations, and employee-related expenses, including salaries, benefits, and share-based compensation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management makes estimates of the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. Nonrefundable advance payments for goods and services, including fees for preclinical services, clinical services, manufacturing services and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_b6O_4NVtFEiqDZuC974WNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2021, and 2020, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense. &lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_wov5DHGArU-cOOZQpY9X4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;FASB ASC Subtopic 740-10, &lt;i style="font-style:italic;"&gt;Accounting for Uncertainty of Income Taxes&lt;/i&gt;, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_b66h3ZVcAkSOQTy4Yt1GWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options (including shares subject to repurchase at December 31, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,928,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,741,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,932,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_QS7OiVjy9kKj-RLyX_0BoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options (including shares subject to repurchase at December 31, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,928,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,741,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,932,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_SViruIUiA0GgBqi7iFeZ0w"
      decimals="0"
      id="Tc_gWw_hsSQdEqsN3InVlZmbg_3_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">9416998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_1fYXv3HVhEKVNJ2zbLsrBg"
      decimals="0"
      id="Tc_q9HZ-hRotk-I_mB53-hAGA_3_4"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">6928111</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Y4ZNWZufSESbSvoIUjVxUg"
      decimals="0"
      id="Tc_9zMLjT9epEC3INfwFY7UaQ_4_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">290500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_O3P6zlOMF0WLM5n7S-Ueww"
      decimals="0"
      id="Tc_jLF4ZWYFF0KyVHNjXerh8Q_5_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">33753</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_rxBgbjMROU2SA9ft8QlsyA"
      decimals="0"
      id="Tc_YbEOUGMiOEKEX4YBtugdCw_5_4"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">4044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="0"
      id="Tc_gxBQ1SUG8ESsqJXhCPKu_A_6_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">9741251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="0"
      id="Tc_OMp5Eu5F5k65duiG_ZfqnQ_6_4"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">6932155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_iVKTdXB3_0O3KHe4TH2_KQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve&#160;months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain &lt;span style="-sec-ix-hidden:Hidden_Sc9rc70L20a7-6a58pPOzQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;practical expedients&lt;/span&gt;&lt;/span&gt; available. As the Company elected to use the extended transition period for complying with new or revised accounting standards as available under the Jobs Act, the standard is effective for the Company beginning January&#160;1, 2022. The Company will utilize the practical expedients available under ASU No.&#160;2016-02, including, electing the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs. In addition, the Company will apply the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less. The Company will not have a material cumulative adjustment to the statement of operations and comprehensive loss on January 1, 2022. The Company expects a material adjustment to the balance sheet in connection with the recognition of right-of-use assets and lease liabilities on January 1, 2022, with right-of-use assets approximating $17.0 million to $24.0 million and lease liabilities approximating $24.0 million to $31.0 million, subject to finalization of the Company&#x2019;s incremental borrowing rate. The difference between right-of-use assets and lease liabilities relates to adjustments to unamortized balances of deferred rent and lease incentives existing as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/i&gt;, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2022 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_iPx0aGFkEUyzm5BeJrht2g"
      decimals="-6"
      id="Narr_quZjNIuytkiL-pGw76sELQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">17000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_fiT7-OIXtU2fTbDpDThQDw"
      decimals="-6"
      id="Narr_xqqUUPlo20mcPXa9ZOeZSw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">24000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_iPx0aGFkEUyzm5BeJrht2g"
      decimals="-6"
      id="Narr_aBsO_SBQsE6RsPS2h-BMNQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">24000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_fiT7-OIXtU2fTbDpDThQDw"
      decimals="-6"
      id="Narr_XyDTDzkYhkigqBpr3_pfsg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">31000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_6HhcAtlKYkKRhpwdXdZp7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;Cash, cash equivalents and marketable securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides details regarding the Company&#x2019;s portfolio of cash and cash equivalents:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides details regarding the Company&#x2019;s portfolio of marketable securities:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.7201729%;padding-left:0pt;padding-right:0pt;width:101.44%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (418)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,344&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 169,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 169,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;S&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The contractual maturities of our marketable securities as of December 31, 2021, are as follows:&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due within one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due after one year through five years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_sG7VPUEVyEaqviwb7LKHJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_62jnW-ZOyUGxlh6h8Z2Paw"
      decimals="-3"
      id="Tc_fzwOb3_i8kisRSrEVABAJg_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">44549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_62jnW-ZOyUGxlh6h8Z2Paw"
      decimals="-3"
      id="Tc_Y351TY8CvkirdowhMEYkmA_4_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">44549000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_vWJMqNXQZEadyp--CRitIw"
      decimals="-3"
      id="Tc_Z34R7Su51kWwx12J0fJTVA_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84416000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_vWJMqNXQZEadyp--CRitIw"
      decimals="-3"
      id="Tc_PTWkbALFxkCn9FJ3SXM5zg_5_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84416000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_73stKRFgTUmyMisPXYo6iQ_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">128965000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_vO0_rQ7PH0ePLp7Sg0IzQg_6_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">128965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_89c_UBK5AU6UAZMtdo0pYg"
      decimals="-3"
      id="Tc_k6YLCAYKc0uDDZihvjdwIQ_9_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">46660000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_89c_UBK5AU6UAZMtdo0pYg"
      decimals="-3"
      id="Tc_4CXItbxbQ0a6Wc0hcN7oKg_9_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">46660000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_I5BRgy8uTUifNJBQXb4LQA"
      decimals="-3"
      id="Tc_-nhO9l9K90GJ7chaXNtDMg_10_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84409000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_I5BRgy8uTUifNJBQXb4LQA"
      decimals="-3"
      id="Tc_tYZxI5hUi0qhL0dfa2Ntdw_10_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84409000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_JdA4EKGM8EuzfT7R3EYZqQ"
      decimals="-3"
      id="Tc__sIXR3UWZk2YwIQ012Eegg_11_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3933000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_JdA4EKGM8EuzfT7R3EYZqQ"
      decimals="-3"
      id="Tc_SWJp38Z2bESQbmnlSNuF4w_11_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3933000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_kqytiDwGhkClAuF6wzXVFg_12_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135002000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_3ahUgQ6wMU2X0aDBo1GdCg_12_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135002000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_hyyeJjlBqEGU_BjGqBHzlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.7201729%;padding-left:0pt;padding-right:0pt;width:101.44%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (418)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,344&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 169,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 169,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_dTyFlaO3mUKM6PVp1FpYkw"
      decimals="-3"
      id="Tc_8h2svkDQWE--2ECDUH7FvA_3_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5296000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_dTyFlaO3mUKM6PVp1FpYkw"
      decimals="-3"
      id="Tc_03W4g5f27ka9N2YqdLFaGQ_3_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ"
      decimals="-3"
      id="Tc_-1miveaEgke7UFPq_-fWAg_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">26503000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ"
      decimals="-3"
      id="Tc_Npu8jpFt0kGVMX1vF_FjIA_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ"
      decimals="-3"
      id="Tc_hXixzHqn5k-myTyzTMkU6Q_4_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_IYvIhh7u10CN4lDDgWfKWQ"
      decimals="-3"
      id="Tc_iORtoC1b9keZyGJl0tVvuA_4_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">26503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg"
      decimals="-3"
      id="Tc_AnYXrxA2EUGyuZEHs9Lbig_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">145577000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg"
      decimals="-3"
      id="Tc_EnxXnHdL-kCaWTb3JhjWJA_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg"
      decimals="-3"
      id="Tc_1fzoCwDABkK-xPM8TDh6Xg_5_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">418000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_t-3ClgNMrUWncuMw8V0xXg"
      decimals="-3"
      id="Tc_KXtTG70jEkCn0hc9yL0kCA_5_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">145169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g"
      decimals="-3"
      id="Tc_lZd6JKueaE23h15-VFCBVQ_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1996000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g"
      decimals="-3"
      id="Tc_VGOHQlknTESVYDhOn5wXwQ_6_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_ZJ65wrgMJ0mNI_5s8o_c9g"
      decimals="-3"
      id="Tc_kDYmaJzNPE2I92u8h3LsJg_6_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g"
      decimals="-3"
      id="Tc_0hhZRExUp0mJahXPAjrlKQ_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">7849000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g"
      decimals="-3"
      id="Tc_9pgBdFFl60WgaDGB-rqhGg_7_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g"
      decimals="-3"
      id="Tc_Cc621Vjrh0CITi7qMLDRlA_7_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_lfQjoEYrA0qYdhWAISR05g"
      decimals="-3"
      id="Tc_WwWLDZhLdk-uCUn-sgVb8w_7_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">7852000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_xPRL2qSjtk65cr6SuA0CKg_8_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">187221000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_o0UmzF_K7EevF745u6fV3w_8_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_xd4RvYszJkyexZorxaeZ1w_8_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">431000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_ltGRHz8xYU6jcjGfvVlV4Q_8_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">186808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_0ZVBL1LBgk-2Lmwe-qa7sw"
      decimals="-3"
      id="Tc_YDXXaVMsH0-W91LOjAbkkg_11_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">6115000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_0ZVBL1LBgk-2Lmwe-qa7sw"
      decimals="-3"
      id="Tc_5dtuAjFh1EeP2XPOFQZEnQ_11_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">6115000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg"
      decimals="-3"
      id="Tc_Q_Lytah3GU26KFYAAoYB0w_12_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">47872000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg"
      decimals="-3"
      id="Tc_baVwn_9ewUaQfUoboDCYBQ_12_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg"
      decimals="-3"
      id="Tc_y6keJKwCkUyfkltGhqC5iw_12_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_Jj3LVM-fmUaM13AXFeM7hg"
      decimals="-3"
      id="Tc_8pN5ipHUnEK7LFfd_1Gk8g_12_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">47877000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g"
      decimals="-3"
      id="Tc_SIcizvdmWkOYyxTCA-h2Ww_13_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">85593000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g"
      decimals="-3"
      id="Tc_73lo77PL90CAsLTRag6-sA_13_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g"
      decimals="-3"
      id="Tc_ZPRGCztlFkGJ6q2hH31h_w_13_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Iun21K9koUKlhUBkFC0O2g"
      decimals="-3"
      id="Tc_ClgOZ8yuP026CratRKgUjw_13_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">85577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg"
      decimals="-3"
      id="Tc_bZbjCfI78kymtWdJk3cN4w_14_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">24345000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg"
      decimals="-3"
      id="Tc_ij97lODGGkmRnUgz-qKimg_14_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg"
      decimals="-3"
      id="Tc_tPOtiZJknEi0IoDzXQISyg_14_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_dk-ROJXHikuxU2d6dX8Xyg"
      decimals="-3"
      id="Tc_5B_tR2MsMUOJT8q6wkwF2A_14_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">24344000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_z0eGE2veJk-OYbHDU3ohYw"
      decimals="-3"
      id="Tc_dWvDkaY9ikKIp-S_UwrMHw_15_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5902000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_z0eGE2veJk-OYbHDU3ohYw"
      decimals="-3"
      id="Tc_fm_tAF0XuEeuQfGRo8074w_15_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5902000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_f1QDfPjYYUCTIBlUA6qiPw_16_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">169827000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_FvtVyYnnREGx1Bx8rpt8Cw_16_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_HEOrAQG0OEmndmWP65St2w_16_9"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_VZd7IhJyoU69-3cCOCVKEg_16_12"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">169815000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_1qbtrf6NrE68ZWj-S8OXoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The contractual maturities of our marketable securities as of December 31, 2021, are as follows:&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due within one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due after one year through five years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_YsI8GjWrCEOPpPjE8jHQnA_2_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">103012000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_hjvDUNUy2USQwSjzCtizrA_2_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">102963000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_OFJo-GIHUkuW1aG7C9NlSw_3_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84209000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_tH464nDmykG8PPadTkTgTw_3_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">83845000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_UWWTqMW58EqbxCf0FdVOEg_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">187221000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_ABv6k_iNx0-MZ1EMczSxpQ_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">186808000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_x5j0jGvW_UK2obYRIYOpRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5.&#160;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 1:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 2:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 3:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 173,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_2NGGv0Ih5kKep5ocx0UKWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,902&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 173,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LKyQmyM_mEOvmrMoP6U72Q"
      decimals="-3"
      id="Tc_NqKat9ukd0qBRyNFGxXVPQ_12_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84416000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg"
      decimals="-3"
      id="Tc_EII3h5FOukeUel3cT8v7-Q_13_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84416000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_xubfLqarekqkZnz8HPVLxg"
      decimals="-3"
      id="Tc_57ZkApOD5UGBbfBHfFmKuQ_16_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_rMsmezVxj0a84jy1lB0R9Q"
      decimals="-3"
      id="Tc_I7UWrmwZMk-FNJn-Ma-mTA_17_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">26503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_avGEAHh5YkKCdU7swCc-rA"
      decimals="-3"
      id="Tc_WIrJklaM0kGUl1ruzQ7eFg_18_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">145169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_cO90df-qlE2w4LRBHX_-6w"
      decimals="-3"
      id="Tc_o4CoS47KaEC14qheoTng0w_19_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_pP402F0Qh0OFBcMuVo7wbw"
      decimals="-3"
      id="Tc_em4TIKboEE2Efp4HirIW0w_20_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">7852000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W8IOiflxCUqSDBcWDbNx9g"
      decimals="-3"
      id="Tc_MuhO1Qa1f0GFpkMoJYiBQA_21_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">186808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg"
      decimals="-3"
      id="Tc_pafVsx53tEKrUcbBMX_pgA_23_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W8IOiflxCUqSDBcWDbNx9g"
      decimals="-3"
      id="Tc_BkyTzfllNUKAOO1nZqyhaA_23_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">186808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cnF35_-O8kC3_ITgQtTTnQ"
      decimals="-3"
      id="Tc_-2NglE2qzEmUOBv4yLn3iw_28_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84409000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_tXtK3dDq7kawG05hiybIvA"
      decimals="-3"
      id="Tc__vU8Nts8l0SWJlvOLVGjUw_29_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3933000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yP080bRNLkKlnvnFLFezGg"
      decimals="-3"
      id="Tc_wTVBWt0zo0yo4b57xq9j9g_30_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84409000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw"
      decimals="-3"
      id="Tc_XrTM6BlRTUu7BQgG1TBq9w_30_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3933000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_B9cbaSVJx0CJKDD0vSu7dQ"
      decimals="-3"
      id="Tc_0-oMOcQsCEOq-RSX1yACnw_33_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">6115000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_p-FfJJcDT02MgnnCC4FKKQ"
      decimals="-3"
      id="Tc_20d_2CuNvkGzkNGP6JgZwg_34_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">47877000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_a4xV6v1rwUKpdSlmiov0oA"
      decimals="-3"
      id="Tc_ByWbQ9QKfUaBnynmt719GQ_35_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">85577000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_2Dnl9qndLEiZA71KgcQs7Q"
      decimals="-3"
      id="Tc_LsJMnILOCk-4PDiL5trLTw_36_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">24344000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_gJE9jyckc0uxCSxe63NjaA"
      decimals="-3"
      id="Tc_hmDOCx2uvUyJ7hVOb4J0rw_37_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5902000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw"
      decimals="-3"
      id="Tc_AvaTKn2Bv0y4O3BL9yxy2A_38_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">169815000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_yP080bRNLkKlnvnFLFezGg"
      decimals="-3"
      id="Tc_Xx-OgTXJRkeRqABb-A8H-w_40_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">84409000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsfYqRN2akq_FcaRoB3mPw"
      decimals="-3"
      id="Tc_6MNiqXVHnkm0CuVAa99xBg_40_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">173748000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_CT_xNjQMBUiJ2WbMxld0yw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, net, consist of the following: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:105.29%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:middle;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,477)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (934)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,795&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_K9kSj_hUJEu3EuDbQTprxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:105.29%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:middle;width:40.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:18.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,477)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (934)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,795&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_Eec2VJTNMkK-WIJuen-_xg"
      decimals="-3"
      id="Tc_gmhSOKfsnkO2LkWJELS6Sg_3_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tb7mAE2KnkKD7-9H_fYxeQ"
      decimals="-3"
      id="Tc_cb6etoxr90G0oU71SIoCtw_4_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">621000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_uM4mB8EAzEu-8Axzi0_XsQ"
      decimals="-3"
      id="Tc_p4Z90GEV-UStBytV-JQFjw_4_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">80000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_9l6O5crOnU6_39cV6VEfVA"
      decimals="-3"
      id="Tc__y7-rFHxlkuuuQD0A8WNfA_5_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1028000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_bS1e6udSiUmjvh8u8711pA"
      decimals="-3"
      id="Tc_FZdT7NXbmE6uOHRcnv2vYg_5_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_nz0HkNmO8kaGfzabjgTXHA"
      decimals="-3"
      id="Tc_AgClFsRipkGh1vDT5rABDA_6_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1487000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_aGYb1YEU4kCXSlYbal1wIg"
      decimals="-3"
      id="Tc_eFS8LqfJ_E2Ofn-rqTCK5w_6_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_jWNc7kjyfUCQZyuO_hmU9A"
      decimals="-3"
      id="Tc_3jnWMV1VhUiS1P6jnjymaA_7_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">13409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_RxCh3NZzy0OKjrjwUe4Zdw"
      decimals="-3"
      id="Tc_Oq86ow3oyUinya0ASbfTmw_7_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1638000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_TZX4Wh_vEUaTQxedl8QHPw"
      decimals="-3"
      id="Tc_k-Dn8V8izEaQDotAnYwbpA_8_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_hr_uYkiIdUi2u9pCZYZyfw"
      decimals="-3"
      id="Tc_0BycKzqTxk2ykRHmA1D6Gw_8_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_UHzW6p3A-UKRYuqlfVhzKA_9_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">26283000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_yvTpILTwMEWJAagvI_M6Hw_9_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_bd4Rfxe-YUuMP-5buA_iRA_10_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2477000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_6Ff6kQajPkKQhh-IdUWZ9Q_10_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">934000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_H1sLk61sT0yS5KlvyYaTKA_11_2"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">23806000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_4wve3Jh8nUm4B5j0WHbv8g_11_5"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2795000</us-gaap:PropertyPlantAndEquipmentNet>
    <pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_uSjDjB-oZUaLH2cKMwLesg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7.&#160;Accrued Expenses and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb__MyofBpKuEK_YGHYHxv-sA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_py_P22lzeU2DDxqUCpfs3w_2_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">877000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_oRQRB-MXvU-w0xEN6OB8BQ_2_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">720000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_9Z_vWOo2L0OJv_dIJewaaQ_3_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">10014000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_FDWDgs4IkEmN-yvZ0xyhEA_3_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5183000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_P621nWhPxUafgs3VIiW1xg_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8498000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_3pzB8uUJSEu1DrJqg49hbw_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">9466000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_WOe_wXL2X0KU1AT4-xRJCw_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">161000</pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_GFlt-XckO0y664_B_ADrmA_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_z7KEzANUn0uon1i5Boy7vw_6_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">541000</us-gaap:OtherLiabilitiesCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_wVctAuLxbkODnchdsSCUNw_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">20050000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_i7ai-OhFNEq546Fqyj0n-A_7_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">15910000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_L8IQpevdt0yC2JBKI5Saiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Amended and Restated Research, Collaboration and License Arrangement with Penn&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company has a research, collaboration and licensing agreement with Penn, as amended, or the Penn Agreement, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, in addition to the obligation to fund certain research relating to the preclinical development of selected products, the Company will fund discovery research conducted by Penn through August 3, 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery research for the Company&#x2019;s products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. This funding commitment for the discovery research is &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$5.0&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million annually, paid in quarterly increments of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.3&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million through August 3, 2026. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As a result of an Amendment in August 2021, the Penn Agreement includes an exploratory research program focused on discovering targets and novel gene therapy candidates for large CNS diseases, initially focused on AD and TLE, and can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is until August 2024, which term can be extended by mutual agreement. During such term, the Company will have an exclusive right of first negotiation to include additional targets to the exploratory research program within the agreed upon large CNS indications. Under the exploratory research program, the Company will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within AD and TLE (and any future large CNS diseases that are mutually agreed upon) that may arise from the exploratory research programs on &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;substantially the same terms of the current Penn Agreement. The Company made an upfront payment of $5.0 million in connection with the amendment to the Penn Agreement in August 2021; will reimburse Penn for expenses incurred in the exploratory research program; will pay an aggregate of $39.0 million in development milestones for each product candidate for which the Company has exercised its option in large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications (in lieu of the milestones set forth in the existing Penn Agreement), in addition to the royalties and commercial milestones for products set forth under the existing Penn Agreement; and will pay Penn a tiered transaction fee ranging from 1-2&lt;span style="white-space:pre-wrap;"&gt;% of the net proceeds upon certain change of control events.   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Under the Penn Agreement, the Company has eight remaining options available to commence additional licensed programs for CNS indications and has until August 3, 2026, to exercise these options.&#160;If the Company were to exercise any of these options, it would owe Penn a non-refundable upfront fee of $0.5&#160;million per product indication, with another $0.5 million fee owed upon a further developmental milestone. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Penn Agreement requires that the Company make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Upon successful commercialization of a product using the licensed technology, the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.25pt;"&gt;Under the Penn Agreement, the Company incurred research and development expenses of $&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;17.8&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million and &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;$32.4&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million during the years ended December 2021 and 2020, respectively. During the year ended December 31, 2021, the Company paid Penn &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;$1.5&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million related to the achievement of a development milestone, &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;$1.5&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million related to option exercises under the Penn Agreement, and a &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;$5.0&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million payment related to the August 2021 amendment, which were recognized as in-process research and development expense. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Catalent Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2019, the Company entered into a collaboration agreement, or the Collaboration Agreement, with Catalent. As part of the Collaboration Agreement, the Company paid Catalent an upfront fee for the commissioning, qualification, validation and equipping of a clean room suite, or the Clean Room&#160;Suite. Subject to validation of the Clean Room&#160;Suite, which was completed in the fourth quarter of 2020, the Company will pay an annual fee for five&#160;years for the use of the Clean Room&#160;Suite&#160;and is also committed to minimum annual purchase commitments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2020, the Company entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for the Company&#x2019;s gene therapy product candidates. The Manufacturing and Supply Agreement confirms the terms contemplated by the Collaboration Agreement. The Collaboration Agreement continues to be in effect pursuant to its terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for the Company&#x2019;s gene therapy product candidates at the Clean Room&#160;Suite&#160;at a Catalent facility provided for in the Collaboration Agreement. The Manufacturing and Supply Agreement provides for a term of five&#160;years which period may be extended once, at the Company&#x2019;s option, for an additional five-year period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If the Company terminates the Manufacturing and Supply Agreement, it will be obligated to pay an early termination fee to Catalent.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, the Company has an annual minimum commitment of $10.6 million per&#160;year owed to Catalent for &lt;span style="white-space:pre-wrap;"&gt;five&#160;years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; from the validation of the Clean Room, subject to certain inflationary adjustments. For the years ended December 31, 2021 and 2020, the Company paid amounts in excess of the minimum commitment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Operating Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leased office space in Philadelphia, Pennsylvania under a noncancelable lease, as amended. The lease was classified as an operating lease and the Company recognized rent expense on a straight-line basis over the lease term. The lease was terminated in February 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2020, the Company entered into a new lease agreement, or New Lease Agreement, for larger office space in Philadelphia to accommodate the Company&#x2019;s continued growth and serve as the new corporate headquarters. The New Lease Agreement commenced in February&#160;2021 and expires in December&#160;2031. The Company has an option to extend the term of the New Lease Agreement by up to two five-year terms. The landlord provided the Company with a tenant improvement allowance of up to $2.8&lt;span style="white-space:pre-wrap;"&gt; million, for which the related expenditures were paid directly by the landlord. The expenditures were recorded as leasehold improvements with a corresponding amount recorded as a lease liability incentive within deferred rent in the balance sheet.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In December&#160;&lt;span style="white-space:pre-wrap;"&gt;2020, the Company entered into a lease agreement for laboratory space, or Laboratory Lease Agreement, in Hopewell, New Jersey.  The laboratory is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. The Laboratory Lease Agreement commenced in March 2021 and is expected to expire in 2036. The Company has an &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_rps2tZ6LzEqxXNkA71X-1g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; the term of the Laboratory Lease Agreement by up to two &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five-year&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; terms. The landlord provided the Company with a tenant improvement allowance of &lt;/span&gt;$1.3 million in connection with the Laboratory Lease Agreement, for which the related expenditures were paid by the Company and will be reimbursed by the landlord. As of December 31, 2021, $1.3 million of leasehold improvements related to the tenant improvement allowance was recorded as a lease liability incentive within deferred rent and the remaining receivable from the landlord of $0.3 million was recorded within prepaid expenses and other current assets. As of December 31, 2021, the Company received $1.0 million of reimbursement from the landlord related to the tenant improvement allowance, which is reflected as an operating inflow in the statement of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The future minimum lease payments under the Company&#x2019;s lease arrangements as of December 31, 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,453&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized rent expense of $3.4 million and $0.6 million during the&#160;years ended December&#160;31, 2021 and 2020, respectively, related to its operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into employment agreements with key personnel providing for compensation and severance in certain circumstances, as described in the respective employment agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Infringement Claim&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On February&#160;18, 2020, the Company received a letter from REGENXBIO&#160;Inc., or Regenx, which stated its view that the use of the Company&#x2019;s AAVhu68 capsid infringes patent claims to which Regenx has an exclusive license and which expire in 2024. Regenx also stated that it has exclusive licenses to various pending patent applications regarding the use of AAV vectors administered via instar-cisterna magna injection, and that these applications may lead to issued claims that Regenx believes may, if issued, cover the Company&#x2019;s planned method of administration for the Company&#x2019;s clinical product candidates. The Company believes it has valid defenses to the issued claims set forth by Regenx relating to AAVhu68. Further, the prosecution of pending patent applications is highly uncertain, and it is unclear whether any patents will be issued from these pending Regenx patent applications at all, much less with claims that are relevant to the administration of the Company&#x2019;s product candidates. Regenx also requested information regarding the Company&#x2019;s relationship with Dr.&#160;Wilson while he was serving as an advisor to Regenx. Regenx&#x2019;s letter also offers to discuss licensing the applicable patent portfolios from them. In April&#160;2020, the Company responded to Regenx indicating that it does not believe it requires a license to any of the specified Regenx patents or patent applications at this time, and that it found that Dr.&#160;Wilson&#x2019;s relationship with the Company was consistent with his obligations to Regenx. The Company will continue to monitor the situation and, if necessary, take appropriate actions, which may include responding to further correspondence from Regenx, and engaging in discussions with Regenx regarding their claims. If any such patents were enforceable and such claims were ultimately successful, the Company might require a license to continue to use and sell any product candidates using such AAV vector. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pasg:CollaborationAgreementAnnualFeePayable
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw"
      decimals="-5"
      id="Narr_hvYntO4lPk6CT-HFszzA2Q"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5000000.0</pasg:CollaborationAgreementAnnualFeePayable>
    <pasg:CollaborationAgreementQuarterlyFeePayable
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw"
      decimals="-5"
      id="Narr_7Gbtce0Fi0yhb_BUj8ufUg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1300000</pasg:CollaborationAgreementQuarterlyFeePayable>
    <pasg:CollaborationAgreementUpfrontPaymentMade
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_JY_Wj1FPNU6c8cjQsZNN0A"
      decimals="-5"
      id="Narr_3L5rnhCAUECq_PLdGDIPjA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5000000.0</pasg:CollaborationAgreementUpfrontPaymentMade>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone
      contextRef="As_Of_8_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_qDWtLlQQI0CDUl_45mabSQ"
      decimals="-5"
      id="Narr_TeYYIXhxeUy6B7bz-bCaOQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">39000000.0</pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementTieredTransactionFeePayablePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_-9UcmhqlFUOIPDQYaqM19g"
      decimals="2"
      id="Narr_C_SSRKMHRE6fp-7xiGiLMQ"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.01</pasg:CollaborationAgreementTieredTransactionFeePayablePercent>
    <pasg:CollaborationAgreementTieredTransactionFeePayablePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember__lny6i38n0-juSxISzMBnA"
      decimals="2"
      id="Narr_bp6MiJ_GZ0mbm7_stLkZ1g"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.02</pasg:CollaborationAgreementTieredTransactionFeePayablePercent>
    <pasg:NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw"
      decimals="INF"
      id="Narr_SBx-QE1XJ0-Sv-vYehJJrg"
      unitRef="Unit_Standard_Option_85izgBp0S0Shu2LfkufK4A">8</pasg:NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram>
    <pasg:CollaborationAgreementUpfrontPaymentMade
      contextRef="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_SCDOkqnfRkWyAeV9p2oFBg"
      decimals="-5"
      id="Narr_TL0qx24LQEGWrI520nfBWA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">500000</pasg:CollaborationAgreementUpfrontPaymentMade>
    <pasg:CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_xXIDvNwAv0OrjSbbakGAbw"
      decimals="-5"
      id="Narr__CX1MLiiSkOpnf2Ni6NdMA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">500000</pasg:CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_r_NUEcfXZUWE7dm8OwgVfw"
      decimals="-5"
      id="Narr_YvAodEKvY06axsKlgDmtVw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">16500000</pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_tJmj89_QHkOSI8IRh38VrA"
      decimals="-5"
      id="Narr_gfPBP2EnPEyNSCbDBSKK4g"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">39000000.0</pasg:CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:DevelopmentMilestonePaymentsPayable
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Narr__whLRGjROEWq84dGyRquyA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</pasg:DevelopmentMilestonePaymentsPayable>
    <pasg:CollaborationAgreementSalesMilestonePaymentsPayable
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_tJmj89_QHkOSI8IRh38VrA"
      decimals="-5"
      id="Narr_mFXXkWE-fkmHmb7DulmeNQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">55000000.0</pasg:CollaborationAgreementSalesMilestonePaymentsPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ"
      decimals="-5"
      id="Narr_4eXCDB_ZWE6mgKj2W3hJWA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">17800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KKuHOgYwnUOUC3x3lVmTsw"
      decimals="-5"
      id="Narr_YgNNhazggk-A-E508UyIxg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">32400000</us-gaap:ResearchAndDevelopmentExpense>
    <pasg:AdditionalTechnologyLicenseFeePaid
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ"
      decimals="-5"
      id="Narr_pqCGTIRYbUuK9pV-lam9SA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1500000</pasg:AdditionalTechnologyLicenseFeePaid>
    <pasg:CollaborationAgreementPaymentMadeOnOptionExercise
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ"
      decimals="-5"
      id="Narr_jGAKkPFSBE-A8KWhlMx5XQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1500000</pasg:CollaborationAgreementPaymentMadeOnOptionExercise>
    <pasg:PaymentsForTechnologyLicenseFee
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_N-wiav8prkSl_YnuMVRQcQ"
      decimals="-5"
      id="Narr_vOPbQoT4PEGge4hqlBxn0w"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5000000.0</pasg:PaymentsForTechnologyLicenseFee>
    <pasg:CollaborationAgreementAnnualFeePayableTerm
      contextRef="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_U2yhmhWXYUGyV29jTRrJ-Q"
      id="Narr_dsuCO--coEOwsV7X_dS_8g">P5Y</pasg:CollaborationAgreementAnnualFeePayableTerm>
    <pasg:TermOfManufacturingAndSupplyAgreement
      contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A"
      id="Narr_eAbyPZVOy0OeJbbMO3JVug">P5Y</pasg:TermOfManufacturingAndSupplyAgreement>
    <pasg:ManufacturingAndSupplyAgreementAdditionalExtensionTerm
      contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A"
      id="Narr_CkqepnWyTEeHsu8tAFr-hA">P5Y</pasg:ManufacturingAndSupplyAgreementAdditionalExtensionTerm>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_8g3nKyOXp0WB3RRJFPY0Kw"
      decimals="-5"
      id="Narr_KHNFkcoWQkO9p4Wjc8MuWw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">10600000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <pasg:CollaborationAgreementPeriodForWhichAnnualFeeIsPayable
      contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_ztDFY_ZYR0CFOa1BBwlJ-A"
      id="Narr_eKKleEdXmUGqYc0wnFpsAg">P5Y</pasg:CollaborationAgreementPeriodForWhichAnnualFeeIsPayable>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="As_Of_4_30_2020_srt_RangeAxis_srt_MaximumMember_F_q5LSFCXU2s5384bFCZDA"
      decimals="INF"
      id="Narr_Rczjg5gqsU-phQK-Y80YBA"
      unitRef="Unit_Standard_item_24po74v6kUOYh01Lzj_3ag">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <pasg:NewLeaseAgreementOperatingLeaseRenewalTerm
      contextRef="Duration_4_1_2020_To_4_30_2020_srt_RangeAxis_srt_MaximumMember_WriT7NhV5E2Q4aLWditgXg"
      id="Narr_-SbVOLY_j0K2aFkpd-InWA">P5Y</pasg:NewLeaseAgreementOperatingLeaseRenewalTerm>
    <pasg:TenantImprovementAllowanceReceivable
      contextRef="As_Of_4_30_2020_srt_RangeAxis_srt_MaximumMember_F_q5LSFCXU2s5384bFCZDA"
      decimals="-5"
      id="Narr_9hcMVLojD0-hW1-n-URsFQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2800000</pasg:TenantImprovementAllowanceReceivable>
    <pasg:LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm
      contextRef="Duration_12_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_7383hJsYRUaX8QecXw1x9A"
      decimals="INF"
      id="Narr_qgtC2vFLz0aBLjBfUEPNMA"
      unitRef="Unit_Standard_item_24po74v6kUOYh01Lzj_3ag">2</pasg:LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_W0Jceks2UUu8HjUo4M49Rw"
      id="Narr_tSiQQ5xfzUOiiRiC-EbCLQ">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pasg:TenantImprovementAllowanceReceivable
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-5"
      id="Narr_dowwri81kUy3VIYISlc8hA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1300000</pasg:TenantImprovementAllowanceReceivable>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_e8i0wNfdJEOwKF4ht1pxvw"
      decimals="-5"
      id="Narr_cmrrzwgeQUi6g31_KR0cTA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1300000</us-gaap:DeferredRentCreditNoncurrent>
    <pasg:RemainingTenantImprovementAllowanceReceivable
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_y5D2t6iUS0WHd8OVXttJcg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">300000</pasg:RemainingTenantImprovementAllowanceReceivable>
    <pasg:ProceedsFromTenantImprovementAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-5"
      id="Narr_BNCt_G_zdkKSl-iFtWpHwg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1000000.0</pasg:ProceedsFromTenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_ywrrk-4i0kqXzk4ono42Dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,453&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_8xQSNW6hYUiHRuwP2NcpcQ_2_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2884000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_B0WRMuuSpES7P2Dhckd1iQ_3_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3453000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_tHRmt0r1lkSs14Se5g6ruA_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3550000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_4jjGjmCg8EiBLrqPxiVcHg_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3651000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_bxrtPg2BuUCPx717Mha7kg_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_hHYutlew8ESCB--CCrbdBw_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">33534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_Nj2gEWg7G0-iOA3WZINE1Q_8_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">50826000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-5"
      id="Narr_g8nm1poiwEOA-pChNDVvnw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-5"
      id="Narr_8w6dSsMh3kCKe9q3kjeYOg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">600000</us-gaap:OperatingLeaseExpense>
    <pasg:StockholdersEquityAndTemporaryEquityTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_jMbYWNpwsUutUwjCpGutTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Convertible Preferred Stock and Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2020, the Company completed its IPO in which the Company sold 13,798,900 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $18.00 per share. The Company received net proceeds of $227.5 million after deducting underwriting discounts, commissions, and other offering expenses paid by the Company. In addition, immediately prior to the initial closing of the IPO on March 3, 2020, (i)&#160;all of the Company&#x2019;s outstanding shares of convertible preferred stock converted into an aggregate of 26,803,777 shares of common stock and (ii)&#160;the Company filed an amended and restated certificate of incorporation to, among other things, increase the number of authorized shares of common stock to 300.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On March 5, 2021, the Company entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may, but are not obligated to, offer and sell, from time to time, shares of the Company&#x2019;s common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent. No sales of common stock have been made pursuant to this Sales Agreement to date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pasg:StockholdersEquityAndTemporaryEquityTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA"
      decimals="INF"
      id="Narr_5ywAfV8y7Emiz8ksbxvDzQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">13798900</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FjALmRT9kE6JDV3gpQtAgA"
      decimals="INF"
      id="Narr_yNFWG2eT9kyNt2J9EzH6mw"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">18.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vjg8ELOAF0mP5tRlxnIVJA"
      decimals="-5"
      id="Narr_SG25fsiQwk2-WwIzAoR3uQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">227500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0aYfPaNDZUKLpHmemdOVpw"
      decimals="INF"
      id="Narr_lNU12kn6aEKQwptFzm3U1Q"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">26803777</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_2_28_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GVNitqFPWE2eFLAMk2cu3g"
      decimals="-5"
      id="Narr_6mZ2YXanfEewoZ2ylImjCQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">300000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w"
      decimals="INF"
      id="Narr_qixg5vgkHkyecFEA6Oz7bg"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_aHwnSqJS7Eaecp2WOoB7vA"
      decimals="2"
      id="Narr_PqgXdnMzskKsFDv2bWr6AA"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">22.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_UUZQNI0W40OSJrIGD5ZT8w"
      decimals="-5"
      id="Narr_271c0TvPIU2U8uNdPEyuqw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">165800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_jLdA8uvJqUuhFQXDPlOxiA"
      decimals="-5"
      id="Narr_fKyGXCqzi06_A36KcHfvvw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">125000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_6cQRUFo1xEqxvR0_DcpgmQ"
      decimals="INF"
      id="Narr_MOC-CVh3CkmWZkI1Wesd4g"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_Cs0oSuJSEUKSzMYtfq1G6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Share-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and Inducement Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The total number of shares authorized under the Incentive Plan as of December&#160;31, 2021 was 7,658,677. Of this amount, 3,637,509 shares were available for future grants as of December&#160;31, 2021. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the Plan shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continuing for &lt;span style="white-space:pre-wrap;"&gt;ten&#160;years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;, in an amount equal to five&#160;percent of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares authorized for issuance under the Incentive Plan increased by 2,712,249 and 2,295,854 shares in January 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options under the Incentive Plan vest based on the terms in each award agreement, generally over four-year periods, and have a term of ten&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Inducement Plan was approved by the Company&#x2019;s board of directors in July 2021. The total number of shares authorized under the Inducement Plan was 1,000,000. Of this amount, 12,900 shares were available for future grants as of December 31, 2021. The Inducement Plan provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options under the Inducement Plan vest based on the terms in each award agreement and have a term of ten years&lt;span style="white-space:pre-wrap;"&gt;. The Company&#x2019;s restricted stock units vest based on the terms in each award agreement and have a term based on each award agreement.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations for the period presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,691&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;year ended December&#160;31, 2020, the Company modified certain awards and recognized $0.7 million related to the modifications, $0.6 million of which was recognized in research and development expense and $0.1 million was recognized in general and administrative expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, the Company modified certain awards and recognized $7.4 million related to the modifications, $6.1 million of which was recognized in research and development expense and $1.3 million was recognized in general and administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes stock option activity for the&#160;year ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&#160;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,928,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,980,889&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (146,787)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,345,215)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and Exercisable at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,651,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested or expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, 1,308,244 options to purchase common stock are unvested, but exercisable, under early exercise provisions as described below. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of options granted was $12.75 and $11.54 for the&#160;years ended December&#160;31, 2021 and 2020, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised was $1.3 and $2.0 million and during the year ended December 31, 2021 and 2020, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options outstanding as of December 31, 2021 was $1.6 million and the aggregate intrinsic value of options exercisable as of December 31, 2021 was $1.4 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $58.8&#160;million, which the Company expects to recognize over a weighted-average period of 2.8&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The 2018 Plan and 2020 Plan provide certain holders of stock options an election to early exercise prior to vesting. The Company has the right to repurchase early exercised options without transferring any appreciation in the value of the underlying shares to the employee if the employee terminates employment before the end of the original vesting period. The repurchase price is the lesser of the original exercise price or the then fair value of the Company&#x2019;s common stock.  There were &lt;/span&gt;no&lt;span style="white-space:pre-wrap;"&gt; early exercises of options during the year ended December 31, 2021.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes activity relating to early exercises of stock options during the&#160;year ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 302,277&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302,277)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Nonrecourse Promissory Notes&#160;with Related Parties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2019, two of the Company&#x2019;s then executive officers, elected to early exercise 688,875 and 309,994 stock options, respectively, in exchange for cash proceeds of $0.2&#160;million and nonrecourse promissory notes, or the Notes, of $0.8&#160;million. The Notes&#160;bore interest at 2.91% and were secured by the underlying shares of common stock that were issued. In January&#160;2020, the Company forgave the Notes&#160;and associated interest related to the early exercise of stock options. An aggregate of 406,897 shares that were previously not considered outstanding for accounting purposes due to being secured by the Notes&#160;became outstanding upon the forgiveness of the Notes&#160;in January&#160;2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year-ended December 31, 2021, the Company accelerated the vesting of each executive officer&#x2019;s early exercise of stock options awards in relation to each of their separations from the Company such that all early exercised stock options were vested for accounting purposes as of December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Units &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company issues RSUs to employees that vest over periods as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#x2019;s common stock on the date of grant. Compensation expense is recognized straight-line over the vesting period of the RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes activity related to RSU awards during the year ended December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 360,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.54&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (40,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.78&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2021, the total unrecognized expense related to all RSUs was $3.5 million, which the Company expects to recognize over a weighted-average period of &lt;span style="white-space:pre-wrap;"&gt;3.0&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective on February&#160;28, 2020. The total number of shares authorized under the ESPP as of December 31, 2021, was&#160;893,170 shares of the Company&#x2019;s common stock. Of this amount, 781,936 shares were available for future grants as of December&#160;31, 2021. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continuing for &lt;span style="white-space:pre-wrap;"&gt;ten&#160;years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;, in an amount equal to one&#160;percent of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares authorized for issuance under the ESPP increased by &lt;/span&gt;542,449 and 459,170 shares in January 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the ESPP, eligible employees can purchase the Company&#x2019;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#x2019;s common stock at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first day of the offering period or on the last day of the offering period. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 worth of the Company&#x2019;s common stock for each calendar&#160;year in which such right is outstanding. During the years ended December 31, 2021 and 2020, 91,125 and 20,109 shares, respectively, were purchased under the ESPP. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with the guidance in ASC 718-50&#160;&#x2013;&lt;i style="font-style:italic;"&gt;&#160;Compensation&#160;&#x2013; Stock Compensation&lt;/i&gt;, the ability to purchase shares of the Company&#x2019;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and&lt;b style="font-weight:bold;"&gt;, &lt;/b&gt;therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#x2019;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $0.4 million and $0.2 million during the years ended December&#160;31,&#160;2021 and 2020, respectively, related to the ESPP.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pasg:NumberOfEquityIncentivePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Narr_e2OHJiBnTUGylKaAMs8oNA"
      unitRef="Unit_Standard_plan_bYBMu5fRl0arekv0DtDLXA">3</pasg:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_YdlvI73YvU2I-mGpcp7oeg"
      decimals="INF"
      id="Narr_91_wmOdDUEe1CHFTRexjaA"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">7658677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_YdlvI73YvU2I-mGpcp7oeg"
      decimals="INF"
      id="Narr_proT6AwZEUSN31e_EmgIgQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">3637509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg"
      id="Narr_FBciUcxhKUiU3dFUwJpvEQ">P10Y</pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg"
      decimals="INF"
      id="Narr_pE6cNpzY7Ey3LXIli4wudA"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.05</pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_DUZDzlEv3kCLP31Wr2eujw"
      decimals="INF"
      id="Narr_e0rhmpR25E-FOnELHQanXw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">2712249</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_By7Uz8pPpEWAL_wK_0BdCQ"
      decimals="INF"
      id="Narr_MTYrg5u_nEK2kM1HCfMZlQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">2295854</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg"
      id="Narr_5aXwDY2X5kmr-Jvnc86H2A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pasg:SharebasedCompensationArrangementBySharebasedPaymentAwardTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_EXnP8TANRUyNXNkBQsZ3Fg"
      id="Narr_lLvwOJq1xE-_E-dsc_yXBw">P10Y</pasg:SharebasedCompensationArrangementBySharebasedPaymentAwardTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_eEb-pqvetEOOQLXyvb5cMQ"
      decimals="INF"
      id="Narr_TLaLokTBikaLrIjwwAadMw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_eEb-pqvetEOOQLXyvb5cMQ"
      decimals="INF"
      id="Narr_une0xL96M0eB4-dZrT2riA"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">12900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:SharebasedCompensationArrangementBySharebasedPaymentAwardTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_TuoN6al3ek-oKV2lUg9dvA"
      id="Narr_zQq-8-Kx3kaAOhHT0ckSBw">P10Y</pasg:SharebasedCompensationArrangementBySharebasedPaymentAwardTerm>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_VMgB9ZKdvkybvb1woVBBkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,691&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,580&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9gQrDgAqjkSE2Gb1oTaaSA"
      decimals="-3"
      id="Tc_vhH8Gxh-SkK6k37RpHj9dA_3_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">15432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yMsCjLmkD0S_oueWNaOXdA"
      decimals="-3"
      id="Tc_PPBeH78DfUGCCTzyohCxug_3_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">5525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_lmvSR935b0WEFgO0Y_lvng"
      decimals="-3"
      id="Tc_7WuijlBiukOt95S_qLtHmA_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">17259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DOc0XterPEO_ABMw_SCRSQ"
      decimals="-3"
      id="Tc_zO9C_5plmE2GqVI6z8MXBg_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">9055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-3"
      id="Tc_xl4vsPTgjEOxRPh1EKhu3g_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">32691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-3"
      id="Tc_xDq6FM-7nk6znAydaBSjzw_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">14580000</us-gaap:AllocatedShareBasedCompensationExpense>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-5"
      id="Narr_nKXY2USw70SJyiwlLzLYSQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">700000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_yMsCjLmkD0S_oueWNaOXdA"
      decimals="-5"
      id="Narr_jv6wWtLQsEmI1SRtc3Leug"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">600000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DOc0XterPEO_ABMw_SCRSQ"
      decimals="-5"
      id="Narr_84egIPqkd0y9BGm8Jk1SSQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">100000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-5"
      id="Narr__iphuLeWTUmifiTozIfOog"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">7400000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9gQrDgAqjkSE2Gb1oTaaSA"
      decimals="-5"
      id="Narr_GCa4WcewnkmGTNvrOTa1fg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">6100000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_lmvSR935b0WEFgO0Y_lvng"
      decimals="-5"
      id="Narr_xs9qiz_QTEq8HdLqAK1YVg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1300000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_kqkFf2HSk0Ct0t8ELLzZxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&#160;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,928,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,980,889&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (146,787)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,345,215)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and Exercisable at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,651,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested or expected to vest at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="INF"
      id="Tc_HSOqjA1mOkSOIARglRCmzg_6_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">6928111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="2"
      id="Tc_QZDUsxNnF022yU98EXXeag_6_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">12.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      id="Tc_wxflquqIxUuZiZfPRT4Zog_6_7">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Tc_IDN2LM56L0qhUgVJHzJd5Q_7_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">3980889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="2"
      id="Tc_fdLRETHuE0iICe6heEXKtA_7_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">16.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Tc_laXBLidEkki35T8rkebRLg_8_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">146787</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="2"
      id="Tc_sLYph3RkUkKFJ5QACWhL0Q_8_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Tc_vAmBOGjr4UCmMmmxnuGT0Q_9_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">1345215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="2"
      id="Tc_bRhVbou2A0yOHUYFcJnfTg_9_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">15.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Tc_vGx22Zp0BkaLH2Sk4P6-0A_10_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">9416998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="2"
      id="Tc_zC7W1mbhMkmTOoXiIHVsGA_10_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">13.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_OLbrae_HQ06MUoHIeqJwPg_10_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Tc_EEIEVAgaD0euoxx4JE1Ifg_11_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">3651983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="2"
      id="Tc_VZdLk-4rb0-YKxIsVHkxOg_11_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">12.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_gxGrAeqnP0qSojWHXCSo1g_11_7">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="INF"
      id="Tc_niRay-Jz4UuK9G17eGJ8Vw_12_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">9416998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="2"
      id="Tc_fnU9pYe8SEqGRgyPrwKrsg_12_5"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">13.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_7uxLDVNbGUGCYdzs5jnakQ_12_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="0"
      id="Narr_MA2LB84e1E60njUNGDrhlQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">1308244</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="2"
      id="Narr_DWE2hae8XEOVl0OJmLucig"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">12.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="2"
      id="Narr_PFxdDdxsjkC8o_EkYbw4OA"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">11.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-5"
      id="Narr_WP_liE9Oc0eCn-SyllVpRA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-5"
      id="Narr_otCiKg28PkSdWEDuvmPMtQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_ALFvrtvrYky_M1kDMEsJaw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_kUMGkT80K0uT_yxjOuHkWA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_0Mey1SDkkk2ECNBOPNl2dA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">58800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_-NKBkLI2w0axRW-tKXB2Sg"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">58800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Narr_eBNq5cHA3Em0LTbKahRaxA">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_GjbeLQaOHU-SHesQklbwsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="3"
      id="Tc_edcOk6i87EGlvvgutNQ68Q_3_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="3"
      id="Tc_5a-_nRFIh0-zfXxuj5YEsQ_3_5"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="3"
      id="Tc_op-KMqgwykCsd2_4_Oxurg_4_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="3"
      id="Tc_fxGN4cLAB02vG1wOcQ2ihA_4_5"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tc_Ktuxy4QIAEiHwYuWPufnXg_5_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      id="Tc_6R_WEXRgd02WjTYz4jqMew_5_5">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="3"
      id="Tc_poyWNiDCNkSQC86wgrBdFw_6_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="3"
      id="Tc_zRgQGMabv0OH7CzYkVkRTQ_6_5"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Narr_0tQI_RB7b02FWZp9QTmjaQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">0</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_XhsqOW1mUUGqW6sahbtydg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 302,277&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (302,277)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="INF"
      id="Tc_n8X9SlKgpE-4Djzm9rWyEg_2_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">302277</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="INF"
      id="Tc_mB_MiT7Xlk6f3719S_sRaw_3_2"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">302277</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <pasg:NumberOfExecutiveOfficers
      contextRef="As_Of_2_28_2019_Dg47llwd60Wt_myzLnSxow"
      decimals="INF"
      id="Narr_H4rG7rfFF0agFiipTr_ZSA"
      unitRef="Unit_Standard_individual_kRSnx8nw1kG-RLCkCGj2iA">2</pasg:NumberOfExecutiveOfficers>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares
      contextRef="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_-s2xGmVdVkGTPHiCmb4BJA"
      decimals="INF"
      id="Narr_e-V8E_lRQEm_7r8V6kBfdQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">688875</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares
      contextRef="Duration_2_1_2019_To_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_eJE-uMNmcUG5vTVEbr9ZOg"
      decimals="INF"
      id="Narr_pF7Mt7G_U0iJ442wGlEjCw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">309994</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefExecutiveOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_0lT3N_zSwUG3WlueyWRnJA"
      decimals="-5"
      id="Narr_my6I7K53bESXu-PrL9EZCw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">200000</us-gaap:NotesReceivableRelatedParties>
    <us-gaap:NotesReceivableRelatedParties
      contextRef="As_Of_2_28_2019_srt_TitleOfIndividualAxis_pasg_InterimChiefOperatingOfficerMember_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_b-40t_BVvU-ZNd20D-z1kQ"
      decimals="-5"
      id="Narr_7t5KEMC5Z02uW4Z2Fg1-8w"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">800000</us-gaap:NotesReceivableRelatedParties>
    <pasg:NotesReceivableInterestRatePercentage
      contextRef="Duration_2_1_2019_To_2_28_2019_us-gaap_RelatedPartyTransactionAxis_pasg_PromissoryNoteWithRelatedPartiesMember_QFerryslZEecn9p62PcHmA"
      decimals="4"
      id="Narr_iWEX2uI9g0ql9xPr1U9Lmw"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.0291</pasg:NotesReceivableInterestRatePercentage>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding
      contextRef="Duration_1_1_2020_To_1_31_2020_i2EyC4gK6EeZimGB107lUg"
      decimals="INF"
      id="Narr_HxqIppYwk0-aZ8uffoB6oQ"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">406897</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_0uJOwyfrB0W9jkfyG-sSgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 360,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.54&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (40,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.78&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="INF"
      id="Tc_XsiMCzt-YEKiELqIdRyLZg_4_3"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">360500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="2"
      id="Tc_uw9wkyrPgkio5opu8ZiHkQ_4_6"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">15.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="INF"
      id="Tc_60dzbCm6xkq60BY-Eas9MA_5_3"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="2"
      id="Tc_8BNLiqtAsUGSGnfQ0ECgXg_5_6"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">18.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="INF"
      id="Tc_p4Dc-Htvb0S0iS7gmMFp-w_6_3"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">30000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="2"
      id="Tc_0Bzufi89602TuCFwM7sMuQ_6_6"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">18.48</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LoCSKTtbL0OhUlAy4bzQyQ"
      decimals="INF"
      id="Tc_Hy24BLAinEqAz9oMC4K8_Q_7_3"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">290500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_LoCSKTtbL0OhUlAy4bzQyQ"
      decimals="2"
      id="Tc_FCOQ67LkJkODmy4UCYbCLg_7_6"
      unitRef="Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ">14.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      decimals="-5"
      id="Narr_ap-J7y4_2kauJUbd7DwkAQ"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg"
      id="Narr_UOoxpJqmQkayDcpk1DP9EQ">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_Hlylcmv8XEyDesAxASGedA"
      decimals="INF"
      id="Narr_CkZMYKacG02Z4oWVg7LEQg"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">893170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7TeewkAeXES9W_l9V_dFQw"
      decimals="INF"
      id="Narr_dEWCBQ3300-yPQdjnYcJnw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">781936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MWN-gxUTckSGX79Osy-sqw"
      id="Narr_WLgxBwLwqU-XZi6Ihxg0gA">P10Y</pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw"
      decimals="INF"
      id="Narr_Z65PzFAdDESso3Gdlsqmfw"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.01</pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_IXEquSLDb0yKA8sbyQ-qig"
      decimals="INF"
      id="Narr_JUs9WWICxUWEjwWUvdIUEA"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">542449</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_MYx6whEmKUaeZZi3nvIPow"
      decimals="INF"
      id="Narr_UCkSS9dp_0GCaEnPSaORFA"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">459170</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw"
      decimals="INF"
      id="Narr__Tz-wXXIuUaZzd3gc02yEQ"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw"
      decimals="INF"
      id="Narr_9xHgnS6xAkSR2Co4Ufaheg"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.15</pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage>
    <pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased
      contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_Hlylcmv8XEyDesAxASGedA"
      decimals="0"
      id="Narr_ADE-7LWlgE-1TyifSC1sWw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">25000</pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_hge6WzgOskii8rTOoQb_rg"
      decimals="INF"
      id="Narr_kC7dKxbmoU2Uqkq8G4iVUA"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">91125</pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_fRoUpLtqpkitwlFzFSV1fw"
      decimals="INF"
      id="Narr_HTqU0U3Cbkqaz3l3S59kSw"
      unitRef="Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig">20109</pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7o4M7PrCLk60fyHubDJwEw"
      decimals="INF"
      id="Narr__gl87WW30Ueb0tM8NVszvw"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_hge6WzgOskii8rTOoQb_rg"
      decimals="-5"
      id="Narr_vTLxq4jbxE-EEMuyUypRQA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_fRoUpLtqpkitwlFzFSV1fw"
      decimals="-5"
      id="Narr_N0vmGPoKjUmudXHA_tgK7Q"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_USiK1cqQY0mhUrqtFhPRgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Collaboration and license agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62,962)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of December&#160;31, 2021 and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;2020. The valuation allowance increased by $72.1 million and $44.6 million during the&#160;years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes carryforwards of federal, state and local net operating losses (NOL) and research and development and orphan drug tax credits:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126,551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,317&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;126,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;116,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,958&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The NOL carryforwards begin expiring in 2037 for federal and state income tax purposes, however; all federal NOL carryforwards generated subsequent to January&#160;1, 2018, are able to be carried forward indefinitely. The NOL carryforwards for local income taxes related to the city of Philadelphia begin expiring in 2022. As of December&#160;31, 2021, the Company also had federal research and development and orphan drug tax credit carryforwards of $22.2 million that will begin to expire in 2038, unless previously utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December&#160;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statement of operations. Tax&#160;years from 2018 and after remain subject to examination by the taxing jurisdictions. The NOL and tax carryforwards remain subject to review until utilized.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_w1Ri1OE8dk267psDLS9ejA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Collaboration and license agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,806&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62,962)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_kqStB6TcnUK3BR5GM0oiew_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">42351000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_-L554CuBN0WiyV2pN4AwSw_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">23464000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_ruDU6TLAZkCqQWF34K2KbA_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">22244000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc__NNbSoYehEue8lEPa3QNjA_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8959000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_qYlaHTuLM0uQNR89LG4r_A_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3976000</pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement>
    <pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_wjrBUF9bxEyZY2ExWxIQMQ_6_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1463000</pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement>
    <pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_10Aw3fxH0UWfNO1G0ieYcg_7_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">51806000</pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_r4PvQ61WzEirPvTguheCxg_7_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">23150000</pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_OjyQuZ3tpEyAWJaD4Ktuxg_8_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">11245000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_4jcjCG-Pm0iNA-ehadmsjA_8_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">4125000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_Tclr7DPrJUeoZP9ajvgDFA_9_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">3431000</pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_gOZsKO9BzUSZcagrKPcsEg_9_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">1801000</pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_QoT3R-_aTU-KFbfinb93BA_10_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135053000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_OwFJn-Hmw0iCeKfRN5w5VA_10_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">62962000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_7VA5R8mh80WGefBfrK48rA_11_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">135053000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_ExXMLSgvy0OBvZsKmNViTQ_11_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">62962000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-3"
      id="Tc_6Khk5f-blkulQcdET5Jq7w_12_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q"
      decimals="-3"
      id="Tc_pXgvj1hltE6tRubC-TpFOg_12_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-5"
      id="Narr_yh-fpQcGiEiMEnyCwOCung"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">72100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="-5"
      id="Narr_Pl6MnzEQO0WLE8Y3RZZjFw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">44600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_K_AzfXNfsku9nT4p5pj0RA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="4"
      id="Tc_GJzX57sBjEWWF6oOuaLDoQ_4_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="4"
      id="Tc_TV2MEVf5FECebExiZQzebw_4_4"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="4"
      id="Tc_Wc9szh0OxkyTARfJ0_7JWQ_5_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.119</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="4"
      id="Tc_50RBJLs_gUu9Xx7u-WP1Zw_5_4"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.126</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="4"
      id="Tc_LUOwvpxFSk-eC0-OWcml6g_6_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.011</pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="4"
      id="Tc_7QCPPGDdSEOPBPAwEGV7tA_6_4"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.003</pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="4"
      id="Tc_LZ246mMx-UiTPVOFFqgVqA_7_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.071</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="4"
      id="Tc_UGfvI8bm10C5lqfbOs75rw_7_4"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="4"
      id="Tc_lCdEnkxKIEKPRm7S1j-iVw_8_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.389</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="4"
      id="Tc_Y0Z335q1YUWj11z7W57Fvw_8_4"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0.398</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="4"
      id="Tc_AMKk68h8SkG-20SYddePHA_9_2"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_6E2hw-1G1kCnJ3yPFdtz8A"
      decimals="4"
      id="Tc_qxYmjWJOPkWdqR-1uelccw_9_4"
      unitRef="Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_Kpoy_OZ9i0GrZwD781_Bpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126,551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,317&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;126,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;116,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,958&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_zzHhTfTUtkmAsOCCTtRAfQ"
      decimals="-3"
      id="Tc_XbkrBI45UEeI7PfFB8b2pA_3_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">126551000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_-AB_b6Gy40yD--yAZUlaJA"
      decimals="-3"
      id="Tc_6kqmCVkjHEGgp2fBFrBcLQ_3_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">69317000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_ou_PBG4RvEihq6A2EvgcSQ"
      decimals="-3"
      id="Tc_J9J-DGOxlUCTRAH5OrCHgQ_4_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">126547000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_sCqVUi350ke4K2VTSeSwSg"
      decimals="-3"
      id="Tc_ZPcriUMMY02mB_246IwuTA_4_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">69313000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_AEwhzMB_OUyIYWxhHH_sKA"
      decimals="-3"
      id="Tc_5dLwL3BtIE2qmUpBE_iX6Q_5_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">116301000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_YBzYmbyXZkO0AKGn6_kDpA"
      decimals="-3"
      id="Tc_gKHyEkyCNkyhG1hH5HWYVw_5_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">69053000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_OZPCcIcvuE2lyKN-UB_SrQ"
      decimals="-3"
      id="Tc_vHTg6wycQ0en0qLV1-mGGw_6_3"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">22244000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yq6XT26n3Eqy2E5_gcwEZA"
      decimals="-3"
      id="Tc_gd6qPhg0p0KDjIQlmPe88A_6_6"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">8958000</us-gaap:TaxCreditCarryforwardAmount>
    <pasg:TaxCreditCarryForwardSubjectToExpiration
      contextRef="As_Of_12_31_2031_nwAcjwnUlECe9uyTYzx_Cg"
      decimals="-5"
      id="Narr_wWhwF0IMsEGbxKHfRYGtTw"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">22200000</pasg:TaxCreditCarryForwardSubjectToExpiration>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag"
      decimals="-5"
      id="Narr_KLhn4Wgid02olzwB7nVamA"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      decimals="-5"
      id="Narr_5KGThFkvVkSYqa9zu0gP8A"
      unitRef="Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA"
      id="Tb_QU8-66Tm40GpZykMaqfYXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12.&#160;Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;None.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -4[8U0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #5.V-4R;3IU^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU!,'1[6?&D(+B@> O)[&ZP24,RTN[;F\;=+J(/(.22F3_?
M? /I=)!ZC/@<QX"1+*:;V0T^21TV[$@4)$#21W0JU3GA<W,_1J<H7^,!@M(?
MZH @.+\%AZ2,(@4+L HKD?6=T5)'5#3&,][H%1\^XU!@1@,.Z-!3@J9N@/7+
MQ'":APZN@ 5&&%WZ+J!9B:7Z)[9T@)V3<[)K:IJF>FI++N_0P-O3XTM9M[(^
MD?(:\ZMD)9T";MAE\FN[O=\]L%YP(2K>YK-KA&RY%'?OB^L/OZNP&XW=VW]L
M?!'L._CU+_HO4$L#!!0    ( -4[8U297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M-[1.JNE0S<3(RA_RE32V9?AA89LZ*%=@[Z^E-(>)ZQO=WT3Z#U!+ P04
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M29\.5$Q_W.%F9X'_I^P-]8DY6HO3@9CI4V>=G4<-T>BJFA^$.7 RFD5.:>A
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M-2U24K=LM0B6Z/25PD^'<*C,:W12":W^$2]CHJ/7]JDBB-(A,M1E[0GM;5^
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M7-&'0"4B@1^,JY7U,5+>YZC6[-ZJT+%1%4(MJBKX5B%Z@V;_CRI"!+$<ZG)
M8%^C2_PC-HJ^[:U.D ^7-H5)RE?JV[.+E[,SN)VULB'R)$Q#[9K":)[9$5;M
M$K9W$+7#S%!U":4@0]L=ZA[K+')!T:B$*)\J4REZI#!5J=%) 4 !8#4YQD\
M7SL#8!"OHK8D4$R*J@N^[ M979I2CA6B7+); ( ZC\@\'?)(FJG[?AT3(P2.
M TB%[DS2''K6JC6!38(;J_466/::):^J'ISQJ0>T,HUX-9SS%4PS]<&I7W2
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M6K06;<4@)ZL'9JR3^Z!+"I:U,57,IY'9L1?5*N9*:AY1'7%N&A8>N37UWJR
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M3H5F@/F"<[4;:(#]5YO%WU!+ P04    " #5.V-4PQ]\/X &  !%%P  &0
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MT%KI@W<>1]9P'7//^F:-:4B-EP904(-3.#+B#:J^((M&6W0K2.$Q_+&+XRL
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M!W!_;6T?O] &Z8<QK_X?4$L#!!0    ( -4[8U3"L4R5=@0  %H+   9
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MOXY^'M/?<4"W2CC!)*W:M109W150%ZJ$G#XQDU4^R4E$KN+>KF'JB3+\2^Z
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MY"#:=K6B2;49TQ[-AC010E_O,!8QUMN.[DZS=339Q<F_&16I<ZE6LBTM756
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M5 $I/=?'4[!%'Y$6QRL. (2:^4!(^L=:!VN7[R0UKCN]O2$(#T;++3<LO85
MC"N+DFY6[/43?!R@2.'&]*-6GX1F02EQWQI+BN+E1X"1VB;NT*:&Z(O]M%:S
M*7." B_0K>\F?[G]&BI/$UN.)J5<G#.:D-7P\#!H#%Z=4][&WE4ROYO=YL!1
MBG$\EKH".>UI8PI5$74O+?(-STP8%W<9FGNQ7SBVVPFMD'<,";F^U4KS=8U
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M- #?2P,X# ^T0/J?$V__"U!+ P04    " #5.V-4I;<Z/;@"   I!@  &0
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M/=!]F^T-JYJNM:V4I4;934OZ,Z%V#K1?*&5WA@LP_.N6OP%02P,$%     @
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M#OF:+V*I,$^P*O<&70M$A9 LJ\#*@HS0\HU>JD!L 11/,\"M .Y;0.< P*L
MWD<!G0K0^2C KP#&=;OTW01N@B0:]CE; :YW*S8],-$W:!4O0O5%F4FNOA*%
MD\-[(AX%0#0&M^2I(#&1K^!X@B4BJ3@!9^!A-@''1R?@"-A )(AC 0@%#Y1(
M<:H6U?A7P@JA"$3?ELH@36M'E?BH%'</B$-PQZA,!+BB,8YW\;9RI/;&77LS
M<EL)OR-Z#CQX"ES'A0WVC-OA=XC7<*<!/FF'3W#4JG[U<;C3$@RO/EK/\'FM
M1WNY<[1_;]4F<"-Q)OZU2'1JB8Z1Z!R0N(RB(BM2)'&L_TX2$=D4MI(D,"0Z
M<ST/SSR_ZX8J2,_;\6G8!P,G[/GUOATK_=I*O]7*F^G/%E^[-4OWJ\(9U!)!
MJZ&SZ@<3HGC[.Y37MX1WMP($O: 7]ARG.4)A+1R^+PQR3B+<)!ONG0L,FP5[
MM6"O5?"'*H$Y9Q'&C7ECW-M3=-W /^0F=#;9SFG5O6:I*HUGJD+EQ3PE$6"+
M!>:$+EM.#V[E4OA55P2Z&Q'W4Y=D5.&W;TGHJ-@=C-XFH4#O$]=D5*%W3^V
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M;S.> BW,A%N4TG0117U]&SI2A,.3J@9'C? (-[YK;VJ,V6I.$1R,1A<[S>G
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M9:+&3> Z0+V/&9//&SW0- /L["]02P,$%     @ U3MC5 <*#QZ(!   [Q4
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MHV1-A3'0]S><JY<3L^=7[_$N_@502P,$%     @ U3MC5/)#S/3/ @  YP<
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULO95;;]HP%,>_BA7UH95H
M<^$6*D"B5-7V,*DJ;?<P[<&$ ['JV-0^@7:??L<&,E8N8]*TE\27<_F=?X[C
M[E*;%YL#('LKI+*]($><7X>AS7(HN+W2<U"T,]6FX$A3,POMW "?>*="ADD4
MM<*""Q7TNW[MWO2[ND0I%-P;9LNBX.;]!J1>]H(XV"P\B%F.;B'L=^=\!B/
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M4E<!MRVG"L&!8JFJLX$*<B(G65N7P8##=1S7/Z(=6\W=:#:-.^]QYV=Q'T
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MS0#XOA1";Q_,;6A]@S_]%U!+ P04    " #5.V-4:9/"RX\$   1$@  &0
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MX[J]W &-09@-^OF&<_5R8P#JKT"SOP%02P,$%     @ U3MC5*RSH/^F P
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MK3QKLK*)9&O3IRR85%V/&<:J,06N#=3^DC&YG^@#BE9W^ ]02P,$%     @
MU3MC5&B*YBD"!0  %Q0  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
MM5C1;J,X%/T5*YJ'5NH$; *!*HW4I-W=>>A.-55GGEUPB%7 6=M)VOWZM<$!
MDH"3CKHOP3B^]YQ[;9]K/-DR_BJ6A$CPEF>%N!DLI5Q=.XZ(ER3'8LA6I%#_
M+!C/L52O/'7$BA.<E$9YYB#7#9P<TV(PG91]CWPZ86N9T8(\<B#6>8[Y^XQD
M;'LS@(-=QP^:+J7N<*:3%4[)$Y'/JT>NWIS:2T)S4@C*"L#)XF9P"Z_G*-(&
MY8B?E&Q%JPUT*"^,O>J7;\G-P-6,2$9BJ5U@]=B0.<DR[4GQ^,<X'=28VK#=
MWGG_HPQ>!?."!9FS[!=-Y/)F$ Y 0A9XG<D?;/L7,0'YVE_,,E'^@JT9ZPY
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M>3<$2):%2]G18N?>_BNA327AFEM3[(&T$\SWM1#ZU+$.ZO)Q]B]02P,$%
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M M" (4G2[(-[^U&\WJ?BS2]@H]]02P,$%     @ U3MC5)>*NQS     $P(
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M;\[I)U!+ 0(4 Q0    ( -4[8U0'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ U3MC5,FTZ=?M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ U3MC5)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #5.V-4R$?SM#0&   Q&P  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ U3MC5'.03;P>!0  3Q,  !@              ("!=@X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -4[8U2=PVNR2P(  #(&
M   8              " @<H3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #5.V-4 RR-?10$   F#@  &               @(%+%@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ U3MC5/,ZJ8C[
M!@  92,  !@              ("!E1H  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( -4[8U0*0- 33 (  &\%   8              "
M@<8A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #5.V-4
MS3Z7J@\'  !/'0  &               @(%()   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ U3MC5(2&?]WD P  JP@  !@
M     ("!C2L  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M -4[8U2BEJ&?A@<   L3   8              " @:<O  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #5.V-4%7OF[0</  #$*0  &0
M            @(%C-P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( -4[8U0]<SM0= 0  ,$1   9              " @:%&  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ U3MC5,,??#^ !@
M11<  !D              ("!3$L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #5.V-4$)R_T>0"  ! !P  &0              @($#
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -4[8U3R
MVBRFI (  *H&   9              " @1Y5  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ U3MC5.C4D7S0$   )#,  !D
M     ("!^5<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -4[8U2N%,@ "!   $4Q   9              "
M@>^%  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ U3MC
M5*6W.CVX @  *08  !D              ("!+I8  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #5.V-4@8.M09 $   O$@  &0
M        @($=F0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( -4[8U3]X8:8U ,  #<0   9              " @>2=  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ U3MC5,DH]R7? @  ]P8
M !D              ("![Z$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #5.V-42^!+=Z0"   ]!@  &0              @($%I0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -4[8U0"=%"C
M6P(  %<%   9              " @>"G  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ U3MC5-#&^T#-!   4@\  !D
M ("!<JH  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #5
M.V-4N0/LL 0$   8"P  &0              @(%VKP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -4[8U1.'H#A(0,  #H*   9
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M970S,RYX;6Q02P$"% ,4    " #5.V-4& F-?3P%  #!(0  &0
M    @(%&QP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M -4[8U3L'ZH4D0,  (@.   9              " @;G,  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ U3MC5%VD9VJQ @  J0<  !D
M             ("!@=   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #5.V-4E.U %+0%  #-%P  &0              @(%ITP  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -4[8U1ID\++CP0
M !$2   9              " @539  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ U3MC5*RSH/^F P  >@T  !D              ("!
M&MX  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #5.V-4
M<9H(2%$%  #A%@  &0              @('WX0  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( -4[8U3FM435& ,  /8*   9
M      " @7_G  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ U3MC5&B*YBD"!0  %Q0  !D              ("!SNH  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #5.V-4^\6S^GX#  #S"@
M&0              @($'\   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( -4[8U27K<4QP0,  "0.   9              " @;SS  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ U3MC5)T(^#[&
M P  2@X  !D              ("!M/<  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #5.V-4_>YCEX(#   3"P  &0
M@(&Q^P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -4[
M8U1LZC1LZ0(  $,)   9              " @6K_  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ U3MC5#_B[.QK P  ! P  !D
M         ("!B@(! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " #5.V-4;2'[V2L#   .$P  #0              @ $L!@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( -4[8U27BKL<P    !,"   +
M  "  8() 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -4[8U0:R585(P0  &(@
M   /              "  6L* 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #5.V-4DBR@EK@!  #G'   &@              @ &[#@$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #5.V-4C$_JC[H!  #N'
M$P              @ &K$ $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
...  X #\/  "6$@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>390</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureRisksAndLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Cash, cash equivalents and marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash, cash equivalents and marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Convertible Preferred Stock and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock</Role>
      <ShortName>Convertible Preferred Stock and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash, cash equivalents and marketable securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails</Role>
      <ShortName>Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureRisksAndLiquidity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails</Role>
      <ShortName>Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails</Role>
      <ShortName>Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Convertible Preferred Stock and Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails</Role>
      <ShortName>Convertible Preferred Stock and Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails</Role>
      <ShortName>Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails</Role>
      <ShortName>Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Income Taxes - Effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pasg-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Income Taxes - Net operating losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails</Role>
      <ShortName>Income Taxes - Net operating losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pasg-20211231x10k.htm">pasg-20211231x10k.htm</File>
    <File>pasg-20211231.xsd</File>
    <File>pasg-20211231_cal.xml</File>
    <File>pasg-20211231_def.xml</File>
    <File>pasg-20211231_lab.xml</File>
    <File>pasg-20211231_pre.xml</File>
    <File>pasg-20211231xex10d17.htm</File>
    <File>pasg-20211231xex10d19.htm</File>
    <File>pasg-20211231xex10d20.htm</File>
    <File>pasg-20211231xex10d22.htm</File>
    <File>pasg-20211231xex10d23.htm</File>
    <File>pasg-20211231xex23d1.htm</File>
    <File>pasg-20211231xex31d1.htm</File>
    <File>pasg-20211231xex31d2.htm</File>
    <File>pasg-20211231xex32d1.htm</File>
    <File>pasg-20211231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pasg-20211231x10k006.jpg</File>
    <File>pasg-20211231x10k007.jpg</File>
    <File>pasg-20211231x10k008.jpg</File>
    <File>pasg-20211231x10k009.jpg</File>
    <File>pasg-20211231x10k010.jpg</File>
    <File>pasg-20211231x10k011.jpg</File>
    <File>pasg-20211231x10k012.jpg</File>
    <File>pasg-20211231x10k013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="467">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pasg-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 149,
   "dts": {
    "calculationLink": {
     "local": [
      "pasg-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pasg-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pasg-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pasg-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pasg-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pasg-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 463,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 13
   },
   "keyCustom": 72,
   "keyStandard": 318,
   "memberCustom": 18,
   "memberStandard": 31,
   "nsprefix": "pasg",
   "nsuri": "http://www.passagebio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Cash, cash equivalents and marketable securities",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash, cash equivalents and marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and Equipment, net",
     "role": "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "role": "http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:StockholdersEquityAndTemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Convertible Preferred Stock and Common Stock",
     "role": "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock",
     "shortName": "Convertible Preferred Stock and Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:StockholdersEquityAndTemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Share-Based Compensation",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Income Taxes",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Subsequent Events",
     "role": "http://www.passagebio.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheets",
     "role": "http://www.passagebio.com/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:BasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:BasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash, cash equivalents and marketable securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Risks and Liquidity (Details)",
     "role": "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails",
     "shortName": "Risks and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_-PSWBy6lg0qS4arBJG6UtQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "pasg:SegmentPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_dtYM95ndTUuz97Ok3LqHiA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "pasg:SegmentPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_dtYM95ndTUuz97Ok3LqHiA",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
     "shortName": "Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
     "shortName": "Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails",
     "shortName": "Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9AUZJzebVE2eoPhm72uXcg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and Equipment, net (Details)",
     "role": "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:DevelopmentMilestonePaymentsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)",
     "role": "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
     "shortName": "Commitments and Contingencies - Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:DevelopmentMilestonePaymentsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Commitments and Contingencies - Operating Lease (Details)",
     "role": "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
     "shortName": "Commitments and Contingencies - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Convertible Preferred Stock and Common Stock (Details)",
     "role": "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
     "shortName": "Convertible Preferred Stock and Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_6cQRUFo1xEqxvR0_DcpgmQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfEquityIncentivePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_plan_bYBMu5fRl0arekv0DtDLXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Share-Based Compensation - Equity Incentive Plan & ESPP (Details)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
     "shortName": "Share-Based Compensation - Equity Incentive Plan & ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfEquityIncentivePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_plan_bYBMu5fRl0arekv0DtDLXA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-5",
      "lang": null,
      "name": "pasg:ShareBasedCompensationArrangementExpensesDueToModifications",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (Details)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails",
     "shortName": "Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_2_28_2019_Dg47llwd60Wt_myzLnSxow",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_individual_kRSnx8nw1kG-RLCkCGj2iA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails",
     "shortName": "Share-Based Compensation - Nonrecourse Promissory Notes with related parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_2_28_2019_Dg47llwd60Wt_myzLnSxow",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfExecutiveOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_individual_kRSnx8nw1kG-RLCkCGj2iA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_56_YvJ8130asBtZzX0rV9Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Share-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q1DePQxaO0qFgEFhku1ATg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ofn7Z-r18kik-U5iFVw3ig",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Income Taxes (Details)",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_yXD_IEKst0ai8BPPLYVmag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Income Taxes - Effective tax rate (Details)",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Effective tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_lk-GYDobZ0qtZewjHNxokQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2031_nwAcjwnUlECe9uyTYzx_Cg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pasg:TaxCreditCarryForwardSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Income Taxes - Net operating losses (Details)",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails",
     "shortName": "Income Taxes - Net operating losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2031_nwAcjwnUlECe9uyTYzx_Cg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pasg:TaxCreditCarryForwardSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_pasg_SeriesOneConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8I2Rilknyk2A7zbSibJ8UQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "role": "http://www.passagebio.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__fDaKU7nc02SGzptbo8VcA",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Operations",
     "role": "http://www.passagebio.com/role/DisclosureNatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Risks and Liquidity",
     "role": "http://www.passagebio.com/role/DisclosureRisksAndLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_9Lz7OtGSRkqIoQZbYOSViA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying balance as of the balance sheet of accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities.",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs of property and equipment Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Property and Equipment, Current",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "AccruedLiabilitiesPropertyAndEquipmentCurrent",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AccruedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying balance as of the balance sheet of accrued research and development expense.",
        "label": "Accrued Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpense",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of acquired in process research and development in accrued expenses and other current liabilities.",
        "label": "Acquired In Process Research And Development In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Acquired in-process research and development in accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AdditionalTechnologyLicenseFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Technology License Fee Paid",
        "label": "Additional Technology License Fee Paid",
        "terseLabel": "Additional technology license fee paid"
       }
      }
     },
     "localname": "AdditionalTechnologyLicenseFeePaid",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn.",
        "label": "Amended and restated agreement with Penn"
       }
      }
     },
     "localname": "AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_BasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of presentation.",
        "label": "Basis Of Presentation [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://www.passagebio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pasg_CatalentMarylandInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Catalent Maryland, Inc. (Catalent) (formerly Paragon Bioservices, Inc.).",
        "label": "Catalent Maryland, Inc. (Catalent)"
       }
      }
     },
     "localname": "CatalentMarylandInc.Member",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate for large CNS indications upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement, Amount Payable Per Product Candidate for Large CNS Indications, Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate arising from the exploratory program for large CNS indications"
       }
      }
     },
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate  for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate for rare, monogenic disorders"
       }
      }
     },
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement Amount Payable Per Product Candidate Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate upon achievement of specific development milestone"
       }
      }
     },
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAnnualFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of annual fee payable during the period under the collaboration agreement.",
        "label": "Collaboration Agreement, Annual Fee Payable",
        "terseLabel": "Annual fee payable"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualFeePayable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAnnualFeePayableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of annual fee payable during the period under the collaboration agreement.",
        "label": "Collaboration Agreement Annual Fee Payable Term",
        "terseLabel": "Annual fee payable, term"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualFeePayableTerm",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_CollaborationAgreementPaymentMadeOnOptionExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid on option exercise under the collaboration agreement.",
        "label": "Collaboration Agreement, Payment Made On Option Exercise",
        "terseLabel": "Payment made on option exercise"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentMadeOnOptionExercise",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for which the annual fee is payable for the use of clean room suite under the collaboration agreement.",
        "label": "Collaboration Agreement, Period For Which Annual Fee is Payable",
        "terseLabel": "Period for which annual fee is payable"
       }
      }
     },
     "localname": "CollaborationAgreementPeriodForWhichAnnualFeeIsPayable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_CollaborationAgreementQuarterlyFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Quarterly Fee Payable",
        "label": "Collaboration Agreement Quarterly Fee Payable",
        "terseLabel": "Quarterly fee payable"
       }
      }
     },
     "localname": "CollaborationAgreementQuarterlyFeePayable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementSalesMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable on sales milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement Sales Milestone Payments Payable",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborationAgreementSalesMilestonePaymentsPayable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementTieredTransactionFeePayablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tired transaction fee payable under the collaboration agreement.",
        "label": "Collaboration Agreement, Tiered Transaction Fee Payable, Percent",
        "terseLabel": "Collaboration agreement, tiered transaction fee percent"
       }
      }
     },
     "localname": "CollaborationAgreementTieredTransactionFeePayablePercent",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront fee payable upon clinical candidate designation under the collaboration agreement if the company were to exercise the options.",
        "label": "Collaboration Agreement, Upfront Fee Payable Upon Clinical Candidate Designation",
        "terseLabel": "Upfront fee payable upon clinical candidate designation"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementUpfrontPaymentMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment made during the period under the collaboration agreement.",
        "label": "Collaboration Agreement, Upfront Payment Made",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPaymentMade",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of common shares reserved for future issuance.",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Additional number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Computer Hardware and Software.",
        "label": "Computer hardware and software."
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred financing costs included in accrued expenses and other current liabilities.",
        "label": "Deferred Financing Costs Included In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Deferred financing costs in accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "DeferredFinancingCostsIncludedInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.",
        "label": "Deferred Tax Assets, Collaboration and License Agreement",
        "terseLabel": "Collaboration and license agreement"
       }
      }
     },
     "localname": "DeferredTaxAssetsCollaborationAndLicenseAgreement",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DevelopmentMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable on development milestone payment on collaboration and license agreement.",
        "label": "Development Milestone Payments Payable",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentsPayable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding",
        "terseLabel": "Percentage of common stock outstanding"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.",
        "label": "Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased",
        "terseLabel": "Maximum amount of common stock that can be purchased"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan, Maximum Employee Contribution Percentage",
        "terseLabel": "Percentage of maximum employee contribution"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that can be purchased.",
        "label": "Employee Stock Purchase Plan Number Of Shares That Can Be Purchased",
        "terseLabel": "Number of shares purchased"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.",
        "label": "Employee Stock Purchase Plan, Stock Purchase Price Percentage",
        "terseLabel": "Percentage of stock purchase price"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanStockPurchasePricePercentage",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2020"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_EquityInducementPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2021 Equity Inducement plan.",
        "label": "Equity Inducement Plan 2021"
       }
      }
     },
     "localname": "EquityInducementPlan2021Member",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in deferred rent.",
        "label": "Increase (Decrease) In Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in prepaid research and development.",
        "label": "Increase (Decrease) In Prepaid Research and Development",
        "negatedLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopment",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_InterimChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to interim chief executive officer.",
        "label": "Interim Chief Executive Officer"
       }
      }
     },
     "localname": "InterimChiefExecutiveOfficerMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_InterimChiefOperatingOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to interim chief operating officer.",
        "label": "Interim Chief Operating Officer"
       }
      }
     },
     "localname": "InterimChiefOperatingOfficerMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Laboratory equipment.",
        "label": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of times the lease term can be extended under the operating lease.",
        "label": "Lessee, Operating Lease, Number Of Options To Extend The Lease Term",
        "terseLabel": "Lease term extended, number"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfOptionsToExtendLeaseTerm",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_LocalTaxAuthoritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to local tax authorities.",
        "label": "Local"
       }
      }
     },
     "localname": "LocalTaxAuthoritiesMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional extension term of manufacturing and supply agreement.",
        "label": "Manufacturing And Supply Agreement, Additional Extension Term",
        "terseLabel": "Additional extension term of manufacturing and supply agreement"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementAdditionalExtensionTerm",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of extensions available under the new lease arrangement.",
        "label": "New Lease Agreement, Operating Lease, Number Of Extensions",
        "terseLabel": "Number of extension terms"
       }
      }
     },
     "localname": "NewLeaseAgreementOperatingLeaseNumberOfExtensions",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_NewLeaseAgreementOperatingLeaseRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the renewal term under new lease agreement.",
        "label": "New Lease Agreement, Operating Lease, Renewal Term",
        "terseLabel": "Extended term of new lease agreement"
       }
      }
     },
     "localname": "NewLeaseAgreementOperatingLeaseRenewalTerm",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_NotesReceivableInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options that became outstanding due to being secured by Notes.",
        "label": "Notes Receivable Interest Rate Percentage",
        "terseLabel": "Interest rate of notes receivable"
       }
      }
     },
     "localname": "NotesReceivableInterestRatePercentage",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_NumberOfEquityIncentivePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equity incentive plans.",
        "label": "Number Of Equity Incentive Plans",
        "terseLabel": "Number of equity incentive plans"
       }
      }
     },
     "localname": "NumberOfEquityIncentivePlans",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_NumberOfExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of executive officers.",
        "label": "Number of Executive Officers",
        "terseLabel": "Number of executive officers"
       }
      }
     },
     "localname": "NumberOfExecutiveOfficers",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of remaining options available to the Company to commence additional licensed programs for rare, monogenic CNS indications.",
        "label": "Number Of Remaining Options Available To Commence Additional License Program",
        "terseLabel": "Number of CNS indications"
       }
      }
     },
     "localname": "NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_OperatingLeasesForLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreement for laboratory space.",
        "label": "Operating Leases For Laboratory Space"
       }
      }
     },
     "localname": "OperatingLeasesForLaboratorySpaceMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_PaymentsForTechnologyLicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for technology license fee during the current period.",
        "label": "Payments for Technology License Fee",
        "terseLabel": "Payments for technology license fee"
       }
      }
     },
     "localname": "PaymentsForTechnologyLicenseFee",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PrepaidResearchAndDevelopmentAssetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research And Development Asset, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentAssetCurrent",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_ProceedsFromTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from tenant improvement allowance during the reporting period.",
        "label": "Proceeds from Tenant Improvement Allowance",
        "terseLabel": "Proceeds from tenant improvement allowance"
       }
      }
     },
     "localname": "ProceedsFromTenantImprovementAllowance",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PromissoryNoteWithRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to nonrecourse promissory note with related parties.",
        "label": "Promissory Note With Related Parties"
       }
      }
     },
     "localname": "PromissoryNoteWithRelatedPartiesMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment in accounts payable and accrued expenses and other current liabilities.",
        "label": "Property And Equipment In Accounts Payable And Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Property and equipment in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PropertyAndEquipmentInDeferredRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property and equipment in deferred rent during the period.",
        "label": "Property And Equipment In Deferred Rent",
        "terseLabel": "Property and equipment in deferred rent"
       }
      }
     },
     "localname": "PropertyAndEquipmentInDeferredRent",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of reclassification of convertible preferred stock upon consummation of initial public offering.",
        "label": "Reclassification Of Convertible Preferred Stock, Shares Upon Consummation Of Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "ReclassificationOfConvertiblePreferredStockSharesUponConsummationOfInitialPublicOffering",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reclassification of convertible preferred stock upon consummation of initial public offering.",
        "label": "Reclassification Of Convertible Preferred Stock Upon Consummation Of Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock upon initial public offering"
       }
      }
     },
     "localname": "ReclassificationOfConvertiblePreferredStockUponConsummationOfInitialPublicOffering",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Of Deferred Offering Costs Paid In A Prior Period",
        "label": "Reclassification Of Deferred Offering Costs Paid In A Prior Period",
        "terseLabel": "Reclassification of deferred offering costs paid in a prior period"
       }
      }
     },
     "localname": "ReclassificationOfDeferredOfferingCostsPaidInPriorPeriod",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassifications Of Temporary To Permanent Equity, Shares",
        "label": "Reclassifications Of Temporary To Permanent Equity, Shares",
        "negatedLabel": "Conversion of convertible preferred stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_RemainingTenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of remaining tenant improvement allowance receivable as at the end of the reporting period.",
        "label": "Remaining Tenant Improvement Allowance Receivable",
        "terseLabel": "Remaining tenant improvement allowance receivable"
       }
      }
     },
     "localname": "RemainingTenantImprovementAllowanceReceivable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_RisksAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityAbstract",
     "nsuri": "http://www.passagebio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pasg_RisksAndLiquidityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Risks And Liquidity [Line Items]"
       }
      }
     },
     "localname": "RisksAndLiquidityLineItems",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pasg_RisksAndLiquidityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to risk and liquidity.",
        "label": "Risks And Liquidity [Table]"
       }
      }
     },
     "localname": "RisksAndLiquidityTable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pasg_RisksAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to risk and liquidity.",
        "label": "Risks And Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_SalesAgreementWithCowenAndCompanyLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Sales Agreement, with Cowen and Company LLC.",
        "label": "Sales Agreement, with Cowen and Company, LLC"
       }
      }
     },
     "localname": "SalesAgreementWithCowenAndCompanyLlcMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_SegmentPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment.",
        "label": "Segment Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentPolicyPolicyTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series B Convertible Preferred Stock.",
        "label": "Series B convertible preferred stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_SeriesOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A 1 Convertible Preferred Stock.",
        "label": "Series A-1 convertible preferred stock"
       }
      }
     },
     "localname": "SeriesOneConvertiblePreferredStockMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_SeriesTwoConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A 2 Convertible Preferred Stock.",
        "label": "Series A-2 convertible preferred stock"
       }
      }
     },
     "localname": "SeriesTwoConvertiblePreferredStockMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options that became outstanding due to being secured by Notes.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Became Outstanding",
        "terseLabel": "Number of shares that becomes outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBecameOutstanding",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of early exercise of stock options during period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisesInPeriod",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options early exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested, Early Exercised Number of Shares",
        "verboseLabel": "Number of shares early exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedEarlyExercisedNumberOfShares",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) unvested and exercisable under early exercise during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Unvested, Exercisable Under Early Exercise",
        "terseLabel": "Number of share options unvested and exercisable during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ShareBasedCompensationArrangementExpensesDueToModifications": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share based compensation arrangement expenses due to modifications.",
        "label": "Share Based Compensation Arrangement, Expenses Due To Modifications",
        "terseLabel": "Share-based compensation expense due to modifications"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementExpensesDueToModifications",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement",
        "label": "Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase",
        "terseLabel": "Percent of the total number of shares of the Company's common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.",
        "label": "Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted",
        "terseLabel": "Period till which there is automatic increase in rights granted under the Plan"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_SharebasedCompensationArrangementBySharebasedPaymentAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration from date of grant (issuance of an option) to when option auto expires.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Term",
        "terseLabel": "Term of award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardTerm",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_StateTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to state tax authorities.",
        "label": "State"
       }
      }
     },
     "localname": "StateTaxAuthorityMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issuance incurred.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Issuance cost"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been vesting of common stock previously subject to repurchase.",
        "label": "Stock Issued During Period Shares Vesting Of Common Stock Previously Subject To Repurchase",
        "terseLabel": "Vesting of early exercise option awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock vesting of common stock previously subject to repurchase.",
        "label": "Stock Issued During Period Value Vesting Of Common Stock Previously Subject To Repurchase",
        "terseLabel": "Vesting of early exercise option awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock options (including shares subject to repurchase).",
        "label": "Stock options (including shares subject to repurchase)"
       }
      }
     },
     "localname": "StockOptionsIncludingSharesSubjectToRepurchaseMember",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_StockholdersEquityAndTemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to stockholders equity and temporary equity.",
        "label": "Stockholders Equity And Temporary Equity [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityAndTemporaryEquityTextBlock",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_TaxCreditCarryForwardSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carry-forward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carry Forward Subject to Expiration",
        "terseLabel": "Tax credit carry forward subject"
       }
      }
     },
     "localname": "TaxCreditCarryForwardSubjectToExpiration",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_TenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of tenant improvement allowance receivable from the landlord under operating leases.",
        "label": "Tenant Improvement Allowance Receivable",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReceivable",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_TermOfManufacturingAndSupplyAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of manufacturing and supply agreement.",
        "label": "Term Of Manufacturing And Supply Agreement",
        "terseLabel": "Term of manufacturing and supply agreement"
       }
      }
     },
     "localname": "TermOfManufacturingAndSupplyAgreement",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_VestingOfEarlyExerciseOptionAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of vesting of early exercise option awards.",
        "label": "Vesting Of Early Exercise Option Awards",
        "terseLabel": "Vesting of early exercise option awards"
       }
      }
     },
     "localname": "VestingOfEarlyExerciseOptionAwards",
     "nsuri": "http://www.passagebio.com/20211231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r213",
      "r229",
      "r230",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r407",
      "r441",
      "r442",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r213",
      "r229",
      "r230",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r407",
      "r441",
      "r442",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r204",
      "r213",
      "r219",
      "r229",
      "r230",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r407",
      "r441",
      "r442",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r204",
      "r213",
      "r219",
      "r229",
      "r230",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r407",
      "r441",
      "r442",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r139",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r37"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r181"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r45",
      "r46",
      "r47",
      "r432",
      "r450",
      "r454"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r54",
      "r55",
      "r56",
      "r85",
      "r86",
      "r87",
      "r312",
      "r445",
      "r446",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r273",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r270",
      "r271",
      "r272",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r88",
      "r89",
      "r90",
      "r91",
      "r100",
      "r141",
      "r142",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r192",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r367",
      "r410",
      "r411",
      "r412",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r231",
      "r233",
      "r276",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r233",
      "r261",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r64",
      "r71",
      "r206",
      "r355"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premium and discount on marketable securities, net"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Amount of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r71",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r131",
      "r133",
      "r137",
      "r161",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r310",
      "r313",
      "r339",
      "r372",
      "r374",
      "r413",
      "r430"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r42",
      "r81",
      "r161",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r310",
      "r313",
      "r339",
      "r372",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r146",
      "r173"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r150",
      "r152",
      "r424"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r150",
      "r153",
      "r425"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r150",
      "r153",
      "r422"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r150",
      "r151",
      "r423"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r143",
      "r147",
      "r173",
      "r416"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r145",
      "r173"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r235",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r29",
      "r73"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r68",
      "r73",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r348"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r80",
      "r81",
      "r103",
      "r104",
      "r105",
      "r107",
      "r109",
      "r115",
      "r116",
      "r117",
      "r161",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r211",
      "r212",
      "r214",
      "r215",
      "r339",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r189",
      "r417",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r190",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,244,966 shares issued and 54,244,966 shares outstanding at December 31, 2021 and 45,917,084 shares issued and 45,614,807 shares outstanding at December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r58",
      "r419",
      "r439"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r121",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Shares issued on stock conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r228",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r16",
      "r356",
      "r366"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent",
        "verboseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net, total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Cash accounts in banking institutions"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r71",
      "r130"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r101",
      "r103",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r326",
      "r327",
      "r420",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r103",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r326",
      "r327",
      "r420",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate reconciliation, total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r82",
      "r283",
      "r304"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal tax benefit at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r283",
      "r304"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r283",
      "r304"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r283",
      "r304"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Total unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Common Stock"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r54",
      "r55",
      "r56",
      "r85",
      "r86",
      "r87",
      "r89",
      "r97",
      "r99",
      "r114",
      "r165",
      "r217",
      "r218",
      "r270",
      "r271",
      "r272",
      "r301",
      "r302",
      "r325",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r445",
      "r446",
      "r447",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r205",
      "r208",
      "r209",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r329",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r328",
      "r329",
      "r331",
      "r332",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r205",
      "r220",
      "r221",
      "r226",
      "r228",
      "r329",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r205",
      "r208",
      "r209",
      "r220",
      "r221",
      "r226",
      "r228",
      "r329",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r205",
      "r208",
      "r209",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r333",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r207",
      "r216",
      "r316",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r220",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r33",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r284",
      "r287",
      "r293",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax examination, penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r281",
      "r282",
      "r287",
      "r288",
      "r292",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Temporary equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r63",
      "r129"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Final Maturities of Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasePracticalExpedientUseOfHindsight": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.",
        "label": "Lease, Practical Expedient, Use of Hindsight [true false]",
        "terseLabel": "Lease, practical expedient"
       }
      }
     },
     "localname": "LeasePracticalExpedientUseOfHindsight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum rental payments for operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r81",
      "r134",
      "r161",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r311",
      "r313",
      "r314",
      "r339",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r81",
      "r161",
      "r339",
      "r374",
      "r415",
      "r434"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r81",
      "r161",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r311",
      "r313",
      "r314",
      "r339",
      "r372",
      "r373",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r118",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r48",
      "r50",
      "r56",
      "r57",
      "r72",
      "r81",
      "r88",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r106",
      "r131",
      "r132",
      "r135",
      "r136",
      "r138",
      "r161",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r327",
      "r339",
      "r418",
      "r438"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesReceivableRelatedParties": {
     "auth_ref": [
      "r83",
      "r369",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from parties associated with the reporting entity as evidenced by a written promise to pay.",
        "label": "Notes Receivable, Related Parties",
        "terseLabel": "Notes receivable in exchange of stock options exercised"
       }
      }
     },
     "localname": "NotesReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r132",
      "r135",
      "r136",
      "r138"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r43",
      "r45",
      "r156"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r37",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Follow-on public offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of technology licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r235",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales or maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r265"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r180"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r182",
      "r374",
      "r427",
      "r435"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total, property plant and equipment net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r182",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r15",
      "r414",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Minimum amount agreed to purchase in batches of drug product"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r210",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "negatedLabel": "Conversion of convertible preferred stock upon initial public offering"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r227",
      "r368",
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows",
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r279",
      "r408",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r218",
      "r273",
      "r374",
      "r433",
      "r449",
      "r454"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r85",
      "r86",
      "r87",
      "r89",
      "r97",
      "r99",
      "r165",
      "r270",
      "r271",
      "r272",
      "r301",
      "r302",
      "r325",
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of details regarding the Company's portfolio of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of details regarding the Company's portfolio of marketable securities"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r233",
      "r260",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense category"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of activity relating to early exercises of stock options"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r235",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r241",
      "r250",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions applied to options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationNonrecoursePromissoryNotesWithRelatedPartiesDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted and early exercised",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted",
        "verboseLabel": "Granted, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r243",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending of period",
        "periodStartLabel": "Outstanding, Beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending of period",
        "periodStartLabel": "Outstanding, Beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r256",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested Exercisable at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Unvested balance, Ending",
        "periodStartLabel": "Unvested balance, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Unvested balance, Weighted average grant date fair value, Ending",
        "periodStartLabel": "Unvested balance, Weighted average grant date fair value, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding",
        "verboseLabel": "Weighted-average recognize period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested or expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at Beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r80",
      "r81",
      "r103",
      "r104",
      "r105",
      "r107",
      "r109",
      "r115",
      "r116",
      "r117",
      "r161",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r211",
      "r212",
      "r214",
      "r215",
      "r217",
      "r339",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r41",
      "r54",
      "r55",
      "r56",
      "r85",
      "r86",
      "r87",
      "r89",
      "r97",
      "r99",
      "r114",
      "r165",
      "r217",
      "r218",
      "r270",
      "r271",
      "r272",
      "r301",
      "r302",
      "r325",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r445",
      "r446",
      "r447",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r114",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of shares in connection with employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Sale of common stock in initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r218",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of shares in connection with employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock in initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r218",
      "r234",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r81",
      "r140",
      "r161",
      "r339",
      "r374"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at Beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events."
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of net operating loss carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of noncash investing and financing activities:",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at Beginning of period"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at Beginning of period (in shares)",
        "terseLabel": "Convertible preferred stock, shares, outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.passagebio.com/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r207",
      "r216",
      "r316",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r88",
      "r89",
      "r90",
      "r91",
      "r100",
      "r141",
      "r142",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r192",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r367",
      "r410",
      "r411",
      "r412",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureConvertiblePreferredStockAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increased"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r102",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r101",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r464": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r465": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r466": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r467": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r468": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r469": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r472": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r473": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r475": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r476": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r477": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r478": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r479": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001558370-22-002719-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-002719-xbrl.zip
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M9PON<Z,.3!N'L*B2E"/\(V9*@"L)V1+D2T+&).;\TV2;W79+ :S1=_[/YF\
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M# A>4E-.6Z+<'ML5OJT5/*E<RAS=6L- " /7Y6=]K,%I\C8)MG,ZZGA>%:-
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MJVEX1=O<1,YF)F<]5?<1B+9LCC=#?L+]S!'#P,=!$N-GM D\7[YZ0<+(PP6
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MC?9THHT$4D098I"&"4=C__G-0/34&75*LLU")\YD$!/O4@KKLY1Q;:28MN2
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MX;\&1ZCL>J\'I=TCER9)?6GW@1621^&">8P:SZS%(&6>!?91:D2-S4PTG$Q
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M&"-Y=*7M5DIS8J@*E-S2F,\O]&*TO1?R4-54NU)<K;D+XL#5E;RO*^?T"6-
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M4^\FO -98X;,K,&G*(SS?_+20UJ8-@HCY$@WGG%KZY@8XX(8%4=4UD 9D$R
M;*^B$((G?K(8:+ 2H3GO=YL-/*T#*W%<*++)Y"!.2E9@[&=1<R4D#BE-RFO=
MF:S-4.3#RILAGQ.ZV@77_JHYK3- #BG0F3)46?BA/RWT=2$,J-8WIABY7>#$
M!Z]_P21KQUF2@/&$7P51^'06^,_46Y#M>I_X+LM@LC!,URS^8!]A!]<+_)#W
M#Z$Z04"8CW@[-P42C[O$#^&<81J1;1RQ7U/R%$6>>/XQH?&S[V9O+X=1RNBD
M-.2KZE',HAG6[::N7&'QP\BSX);[<D(& D)8'SY0V6TKWZ>C@^_3M0X'V3/B
MTD"I?L:\R[@PB.X\!HCAIJL9*?H3G<^084!'LV.'^N5(1XA*J+C8(I ^ E&)
M*V1EHTTAK#6LMVC1 KQN5B03@TC<^!.37!*2B5+Y*S+LQV!'40J+VU%RK6;'
ML[CF<LVR(TIO6-@X<&[KFDUO:&ZE?;XVI;6HTH\2TK'"@'GD99$>9!"O>PS1
MIF]\"9X+4G EG.VB@".6JA9+P+9AR::A9"!:[5(8(C=L/-SL-@1@A\V/MMDS
M>WR6$Q7V#$ Z'#OFEYMM$.TIO1<3M/K;Z\N "\,/8\&QA*?0_P?U;FGL1^)A
M0?W-=?/\D,/:Z*:NW[(WS PQ1(ZO\T@U*Q;YG74O.R&P]1EF@#0+LMS Z6XT
MZ(K8QA(&)XHR&/F<A#"9Z%,4[U$@;[WI^//IHEI(LG13_UDW)S1">#98.M1X
M]:#9E^HLT'&P<J/!H&#/0"_CCQ#V[!FOW!9+@!O+(CFD.;FMMHPP,CS+/O+R
MQ8D]V42PXRC&AR39;<3O>F/;("8SQ+GA1FW#O/X<9H9_!A0UD:[4XB+(M"!<
MJ@P7DP4I!".29*A1$HF)7ZC_M$XAP7YF<^\G"GN:A?V<[3: TVUIE($JCAGY
MIX@?9*,>MV;/'%"3R&QPL(M1ZG%.A\(L<*R3(B:"J&"8W2=$G*9-8QOII%)N
MBI@&8FF/@0EUXF#/YIPT=OU$'/^44S>;*%/8YX[]?^R[8"D0C9NKVWRS)RGD
MB#/$0)52$#WH($:?0>KT+@E1X$[)-<N,!-\N2&1E*+^@*QK'U'MP7NL.6G8<
MT[M20QYJ \U4/\IW(H4XX(9J9&+<SSE#)3(B>/.%:DRG$C#9R\OME3)[.:6]
M<)P^D);P5RL*P$F+"G9W3DH'%0;H17(V^-3?8(J]N<[T9H%4 ]0R$7X%>U(6
M4"0@ ?XB )8M1PO+^<)R & Q6"ZNB& 3O<2<ZV95GO"(DN3<B>/]*HIAE:G]
M#$(W$MC1J8=!*FC4H3]F].FCAH&)OW0V"DH[5ACB 9A)C2,!2DA3^;036,B5
MN1H\GP_/_HH4[X^=[^63T .#-+=$&ND:ZA6GXNN;83_GWB*U"4]4GU>')YVS
M]#SC/O&9])&TYV3Y6?*"< 9(5M=$=H\)DX6A$10YNEGQ99SEJY\HH4O='FF\
M:JM:'885C5&/N6TR]XY<)]L9Y8M\7X"F5:<MU?OD;-B/#[$3)K#F'X47T89A
MB<I".AVQN[&V\A5_;NV%V;'UA3?DX8*J31^_NKWY2#>/-%;81/X[<H\]4J52
M+2C_(V+_.Y:Q=QV?VQN+/G7S3&,X LR+\8B#'XT^UM0>N<^UJBK[H+(Q8I]L
ME[EW_92(D7TY@\1\]QCX+H/%%862'F/.#J_]D%ZE='.8=[:W1NJ(FFJJ9XI%
MT]G-%H\E[WWCC5$B/I B,=TRZ>$HWLH/G=#U194+,'\"RZ.B%+0/-6AX.:_O
MR,.:PM6"O$U1*8/-,;.[T["."K4,^:J0/"-UDB1B'&!?^\5/U\3CZ0#9\ !+
M8$.)"<:Y14S *"8;)]P3>!<(J$,=#B&#Y8FKN0]1.WGE7X?3MSH9X&_#Q+Y[
MN+A4VP I6JB5.7JMF/\5\<!4(^2@"PJ$T[+X9K!)7;9UNDP8+/S-0>HE4,H?
M'BQA0$JO0C]E:'K+!_N;;*Q7&*1+?^2AUMD4<B1J=T8<J-UUZ.O[.2?Q4D/.
MBV3,B.!&;A1IYC2A/ITUX-VQ;<8-Q;F3H:]^U&SLC,8$.:B,8]1Q'@)"L!.E
M=W[%J*+X'@"RF3PK*\6]WS\PY@T;07H]D8=K!_4/1O^V;H@#JXOTO2?N4+?R
M&NI6D@=&P8<)-C_U:7_S2*D^*-^X>Z37<ZXN?ZR^ELN7W>;H\C72C^#R]G>3
MQ%A$XT+QQG5_=6ODSMVBINS0BJ:(G;A-XOY/) BZA.4DW@OD);PP<+1*7^P^
MF\=F7+Y+]5Q6U1:YPS:J6-FBJFN(V%F;Y>WKJH)J6538X([4M?,8Q=!ZW^QP
MK8V1>IR>DL5VE+(E]MVH=L%[[X'D.U )W^%1GV L12@]=>*MH/&L4*><S?=R
M=FQ6#14>65;WP7^%GY+&@:*Q ]+8U5>V\@Z-LC7B<4-#Z-[G&G+2/+]99<0M
M^N[ =:WW^WH"#8LVXW)$'CT3F%L.OQ'9(8[?*;3N"P"J95OK2U+U.L-1U\;U
M*(UNLPS)8\7;XZKL,[O@J!'=L(<O"/ 8M ZE>H5%*B%VQ0]AL6@614#N=X]_
MIV[Z$+&\F1EQS0143ZAZTD'JWH--4[ZJTH,(]AG:()T,3-[4$[=*-2CRQL^%
M$P6,$Y((\?@MM4+ ;Z=^,L6&^>Y[6<;BD'I0#^DSR_R3N_O/C5/#MCY(T::3
MRO)(VM@!\3"J)W=?5_^<%[>*R^)6 AAVP,BB3Q<EWD&:1D^N;XG<?QO4D[VV
MIAEB7VV2MJ^'YC0SM\SAUG;%Z:7W]UWVSO>'*/Y$7Y:N"X\EL&'B-HY"]J,K
M7N)M6J#H2 .Y2_<R266RTX4 XC#HIT?O:5!!G-RG3NCQXA^?MQY4SK$^V8<C
M!S>KI1>UW[]3-$7N]$T*RKY=UPZQ"S>*.XJGVC\V4HI72">$>_?#VS_]\*[1
M>77[(O?F3B:H0+=.1\3^WDW^,0( &)W]\,Z<_R=Q*OD^^]>AW[-?_>T.WC^I
M25$._X;4;VM5 +^L_ &AW]7+UW_!PDG]).7OI7^D#CR3R]]Q,#W\Z[M4+5@>
M_Q6[6QT#WL&?,+N6L=4PA7,9'[&UW.NC>-M2Z6"'?T?L8K6JY$Y6^2-2-ZN7
ML:^C9=2F]B?GM=F?#OZ.V9_J5"G\2?XC5G^JE;&W/PEJZ+:ZM<\'7"O*A(Q
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MOM(P$XEPF894V3<4YK?,$)^<#5V^^JKCE@=-D =;G4)RO,A_1^SRM6+VOG+
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M.+"6Y_;=:NDW",'RC/,$KW?MTB1U0L\/G]B0O8G"; 1.CDS7XU/TXS+C(6F
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MW#:>)SZ@:)G<Y'C1R/"$AP,]O3&@?2DID42=_7'9<3_ T<G8F,+#)'#DAS\
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M52[GFC]V8"?UFMHV^<,%?JY]%)-M89>8!@X?6B(VUKAB!YB/,]LH\?G!^AE
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ML#1:/L+4_#B-M)]]+#5_W:!7T102PBN%((5*+8N+AJ"16!X?'=MDZH7<LMT
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MA'?R%HJD]R+/^A?CT6BDFQ(2%W*>0Y.+\!I\"$UYL'A7K0(5W5V$<-%=@V=
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MYA-A*X!8,<TQ'CIX=B,C7+6SR. D/(9'U9,5>J1\RZ-5NPL0+KIC?%0]\N#
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MWK6S>H,V0<)OB ADOTSG<PI097>C'4AKPU(6QK7PMI.:^@:@T9N0T(\^6X
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M-.(Y-(%+U]K%M?067PDQ'.CODARH3YC3-7 1??9"2)CYM8Y)F (<H*KH=AU
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MU0FVS#A:Z)]:NW]X6; KOWO9KW]RK#0K),^;M'7@$BYC&"Z@%L;T$GDQ)?Z
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MWT7RL&^9KJ%$9%,SK;-_\?2_7X%1#1BLB%18^CC2M3 :1E"/O/@,:1,TLQ<
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MXQIX9%H.E()9<0]DTAI2#1MJZT^0I40TTQS"^I(]KZ1URF4T+?"=,^E&96=
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M-N3YT C>#!B9X -^=%4R'4!:]@3K$_")/@+&\7;FY&HWI7Q$2'-$,RI85V7
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MLWP;6'2S58NR HMJ>X$\TDUBH8!-3[S'N1WB)8D /M/D2N\X$[:*Z9GRGM(
M6%ZVQ%D.Q!J+GK 8(<NB7%@K"Y>4/D:S'E3H5=]0B2!!9>]YYJQL&DP>Y",R
M_^8<3TP-3ZT3:*1I67@J:RY8*H',2*!UUV3)<,QPJ6/#F%O10=<2I %9,LMT
M#0!Q,/ 'SQ&3G::^4%LET !YJ_>4G]D+:9%$(.E73>-*U7P$@RG#<F"8(^OW
M9-Z-#5+LYRP;I'\1R!F?FROJ")/G\%$4?FM1"!@IZCQQ@W#BB6<O3QE+!^V2
M1=(YL]H9W@=,\^6L=,*4A*"ZEQR\ .F% ;\:(S(W9+Y#,WT+Z<N):9 TIB^%
MVH_L_%NS,V%'PGEXR0( 1B;N(>4B+[=TD5)*U^L)[RL+LYQ"J9>J-]]C0!-%
MO8 D\+&7$D8;AJQ0FNGN+9YNL%_\>+M+^=??OK*0.U@@G;\?>[("PJC#4Y[1
M1'-SF;$%!@W=AT/Z<>3YWY[G5ZP9/_;"EG2"R_*+''354B(C!!F& 3RW;.9X
M@AD1V*YDNZ.1]LQN)9H:N)T)#RR%+G9,H3NFT+TUA>X(N-\?<$L]6.8![;R(
M+F_:" H94BQR[+!M!(OMN@:&<#BD/K*\Y8!7R9;1F>41B!22ZRK+9B8NY,A/
M"=STCJZ_*X+M<9EOR@3UT+5,Q+;XS%.FO9QJEAA-'F,MVML?/UDS?OR(S[9-
MN5L&-=^T#&.C*UTT#F12H^9DTW9;+\$+DL)75V*?F3Q_:6V1I</V)&+E]-LH
MK?A1:1V5UCM+AF EC5%"24C1F!B78J(H2BF<%J08XN-=,1I-*[V>5S+$>^)"
M&Z:C\40L'H\N7:!EK25!3*52R? 4&0F4RZ;3QOI*RP9FO?"!E(H+HI#:;Y^W
M]Q#ZXI44.67_;ON[C8]@,[LJPV99;T3[K,9$NY_:97.9AN%<):KUJ>(^C=(G
M:F/8-(4G=!]9<$1K]XMQ^@"W]^$D-E=,W-:AUV=E]TS9!3UK&L&8[WSC'?)\
M>S\R0#=W$<ZV$&3U66/3M3E[9A-&H39!KMH\"::?0)AZGDY-[ QSGL;!\E%8
MS&/D[:N'I1^VVQ+4/5&PL"^?;NAUM1[D$7I;T72(M1$ Z@>7-+M+06NF7:C.
M8)L8_ '04,9\>+1%S2_1L)S60L8R3VIAFYQ[*B:&A??BX'1"=VG8AL;NH4J$
M'S@/5!^88)9]@[P=RW2I"":&3@F2!X%2(HP&W@2Q6?>ZX\TL'08-P9.NNW2R
MB"D!+C;=-^AEJ&V(P,^S\/M@^$$TU#=HP(0#(V6>6A$(''F6#@VPTD%0<*-[
M7>EN$Z^T!YF2^=K#A@4+3UI@SEN62Y@&SXLCM T5K"&O'["R8<\T,@@5^84$
M*'_!A<4/-%K<\NA?9Q%9>MMYJ[Z3N)Q ?1&%[?S-6Q[&7=)MB;>J9L/N9$23
MF,A4>?O'UR6)<@7;B4 >(;>3@8#,L;40DY6O&;+%[L6Q1XLEG'FEA)HU@AA:
MGO$<EZ-S3,=3R^=.@H5F @5NO.(8\\V85*[9XB@MW$AN\7<O>.S-LFDU7YCI
M_82OV!9P9+'-%%Y1#]@Q:<%Z*4M^88NB( PLGY'N#5HAM,_EMHWU+E2.(/R.
M\8B#_=8]4U/-C0*TJ88+=(^MX4X@BDF=F+Y&&%:;;Z]<3F1WB&F#GUM_.N/J
MV?,*+\RW@ 1 J,>=5P2?1?O(Z).NVJI"_F>L1Z[NR%/U;+'%BYO?X;7?LPCJ
MFU#6R;1H[I).T8"^:*>W%%MYYI+4LU<-/KKY95>$#[KSS#S?N]CM!;Z@V^IT
ML=CAR<!<QJERF>_]JF<K93[&BA<0:LF$24!_R$0DW*&I$"UAF:,!<QXKY3Q,
M5*;,Q^D#2)^9]#+<#I4<0'41N]&:SW^FW(0G<A4^P?!P0+I@.I$*X5X<:9G$
MNN1:,^**BAFFBBHM^,0R!& 'K;(8!WT>&8@ C#\[I&T$4FJ;"X'T+M$V+MCQ
M/,[ZY87H,V2<CC00!I"X^40MO7FG^<]H3\11(![EZNO89'C4;_D<5#8)H0LC
M(M8CF\UPJUPX_4QK:T>FZH%>)K0([G?WLTC9!FV6^.^JFK*N*D$);K=E% RJ
MW'K6@*$@YZGY+O7:NRP3B0((1OI\O@-+B%!&B]I59,H-[%KS=1F?0Y86V9<7
M'#>G\\V'/"+?,.OSG%OHFQW/R"&Z#-X?M'48Q\&JN6L1#PJS  2UY.A(6&])
M1TS#),^1N5HV'I: U3=/8/QKL#PW36@=# 53+B1R *'\A:T U@8@@>T5=:*V
MI(P4IM[GPR+3309S2D?D)138@.2F!5;DIMSXI9QC:O=Y2[@KN,Y,QV5%-.^Q
MZQL]\]UXLNO05 :L]/%ZF3+5,,PQ\M?GG&?M/G]L04T$.:!H1%0',9*(K'C$
M9:Q#O$-HP^NB=YNF=BT ,8)S8W;48>#!$\;*E/R0]]1G4;TETU<W%:1Y&[6(
MR:0'&)-<PIKMF7/LB,5@O@;8-A&PO_5 GNFF^2VZ%KSM9)5CEB2&ZOF-";FO
MD"6;;1EBMBUY'93 V%P0+R!$B[U ;$V2A0B7TKOH<M/:2B@M1>FG]Y[X@50R
M_ZCOEP/DAI@8I<0DA^EAQJ -Z3*P/0Z>\L_S]<TK\E)31O*,^B C>XV)GI=-
M:MA[O!LPJU5CY#+;?H"UD5= 9SG=9O/6/8H5/L7F:\6!(":FQ[)CKQ04%%>#
M&X'1[749VKBWQ=]6  4\=<^[\VQ,9F)N["&X*;#V/6!KR2N>B.]P^!KL>>T2
M:F=\LX>]JA;@-T\"(D1H">)M\%MA<YSG0ZXH.+]@H3'7;IY4,N_VE&M#C<<G
M7]'-49<YC1Y>RG1SZ&X6_ 9. %H_R]P,IGNJ96](8#_Q;/,35H[R"=,4Y17$
MS&1N!FXBY2,GVUH".M\OT-*U_'4/ )S1@!J21)7:+FVOYQJRY\OXW*)N#UMM
M(^QY.2O\]5/=,49$H9I GTFU@S:S3=O4:0Z&@R)]I$&1"3(8W[3[S[_2L<0O
MN, \(.)WL'FS,2C-S1,'#D=PXNA,"2].TT?-1Z/ZUNE@AK'A:E U#!Q\TA8;
M-_%P6,(O]<X#]Y&Q^&4]Z2/DQ@AYBDT2S238/$?@)WT6<RT/$IX=S!2BZF9@
M/6#C::9CSB?]3)-)0_J" ]Y#B4PYMS,IV#RO.(DTGL* :Y'&$8S;/0=2GA<:
MV VVI'Y>R@ZEL+.LSUG^!U6&R]&Y0$H5V^?.>N?MWR$PUB>4\U)GH;H)L3I,
MEQ7@5"%\R<FT1)>!B+G>-YCG7<I5B &EZ*2'5/-2DR 0M%HQ,WS5U27$[L%Q
M8PK+:I&)TVI'9-.R_#70'N$UM3\@MBDMC$ML&NI\$(FV,)ADE%W\Y<+%4N,<
MI3V.] I">=;@&G3OI^SEKMH.I.^YX!]8_<_8Y,2.FB\B6UA7<: UXI434\L-
MU"FE,35B3OEA#S^3>>;O9MQH<^P6>/+RE;P,;']9>IZ(M*;R_*UC*ZHN8]-H
MVKSBZ]*4++3LIA=!BO4!GQ>1."[^'A=_W[3X&Y@A44B<"J.]G!#T%EM^ 3 0
MS*<0L;0)8HY5/7/C]B6"#^Z(K=) .!TV*P%>>%4(*;#YQ8L8KB\YIEX6RLL!
M[@6N0-S6KRF_'H:D$$=K$A*L];;B><MP'!HC5?,3B=C2DI>-$]P'NXAH0D$.
M '<(D&I<!<TXD1<3ISZ"O2(X.M<39+8,TX@P9P(^S1T*JJ=IT?"3U0F$&(SJ
M>!6 %SY7)L\BI>7"HF:. ?DW;*&.%29A:5"!=N?!"'=$VM!=6G<8]<GT4TWB
M]_1TQVA]('JR$?5/@L7;?(6R.(/ 9@4H@RG9;.<"W<G#JAT'E: WH^MI7)XV
M)(/V1W R/T>#;0=EI@9]X91H2 ?H1+?^ !<&.G#B&\<S9J^ *^JRY:W%*J&W
M6A/<T+^DY%8V-3]?1 .NK@<RMJR=+IFDFMK#$9 =R"4+.-J!Q/:%K4OSSZ!Z
M*@U*$!YE=:V)>(#_ZQI^V"20AQ8L"/),]8]--LG)QO3\E2(?;+OX<@3Y.T1&
M-,^W8R%PW_""V+>'!8$H,IA/WA+G<C!Q?3F !CNA_7ETWG+[KP[1G\**\'P9
MV#-/:5DW2G;P/;S%# @'0@( \<^)3_($ 1-P!YF%NE@]WK8K;RE :&\R4M>'
MM)'ZGC75ZU%KZL6<E5T(M9B">9#7R]_?O)[MIV+":@R+I=-"#/XPP0H@-C]B
MAV@L3<A".%:(!4!A3OPDASX HU_.QZ8:C*8@T!+K5/+7]JVP6*F]M"_+CZS.
M%E@5#'=!5)LH"UB[US'4T;1]V':\"A++/+B4"+J H9?XC":JK"VYK'*O#]Z?
MNIKW^MPIP#YO$V>(\J=>OT#Y,=D++P=#84\7K"&043PQ'(2<'*)^=.RPEA$K
MG&8OU;LWB8:DQH1GOS"E,^\=E<*W]@^:HS;0<D]I^7BZ$(/FAR[-TPQ\!8SI
M01&!+&=/*2ZO?[ @75"ZY\8?;(A7:36)LX_GBA?S,J,+/E'U/F=;,N3UV_T(
ML64%08P*4X$?\GSB]&'4_P$G6?W]XYQ8& -V?I)-$9XT"[O]_O,O@:9%\K_R
M]+R5$3O7Q'58-@2U3[VH(U9^^,,CLSW2T.Q,-4""(EW-E(>_5GPAZI,&?%3/
MZ8=^K_M2X'@NH@&Q5)P)*O?SJ^8U!.=U/@<)ZT'6EZ'/0XT7DHK"8JDM#*^%
MM1NPF?WE%^8D!>+D4/R?Z#H'@:V_QZ Y+*NL1,X7BR%T=HDJAVJ_Q#6EJR*E
MX%>:,CJ %6_;\8]'H(5G(!^/+D3J'CUHR7\VRGE,F:(^<?/04I!QT2-_69;N
M1"1\ZVC82V@E5HRJ@'<8Z*L7X?=688F1$;BFVFS=D][AK>H1?IL]8=O#25@>
MLQT\\GOAY_$IF""E,E^FAS$O\M3P*=< 1XT>U31_F=^#^9$Y7I-(EEW?7:,1
M2G#V:.JB9F]HFSKDL%9OS+T9_S &2MX3NE)#34(O"Y;".IS6-L;L2=+Y.=.<
M^%FHX)CY9WUYI[0Y$Y/YN@8W(W8>47XYGUEIJ2QO;8),_',+$?/5BFTR><H5
MJ!$)55B<9;X""JWI9O\^[A #LLEC0/88D/W:4QBVZN %Y"7 $G4&%'\ &*@F
MHF>JT.R4U\AI%SL3"+$FJ 808U[+2XN1GM)FFP7?M,9(0[2;TM;@]+"N%T+2
M,8*0$W$- TMWBV-1YUXQ/6>26-W,:P[J2M/JTQ,EO4V"<)4"F*_+%Z5Y5O.C
M&"03EBKE*I"2.S!I M+J"B=3A9ZK3K63:GB'+7+(*W)%NJZ:,CU3B+3_X"GM
M4VZ/AHJ?4X18U*=4S;-%6F,,Y]OVD6<UP OR$#/PCM7Q#A7S@Z+MT^8I5S1-
MMGI*;\RLC!]R"/)>JO!<<2S/)9CO@_^?O7=O;MO(MD>_"BJGSE1RBF3TL&4[
M_LU4R9*=^([MZ-J:R?WO5R )B8A)@ <@)7,^_=UK/_H!@!*M6#:5L&HJ8TDD
MT&AT[]Z/M=<J*TT-"2#YY/R8<\[D-DP7^7S*U#/%HK*LH_E3V@;"F#=^%#D>
M1Q3:.8@9@KC7,V#.LOY^<HY;]N1%<(U:'K4G=^J/K#%@GA7]:3H$/0[>]#3K
M@W_F;(*LP?Z/!\UG0&.%+/J\:*QT &W3RZ)4849)L$@XR!)XH=OU5:K,WRA
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M Y//,[^9PS;8+ !,9IS$]<T'8LZ"/1[R4*V]*\ G-S (-#OHZ4A!&$4.#>Z
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M]> ;!X\2Z=;J"8^OZRT*^SJXW<X9\B"5T#*M7KE\G,V8L84YXKI;1_CYT4/
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M,#D'>\'?'"ZT#O+H8EZ?&;;5$*/\%P;08M#[3]JFL;W<K/=;<J6<#>5ZEAO
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MEZ3)J4/3 %='F>)'\\2<RK8$ME8?MN%M7<A[C@DWR@Q;DDX6L"@*, CE4F?
MFR=T+*ZSKQK2JWV(#G/E#[H"1(?3X#U=YQ/@USR/M&W,<9(TRZT).LITNR+"
M,RV[E.MIU[1B]H#=!M  BAHO:&[ \FO>^;/X*.1Z2>Y TAT 1>4SW;\T7W!R
M=/__4X&HF+5A1LQG?"J=1U1Q!D)[63E;> MF=MPAGG2\%I$W&.RNU?/%?N6
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MWD87ZZ2:-%Q2V0%3ZMS08QE8(F.3DR2B'@23N)SR NS'AF-(!9KPA,3L+!7
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MU3.U,&POZ\(*V39Q3>8\7P7EW^$]CB?Q)9'OXP:X;FOW2^E#P(4'#5QQZ*V
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MR"I"SB*X1CL%<E]A;Y0Y'M5 &4WI5YQ^E XB>$GGM"HXCK>\%SPF8W\P$C#
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M.2<OUM)I5C?3\+%W*D&F,_ZR!;&W47 Q"=X*V 0L@ Z$HR23C@#)"X9?#6^
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M^L+!"P^NSIE%#]F8(V6S$.H'D/8A$=[Z65H2K,#]^^A8Q55#L#F._S<FAH
M9!+_N$V?LP3P6[$\7%RG[+\KKR>E]:2>+E'B3G[B<#HV\SH%ZOQ>U8[?%U8
MDEO!\7$SY-H_^DHZ5;O6 "V,_R#XG<Q/](65L0PCSP)TU2\A2K/!4SJ+ :46
MY1GK6F&72T4PGS3H0^*.%1NCX"68 8*NPC>+K'+&OMN#H.C< LX1,$%7/"?Z
MBSY9[]X"9"9M1?0C5W14XDNI^[5CVS7(D;G?H_%UM6*;D7(I TO91/I__G)X
MBA;T.9S])1J_>#D_4#">>YP&[#D7PE%H;=Q4C'1O48_528A7Q.]KZCP]BRJ.
M;JU>)JC.B0:DHF(*G-J.9 \O]WTQR[O61CM5Q!]=!VG9!WH=S"L>9U-,M&7$
MR KU.>$0&N8="&)##-4,]Z1)3K#[^9I,%]/8*>&K>0%@02VX$8]JAE=N7(/=
M8.QA?Q>=\X-_>^,+R3RDT:U:(8T8WVHDA>Z'F,KB&AY1AP!2>THTNESF)EK>
MCK&TUVDB:4"?%XXGET?F19PM[".?6OHN@7]+QHOI@@@GE)=$U<!5["SJ^VLQ
M'I+(LW BP4,RMHVS-7T8QZF"?=7A&%\SX:EG J#OVD+AF#=#!-\:(\Q@;:$&
MY7WVC!5=!8<W%N=)-4>0B[Q]]\K9]X+N$F.A>(<$/Q9YO,'6D9!DJ&,U.M6@
M!L2HV/#=P*.!4TH::K4ZGKR(HFF#8ZAGVN:^*"B2SC<>O&"O@F>MLQ&#;YHQ
M*)/!]C+_H4C,QXBTQ8C"2=3OY8@DYMC#4>4-Z*/[D3Y6.P1\5,R0?/]&]7"#
M=VH</C[LAZ-Y-[DR]4+V&]=RX2;D1&P)T"^8GDFP*>8")OT6+=1J%U7<'GS8
M/H="]^+&[D.?CAZZ6>1OCSMQ+1X*ZCL>LVOP8WY::8H^U>%,^8*F?:;C:(?!
MA1_3&TX1\R]35#.ZE-\8_$Y.0PB.UO#5+AI7U4*R;UZ 1U32GE<J6KT/?'VY
M&+H(B55)] '8T4?TS)6:M&G!^F+NM(40)].,M54IVL)&V?*+#GM @[AZ"+F;
M(17W*A8!N'X[__;)XY-']W]],LWGOSZ\]R3_]>GT\;U?9[.GCV:/[]^?/?[,
MK8O[55$/[8YH1P:'S!,I9A\,YXK8$ 7]ZI"OUZ-.\;[#[S+^-2F^<+JL5TR'
M&U#:+[(GH GHSP].'AT_B7#4'F8M ?A\_!W IL=BQO8$@U92=&L" %49=/.
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MX,A) (X 6,EYN>ITE%:?QPC,8^%M"\C+ 4GJI@<V#V>_K"A>7VK*2*[GXW
M,8>(K=]%B_T-N UT8= !<G1'3-%%:$K#6WO DRY8,=@]%!9KN,(0,-",<1QI
M+M13[)K1V GFA#(Z/FJ_F6ZCHD1[C@]$,Z>0@I(#X5=/NK/42:L3>)/+4D-!
M"O6?L%DQ^J_<8L[J>^F)9O@'.YE!':'/P>?)A6=U@%%5Z?*S6-%IX9Z[\?@<
MSUV(7#M_*V.8;GT57@=&_*);FZBT%?H-J26",F6B9@UH*'MW#Q)U[6!8E>'Z
M\UQWB97 QB;V*+Z>";Z(#8\IOK :S82V0HBEK,1\5HXGSY/7*!E9I6.4I[>/
M66&H=L]DD2 P]<2?W*UD[1=! #'Y%@I1P/-Z0C6-ZU(;6^*J)>9 )@F9J3BA
M$\G3J[E72,*86:=$(DFX>ML66T0,GLW,HZ5$<<]62%#3:#&:1#S_G4XY@PM'
MP=/Q3-[D?/ERXDV/EV8Q7>7'3# /+DST),B"2?+W*\Q,?0;M1PK+*/(U*V9&
M*7I[.6YA,0U9EERTT5TPBR?.ELMV,6)L/U)S[];&4][3:B.@SL_MM.S#@T?/
M:S_%B&U3?!>^94N[KO900!D8%0KEJFR5B77/=3!^D+B*/[NK\(EDY.?R8,][
MQ+6O8Z;J5.*AV^+<$/O_V2__^_+YT<G3"765%.MRQK!41C9&+:XT]GM:B/OP
M\SWN[#5H]"^CV^0AE3QX\+#BN02#&/Y7^P08W;TL\E501;.FE!:J-AR;H)%I
MAB005LK^?^TFR6B34_A'P>*6%PS^)"Y+CN=T4GNIN9X^?314D_6$D9EH0HP$
M ]G*^(-\%G4?S]J3'L(DE>71];H3T92M"_;RI9,9>O@R&* :+**8\'&A4RJ#
M*BVI@[J>BT=:!(T]:\T/TD,-C0T6T;  HKVT%Q +G4-8BC&#2R,$$<310RWK
M%J8RJ-47=,_W.35[\. #NXY[<DE5=)M5^>+MT?-)$HZA169R_OV+M_?NFP?T
MX^G/^?NCL_%O_L_K>P\8;]UCX<3^\^!"?3XKY&)6G/29&64JHD_0P0_>MVR#
M*&^\"W"L,M[A3HZ[^O: <#P@'&_+%/!PS>E. AQ1G FL7\(?UMIZFOF_5.]G
MWABH(7$L$JJ@48AO.M^HP 8#Q,%[C6JO_?K#5C4;2S5=9VH/@/[_^-I !-#!
MV".'&-E-DKD4?7]B8+*2%)YYA/WK14*"EZ^_C]2PJ$HT79GR&\@]U>FHA2,^
M_1QNPJ&\>Y#JCY#JHFIJ3LML@C0CX>!E_4 T?)"I >U6<#+%BEL]I54N!9_.
M9SZ0OQV_H?"DYM;SYTUW,3EUM,(V-;V8O'A^FAG#2\Y9(^(E"!N8P%LN*-A+
M2WOB.*1QA/M-"%!D^+:T9U&XEK%X)[$A/AP0=A\.P.$ [#D "W,JP226*,[$
M)]6T0N\KL-S!62".L2"'M4%D1!^K.\"-@E)L1L(R0@K#00I^,,8^MIP);0JD
M)3$)*+CWBV*.D2DH1%-RY8*JHY6,=Q=JM,:QM;4,CDT?M+_R#E7V"2$*MIJH
MH.P "-SF2-M_A90UC5<CLAFI<^J'OCHZI^H$S?RLCH+3SRP27X^=\"4/OKEH
MN.!EJ\ 6COKXO*BP%YLZ_/)@S YG.9YE[QC%T)3;P#X<92:RO9V<%U7E/7X2
M9KL(1\%QTFT_@T@$C',RCJZ]X@@L W2I"[*?KDMXT]!"9O#YJWG>4 KS?3GC
M@8<:\8JR<-R-A#T)RJ(4-T\Y$6-S?J:# @G:,$/5%(,RPYK $5 >^MP.Q^<F
MOB %Q&>O?Y$PU6JC%+AJ7MVRO_,BG[/7QGR*0=;H<R3<G3.6T#,DO#B?/2%T
M$/*#D(\*>:OCN:.D,\H3J4GHR?(ZY"@C37$X7OTR8D+.@A>S\IZ>E7[:)8WT
MOF!AQF6QG'957\WK*P49UALJ![2<GQ6@M3=K8=DEX^)X!L=!T ^"[@FUA2BS
M89C'(B:%2!G/F_R*1#%R .[A45L$Z:CQ54XOL3I.:PJ81I0SQ,B*H$&&IP5N
M8>Q;1%5)E<6J.,CJ05:CXTYJK)7 E)$)L[QQGNPDO\J%*ASE<!F+:IKY2Q:1
MI.G4KU K]9/PU)?*FY?0:([D!?A^^ENV!9Y9?.S!#@[-X>Q\X.STLD<6!<+[
MCIZZ.TL,2.NAT4"2..N0<:K^#8=L&GFGVW+VKI*9 4;T+VGEDOB,PW[B=CB8
M14L0\^2K!#RZK,LYS!+EF1!\, $V83$V; V+&O@:IB]76UG(O&2BJ92!O% [
M2\(B ?(9%B84_=X?._2G'<YEKS^-\*?SI)&\NJ#^%6,R,-)7RR#)"(*N8D2;
MA TXC225JY5!OX)H&R2]G2W#S58@DP3(-KS@=([\[]BB9OBH1P^'&R\2";@1
M7O_MZ%^3F08VW429,O.&VV/4\1C#S8P!2X/F:*D/C')T7?",K7L(,P160=?,
MT3FP*F=*;9%>.O-7\PUT[89^S+.0':NOW"1CK4\_:HIMUU3<G:1+N%H2O ]3
M6631DV7P7*:43$3L*ES/H("AUHDBGRU)V#AQSQ?6*O0H+M0)NYJ/+V WC/K4
M6@1EBCRU'T9Z>AE-3KRJ7+^1J>RZWFHP,C*.BL&N2LN?YX#\G7H4/#\U>E>:
MG$=H-N7,XRI=DXD3WVE9]\8P,)<S]MHA@NG*TZ;.B7;*#:('+I]QZ#KQ'B*R
M# HNO.[+FK30:D O^X'S82A4_@5(@NQ%%&&SZ[6TH%QB$$6?C!:T[SE@9P[T
MT$@#VP@QM R/KW9<K..6/RE0A5MV58^[0WL:OB!2^SK<G1US;I:3Z4@%&GXP
M=67 088*O?Y:8=*_-]JN3ZTK*'-W=2OMD_(3&;(9(L*H7$F#B4S_4+H?,G+4
M&S0+._"&7J*_K'4]T3Z0.(! ^:(@1/DFW%!U)<$W#0Y.A1F"?>=8%QS(KC&C
MZG>4/VTWA=#LTQ_GVR6S$@:5<YG/9M*TQP?2\AXJZ 7):3Z3PN9L*3^!Y\HU
M7NO,4NTC'5C:-ITK#D/?,CG!X1_;"=5H^97'6C2HDE;H1'(=9C'E A]Z%53%
M$><8Y>)_"\Y&>,8W6V/^9RWBK,J=!&8_.0"S#\#LVP+,[EMX\UQFJ[K5GDC[
MH\_S.VW"+ @:&INNR-^QKWFCP^Q5"RX-=2*\:A0#WYK>=)DC6*":(D7(D2$N
MW'QB6U>V8HS0UU?UO=+@ \9>;.%=2(:HC+3O<=_B/KLXR&GLGR2"Z5EBJ,:&
MJJR'#97PZ!WFW@]DB%6K><WM4EGJ%6LKM'K *VHR;=:?EW_@XU[@J/O1G^+N
MV\/ZKP/N:%VM=BC5H=D,SJE-9ION$LQ?MUW6362;&+M_\#4MEA("$PD=^F-R
MN(W6(CD"782'*XN&F2F4>7/<QTH'(HH<TFF,4D79@61AOZ32:^P#/<:!+#(H
M2>^^L ]  FJ:KB;TQ]4N)@5:QW#@O;AED5^6S-,"%RA.".P_C\XI'&F;O6Y:
M3N1PP5Y@?2 >B-,C[$FK.IVT:&0^GF:#UI*,Q7-#U(Q$M^D=N-Q/!)$K_4XC
MX22LE@UBJ1)^UN%X1S<F*J&T3,8]?;-'MK,Q "P)[IH4T28\^3]";-#.2VW]
M]Y,5/<\7HX8R@Q+Q^R?%M UV(PM*IUPA1,T]]5+=7(2P\U]&IQ!EB>2KVR(E
MC?BM+T!9PK 1Q[$Q,G$P[A+E25$C<?Z92=%@8&=O2N<OX_5]#.8D66(M\B^9
M$AIOR<U6A'6&?.D (9E2? 2T] C8V2T1-"N)7.X96O5[)<(F7JP2&BU^=]?
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M]1PA<T:^?+H)K]W32C$(3%$QJD10!@Q@TW#WFC%EN$[I+212'V8(EG[320)
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MKWMKL]#183HF!5":DT:A6*6GFO("/BNIX$;YCP3M;2FQUE;]ZTSB(M1N_]E
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M(1J5D4+P%5DG7Q0/-HP(GOC%\ZTT6XDS!$\.7ZJ@<K%.![A3XPZK.[<:FTX
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M2X>/MEXJA?#R;]\Y!?+U?4RB^+C= &PV-GOA_#2!.>JPX%\K_2GM;Z!Q4G
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M]BY%.WX1WE)_"#OW10AR;3SC+<1F2%,:R [_F GPY(W,6,CMCS"1Y.$L]0:
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MQA!ST"8+8_P.X,$F^E^J=F0]2.(.PW5$\BB_KP<MX,>F.=)E35XEKKW<S?6
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M K<J1$ /()26-S6S;37)T_O=T78"\A;8]P&1-OM8X]))@D=2\QZ((4GK.X7
MT2B_U\%6F^9'U(_U35AIK-EI6#PMO ^J 398[L@$H_4V+O;8[A-:#)=S,\,6
M$>R8%,E0;ZG6N@G./RRO+F&E#(0ILS8/OG7];<Q#J9\5#Z@DQX%P'.ZQ,E1-
MDYF@:H#JBS .'6V>(%S/B!%RPAP$_42V<+YF1LO4;?FDXZ=WE19GYC4)K6Z9
M$Q4A[@ =K6&Z#L]#@7LM)-<@9(7PZ-C>ZH"\A-_)/T>S%A]+!:7PD1.KM:.P
M"TY/UBK9/U$3Y*5V0*IE>_,+ UH^&G>@$('UC.1YA)C$):F:M9M]J$&^;CIE
M4J07C/]\H2TLSKO\=TH_P+)F0V3+E)(I(>)?O/@'9:MCNR4RES[A=*2_W;9#
MR'*YF#>$?ZBX!,T1HZC!H.$FUV3"=50,F7"4"/D<5271CH;/A&QSVXZ(\0T3
M^_)OW^$6E,E=9X^9S9-*M\F7&P1O3&N(&W-FXQZR1B79&&E2%YB4TYD\6 (A
MYT6?K,,&3P,KZ 72M/3>68-HZ\MY96L4M%/S4PNM>'5VP6[ZE>6T^,GF)_+/
M,#L69,,=_!D%R9P[\N5-R-+[T[-7=?!#X5+A/-,W\BF^()3.;7=#*'IF5CF
M"S#L]K8;^\@4./O>R[H+^[KP :X4\(?^0BWMX"#G%WJ7;,,9$Y8&@.J#6:OO
M/&%>U"X0=B$Z#\?538@'28RK$[.M5,:)D6O[YB=ADN):)K_E_YV:45PKV(U
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M-+3. U$ZMQ36V\R2K\?O?[4&"T3AWLSQ(OZ-=> 0I_M%XB3'K9!+HY+&JPZ
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M.H+EQV:J9B&A"HGP'3-L)4T%]/D$%[\L%.,&]Y+6DW9KTOOP;$#GFZ,J/[+
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M_6Y+44G6%>[MZ-W>5.B6(9.)U';5Y=6"&I,5'=5&,DQM8#&A48J-/ICGX6S
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M!T31F&!T=K.(='2\L(Q"C6=#?:N9H$:;;?SO:C]T\+P/9;71 "L-RRA];",
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MG$^EO!]<?U::N? )ET3RHF<T)U&??);EK]^=RU_G\M>_MOSU89 R&;GZ(LK
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M&V I8Y1$?"LL0-)]*/A%JMO@*\%+N@O]DJ?!65#'ZK<X"--^L2[LMA?I^25
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M):*V74]<361'61F'Z>W1SV #K<(K[K9>'T'ZA(1'%5PL6' #>MUYASF&.B-
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MFR]7?Z!\I1;_WTJUY%N4&GG>)%_S_;>7J7]%&U&TUK4XMTG]:T>4[DAU;$M
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M.CEBH;4=T3T^RC#=4L-5G-RA?E<3H:X(]G GI^._?9A3D:O,H5*4ZP@BTR1
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M%A$>8==88@9^ @@6D(!CO:;$$;*H*:VMTS9*R>]*5E(A/M_T[J_*^-S?N@)
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M1\._L4?:49*R8F+LAG3S\"^F_M>^#E@HAAWNAUI.RR+NX/@Q2EXB2-"?*#U
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MP,$0*,/F$0O0= \+"B?QX (<*(2!!EY+[/J"<JHR#%6T_77?)87&1ML A 1
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M$OVF3HE-XBP0)5<&LY:[8R<]>D"#)@B>R5(Q3::*[R8B8^6E/"_F\V*VQ4R
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MPN$'D"P$$4'AM(!- O5X1U"OC:R'50RCVWB.<@F[XU-4-#(>EF81,/V^ZC7
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ME@8>HN@R*XQF,4./HLX\Y!8+JIGL?*F==(=L4R,"RFP2MM+5HK,.S$F?PZ]
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M=OVQK&A9^XYZ,Y4O[/"37#9[=Z3\=:87QZ_JX4B="8IQ_87/F<*5"VSP6ZJ
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MNPL;21M"]!CH/^76.M-)A(^5TFO7\ ZM,]Q_^L;^0E+2C>@XHACL^9Y60_9
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MV1I.LNQ--I4&&VQXUS&\J!JX_&J%'OI03+YOIG7P31<R'='YX7PM33781VR
MQ(U^JLXT]IED=E5;4C/<\-46^\+5E'W(YT96@FUDV;*I(Q!CF4CLO*^+T6=
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M*>BF&"[I8H#64>W'N+,9S'4YAV?!9V?FM0L&YCQ.Q6IITG8VI$.0+7!5*J,
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MG<(R>6[JPM1B.\H]UW42%V[/=-+]1N"E3@"+&EDQB*,W=4!*\M"+_&GL!=/
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MLCK[YUF!-W+&LLK<$Z)H6%08[B_H(IZ!55>5='75U7D\6QIQ @52/("P/$?
M[M4&7;W[2)-=]C;9M4UVW7.RZV(G<#-'S!ZRB(S>Q'5=G?T_5X4)N/L($8;5
MD4!C+Z44&BK]PVI6I"ID_T+ZF'>#ZXQ&'SPA9FAYR9[0D%VY:AJ=&2SCV3G<
MONIBE"%(XFXL.2K3)[PW"AOP"N,$9%7VOMXL8::D:E7U08L5SKR[?(?&L%AU
M1AXLF4@?=H]V5441,D*DJ5B@_12WBPKV";QC,1,R/&3REVM&BJ&1*"W?H$^M
M%+WR_'F/_EQEQ\8%(0DIR),26,DD,I.4A9.48S-#R<92AZ15\;'.J@8A]RG4
M2C/A+.I0GE/E0X=F ?9\29&V\KC"Y8 -*)A601"!@F0 V# OTTQ:GE2-Z-9V
MI/5*](:_*<],CF9".:'.ZV 73L"<JVHZ#/BHFCS(,5LZHV6-S!2\3*<\)/P[
MFI](O<-.)GI]56W8R8F8%>*4ATGW-3JAI/<,D[.HT]4<*6)2W C>-2VW+(5@
M4'),FI9-\MT3S4:[]6!<K'C34] YY_A+7%EA[/G:ANF!HD$"H\NP'@CLY9BB
M/A0)YYE)&J)=3"RMB#R)1XB&2%80]K^*FS>F=/(T^1-2<%;S14L*HH[K'1'W
M_':"A71D2QO.B'E*M>JKL>2I2>LBX2,_K^@GR[B8X3_?@,4F,R&*\4.&4@;/
ML#; Q:P19["B@DUQV,R7N+>VM?,+G08I,;2/+<#]IA'BI^95LQRE2HU+;\ 0
M"Y38=C^:CA-@:J"-)_>A4 R\,XM+GAO%)2_DP;\3$7IW28E+HSQ#H\*.E&>S
M;-T^*B^IRE*0 SK,RG5!D=UOF@%T<\DFOS!NWWE')TQ(?4QA+#E(U%?H<O;(
MNM@_ZK"N=7*(HD:]9T2.VK05J. ,-:V^Q_%MBH2,L_W@^W"M+*K_F5!BKCF-
MEC&RI:V(_B>G\ 8-Q]3&2O<CDPX2/I.ZA)<(V@)0!A2@XV/8GK$$HU^GA3CC
MR)4,*(SEF$V*IK92:41NAPY:<"RKM7J:E@F-6*Z(6$LM'*Q3@[(TDY>X_/U:
MM("\_$H>_4W+P]QW(S. H>,H%.O;H5"(#$?"G;:(BXP#'A@G4%_:'?U4G4E*
M-+XQI#QV0@L]QCU2:2>@"N#(: :[3ABY9;C#BT<N72:(40H>24.+D1 /@]#(
MC<L7LFD^F!3,G0.#J>%;S;)W#DG/BI.'79DRE]71T5XB@5H,GTGB&5FBS0GF
MFB@.=($AUAZ9BX6^*^X'.F"&>]F-HLESJO(Y6FYD$<X,AT^#)8XF,IE$8Z39
MY2*T07'."\@7PH*06D"#&UXZ.T=BGQ)\3S M.':5G=*K.]&WXZJ2UIH:3B?8
M*$0CE1*7 O=HIBXA/S8E%WL%9MJ44C%]=<UJVJ\-VVD69+/%(6L5V7M)*S!2
M_L9_-F;HT."PD7MTTAK$<N;$DE6"L<6!Q_8PUZ)5K _F:C\B:_T92>:^8:W?
MU6G42]WQ%:3.,EP-TZN(S^(:5IK8QOBWJNBDD2(#3^UKGTX=B?)1B8,/N3YE
M$4N!MX4^IN89 4T;%S7;]3J(S>.0GU1A8!H66PHF-R=SH]&'VB>UH?*VSG5S
MG2[?F/CI9[,X_;ASE)Y4Q+)%D]K!.#Q^8%YE8L:N[N!+U?!ITMTE+1I3]DFE
M8V\."M+.#.];]H)TAIL<Y*9 KDUUY]'A4#X\?+;US?$+J@I6GB$Y$I@\,G%B
M9HH'<F<64V>+NDO4%9C/67LU>QT^,'ROKC_=?^<:/1OG/J6;H^H)%JL$3KDN
M6P/[IL+8&X:XQB-%4D]RK2H/R._J5L5QMK?YN).#;=$R>!)Q*K'*=_2<D<EI
MKOR*6+:VZ,\JGLG1>2%FV>YH7^:F3=]4=[# %R]?:@RSH(XOET/!JP1GU UL
M:+I.PU91F2S,ZICTO3P#<W!&8FN&_&7R3AIXM7(#QS+#<T[ZORA/A.0@EK85
MR#S=\9B+,-_$%M:8EW6#1M!6?DK,B0G:-K =7.O8>O[RVN(;\6Y.%NJ>=H*=
MB8%*:'5JW$A7N_G^<:9)G&V:9)LF>5@]00:A93$P8VDB?O.O%THKM[?'_WQ7
M4&K$=G[X36=+*0[?K+ 6M$!U8@1KP32@BXQ_=-ZUG&:B/$;/.6<R4E7Y1!']
M6-UA*1.ADK4"VU75HG>#M8/K:H[.J^"Y-1P=\\-\A>'C*[)/N& 9HVY4LD!O
M1YL$9H!/*RJCTX '1<T1:.CHFQ"N\S;.MW8!:I-*U;22\25S#L:[VZ>3JX Q
M];(SG0)CI" +,?[W;^S<6N+DI!J?%3E\ZSR=49X:'A'KV IFK'='>\W:\AIE
M9QE[2IQ16$FN8G'1*EYCV5;$TJY>:LA.7V"DW8!>+R\=\0N#\T1FB [.M=L^
M:'9TB\-O_51=!+#]3N"ET4GIU559H5DA*[V3VZQD;/7?$1AU Y'RP;A$CA?4
M1?%Q>9HX*K]05D_-<^UDVLRY*BM)4E_?693[(L>W7:"?WSX[PIR*N5<O9AP6
MOI,=^DW6?)4C5+F.]0,L!W[V&!1'=4;57W1XZ;?V#V@K90(6L$TC_ Q&%:QC
MO:2*O6?HHF!(Y0A_M%HT-#O8)\>R'<U,K::].VJK"_EG^^_'H^$AX)%.XY*I
MQ$=QAN<-JZ9@$8C*_K1HNAE7C&=ETJ%L,*H&MF #VE,HJF>L8XM37>UJ#DPJ
M#XIITL5!]C,F'MNG,E-X3*6=6+I9%Z>H+_1H;]/([6P@Z3<AF^JU*L6+BIH9
M\(=P"?#5KVX1I5-GE"@D'7>5E20WC-[76O:"TLUH83/*!@766/.CIE];%[FV
MM/YQ/2O8_='!"U#83XJGK#$X-3F:5>"%U!3C'Y9.'/>30G\+-#U83SBD&??[
M%37,JD(E<(YZ>H294OG."];(Q-_L2BW=;APL&6_6:!BC1MLEZ=R\,N3.2T'K
MR?MPV2;TU1H%@'LW;&\K[DP"Z3:OQ9S<Z,V[U-_XAG;AB2WWC0R+N,%0D;Z4
M82?A!WG1@*4GX?ZN@"M$)<&C)[%\,(Q*\]ASD7FU).@72MC"( G[Y%24*EN^
MI Z))78E6 $8&+(A J4L&7@FAV[%7"?Z8Z5-9PA-0?4@,ZP_P0!>,<,>.M*F
M*D0S%R!ZG,REGM<+0C$D,'"T3\0L4R@8*.^S@LZ>^)0* >?TV\"RS"+I1@?K
M*92#5=+R3K:6)^/1$\?8 @XA]I=,ZE!*@\,@2EH;M31X%Q >!Y;>U\L"Y3P3
MR=+L_\U:4!,93P+72+9-R0.'1_6)^[3;K=7I-_1W;[\1HY7L@U)W>8V[UX-4
M#:J"8K/(XXVUQ%P/I2G(A$8!*V]>-Z.)CQT]%,BX:$@@HGR'DKF=5=J44DT:
M@YI?G=VA.Y!RLF<%MT)MN@UUAX>IC-6MA6H22WE.L;P"A+X1LU,AA98N,L&1
M&TX;7>6F@O_2GBE_3AY3(YG(;:AS<;7'J1J?CL9=JZ'9:+K<7?8=K;E94[4Z
MJ)F#3% +#-:"R78*E(2Q,NI0__#9E,FD(37$^F>#WH$]FE$^F31#3_G( *Q4
MMU+1]KYB=[YBZ HJ;V$C?W:NDM6D1]LK 74(R1=EA0VGDE3QQOF/BGPD"MI5
M;7'<P.P=WYQ*QS*Y_670P>&;W$+5YT2R=<%Z2NE1D9:4N@SE-FS41V-5T&YN
M7(V6&\66A0K9,O**5%%&9:+,;YCUCSA,U"3*WMHT8E)+1[(@A/$D"!=F\PS5
M4$^JBJ>FXO[4 T*3/ZO,S5K;(#8P5G"KT.X-UHK19NVQG+RC,>!:H"/,SR%O
MF!2<"M%0]G&#ZAE?-']6R;7(5JG(.@6?1A\#MIM2]AWW(UV1@=DIJKPM(+1K
M088^MNB]NXW>;Z/WUXW>2Q *SPT2-W.\:#JUIY&7IEZ4Q$D<!=;4]QPO"Z=.
M+$$H^!L'H&V"O7^OP"8MEO0TT"?PSYG\UW.I">X+N0+'Q\HNV-O=1.+%?YJ3
MH.O/F,;HN=9HJD+Z-5^,[XKFXTV&:NG,%V#1ER#RX56L-/$)=E0U;]&8N+Q-
MQM6HW@G;I%.RA]4=GL@ &S?(<HWI.3\+U7;W87BI=Y/J<%FA%)U2EEZ71W#'
M $<Z#' SJAB1.*FZC(MZ'3H/5>@VZ6I&?<N)2..5K+!G5JNV=W SKA.W?@PB
M1W7M]NZ$:)K<:(>N2(Z=IO 2MGL*!2C:&[#&>3/J%#O%U_%2U0SH91UX+:P<
M&OV=6G+EQ_]9U9B[D+O67X;F!"[B'4H?%&3GM;!W&5M % RISOA%X&[F10N8
M8SP-+!;0UO^M:B&IQ;XS4_;0= HMUMEY&2Q2V2L.B0Q9C>W;1F@^Y!68A-U^
M?6XH(+_OI)JQM3^\E>Q%2N"O<UUXQ$X:%0#JX7*2I0>PISLC:A.>3YJ82HC1
MD01;S=R63&#QJ@KDJ9GGF)S3"S<L*;)'R%CRF[1V/D-K[)'E> '8,MGUW[JV
MW\-J45B&XS5^!%E).XBXB^=(]Y^<4=B_K!CE@$+_I 8RA*:H=4<1'T/=%]TM
M@">2!G:M2;DD<?F1F_[AT\M56]IBGA5JO"C%N=H<K/J$%Z$;0%LK:V<S09?C
MF#-W-5G4BWB!QSJMZD5%1S:I5 =/[PTT%?PY>D3TCR4JAQ5BM;0*ZE[O"O+H
MAR\,LS[1T-UXH.  C*CXOTSQBI"B+E5VW,:PJ3H7Q9[W [4/!J54>WQOY^43
M*3--SC-YC(8\@#)_WBHQ7<QDE WK!*HNVET?,4GAF2X 6&$R^&]NEX9/8H%>
M.R6C;7\/Y%8]J3,+$-'E3.AD?9L5;!:D;>2CN+;0]&37&^#G<08WQTM.9ET9
M\2Y>NQ6H<@H\0;).S@1%D3<=,IS:Z.1\@4O.K3Y=M:_FW-UF%4*@'(DNURZP
M1%AZKHCRT+TB$*31N"8*\!3YFN!@=$D,./$F]W7K"WZ)+^AM?<&M+_B%OJ U
MC8/8#]PH\'PG\APK!J_0RR,GC/TL]JTPG/IKOF#X4IWE(WV4X4HDY"+Z%W@9
M]^\+AI>X@GH2HW86+0*3FL?H>;R,;[/>8^.9'YC<X=[1T=Z/+T;/#MZ.>1('
M;_9OM1KE<T9W\.;YB_^,WK\=[7UX?O#^Q?/1RX,W>V_V#_9>C8[>[[U_\?K%
MF_=')AIF!N+I!"*/IA,0.<].TRC.)VED!U[BQH&33BW1$;[(\29.&KIAY.49
M?"/+DBA,;?B;@$<XPHN=2=;[QL0)_7B:16GJN/@Y.TJFJ1\%EC-U?&L"KU#O
MD':MU)Y,F)/B?;IHQ/?J+^:*H;*1B@:/7,I'M:O:K,6RI]?6+X]EK=ZJP"-8
MC6SD_ %E)Q\Q!07G7,3-9&@(X^%8)8CND+H0U;\I)_X]WP)GL *7:E_]^SB!
MJWZU%#^@(KZM^_$2- W^(/SRLVY\^>>%)$OM@E_&A;5=[YM=[\DEC,C;]?Z,
M];Z<NO$S-,O=33G\C"G?T#'^XLF%_;E=;(Q\UN G U1U=THW&E[DJURAYO@0
M? U=5_R8)=-[A))YGY.[3)O?LAM]Z7379/5SYO^9Q+A2C.^5+YI,>&? <7WW
MXO#MN_=O7Z)-?_@"_GCS_MV+'P^.WK]X]^+YX8=GKP[V]_;WWWZXGG>KZA3R
MT4')B R8,'@GCHL&X^G9Z) +IXQ"]Y=%/3=\X-&&39S2/)ZH3Q:?X*7EF]4<
MUB&ER!^(QCN<X7.91HEL^'\8<XO>5Y'M1*[\U_35W\';Y8]'[S[^=5#]^X_D
M][='OQ9[WXS*> XOS$3Q_1[6953U&_C!-^1K('Q;E,VGU9][?[W[X\4OYQ_.
M_O.?].=?Y_\YVRAT/-Y?#E__.'KUZE!/L#/NB[\['MWA9%]5W$)J3+AYL??N
M71#^9;WXY>#OOT7\S/M[X>Y=,N$>+O_>]28N!T6R,3IX_OT=+@2^\B SEN'?
MQ5EP<E =5-9??YQ9GWX]$F]_BB_;=SOTKS/SSZ#V[=\K#TK;W!K'KVDEW?V$
M+^)A[ZZ ;4^^]/JXH]US+K@KGC&FS!%"RC21-W%=/[C>O2"?-.)'K84\'Z(%
M-; P=R'6]R7#Z].U[>#QFD 7B74;%:[RMQH1-"XS!)VIQ0D6QYR*5]7U1-V(
M.8,9]-9 '"T9UD:_8?2J:K[P+#RH!?Z':?VA$Q-^!5K?/![[;2O/82UAJ8ZP
M?AR$^2:.A_'\D7[!B-[ &1O\&U83B;J1>":C%W^M,'O^Y+G 5N[ET]'V.GD<
MU\GTZ[].D(SQ)5:C1;;O!%9X(V<$:Z;HH=N[XBNZ*QSKD=T5UH#L(ZQ#LZP&
MR@:BB1.$H7^] T"/E:U8U6@HG_^H=+[US]+YEB'D=D_(OZ-<_ --JSV0>K4'
M,HQ'5S;G;\OFMF5S7UPVE^?>)(@CSTH$_"&2*(ZS.,JF<1"F8FI9>="I0_J,
M?,HMELU]3C47CWCT]N7(&/.H'?2(1SVB8;]Y?_#FQ]'+@W>O'Y)JNH5AO.<Z
M==/A) _T684UYMASH9!\_R>I1]_]ZS!N&L1Q>%94X]%!F>Y^?R<+U'DLD0O!
M0WY"G 0T"O"!<=GLR*<^5+JAB\  !T__VT514AL]E>TC-.#ZHO2_TV;//O-E
MP^9F\2^SP-'JUB+:O=+$&SWL'6'0=-6R=US"HW-C.E/J&#CPY#^N2>KH"1/*
MTG>>2EB8M7X%_@LFS^@<,,V[B3'>=+S4JAOH3#N!SEG58+^.$>Q9Z&!/HX,]
MS4"P1\A@3R:#/;*]J.WZRB68&'?5P]]*;L PX:QYO"4Z%:,G6._)\$@S"5$\
MU,#P5-88'Y2R]XP$<//G-00 @BCC@Q%!939K&R@DKG33?X2ZC%1CQKY"4?B,
M7>D"=],7"_Q/=TOP1U=:.*8E07!X7/IK4%M]?5?%;2JW9YK-2:HYK6QNXYK;
MS#"FJ(104K%]3[9S=N52@TJW.-/<M-O[5D']F.+3@@A&D/*KH\(WC:'#R$8Z
MCB&#&'-$X<FU0H<0;PA,H<I+-$RGK#-1I\FH-WD+.J@A:FF^VI]\*$F3DK)O
MGHZ>'.[OO7WVE/&VZRZ]9H)-5FU=BZ1&IX.M&MW4&P?XX?#7=)!RD5$WM=$2
M.XO/UB"]44_6JYE0% ''JUE+!4O&BM$=C21]JNEK']E&6Z(\6@^<U%=X,/N7
M8TLTW4K0IKUH<9WD>O(BC=[WX*VD!(P4[RIRQ#"H(5-H\)[AJPA;-*$V1X/E
M#2'':WHU8P^<G0C9,7G!220H?,)SEQ<([JCZR%@_0_:)PU6*).?(OP8#89Q?
M+8F-)'9KY1A-B#'\M.9^0^3?*X_A.#/[.,]J3,3P-"MYG[2D0[ '=35C2.)V
M!AI8AJ 1$0Q ,]K0/FCX+7,H<KG@7<021ZLN^T.O_+Y1 JN*<U1WVF)58Y.L
M;#)%%<3MCSTMU"(E$ECI!DWW.=-N"6J8U5#JO[+B_E'Y^J_]'+XUCYZDO)-2
M)3$L4Y%1NRLVZ3<- TX)B7RQ2>C5_FPBZKS@0(S-X]H? IYJOKTR5N+$+(E#
MV1T=4==O^^&6P>]3C/SCR'A!U"08!E=TEH*8)5)A("8M-:^VHH5I 4D4)\(P
M7V:[E-3]W0Z "3/UPX<,,2:P(-/:0$%H22BP@QG1$-J[G!K"SP32+S7]5Z#8
MHTDK+5V3M'3#X'\; -.0DY'0B=1\KA5ERVMIV-Q?]6'I&X_?-=^-VIK1N\$*
M9&!T49\R"<:0"HQE/2:H41!KQ[*G=X-DV*LF%679G,].X[*(.0CS&OFTI&]$
M#?;.0Q*61Q= GVP#Z-L ^I=BD&5N.'6R/$H#[.9-73N*199$$]\3@1?F:9:G
M-QH>^[)VI38TIN(]Z:YN8.(I;:B"O9L9?!;C0[_*MC.-R/'SQ'7R+/(]UX\\
M.\ZBJ3WQHL!-A!\XPDI%V(ECOD^CJ?CWZX/E'U%@Q3_N16_*OT-G_FX/2^S[
MGSS_X_27G;.7S__\,*E^GISO_W+R,I^?14XO5 J?/'@Q?;.JW5_.K?,Z/EAD
MKW[Y9?+S,7QR[9F3JJZLPYTW[H?SQ>K-R;\#?W56_AL^Z?<_65N+6;;ZXV3O
MX_Y_WCT[W/EMVN39OR-W_>W!+S^=[)_]??SCBR-GOXF65?+[KXOCR%O_Y%G:
M?/CMTR^O/[[8J0Y___-9\<RO]_8B?_V3A_7OR\G+T_^4,/>/O_]4V.E^_N<9
M?')M1@?.CR_^^'3\ZITU.7US:#^;[6?O$OSDVHP6^:F;_?WWVZ4E9G_^<?[R
M_?S3\M>]:++^]C]_V:\/=G[U5R^<%\\./>=]8I?I7A2L?_+C'S_-3F;)X=PZ
M_W Z.5D6>7!8GD7A^B>GO__B%^'/[W[]Z)RO3O_XHSQYX\_^'4W7/_GB/V<?
M4F>Z*E],CF;'\Y/E[..OX;\CVQH8Z#Q_OZI6DS^LWZP/6?4J^1@DK\\BVU[_
MZ$OG3/SZYW^BDP_Q\^<_'O\6?HC$RW]C0\?:1Q>OWA_]W9Q.8ZMX-8M7BX/W
MK[R$/KJV^C^[X:]_K0Y_?_YB_O.JV?LM^_MY?;Z''UU;_BAL_IB<G@>O/ZSV
M[#^]/]XGDY6 CPY(U)\[;S]\R']WYQ\FQ^]^.C__M +3X#BR!T1J[]"9+'X]
M"\\_[)3S8GEV=GB>U; " S*5//NK\/?^_L]/'XH#[SA<_O9VYYE''UV;UD]_
MU\\^OM]/#V$ 1]YORYF7_ @"8 ](U>F9=^X<I]5+:WZ6OHB:HXGX&PZV/2!6
M^\'I:O)\OB@_3D[J<'GX8J]^]0P&,"!7_IL#\=RQ#U]\/+=^GO_Y<K_X7;R!
MCPX(UB]GO_YZ&N]/?WGQ]N^]/)HVK_]_]MZT25%E:P/]?B/N?S#JG/?&/A%:
MAWGHO4]'.."L..'TA4!($4%0!E%__06TNJN;ZAJZ'<#*$^_;N\I*(7,-3ZY<
M^>1*7@Z?^H)EF?1>VWD;0Q5&AH04G%%#+PCYL"D>>RJ!V@MBVSD@&E$D6F4=
M<;NU %)>,,)"U^'U&C$3A$9U)F_&/;DZG08X]8)EY3S$Z5(M#=$]K^5UAAP^
M*;0#^'E!L<UZH=2BMS:'4-;:++%-K54B@J8O*#98A^%>:6^,!0\Q%'2FYPZM
MP%RP%U3@>A5+9)?J1N?G"#$:$6,W  \1>T$%@6>WF@6;;.H;;".K0*V[;"WH
MP LJD!25:N\UK<%)9E>:318#K-8()/"""BBK<*A[MC 6L(ZDC9SA''<#",1?
M<NY\BQB+VQ&K2^:PR6_TEJ2Q?M@T9J^3U=XU+'731/IXE\16!K8D*VK8],E>
MSU6PXQ3*12&AY+G6TP?'>##ZY/(U/7YD:-&/^"W+3)P6'-&+8Q40TECYX$VQ
M/[L;Q+2BFT&.P\0?610J(@&*P!X)"BHB 8H(UL?8+4L.04T\8RG?LC8.5 14
M1,(4@:*/- TU<3Y-?/#(R9MQZU6)C\6@AS-;>X7Z^.RY'Y'212/*NQ)1L H+
M/_S? _GPN]C*/-+IKG;UQ,[+X&CVHU6O7O*N&XOB_0/_*]JSMKSPT'RXX;T+
MZ8 99Q%=@2BYTG]^E$9R/>ICP_YUC;?9+YP#^UWG0+%'BKFY1?R)<X0<U3.9
MP5M1V!V;P=$#TFT&R#FP\;K3ZFLCRD?W7*0%X>*#>W==RC]-W"2%AG'9I,C%
M2TO]A#AIP-.+&MW5^WX#HWMKM7L[H_O-R/:6U>F"9Q:CVV3<TQU%7\X&W+<>
MUYFQ_-;#N1F\)ZA4R 41_];JO;/AW&Q>2(FU)CW0_\9_#?EUX20174[W=+ST
MV0UYZ8SSKV^>-U@0_/LN0OP,_@,3.W,J=%RVC]?693Q3.Y8Y#L\JBOW3R311
MZ)=$<5Z2&@)MR@C6KQS6[LQBAG+^X8?BR'E'Y.?/JR'OQR6QQC4<%Y$TIM#I
M-"?#E:0^9!0@:RO)</[WD,,?PH,8*\G]WX.V<[^8WDJQW-/?G\HF>TY.E:3U
ME]!Q\J82_H?[[C5YMRC9=G@H?1A>)/J0":] #[Z%/SP1@=3";M2SQKF^GJ/9
M36'6]C"L$S(L\;!T$)-E*?*I?/*3*%*13DJ&+UY]D&?QQ9NO?*[KBXA(4N)D
M6V=0')&<@CL]C!%[R':O[HMUH^4S#0QAN=R2W^X6$FDW#FK@BU3@BSB911#L
M%5],X:KPY]F_]=(-N'>S4+Q5,/#YQIW(%67* XS\5M*,T#7+EMT/@.M[X8,2
MF+G??SNE>5Z MS)E+^1^E:1UBMW4W99(#7OCKDA%H09#91F$N5RH\?F<X+..
M.Y$+])1'-'_N_+627#-PPMOJH.S;6WVGL#5>#9P_C&TH-LN@KZTSTI;&Z-A@
M+6G*\5YQYU0;YGA'N_Q#&ARF-1*;UCA;IA3F-OXP]#AY$W=TIF!EQ8>>=.0
MO!)N;"O]HL34>EP#Q7V7+'%M.T <.@HWLC1&P;Q&>@9Y/F>$R8T_"P5^SQE;
MB]5,RO'CLJ"UG?5^=]CS:S4\(!U._UD".?_DGZC$QE,\$);M">NE' L0@2TP
MK'58J ?F.,Z?X[@A8>_RP40"QYL8R#M;_+&6'/4)[WHGSPT K_3=;R/8^S7J
M+;D2HR\48HOTO7;U@ QG"K57128,0>@L2=$PWW&%?,>M'>.B@4P"QYL8(#A;
M[//'0-!CZ&%CU!U/!6E":*,UZNPZ; @$8?B#9%D*O8OD!Q.]8&"Y8:5.F.>
M>8Z[AI?S;[&\L8C"5&52I]=-5,<84' \KVF0C"I&Q7APC,PB%,QII&B0,*=Q
MZWG]O8YG,\HZGR^"O##:E941OYCZ/)L/'"^8OG&4SJ(,?E_YBRAE$=Y=X>ZC
M5$5(Q%P?BQ.; &8KTL[(N$(VXM. T05V.XZ.US&D8%UA*MR3[[7!2]CD6L5U
MO[LV5AR_[Z&YQ;0_]L+"?T@8%6!XED$N&!3<VI 3E&5(J0-#LL0%=D@^Y,"$
MF&MZ361%(UZ-$E>DWRHW;35TX""ZP+(TFV9B1/#,:'\(I@%^)TRXS\3E*6:
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M.ABO]E9%Z+,UC^OS2H=AU'=)ROK^Z(SD9DI !JL9L(_3,XYFCS^$P[R.-*^
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M9<HJ55L$TI\<%LU*M\>@>%YDGW(<.!/?7X$Y#NCY?Y3_N/E8[SM!\F[GUWI
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M=&])*VJCKO*B$P@7C^N!J4QM4EVYF"XQE;*Y6?=SDP 4T!=6.@6R*[:)6CG
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MQRC*VA_VPX*,^$&,&I(57X]14U?J+!15=)M[2$V,LF\9S0P5:(*C^GW-763
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MD</]AD08>3J/Q%POK&P!16$'>:^ >$.^O.S+W4[K2$2/#LM$825Y3^67^X$
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M)HZ*@7$@HN?D5$E:AP]SP2IP+2XB<Q2#\,,R@U^=_$YSOK4Z[EU'') 66,V
M+>YP!>MMM0['Y<8MX9";= K:P7_(*$#65I+A_.^AUBX_9.:6O9+<_SUH._>+
MZ:T4RSTU>,B8TBH0ZND-7XZ9"]YSG7!T@?@#C K4&K1 'KX5&1:8_8#>6"N]
M[[9SI?IHQO!D5Z3"@IT$F:50(LL@]#___5%ZYTN%7-=L;D?X?36-?F,D^/=9
M;E$)S[K<"0@(_9(HSDM20Z!-&<'ZE</:G5G,4,[?' %R^$< X!G![-B3;PB
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M&\22>=F:ESC<]I'&HK'QISI.X>4HEHQJ KX53":?#M4&;B9D0$&>4^"]EJT
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M2)=<Q^6V4Y3,A<)O4;81^/O7YJ1(&@C-2"WR9\U>ZA=(4916__P7_N,^15
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MI;RQV.?&/_#= ]\@\>*3E/U(UBUJ40?? :W\!2^) ;!!L1- [B,=Y9T&!-M
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M":7')Y.;OKG\N'OS2P!6,\2E>PI#KTL]U>P9\48FC>1'_#/FU^,YG#KV8J$
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MH@4Y7N13Z?WE:1EN5(%4',[@Y.']IN!*+\@<J)+QZ+K'3C 5Z7O$M,0ZGP$
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MZ-DI"_#DF9X,XQ?[0\6!96B.#9ZL_8O=IT.5\U9G"BYM^^^GW(O( _UBL9>
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M1EMY[5WP6?Y,YY?77L[YFP*^[<SR"NM^H?/=$^5V+LU];>+>UVJ^GE7=).R
M5;\7JR9NP$I<@U<CU^G._1%>O74X>]L3(_:ZY\.=%]W\\NM<9W9H[ES,+IYQ
M=27]_UU9[JJX\1W=! LX[GN<H]_'0?D7.PY7]0:WO@1NO/WK3^JYJKF_[P8C
M^7J.#<"4F_+ZK\$ -Q#$!LO^V<!,0/\O6W8 \MP#WW\;' BWO_WUIV+H8.VW
M?QU! EC?$_.YFH-VO?/<XTWXG_/Y7U=>U@O2&6(.NON&O.8861/=_C?TD*,K
M;FL,'OX@M&P8F(CF4.!;:4$8I<42']<EDF[E-C-[8+ =B?MUT%"#LX3::+^#
MAM<C0T!1#J</T7\RNQ"'6RG6=@@6I@J6I2P2I0H^0-Y^O.VRD5QO?\S[#4+P
MX?K!T[9C"C@U#0^@GG_D7M?[+.HC#71I??IY>R.M;4L/[\'ETKHQ75>$:::V
MF)H5HQ[CXW3C5V@()&4J:M;__2*87R&W'\O__5)6]F_=F0X-V_O\:6.1TYNV
MG4E:L23-0)/Y%;(@C\)O,K^VC2_G)=%...J0G">;ZVHVMWKLU'&+2N;7'S82
MCE QOS6U3_SOD*%R&[J+O;Z,GUUU>3[T]U%=1,"N[W&.[X]?KYP1]@E^O0/8
MLFW8HO9\RZ\ NSP_=GEM7K]5;//:^W*#[O9W<)83'-\O;L"@DZ&!49>G<=IY
ME,97<98SA0(C1[,U1P4\T!BIS2[B!.X[?GEG^2<JN-/+OK8<7QW,>P;$OO:^
M7,,G_XE2\0R&?6WR7UTLGL&XK[TO7^GZ7\_//R"X.VS75?4^[NW? I<'R9*W
M?C858$P_?(VWD'@94/9RKM>=+_(6DCB_.#'@I@!3]V03E7(*60@)46P%!#F>
M08YGD.,9  7!LH,<SX#^08YGD.-Y2P"8F^.90I-#-;!M^$!C%!H"W)0Y +8"
M8.MV@*T@-RI8X\WB5M\X"8*^=!+$=K"BB[JDB%I!MVS306,/'K9OA6JCM&N#
MO&>LG,&H/!=-H,[5OKYA\_5.>?7Q1 IN(2H:PBFRAMD2-=#:HA5I,+!WOYW(
MHXC&^RHWJZ6C?"XY&"7SH^RTY#0$*B;$?OV)ANE$D',<0)0W#%'>:\JFY\D:
MTRDPD9()S<09ZM838(\!]OCML<<@!RF ENX/6@R<YC,XS5N#5T?VSONV6;&F
M8--934B1C4S6E)8DFXF/7]+[A+M<B/-=<[KL5U0B6RWJ1$4DIFU.H.+(7:9C
MX2C)!&G' 8!\AP#R721(^EZU.3-,&)=#!3*P]\[V X0X0(@#A/B[$^XGK#%
MB._"V?7LT*';Z3U%7.0R7%Z.]M12:LC'K65*(DSN&DYOMV 654VLD&J.URC3
MV33B(#L6*!8YO50D&J9BB0 E#E#B "6^CC_+/[0>0F,#3EM'.N82#NW/B\$"
MO/A;Q)X!I!(L.\"+?ZP+S;=R6[MWTHN6:@ER."+F6H9>1LK-9/Y1(&++:WC1
M1B1EM"+QDIA)49&Y#(RV/B:7 I7 7G0XP;(!<AP@QP%R?,O(<=70B2_PMN^<
M26^PDNS5_.QO61$C0'2^5:W1J[G;WX>Y ]_[_;XW=($!W-M7'/!9/4+26;(A
MD[5L4JHX'2.^'%S% 0?32+M0&AB9#)T9S2)YQ2QTH0-.D\@!CX?9*!V V)_R
MMG^ZS@NJVUZQ6(-;W79ZJF1#@(('E6V#RK8!BA[40PWJH0:1P#LB@2Y;J"DC
M;97BYZUT4NJF!]55XBK7%"N.7*,:(C4B<]F96C&*/279X 2XGP@\9V-AE@S@
M\Z"R;5#9]D[A]Z"R;8#/!_C\C52RNG/*!P#^-P#P ^X/L-P?C.5^9E?N!NP=
M^0=4(=&R0-#![/(X+P-E8&@X"%[_MET(WPC=7F&I]XE2?;>N9!S6)6_K0C83
M1QUK%67L3,GDI4&R\BC,QIQ !UW(KH>ZWX..>B.0'NBHGXJDOT-')=5U>S/2
MM"I?XFHU2N_/U[*(=50 G5\/.K\/+?4F-/RVM50 AP=P>%#MY/K53@) +UCC
M]RV'$E VJ(_QC>MC_# X&3US</#,)4 [ F>J#>&':2#AL.U__T'%R'\S5-C]
M 4:=Y.___&MP/L_IZKMP.T#SG:_[%LMJW!2(=^?T_Z'+OL6Z&P'];P -N_-U
MWV(=AJ]W\JX C<5>]^XX+UG@C'[<EW*SZXP&P-;W ;9<BIV1;E\=]W_CJ?],
M,"K@N ! N@F6^X;HT--CMI1HR2%1'X8D] .8.\I"U- A_^\ !PIPH  '"@+B
M8-D!#A30/\"! ASH9G @KV!GQ=#!VJL*%!I! @1%.F\7'#K?[8X;RB^\;!8T
MN6LF X,33A^B_V1V(<I!IC(6A@J6A2P2A>>3GF_VKH>D9YFH0-18-<4(A?:X
M8;?;^L<[09[>M+?E51-T=:QEZ/DF,^5KR45D7=8992G0K'_W@PR:XGR;-9[O
MTL8-J9Z@8N_-0H3G2[^_37[[UK"?WR74;T4<FJ%>Q '8%U21#*I(!E4D@RJ2
M017)[Q3U[>Q8'9FQ\P=]%[\\:S_:)6:8GL=5<9DCH[*R'A06'^^$^IF@3UCP
M;-6V6(UL=8O:HE;NY"8\#/IP$R<FG&"8X"IM4(4RJ$)YS]=NW>)#TG-9 0'
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MZS5*5L'$8N DZ&+,&@L4=4RE?&(IE1^)ZDI=%V9T4>DSFP;/H:$^F0[\TH-
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M&(_=#+_#D=E!+%I>D=5%AB9ZLME\;*1+NI?<<]$> ;AN/(PR3 <,,ZL9T"V
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M2Y_GE_&HGJS3&;V>65=;J4$ZV2J5(N/7L*33K'+,#*9B'>0X[0.0NY-U\VM
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M%Y2!,+J[J2'(VX.J<;"^NZB.:U7/<-H',JLH51^J4L.8PI!;L<%N5?B#)OS
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MHVI1%[6U>QZ%3J_\'@W(^;%@F+Q_RH8,VLY3#A\>MOFX((S/_;+@Z/S-@*_
MH>U",>&H!60]N,3I40Q[JG:XRY'/;\>A!:[@C(VMY54LS,N2%_)[.?5P'+2\
ML9.6]U3R"=+(A+(BW,2+WWG\'\&<6;3=CY4WF?GJL:IR<>J1H,8G2\Z?P0]_
M_ICB&59\ZD)LQ>5X?<^IEJ=.QPM$N)COL4NBHD^G ;^F]>,,R\A%J]?DQ4>V
M :3');5*?-@9*<-0#(#3'HA7WJ-M8%=DB#]S3?$)?V0^ME/T(EO>D&*R/$F.
M^$R]6GG6'_&(]KQ;<M33Y55'A"Q*0+5HGG?8_(0W(I5(HKE\BR/B8RFGMN*T
M V*WE$8CNAIM^)JB-)44D1FDRHVW!_J>D_+Q$/_<_HPWEPO?%GQ38Y[+>RQ#
M8[DT%992^373*?0*+4UB9>YT,?+7ZB:^9-7>Y;]L,Q5<NFVKM0W KLSB\-BY
MX3".<B(O_<LN?OJ]S>MP4C:WU^ \N49YH#O@[E"P+'RKW-^\%N)P3Y !JY#+
MZFA8S-26I6Q$MJG9:O%QA#3MN5Y0DNT42DRQJX8N/>D3N<\>TM0T-\LQ:/!*
M; Q76VJ24OLU]H!$>,:+?)*_^:(D(OCC4YZEC\_L2B296UG8X8);E7$QC/Q]
M%[C?+/);;/O#LK^.IFD[IO MLIL?LK7.HVT7I3&J _,"<0_(XNT[U,98;K=W
MR=#6NP='?NE<Z&H"A)T^*Z-/D#34WV5XN?).[^QQ]:%$:J_Z7!9RVO,D.DF8
M9#5E"SEA,U1++8U0LG9WEE_B#A$OU(* V[I5CF[T<<3B[Q _/]]30=0>>37M
MG^*@""(WEGX(9_D)'[BVGFC)(?3I!>]5?ZAMXO?/2:."G+0@)RW(2;NQG#31
M[W,I2<M$0^[T%VK)R=472V&]B!<:T-Z0OUPR;D>6)O(\DZ/'7;+5XM<.R1 I
MR5P*]/'(9JE>2MEJI\NGENU$K]$9:Y,V&DD_'5EOC99 ;:T2)+!*Q-)*K*?+
MV5A@CI]92+*@6=Q(';6F6/EAG<YVI08G1(Y'&@(]'FT4I<6+29K+;0 8M&1.
MB!Z/K"S&J4*KEN;YTEPI5].14JVAC878\<@AF1FEB%E^IK;$DI0BVTMNF4?=
M0(]&$GU[&A^VEBDUEDS+2<FR8AF;$]CMVM^?#?@5^7TH'/4:O/BGNJ[_NBUK
MLKO=]O0PR\,1=W?&+&1Z3_E-N$F,B#+AD.&V?G])C\]3V(#?^W5=$1'D9Z_;
M[C6(IXT^UTO35(F(0JKSQXT:,70C0J>7%VK=N6<1R(>7W8?=-\FWUW[ _6BW
M=M?M.8SO&<TL\-O_87]2R$QY$T(Z17*5O.]F8)LH.K;A_\$UB/@O!W:3W+4M
M]L8<>R:VZ4_,>R'E+OK5ULKX*6SL(4J]U 5[3U'N/1^=:".GS]\U_W>,U?QV
MO0P$.+UJW3V/"[_8'RH.+$-S;'!AJWZ>[K\[[^S3[<BC\8 0-T (Z&1& D+<
M "$2#W0L(,3Y"(%[J^/_O\<T>.;.VPUJM@K!+5"&(3_:?)X^G]X5]FA37@H#
M_L+PA.%8HCZT]OS]BVKE+UZC>X9]_.^95NNJOF]#\0OOAJM_KK@;3\-D[ *^
M24VPLQ/MU=^J-SZA*_:*&4@2 */1Q;?G8#=@;$.?3>BOO9@/H9[G$/\KK_M_
MSB>Z7[^2%Z0UQ!S@N[=71/CE(\47P0"_F$S: 54XH?82: M4;MV6K:>UA=N2
MP*X:K6HW)O=X)=]TEG6Z*LVDA@"G#D4XS+*G:J%]3C%]M19BOH/K<3LJYTL7
MZ?L(9U(R@4:YM$;I =%L+XT3BB1)=IL5QVG-,JUXG4[+DCJDE(; ($7"A"/1
MX^/M._!P(H&'\\T]G#-KH,#-N992DDUPU#L!JB4[WYS:I$EI:LNB(BT0'<=,
M!YVX8;44C9XJEO>]_)MHX-\$_DV@2LZG2K*&8Y[0))'))#>9IL9L1DF6S7E]
MI72D_%B(NIHD%CWN?7L'#DXL<' "!R=P<&Y!*RF+4_[-8&7:]3&==/A4?16G
MXA59C*LH^P=KI7CTF^,W;1F8 .=(!E[.-SDWNKP*NMU3H!^BCS@DD"\H)3G?
M<VP-+-E,*Y4DB%3*' R32R&.E1*,NICS:Z5KF]FO%_3 K7JR[D.]P$"]X'4/
MNXK2N^C1V=67&NC $VJO.J''F>XXGB,)I<8QW7ZAFJ$:J"_ZKS]1,LS2Q[7,
MGJB]?^'LUN,KN3<BN%]9<^K9RD[GOS+X13?4? X[Y*V7>E2-67U*S0QEF:EQ
MQ"PE5].=A;Z$-O1$BZJ#+F-?W3DLEJ'E)4'E*#6E%YEU/3NT-^Q7[!"[C U;
M5D5FU%0)).:,.@&]&KY.^4+=P%UCKKV"=T]JRKF?G"@LM]^F*[Q_NP^WVCPL
M5W;6"O^?*B&7F<XTP^WG\L4=0YY6!#DHWP)VT]I6</'JWJ@ -Z2TT)UWS:LM
M@'N&XG*I4\02N]8<%H"6%=]@1M?DO6*"DF)*SM2RT=]QX17(CI9D*H-=)=4=
M,4]/Y6;H5W=[@Q;T$6)=]\9G"G41O=0]S]K3VFL4&SY16G%[:QC=%$<-A=P;
ML,U,+E-]3!9J[G?1C35<@Z<)QD!?^?=<W?Y+6' 6"IPF;GGZM/7&DVLZ'->1
MG1B+BNI8"J*CNR&6WST5MU;%-]#<=[AO]&O1@)6D.18BM]<YU:US@$?NE[*A
M(P_^-W%G#V^F>(**6P/\Z%&6V]G%5 P'S@:XU9J\68FSF;;M6HX:Q)M#O[N?
MMU:X+J^*#YSH$-U>LEPY62@BG!.<@$E(^&^Z&(+^C8[^.G&K082]:_?N[J%%
M[;\.%:"&VLC549:%RO7YFX2^X2US #34-0X/#X>4D3<T[+:@/4F*F2;JJ)WS
M%-BR@>_R^Q/WBNP^5_C\J+C1T\8;/G=M)^7MN=L]%U4<\/<;/?YP41; -:"@
M!AFL_<6Y6>5N]22/@1Y"6=0_!Y@N/\.9H$8D?JG2E\BG6"$9BJRVAD;54S4N
M > D45]@'5]BA$P%\&5\MP"I[2DVMZ"&-V/_LCBZH.:]T)OPJ?>*^*9X.#3%
MC7]1 5.L)_=I*>*Z8AI8>+U!<#O 0YH\(U:G*+$O "9J%V^Y)3%=,^[VD=OG
MY*?/='<=3EU69NY<T^:#JQ"Z"GRHC@1/0V4A<8$#W&P&E:URZRH/H4^*^,?P
MYN'/9^_"'M8W>'K&:(3[)!NAH6))#MR;7=-IO GN1J((R=M:5$%K9$!WP-J2
M88I;7K]8>-.KP^8:?&]_%+ACDL=>GGX8&I [=</V&1C]#>T@KEFY;3Z-2VS"
MAWHDV97Y/F ""^G-9_C!EB'#V0IJJ;W5  IB?\?_[<F.OT";@Z(]N.$4W#X+
MOQ9_+N^Z?N/7[Q%F7V0QB_N%07&'! -ZG)XBL!3;V1IMK&5T@$KQBJA3M2VJ
MF%"F 2F RH6Z;IOE6PNDQQ0H7,X0A/;JX<%7C%Q)WBN4APNINY;(LSBX:J@^
M%L=N#06?3_!2\/JVJF*/I173$R]<-1TM#S?7WHHS*IX#D#Q( /,6=D5P^VU7
M*/$ 1X,4@M_0UGO]Z _9:HJ+QWL<<L@@^UOI>/;* G"/L5XY;AKA-K+'D]B9
M%*\<Q'$=AAN)*R]U>1;7!&G9AJ2BLCA00Z#:0/::TX=MZ.X9)N0[]R_'=V8G
ME4&O6YTM+=ZQ^>4D-<LY=GM\W-'D]#A\XYFZT W;=[B-B0=4U "C3H@_ZZ9?
MK =O"F8F5)@="B3^PY<$!,^5:'C.*4:%(W'%Q5#=@?I'"M60LH=<_I7(1&&O
M$.(3F[#7F0_JA$*]AM3+KNR6/\Q"A9G>&)9;,K3D".?2XWW"I%A540D^JF0[
M2T9YKIH?LQ>9,T<MO5O. +K+"F3X%HRA:R-,;EP:RQ\!)^[5OUI,QFRF7..R
MY+0>M9O:2B]TBB_6]WLYFL?O*F"7Q^UJ[5:T;^%%0N+@CT[7&(ZNE]RHPZ[C
MF:FR855KL%JD-Z@3+A..)]AP@CQ1F\?=/&15$3TDE[TM-(=M?1W7B@S]H9@T
M^SW5=O6BQS"JW*O>@\L'H(8:GK>Q[>JWUZG%?2AN\2+" 9AE#8]E44L.Z2T8
M5EI!I?0P/N,Q U%O=9/KF#8FYZV(:":+N1AO-TYAHY^C?G;"E:?-=D+-Q(KI
M#C.>-6QN_!GJH^G7T;)/4GA=S79S-(#O6U=MNIC(;/*Q*>K\P#Z<(NX,FGF\
M(8=>QS8,U0%N582+0%T4*OQ*<7M?0XZ]$EA(LA#ZX2E05W_ZZO,DGM;*T=&1
MI326*DUTEX4-9S09!Q53IN,GFD_O,$=T( AGC+P1Q.9;.4&_(%<+]UX([_5;
MM<)[!<NVXK$M9G:B)"'VSGTY@\[C= J&BNM7N8UN_'#0LQ:29EA>LU;T9Z28
M#5^+,SZ6\9?RM]=*"[I4S\1&AF,C$ D[A3OE(NW9U=G6KF(]XW^V+5*,>M^.
MD6=I@[VF69>P K1 LUN^W/WR$;XDQ=ZH+E;3?;Y4GN6G8#JL=6;+CRL"UQ%!
MM/?>ZQH US!0)Y6#5N4I6M5C8J;46,[L[&;*\!3BQEB8):$)B,=?4O_[JA\S
MVU^*3^U]PSR",>@0T\CM28&'FEYS< PFNBV!,>F@Z?#:&;BE@,.H'C=B,LS'
MJ##?V$+EI"73;2^!>B#@8K88'G%LV3#QD<8SLWQ[N=]W,(=K%3['#+E.5;'G
MV7HW0X-LF:NHM.0P[R^BN.,%M.@]+N"V6W-2+<6F?;KW*.JC#%@:?7JM%::3
M%&0$AB1?*,^WZXBZ?Y;V[6K/T4'M.1#4G@MJS]U6[;EG*J"]B =\29Q:%/7#
MCCE/PE7H%N'S&K=\&8'ZJ#T)4D[&KQYFC?&G"X>R!UC/4;WGU\U6#?H9J-BK
M[?9S0<_T^]#S_4:U0'8C9*U5- NY=+3?9C_ATWPBM)TKJW%T,5;S_\_>E_:F
MCFQK?[_2_0_6OF]+W1)P/3#N/G=+#(80YIGDBV7LPA@;&SPP_?JWJFR# 9.1
M*0E'.KL34M@UK+G6>I:R D*>3<=KZ\1 ^O4G&2)C9(B\>[9!63\G)0;^8:&U
M9H^M!,L#84KW:GHF,=]QO.C3^;GUF=07M<K:5$IF/C>G!STCGDXCQ^IE/Q=?
MHEW,J[TFYUW0RZ43E$"VY_5BA^XD[:I89U?V# 4=XK& ID&>.>DZBN]W=5_R
M=,_3"]6YP'=\W5@0VO=>$QUTGJ:_=8![87/P.;XJR>H+H'G!8_2X$%$N9_&7
M\)]".R+G4)7@*^:![=Q7HFLR?Q?9D+-'FXN.D'L_!U>.916^[=I*PN"^=#Z7
MRFE L>N![XBL\[32\@6*8AN6VOS\6B\1CY]0 X/:,+T%)=UV,\!'LSF9'EPE
MWONT)KK;458%]VGCLIA.VO/'6<<>Y1O]7%VM+3^1OW9$Z75Y%2&.[.L\/]\-
M2ZM"/SM;RV2<2S/QDO PG,\1W]&QEU#6K1%T;Z211USHKAC3);1*43>CLP;5
M P[OM(<3%QK-3EZGENQL.6^27$Z82I/&![KIG, FJ=2RX6QWQ&252>]9*5(]
M8(I1"5G6 <8(/H+] ,:(GP-B *!XF/ BV)$#^+)Z3Z#@&WO(DV>3@J>!J]_@
M(L_U\"+5F ZF;,^@5D\5>]D3I@AG^@ 3.C]FQT_A3KRAA/7!8I#--]C\<R#.
M-&LQ;8H)-\*=U:K Y)N)>;^N24$XTW1UEI%*S8I SF:5]E,\%W]4\3-C^R-G
M;-)DBBN0(UL%I95[K*4J57L1A$@]:72&7,\4PDHK.TQ+U8EEI!8(MN/@[=/Z
M2BP5A=J:+'3&G<ISM6D_M]'(@[?WN;J:&O$YOK-BK*2HY81,O!2(<ITK/"AA
MFBV32KC9[ECMZKACD@CE^N#M%#D:/C%B,J&$VZVB:J<D+3YNP)'>V\\-P)R#
MJAVZ3K8!>3[KRS]L.AF@6=VT3,QC&=0KUTL4/[Q8SIJDWK(?6VRGU%I7GJSA
MC"K$ RZ6@\?=RL4R148(O-HP7B[AWY%;R9ETKO91R,+M6(,Z!%TGZ?6-*@IE
MU'&#ITS%C@V;*@FW5YF3.2M7[I\\8_U=_6*]AK!X0S?[B;<S4(\ NO;P*&>T
M=J>P4DM\NF(F]2IJQ89 .@Y5"7 .:MM:".V#^1O;=C1))8G D_3WD=X8K'BX
M\U?G5YH\]FWW&P</=3L8X;3OS5>AM>\HK+WO[GP>P;3#+^!1FB@GA] UU \4
M;'SM+?K\[EOQ2P\>=C%*M73(6[Y["M>Z]EU7')_X#D3^7M+\XNV4_^[KC*!&
M8'!"54@06S,L@& 11;B6UY.HSHL)YFG>H8OA26$J3!,ZD#YYTXW%H5\:^NS#
MS.I 0:01L7C\=?0JQ,];*8I;3&IBKL,"*ON0;S?!<LQ#WDJ$XK%D*!YP)18A
M:D/'^G)ZQX;NA_+^0YGS,NYAG]>- N+FP+.9&GH[GEX\LYU6E:$ QTZDHM3
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MAZ$EH /W,[]I#U )BW<'@:*G!O"7*0QTWND2Z7171\4Q^^5?.,YJ60!'!T6
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M#W^?HZP7EPT%'5_\^*,3&]0J#:X>@3 @>SZLH@@%?#XJJ??0->:./>@:<UX
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M/!<?#8([I:D(JE'R%4Y%J4@B=J;#VJNN8WRN&D^,#"0)_Z==RP9FU:&?(5=
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MTSDRIZ9[4SF.?L&P>>H*C7<@S- ;T1^ 6WU/R,/=W]%=$Q3'2#([GR%I3 P
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MRLB^ ]",<IN8XD[0!FI5"X6B*4-K8R@+*-0$O^!$N%W#4 3PBZ@M,'HV;YH
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M))N6;B 6Q8DPO.;TV$;=X8:V91L XYRA#K*^28_XG5Z2WJ0#>R.).N[4/0'
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M8]GDI(Z=ZB\3=KA7IYX7D)RATJ3H@ 2H;^ ;?W_GMPX@.6FH_$64(<$80!/
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M/Z#IYH"0!^SS;(E=IQ:@^3O/=Z-: HIWH; ,,N#AS--.^*8)4'# ,=U1E(-
M-A)-_OOZ!$)X)/4OCENA6!)\S@B)S::MPNE1#!^F8G\#!PZ,BHGN;_;FO%MP
MUYW((<$NG0 *%*;89:%23!0'QJ"%CA#G0S@FA2C9-S!$3 "OF;OSTW%\QK=-
MB))PH #Y^#@NAL*A(D!Q0<=7Q6$V$4!OA#=U#:M@WH0K1UBVSC=DS7$/T:D9
MT,"6#>>; ^ =E+.QVQ>Y?IF!=]>-Q\EPCV2T-7 MT G",9SM;NQL@6QB)\_
M2\>+,4WTXP:I371!UM#CT1\0H[COM" SNH<.#V8*O=RAO/44#7PXZ,MH22AR
MK4]L5<)^N^O;M=ALQ"\ACA&@PW+ >;EN6[Z 6^CHE_P;#]UC''V\UA;S@AM,
M=K<3/GEB:[*P<Z&SYUD'RQSTGB!YXBS^J'@P'1J?POV!HW!(77? \_$IJBL<
MI' DNK&1Z)OMV?)HA*ALYK4-#[B;@C;K& \3F@Z79"&_?P3?BN/0FR/"_#1U
MKME".)SLL8JNP;D%\@MB-R0TYZ[ND0U"Q_X^W [3D:O;+20T@"@;4C1\'-P&
M%<D"M)=C6Y3P 'DK,5U=)NBF%?;:S3NV+=P>%(.%K][<9QQ9;X3(^*/2N\+X
MLW+W!<7CD%>P+D$OPHPDXN,*N2\P;6%$B'#K0V^=V +*]ZTV(7C+Y8^ 4U+1
MC>$IH[\[.CX10=Z7/ZERB/_G*7[/9O%G&+T$K;"E[0T;[F@O=)R;FQ;7GB%J
MZ'IG:XP[(R$1;3 :3K-PSWM%GBA&CSFP=H[O@[/TVHXEXXA^<PII&A,RNG8&
M)DHUD"&1NSX&BJ.AX"K^783BP+E-=W? I0_G@FM+;H:W Y'M9KTVU+G2<6Z[
M]C7[<$>SP]_\JN2(T,51>U>?;>7,8(7UNWW$$L0,X%CT'V OYXMH@,,:CAI!
M+#70T=T_9#412E/!TI$X]AV$SYJ DEK7-*"^:BT8.V8WE$[N%1K."0C:7QPI
M148:_(@W-J)H.W03R74R$"!Q.2?G)4Q@/U5 I@*> #:8.Y%6A"BDT_4(@8CK
MS83A:72D-^"SH32%?HX,#@0-$E._3XHD^@&8T!<RM" O'D_/BD>8U/G3L_Q1
M2RI")UX0?6].//MJRX+>0?S-Z\*+2"8N@>[_CD5,O4LLQQC$<A=HGJ'CF.BF
MJ[9ES2\31 "_J(:PC6DX5]S8Z.9E YM.0Q7=@2 Q9$'18?+"]GX,!<LW%V:N
M7<+C7AO_OB=[_:N1RYT+;I8+7G60=VG8 !OO%6E\S\C'B2=3E$EAO4G?O:39
M0J[FY!T>@J\#\M1R^ >@BU=1MAQKW4"7IDBY37C/<0EXL)O&Y&12F(<!)I<Q
M73OA7_3KD730TYS.:T;C7?O>Y<[/ECM;4QLE7T(RQJ+$V 9.+"<O#_&RK7G\
MC222,+-E1[V&"-O$Z6X^E;NK<=U,.IQWAQ,P>!0N@0M#81XGU0Q]Q38"15CD
MK#+B'9YFP.9F@,#CU0]QQ$761JA[MC^(9X;>X3J@-#:4$N<>!MY4? 3$1#9]
M.X("S=#ZT0T0PKF=KJMAKDPX8B=_T G^;>,9;XL_86GNYE>B1P0<RX[R<5P;
M8*)T.2='KV[H8R^E$U]#K/;B1+L!>_0.)XO2B[GNI=MB3U V%8^4W."-+Q46
M3M%SX@?;4_%EMZ(;!-D]$AP(=V,[(D!7DWBP/IE"9W.S ]BG]-PW?2<@CEZ,
MMUG6D6$:(=*B\W"4&XK-6,<Q1Z?ZAEN ?47I#^DM>',GF(M"?*O3!/A>GYES
MI^&LQ3O(MX3W4"ZF;+KIJW!ZZ.J)L*?P[+V4-D1MDZE#(5\SB21Y3R*Y)Y%\
M-(GD,A8N/T!72DX>MP)4>:3K.%CG"ENL94S/#4"1;S?=7=/WG1/,^(X8P.G'
MIHUJ_$7'#?"N*I!0PAI")"0=R@ W&HF*D*8ZVD:D0MQW;\7Q*4/HIXXDAUZ^
M/?]P0#6$32-T'WG\^OKM=@/_0GXV"E3#!2F.9D 7=OC%SN)\*L?VYB(8,K;-
M?/?1[IUF5I] L\9RE&4+1==U7(M5,R1>\[M]:' ;BC(12C#G6R8.0_^=K;5J
M_R":093R'_FEO)"#NPA\;4']B^/NDE.UEC?X"5CHAD+\39,4\\]__E?^X[N=
M\BQ0;[6; _,M&Y4L!-\='4MW?]_1P W?6E^^:@YDKWD[?5L,T#Y(;$ SSD/)
M"-5+N$2(.G"J/-Q -R[T@%1A6M[%L_,=CXA%@"()SIVJ))L63J"8V@-XS#B"
MX*9]#67X@JT_\HZ+&#@U=&2J[G#" GA)TG!B;B(&/&NT0HF "U] @O9=2+O)
M%[X+&K<6R3EW^F_^'^<GEZY]"1?;/ MFDUNQ^V=,2Q-==+('7#9ZA'8/W"RX
M1TC69&Q3QES?0A_9T\UC(473./4%ATN=NW1>055F<WY3EH*%QQ(XAI0;%\+;
M:3MG!+^$K=K55HZYMB2F_DWLYWW'Y'D0>R?O70A_2IC=%C-<KVCX4TEL6Z_G
M0(SJ1Z]T3[[M7@>"P)W?DSG(^,!W[]#T\#EM[Q2VZ/&;3!T!73<ZX8L-\?N<
MT(U/!=D2W<FZU<[.O:SXS_;*T[V<%7?EP,Z5K,-'7L4:]($\/PPZI ;*"\$)
M6"]44/&6$QGQXB+HIL.]:<6BQ0D'NZ[ZRK'F<"CXX O!"LJ\"+]](?9ZF1YO
M<E[[7'X+@ 8?!3;Y:KY^ZN[KWWW]3Q:,B"*9&)*I(9>"%B,7'<9C7%(@28Y*
MT(R8&I#4D!H<E@QD:L@S+VXS.[EXG$JD$C=0+I#Y2+D 7@[A6\^-U'7<Q??W
M%=]1\BZ^[^+[D^*; E&0)&-Q+A:C2"XJ I[CX6<<-+MC@U@R$:>&NQ5?,A+?
MPDGE] O2Y'CNK__"?6J ,+YR=P0YD<I&"/0_7Z7"MNHIKQL !7P?_07JCK-2
M=V\HBYH#P@+_<.*<X#<*3J\H6M;PG?@ U9KO2.&M &+B;M8')H^[Y/\1DI^Z
M2_Z[Y/^LX9Y,,.( "%R2%*'AGAC&N%0R%>/B($H/A@S)1Y.[DK^>;K:+Q2(7
MC=)069S74G^IW>:^X$'S<LQT.#M?-3-2!129\S+S6.\FJ^966/&:F-6-J7XM
MG^.S$G]PN@D?I4JWS&;K'D'6=%0BILECI?2Y;=G$9ML);]_Q#2+>>73?1110
M# \G3E\,<BJPHM"K?D4&#KK@0EA1[AQ% D5R90QQ [D;94,)N" /!27KAKY<
M$:U-"M%^FA$:@T =O=NG"@ XK(MN&_V@<TY2$ZI1]!4WM]BL5\!)T20A0K&\
MN2#9UO$.900D1&"DNA>+>7?NO,X#\?535#!]5\%W%?Q)%3Q(Q,&0!$,.W8IR
M42  ;I D&4X@8Q2=$ "92("#V!E%;40JPO8"FND$T!@Z&DV2UP^@4=11G)6M
M+O#/_"[V+RKV[U+_$U*?N4O]N]3_I-1/)%/D,)D:<C$>.5ZQ00K=G0RX1")%
M\T**!(DX=2CU:3<'9U7SD&7UH8L9F\$9T8)\ [*?/BK[O>D3F_GCK7;SIKTE
M0)'E_!T["97=(JNF"R+JDY]P"$*HN R:X5V'W%V'4RB1Z%V)W)7()Y4(2/(Q
MBJ< QS!T#(7D&"X9@^J$3D096H@E@,@(ATJ$<>5MTU<[@^)@KF1M&_P-X#12
MS%$EXJF+G?GOZ(;V?LF\%XHBBIMDT'NDZ:XNOI"ZB-W5Q5U=?%)=)'D@1N/)
M 9<:@ $7Y4FD+BB12T039"P:9T!R$.!S1.L>0-T6V#8/ -(8;LL7\P;41?2H
MNMA,WP?,2Z %8,W@+>&N#.[*X,LH@_A=&=R5P6>O'>()BDF!* >BB007':;B
MW(!,Q3@PY(7A4(R!)!,[O/GO<@P52R3HF[SX[^[?^\?8Y0@*  OIJDU=T$9:
MMH01$&] =<6.JJY7,XZ]]>TARV\5 EXC0F7TR[MWX )]CD4\L>G[!'$K%GAH
M#F&57^FV]7LH+X'H9U5/W#A,M0LGY Y+NAEON^ UGYKT/O(-HL(787WP)'91
M</ZF_MF?TQY,CGPZ4MNAAD!I$D 3YF]42QR .A,L6G&)VT:L7SRAL(U-C #T
M+[_MY&>F35$KJBMS+!K>=$ ZL,5RS"SQ,EO");>T?_O0I%=K&[2;CA5I3Z<J
M_AW!F.5XBX^X!;C?B.&@4KY1GJ-OG>?\<OC+\QYA>HMY&Q/J&%E!W& 70:]A
MA:L^414W1O46T":$\.^;)[I%YYO?_7Z3O &7W^#6!\H(IPTC1J2%?@D"&#)=
MD8#*AWW\_4;)$/E&W'RCK,S<%"M[]E7D0VSK6MHDM*:'(#K@$C&2YJ)1^,^
M@39W:CA,#I(#DAGP<=<,=1C]5+B-[I2PH\7;ENY]X'A9^)/30CLZ]/K"@9,1
MFO+(\_^W=Z[-;=M8'W_?F7X'3#+IM%N)YDU7IYUQ'*?UQDF\L7>ZSRL/1$(6
M-Q2I\F);^^F? Y#4Q5)LV19%@#J=J2/3%(D#'!S^\,<A,'N'?G)'XM#W7%(,
M4\M>8O"AX<7#[YO,/$*DOSYTWMM!1 Y^?_2TSRE_:7[V?LG#2S$^5KVFUNE^
MOW;%&JS 07//**^&E^ISS;CFY;9:+<VTU7:E]RQV(F^29;]MY  /1U.M:Y>_
M/.=+#%[G"%MQ_);6:JGM"YPSMN$$$ )VL-"LE$X #Q?C@?"GA!=XQ5HMGT-M
M2S&A5;X[R-#X;:W=4;OQMTP6X$O%;C9;N-I[&%-M*3YUE(]/@.!<3/WME?GJ
M^;%*5_V)Q<?1!UOSUC0*O'C$W&U=\$\8\//)R^7&VW!7C#6#%3&N>T(#/=Q'
MQI[K^FP)V[=RJ64JWFZ9%VKF$=)\0H&7R*VL\CX&14\H[S)DE%C!#SZVGU+@
MI0=CB37\8%C?/'+>KVW]A>[QC!Z_4URR-&.#9VK)\6*W@$B+:S9CYC3A$111
M)^FS#'^6=-.?_D[#Y/#1VV6G';[*Y]Y'23*)^P<'M[>W&MQ!NPYO#HXB9\1W
MF#Q@[C6-#ER:T .CT^V8O<X!>)'1:G6MCF["Q[9I]0XF-+YNFOQWRS+8G658
MG6&KQTQME(S73>L_L6(>20)8L[3@J]^_LGSY:9[^Z@W%+J1<MSZ=I0J)#2M<
M<<XG"O822RS"R-_5OI=!4%6<WZF?&7KS7T\R=_N/B1WRVW_3&+QBNEP%X-A-
MJV=:FX28,I\^.VWW3W1*C&S]4?VI[5_B0VR7SZG]>9@\456N)+;)&']DC 7[
MUT]+X4D3>7+[//E$G#1TN]WJ<7SLM7K&03+F>SCT.EW7N *:;!H5<N31.%NP
M.WM?*F?*=U.?WL;+]&BV]QH?N_DB"3)&;Z3'$NE1^'YGK_E1EO<RMO<,4\^B
M2AZE6S=I\Z>!$N94_5 JLX%VDSJPRP:2Y#E:<J_:@0_NWL+*.:#DGJ:2.=OF
ME=W,73_78-E!RM[^A)%D_B8K',DX;Z7;';O-A09=[_;L VJ:MMZQNO]C=TW[
M:D<R0Y:]F+VR.AZ'0?9J^>(\55D*@GJ.6P$S7C2-@R,D01E(T+*LIFFU3<-&
MR),!\CZP093R-S:-;@EZCV3=!#%.)HQ#/4P%Y$,]3&ZV03U,00I"/4Q!5$(]
M#$%*2I"RMY_P(IF_R0I'DNMA[9:9Z6&MMI[I856F;Z]-NSD-P!2^0]9/KZW>
M(?G*KQ*3H^N(B05,BGR<H_0:GC)9DJ,I,EN-7H,ON<(O1L=A<"V60/G*KKV8
MO^6?+93OY,LDAT/"5PB+%]9[+"VE1[V>4XT@AR J XBB'"<78\[D. O5.(1(
M55H2@5-9DQ!L)+<((4A!CD!24M U$:00I+:BQED(1ZC&+:^J8.BZ:78[\U45
M#).OJF!;0WW08D.VJS2UA047N2HVU\MX<QN=PYCD^U-Z;'77!03)W5DTVZ$8
MZ;!B=BKG'4#DOA>]G9C)8T\6D?>9ZI2 )U2A5  M5*'DA@=4H13D#%2A%*01
M5*%0A9(2I'A06S)N;4J.V*'+/OSI=4?OEL54LL.,Q*K1=];B-'1#[[F,=BM,
MYGK/;I@?3K*=O?(-A$7.U;'O!;Q]LPWAIFM2N2:1YQ,C3W"8)7$-6'++6+ N
MC>L8JL?G-X*QW]2'(PV^Y.>>+LJ$:WKNZZI,>[^FIV3 @WI#B2;-M[$V3 T5
M"%0@4(%0<'R."H2"KHD*!"H0VU$@,!$&)8U-)0USJ'>Z[J!"2>.,T9C=4RGT
M)Z@4X7C,(H>1B[]3OK7W.8V2@$4Q:9+SD>=3E_F3D4?)N4__1QOD3#O'=]!J
M):2H5^N2<"=FV$A%E*4I39)U$,1%F7 1E3@5R!)U-[FA!G4W!?D'=3<%*0EU
M-P0I*4$*[KG)8AZ8PU.QX&4-+:/7;E4H>'WPHC@A8EDFD<>3A.2%&MBJT$7$
MBV7&(?P)KDQ.3\G9.2;N8.(.)N[L4>+._CR)<#/>Y\4?&6/!_O73<FBTA31:
M^6Z\#RP*:NB[WR7G-'#9.,BVQN%+$<R2Q!^"2[Z$I^M%S.'+A8HCX1"NP*+2
M5BJ0&RBWO8BF>CQ9TNJ5D@-EJ6M$JO.PVI\'"D(E0N7N^^E!0@<^@W]=[^;W
MM_"CN+[C,QKU!V$RRJ_3A,])..Y;_!K%??0W.Y!R37N2$'W^/P=.NY/U$5%L
M\?/''Q:+/Y?"FE!Y8=1_K8O_#A?LRE\],$7]7+/F(&+T6Y,.X=9]ZM_2:9S;
MV>EIUIO#01BY\!>]*!:O",+S'UMOR,)G4;_W:W-,[YH+=98W1]-GPZ2??ZTX
M%F7O0^0'P]CC[-2/F \0=</XU9>N*YH&/*IO&EI[LO1.A6UHG59)C37W+=$J
MUKQI (PS@'U]^>5X'6X^#I"7W">S?1;!#X)D%?T>]-;EJEY7@\+I9ZXBVI6[
MB4\G,>L7'Q9-YC6;URJ_OI.5J^@9HAEIFH3%@:P-Q9&EIE[HBODYJYU)[F%>
M&U,R:CO:W.(>%##<E&X3"E,WNN3D[Q1<@;]9#/T7C./S%T&#4!AJ9M]IB"\-
MX>(QCT#TED9PG6+DBCM*U&HPK%ZEUWM,CGDJ,JH%DO423$21B0DQHU<!?"Q-
M6U*O^C%=5SYS9"0<3-=5$(,P71<I24I*@GMV,$%"I@2);L_.%*N.U<T5*VM7
M"1)\A+9>B>*2TW)21%5ZE-Q(==$T#HXP+V*?\R*,+B9&[,6#!!,C,#%"W7Y:
M#DQV$28EATE[MS YGOCAE#%RD83.-W*>0MGYFUB+3!G-F!*94;YHC<R(S(C,
MB,R(S(C,B/T4^RGV4_G[:3ECN]ZO.+B3?'"WHSUYOI/(F@WVQ(N4\U<JL\4\
MYJ1K;[Z>Q[LH=1CY(_3=>.PEHY4I!4EF-B4IAH1/*!PLXV 9!\O[ >$2AA\9
M(X2,G77_^E!)6UYN$I(0D"M=:V1GBXT<AT&<^@DTP.HFE/^D@7B2B0>9T5M\
MS8N$P>S/EK$Y*_^3\F+_Y?EQ&#3()^V]UB#G(_AG;^=4$!+W&1++7)UD ]M[
M6MM"+$1M5J:X(V,(V(NN61)M2K+#NA+R5^5!2\J%$F:+1 ,U]UH+BT2W+9TO
M$FWWAG:W32L5E2\F -)AQ,0A1L&B!CGF*Z$,PBA;OH^??N8Y+(C9*FKS]6];
MFV/T)1RZC("G&(N+_*1_!U"'4<R3XN'(.0N">.K?T,"C"VRMX>N+RB]IK5ZM
M2S+6P"W4I!H$':778"DQ]F#-A2WP'KY *''C(7Q*/6)6K_IQF07YS)$1:7"9
M!07!!Y=90#"2!8QX'#,W4>A0FD-I[B%ISK([YH(TU\ND.:/;ZPTZ.UL98KY-
MV^=0(\9LC[;ED6:#;^+&);-M*GD;J';)<U4[A&$4[?:5<%&TDXI=/X<W;#Q@
MT6S'2Z13U>FTV,-"DLJ7<7.!7EO3K:=N+U"SI["IU0_BK5V;]!*)4WU!\#[5
MJ?\L6'RT=4WES;D/@.8.3*I8XMR!#U:/B1WU8\=23U/>FOL,N4=KQ^X:B_@X
MUBI=X:R92U;!1E(*G(9NMUL]T]#UEMEK'R1CJ-2N;G?=UA77-YM&JQIMTRRT
MS=F W-P3<5/]1UG5&/STMXX0;<M[^:EE6O!\0FJ5@%J+-QKYNXX02Y_<2^K5
M2>J.I2L1 04[N0VJ!$J53["J.<R@IB<A^-1,P*L[]Z!:AU@DD5IG[^J-X9IY
M)HIVFXIV[6I$.ZL0[=XS)Q/M>BC:J=C34+2K+[LJ+=K5G511H4,4K4GCU<X;
M49Z3T)RJL07E.041!Q4[V3D(%3O$)$DPB2MVK4*(0P1"!6Y!@=,-JV.8O04%
MSLH5N%T)<&>,QFQ%=C/RM?8VD,C^#"?LEOD^.:;C21J3+[<!BQKD[.P8Y; *
MN;+;_(BL* ,K/OO]7*3 %YLTCV?/VVNF9D]?Y#R%&Z]VWBBA''9_*EW7ZZ:0
M;<?"JN%FQ\V(;(0ZF@R-ACJ:=-;4C:^*M4X.7._F][?PH[B2XS,:]0=A,LIO
MUX3/23CN6_RV1531W^S 3M.>)$2?_\\U-KN;&2**+7[^^,-B\>>/!+Y62ACU
M7^OBO\,%N_(U4DS1<->L.8@8_=:D0[AUG_JW=!KG=G9ZFO7F,%MZI:\7Q>(5
M02"P6JTW9.$SKY"5VN3KL"S4V=(Z*_G7EI=:*0Z&L<<3FOH1\VGBW3!^]:7K
MBJ:!/M8W#8TO_#*&7W/#; /B1TF--7=!T2K6O&G>TEPF>WWYY7B=HO6X1G4I
M5KP)A^0X%$O7Q"O*TH/>NES5ZVH0E]1Y@;;=QI',/JO:7,U>7?#2X/N:]XR#
M9#S@ZUT:>L?HW;&[7L_=F;+-;TM._DYYHN9IX*9.EO1Y[M- TAW(U1U6*CB&
MO&AV<1 HPR PRQ?MZD\39W%XMY5TT=3'7-':#-XD!L7G&%82KW;NO1N%\"J;
M#+\K;RB=H8OEW@W#M(P[GMCA&IUJ7JVR9YN6IP'+UT(RU'RM2A*'1%I7VB(D
M>YS>D:O1<'I'.FOD&R'\1QWF%QMD(%^C.+PJ#ANVW=9GNR$9?#>D'(^KH>/6
MO9V0+.1CY&.5^/@9^S$A]):5[VUAPG=%/#M;[-E&25L28*VMI,WQMH=:<NU9
M=YV(VZL&4]LKB]H;JBJY!%%5AAZ+4JY\YLA(M2CERHZ^*.6J1L9J2;FFCJR[
MCZQKZM6P;F=E40I515E$72DZ+**N?.8@ZBK?:(BZTEF#J/M"U#5^1;RM(]Z6
MEK9@[HJ13\83/YP*8IVQZ[W<!3/GY V0]L(;AP$E'Z%9M>JS"'#U%36H%G,-
M9$%5S#7 7 -)6D *S*QSKH%I_IH+L,BF=633==*K%%CYB8NHI+4Q5)[X7LQ"
M<@$-%]!8 JY$B)00(E$:59 W41J5'4I1&E6-61631BVDT'VC4&M7%'K!)C2?
MI%^AT"].$HHD 'UC$/VGY_OD7ZEW[;,I8BABJ 22M'QD6D(SJ@&K)<PVU-)Y
M94?:$KJH7 8BY>ZV.8!W-M'R$6Z5AUO3VMUZ \=A$'-Y-1R2C^>?_B!G9^<-
MH%3B!2Z;\#Q6^%LD^)7QY-5).O ]AU#'@<B60+V3H1>-5R@6\1'Q4>DXHP8K
MU@P,:TB!B'R(?-(V1^W\2Y4U8Q&/$(]4\TK$(^4;#?%(.FODPZ/:YBJ:-NIG
M5>EG^4YKY^$MBZ["X=51DH11P*;K%*['-2MQ&:Y8%9?1R%<V9!$+'$:\F(RI
MRXJ7L6.H IJD$2-\[SPR@K.2$/4J!#*Y+$0@0R!3U"0$,M2K4*]2A\;P95<D
M)B0F)"8E&PV)23IKY".FVDI8EH$2UGZD@%G&#E/ >&4/H;K%&PY\O<#("QQO
M0GUR<L><-/%N&/DRA#-81,[3*$[YFPQ)2+ZF/A3 L&C3L'^FOXB7&XR6F_\&
M[ 'G<PWN BX2>8D')Y_<.2,:7#-RY(B<,Z-GV0U"8W+DAA/^/L7B]5&E0^:4
MRD)D3F1.14U"YMRM2G>0T('/X%_7N_G]+?PH"N'XC$;]09B,\@LTX7,2COL6
MOU 1)_0W.RBY:4\2HL__AUL:=B\S1!1;_/SQA\7BSX-\TPG],.J_UL5_APMV
MC3+ ,$537+/F(&+T6Y,.X=9]ZM_2:9S;V>EIUIO#01@!*?3UHEB\(@B$2JOU
MABQ\YA6R4IMC>M=<J+.\Y9L^&R;]_&O%L4@4JC@8QA['G7[$?,H!AU]]Z;JB
M::#7]$U#:W./AE]SPVP#(D))C35W*M$JUKQIYM.HEU^.GS=Q>LE]DF/7,?P5
M7"%>(:P'O76YJM?5H'#ZF:N(=N5NXM-)S/K%AT63><WFM<JO[V3E*GJ&:$::
M)F%Q(&M#<62IJ1=Z?7[.O#/UVIINB1;:ULAN>Z.O36-V%6,>H'8Q(+!TLUA6
M_()& QJPN/GESF?3@N%-73>UK0+Z%C%X6["Y3<K;%DMM$V*V1 ];?&PKH<C@
MC)<"X@UF:*/4@%(#2@WR-QI*#=)9(Y_44.?I+7/+A"0[FE0PK[2SQ5L?F%?Z
MX 44/L*G*N:5GCJR+6<6"@>Y.,C%#%(<3^-X&L?3]3 2Q],XGI:KT7 \+9TU
M\N%1?<?3IF;\ Q%I+\;UI@+YHD:7_%N[T(ZUV0C<L%KZH\/TGMZN<)BN*HPA
M<2H>MY X56PT)$[IK)&/.%&00]J4VB3$HUH8B7B$>"17HR$>26>-?'A49T'.
M1$%N7P0Y^1-M4)!#XD3B1.)$XI3<)"1.%.10D%.'-G?[J$5B4MA()"8D)KD:
M#8E).FOD(Z;::G1+AODL <N;<,@1=]7,ECC)T WM]/,%,E9UC/6?=U_/R&D0
M)Y3O^O$^=-(QN"ER$W)3]18B-R$W*6H2<A,J39N3$.I/4K(1)H0A-"$T(30I
MT&@(3=)9(Q\TH=AT<?PG E7%8M,EO0N#<#PE)W<)"V*>"77AC-B8HOJ$("61
MA0A2"%**FH0@A>H3JD^*P])^J4_U(R3$(<0AY1L-<4@Z:^3#(=25CH_.$)7D
MTY6.J>^D?O8^WYD7?!O0>)[CM-V]EM1K*"0F^<Q!8E*^T9"8I+-&/F)" 0FI
M2$&3$(<DMPAQ"'%(KD9#')+.&OEP" 6D]R<?$)7D$Y#>LZ$7>*@?(3"I80X"
MD_*-AL DG37R 1/J1PA%"IJ$."2Y18A#B$-R-1KBD'36R(=#J!^=';U#5))/
M/SJC ^:C=(2L)+\Y5; 2@A&"45T?0U* $>I$"#\*FH3L([E%R#ZRFX3L([M)
MR#XH"FW<>%[0'&7;E1FF]GR9Z/SK"9*2?#+1><1B\. '7U13HH81W"2W",%-
M=I,0W&0W"<%MKT6KK:"8C1A6'88=AS=\!U]ZS<@I=S_J)-X-\!9-*/G@^8S\
M/.1[ B=\XUX:PSF^%S#"X>T7G+E#")+-'(0@V<U!")+<&ODAZ""A Y]MZ^:Y
M14V?#9-^RRZ*XP50?TF_*8[,BT/X_X:9?7AF_8OB%]\9A)$+7.2$OD\G,>L7
M'PZS/_3Y6L*/8!\OKO#!D9<P05BL'X2W$9VYI:FURFH[\>MM!H&#T'?SNFH.
MPB0)QWU>5<4A*.,ZKUV\0L!APX<S?B4/>*Q*AIP&+K15 D6!0@!F<16+.' F
M1RT21O!Y/&%!3),PFI*)3X/&TI_I=<18+GVM$V>+SH!.]7A;\+YHVH=U<:VO
M[-J+P5' H4; YN'8$Y@^"2,NGL*!(4E&C+"[$42EA./[A$7Y22F$MXB<)FQ,
MVKKQ\^"7GPW]%_X-N&B^3%A,+IH?T>NVX'4=O5MWIXN=$7-3'TI( [=P.7"X
M-(I3?FX2SIV-_O)SZYZO"5<CE^"M"]<7H2_F7QVF4>#%(Q*GDXDOHB'U_2FA
M$"DGT\+/'RD*7(:?=7%R3-()W#%B?Z<LWJNPNHD'_&-G#KI):2Y'7DP<7H=#
M_A3EG@('7/Y$=$D0)F3H^?!I" ]*<+5)&#,1]F+FB'.-;N$<)W?.B ;7C!QE
MC]40#D:W7@QMFP[^"Z<7_N%[-$.X[)LT*2[6@/M%)!Z!YQ&(I@-6%,,+G!!N
M'5'N?(,I.-:018QO(>L%<%$:3'DIH?KRH"N\D#EIY"4>%#<OT/U":J5"[_?'
M$"MA8]-!A>O=_/X6?A07<GQ&([A$,KK7TA:_:S%"U]_L8!AAVCFXZS-N-UKZ
M0K'%SQ]_6"S^?%,/WM_#J/]:%_\=+MB5:Y^FZ*_7K#F(&/W6I$.X=9_ZMW0:
MYW9V>IKU9AXE\F)98BRA:U;K#5GXS"MDI3;']*ZY4&=+@Y;\:\6Q*!-D\X-A
M+-9LZ$>,1]H;QJ^^=-U9CS,-K;TLZMH&#,]+:JQ[0RIKWC1O*1E!'_KMU>O+
M+\?KO%-\+IY(:Q]2ER)J0P<^AK^"*\0S3Z6;>.MR5:^K04H\][=75U:+=FW#
M&5X9[K!]91L=XZJK=ZTKM^WV]*'9:K=ZW5?97;-O\&>@T?X Y33TCQ?I&&IA
M>M6QK$[/R,\K]>&_;@3+B_33:Z.M'QIM+?NP^I.7.#]);WXD><FW.1N_..@V
MN@^.N>>(P =54W(3^BD0003WY<'83UT&:!!G9>1>X 69B.WECWTORB+U/:OF
M3#RK#_(7 \RY 8CVX2F0/W,@J!>WB5-G5-Q)KMP$U<*Q@>$8P_$+P[&M=QP*
MH?A*M]S.E6V;PRMJVNTK=V /[+9I4--<#L<7IW]\/KK\]]>3"XC;/:NEEQN$
M'](Y[P>Y>=&J";+G"R,WSJ9YW.1C+X'8%QD5YY'2X@AKM'YV?\D.W&/<9?H>
M$J-GV8W\LDO#21BW38E#TQA";<+9OXCUV2 Q <86 AH4"@ \AIJ$$_F@  HU
M8,#F0Q[7^85%,,].$'>*6,II7-R ILDHC*!67.T)@NQ"7?*.F7=*[IY.YM9%
M8!51 .X1%@>R$"".+$6*1?DY.V<U%C\XG,Q">#$?J6N]GO+3#TLFM37U9X>6
M#+)-S5:FC1[/.%':_Z!C\X._O3)?;=1TN[;M_.CBXNB/$_+N]$N#G'X^OJ\(
MU+=E,#)(;I("_O<>4*%//M$(!FA6@YBZ:<KO8^^F_6?Z34XMA9@ZN2-QZ'LN
M*89).S7C(#X@[Z+48>0/P-YX["6C!CD?:>^5\J#:1;#/=,Q>Z%]\8%JQ<[V/
MM/7.A<_'2KWKTDO\9[O7;G->1QX;PI@4QJ<BV?7+<.@Y+!+3A?SU(\]=VG@=
MG0EA"V$+84MBV+KPQF% R4>XDU)^4[NX50_$0G>2Q)U48ZH/7D #QZ-^P515
M)K%D)TXV7BM)$H>4I!C*32";.(&,$\@OS><Q7,-R'/NJT]&M*]L=VE>]5K=[
MU;9,PW:II5-J+DT@GX>W++H*AU='T!6B@$WEF4 ^__+7R5?RY0,YNKS\\O7S
MR?]5,X]\0F%,,&%1' ;D=A3&/"L2VLES4WA*\/E9FJ01(W0R@0;CD[A^>$OX
M=.U@89XV2^6%<T*/3S^OEW\:BQ@LOG#B7M.(O-/XYM>LD:4#\^)D.:'C!KF%
M;Y-AZOMDPAM2I(ZF@SCQDE1,./-O1&SQ4(.GT?.)Z3#BI21)E#)QFD]OX4*$
MYGX M0.UZR19P:_S.6M^P L6OQ\ ,#;X:Q].=IDX8=05G^!T)B0*7F-B2IN?
M*_X$)<LGNZ' ;%[!C86ZY=/< 4].S4YP*'_Q.IG"#;(\55[/C>)&/(M6)*J*
MTD)UP)T"-YOK%_/_4."C(.!-]I7Q]PMX$>YE3RU>BI<V%I:)&N97G.=A\\9-
MPNS>(@V7N/GJ+C$OKA,&09Z^*TZ]%2TLKG,OJT T<9%9<!R.QUX<BR:ZYOD$
M6<(ME"BFP-'?;Y=XT0'$T<SKH*YXOD HCD']\A2RK"Z%'P& 34EQ(:B@X+I!
M>)K"<%IX'Q@R]**Q^!5ND.42/U86[A90V3.78_S(_+<LX2WS-6AA*!U_@XCG
M2^0I$6X8,)X"<>-%2<JR&@R'&GDLG6/#A TH6I0Y ,_6&# 6%$D86<?-DR^&
MH0^_<<LSQXR77?9>XD?NI_QH[J9%ZV8^0%SQ_I27OTGE5I1V6-ZK?E5EEA0%
M*]9PR,S<;)!A @)9#PTR%A[&"]?GRPT,P3>*6BM^;_)7(/H9<-U"/3T*.CE\
MBAL7I](!#)JAEY0,.%L9;2R ZL:O%UM:Z\%5/4JN\M5Z+E[4J%5]WQ]+=]'-
MT<UK[N:FKG70S;=8[4]42_.G:=43"X\M(SI8NLOBR)2+QOE8[NW!8!-I=?/^
M7@+IV9K]N!,\YRVX)S]95&YR(4]C<S\EPJK<W'R6=[FUZQGE*A/M'RG8!FEU
M:G:_LH-K-5.JC[3F+-.H0>XE)&6BVF)6TGLO8DX21MC0#X=5*1M:I,5D;6HU
MLG^7$V1>%$4E,[F],C.G5,1:,NG[KKUJY6[BF43-^M9;,X?G)?!E!_[Z\WGD
M!8XWH?YJGN4O;P\\:8E15@=X=("^>P=X83[C/3D!#.P^0W^6EB57*^R[B7K8
M ]0,@=_)>1+$=EPL"<1GU2*6T&B*#:YZR-MSDL/@5:/@M3&_S>,;CVM'CA.F
M67(%XER=8MNV<<XH-GBH-<]]HG=\/X0_PEL6K+R%B%U!S= HN]HF:TO*%]3V
M'-@P.M4P.I6Y?P4VN(1!;/MDUJD_F!TE(P9CU6,^6 G3R L3+VZ03Q@!:Q !
MD<_J$MKVG,\P2-4W2"&F[5DLVS*F&3VM5W],NZ!_>P-R&OMTC#U ]9"'7%:7
M6+;G7(91J491"4%LSX+7KA;:4Y6X M>;D(\4"N-1]';5PQM"5UWBUMY#%P:F
M.@4FY*X]BU\X3_D,'#OSZ)A\I8GC>\,A$]H_9FK4) (BFM4EM.TYFF&0JF^0
M0DS;LUBV;4PS-6,/$OW?LRABOD_.PPC.Q22->@0_)+2Z1+4])S0,3W4,3\AF
M>Q;%)&$SB6J$L]=E."9_A=YMZ#(<=M8DM"%YU25F[3EY87"J7W!"[MJS&/8R
M[MKK7>U<+Y[X=-KW M\+6'/@A\ZWHIV-MMB!#+Z1%ZBRE76_7_ZZ;H=G;74[
MO-S$Q>WI\D-+N]/EQ_A#V\KZ]?U=]&Y"SUV_B=ZK66D'H3N%?T;)V/_]_P%0
M2P,$%     @ U3MC5".&4O]UR   >Q8! !@   !P87-G+3(P,C$Q,C,Q>#$P
M:S P-BYJ<&?LO =<5-G2+[J1K B"Y-0H44F*Y-0HDD2)$B2J@"3)()E&$)&<
M04""9"2)Y"PY28Z2<\XY--UW]\R9&9SCS/G.]]W[WOV]=UJ;=KMJ5?WK7[7V
MJE5L0 XCIX K#R1E) &T"P" !OX!D*. .("#A86-A8F#C8V-BXMS$8_X,MZE
M2W@41%<)B&DH(;0TE-34= P<S'37V>BIJ5GX;K#=NLW-S0UA%A#AYQ+FN,/-
MA5*"AHN+BW<)C_SR97*N:]37N/[M%_(K0(B#EH_>CHYV';A B(9.B(9L " @
M3DRT7U[ /UYH%] Q,+&P<7 O7@(%BJX %]#0T2]@H&-B8F" HZ[@.(!!B$ET
M[?9=K*N*S["O6Q%SO0[YB$-_+[^61*EGB^'.<VL/W(ND9.04E(Q,S"PW;G+S
M\/+Q"PB*WY>0E)*6>:#\6$553?V)AIZ^P0M#(V,3&UN[5_8.CDZ>;[S>>K_S
M\0T-"X^(C'H?'9.4G)*:EIZ1^>E+06%1<4EI67E=?4-C4W-+:UMO7__ X-#P
M]Y'IF=FY^87%I>65[9W=O?V#PZ/C$Y1?:  ZVF^OG_I%"/IU 0,#'0,;Y1?:
M!7N4 "$&YK7;6$1W%;&?65V]SO4:A_A>R,?\6ESZ.TI;),^M>RZ2,G!/,VZC
M7/O%L_^:8Q[_+<]^=^P/OT8 /'0T,'CHA  4.#QA27*_B'JS0G2VV;V])?)&
M25=D.%)NBY,457S;^$ID^0EWZ>9@6-9WTYB7:B<N$V:5T6C%$72>'CC"'CAT
MGF)D&4G^W6@2Q"] %50:VY+1B5I/:F&LR>.M7X2O"4#[3_'BG52_"@"[71F)
MF$F^6:X9FLL]4HSUMYXP2D==E/_6P'+V"-!(\NVJ&*0KJ)'E\[6/F JUFF^N
MN/F^Y>M<PONG:&*4Q,IZ5@PF4[?PT.KQ"/=I,@NTQ,T@T<*91/J7.X<IA/$+
MT1A)\.Q9V1NZW\TKDW)U4%S\CE@6AM2G/A+#)%;\ZS>7*NO56RN8HLD)9[)G
M+!?21PP06_",TX<U$Y (L8W\9*'/*HJA\F(W ])R,'<Y0TAZ?!!SZVB$-3TU
M)_UH60?1L$KH3=$^SD/O><6G)Y V?^I9;-'WB;ANO_R7U"_:/E&R7+ H;#^;
M/E;\5?ZM+Q"[SH4$'-P>NZ;I;A*T?4QR%V@/(C+Y/"9#8:N=+8GW/!D)O$E^
MC 3B\Y' 9+X:7#EMBA%N6HNFW[QD&I7'F_+IGFK90G^$M$Q6+'0KW"1A=Q!Z
M>L#RPR3U_L?.3P[I1[K*"I  KF0F$A#10P(USX..'O#('Z]"SDY) B1H!UWK
M_TXBA-J"VX_:Y,GP%-I$FBFKEP$69[5ERBVZA(>>OFZ]Z:]XE))7.B"_RQ/#
MZA0_P;K4D<#F<+9>;>VJ!*>IZ,Q!P<9+)/#'2#*"*$ 9X=2,!-P:]12EBA(L
M_T](9*1O2Q;,E81QWQ/CNG-%(+N<126MW*<_5G7!0'D;NP$(-O"D1[SWE3]2
MUT "\ -/!-RW;=!,.+-R#T*_?\ 3I>//D$J5O+#Z?#L\;6I%1+@S'4%*6@-R
ME AR=#WHW+3YC$]<B.Y&6%?S89P\G(T=AG"^"^*2@&Q]+D("Q^O89\<D[8IB
M,*/G-8NSIW^MI[:PSWPS)'Z"?26;.+2MYO:2 #U3ENS5>E:)F\1V_ ;//"YC
M"IO?YC 44%]& M//3)' [@C!Z0X8=B^O/"30903=;,G52" VXVXE>EKQ63$L
M\!$&$OB'U=B_LKJXD<W!UKK;S8+?,W<+RO6!,E#(\47@$T+K?*#3&@O+ZJX%
ME;]\1*>:X'FFH'^89XW,'.PU_!*ZAC:7_&YX\4.P].Q68D1@8U4:8C?I/+3D
M\PC*3%C(#MZR(MR@E2NP/Y3=% IZIT-/2.KKP(=O-8<>LY"1:'J[D1EFA-B5
M1Y &^2"!Q:H2!#IHW^@H >$\"IOBSU4](&!Z^7J'CWXD2TW(6FY(:#8PC]&.
M]Q5LJ]!%'K2W7K-%K8@$+DDU@$8F1I$ 6J-5N-)"E-69#2%\;0VD\G==R>=M
MS+(DQVC7K[X/6C0T_'$ZY)QF-7HS,Y[Y?M7![6BF"(_K^-GR=]6:O8M$3A^5
M HT,'RL;;[8E../A8@3)%1ZG:%GQ9[IPO9P$:4F>@1UOFB$!]YF@(PU19G#5
M'DP>X;/Z)T5Q5X3L?Y/:+2CX&ZDLGU1=F;36C)SL!+T C\+ANKD/>I-;(-ZF
M?/6HPN@^<"'T;$/AA\5(X*N5%)P=<A4,@K,%')ODV\@R7U1DTPQY?_."HQX'
M&;N'\P&@'S] ,A_0F<#_=H4TH,T;"+ZKW.W!3S^FO!",*/"5C8T>7OD;FE([
M..;^F<M/AQ!BN!H%?@GOJ!/A@5VN4D@X5X3(91[>^.1 WG*GCC@^.'L-*:RK
M,>^7>)H=%2#<V&$@H5=6%-OB^T>6!:N+-(^CQT!71K<-X7 P]WZQ/.D'79P9
M0H7!LE^9('L0\<(>NE4,?X($H*0U1_BHU5 RTW5\5(1R78N'&'O0%'9'*.%(
MTXT-"23XZ<*QP;O4'QIS*2,>5V J1C(#3C'HJSPUT7'-?X%+@.]MD9\C(<.7
MIQW,X;>O7X'D]MZM2]#S;7NJXAN/P\_M:[=-.%Y0^H-]J7.ZIOM)GW["94Y$
M9PK>'GQ?7?#WSEF3Q;@V>H<<>"DN-C ]Y+5.YT>HJ+H[Q+0[WBG[:Q,9B;I/
M<N#?-F#G<-MOS<Y<[GJ7F]Y79.^W[C!YZ;H9GI"_TY#70(Z00H)L_]/J(NLP
ML>G^()/+-_1N2AJWCD.>]#QQHQF<VL;W-LL8#?$A6]3=*+'2"*?=,<Y*S!,=
M1 )S/'8()+"7=_?\5:)A8H\$,: H08S6[# D7C-89''Y+% V@^A2LV-NCB^V
MU\.'7'P7!(1M14R%'>@TCB*;+DGGP@IR7C+:1BR^I$IFL>SRX..U=B3/NYOD
M[A1_BWO=4+)WHPB[H+^P=;VPW6O @H-3G'UNWC( \LUY[FW=+/^G&*RW0\6]
MZO68:_:+BE\B3\8OW:<O7@QV&1*&-\"_'^29Q^#D7G-XX</@TS0DI2!.<(]
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M;XM1&\1%S%?-;=JG=MG9S4L="/ ]TU,DQ[QD.']<D*!UF"U3R*ZL4-BO9,:
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M;PQY!1]^5"\\2T_/\[U'C**<)+O8Z7DC:UNSE0&1Q'PX=I+7V#!Z=TQODB_
M\H]WF'K9VU'I\&\?/3FZT\MX%NT*9FADUTL\B%_6$Z"/'?($Z)A?=^GK^[@P
M<].F7>ZU!+$J%E@0*V#F"$3PD%,,WWP[%_:Z-V^$_*GDV^DDT9>CQ9%X +#C
MK,I#8A7GYY]MVE0<0,VDR\2M5HMN/#GT(5"JVB$-K6&TNOW GX!U0X]B<12J
MT9Z4P'\,#PA]J2-%WTHK@V_E#@D4VU\(B>E;:U/E-M"GF,<:ZH*NN]&PTOJ*
MI <[R],_Q>'8O[%^H2Z_AO +"YI5E^)Z3$>Y;>B*9,"]-,M$/*N'OFI>)9*-
MFACZ3I0&-QXL*45T*TJ08& 2*T@#H9:8@,+ ?* 0DQH0-2VUGVN2L\(GN;+\
M'A+BH+BNPMJ;C"^]XM(I6)ZC4O2E&^2H?Q9UB.#C;J\P-;NXV*42T?A-+M^Q
MXM)36B<B"2W7>[W;MLMYI*-\?!Q#7HJR7N-?F3-(VGND-.,4&]MN*11'GED@
M 6#)[D5?2X"^MS'^<.CXQU:=6[<J]<9VY=Y]#3;N,#+#0#<N-;Z(B[ZYF-?1
M1\/?:!.N4$C5J".G51'W(73Y[9,TIC89/AU>75-S :H[J^LJR8(/\RG,)3(X
MC7'#GBJ(.[Y_B=93O-]H7:@0$< 8:%;25I-%(W0_+Z-3PTR0/UB@A)"-34O_
M*=YV7X7-8)2&*?F:';D9@Z>IUM>5D"]3B+4-.OS;82-E3BS%D8PS>\92SH@;
M>?V@Y_AT2;Z2UQ[G\P/ZW9B/)/KO7?'/%Z =B%*2OQ'_PJ;O\QX)C4WK>+P7
MOW53K03QXQA4OE-.D$7R"RNGMG/[4!M;>\4- \DB,B*L]C)#B61<&@R6HR-W
M,4?3X^A@O%):UM+ (@!@+VH9$&^F!BP_9Y1AJ!A;F]:\%%2@G3UX>XR*)<8H
MDM]Z<^&*@\OUX,2K8X$><1GB*>3[1HF\EG>I>X65Z:688_@;GKK.B[R*F!TL
M_<2RP+DJJ!EU@B@1G"3BC2P.2PV_PBTIW9&=L7TA,U"2;/'EX7CW@"OCDTK&
M[*;>!DI=YM: 1;&.HIUA)1NM 6#*0S!P3ROJ7>7Q>D]>Y7)N]IN"91T('Z%F
MMN)Q"='#6A5]J])%D;IU\OU/;HRE=R8;LL@#1W!4+]GMJG0V;C3*4# S;V?[
MI$7.&,884\I0S\=URH@N1,M4^-J%/6)$ G@>OBR)7UF2HMGBM0PJ#CZR+N%J
M#V?9UJ8"=C2/[MX5$! QRBW-8J4)454%4^Y]'2A](;7HFODT@SN&KXQ(649&
M6MQ[VM>B9>GM,\N%TR0E!W9-B05:76Q)]Z.,9C,NDNV>#'"=D V'*00_V0B_
M)$,G5O80RN6U'KZYJJ5-'.DMVU#BG-S#;KYW!E61673EHHOQ</59;S"\8A,Z
MZJQ'72*0L3?JC,O!P="_L;=(U'XK\E;Q%$MSFZRA\'9 0H#C&7GJLS-#[8!)
MHBZ\^@<[J3*\ZM=YF[!-#4KYETPO^M[XL!-UIQ3<)(F(%;6Q/5V$F'TJ)3"#
ML5NP7=:#RCWS%GL]/I()L.2F9\'I>CG9A(78YQL"\[6KESZ* -3F<-.>3_QT
M()M37A>D*+U4: ":FP\(4E(?*7OX+I$LCDS"W^;63"(BEGA^_W<X):VG@DZC
M%4]*R(@6>^6:J(P&]-8-)&!/#XV3EP!L)K^[@:1_# 6K4DSPW.F7?,K94+/'
MI0F6)(6P;;ON'KF9_"Z8P5$4XJTL#$X:A. (6JLA0@+=K>"*]>A! HT#9WJZ
MO2Y0#!N3$:^J#]:\#<8)1GK^4RJR-90.)G5"3\R+VG&2*QYM"3V\?7V1 KN/
M6XM-ZBQJ1O>$@AT);&E C\JA7^"R2$"<L09Q20H)D*GM<UY9.A'Y8.\4F&YL
M9L%Y4L88#B"!C1,$">51K+CC2WIMC8X$!8P1-!;15X+K^TG3^H\1[=N<9WB1
M2."('0+7AOS)J1P*G@X.=N53KD?WOG.^D=1#ET9_0Z-)&T$2Y5,H(MGFW"ZB
MT69J:N.3*A.>#5,>\?/RA?T]+<]UB9<)GPQ/L _'C)R(!<M>C%)EF!6@R7KA
M]_E?L#4DKM@EK-I=V=<2<M^3;>,K(-*:-*UWZ0?UMC]HR 7+1(F42S<V*1'$
M)>XO9*@C+HK(.3L/Q%8I-34-"F5EE3[WD%21H?FJRGXH)GJ<M,:FCP3^#L)@
MN<DK+A/.]-0Q=@>?!>Z+4^6Y5J%"%XLDZII%_C8PVI>)M=C^5<;DVV=H#!=>
MF-%^ZXBAN"6G?C";*CJR<JG=+GY")9*I<T@YV-(2IBA1U\1\H.L#6](O00*U
M1DA@9NG'$%JT7I>@DJ''E*!@."#1,)/KO,R]PB57HS_,L/N8Z&+\&[T<LDL4
MT'^1O%AX:-@>7#=98RN<^2M'?908QLALJ/'"W%E*GY G_*O$_]]#QW];3UI[
MFD.P9,-1X)@_K)L'=E2^M"* !/IK>OV\ I77:.E 60^4K!\8T9X#@BNP[EI4
M@!M!*E=-/EU6JLVM;BNQHJBM%9.IW>MZ>&H(KCN%4^QWT*6G*,J?(X%M6U?/
M!LC>+134?-! ]4B<[Q.15>T&=H7@WL5Y#&K"X[ZKZGTZ;;*UKD"Q?PA#]N@]
MB/B'YZCE\70;^PR/%(P5FRZ88)\=/!%O+X'9Q@FZH['50=-P@YN#ED^AK;WG
M]<:-/2TV?]T?1*2&A>^"!&""!)"AEN<GEE+UQK_%-I($6F6=IE)3Z-66ZW1\
M?L%=OH]:"5P9$ /PZ$<&B0%/17S:V]4!TZU$E\KT0Z<R1!^SEKD?KK%>19 N
M>"(!45#QX3KLZ-.B[;+N8VLY!W4AF:S8FBWO[^#IJ7FA9EH*?NU =W?;ZCCO
M2)4,SMZ!C7 %^=P< ;$\AM6-=<,6P;,.XBP/"9!(,=(V.+^$V)K_:!_RAS)U
MW:T2;LCQ?@T2J#$% X3J0-B +B> _IP>U,!5J,.=L8MK#R4W_[ *RN"X1L'A
M6FZF"!*O/T^ _$EAJ]3G__LAF&Y;B$&=)N"P44;H*8\0@G3(NV8Q  F<'>LB
M;@8^$/%>_QS74W3.*'@X/Z<*S(.ZD:U#^#;*).L_?#"MG]QM B,!_S425PZ&
MY1<DA_[PX;'-$5.;@\8=>]N/I8P/%H]5Y>'L>02P+BK0BYU?O"BN%$$"PJC@
MMJ&"RZ*DX=-?6_2BYXX+5Z\L$<>FV-Y8)6RV,&$KVS;O^*P*WH<$?#)JILT<
MG!$.X(J;C "76 8(KVAZ\W@6A@3<U)" ;X[ [-C" 86A/KBR+S8_ &D;G>R
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MO[U <USND!6[\A?:]R]ICV9W7)*_$B'VW*M)C!F8717#/:?J''+EGK_4LJ>
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M]L9_-@.K3+9]*$BE,F%]<,3'U!D:-RVI6*[C0&T_6YHG*]U#3YCT*9'\(A9
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M^9[>VNS =+5\7;Z+8\\Q B4I%7'PL_)NXT'VW9Q0@H6-^QL_S5^@< &&N>B
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M?HCI5)IKJ7TQMCOA!;%> 0;'SA[\9_69[A80JFAU"]#&AM?;GY76R;['SVI
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M.D1]H"57Z_W>6NC^8REG%DKV::I.[Q[L<-I+S >DT,'K1KCF[ER9AX@@/XG
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M SK3:@+]U/7N 6<JE_6?LA0'4/Q>S4R1D3,.%;V@I18W"(@NZ,N84^6:6DJ
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M<N ^=T[F1DV;44^B.\,[.66!?_9I&JM53=6/$5'#D6YU2F$T%#MQ>8^O"SO
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M!1_5/6(\U+U+C,G],\&G.V=_SZ>,!!; 3?CRD&.S!B<X^@$ W>_^ . 68WH
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M:T&<,*]*$D]\]-3( HK)+N;V[( %MOG5L6 BAZ;<N]LX+<A-&VO0)FF.AR0
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M- 8JU3,^3=5$C=LA+R[M;IH2 'RT<#_PV<U*-SOV0)82^J3FE/\ Z#38N7L
M;*FY__R+&]>='UD2[/^GYV?Q^9'!'J;^!U!+ P04    " #5.V-4@QV@^8=<
M  !J>@  &    '!A<V<M,C R,3$R,S%X,3!K,# W+FIP9^R\!5A<6](HNAL(
M'B1!@P=-<'<+P4.PX!"".P0('M)(<(<  0(T[AK<W=U=@P=WZW[DY,P<F?/?
MF;EW[G_??=]KOO7M9JU:M5>MJEVV:C=L"K8$8,E(2$L (#@  -W] ;!90 Q
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MOG\:XCC;%,]9&+;L;U/P.%**NOJ1A\_;4H,^%2-JSVX.T/:)FI^9$.4AL[^
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M<H\1Z1:T[-B'#D5(&/_!XU%U:.^KM*^/CMJE;SL.?=^H!YT\@L3UB]_[T9W
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MP];)+LYZQB#1^9_[^^]LY^ ZW=SB<1]4_RY81/_Y+>1G_Y,3!?@_W1#X\Q2
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M%N\P3"3" &'92[(#B&"Y\+JNRX? E-ORS#L;.O.A#&QEUGA\B;_Q.]PV+V!
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M?^BK].S@D@P-YA_N[=>"1VJTHW6 6=6?PN50S-N6WE-HHOPEB:I#8W@S_(D
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M5LUZ)MVR__/L_'MGI*'\"@)6K.^P[X.XX:AH4N\R@>+>O?ZG*8>[I+HZ[,'
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M1"K3P,R1X(O4(@9R<NO!(04#@A+7@-L91[M$T&DY).JLMNW.P=?^UOU9_IR
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MY[E_5_ZN ZAU-.&: " 1  #\=P!_\0!U "D)"9CD%BD8#"8C(R6'T-^&4%!
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MC):),Y58YV',FS/M.4E9,1' 7X $9QKF*!E0__3VOF4^C?7WGL6V*_V/:(D
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M2Q^G2(:._07(X=$?X-(N5)#/AL=S8LR7!A;BC/Z3/GX[,@LWJLXW[SB'PK,
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MSGOKBON0YM1] 0K!GR^%*>N"_=ONRI L%TPD&*GT1F]->HA'I!'<G=U9>I%
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M9K(5O=%R,)9[%%E&'K9%S[J.N::S9.\D5.2"A],F_IXZ>(>#KCTUL5IW.M6
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M;-?#YXECGF.6=?L5O*PDN=Z!W(\Q!H;I%B$I-=+"=M(=$'I;Y:<6&Z;6U5M
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MWGP.%(3F>5L/*#H+\6X993:[/IE?O_$+)#,_[Z*4RR":K:&R[4/2/;E_2>C
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M;N@2,V7)W94^?;G;Z'9A.)9%WS8%CE!.#/98GS$0DI7_WB;AE@6 4<8$=PL
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MU(S?A1F*P7TK_L7""B#K[8(4BX.PH=%D-RW-.\'[)C41D5JM1^"_'UY4W3_
MFR6V??O/O[-4ZS>\%?2I;X?&)"\&F<3>OT7BI'4YRM#L^(-:^5']X8V\._U7
MCT#VW;N[^XY-%7COU"/P@^+](_"1X)[ISQ3"ZI^A^9/&\*S^,QV&_K4P]C*6
M8G/:$C)DR@"E-W41!(665VX,W],]DD4ZC2@Q7<KJ_M5M]7,RR;QR9%JDH!DM
MVE,[?[S7AZK5CH%\^$F;BVZ<^G5J  H*"\WK,X;H)!>V78):9'S%26E=$TG'
MYACCM/E*[EY1RH[9>I>F8,($6\6&\YMN,;KO9K65.)\%'9SX]U;\A$3KH_]Q
M3:&4*%)"]QNDB;7->9\EPQYKA<K13JSAI1B3?HUGEJWGH)%C5"9_#G9:>!^\
M.QL>T%+U<!_S"(3FW:'[WF+O=UR?B\'I_7@MR^T/G__&3:CT-U #C\"O<+&O
M1;^%?ESV6\R@WZ8 $Y+%?SJ'TCD]ZESJU4/82N&;(>'EJ?YN]_Y!<2HBHJB'
M(+$'5-=W=S<TCP">W!7A(W!)->M[LN5[+P/83NJLSK_^W:6Y:_Z68MPC<$;H
M:ZSZ"$@L:\/A<H] CQK*Z'\Z!_7Q+X81GIB".\7F,#<+^;-62E_4"L!N4H>X
MA6JO/G3I("TGW7(%N7I3Y!'P+_S35^9@I;%0_!&KF'^"$["06]WQ3[#Z+^"0
M63OQD_[9W=O&$G\&8^H%TVWNWYJ.:J"9_?^F.O\6AQK6R[L#-DV*.\G]_=$<
M1]HF,R&SI73'(-3"V[E_,ZXRIG>[R<YB3]K'SZS.]BXT#^ A%+(W#8@_100S
M/O+,UWO/G.%;I6A]958AC.\Y'=)-I$/:1<9\[VY[J[$O*+*]TVA<+.-+^=Q"
M 8_"9[$1L2)Y28A&=2RUR+(Q66]V^1X6Z(ZX'2VE;SR+NBR^^)701V P!VOH
M'X[W?8$6^1*H%JB8;W51=62E8#$]4\;%&1+$]LZX>\VCXO,S2A:.9VG2&&#L
MK]'/_7Q@.=*!JXC*22#7$'W#'O=;'MLAQ.Z4PJV!]T$M5G6TM5*N@#UA/0*+
M1*.IM59+@E4!-\8;]Y/S-/@63IJ#U?(/.]+KSY3CGC4R_ Q92%"!B5\$D!$&
M^#MV7_Y\Z?[]MAG*!D[-KV.M\$\^Y[;=Y(=T4L*)9-HX'(5A)2TS6O*N3Q#B
MV*X(6:[EA:)]\48M+6^%TUQ2^$A(+/;W=^U3&9-QC64!=.Z# W'RNK_X/Q9(
M\VV'@N8Q@Y#-[IQ?%3:91.+Y5U/B<P=<YF"_@^,/)YT>C16(9E.U?5VF<)?+
M=I)%Z+LVXJ=N0JEO$RO]5I\OYW7&ZCWOIQX!\G-L5D"B?6!A$&9TOWI:L3V+
MMU )AT:RB:O=;'$="Z4LAL]/\L3ES==1VZ>=@!0/<>F/3<=FJ5#K :N_]+-O
M2"!.R2,04+1"1Y"Y4]FOV*</S%Y%I3"#=U:U^OJ&]?DU[)-<A1MYWU!D ".9
MC?3%SVN-C=6-$$D%\\@8X1N=F#*4Q7ALCXU&%Q]I:YAF^X_(_IU*18+,HB]D
MY4&GO4-Z"^6"@6H&"\'R9N%SZ'C!:,PZ6]=C7E!H:E%OP=Z$KO3((/ZFLZMH
M_L23OQ-$48F*]Y,2;Z:C+(E!/OQ$<> @%LN@O-U;,5MG&CZ(M;L0ET'F3'Q&
M_P@X1$;C?" '1K)[&LO6[PRM*=!$QWY$,2L(X%R\,'A&@EI%UF=3(+L2/@\"
M\8N49;>=PK^XW7IG*@*L?=+/QCFYKR"MOV@=!/@K@YP($9T<!Q']B/_2\FN$
M)4K>[O'BOUW47U3"1)M2VE56BQ5B)SSWN=NH/R QG*QT=:\_KXHGS?'E_!*/
MPPDVOE;"&IXX1U5^> )(>&Y8!&A.V^;4<CT4)+XZ7/P0-:08'<+JEL7?N=-"
MOGLB##+V\8;X,+&X4^X)U\CJ2I>7:B<M?UH\[W6A^JM!7VYHH]4^9>ZO6=^8
M/+H33CS2HZB[Q#'4ZN 8ZW7.O:>O&5)BF9+2LESYA?H+>;]M1VMC\N*(INEL
MUY*H"?_@&(KCS 0R,?7S&+4S0I@+Q(9<!AQ[Y(F3#F)<@7$VDHV3_<YA2.5\
MZF$Z-*NQMM*J)^/*<*BUHD-A[B"%OSRW8X(BF%78@OYO;E;^2PK?V1!2LF)G
M6-[N*TBW3N:G]G.R8<?!DW+-E2K5FU]5H2RHQN\KHU^+54(Q0I6:@1:,IU]9
M"2=JIUC!RA<E1'=1:9*<&EIX2[-(#+D.5&M3 Z-UGUSDT'UN<$=&C;SLYT&8
MMKJ>L-;"?;N(;YPJQ;X>\"N\5O>6(?'6+<K&RIEYF%6AKB9:Q.\*"4ET]LN?
M?=PF'.&L5/4O2IP? ?QMK.>6X<<TA[MDMY<5+3MYTS_MCT:UCI4H2/SW&:3E
MFME:+?M(;7_X4GI/H(RE?X %%6<L+.FS &]>O69%&Q!C>6E0CH/]X\(JX>W(
MU174<8DKL;;>9++_D[\7T^")'\O'/Y]M&6F9@["]3%=Y#G5V='DJJQ,FTSG.
M-D%C5U]D *\W+5FV2=,<K6AO[;(\/)XR(#1M,OWT]?)VXK=).-'2(V@+<]W2
M4&GK!WF:HQF8W5?*4T;GUI<]FU/.AN-CM+_ZT2<19=R@"4Z4&!RG4B*XU:K_
M<]"DS(H#K1;LM.LY&Z&^-D@P_:$OPH3[8&<%>?^93-)QP?I=*P7INF<E;G^J
M.5,ISH<@@5LU)%<: MV]VANG7D?Z?"O6<UF_<K1^]/%X'#4O1 ?NJ08)9$1!
M\JV7'9C+-E;D]2WZ2L(83V8F5_DII-Y;B><H=/$STGBU_*1XPY'3"[#]40)R
MPM^D\96VV]()&P;F6%<ZW5\R2+G9/<GHFP1YQX8,Z>J4)O>3T>*C^!0C4:L2
M+4@4KBXOZ;_MOF*KL3'%OI%@)C6BH]W"&^#_V<=B 5UG/Z)KCA%BD(ESGD,V
M\Q7</KJ,>BN&::T5KZ\O6N!%.LQM&,_@;E@0=@Y70P$,J &R$WT8*Q\O[&5!
M^Y)C_FE/]==HE8/S2#-*'%5%H.-OO+(!D ?B'9Z8\H6[^,77+-66R\57<Z)F
M?"@BM?-Y6D'Q@WRG>P,94@&V_=+^E&APW*9XY9?2'5Y=1&A!,$]4NA>R3[Y9
M"5:68]8, LPB<@Y;6,C+E:'!QDHV.65'6E5H>Z&V:3F>SZV8?M)5@CNPICGZ
MZ,.)Z,$X!3MA0+7VSG@A%PJG.!7<NJ[Q5,K;WG([<#J8B3>#$C/+6QO;!4L+
M2A*,H1]@/;%8=UK1S_WB$=!!8)MYD/6Q.OAR@&Q?VY@,$QZ#Y,5+M#PQ!S"W
M-AF%,3?\A YG:&P"CK+-5N\>LBR6BXYWR<85+R :L//N?D[=]J2Z<RD*?<,1
MWF':NQ&'7UW7QFGIK[Y^:YE,W'-<HG"$;+>$2=Y$,@R79O8X"5)>;O(@[.F6
M0MU/W['VH8"E0-(W!L8A>NNNAARO,X^TE2<K(3DQ-E(7SST6/<:<G^&:BKF_
M;"7**K+Z8O/T236?\Y*BL<;WV'F$%KA8$ #9NRU(+L$8-G5(R'?BL7U=BYU;
ML=/6H37U,P9G[Z)SW/9J[JTX%BFG7)O#T%TV/RAA@(@H*\[9Q]3J2KK-F_^^
MQ[[VQKX&LM22_,&TD)1@RD^$Z_B6@ALML6$O'R]'<Y#5]T'S_<M1&\XVP9"0
M_+C4O&A3BMJXS-X7^5?C*,U=ZR)2AT.C5@*9Y3M<%EL7O,YD8GSJ\U<Y./*%
M;6'DW -=ZA*L(PX U6 EM0^+9HJ:=O+8CE+W:1V)OQ$^,F#_^N+]W0) N5-6
M%?P2I0$&C>=>ZG5+$35;;'S_H"9@E[H7G8BPV%^\J/01:KE=@,>ZA,T;+RZP
M!\OV]L;.?L\PVV5,:,JNJ=#Y<Z-)0)C;F:$D?E4I^2G=]*:2V04B8:I!0J?M
M^V\^^S9E-HO/75LCTJU4ZJ!VU#;^?/8L06_HHK?!I^C^(I9([7+:,JX"6F2H
ML.22/?5!X@0KRB(N5F;2NXW*_Z(;38B&#@JG[/$7]6WP2ZWZEK->QJO$M37O
M,H+ V/Y^@K&=\0C(T=]FZCLQ]B[;36YW^C9 %G9'ZYQ$*X:ZCIE;.P41[V;-
M&NKC?12A4*'A,- %#*$&-Q-%H<OT9$^<:I9H]V0CREJ)VZEV49JVC@13..-F
M5< @,CL1E_F[1_*M_F;#QI+%EOXC\/[P89/.X"9US.?6E!!AT9\4$8WVFK!^
MYTKOYW9R% 23Q.VJ#&)9TT]9'<PG74TA)Q9"N9,!9YKA^,DF.5MI',YDW'3!
MEDFD ,MFTEINRVI>4T/-TR!&(J-]_REM_5!8ADN.>]078D.4@=$P/;1R'L/A
MMIZ,Z8O]0N#EJV&#9BA[!?Z.SC;Q;:(QF2)!<%@T=K>L[,=O=0@_ZK21-JDD
M]WXZ7C'9,\ '9)I]:S<MG3QQ+K!YWT=[S7#\?KC90]!KY8P:A_8>EU!UI3C&
M ;VWD9CQ*Q43TN1S)*0,7$=HLSW: 7E6V4[[5G*-M*GV:\I00YV?&H09.,H7
MT!K6>C9)$=X1/0,IY+D83^%S88GY&EP' >JF'!R)W":T-LTR&<M11Y&R.FC#
M' 9MB/5B&&49P3@S9T9V?W@6F[M6<VO(J\:9"@.1I5B,&;\7<=+&YRAN6_@2
M1[V VU80<CQ &6_E%1E^P9)I\@B\J6W.VE1_$[XIZ:F2HXEV$H(<F7$U3N1Q
MT-(>53";#:LP/)I:D:![$]4@&*\I]4+CNST9",2#L(KXE!8O#IK<;$A]9/=!
MS8Z6(:]MFBY+]GDM6[,?V WLR[S_?]Q[]&^GVI<0(E=[%M>'AZJ4[%\_TX>7
ML]\*Y$]?RDQ7% 5:DUQ3._3=A5W7^+8X]@JQ8&C<:^..3;%JY ?SPM9UJ(HF
M;M_4?]_+QMFJR]K;@7+@&<*E;)Y'??9J/K:IG#X,SK9([M[86&/W]72X6WI0
M$0 W&*7O:V7WD!O6'XUFS$G8L>7<29=4?]-Y\'+^I5GM:V'QXJ&4AN?9!5FL
M'<:^G(&V0.4O614]FX-0NRF,,"U.C$2V6H0 E-W8KFKE[&X^ D.5NSMC)/D+
MEANY4=;!6AOJ]-_]%$B0XPC"GX0(G]L96UWEX#^(MNK7J,%X>F> .DX6@<]Q
M(K:\F]W=O/"!C+)0^"'E*54-8'1$8 9'*5WZQ7ZK0"M_LJ[ODEK A!OY\<(#
MB<I'@)_*$JGB:WN$>DWT/M:*_BY%, YRS)Z6=72<"<PNE2BOR4UR]04I*JOJ
MS[*9?Q[NP"3:<L2IKS*D]"LR37<2GJEXZ)<WF  *4/0/.PMXDM#EPW]XE6$&
M2,K&T4K+O/F[(Y$RGK8<K-N-7,-H<8HWL0US[QR\R;<>@75#F4= 2BZLX]3X
M$9B?D"Y@."U+.19V7B^NC\L?+>Z_JKA[H9:$]4.?=-0E%=E,.]S@ ^5L^CM1
MPWL5HRD[/GR!"_%QQVC]E5;77\[XQ4@]<(8UMXY^^+!$D&#2\DV.*WEP :2@
M.W[IIBFNQ[):>HJ;<[!3$_F*9_7(&S=_V.&KT:>P1\#-2=8QN%\X?"BAVS&3
M>?B5S=WPYYQF@KH4YUKY3=2H87_!6:M[\F>S[.P?YI5?Q3.#XU)86EZ*.ZGR
M]Z(JMM<+JGO:VGT;8:?G/EK=MJ=HN-VL9!:HIQ)]YK';UB KD:*=)*&>E4_0
MZ]SB&UA0,X=_I9#LT87]-&ZF#++8'8UV.UUTZK1D[;0\ !W]MKW[72HA6"7'
MXE,F.*6A6H%0PZ [7@5>H2>.\8#JVUVZ>'"K,EK=%*'>\"(,4V8D!VOSE^>)
M#MLZ14:G_\;"YOF7:&V/,)?S10?.K(7K/96$;CX;"K"&SM=5P>)D?-E!KPQ?
MCX]R,#_!^M9&SY&GPBHOR#A#GOC=NI:444A.I,C%'PWG1W'3X=1B!8DW,78H
M+OQ';V<2X?_]NPN>N=>H;>E?/W +Y43O^RDK5\FI*6Q8=@#SJ(:/U7</?!\Q
MIX#;'_N(["?JNY%PSJD;'"47;%C9F>A7H* 9F_ -<" PBSC&3%7\RK4)%>;S
M9B@_05Y_$5_(%1C+Q:U0ANC^\D<E(@Z^=?(<WU=# SG"ACY2AN1UG"0R@8<3
MT@$05>>HSCO" _Q%)5:38=Q%GMZV(GH3&DN6"X>B*B\I(2^6T)!>P38^G*OO
M%J?Y47CG.0X]A\NM)S2%0K?A]B'W<NZ5-KS!VH:AYU7'7TLW+4&T0I@Q)?=,
M2,W%._XL@0L\"O2[_*[([\]*F')0/-4WCSE,)S1$VKBD33SB\D0T$_%NWB2J
M(0D7#W3)]'%.N%SFG]-=?%A]+MS)>P+CCE&>251#5H$@);)AFO4YI:J?/XBP
M,'-@ZL@48[3/X33()M%Y*LE&+^MP5$#4Q?$>L@AH8WNI3UNE(&1(TZ*)<8L2
M^$'1I!-(L43B.P6Y?A357/V6-RUGT!J2[\08Q1%MXY\XLF@O5!/!?7Q/?F[=
M.>OSJ"$[=A$*M17'\5$VS"(QSLSPIKG6QR9*?M8%6\DSTA(+\%\B7Q5:UZXN
M[DT-%RX4+$_T#;Q5)[7S;?/29H?MQB!R4N/4#]!<XK^^59,N93K.7AH;'HQ
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M7Y2*Z.1)YLU+Y6PZ2MG<TWUZGRN:..$>YB"'D'LZGG9&(^Q\B7PV_,M-=DD
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M[<2^>]/,SZ<^/3ZNN1G^JKEK-20?WUJ7YE[3!TF;835<4XI=G+Y-E?A0DG7
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MP>\]+7'LBM=VR8J2W_;XX-J803,V;=GV4B^_@#]\E;*,LHOCHK2DC4=);5S
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M 248&MBX.^@"/X90LC'+V)U_QT@ZM].<?J+L"R_QS]@@MGE!C'[4=>'9NIK
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MIF2<TL)BPW)@H.'N-\4I?_8AD-4N7BLGWE5#-N10AJ!J/IL.=[1LI=$K7/W
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M%*ON__(I,?7]4D-,^I%^7?NT]F+#0(U,;_ 5N.Q9P/48'O&+TR5\0D@-PL*
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MD3_[-4!TV#;Q(7JP U->>=:+S]J9'Y_N%8UHQ7(,8)LG@/?L-TJMI-^%*U6
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M#?='5/RW\;G5W6BT/.HG!.]=)M$)Z7C7Z&%_0/L3V7\/6/#_)V3_!NS?<2T
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MI275@O;?ZCT?+;I%Y,<I6#4DFQN2MV8IZ"M1R:O5)0JE2D<L"PT_Q1D:D'3
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MH/DD._K9/R?L=::/^()JP>37M]BZI#,^YS-0#_G*?E%^5WJ^\5J]'_Y%NPL
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MJW)K:(1CLWH"#Z?9/>UG^L#..NE1AGK1*D[BQ7U6&W<R[\TLI+XBIBLG(/3
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MCO*6S;Q/-R9XSRG(7@KMMI&+V?_?! !02P,$%     @ U3MC5!F-.F?/%0
M81<  !@   !P87-G+3(P,C$Q,C,Q>#$P:S Q,BYJ<&>=EW58U<^>Q[]P#ET2
MASB'$A"0@T@C)26E("5="B(EG0*2@H!T=W<<Z0;I[N[N#@FIL_I[[MV]N_?N
M/KO[F>?]U\PS,Z^)]V<&.8U<!AZ\E)*5 E!0 0#E=P&0<X $@(F.CH&.AHF!
M@8&%A8F-2X*'BX.#2T%$3$!"!:6AIH)24M(RL#'1TK'24U(R\SUF9>?@YN:F
M8>(7?L8IQ,;%S?FG$Q0L+"Q<'%QR/#QRSH>4#SG_SX%L!@@Q@0&@$81"!Z 2
MHH (49#M ,WO>:*A_!7 WP(%%01&0\? Q,+&^=V@\@& B@("H8)!:&A@\._:
MS[_K 3 A&M%##C%T8J5W&'0V))Q>X>F8].*E+1#ED6,&+@-;;RQL4C)R"N@C
M1B;FQRS</+Q\S_@%)%Y(2DG+R+Y4>:.JIJZAJ67XWNB#L8FIF9V]@Z.3\R<7
MGR^^?E_] P(C(J.B8V+CXA,R,K.R<W+S\@O*RBLJJZIK:NM:V]H[.KNZ>WI'
MQ\8G)J>F9V975M?6-S:WMG=V3T[/?IY?7%[]NO[#A0* 4/X>_Y*+\#<7*A@,
M F/\X4)!=?K3@!",]I #G4A,">.=#3$=IQ<FB7AX>FD+%CV7\C'$P'8$FY2!
M>^71R1^TO\C^=V#>_R^R?P?[#ZY9 !>$\GOS0(2 "'!YS9SAB?U_D921)&L[
M&H@ATA/MB:2-%62AHNJ,[2I;/*2V\TT0X2]%S^*[RFPD,"PU=H\$GEY-\:T1
M^&MY^!49FCOYG>XJ.]+U\N91O2(\WUF,1P+8L2V 1S>AQS&=_CU+[0]R-ZJQ
M]=(0?=R9(JZN5$YB. V[BW?[<N@4S\S+9^H\_0N-9+_B!B8V'&4B6U/)5=0F
M#,LF+):K-1/-Y&$/2%(2?1PO!UQ$+B9CD8 8CL+-[8\U/?H5A2]0W\E\V%Y,
M#HSD8S=BF=O3 Q/;]?I:/1,)M&8?*]RAJ",!5 8DL%HH]X(]T'W/XXF'\F.!
MP>>G C>N]:Z53ZR$[%B2B&%^P#TD +%==YCN%@O5#]@8H]-HC2,=Y5=-9#A\
M5'N(+ERPZ+623-]&.CJW0^H]^UB_WP%_(*:3JT?8UUP=M];J<-\>/J<2=NQ8
M6#14=.4C.6FYW!#[*@;R*B[]]%L L0<\XMEJW?6J&VNSF]3)H,)M53D2&(',
M@5*BZ;%9&N_VH9:I=I]MY]Y6!V2'-T*D%+;A9*W4C+'M"?:GNM-4SZ]G]=E<
MU2(_R17442X[2*F,C3NFX0<&;MCK4P3K=_!=BY6QMY&'S2Q0<+)]4=CH\PKA
MK07E#VFQWIJ2I.#\F#H\<!]B2[&DKZM<JLDJY5#V7$L*X^@ZP09V\Q!T-/X/
M-/?48_1H>6??^@V.6A=MQ FE]P<J6->+#F+HF1?*:[7JB@N2'V:ZQEO<CX?G
M]YB4H9\<1(@( +62=GSW'-6$IOD9[0G)D]FLI=IT/1NYAV4,'PSP(3(MRTEA
M0(Z9'N/XST)Y7G@RV]R-BE(=;TE[=6H-ACGO9E@:O>].-<,Q,R@_H^26ZWL?
MHL6M^O?B[G8>%#-I;)P9LJ519BZ_=VLKH5V'SJ>A!C+_32RP/*W501,B-=^L
MX#"99,7PH%";R2_@"9_55#+3)L(*[RWELR"[;D/]QWR4:T+WJ@,$7Z&3&+?J
MLTM;2&!&G?B$J<6E,SY[1M#<!5'=9-OT)D]'^C0UT=L]-=A)L6TD69),\#;>
M]V5DD+:2,('X5?;*T0-SWFO5L/H;R9:W*>\%U7U9;>VV\1QGOL<*4:P4:UUV
M5)&NW4C(L>G?<3[3U!()#U4):12!7A!<J4.G[@CJ_AI6+:[A";;=2ZZJE!_A
MW&;C498CV_9J-'[<L$;T46?+\\)&U:Q(EQZ["70.KYZU1I-%LSKWE!:KIQ8'
M/12HFN+K+J?F0Q&R,X+)6%650D/W#_8(R-SD3G2J+_E*8(R5,AU936K+(ZA.
M#_AW]+ZEF\3<TXR.*53&;&J$Q_OH]+YW?^V2L.$&<;+(<][KG'*TZQ)NB-0"
MQS#.%_M;6TNG(TZSC)^L%>+<F<M6C;"J2;ZZR0K975%D]X/TE?*O):=;NQP6
MX102$#EKZX[SP WMBILR<^J(J<IR^OQ_C!_B3']]EWHAZ2))@K))WU*WY7=P
M*^AJE3>0SQLN4*B5708GS_[%2!NB?62YA9@?G_WN=\[O9L66BE=>_?7<O/"S
MU*G2)>$*A@OA_8R,PO+$#HDB!GF=_)AS5T>UU8=.>#'G+#D#O/T+5C6S2.#Z
M9SC!B[*)!D$17P>*G]_VHA7P<Q*YU;:A,A_P8,!RN-=I>$J[G5ZJ%#.HJ]B-
MXS/^MQ778FV)^MK 07EQP3YF64[:!.7N:;"5'KKH.08$OJU5.VQA867_[9>;
M(&,Q3WN";4G$)LPBLT=I4'01YT&N-9A Z[R7&11VC.:[F6SH@5)94S$J.6C?
MY]KP::3]#>G"$NR2L'ZS2VMO^Y_=%%=)D@104\M=*2;3K W94AD]8-L,=J0?
M>F"0R=\\U&@V;B6D5*,>#@E]QHJ2AKF__X1[&TRJ5C+W M]1@EPL-:V0Q,L'
MUQOS(OL?COZ_4'I=S:M7LHCW0['8W,%>D9Z<'M'RTEH/*'E33[3;ZF+2S8V
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M(+?/H4B[56X8_<E-.QCR2Q8Q=$]HC 32.B[O+C57;" %8M6P>[!BL9I-O;H
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MZ:%Z>2TD;%I$LEW%\I3R3*YPV =-MN?X+'8.-(5C1X=.]FK27V_%R/R?9*?
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M[&KIWI<6[%ZRRW\ND"6NF\O']"(V 3V?&/^G'/:?Y8&<^3=02P,$%     @
MU3MC5'O*%4;+LP  @<\  !@   !P87-G+3(P,C$Q,C,Q>#$P:S Q,RYJ<&?D
MNP507%&[)7IPU^!N"00+[AH<@@9M+ E.(\'=W2V0X$[C!'=W"&X)[N[!I?OQ
MWYEWY]T[4S/WOJJ9^^;-[EI=775.G7.^O;_][;76V0W[#5L'<!5E%60!.'@
M@'OY + E0 I 149&049"14%!04-#1<<DP,+$P, DQ7^%0T!)1DU%249!0</
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M @-"8R_"GA&<Q1\O^&$ 956^K4LKFDFC@OT)T:&TQN>_W_@VX;H,]MJ](V
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M#?C*=&D>S0(^RE;:V>R-'+V;E$H%]6Q^MD;6XNQ1GZ9E_78NSSBEKM5CSNX
MG-L2G=X2YQY#ZX-K1A0Z1G*VV4=I 7%M5I\CN\B!Y]A*_;/BR-R7O"3 !%
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M%O+?2W#';/RB:38HM77-44.2X4$D_=^<D!MAZ#7?^K;);O<32UDIJ"/)K/*
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MO4FCU"D-0CC.4<;3=CQZ+C]<,#QX?B?_.4WHI4&5-TDX"-(3"HLV:9SWYK6
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M<."-"/D\<J8;]2]$I/POV%_#IN+2(<7S^SIXC3V/?J^DC2ZS3>9,>&^$?$[
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M9&R4-)8FQ@\]DQT1#2GVH><Q4O9Z%.U69[93Y]T^],3,H5<FEQI%2NA\[AN
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M '2X8_*L-"20#<\?S/+GTW9TS9TI-"(=(D<R&\[E8VF4K=@["@Q&'M[Y$?U
MQHC932U$58W\:CIS['B_!QN9KGYRZM9963;UVX]V&" YICKCHY+%N$=4M'Z9
MSJE^(L+4+&_C)5Q(,W'R/IYPPU,B? Q?[ BQ7^ORH7>KE-^IP.GGZ$^55>TV
MJJP!,)CMAI(R.F%T)>JU5";TFE^3^"0!G$=RQYK!/3?8R&L#\[6?2FM7(R>J
M29L4#;0U85-D'/AVGI9O&IV]>&O;MR[R2Y,KMG%I]CD$<*/3%S8&_<%*MK:E
MDTL0$>FIJ8YM QWU%J]&T"-.XX\LWBY*-M:[449JNE-'25#">IO)=:,(480U
MA[H^[)*^]M"4^+]73H-O<'(_T<E&NSU%L*> )$\IHC@U52&/WRW'Q$X373_8
M^)$RTI@>X?I_Q;VEJN]'S3> SN[BI[B&^C[U<[S66N!.7*<4<;RY$$ :*T(X
MNC',0A=.$ZDJ&5<K22+;^&(1><W[--9'<8QXO&+JRY3R"G*CR _48X+*=@C"
M.S\(^CGKZ^^&+<TS-CF33&MRNA_^EB?Z,E/-[<=W$!(Z]DTF7<$!)+<);"(K
MA\_O7NNWBXVB\2$)H0G_0+THL9#O,>CC8A*W$%8;R0VA+XZ(RFW\(?DIBO#+
M,0U%>X0$?V9C0]#(!+CHQTL,>E,7H5_/S)6TM^#/HJXU,9.R_L%@ D\X7M:#
MSMZ),G)9Y'7*]_Z\2-F]KTY[G%M.OB<I? ,/$E-5Z>W]W9&=S2"]VXY\@T."
MJCEMW3ZP&5\\_B\""UHR]CEJ"L8TU.^:1;>,/5#8Q_'P)?L['AR>!$&^D9E>
M4=1ZT*;.R!O9HYT<C5^Y4Z[\LO29E?QB(0QI)<S%Q/)+LY4#^,7V'(/G_>/E
M2NS?!D51]RS?N$@,,NYB2FW03C7&M*8EE&MG;4F]+W(9?;<6QG;I=I@FX#M
M-)I_"^H>+K4B&OMJZSVAP&(ZQ4J3Q.@"9>E)IHYZBS05,J.6HC[BX?9[1$/*
MSMW3)F^1:WCKO /]VIT$:?\:6IQ><] X2L!6FVP*V3[8 *WRP@%CCAOO,CCP
M?0KJ@:>\5'+\. KQ;G.Q\EFD>')4"+XFO8_5F4[[N3!\^D=*88+I:O@8D4.1
M[GXQ6*NYD@+Z^\([%?4+PW"70NW)S'@?3?OW8)I O'07(/J..#ZSOE[.LGF
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MFZYY]S^,Y6>OI0NW%#]XK<8*H83L0M:QJ^S:Z.^94ROAP+'@,[*C:41YWW-
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MRJ+(M'T"TQF>12XPF]0_1^CEQ=9S_..N_LJP+Z6O;/2NUS"B^/#QZ2^93^!
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MT\H"W"E.BL-SM@K!]F2J-62OU@:>&I[? IX4Q5_15D#$1#,M8BC:&[LG,?*
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MO)9/"^\@O23XKYQH1X>K8)/%B6S/)4[(L/0F,33-?!J0Y2=Y)_1#5ONE*/]
MHSH@I2G0@JQ00U6A3UD$Z! 0Z!H]6Q=0@0^&WFU<Y@ "K99>;W<5_ 01*-JP
M !SZYZYAB+9>6=7;J=@[ZJK"S_*19 [ZM3T:H67I\A!QCR =@K,+(18'+NJ2
MB,MX"Q\@2C@>2#CT?=Q/-":)6A0P'D'%(2-$1G97UKG"4W280Q"BBPBZDW8
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M2MKZ3$P8\TB'AB$%_W_)?;  GJ7E";A6/Q@G"P&'3#U@GDTD."4G7#J19#;
M6TUHP,A^3%D\6CP9]$U(CEDQ)T.&(OY@ -=#0H'_I=(A,";XR@3IB3RIGIZ'
MT:+ I0B/T?J>W;- <(NZL6J"+P?9">>\"'TNR!7$#4&>=!SN4INY8X=3^*23
M\FFY5,W+Y9NP"C.(0L&87 FNZLX#9@7@B*=XI<,\+YRZ][!XBCQ)?R:>[XT#
M?\!%FE7YQ46YOB4E HO#OJ0NY4P&P)2FY_GW<9_J4:E$ZOR>6TF+2_?>!C&\
MA %$<>![##B8"PNHFLD#F4(15^'C6'\9U/.(;1J/"RB<39,@N1SWT:,A" 8,
M:=)O$>^5N-E,1RJKVU7C=@UFJ7:G*]L=Q,W^C#P6#U56&%D<#E:Q0-XJQ7RH
MA0E_M9FBX<@2#Z@W 1M & X=0(7!PKM*8=TILBHU;H>"M%F8J!4. 1X(,&-'
MU%6M:;KM5(N;;M%LSFWF@BF/HVOI1+';SS7M*<O^^=KH&GHO+_D:,Q04-G20
M]Q*6\IN'(I3\_M49F?:1K?;G/(2KP$X(98T\0!&P"UD=>(?892A["A9RQ$,T
M[\#;420 J]#PGGG4$R%V$10B'83R&L[+C@[X1N[E8] +D!,$:2BS/O@A-I3X
M[_M1W+(_713P]P0KAX1DC 4  U!,O(ZJ- !%]"=A[1>7^1H:;1Z.73JM<0_C
MU$(?W-S7A: 8QXI3VZKT54L#O)C(,HRE/N) -<\/1M0]2\?4\:54T(ZL! +*
MVHQ?\I>I *&\62?PAP$=+2+2^.8 ZP6Y3-"\ C\0NRG,S=P:P))[EAO93/;!
MC$+M=9")'WPE?B3<9(*>Y3 [<L$'JO@2X\XGQ7480.#@D!>BBB'IH?9:NK^[
M<-764?DF 5M9 =A^9 _97/[+X ( Q=A;Q-?E\_"E+*UL'T\H!Q8S@(/=A>&3
MV=7@?HCFGMUS/PK!'L_HF*<,.P#DMX#B]X3AZ@H,S_RR=+;"@>0H20V) [Z7
M?6.!!=X8( PQ@C].(%:G'H74BS3@.PI@4\#J8;P,#2K:T7?,]#[7F$QK<<5-
MB!\L%::TY>@0FB-A'G)CYA%<JM*:2Z4!&*JOU*WZ]W1K-3D9PM\/P@^6$*Y#
M##$:NTRP642 * H2$(SI5$(D3/ #P F528?<'> _ U;C>49;8?C!\, X7P C
MXB_"F<E=CGU"I8H.O0?*W8!1&X)JW!X:40QE_#ACA82)N:Z,D2&<#]A\8'^B
MG .VR\>;6&U+^'(/*\Z4T_8>V9+H]*]J^U-X^F\4"CZ8/B/V6J\O*83NK/XD
MZ]V[.%Q2H4X4A!$DB BFQ+P?:&6MLM[ Y^<N9((GF@!*V7+ @Q Q[0[(_C\.
M2Z5\J53*)<.L] 7D"L9(8+KL<OH,$T^(>Q32L4FRZ]5GT$E&0 4+Q($;<V3L
M4%@U;ML/I[AS1#-X_[@O>%O8/EH1 -EL  !!L$D;N4]SI*Q5C\EZ>NLP;#_@
M0-\U<^\9;OLBK=0+"S'!2HB54B+$#\QCZ! ".IZBA;<C2VQ@_'(ROK3>^WVD
M_*"\4<KG&KE1>M?O,#U,X1<<-G3$.!1:\H")Z>OL#AUHNWA,!C^')[%R)4+[
MWNGW2A 6^XEHR(B!Q" HC^TDBX0RFZHEV0<K#'^/?<P%U-_A.#[/6MTEIV(8
M#@8YP(@$IH=^(S3,@\BSXE1Y"&2%\8 "+'H8'[N!UX#$1&W8EX_/0E)O];!9
M!WY9$/2$) JE_8>&P;U_SX,H)/= $!ZTJ-P O^Y'@D#,15P^XD(Y"G ANOY)
M(U<PFN72 ,27)ZNX$T*T-<N=U;$_#F?[<L34]:6Q\,I6!/]"_ G:A]BS[P>0
MHOVQ5]J3_(M/UV>?PS&UXL_0(X ?.YE&6?+CD_F9?$),4=CIALN'8&B#\21L
MX@#O"S@#FNP)\#CQ#BO&W"33"GU?"']42UW!,J,5K%SR,7L7X C2/%Q:Z>[0
M_'+;_EUKD3+\6(.P2>.O# VCEI/$?LJ$H[KRV;0J-Z(K%;,FW;1^TX/>@1\-
MG8<V /RZBZ?'\NC8BRR7<8L PB'G\UW(D8(XPPJYRSR++3:96Z-Y:VCEIPY*
MS_DB<F0XP@5PP\)*H]-V]^JX0LZ+_ (-7%YZYX\![?<AXHCCU_VAZ_=]F [5
MC[@L^NK;TU" C76FN1]:&7*.?8/H-PS5\<\<PD54[:*T"-NW3TM*]41SI8K_
MU+].D(S5I];788#G2DNE-ZDBOL4O' 7H"LPLP];X<VE)SZHI14O5$\97TN6$
MRX6*8SJ$8!B2\Z\%.A LJ%%W0J=A;-M.3K3*P6]GRNS&M86EI0+$=U36N&D4
M;/%0XO1($CFD+@6%"J>N!=9EQ&U02HWL6SER>]/8K/X1&DS=,'('D'9B40;8
M SM'/MQ<EDD#\@\+ AT+ @?L]^&V3(;4&[H<9&7#3U@HRQCXMM,CS4\;I@M)
M &)8CEP%P#FP>2.LGG%A, S'.27[5V9CP]8HWF#R(A?/D?<'.5*_-2OZYHPY
ML*L(O7SH$D_\;/M^>]6JD-AT#W.X3?X58M--I$$0S,8X#V=;&4]8^5-YV]&[
M'RMD/UW( DG2)N,&.</&T]>-4BBEM4D2<P #)_=@"^K%<@.II-%)(38.A$^M
MJ2LC [W7T7/JX&^?YUZL=91@BL;!P! /TFE; AJ2Z3$8/I5N"RS_EU>7VB=!
MRCP@4\5T N]"4%W!M+(DI9IW='T+R-Q_M4!U<=]PT\%J;G%_<;Y/D4@^.1^3
M1G[-)N9^NI),E</\A#@^W#AOME_DL&M[+AH$,*1Z]&.G92>[<59V_& S],D5
M+W1]"1<7(7,'2>F.;*4VZ]0),;17]6))N?-";1@,&T9C:,5L=.*J,)KB"4+
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M [1J EZH$2CH6 ! %@&<!&;:1L?2!;;@@Z&WJU<9P$R]KE\TVS%>!1$@PV@
MFO0O;<,0;;TT-DKEW?,9#QQ;L0B_\L</N7Q4M0?GEDM#-*\6'B#N$J1#&N!
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M98FO _HX@*;3YYE@"<W"M BHB".RY7BBC04Z&06 X;27,#/;6EP5,X;]?DR
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MLN3K<)";/Y/4FP+SQM5C8)?,L9&C(N4 =7E#'27X]A0VX:E!3NI9'N9%CGO
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M9?NRA^C'>7JNN^<;2(H^.S\Y_7"RC(0[08RQOM]&^X]*<*8L<5&# 16-)-X
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M%+9:P [E3CMPUYMO>J(!QQCJ,,>!A@8JIOXBU7AY]*I(33-Q2.),)L=K4*H
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M2;0?[V4;7.Y:@??H2*+U]-\A1:SI] ^=!.[)+_'HT/HNIWN\:"P<^J/*,O2
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MF'+L@NUE?,XLAKZ(\TP<R3Q58DVF(E ]X%2!T!$]V(3W OB($URH-",3NF!
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M2;3WV)8< "1\8ZK-T5>!69J9+8B)>W)A<E0@GXZP),%PZ:C$5=V.X\0 O ;
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M8!DQOHN #>SI@&J=4 JV%+_G9-:X>IH\TG_D%3IC3S]E'[B:UPD3;D9.A9Q
MDP(_JL6OI9ST=W?E?B(H"XP1/6IV95NX<C([M9!*8%EXHEA9:$-B4[T)G\Q-
MCI)MYUWM_>[*4[[RE*\\Y2M/^>-KE'M/H%$:IT!JM#;Q";CO7$40;(A)YO'
M[KNDE65\:P1I4H4N,DM+(B4P4=@OFOH&HO;@N+X1?P&G!%$%*[DR2RY!.;ER
MEANF?)1DN$E@=AG&)3V%E$RD7I?!Y?P61B/&2W^HP^[,A1KUR*YS\;?(O%"O
M_"P:)J_\*R'A]T^1D<Q9^RZK\XNZDN'<A#Q5B&VK #A'GGTFB^IDSAW;:;U(
MOE,*Z0P-%,DQ4E<QJIVVQD%QH^Z2KZI:ZU18F4Z)7.-4CFH>R43SB2+<T'*-
M)S#19-T40J )1C8N>F_6T,<*?U]KV _>X8.? \P% ?ZP[K(^7(I-:5^4ZV'4
MZVJ4D<VEZHGTK&NW!+<[-E(XXX"9*CW,G.^HLJSEJ%AX52(>6/;"&<1$.N"\
M3 $-38X9L@PW%OJ-/@2Q1E8S>3Q,VA_\ZHDC>O-XG?+ 4&A^0Z=4)6/-4#L^
MAX+5.J1UZH<Q9K>;JAQ;**D' Q40T?&!41D2AI4D5R [U<!$59Q="F0[C%4D
MV1W"QG)@JQM*W@5MKJ)+L/?4-Q48IUF1(E>YS["JU[AD.PZ*4>Z^RVN;I&_R
M(5'P7\!.N$7.A)\!T]2MGZ$T+>?1%>6//3%11\4NG0DOE5]%A<)%--5S3L))
MP+G3Z=S@Z:IA/ZN^=7"53?[Z%HYL4, 5>9GS+/FS[H5?W-!RID_"JJ$3NJ=[
MU;DD:29N!JDK%Y(X9$MGKNT.]YE5()'Q!JPA<BAB>[U:2H:WH=@F8^@'>B9[
M_V7HB:]+$-07+PA.^-) 3$)!$$KL"G2O'*B"0SHNQPD1-X3#W2QTQP\&"T%S
MDR;N@%'7\MTC96J,V=RSM5'*7<3"-2%)6H2?38/Y67WR;W W1F/AKD2A-IB*
M+CFDAD.A(-%2#DW'A&4VQ&AKD%)-^0F5S%_3>[!-E^ZH4B0@3DSB=(#>W3@:
M#[B>%KYG#I9EB>[FG'Y35LC+E]S<!1"*;I1BC##SF$28 0TQG=@&][EKL,U2
MF,BO?N23I1SIQSB5!4![[EZ5$]<-E2HOY[M8::K.^<9+@VRE7FG82F]P=[W/
MM "V(7H>V\K@6;Y]6DZ!"EF29_U>7BD>P%'-'5D<.:CH3^PL81O$1*17Q5>O
M5GHU%B^]VO#D(-(]0Q0'@/SB.,\HT_!$4SZ.VI^CS*C$7TOIDY6Q*S'N"NU9
M#7?OUBY(R *Y! 3#5X(U4I)2Y$=@B97FP'UMM619DT?*O*56B"6$;7#K:L*
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MB\[7B]:*)<\![-G7-CXEX_M1+H=7M]S%Y#:[<3"&?_K9(/SX_U!+ P04
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MP\G;40X'[\.17M+!>RE=8+YZ?$E=*>$;(\6H';C#H1\=OQZEQ@JTW1 .FEM
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MQ)('_@Y%'L&8 *6*3S<!AER).<D "0AB!#?4JPN4%@#1:U-#((AL+=5$B5R
M $!3 G[L=-KJ$U*=D%C(F2YQJ]B8:P/5J2$4&YW>H&6S C]=*O-(VQT":XG
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M-KQ6;79Y)UQ=')<WT8/_ 5!+ P04    " #5.V-4Y+0"1ED%  #&%@  &
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M&XHH_,Y6IVY7FZM.O@MPWWZ"^Q'A/NC;O8,GP'<$N*.589O=,,L#N#PQ)^4
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M2P$"% ,4    " #5.V-46&\.E203  #FR@  $0              @ $
M<&%S9RTR,#(Q,3(S,2YX<V102P$"% ,4    " #5.V-4F?4 KX .  #+SP
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M,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @ U3MC5-TVT(FH,P0 JR<D !4
M             ( !000! '!A<V<M,C R,3$R,S%X,3!K+FAT;5!+ 0(4 Q0
M   ( -4[8U0CAE+_=<@  'L6 0 8              "  1PX!0!P87-G+3(P
M,C$Q,C,Q>#$P:S P-BYJ<&=02P$"% ,4    " #5.V-4@QV@^8=<  !J>@
M&               @ ''  8 <&%S9RTR,#(Q,3(S,7@Q,&LP,#<N:G!G4$L!
M A0#%     @ U3MC5/$9WH[]&P  #AX  !@              ( !A%T& '!A
M<V<M,C R,3$R,S%X,3!K,# X+FIP9U!+ 0(4 Q0    ( -4[8U1;W9F8)G<
M "&-   8              "  ;=Y!@!P87-G+3(P,C$Q,C,Q>#$P:S P.2YJ
M<&=02P$"% ,4    " #5.V-4?5>)EZIC  "C>0  &               @ $3
M\08 <&%S9RTR,#(Q,3(S,7@Q,&LP,3 N:G!G4$L! A0#%     @ U3MC5+R0
MW[QW1P  YE   !@              ( !\U0' '!A<V<M,C R,3$R,S%X,3!K
M,#$Q+FIP9U!+ 0(4 Q0    ( -4[8U09C3IGSQ4  &$7   8
M  "  :"<!P!P87-G+3(P,C$Q,C,Q>#$P:S Q,BYJ<&=02P$"% ,4    " #5
M.V-4>\H51LNS  "!SP  &               @ &EL@< <&%S9RTR,#(Q,3(S
M,7@Q,&LP,3,N:G!G4$L! A0#%     @ U3MC5&,5J6P>#0  170  !D
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M9#(S+FAT;5!+ 0(4 Q0    ( -4[8U0Q\0VE7@,  $X)   8
M  "  5#J" !P87-G+3(P,C$Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4    " #5
M.V-4Q'%S2G\)   O/0  &               @ 'D[0@ <&%S9RTR,#(Q,3(S
M,7AE>#,Q9#$N:'1M4$L! A0#%     @ U3MC5(5[<^)]"0  %3X  !@
M         ( !F?<( '!A<V<M,C R,3$R,S%X97@S,60R+FAT;5!+ 0(4 Q0
M   ( -4[8U0MR2,28 4  %P7   8              "  4P!"0!P87-G+3(P
M,C$Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4    " #5.V-4Y+0"1ED%  #&%@
M&               @ 'B!@D <&%S9RTR,#(Q,3(S,7AE>#,R9#(N:'1M4$L%
3!@     8 !@ ?P8  '$,"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
